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SYNOPSIS
Detailed Title A phase III, randomized, observer-blind, placebo-controlled, 
multicentre, clinical vaccination trial to assess the 
prophylactic efficacy, safety, and immunogenicity of GSK 
Biologicals’ gE/AS01B vaccine when administered 
intramuscularly on a 0, 2-month schedule in adults 
aged 50 years and older.
Indication Primary immunization of subjects  50 years of age (YOA) 
against Herpes Zoster (HZ). The study population includes 
males and females without severely immunocompromising 
conditions in the age ranges 50-59 YOA, 60-69 YOA, 70-79 
YOA and  80 YOA. The 70-79 YOA and  80 YOA strata 
will be combined for primary analyses.
Rationale for the 
study and study 
design
Two studies (ZOSTER-006 enrolling subjects  50 YOA and 
ZOSTER-022 enrolling subjects  70 YOA) will be 
conducted concurrently to evaluate efficacy of 
GlaxoSmithKline (GSK) Biologicals’ gE/AS01B vaccine.
Study ZOSTER-006 will provide pivotal data on the overall 
efficacy in prevention of HZ in subjects  50 YOA. The 
primary endpoint of this study will be overall HZ vaccine 
efficacy (VE) across all age cohorts. To this end, ZOSTER-
006 will evaluate VE of the gE/AS01B vaccine compared to 
placebo in reducing the risk of developing HZ in subjects 
 50 YOA. This study will enrol subjects in the age ranges 50-
59 YOA, 60-69 YOA, 70-79 YOA and  80 YOA in an 
8:5:3:1 ratio to achieve comparable numbers of HZ in the 3 
main age strata (50-59 YOA, 60-69 YOA and  70 YOA) so 
that a balanced estimate of the overall VE in persons 
 50 YOA can be determined.
Apportionment of 25% of the  70 YOA cohort to persons 
 80 YOA ensures that this particularly vulnerable population 
is adequately represented.
Assessment of Postherpetic Neuralgia (PHN) VE would 
require a large sample size of subjects ≥ 70 YOA due to a 
relatively lower incidence of PHN in younger adults. This 
cannot be achieved in study ZOSTER-006 without impacting 
the intent of the study, since a large overrepresentation of 
subjects ≥ 70 YOA in the ZOSTER-006 study would not 
allow an accurate assessment of HZ VE across the entire 
 50 YOA age range enrolled in the trial and may potentially 
underestimate overall efficacy of the gE/AS01B vaccine, since 
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HZ VE may diminish with age.
Study ZOSTER-022 will address VE against PHN in subjects 
 70 YOA, in addition to providing a robust estimate of HZ 
VE in that age stratum. 
After each study (ZOSTER-006 and ZOSTER-022) is 
analyzed separately, a pooled analysis of HZ and PHN data 
from both studies combined is planned and will be described 
prospectively.
A saline solution is included as a negative control (placebo) in 
this study to evaluate the efficacy and safety profile of the 
candidate HZ vaccine. Use of the placebo control and the 
observer-blind, randomized study design, will allow to control 
for potential biases in the conduct of the study.
Objectives Primary
 To evaluate VE in the prevention of HZ compared to 
placebo in adults  50 YOA, as measured by the 
reduction in HZ risk.
Secondary
 To evaluate VE in the prevention of HZ compared to 
placebo in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and  70 YOA, as 
measured by the reduction in HZ risk;
 To evaluate VE in the prevention of overall PHN 
compared to placebo in subjects  50 YOA and in 
subjects within each of the following age ranges: 50-
59 YOA, 60-69 YOA and  70 YOA;
 To evaluate VE in reducing the total duration of 
severe ‘worst’ HZ-associated pain over the entire 
pain reporting period compared to placebo in 
subjects  50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and 
70 YOA, with confirmed HZ;
 To evaluate VE in the reduction of overall and HZ-
related mortality and hospitalizations compared to 
placebo in subjects  50 YOA and in subjects within 
each of the following age ranges: 50-59 YOA, 60-69 
YOA and  70 YOA;
 To evaluate VE in the reduction in incidence of HZ-
associated complications compared to placebo in 
subjects  50 YOA and in subjects within each of the 
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following age ranges: 50-59 YOA, 60-69 YOA and 
70 YOA, with confirmed HZ;
 To evaluate VE in the reduction in use of pain 
medications compared to placebo in subjects  50 
YOA and in subjects within each of the following 
age ranges: 50-59 YOA, 60-69 YOA and  70 YOA, 
with confirmed HZ;
 To evaluate vaccine safety and reactogenicity.
Exploratory objectives
 To evaluate VE in reducing the severity of acute HZ-
associated pain compared to placebo in subjects  50 
YOA and in subjects within each of the following 
age ranges: 50-59 YOA, 60-69 YOA and  70 YOA, 
with confirmed HZ;
 To evaluate VE in improving Quality of Life (QoL) 
compared to placebo in subjects  50 YOA and in 
subjects within each of the following age ranges: 50-
59 YOA, 60-69 YOA and  70 YOA, with confirmed 
HZ;
 To evaluate VE in the mitigation of Burden-Of-
Illness (BOI) caused by HZ compared to placebo in 
subjects  50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and 
70 YOA;
 To evaluate vaccine induced cell mediated and 
humoral immune responses and the persistence of 
each type of response after two injections of study 
vaccine in subjects  50 YOA, and by age strata;
 To evaluate anti-varicella-zoster virus (VZV) 
neutralizing antibody (Ab) titres in a subset of 
subjects at Month 0 (pre-vaccination), and at Months 
3, 14, 26 and 38, in subjects  50 YOA, and by age 
strata.
Study design  Experimental design: multicentre, parallel group
 Control: placebo (NaCl solution)
 Vaccination schedule: 0, 2 months
 Treatment groups: Treatment groups: 2 groups of 
subjects 
 Vaccine group (gE/AS01B vaccine)
 Placebo group (NaCl solution as control)
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 Study allocation: Eligible subjects 70-79 YOA and 
80 YOA will be randomly assigned to ZOSTER-006 
or ZOSTER-022 at Visit 1.
 Treatment allocation: Eligible subjects will be 
randomized to investigational vaccine/placebo 
according to a 1:1 ratio (vaccine:placebo). Subjects 
will be stratified by age: 50-59 YOA; 60-69 YOA; 
70-79 YOA and  80 YOA in an 8:5:3:1 ratio. The
70-79 YOA and  80 YOA strata will be combined 
for primary analyses.
 Blinding: observer-blind
 Biological samples to be collected:
 Blood samples will be collected from all subjects at 
Visit 1 and 3 to contribute to the correlate of 
protection assessment should the subject experience 
a HZ episode or be selected as a case control. 
 Blood samples will be collected from a subset of 
subjects at Visit 4, 5 and 6 to assess persistence of 
humoral immune response. In these subjects, the 
blood samples from Visit 1 and 3 will also be 
assessed for humoral immune response.
 Blood samples will be collected from a subset of 
subjects at Visit 1, 3, 4, 5 and 6 to assess cell-
mediated immunogenicity (CMI) response.
 Clinical specimens of HZ lesions will be collected 
from subjects clinically diagnosed as having a 
suspected case of HZ.
 Type of study: Self-contained, and will be combined 
with study ZOSTER-022 for some analyses.
 Data collection: Remote Data Entry (RDE) on 
electronic Case Report Form (eCRF).
 Duration of the study: Each subject will be followed 
for at least 30 months after Dose 2. The cut-off date 
for final analysis will occur when both of the 
following conditions are met:
 The prespecified number of confirmed HZ and PHN 
cases in the modified Total Vaccinated cohort 
(mTVc) required for final analyses of both ZOSTER-
006 and ZOSTER-022 are accrued;
 75% of subjects (for both ZOSTER-006 and 
ZOSTER-022) have completed at least 36 months 
follow-up after Dose 2, and the remaining subjects 
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have completed at least 30 months follow-up after 
Dose 2.
All subjects will continue in the study at least until the 
cut-off date for final analysis regardless of their date of 
enrolment. Study end will take place when both 
conditions for final analysis are met and a minimum 90 
days follow-up is completed for each HZ case that occurs 
up to the cut-off date for final analysis.
The exact duration of the study for individual subjects 
will vary. The maximum total study duration for each 
subject is expected to be 4 to 5 years.
If a delay of approximately 6 months or more is predicted 
prior to the simultaneous end dates for the two studies 
based on the rates of accumulation of HZ and PHN cases, 
then the first study that reaches the criteria for final 
analysis  may be continued until the second study reaches 
the criteria for final analysis so that the two studies end 
concurrently.
Number of subjects Target enrolment will be 15,980 eligible subjects (7,990 in the 
vaccine group and 7,990 in the placebo group).
Endpoints Primary
 Confirmed HZ cases.
 Confirmed HZ cases during the study in the mTVc.
Secondary
 Occurrence of overall PHN
 Incidence of PHN calculated using the mTVc;
 Duration of severe ‘worst’ HZ-associated pain
 Duration of severe ‘worst’ HZ-associated pain 
following the onset of a confirmed HZ rash over the 
entire pain reporting period as measured by the 
Zoster Brief Pain Inventory (ZBPI) in subjects with 
confirmed HZ;
 Incidence of overall and HZ-related mortality
 Incidence of overall and HZ-related mortality during 
the study;
 Incidence of HZ complications
 Incidence of HZ complications during the study in 
subjects with confirmed HZ;
 Incidence of overall and HZ-related hospitalizations
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 Incidence of overall and HZ-related hospitalizations 
during the study;
 Duration of pain medication administered for HZ
 Duration of pain medication administered for HZ 
during the study in subjects with confirmed HZ;
 Solicited local and general symptoms in a subset of 
subjects
 Occurrence, intensity of each solicited local symptom 
within 7 days (Days 0-6) after each vaccination, in 
subjects included in the 7-day diary card subset;
 Occurrence, intensity and relationship to vaccination 
of each solicited general symptom within 7 days 
(Days 0-6) after each vaccination, in subjects included 
in the 7-day diary card subset;
 Unsolicited adverse events (AEs) 
 Occurrence, intensity and relationship to vaccination 
of unsolicited AEs during 30 days (Days 0  29) after 
each vaccination, according to the Medical Dictionary 
for Regulatory Activities (MedDRA) classification in 
all subjects;
 Serious Adverse Events (SAEs)
 Occurrence and relationship to vaccination of all 
SAEs from Month 0 to Month 14 in all subjects;
 Occurrence of SAEs related to study participation or 
to a concurrent GSK medication/vaccine during the 
entire study period in all subjects;
 Occurrence of any fatal SAEs during the entire study 
period in all subjects;
 Occurrence of pre-defined AEs
 Occurrence and relationship to vaccination of any 
new onset of autoimmune diseases (NOADs) and 
other immune mediated inflammatory disorders 
during the entire study period in all subjects; 
 Occurrence of medically attended visits
 Occurrence and relationship to vaccination of 
medically attended visits (defined as hospitalizations, 
emergency room visits or visits to or from medical 
personnel), other than routine health care visits, from 
Month 0 to Month 8 in all subjects.
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Exploratory endpoints
 Acute HZ severity
 Acute HZ severity as determined by the mean Area 
Under Curve (AUC) of the severity-by-duration of 
HZ-associated pain as measured by the ZBPI during 
a 4-week period following the onset of confirmed HZ
in subjects with confirmed HZ;
 Interference of HZ with QoL
 Interference of HZ with QoL as measured by ZBPI in 
subjects with confirmed HZ;
 Interference of HZ with QoL as measured by EQ-5D 
in subjects with confirmed HZ;
 Interference of HZ with QoL as measured by SF-36 
in subjects with confirmed HZ;
 HZ BOI
 HZ BOI as determined by the mean AUC of the 
severity-by-duration HZ-associated pain during a 26 
week period following the onset of the HZ rash in the 
mTVc;
 CMI in terms of frequencies of antigen-specific CD4 
T cells at Months 0, 3, 14, 26 and 38
 Frequencies of CD4 T cells with antigen-specific 
Interferon gamma (IFN-) and/or Interleukin-2 (IL-2) 
and/or Tumour Necrosis Factor alpha (TNF-) 
and/or CD40 Ligand (CD40L) secretion/expression 
to glycoprotein E (gE) and VZV as determined by 
intracellular cytokine staining (ICS) in a subset of 
subjects at Months 0, 3, 14, 26 and 38;
 Antigen-specific Ab concentrations at Months 0, 3, 
14, 26 and 38.
 Anti-gE and anti-VZV Ab concentrations as 
determined by Enzyme-linked Immunosorbent Assay 
(ELISA), in a subset of subjects at Months 0, 3, 14, 
26 and 38;
 Anti-VZV neutralizing Ab titres at Months 0, 3, 14, 
26 and 38
 Anti-VZV neutralizing Ab titres as determined by the 
neutralization assay in a subset of subjects at Months 
0, 3, 14, 26 and 38.
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GLOSSARY OF TERMS
Adequate contraception: Adequate contraception is defined as a contraceptive 
method with failure rate of less than 1% per year when 
used consistently and correctly (when applicable, as 
mentioned in the product label) for example abstinence, 
combined or progestogen oral contraceptives, injectable 
progestogen, implants of levonorgestrel, oestrogenic 
vaginal ring, percutaneous contraceptive patches or 
intrauterine device (IUD) or intrauterine system (IUS), 
vasectomy with documented azoospermia of the sole 
male partner or male condom combined with a vaginal 
spermicide (foam, gel, film, cream or suppository) or 
male condom combined with a female diaphragm, either 
with or without a vaginal spermicide (foam, gel, film, 
cream, or suppository). 
For azoospermia, ‘documented’ refers to the laboratory 
report of azoospermia, required for acceptable 
documentation of successful vasectomy in the subject’s 
male partner.
Adverse event: Any untoward medical occurrence in a patient or clinical 
investigation subject, temporally associated with the use 
of a medicinal product, whether or not considered related 
to the medicinal product. 
An AE can therefore be any unfavourable and unintended 
sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally 
associated with the use of a medicinal product. For 
marketed medicinal products, this also includes failure to 
produce expected benefits (i.e. lack of efficacy), abuse or 
misuse.
Blinding: A procedure in which one or more parties to the trial are 
kept unaware of the treatment assignment in order to 
reduce the risk of biased study outcomes. The level of 
blinding is maintained throughout the conduct of the trial, 
and only when the data are cleaned to an acceptable level 
of quality will appropriate personnel be unblinded or 
when required in case of a serious adverse event. In an 
observer-blind study, the subject and the site and sponsor 
personnel involved in the clinical evaluation of the 
subjects are blinded while other study personnel may be 
aware of the treatment allocation (see Section 5.4 for 
details on observer-blinded studies).
Burden-of-illness score: The HZ “Burden-Of-Illness (BOI) score” represents the 
average severity of illness among all subjects in the 
vaccine or placebo groups. It is calculated according to 
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the “modified” scale described by Coplan [Coplan, 2004] 
as the sum of the HZ “severity-of-illness” scores of all 
members of the treatment group divided by the total 
number of subjects in the group.
Eligible: Qualified for enrolment into the study based upon strict 
adherence to inclusion/exclusion criteria.
eTrack: GSK’s tracking tool for clinical trials.
Evaluable: Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, 
included in the according-to-protocol (ATP) analysis (see 
Sections 6.6.1 and 10.5 for details on criteria for 
evaluability).
Investigational 
vaccine/product:
(Synonym of 
Investigational Medicinal 
Product)
A pharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, 
including a product with a marketing authorisation when 
used in a way different from the approved form, or when 
used for an unapproved indication, or when used to gain 
further information about an approved use. 
A NaCl solution, also referred to as saline is used as 
placebo in this study.
Menopause: Menopause is the age associated with complete cessation 
of menstrual cycles, menses, and implies the loss of 
reproductive potential by ovarian failure. A practical 
definition accepts menopause after 1 year without menses 
with an appropriate clinical profile at the appropriate age 
e.g. > 45 years.
Protocol amendment: ICH defines a protocol amendment as: ‘A written 
description of a change(s) to or formal clarification of a 
protocol.’ GSK Biologicals further details this to include 
a change to an approved protocol that affects the safety of 
subjects, scope of the investigation, study design, or 
scientific integrity of the study.
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Protocol administrative 
change:
A protocol administrative change addresses changes to 
only logistical or administrative aspects of the study. 
NB Any change that falls under the definition of a 
protocol amendment (e.g. a change that affects the safety 
of subjects, scope of the investigation, study design, or 
scientific integrity of the study) MUST be prepared as an 
amendment to the protocol. 
Quality of Life Quality of Life is measured, using three questionnaires 
(ZBPI, EQ-5D and SF-36) to be completed by the subject. 
ZBPI specifically assesses HZ-associated pain and 
discomfort during an HZ episode. EQ-5D and SF-36 
provide multi-dimensional evaluation of the health status.
Randomisation: Process of random attribution of treatment to subjects in 
order to reduce bias of selection.
Site Monitor: An individual assigned by the sponsor who is responsible 
for assuring proper conduct of clinical studies at one or 
more investigational sites.
Solicited adverse event: Adverse events (AEs) to be recorded as endpoints in the 
clinical study. The presence/occurrence/intensity of these 
events is actively solicited from the subject or an observer 
during a specified post-vaccination follow-up period.
Study determination 
number:
A unique number that assigns subjects aged 70 years and 
older to either study ZOSTER-006 or ZOSTER-022.
Subject: Term used throughout the protocol to denote an 
individual who has been contacted in order to participate 
or participates in the clinical study, either as a recipient of 
the product(s) or as a control.
Subject number: A unique number identifying a subject, assigned to each 
subject consenting to participate in the study.
Treatment: Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject, 
identified by a unique number, according to the study 
randomisation or treatment allocation.
Treatment number: A number identifying a treatment to a subject, according 
to the study randomisation or treatment allocation.
Unsolicited adverse 
event:
Any adverse event (AE) reported in addition to those 
solicited during the clinical study. Also any ‘solicited’ 
symptom with onset outside the specified period of 
follow-up for solicited symptoms will be reported as an 
unsolicited adverse event.
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TRADEMARKS
The following trademarks are used in the present protocol.
Note: In the body of the Protocol (including the synopsis), the names of the 
vaccines/products and/or medications will be written in italic font and without the 
subscript symbol ™ or ®.
Trademarks of the GlaxoSmithKline 
group of companies
Generic description
VarilrixTM Varicella vaccine consisting of live 
attenuated Varicella-zoster virus (Oka 
strain)
Trademarks not owned by the 
GlaxoSmithKline group of companies
Generic descriptions
Varivax® (Merck & Co) Varicella vaccine consisting of live 
attenuated varicella-zoster virus (Oka strain)
Zostavax® (Merck & Co ) Herpes zoster vaccine consisting of high-
titre live attenuated Varicella-zoster virus 
(Oka strain)
Enzygnost® (Dade Behring) ELISA kit
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1. INTRODUCTION
1.1. Background
Varicella-zoster Virus (VZV) causes two distinct diseases. Varicella (chickenpox) shortly 
occurs after primary VZV infection and is characterised by systemic illness and a widely 
disseminated rash. Herpes zoster (shingles) occurs when VZV reactivates from latency 
and typically manifests as a localised, dermatomal rash.
The typical herpes zoster (HZ) rash usually lasts 2 to 4 weeks and is usually accompanied 
by pain that is often described as burning, shooting, or stabbing. In some patients, even 
touching the affected area lightly may cause pain, a phenomenon known as allodynia.
This HZ-associated pain may be severe, and pruritus, which can also be severe, may be as 
common as pain. 
The most common complication of HZ is postherpetic neuralgia (PHN). PHN is defined 
as pain that persists after the resolution of the HZ rash. Affected patients typically report 
constant burning, throbbing, intermittent sharp or electric shock-like pain, or allodynia. 
Older age is a clear risk factor for PHN. Other risk factors may include a severe HZ rash 
and a painful HZ prodrome. PHN tends to improve over a period of months. About 70-
80% of cases resolve within 1 year, however, in some persons PHN persists for many 
years [Dworkin, 2007].
Other complications of HZ include ophthalmologic, neurological, cutaneous and visceral 
disease, which can result in severe disability. The most common ocular complications of 
HZ are keratitis and uveitis; other ophthalmologic complications include ptosis, 
episcleritis/scleritis, retinitis, secondary glaucoma and cataract [Schmader, 2008; Carter, 
2008]. Neurologic complications associated with HZ include myelitis, motor neuropathy, 
ischaemic infarction of the brain and spinal cord, aneurysm, and subarachnoid and 
cerebral haemorrhage [Gilden, 2009; Schmader, 2008].
Age is the most common risk factor for developing HZ. The incidence of HZ is relatively 
constant at 2-3 cases per 1000 persons per year until age 40, and then increases 
progressively with age: At 50-59 years of age (YOA) the incidence is about 5 cases per 
1000 persons per year, and it increases to 10 cases per 1000 persons per year in people ≥ 
60 YOA [CDC, 2008; Oxman, 2005]. While most HZ incidence data come from the 
United States (US) and Europe, available data indicate similar incidences of HZ in other 
parts of the world including Japan, Korea, Australia and Latin America [Araújo, 2007; 
Garcia Cenoz, 2008; Kang, 2008; Toyama, 2009].
Half of all HZ cases occur in patients over the age of 60, and individuals who reach 85 
years old have a 50% chance of having HZ during their lifetime [Oxman, 2005]. The risk 
for PHN is also highest in older people with HZ, occurring in 18-50% of those aged 70 
years and older [Oxman, 2005; Scott, 2006]. Patients with impaired cell-mediated 
immunity (CMI) due to disease, drug treatment, medical interventions or advanced age 
are at increased risk for the development of HZ [Cohen, 2007]. Since the loss of VZV-
specific T cell responses as a result of aging or immunosuppression leads to heightened 
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susceptibility to HZ, vaccination is considered as a means to reduce the risk of HZ in 
older adults and immunocompromised persons [Oxman, 2005; Sperber, 1992].
The potential of vaccination to protect against HZ was evaluated in a large efficacy study 
in which Zostavax (a live attenuated HZ vaccine that is a high titre preparation of the 
varicella vaccine, Varivax [both manufactured by Merck & Co]) partially protected 
immunocompetent older adults against HZ [Oxman, 2005]. In the overall population (≥ 
60 YOA), Zostavax reduced the incidence of HZ by 51.3% (p-value < 0.001), although its 
effectiveness decreased with the age of the vaccinee. In particular, vaccine efficacy (VE)
diminished to 37.6% among persons in older age groups ( 70 years of age) [Oxman, 
2005]. Based on the data from this study, Zostavax was licensed in the US and other 
countries. In the US, Zostavax is indicated for prevention of HZ in individuals ≥ 60 YOA 
and older [CDC, 2008]. In Australia, Zostavax is indicated for the prevention of HZ, PHN 
and for reduction of acute and chronic HZ-associated pain in individuals ≥ 60 YOA, and 
for the prevention of HZ in individuals 50-59 YOA [TGA, 2009]. In Europe, Zostavax is 
indicated for prevention of HZ and PHN in individuals ≥ 50 YOA [EMEA, 2009]. 
Zostavax is contraindicated in persons with immunodeficiency due to malignancy, human 
immunodeficiency virus (HIV) infection or immunosuppressive medical therapy.
Although no immunological correlate for protection against HZ has been identified, 
current knowledge suggests that VZV-specific CMI is of primary importance in 
preventing HZ [CDC, 2008]. The role of humoral immune responses in preventing HZ is 
less clear. However, VZV-specific antibodies (Abs) may help control viral dissemination 
in immunocompromised persons and may thereby help limiting the severity of HZ. 
Furthermore, a correlation between post-vaccination anti-VZV Ab concentrations and 
protection against HZ was observed in the Zostavax efficacy study [Levin, 2008]. While 
VZV-specific Abs may not be directly protective against HZ, they may represent a 
“downstream” measure of the CMI response to vaccination.
GlaxoSmithKline (GSK) Biologicals is developing a candidate HZ vaccine consisting of 
VZV glycoprotein E (gE) and an adjuvant. The VZV gE was chosen as the subunit 
vaccine antigen because of both its prominence as a target for host immune responses 
[Cohen, 2007] and its functional significance during viral infection. Since the vaccine 
does not contain live virus, it is expected that this vaccine will prove safe in all 
populations including highly immunocompromised persons. Adjuvant System AS01B
used in combination with the gE antigen was developed at GSK Biologicals, and contains 
the immunostimulants MPL (3-O-desacyl-4’-monophosphoryl lipid A) and QS21 
(Quillaja saponaria Molina, fraction 21; Antigenics, New York, NY, US) formulated in 
combination with liposomes. MPL is a chemically detoxified form of the parent 
lipopolysaccharide from the gram negative bacterium Salmonella minnesota. QS21 is a 
natural saponin molecule (triterpene glycoside) obtained from the tree bark of Quillaja 
saponaria Molina.
Three recently completed trials in healthy older adults have provided clinical evidence for 
the immunogenicity and tolerability of GSK Biologicals’ candidate HZ vaccine, 
gE/AS01B. 
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 In a phase I/II exploratory trial (Explo CRD-004), 155 subjects received two 
doses of either gE/AS01B, gE/AS01B and Varilrix (a live attenuated varicella 
vaccine similar to Zostavax), or Varilrix alone. Of the 110 subjects who received 
gE/AS01B, 90 were 50-70 YOA (the other 20 subjects were 18-30 YOA). 
Subjects in the gE/AS01B groups developed significantly higher CD4 T cell
responses to gE and VZV than those in the Varilrix alone group. Immune 
responses persisted up to 40 months after administration of the second 
vaccination in older adults receiving gE/AS01B alone (the latest timepoint 
evaluated). Reactogenicity was higher in the gE/AS01B groups than in the group 
that received Varilrix alone; however, the incidences of grade 3 local and 
general symptoms were low. Based on the results of this study, gE/AS01B, 
without Varilrix, was selected for further clinical evaluation.
 In a phase II dose finding trial (ZOSTER-003), gE/AS01B was administered to 
714 adults ≥ 60 YOA. Subjects received either 2 doses of either 25 µg, 50 µg or 
100 µg gE adjuvanted with AS01B, one dose of 100 µg gE adjuvanted with 
AS01B and one of NaCl solution [Saline], or 2 doses of 100 µg gE/Saline (no 
adjuvant). Subjects in all gE/AS01B dose groups (660 total) developed 
significantly higher CD4 T cell and humoral immune responses to gE than did 
those who received unadjuvanted gE. Also, 2 vaccinations with any of the 
gE/AS01B vaccine formulations elicited higher immunological responses than a 
single dose. Comparison between the 25 µg, 50 µg and 100 µg gE/AS01B
vaccine formulations administered in a 2 dose schedule demonstrated that 
humoral immune responses to 50 g gE/AS01B were significantly greater than 
those induced by 25 g gE/AS01B, whereas 100 g gE/AS01B was not superior 
to 50 g gE/AS01B. In addition, cellular immune responses to gE/AS01B
vaccines exhibited slight dose dependence in favour of higher gE doses. 
Reactogenicity was similar for 25 g, 50 g, and 100 g gE/AS01B
formulations, but greater than that induced by 100 g gE/Saline. Overall, 
vaccine safety and tolerability were acceptable in all gE/AS01B vaccine groups. 
Based on these data, the antigen dose of 50 g gE combined with AS01B and 
administered as two doses was selected for use in future trials.
 In a phase II adjuvant dose comparison trial (ZOSTER-010), 410 adults 
≥ 50 YOA received two doses of 50 g gE adjuvanted with AS01B, AS01E (½ 
dose of AS01B) or no adjuvant (gE/Saline), or saline alone, administered on a 2-
dose schedule at months 0 and 2. The objective of this study was to compare the 
immunogenicity and safety of gE/AS01B and gE/AS01E groups. Analysis of data 
obtained up to Month 3 (one month after dose 2) is currently available; an 
extended safety follow-up is ongoing. Subjects in the gE/AS01B group had 30% 
superior cellular immune responses and 40% superior antigen-specific humoral 
immune responses compared to the gE/AS01E group, which were both 
statistically significant differences. Local and general reactogenicity were 
common in both the gE/AS01B and gE/AS01E groups; however, approximately 
11% more doses of gE/AS01B were associated with local or general 
reactogenicity than gE/AS01E doses. The overall incidence of grade 3 local and 
general reactions was low for both vaccines, and similar between the gE/AS01B 
and gE/AS01E groups. No related serious adverse events (SAEs) were reported 
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in either the gE/AS01B or gE/AS01E groups. Based on these results, AS01B was 
chosen for the final vaccine formulation, in combination with 50 g gE, to be 
used in future studies.
Please refer to the current Investigator Brochure (IB) for a review of the pre-clinical and 
clinical studies, and the potential risks and benefits of GSK Biologicals’ candidate HZ 
vaccine.
1.2. Rationale for the study and study design
Two studies (ZOSTER-006 enrolling subjects  50 YOA and ZOSTER-022 enrolling 
subjects  70 YOA) will be conducted concurrently to evaluate efficacy of GSK 
Biologicals’ gE/AS01B vaccine.
Study ZOSTER-006 will provide pivotal data on the overall HZ VE. The primary 
endpoint of this study will be overall HZ VE across all age cohorts. To this end, 
ZOSTER-006 will evaluate VE of the gE/AS01B vaccine compared to placebo in 
reducing the risk of developing HZ in subjects  50 YOA. This study will enrol subjects 
in the age ranges 50-59 YOA, 60-69 YOA, 70-79 YOA and  80 YOA in an 8:5:3:1 ratio 
to achieve comparable numbers of HZ cases in the 3 main age strata (50-59 YOA, 60-69 
YOA and  70 YOA; the 70-79 YOA and  80 YOA strata will be combined for primary 
analyses) so that a balanced estimate of the overall VE in persons  50 YOA can be 
determined. Apportionment of 25% of the  70 YOA cohort to persons  80 YOA 
ensures that this particularly vulnerable population is adequately represented.
Assessment of PHN VE would require a large sample size of subjects ≥ 70 YOA due to a 
relatively lower incidence of PHN in younger adults. This cannot be achieved in 
ZOSTER-006 without impacting the intent of the study, since a large overrepresentation 
of subjects ≥ 70 YOA in the ZOSTER-006 study would not allow an accurate assessment 
of HZ VE across the entire  50 YOA age range enrolled in the trial and may potentially 
underestimate overall efficacy of the gE/AS01B vaccine, since HZ VE may diminish with 
age. Study ZOSTER-022 will address VE against PHN in subjects  70 YOA, in addition 
to providing a robust estimate of HZ VE in that age stratum. After each study (ZOSTER-
006 and ZOSTER-022) is analyzed separately, a pooled analysis of HZ and PHN data 
from both studies combined is planned and will be described prospectively. Detailed 
information regarding study ZOSTER-022 and the pooled analysis of data of both studies 
combined will be included in the protocol of study ZOSTER-022.
A saline solution is included as a negative control (placebo) in this study and provides an 
objective baseline for the evaluation of the efficacy and safety profile of the candidate HZ 
vaccine. Use of the placebo control and the observer-blind, randomized study design, will 
allow to control for potential biases in the conduct of the study.
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2. OBJECTIVES
2.1. Primary objective
 To evaluate VE in the prevention of HZ compared to placebo in adults  50 
YOA, as measured by the reduction in HZ risk.
Refer to Section 10.1 for the definition of the primary endpoint.
2.2. Secondary objectives
 To evaluate VE in the prevention of HZ compared to placebo in subjects within 
each of the following age ranges: 50-59 YOA, 60-69 YOA and  70 YOA, as 
measured by the reduction in HZ risk;
 To evaluate VE in the prevention of overall PHN compared to placebo in 
subjects  50 YOA and in subjects within each of the following age ranges: 50-
59 YOA, 60-69 YOA and  70 YOA;
 To evaluate VE in reducing the total duration of severe ‘worst’ HZ-associated 
pain over the entire pain reporting period compared to placebo in subjects  50 
YOA and in subjects within each of the following age ranges: 50-59 YOA, 60-
69 YOA and  70 YOA, with confirmed HZ;
 To evaluate VE in the reduction of overall and HZ-related mortality and 
hospitalizations compared to placebo in subjects  50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 YOA and  70 
YOA;
 To evaluate VE in the reduction in incidence of HZ-associated complications 
compared to placebo in subjects  50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and  70 YOA, with confirmed 
HZ;
 To evaluate VE in the reduction in use of pain medications compared to placebo 
in subjects  50 YOA and in subjects within each of the following age ranges: 
50-59 YOA, 60-69 YOA and  70 YOA, with confirmed HZ;
 To evaluate vaccine safety and reactogenicity.
Refer to Section 10.2 for the definition of the secondary endpoints.
2.3. Exploratory objectives
 To evaluate VE in reducing the severity of acute HZ-associated pain compared 
to placebo in subjects  50 YOA and in subjects within each of the following 
age ranges: 50-59 YOA, 60-69 YOA and  70 YOA, with confirmed HZ;
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 To evaluate VE in improving Quality of Life (QoL) compared to placebo in 
subjects  50 YOA and in subjects within each of the following age ranges: 50-
59 YOA, 60-69 YOA and  70 YOA, with confirmed HZ;
 To evaluate VE in the mitigation of Burden-Of-Illness (BOI) caused by HZ 
compared to placebo in subjects  50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and  70 YOA;
 To evaluate vaccine induced cell mediated and humoral immune responses and 
the persistence of each type of response after two injections of study vaccine in 
subjects  50 YOA, and by age strata;
 To evaluate anti-VZV neutralizing Ab titres in a subset of subjects at Month 0 
(pre-vaccination), and at Months 3, 14, 26 and 38, in subjects  50 YOA, and by 
age strata.
Refer to Section 10.3 for the definition of the exploratory endpoints.
3. STUDY DESIGN OVERVIEW
* Blood samples will be collected from all subjects at Visit 1 and Visit 3, and from subsets of subjects additionally at the 
other visits to assess immune responses.
‡ If the conditions for final analysis and study end are met before Visit 6 is completed by all subjects and it is decided 
to conclude the study, Visit 6 may not take place in some subjects.
Note: In case of suspected HZ, the subject will have additional visits and contacts for follow-up of HZ (see Table 3).
 Experimental design: multicentre, parallel group
 Control: placebo (NaCl solution)
 
 ( - )
i l
14f52be5fd11c61d592d2b59e6184d3d
CONFIDENTIAL
110390 (ZOSTER-006)
Final
07-APR-2010 33
 Vaccination schedule: 0, 2 months
 Treatment groups: Treatment groups: 2 groups of subjects 
 Vaccine group (gE/AS01B vaccine)
 Placebo group (NaCl solution as control)
 Study allocation: Eligible subjects 70-79 YOA and  80 YOA will be randomly 
assigned to ZOSTER-006 or ZOSTER-022 at Visit 1.
 Treatment allocation: Eligible subjects will be randomized to investigational 
vaccine/placebo according to a 1:1 ratio (vaccine:placebo). Subjects will be 
stratified by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and  80 YOA in an 
8:5:3:1 ratio. The 70-79 YOA and  80 YOA strata will be combined for 
primary analyses.
 Blinding: observer-blind
 Biological samples to be collected:
 Blood samples will be collected from all subjects at Visit 1 and 3 to contribute 
to the correlate of protection assessment should the subject experience a HZ 
episode or be selected as a case control.
 Blood samples will be collected from a subset of subjects at Visit 4, 5 and 6 to 
assess persistence of humoral immune response. In these subjects, the blood 
samples from Visit 1 and 3 will also be assessed for humoral immune response.
 Blood samples will be collected from a subset of subjects at Visit 1, 3, 4, 5 and 6 
to assess CMI response.
 Clinical specimens of HZ lesions will be collected from subjects clinically 
diagnosed as having a suspected case of HZ.
 Type of study: Self-contained, and will be combined with study ZOSTER-022 
for some analyses.
 Data collection: Remote Data Entry (RDE) on electronic Case Report Form 
(eCRF).
 Duration of the study: Each subject will be followed for at least 30 months after 
Dose 2. The cut-off date for final analysis will occur when both of the following 
conditions are met:
 The prespecified number of confirmed HZ and PHN cases in modified Total 
Vaccinated cohort (mTVc) required for final analyses of both ZOSTER-006 and 
ZOSTER-022 are accrued;
 75% of subjects (for both ZOSTER-006 and ZOSTER-022) have completed at 
least 36 months follow-up after Dose 2, and the remaining subjects have 
completed at least 30 months follow-up after Dose 2.
All subjects will continue in the study at least until the cut-off date for final analysis 
regardless of their date of enrolment. Study end will take place when both conditions 
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for final analysis are met and a minimum 90 days follow-up is completed for each 
HZ case that occurs up to the cut-off date for final analysis.
The exact duration of the study for individual subjects will vary. The maximum total 
study duration for each subject is expected to be 4 to 5 years.
If a delay of approximately 6 months or more is predicted prior to the simultaneous 
end dates for the two studies based on the rates of accumulation of HZ and PHN 
cases, then the first study that reaches the criteria for final analysis may be continued 
until the second study reaches the criteria for final analysis so that the two studies 
end concurrently.
4. STUDY COHORT
4.1. Number of subjects/centres
Study ZOSTER-006 will be an international multicentre trial. 
Target enrolment is approximately 16,000 eligible subjects using a 1:1 randomization 
ratio (vaccine:placebo).
Refer to Section 10.4 for a detailed description of the criteria used in the estimation of 
sample size.
The following subsets of subjects will be included in this study (see Table 1). Details 
regarding the number of subjects included in each of the subsets are described in Sections 
10.4.5.5 and 10.4.5.6. The randomization of subjects to subsets is described in Section
5.3.4.
Table 1 Subsets in study ZOSTER-006
Subset name Description
7-day diary card Diary card completion for recording of solicited adverse events (AEs) (from Day 
0 to Day 6 after each vaccination) 
Immunogenicity Blood samples (approximately 10 mL) collected at Visit 1, 3, 4, 5 and 6 will be 
analyzed to assess humoral immune response
CMI Blood samples (approximately 20 mL) collected at Visit 1, 3, 4, 5 and 6 will be 
analyzed to assess CMI response
Note: Blood samples (approximately 10 mL) will be collected from all subjects at Visits 1 and 3, and will be used to 
assess correlate of protection.
Overview of the recruitment plan
Study ZOSTER-006 is planned to be conducted at sites in multiple countries in North 
America, Europe, Latin America and Australasia.
The recruitment rate will be monitored using a study specific central randomization 
system on internet (SBIR). Prior to randomization within each study, a SBIR distribution 
application will be used to assign subjects 70-79 YOA and  80 YOA to either ZOSTER-
006 or ZOSTER-022. 
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Transfer of supplies will be tracked by the central randomization system. Monitoring 
visits frequency will be adapted to the pace of enrolment. Enrolment is estimated to last 
for approximately 12 months.
Vaccine doses will be distributed to each study site respecting the randomization block 
size. In addition, SBIR will account for the number of subjects in each age stratum
(Section 5.3.3.2).
In case any countries would fall behind in subject recruitment (in a specific age group or 
overall), a redistribution of the enrolment target per country may be made to allow other 
participating countries to enrol additional subjects in an effort to ensure full and timely 
enrolment of the overall targeted number of subjects specified in this protocol.
4.2. Inclusion criteria for enrolment
All subjects must satisfy ALL the following criteria at study entry:
 Subjects who the investigator believes will comply with the requirements of the 
protocol (e.g. completion of the diary cards/questionnaires, return for follow-up 
visits, have regular contact to allow evaluation during the study); 
 Written informed consent obtained from the subject;
 A male or female aged 50 years or older at the time of the first vaccination;
 Female subjects of non-childbearing potential may be enrolled in the study;
For this study population, non-childbearing potential is defined as current tubal 
ligation, hysterectomy, ovariectomy or post-menopause.
Please refer to the Glossary of Terms for the definition of menopause.
OR 
Female subjects of childbearing potential may be enrolled in the study, if the subject 
has practiced adequate contraception for 30 days prior to vaccination, and has a 
negative urine pregnancy test on the day of vaccination, and has agreed to continue 
adequate contraception during the entire treatment period and for 2 months after 
completion of the vaccination series; 
Please refer to the Glossary of Terms for the definition of adequate contraception
4.3. Exclusion criteria for enrolment
The following criteria should be checked at the time of study entry. If ANY exclusion 
criterion applies, the subject must not be included in the study:
 Use of any investigational or non-registered product (drug or vaccine) other than 
the study vaccine within 30 days preceding the first dose of study vaccine, or 
planned use during the study period;
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 Concurrently participating in another clinical study, at any time during the study 
period, in which the subject has been or will be exposed to an investigational or 
a non-investigational product (pharmaceutical product or device);
 Any confirmed or suspected immunosuppressive or immunodeficient condition 
resulting from disease (e.g., malignancy, HIV infection) or 
immunosuppressive/cytotoxic therapy (e.g., medications used during cancer 
chemotherapy, organ transplantation or to treat autoimmune disorders);
 History of HZ;
 Previous vaccination against varicella or HZ (either registered product or 
participation in a previous vaccine study, and including previous vaccination 
with childhood varicella vaccine); 
 History of allergic disease or reactions likely to be exacerbated by any 
component of the vaccine. Additionally, consider allergic reactions to other 
material or equipment related to study participation (such as materials that may 
possibly contain latex -gloves, syringes, etc). Please note, the vaccine and vials 
in this study do not contain latex;
 Significant underlying illness that in the opinion of the investigator would be 
expected to prevent completion of the study (e.g., life-threatening disease likely 
to limit survival to less than 4 years);
 Receipt of immunoglobulins and/or any blood products within the 90 days 
preceding the first dose of study vaccine or planned administration during the 
study period;
 Administration or planned administration of any other immunizations within 30 
days before the first or second study vaccination or scheduled within 30 days 
after study vaccination. However, licensed non-replicating vaccines (i.e., 
inactivated and subunit vaccines, including inactivated and subunit influenza 
vaccines, with or without adjuvant for seasonal or pandemic flu) may be 
administered up to 8 days prior to each dose and/or at least 14 days after any 
dose of study vaccine;
 Any other condition (e.g., extensive psoriasis, chronic pain syndrome, cognitive 
impairment, severe hearing loss) that, in the opinion of the investigator, might 
interfere with the evaluations required by the study;
 Acute disease and/or fever at the time of enrolment; 
 Fever is defined as temperature ≥ 37.5°C (99.5°F) on oral, axillary or tympanic 
setting, or  38.0°C (100.4°F) on rectal setting. The preferred route for recording 
temperature in this study will be oral.
 Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory 
infection) without fever may, be enrolled at the discretion of the investigator. 
 Chronic administration (defined as > consecutive 15 days) of 
immunosuppressants or other immune-modifying drugs within six months prior 
to the first vaccine dose. For corticosteroids, this will mean prednisone < 
20 mg/day, or equivalent, is allowed. Inhaled and topical steroids are allowed.
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 Pregnant or lactating female;
 Female planning to become pregnant or planning to discontinue contraceptive 
precautions (if of childbearing potential);
A list of criteria that will eliminate subjects from According To Protocol (ATP) analyses 
can be found in Section 6.6.1, Section 6.7 and Section 10.5.
5. CONDUCT OF THE STUDY
5.1. Regulatory and ethical considerations, including the 
informed consent process
The study will be conducted in accordance with all applicable regulatory requirements.
The study will also be conducted in accordance with the International conference on 
harmonisation (ICH) Guideline for Good Clinical Practice (GCP), all applicable subject 
privacy requirements and the guiding principles of the Declaration of Helsinki. 
GSK will obtain favourable opinion/approval to conduct the study from the appropriate 
regulatory agency, in accordance with applicable regulatory requirements, prior to a site 
initiating the study in that country.
Conduct of the study includes, but is not limited to, the following:
 Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review 
and favourable opinion/approval of study protocol and any subsequent 
amendments.
 Subject informed consent.
 Investigator reporting requirements as stated in the protocol.
GSK will provide full details of the above procedures to the investigator, either verbally, 
in writing, or both.
Freely given and written (or witnessed thumb printed consent in case of an illiterate 
subject) informed consent must be obtained from each subject prior to participation in the 
study.
GSK Biologicals will prepare a model ICF which will embody the ICH GCP and GSK 
Biologicals required elements. While it is strongly recommended that this model ICF is to 
be followed as closely as possible, the informed consent requirements given in this 
document are not intended to pre-empt any local regulations which require additional 
information to be disclosed for informed consent to be legally effective. Clinical 
judgement, local regulations and requirements should guide the final structure and 
content of the local version of the ICF.
The investigator has the final responsibility for the final presentation of the ICF, 
respecting the mandatory requirements of local regulations. The ICF generated by the 
investigator with the assistance of the sponsor’s representative must be acceptable to 
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GSK Biologicals and be approved (along with the protocol, and any other necessary 
documentation) by the IRB/IEC.
5.2. Study Determination (Recruitment/Randomisation)
Agreement
Eligible subjects 70-79 YOA and  80 YOA will be randomly assigned to ZOSTER-006 
or ZOSTER-022 at Visit 1. Prior to study assignment, these subjects must sign a Study 
Determination (Recruitment/Randomisation) Agreement (SDRRA). The signing of the 
SDRRA is not a consent or confirmation of the subject’s participation in either study. The 
SDRRA allows the sponsor/study staff to collect limited personal information about a 
subject who has been contacted to participate in a clinical study. By signing the SDRRA,
the subject enables the study staff to input age information into the SBIR system. The 
SBIR system will review current enrolment in the two age strata in both ZOSTER-006 
and ZOSTER-022 and determine the study assignment for the subject. The subject will 
then be provided with the study specific informed consent to review and determine if they 
wish to participate in the assigned study. The first study related activity/procedure other 
than the study determination randomisation procedure may only be carried out after the 
subject has confirmed willingness to participate in the assigned study and signed an
informed consent form.
5.3. Subject identification and randomization of treatment
All subjects 50-69 YOA will be randomized to vaccine or placebo in ZOSTER-006. 
Subjects 70-79 YOA and  80 YOA will be randomized to either ZOSTER-006 or 
ZOSTER-022, and then randomized to vaccine or placebo. This procedure ensures the 
compatibility of the  70 YOA subjects between the two studies and facilitates the pooled 
evaluation of both studies for HZ and PHN episodes. All subjects in ZOSTER-006 will 
be randomly assigned to two treatment groups in a 1: 1 ratio.
5.3.1. Study identification
ZOSTER-006 and ZOSTER-022 are similar studies, differing essentially in the age strata 
recruited. A SBIR study determination application will use a study determination number 
to assign subjects 70-79 YOA and  80 YOA to either ZOSTER-006 or ZOSTER-022.
Subjects 50-69 YOA can only be assigned to ZOSTER-006.
5.3.2. Subject identification
Subject numbers will be assigned sequentially to subjects consenting to participate in the 
study, according to the range of subject numbers allocated to each study centre.
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5.3.3. Randomization of treatment
5.3.3.1. Randomization of supplies
The randomisation will be performed at GSK Biologicals, Belgium, using MATEX, a 
program developed for use in SAS® (Cary, NC, US) by GSK Biologicals. 
To allow GSK Biologicals to take advantage of greater rates of recruitment than 
anticipated at individual centres in this multicentre study, and to thus reduce the overall 
study recruitment period, an over-randomization of supplies will be prepared.
The vaccine doses will be distributed to each study centre, respecting the randomization 
block size.
5.3.3.2. Treatment allocation to the subject
The treatment allocation at the investigator site will be performed using a central 
randomization system on the internet (SBIR). The treatment numbers will be allocated by 
kit. Within ZOSTER-006, the randomization algorithm will use stratification (preventing 
further randomization when a stratum is complete) and weighted minimization techniques 
for each parameter, below:
 By region: Stratification
 By age cohort within each region: Stratification 
 By country within each region: Minimization 
 By site within each country: Minimization 
Note that as soon as the target number of subjects in a specific stratification group has 
been reached the recruitment will be frozen for that age group.
When SBIR is not available, please refer to SBIR user guide or Study Procedures Manual 
(SPM) for specific instructions.
After having checked the eligibility of the subject and obtaining the signed ICF, the site 
staff in charge of the vaccination will access SBIR. 
Upon providing the subject identification number, the randomization system will use 
stratification and minimization algorithms to determine the treatment number to be used 
for the subject. The treatment number must be recorded in the eCRF on the Vaccine 
Administration screen (Randomization/Treatment Allocation Section).
5.3.4. Randomization of subjects to assay subsets 
Subjects from 50-59 YOA and 60-69 YOA strata will be randomly allocated to be part of 
the 7-day diary card subset (note: all subjects from  70 YOA strata will be included in 
the 7-day diary card subset) according to criteria defined in Section 10.4.5.5. Subjects 
will be randomly allocated to be part of the Immunogenicity subset according to criteria 
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defined in Section 10.4.5.6. For operational reasons, the same subjects may be 
randomized to the various subsets. 
The CMI analyses will be performed in the randomly selected Immunogenicity subset in 
three countries (Czech Republic, Japan and United States) at designated sites that have 
access to a Peripheral Blood Mononuclear Cells (PBMC) processing facility within the 
acceptable time window from sample collection to PBMC processing.
5.4. Method of blinding 
Because the reconstituted gE/AS01B study vaccine differs in appearance from the NaCl 
solution placebo, the study will be conducted in an observer-blind manner.
Data will be collected in an observer-blind manner. By observer-blind, it is meant that 
during the course of the study, the vaccine/placebo recipient and those responsible for the 
evaluation of any study endpoint (e.g., safety, reactogenicity, and efficacy) will all be 
unaware of which vaccine/placebo was administered. To do so, vaccine/placebo 
preparation and administration will be done by authorised medical personnel who will not 
participate in the clinical evaluation of the subjects. Immunological data, which could 
lead to the unblinding of the treatment groups, will not be available during the course of 
the trial to any investigator or any person involved in the clinical conduct of the study 
(including data cleaning), until after the database is locked. Immunological data may 
however be available to the Statistical Data Analysis Centre (SDAC) and Independent 
Data Monitoring Committee (IDMC) in order to answer potential questions related to 
safety, efficacy or presence of correlate of protection during the interim analysis.
The laboratory in charge of the laboratory testing will be blinded to the treatment, and 
codes will be used to link the subject and study (without any link to the treatment 
attributed to the subject) to each sample.
5.5. General study aspects
Supplementary study conduct information not mandated to be present in this protocol is 
provided in the accompanying SPM. The SPM provides the investigator and the site 
personnel with administrative and detailed technical information that does not impact the 
safety of the subjects.
5.5.1. Data collection
Starting at Visit 3 monthly contacts between the subjects and the investigator and/or his 
delegate will take place to collect information on any event of interest that may have 
occurred [see Table 2 and Section 5.7.3.14 for details]. The contacts will not take place at 
months that coincide with the subject’s scheduled study visits. Also, subjects with 
clinically diagnosed suspected HZ will be contacted periodically as outlined in Table 3. 
The contacts will take place using the most convenient method suited for the sites (e.g., 
telephone calls by site staff or designee, or SMS text messages through a call centre, or 
visit by the study staff to the subject's home). A guidance document outlining the 
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information that needs to be collected at each contact will be provided to each country, 
and will serve as a guidance to develop the local script. The logistic details on the set-up 
of the contacts will be documented by each site/country. At each contact, the subjects will 
respond to a standard set of questions in a language that is understandable to them. The 
investigator and/or his delegate will transcribe the relevant information on any event of 
interest in the appropriate section of the subject’s eCRF, in English. In case of ongoing 
HZ, subjects will also be reminded to complete Zoster Brief Pain Inventory (ZBPI), EQ-
5D and SF-36 questionnaires. 
The diary cards and/or questionnaires to be completed will be distributed and explained 
by the investigator or his/her delegate. Any supplied diary cards or questionnaires should 
be preferably completed by the subject themselves. In case of difficulty in self-
completion of the diary cards or questionnaires, an aide (such as a family member or care 
provider who is not involved in the study) may provide assistance with reading the 
questions and/or transcribing the subject’s responses on the questionnaires and/or diary 
cards. When the completed diary cards and/or questionnaires are returned to the study 
staff, the study staff will ask the subject (at the time of return or at subsequent contact) if 
he/she received any assistance in completing diary cards or questionnaires. If the subject 
had assistance completing the diary card and/or questionnaires, it should be noted in the 
eCRF. 
For all subjects:
 30-day diary cards: To be completed by all subjects for unsolicited AEs (from 
Day 0 to Day 29 after each vaccination) and any concomitant medication and 
vaccination taken from Day 0 to Day 29 after each vaccination.
 EQ-5D and SF-36 questionnaires: To be completed by all subjects at study 
entry. Also, to be completed by all subjects at Visits 4, 5 and 6 (subjects with an 
ongoing HZ episode will follow a weekly schedule and do not need to 
additionally complete the questionnaires at these visits).
EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed into the eCRF for subjects who have confirmed 
HZ during the study.
For subjects in the 7-day diary card subset (in addition to the above): 
 7-day diary card: To be completed by subjects to record solicited AEs (from 
Day 0 to Day 6 after each vaccination).
For all subjects in case of a suspected or confirmed case of HZ:
 HZ-specific diary card: To be completed by subjects who develop symptoms 
suggestive of HZ beginning immediately upon development of these symptoms 
and prior to visiting the study site for evaluation of the suspected HZ.
 Zoster Brief Pain Inventory (ZBPI) questionnaire: To be completed by 
subjects with clinically diagnosed suspected HZ on Day HZ-0 (Visit HZ-1) and
daily from Day HZ-1 (day after the Visit HZ-1) up to Day HZ-28, and weekly 
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from Day HZ-29 onwards until the case of suspected HZ is disproved, OR until 
a 4-week pain-free period is documented, OR until the cut-off date for final 
analysis. For all subjects with HZ-associated pain, ZBPI data will be collected 
until at least Day HZ-90, regardless of the cut-off date for final analysis.
 EQ-5D and SF-36 questionnaires: To be completed weekly by the subjects 
with clinically diagnosed suspected HZ from Day HZ-0 onwards until the case 
of clinically diagnosed suspected HZ is disproved, OR until a 4-week pain-free 
period is documented, OR until the cut-off date for final analysis. For all 
subjects with HZ-associated pain, EQ-5D and SF-36 data will be collected until 
at least Day HZ-90, regardless of the cut-off date for final analysis.
5.5.2. Evaluation and confirmation of suspected and confirmed HZ 
cases
5.5.2.1. Definitions
A suspected case of HZ is defined as new unilateral rash accompanied by pain (broadly 
defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. 
Subjects clinically diagnosed as having a suspected case of HZ by the investigator will be 
referred to as a case of ‘clinically diagnosed suspected HZ’, and followed up. If a case is 
not clinically diagnosed as suspected HZ, the investigator should not progress further 
with evaluation of the case. Also refer to Section 5.5.2.2. 
Determination of confirmed cases of HZ for efficacy analyses is provided in Section 
5.5.2.3.
The HZ onset date is the earlier of the following two events: 1) the HZ rash start date; or 
2) the date on which pain at the site of a subsequent HZ rash is first noted. The HZ onset 
date will be confirmed by the investigator and recorded in the eCRF.
PHN is defined by the presence of HZ-associated severe ‘worst’ pain persisting or 
appearing more than 90 days after onset of the HZ rash. Severe ‘worst’ pain is defined as 
HZ-associated pain rated as 3 or greater on the “worst pain” ZBPI question. Alternative 
definitions of PHN, based on duration of pain of 30, 60, 120 and 180 days will also be 
used for reporting purposes.
Cessation of pain to assess duration of HZ-associated pain: A 28-day pain-free period is 
used to confirm cessation of HZ-associated pain. If that pain-free period is not achieved 
or if pain did not cease, the time-to-event will be censored at the last day of HZ-
associated pain.
Acute pain is defined as pain measured during the 4-week period following the onset of 
confirmed HZ.
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5.5.2.2. Evaluation of suspected case of HZ
All HZ cases that occur during the study period up to the cut-off date for final analysis 
will be followed and evaluated. Any HZ cases that occur after the cut-off date for final 
analysis will be recorded in the study database and referred to the local physician for 
follow-up.
Any symptom/sign suggestive of HZ must be evaluated. At Visit 1, all subjects will be 
educated with regard to the signs and symptoms of HZ. The subjects are also given a HZ-
specific diary card that they would complete with the date that rash and/or pain began. 
Subjects will be instructed to contact their study site immediately, and start completing 
the HZ-specific diary card if he/she develops any symptoms suggestive of HZ. The 
subjects will be asked to visit the study site (within 48 hours if possible) for evaluation of 
the “suspected case of HZ”. The subject will be asked to bring the completed HZ-specific 
diary card when he/she visits the study site for evaluation of the suspected HZ. The 
investigator will perform a clinical examination when the subject visits the study site for 
the first evaluation of the suspected case of HZ [Visit HZ-1 at Day HZ-0]. If not 
considered a suspected HZ diagnosis, the investigator should not progress further with 
evaluation of this event as a HZ case for the purpose of this study. However, if meeting 
the definition of an AE/SAE (Section 8.1), the case should be handled as applicable 
(Section 8.3). 
The schedule of visits/contacts that will take place for follow-up of clinically diagnosed 
suspected HZ cases is presented in Table 3.
For clinically diagnosed suspected HZ cases, the following will take place at Visit HZ-1:
 The investigator or his delegate will verify the completed HZ-specific diary card 
returned by the subject. The information from the diary card will be transcribed 
into the eCRF. The investigator or his delegate will record relevant information 
regarding the HZ episode in the eCRF (such as date of onset of pain and rash, 
date of clinical diagnosis of HZ, location and nature of HZ lesions, HZ-related 
complications if any). The HZ onset date will be confirmed by the investigator 
and recorded in the eCRF;
 The study staff/investigator will ask the subject to complete a ZBPI 
questionnaire at Visit HZ-1 to rate HZ-associated pain;
 The rash will be documented by digital photography;
 The study staff/investigator will record concomitant medication/vaccination, 
including concomitant medication for HZ treatment or any HZ-related 
complications (Section 6.6), and record intercurrent medical conditions (Section 
6.7). If antiviral therapy is needed, it is recommended to use valacyclovir,
acyclovir or famciclovir. Concomitant medication the subject has already 
received and/or will receive for HZ treatment will be recorded in the eCRF. The 
study staff/investigator will check if the subject received any medical attention 
[hospitalization, emergency room visit, or a visit to or from medical personnel 
(medical doctor)] for HZ or any HZ-related complication.
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 Rash lesion samples (three replicate samples on the same day) will be collected 
from subjects clinically diagnosed as having a suspected case of HZ (Section 
5.7.3.11); 
 The subject will be given a supply of ZBPI, EQ-5D and SF-36 questionnaires. 
The ZBPI questionnaires will be used to collect information on the severity of 
HZ-associated pain, the duration of HZ-associated pain and rash, and the impact 
of the HZ episode on subject’s QoL. The impact of HZ on subject’s QoL will 
also be measured using the EQ-5D and SF-36 questionnaires (Section 7). The 
study staff/investigator will provide instructions to the subjects for completing 
the ZBPI, EQ-5D and SF-36 questionnaires and explain the importance of 
completing and returning the questionnaires to the site in order to provide more 
information on HZ. 
 The subject will be asked to complete the ZBPI questionnaires daily from Day 
HZ-1 (day after the Visit HZ-1) up to Day 28, and weekly from Day HZ-29 
onwards until:
 The case of clinically diagnosed suspected HZ is disproved; OR
 28 days after HZ-associated pain ceases. The subject should continue to 
complete the ZBPI questionnaires weekly until a 28-day (or 4-week) pain free 
period is documented (i.e., '0' circled for item 3 of the ZBPI questionnaire at 
each assessment during that entire period); OR
 The cut-off date for final analysis. For all subjects with HZ-associated pain, 
ZBPI pain data will be collected until at least Day HZ-90,  regardless of the cut-
off date for final analysis; 
If a subject with clinically diagnosed suspected HZ has not completed follow-up 
until at least Day HZ-90 at the cut-off date for final analysis, and the case is not
disproved, follow-up for such a subject will continue until the Day HZ-90 
follow-up is completed. The study conclusion for such a subject will thus occur 
after he/she completes Day HZ-90 follow-up.
The subjects will be asked to complete the EQ-5D and SF-36 questionnaires from Day 
HZ-0 and continued weekly during the entire period that the ZBPI questionnaires are 
completed.
After Visit HZ-1 until Visit HZ-7, visits/contacts will take place for follow-up of the HZ 
episode according to the schedule presented in Table 3.Follow-up of HZ-associated pain 
persisting beyond Visit HZ-7 or other complications will be done at monthly contacts 
between the subjects and the investigator and/or his delegate that are planned starting at 
Visit 3. If the case of clinically diagnosed suspected HZ is disproved, or if HZ-associated 
pain ceases (defined as a 28-day [or 4-week] pain free period), subsequent follow-up 
visits or contacts related to this case of HZ will be cancelled. The study staff/investigator 
will inform the subjects to stop completing the ZBPI, EQ-5D and SF-36 questionnaires 
and will provide instructions for the subject to return the completed questionnaires to the 
study site. Collection of subsequent HZ-related information will be stopped and no 
further information on that suspected HZ episode will be encoded in the clinical database. 
The following will take place at each visit or contact that occurs after Visit HZ-1:
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 The study staff/investigator will: 1) record relevant information regarding the  
clinically diagnosed suspected HZ case (such as the location and nature of HZ 
lesions, HZ-related complications, if any); 2) record concomitant 
medications/vaccinations, including concomitant medication the subject has 
already received and/or will receive for HZ treatment or treatment of any HZ-
related complications (Section 6.6); 3) record intercurrent medical conditions 
(Section 6.7); and 4) check if the subject received any medical attention 
[hospitalization, emergency room visit, or a visit to or from medical personnel 
(medical doctor)] for HZ or any HZ-related complication. Concomitant 
medication the subject has already received and/or will receive for HZ treatment 
will be recorded in the eCRF.
 The study staff/investigator will remind subjects to complete the ZBPI, EQ-5D 
and SF-36 questionnaires, and return the completed ZBPI, EQ-5D and SF-36 
questionnaires to the study site according to the instructions given by the study 
staff/investigator. Once the completed ZBPI, EQ-5D and SF-36 questionnaires 
are available, the investigator will transcribe the information into the subject’s 
eCRF. A new supply of ZBPI, EQ-5D and SF-36 questionnaires will be 
provided to the subjects as necessary. 
5.5.2.3. Confirmation of suspected case of HZ
A suspected case of HZ can be confirmed in two ways:
 By Polymerase Chain Reaction (PCR): 
Rash lesion samples will be collected from subjects clinically diagnosed as 
having a suspected case of HZ. The samples will be transferred to GSK 
Biologicals or a validated laboratory designated by GSK Biologicals using 
standardised and validated procedures for laboratory diagnosis of HZ by PCR. 
Refer to Appendix A for details of PCR assay to be performed on HZ lesion 
samples. Refer to Appendix B for details of the PCR testing algorithm to 
classify suspected cases of HZ.
 By the HZ Ascertainment Committee:
All cases of clinically diagnosed suspected HZ that cannot be confirmed or 
excluded by PCR [if the PCR specimen is inadequate (i.e., negative for both 
virus and -actin DNA) or is missing] will be reviewed by the HZ 
Ascertainment Committee (HZAC). The HZAC will consist of three to five 
physicians with HZ expertise. HZAC members, participating as investigator in 
this study, will not evaluate cases from their own study site. HZAC members 
will be blinded to treatment assignments. For every such case, each reviewing 
HZAC member will be asked to make a clinical determination of whether the 
case is HZ based on review of the available clinical information (summary of the 
rash and pain evaluations, digital photographs of the subject's rash, and clinical 
progress notes). A unanimous diagnosis of "a confirmed case of HZ" or "not a 
case of HZ" will constitute a confirmed clinical diagnosis. HZAC members will 
discuss each non-unanimous case. A suspected case of HZ will be considered a 
“clinically confirmed case of HZ” if the majority of the HZAC members 
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concur; otherwise, it will be classified as “not a case of HZ”. Further details 
will be provided in the HZAC charter.
5.5.2.4. Evaluation of severity of HZ-associated pain using the Zoster Brief Pain 
Inventory
The ZBPI is an assessment tool in the form of a questionnaire completed by the subject 
that is specifically designed to assess HZ-associated pain and discomfort during an HZ 
episode. The ZBPI also takes into account the effect of HZ treatment on subject’s pain 
and the interference of HZ-associated pain with subject’s QoL, and general health status. 
Previous studies have been shown that increasing HZ-associated pain scores are highly 
correlated with worsening of subject’s QoL [Coplan, 2004; Schmader, 2007]. 
In each case of clinically diagnosed suspected HZ, the subjects will be asked to assess 
their HZ-associated pain and interference of HZ with their QoL by completing the ZBPI 
questionnaire either themselves or assisted, by an aide (Section 5.5.1) until the suspected 
case of HZ diagnosed is disproved, HZ-associated pain ceases (defined as a 28-day [or 4-
week] pain free period) or until the cut-off date for final analysis (for all subjects with 
HZ-associated pain, ZBPI pain data will be collected until at least Day HZ-90, regardless 
of the cut-off date for final analysis). (Section 5.5.2.2).
Information on HZ-associated pain is derived from the ZBPI question: “Please rate your 
pain by circling the one number that best describes your pain at its worst in the last 24 
hours” (item 3), so called “worst pain” in this protocol.
The following outputs will be derived from the data recorded in the ZBPI: HZ Burden-
Of-Illness (BOI) score and HZ severity score (Section 10.6.2).
5.5.2.5. HZ complications
The presence of HZ complications listed below will be documented in the eCRF at each 
contact/study visit, independently from the AE reporting. Any HZ complications, 
according to the definitions below, will be recorded by the investigator only in subjects 
with clinically diagnosed suspected HZ or confirmed HZ. If a recorded complication is 
associated with a case of clinically diagnosed suspected HZ, and that case of HZ is 
subsequently disproved, the associated complication will not be considered a 
complication of HZ.
HZ vasculitis Vasculopathy or vasculitis (based on clinical, laboratory or 
radiologic findings) that is temporally associated with an 
episode of HZ and, in the opinion of the investigator, was 
caused directly by the VZV infection arising from the HZ 
episode.
Disseminated disease Defined as ≥ 6 HZ lesions outside the primary dermatome as per 
the investigator’s judgment.
Ophthalmic disease Defined as HZ affecting any eye structure as per investigator’s 
judgment.
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Neurologic disease Defined as cranial or peripheral nerve palsies, myelitis, 
meningoencephalitis, stroke, etc. that is temporally associated 
with an episode of HZ and, in the opinion of the investigator, 
was caused directly by VZV infection arising from the HZ 
episode.
Visceral disease Defined as an abnormality of one or more internal organs (e.g., 
hepatitis, pneumonitis, gastroenteritis, etc.) that is temporally 
associated with an episode of HZ and, in the opinion of the 
investigator, was caused directly by VZV infection arising from 
the HZ episode.
Stroke A diagnosis of stroke requires that criteria 1, 2 and 3 are fulfilled 
or criteria 1 and 4 and in the opinion of the investigator is 
temporally associated with an episode of HZ
Criterion 1: Rapid onset of localising neurological deficit and/or 
change in level of consciousness;
Criterion 2: Localising neurological deficit or change in level of 
consciousness that lasts greater than 24 hours;
Criterion 3: No other cerebral process, peripheral lesion, or other 
disorder is the cause of the localising neurological deficit or 
change in level of consciousness;
Criterion 4: CT scan or MRI scan evidence of an acute 
thrombotic or hemorrhagic lesion.
5.5.3. Independent Data Monitoring Committee
In order to ensure the safety of the subjects during the entire study period, an IDMC will 
be appointed to 1) monitor and follow-up the safety and tolerability of the subjects 
enrolled in the trial and 2) make recommendations to the sponsors concerning the 
continuation, modification, or termination of the trial. 
An independent statistical team (i.e., not GSK employees), appointed by GSK 
Biologicals and not involved in the study management, will be unblinded to treatment 
assignment and provide all necessary tables, listings, figures and individual subject data 
to the IDMC. The IDMC will consist of four to six clinical experts, who are not 
participating in the study and an independent statistician. 
The role of the IDMC will be to review the progress of the trial and the accumulating 
data to detect evidence of safety issues for the subjects while the trial is ongoing. The 
IDMC will be held to evaluate the safety assessments (e.g., AEs, SAEs, fatal events and 
withdrawals due to AEs) during the trial and make recommendations regarding 
continuation, modification or discontinuation of the study to the sponsor following each 
meeting. 
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The frequency of IDMC sessions and other operational details are described in the IDMC 
charter. The IDMC meetings will consist of an open session in which the conduct, 
recruitment and general baseline characteristics of the trial are presented, and a closed 
session in which the safety assessments by treatment group will be presented. The GSK 
Biologicals biostatistician and a member of the Zoster vaccine program will attend the 
IDMC meeting open sessions to immediately reply to any questions from the IDMC 
members. No GSK staff will participate in the closed sessions.
The IDMC may be also involved in evaluation of VE for futility analyses and prevent the 
continuation of a clinical study that already showed its inability to demonstrate the
primary and main secondary endpoints. The futility rules will be described in the IDMC 
Charter.
The IDMC will review all safety parameters and efficacy data together before making a 
final recommendation. In case of a serious safety issue during the study, the sponsor will 
inform the IDMC expeditiously.
5.6. Outline of study procedures
Table 2 summarises the list of study procedures to be followed during the study visits and 
at the study conclusion contact. Table 3 summarises study procedures to be performed for 
the follow-up of each suspected HZ case.
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Table 2 List of study procedures
Type of contact VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6f Monthly 
contactse
Study
conclusion
contact
Timepoints Day 0*/
Month0
Month 2  Month 3 Month 14 Month 26 Month 38
Sampling timepoints Pre-Vacc Post-Vacc 1 Post-Vacc 2 Post-Vacc 2 Post-Vacc 2 Post-Vacc 
2
SDRRAa ●
Informed consent ●
Check inclusion criteria ●
Check exclusion criteria ●
Check contraindications ● ●
Medical history ●
Physical examination ○
Record demographic data ●
Training on self-reporting by subjectsb ○ ○ ○ ○ ○ ○
Urine pregnancy testc ● ●
Pre-vaccination body temperature ● ●
Blood sampling (approximately 10 mL) 
for Ab determination in all subjects ● ●
Blood sampling (approximately 10 mL) 
for Ab determination in Immunogenicity 
subset subjects only
● ● ●
Blood sampling (approximately 20 mL)
for CMI response in CMI subset 
subjects only
● ● ● ● ●
Randomizationd ○
Recording of treatment number ●
Vaccination ● ●
Dispensing of HZ-specific diary cards 
to all subjects ○
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Type of contact VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6f Monthly 
contactse
Study
conclusion
contact
Timepoints Day 0*/
Month0
Month 2  Month 3 Month 14 Month 26 Month 38
Sampling timepoints Pre-Vacc Post-Vacc 1 Post-Vacc 2 Post-Vacc 2 Post-Vacc 2 Post-Vacc 
2
Recording of intercurrent medical 
conditions according to guidelines in 
Section 6.7
●d ● ● ● ● ● ● ● ● ● ●
Reporting of all SAEs until Month 14 ● d ● ● ● ●
Reporting of SAEs related to study 
participation or to a concurrent GSK 
medication/vaccine, or any fatal SAE, 
after Month 14 until study conclusion
● ● ● ● ● ●
Reporting of new onset of autoimmune 
diseases (NOADs) and other immune 
mediated inflammatory disorders
● d ● ● ● ● ● ● ● ● ● ●
Follow-up of HZ ● d ● ● ● ● ● ● ● ● ● ●
Reporting of medically attended visits 
until Month 8 ●
d ● ● ●
Recording of concomitant 
medication/vaccination by study 
staff/investigator according to 
guidelines in Section 6.6
● ● ● ● ● ● ● ● ● ● ●
Reporting of pregnancy ● d ● ● ● ● ● ● ● ● ● ●
Completion of EQ-5D and SF-36 
questionnaires
-by all subjects  (subjects with an 
ongoing HZ episode will follow the 
weekly schedule and do not need to 
additionally complete the 
questionnaires at these visits)
○ ○ ○ ○
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Type of contact VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6f Monthly 
contactse
Study
conclusion
contact
Timepoints Day 0*/
Month0
Month 2  Month 3 Month 14 Month 26 Month 38
Sampling timepoints Pre-Vacc Post-Vacc 1 Post-Vacc 2 Post-Vacc 2 Post-Vacc 2 Post-Vacc 
2
Transcriptiong by study
staff/investigator of EQ-5D and SF-36 
questionnaires completed
- by all subjects ●
- by subjects who do not have an 
ongoing HZ episode ● ● ●
Dispensing of 7-day diary cards for 
solicited AEs to the 7-day diary card 
subset only and 30-day diary cards for 
unsolicited AEs and concomitant 
medication/vaccination to all subjects 
○ ○
Daily post-vaccination recording by 
subjects of solicited symptoms (Days 0 
 6 after each vaccination) on the 7-
day diary card by the 7-day diary card 
subset subjects 
○ ○
Daily post-vaccination recording by 
subjects of unsolicited symptoms 
(Days 0  29 after each vaccination), 
and concomitant medication/ 
vaccination (Days 0  29 after each 
vaccination) on 30-day diary card by all 
subjects 
○ ○
Returning by subjects of 7-day diary 
cards diary cards for solicited 
symptoms and 30-day diary cards for 
unsolicited AEs and concomitant 
medication and vaccination 
○ ○
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Type of contact VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6f Monthly 
contactse
Study
conclusion
contact
Timepoints Day 0*/
Month0
Month 2  Month 3 Month 14 Month 26 Month 38
Sampling timepoints Pre-Vacc Post-Vacc 1 Post-Vacc 2 Post-Vacc 2 Post-Vacc 2 Post-Vacc 
2
Transcription of 7-day diary cards for 
solicited symptoms and 30-day dairy 
cards for unsolicited AEs and 
concomitant medication and 
vaccination by study staff/investigator
● ●
Study Conclusion ●
Note: Starting at Visit 3, monthly contacts between the subjects and the investigator and/or his delegate will be scheduled for the subject to respond to a standard set of questions, in a 
language that is understandable to the subject, to collect information on safety and the occurrence of HZ, and to follow-up ongoing HZ cases (Section 5.5.1).
Note: Futility analysis may occur (Section 10.4.5.3) 
* Day of first vaccination
 is used to indicate a study procedure that requires documentation in the individual eCRF.
O  is used to indicate a study procedure that does not require documentation in the individual eCRF.
a Subjects 70-79 YOA and  80 YOA will be randomly assigned to ZOSTER-006 or ZOSTER-022 at Visit 1. These subjects must sign a Study Determination 
(Recruitment/Randomization) Agreement (SDRRA) prior to study assignment, and will receive a study determination number to be recorded in the eCRF. Study assignment can be 
done prior to Visit 1 if needed.
b Subjects will be instructed to contact their study site immediately if he/she develops any symptoms suggestive of HZ, if he/she manifests any symptoms he/she perceive as serious 
and, in case of pregnancy for women of childbearing potential.
c Only for women of child-bearing potential. 
d Study procedure to be assessed only after administration of vaccine at Visit 1.
e Monthly contact after Visit 3 until study conclusion, except at months that coincide with the subject’s scheduled visits
f If the conditions for final analysis and study end are met before Visit 6 is completed by all subjects and it is decided to conclude the study, Visit 6 may not take place in some subjects. 
g EQ-5D and SF-36 will remain as source documents. The information from these questionnaires will only be transcribed in the eCRF for subjects who have a zoster event during the 
study.
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Table 3 Study procedures to be performed during the follow-up period for each suspected HZ case
VISITS/CONTACTS IN CASE OF HZ
Type of contact Visit HZ-1 Visit HZ-2 Contact HZ-3 Contact HZ-4 Visit HZ-5 Contact HZ-6 Visit HZ-7
Timepoints Day HZ-0 Day HZ-7 Day HZ-14 Day HZ-21 Day HZ-28 Day HZ-56 Day HZ-91
Perform clinical examination ○
Return HZ-specific diary cards to study staff/investigator ○
Transcription of the HZ-specific diary card by study 
staff/investigator ●
Take digital photographs of HZ rash ●
Recording of the HZ onset date by study staff/investigator ●
Collect HZ lesion samples (3 replicate samples) for 
confirmation by PCR of a case of clinically diagnosed 
suspected HZ as specified in Section 5.7.3.11
●
Record relevant information regarding HZ in eCRF by 
study staff/investigator ● ● ● ● ● ● ●
Record concomitant medication/vaccination according to 
guidelines in Section 6.6 ● ● ● ● ● ● ●
Record intercurrent medical conditions according to 
guidelines in Section 6.7 ● ● ● ● ● ● ●
Record any medical attention received for HZ or any HZ-
related complication ● ● ● ● ● ● ●
Dispense ZBPI questionnaires to subjects ○
Completion† of ZBPI questionnaires by the subjects until 
HZ is disproved, pain ceases or the cut-off date for final 
analysis (ZBPI pain data will be collected until at least Day 
HZ-90.)
○ ○ ○ ○ ○ ○ ○
Return completed ZBPI questionnaires to study 
staff/investigator according to instructions provided by the 
investigator/study staff to subjects
○ ○ ○ ○ ○ ○
Transcription of ZBPI questionnaires by study 
staff/investigator ● ● ● ● ● ● ●
Dispense EQ-5D and SF-36 questionnaires to subjects
○
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VISITS/CONTACTS IN CASE OF HZ
Type of contact Visit HZ-1 Visit HZ-2 Contact HZ-3 Contact HZ-4 Visit HZ-5 Contact HZ-6 Visit HZ-7
Timepoints Day HZ-0 Day HZ-7 Day HZ-14 Day HZ-21 Day HZ-28 Day HZ-56 Day HZ-91
Completion‡ of EQ-5D and SF-36 questionnaires by the 
subjects until HZ is disproved, pain ceases or the cut-off 
date for final analysis (EQ-5D and SF-36 data will be 
collected until at least Day HZ-90)
○ ○ ○ ○ ○ ○ ○
Return completed EQ-5D and SF-36 questionnaires to 
study staff/investigator according to instructions provided 
by the investigator/study staff to subjects 
○ ○ ○ ○ ○ ○
Transcription of EQ-5D and SF-36 questionnaires by 
study staff/investigator ● ● ● ● ● ● ●
Note: If the case of clinically diagnosed suspected HZ is disproved, or if HZ-associated pain ceases (defined as a 28-day [or 4-week] pain free period), subsequent follow-up visits or 
contacts will be cancelled. When case of clinically diagnosed suspected HZ is disproved, collection of HZ-related information will be stopped and no further information on that 
suspected HZ episode will be encoded in the clinical database. 
†Subjects with clinically diagnosed suspected HZ will be asked to complete the ZBPI questionnaire at Day HZ-0 (Visit HZ-1), daily from Day HZ- 1 to Day HZ-28, and weekly from Day 
HZ-29 onwards until a 4-week pain-free period is documented or until the cut-off date for final analysis. (ZBPI pain data will be collected until at least Day HZ-90)
‡Subjects with clinically diagnosed suspected HZ will be asked to complete the EQ-5D and SF-36 questionnaire weekly from Day HZ-0 onwards until a 4-week pain-free period is 
documented or until the cut-off date for final analysis. (EQ-5D and SF-36 data will be collected until at least Day HZ-90)
Each clinically diagnosed suspected HZ that occurs up to the cut-off date for final analysis will be followed at least until the study visit at Day HZ-91.
The study staff/investigator will dispense additional questionnaires and provide instructions for the subject to return the completed questionnaires to the study site. The subjects will be 
given a new supply of questionnaires as necessary. Follow-up of HZ-associated pain persisting beyond Day HZ-91 or other complications will be done at monthly contacts that are 
planned starting at Visit 3 between the subjects and the investigator and/or his delegate.
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It is the investigator’s responsibility to ensure that the intervals between study 
visits/contacts are strictly followed. These intervals determine each subject’s evaluability 
in the ATP analyses.
Time intervals between study visits/contacts related to study procedures performed in 
subjects participating in the study are presented in Table 4. In addition; starting at Visit 3, 
monthly contacts between the subjects and the investigator and/or his delegate will be 
scheduled.
Follow-up for the occurrence of any SAEs will begin at Day 0 and continue until Month 
14. Follow-up for the occurrence of SAEs related to study participation, or related to a 
concurrent GSK medication/vaccine or any fatal SAE, will continue until study 
conclusion. Follow-up for the occurrence of new onset of autoimmune diseases and other 
immune mediated inflammatory disorders will begin at Day 0 and continue until study 
conclusion.
Table 4 Intervals between study visits/contacts 
Interval Length of interval Range (days)
Visit 1  Visit 2 2 months 49-83
Visit 2  Visit 3 1 month 30-48
Visit 2  Visit 4 12 months 335-395
Visit 2  Visit 5 24 months 700-760
Visit 2  Visit 6* 36 months 1065-1125
Visit 2  Study 
conclusion contact Not fixed Not fixed 
Note: The date of Dose 1 (Visit 1) or Dose 2 (Visit 2), respectively, is used as reference date to define the interval 
between study visits/contacts.
* If the conditions for final analysis and study end are met before Visit 6 is completed by all subjects and it is decided to 
conclude the study, Visit 6 may not take place in some subjects
Time intervals between study visits/contacts to be performed for follow-up of HZ are 
presented in Table 5. Refer to the SPM for further guidance on data collection during 
follow-up of HZ.
Table 5 Intervals between contacts with subjects in case of suspected HZ 
Interval between visits/contacts Length of 
interval
Optimal Timing of contact 
(range of days) 
Visit HZ-1 (Day HZ-0)  Visit HZ-2 (Day HZ-7) 7 days Day HZ-7 (+/- 3 days)*
Visit HZ-2 (Day HZ-7)  Contact HZ-3 (Day HZ-14) 7 days Day HZ--14 (+/- 3 days)*
Contact HZ-3 (Day HZ-14)  Contact HZ-4 (Day HZ-21) 7 days Day HZ-21 (+/- 3 days)*
Contact HZ-4 (Day HZ-21)  Visit HZ-5 (Day HZ-28) 7 days Day HZ-28 (+/- 3 days)*
Visit HZ-5 (Day HZ-28)  Contact HZ-6 (Day HZ-56) 28 days Day HZ-56 (+/- 7 days)*
Visit HZ-1 (Day HZ-0)  Visit HZ-7 (Day HZ-91) 91 days Day HZ-91 (+ 7 days)
Note: The date of the previous visit/contact is used as reference date to define the interval between the subsequent
study visits/contacts
Note: If a case of clinically diagnosed suspected HZ is disproved or if pain ceases (i.e., after a 4-week pain-free period 
is documented), subsequent follow-up visits or contacts may be cancelled. Follow-up of HZ-associated pain persisting 
beyond Day HZ-91 or other complications will be done at monthly contacts between the subjects and the investigator 
and/or his delegate that are planned starting at Visit 3
* If contacted early in the window, then remaining days in the interval will need to be captured with the next contact.
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5.7. Detailed description of study procedures
5.7.1. Procedures prior to study participation
5.7.1.1. Study Determination (Recruitment/Randomization) Agreement
Eligible subjects 70-79 YOA and  80 YOA will be randomly assigned to ZOSTER-006 
or ZOSTER-022 at Visit 1. Prior to study assignment, subjects need to provide their 
signature/thumb print on the Study Determination (Recruitment/Randomisation)
Agreement. Subjects will receive a study determination number to be recorded in the 
eCRF. Study assignment can be done prior to Visit 1 if needed.
5.7.1.2. Informed consent
Before performing any other study procedure, subjects need to provide their 
signature/thumb print on the study specific informed consent. Refer to Section 5.1 for the 
requirements on how to obtain informed consent, as appropriate. 
5.7.2. Procedures prior to the first vaccination
5.7.2.1. Check inclusion and exclusion criteria
Check all applicable inclusion and exclusion criteria as described in Sections 4.2 and 4.3
before enrolment. 
If a subject is enrolled while not meeting all inclusion criteria or while meeting any of the 
exclusion criteria, this must be reported in the eCRF. 
5.7.2.2. Collect demographic data
Record demographic data such as date of birth, gender, geographic ancestry and ethnicity
in the subject’s eCRF.
5.7.2.3. Medical history
Perform a history-directed medical examination and record any pre-existing conditions or 
signs and/or symptoms present in a subject prior to the start of the study in the eCRF.
Treatment of any abnormality observed during this examination has to be performed 
according to local medical practice outside this study or by referral to an appropriate 
health care provider.
5.7.2.4. Physical examination
A history-directed physical examination according to local practice should be performed 
to ensure the subject is in good physical condition.
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5.7.2.5. Urine pregnancy test
Female subjects of childbearing potential are to have a urine pregnancy test prior to any 
study vaccine administration. The study vaccine/placebo may only be administered if the 
pregnancy test is negative.
5.7.3. Procedures during the study 
Note that some of the procedures to be performed during the vaccination visits, i.e., Visits 
1 and 2, (such as history directed physical examination and urine pregnancy test) are 
performed prior to the first vaccination and are described in Section 5.7.2.
5.7.3.1. Check and record concomitant medication/vaccination and intercurrent 
medical conditions 
Concomitant medication/vaccination must be recorded in the eCRF as described in 
Section 6.6. Refer to Section 6.6 for details on the medications/vaccinations that are 
forbidden or allowed during the study.
At each study visit or contact subsequent to the first vaccination, it must be verified if the 
subject has experienced or is experiencing any intercurrent medical condition listed in 
Section 6.7. If it is the case, the condition(s) must be recorded in the eCRF.
Intercurrent medical conditions except HZ prior to one month after the second 
vaccination should be reported in the AE section of the eCRF.
Any subject with a clinically diagnosed HZ episode between Visit 1 and Visit 2 should 
not receive the second vaccination.
Antiviral and/or pain medications administered to subjects with a suspected or confirmed 
case of HZ for the purpose of treating the HZ or the associated pain will be recorded in 
order to establish the link between the medications and the indication.
In addition, any medication/vaccination taken from Day 0 to Day 29 after each 
vaccination will be recorded by the subjects on a 30-day diary card (Section 5.7.3.8). 
5.7.3.2. Check contraindications to vaccination
Contraindications to vaccination are to be checked at the beginning of each vaccination 
visit. Refer to Section 6.5.
See Section 5.7.3.7 for an additional criterion to be checked prior to administration of the 
second vaccination dose.
5.7.3.3. Assess pre-vaccination body temperature
The axillary, rectal, oral or tympanic body temperature of all subjects will be measured 
prior to any study vaccine administration. The preferred route for recording temperature 
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in this study will be oral. All vaccines may be administered to persons with low-grade 
fevers, i.e., oral, tympanic on oral setting, or axillary temperature < 37.5°C/99.5°F, or 
< 38.0°C (100.4°F) on rectal setting (Section 4.3). If a subject has an 
axillary/oral/tympanic on oral setting temperature  37.5°C/99.5°F, or  38.0°C 
(100.4°F) on rectal setting, it will constitute a contraindication to administration of 
vaccine or placebo at that point in time (Section 6.5).
5.7.3.4. Randomization
At the first vaccination visit, randomization will occur as explained in Section 5.3.
5.7.3.5. Blood sampling for safety or immune response assessments
As specified in Table 2, blood samples will be taken during certain study visits. Refer to 
the Module on Biospecimen Management in the SPM for general handling of blood 
samples.
 A volume of approximately 10 mL of whole blood should be drawn from all 
subjects at Visits 1 and 3, and, from all subjects included in the Immunogenicity 
subset, at Visits 4, 5 and 6. 
 An additional volume of approximately 20 mL of whole blood should be drawn 
from all subjects included in the CMI component of the Immunogenicity subset 
at Visits 1, 3, 4, 5 and 6. 
5.7.3.6. Treatment number assignment
At the first vaccination visit, the subject will be assigned a treatment number defining the 
treatment he/she will be receiving. The treatment number must be recorded in the eCRF 
at the first vaccination visit.
If there is a need for a site to use a replacement vaccine at the subsequent visit, then that 
treatment number needs to be transcribed into the eCRF (see Section 6.4).
5.7.3.7. Vaccination
 After completing the prerequisite procedures prior to each vaccination, one dose 
of study vaccine/placebo will be administered intramuscularly (IM) in the 
deltoid of the non-dominant arm (refer to Section 6.3 for detailed description of 
the vaccine administration procedure). If the Investigator or delegate determines 
that the subject’s health on the day of vaccination temporarily precludes 
vaccination, the visit will be rescheduled within the interval for this visit.
 The vaccinees will be observed closely for at least 30 minutes, with appropriate 
medical treatment readily available in case of anaphylaxis following the 
administration of vaccine.
 Any subject with clinically diagnosed HZ episode between Visit 1 and Visit 2 
should not receive the second dose.
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5.7.3.8. Recording of non-serious AEs and SAEs
 Refer to Section 8.3 for procedures for the Investigator to record AEs and SAEs
and to Section 8.4 for guidelines on how to report these AEs/SAEs to GSK 
Biologicals.
 The subjects will be instructed to contact the investigator immediately should 
the subject manifest any signs or symptoms they perceive as serious or in case of 
pregnancy for women of childbearing potential.
 After each vaccination, 30-day diary cards will be provided to all subjects by 
study staff/investigator for daily recording by the subjects of:
 unsolicited symptoms from Days 0 to 29 after each vaccination
 any medication/vaccination taken from Days 0 to 29 after each vaccination.
 After each vaccination, 7-day diary cards will be provided to subjects who are 
part of the 7-day diary card subset by study staff/investigator for daily recording 
by the subjects of solicited symptoms from Days 0 to 6 after each vaccination 
 The subjects will be instructed to return the completed diary cards to the 
investigator at Visit 2 and Visit 3, respectively.
 Collection and verification of completed diary cards will occur during 
discussion with the subject at Visit 2 and Visit 3. The investigator will transcribe 
the collected information into the eCRF in English.
5.7.3.9. Recording of new onset of autoimmune diseases (NOADs) and other 
immune mediated inflammatory disorders
As specified in the List of Study Procedures (Table 2, Section 5.6), NOADs and other 
immune mediated inflammatory disorders, occurring from administration of the first dose 
of vaccine/placebo onwards until end of the trial will be recorded.
Refer to Section 8.3.2.5 for information on recording of NOADs and other immune 
mediated inflammatory disorders.
5.7.3.10. Recording of data from completed EQ-5D and SF-36 questionnaires
 EQ-5D and SF-36 questionnaires will be completed by all subjects at Visit 1.
 EQ-5D and SF-36 questionnaires will be completed by all subjects at Visits 4, 5 
and 6 (subjects with an ongoing HZ episode will follow the weekly schedule and 
do not need to additionally complete the questionnaires at these visits).
EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed in the eCRF for subjects who have a confirmed 
episode of HZ during the study.
 
 ( - )
i l
14f52be5fd11c61d592d2b59e6184d3d
CONFIDENTIAL
110390 (ZOSTER-006)
Final
07-APR-2010 60
5.7.3.11. Follow up of suspected HZ cases and HZ-associated pain
Data will be collected on all clinically diagnosed suspected HZ cases that occur from 
administration of the first dose of vaccine/placebo until the cut-off date for final analysis 
(Section 5.7.3.16). For each suspected case of HZ that the investigator concludes is 
clinically consistent with HZ, data on HZ-associated pain (using ZBPI questionnaires 
completed by the subject) will be collected until:1) The case is disproved; 2) The subject 
has no HZ-associated pain for 4 consecutive weeks; or, 3) the cut-off date for final 
analysis. For all subjects with HZ-associated pain, ZBPI pain data will be collected until 
at least Day HZ-90, regardless of the cut-off date for final analysis. In addition, subjects 
with clinically diagnosed suspected HZ will be asked to complete EQ-5D and SF-36 
questionnaires weekly. 
At the first HZ evaluation visit (Visit HZ-1 at Day HZ-0 – The visit at which the 
suspected case of HZ is first evaluated by the investigator), rash lesion samples will be 
collected from the subject if the investigator considers the symptoms/signs to be 
consistent with HZ. If during clinical evaluation at Visit HZ-1, the investigator 
determines that adequate rash lesion samples cannot be collected, the subject may be 
asked to return to the study site for collection of suitable HZ lesion samples. Three 
replicate rash lesion samples (see Table 6) should be collected on the same day according 
to the guidelines provided in the SPM. 
Refer to 5.5.2 for details on follow-up of HZ cases and HZ-associated pain.
5.7.3.12. Recording of medically attended visits 
Refer to Section 8.3.2.4 for detailed information on recording of medically attended visits 
occurring up until Month 8. 
5.7.3.13. Reminder for self-reporting by subjects
Subjects will be instructed at Visit 1 (and will be reminded at each subsequent visit) to 
contact their study site immediately 
 should the subject develop any symptoms suggestive of HZ, and to start completion 
of the HZ-specific diary card immediately upon development of these symptoms 
prior to visiting the study site for evaluation of the suspected HZ;
 should the subject manifest any signs or symptoms he/she perceive as serious;
 should the subject become pregnant (for women of childbearing potential). 
5.7.3.14. Reminder for monthly follow-up contacts/yearly follow-up visits
The subject will be reminded that, starting at Visit 3, monthly contacts between the 
subjects and the investigator and/or his delegate will take place (except at months that 
coincide with the subject’s scheduled visits) in order to collect all relevant information on 
any event of interest that may have occurred [including SAEs (Section 8.3), NOADs and 
other immune mediated inflammatory disorders (Section 8.3.2.5), occurrence or follow 
up of a suspected episode of HZ (Section 5.5.2), intercurrent medical conditions (Section 
6.7), medically attended visits (up to Month 8 only, Section 8.3.2.4), the use of 
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concomitant medications and/or vaccinations (Section 6.6) or pregnancy (Section 8.3)], 
and that information will be recorded in the appropriate section of the subject’s eCRF.
The subject will be reminded that the current study still has yearly follow-up visits 
planned.
5.7.3.15. Invitation for a planned follow-up study 
If study ZOSTER-006 is extended to include an additional long-term follow-up period 
beyond that currently mandated by the protocol, the investigator/study staff will ask all or 
a subset of subjects at the study conclusion contact if the subject would be willing to 
participate to a long-term follow-up study. If a subject declines to participate in a long-
term follow-up study, refusal will be documented in the individual eCRF. 
5.7.3.16. Study conclusion
Study end will take place when both conditions for final analysis are met and a minimum 
90 days follow-up is completed for each case of confirmed or clinically diagnosed 
suspected HZ that occurs prior to the cut-off date for final analysis. 
If it appears that there will be a large disparity in the study end date for study ZOSTER-
006 and ZOSTER-022, respectively, then the first study that meets the criteria for final 
analysis may be continued until the second study reaches the criteria for final analysis so 
that the two studies end concurrently.
When the cut-off date for final analysis is established, the study sites will contact the 
subjects for the study conclusion contact. If a subject with clinically diagnosed suspected 
HZ has not completed follow-up until at least Day HZ-90 at the cut-off date for final 
analysis, and the case is not disproved, follow-up for such a subject will continue until 
the Day HZ-90 follow-up is completed. The study conclusion contact for such a subject 
will thus occur after he/she completes Day HZ-90 follow-up.
At the study conclusion contact, the study sites will provide instructions to the subjects 
for returning any outstanding ZBPI questionnaires.
At the study conclusion contact, the following procedures will take place:
 Follow-up of any cases of confirmed or clinically diagnosed suspected HZ and 
HZ-associated pain (Sections 5.5.2 and 5.7.3.10);
 Recording of any SAEs related to study participation or to a concurrent GSK 
medication/vaccine, or any fatal SAE (Section 5.7.3.8);
 Recording of NOADs and other immune mediated inflammatory disorders 
(Section 5.7.3.9);
 Check and record specific concomitant medication/vaccination and intercurrent 
medical conditions (Section 5.7.3.1);
 Study conclusion will be recorded in the eCRF.
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At study conclusion, if the study vaccine demonstrates sufficient evidence of efficacy and 
safety such that a clinically important benefit may be reasonably expected, placebo 
recipients will be offered cross-over immunization with the study vaccine
5.8. Biological sample handling and analysis
Please refer to the SPM for details of biospecimen management (handling, storage and 
shipment).
Samples will not be labelled with information that directly identifies the subjects but will 
be coded with the identification number for the subject (subject number).
Collected samples may be used in other assays, for test improvement or test development 
of analytical methods related to the study vaccine and its constituents or the disease under 
study to allow to achieve a more reliable measurement of the vaccine response. Under 
these circumstances, additional testing on the samples may be performed by GSK 
Biologicals outside the scope of this protocol.
Information on further investigations and their rationale can be obtained from GSK 
Biologicals. 
Any sample testing will be done in line with the consent of the individual subject. 
Any human pharmacogenetic testing will require specific consent from the individual 
subjects and the ethics committee approval. Any anti-HIV testing will also require 
specific consent and ethics committee approval.
Refer also to the Investigator Agreement, where it is noted that the Investigator cannot 
perform any other biological assays except those described in the protocol or its 
amendment(s). 
If additional testing is performed, the marker priority ranking given in Section 5.8.4 may 
be changed.
Collected samples will be stored for up to 15 years (counting from when the last subject 
performed the last study visit), unless local rules, regulations or guidelines require 
different timeframes or different procedures, which will then be in line with the subject 
consent. These extra requirements need to be communicated formally to and discussed
and agreed with GSK Biologicals.
5.8.1. Use of specified study materials
When materials are provided by GSK Biologicals, it is MANDATORY that all clinical 
samples (including serum samples) be collected and stored exclusively using those 
materials in the appropriate manner. The use of other materials could result in the 
exclusion of the subject from the ATP analysis (see Section 10.5 for the definition of 
study cohorts to be evaluated). The investigator must ensure that his/her personnel and 
the laboratory(ies) under his/her supervision comply with this requirement. However, 
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when GSK Biologicals does not provide material for collecting and storing clinical 
samples, then appropriate materials from the investigator’s site are to be used. Refer to 
the Module on Clinical Trial Supplies in the SPM.
5.8.2. Biological samples
The different biological samples collected in the study, the quantities needed, the units 
and the timepoints are described in Table 6. 
Table 6 Biological samples
Sample type Quantity(approximate volume) Unit Timepoint Subset Name*
Blood (Cell-mediated 
immunology ) 
20 mL Visit 1, 3, 4, 5, 6 CMI component of 
Immunogenicity subset
Blood (Humoral 
immunology) 
10 mL Visit 1, 3 All subjects 
10 mL Visit 4, 5, 6 Immunogenicity subset
Clinical specimens of 
HZ lesions
3 replicate samples, taken on 
the same day, of the highest 
priority lesion type available (1) 
vesicle fluid; 2) crust; 3) crust 
swab; 4) papule swab)
NA scheduled in case 
of suspected HZ 
for diagnosis 
Subjects clinically 
diagnosed as having a 
suspected case of HZ 
* Refer to Section 4.1 for description of the subsets
5.8.3. Laboratory assays
Please refer to Appendix A for a detailed description of the assays performed in the 
study.
Laboratory assays, which will be used in this study, are summarised in respectively Table
7 (Humoral Immunity), Table 8 (CMI) and Table 9 (Molecular Biology).
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Table 7 Humoral Immunity (Antibody determination)
System Component Method Kit / Manufacturer Unit Cut-off Laboratory
Serum Varicella Zoster 
Virus Ab.IgG
ELISA Enzygnost 
Dade Behring
mIU/mL 25 GSK 
Biologicals*
Serum gE Ab.IgG ELISA NA mIU/mL 18 GSK 
Biologicals*
Serum Varicella Zoster 
Virus Neutralizing 
Ab.IgG
PRNT NA ED50 TBD GSK 
Biologicals*
*GSK Biologicals laboratory or validated laboratory designated by GSK Biologicals.
ELISA = Enzyme-linked Immunosorbent Assay; PRNT = Plaque Reduction Neutralization Test
mIU = milli international unit; ED50 = endpoint dilution 50%
NA = Not applicable; TBD = to be determined; Ab = antibody
Table 8 Cell-Mediated Immunity (CMI)
System Component Challenge Method Unit Laboratory
Peripheral 
Blood 
Mononuclear 
Cells
Cells CD4.All double 
CD40 Ligand or 
Interleukin-2 or 
Tumor Necrosis 
Factor alpha or 
Interferon gamma 
gE ICS Events/10E6 GSK 
Biologicals*
Peripheral 
Blood 
Mononuclear 
Cells
Cells CD4.All double 
CD40 Ligand or 
Interleukin-2 or 
Tumor Necrosis 
Factor alpha or 
Interferon gamma 
VZV ICS Events/10E6 GSK 
Biologicals*
*GSK Biologicals laboratory or validated laboratory designated by GSK Biologicals.
ICS = Intracellular cytokine staining
Table 9 Molecular Biology (PCR tests)
System Component Method Unit Laboratory
HZ lesion sample Varicella Zoster 
Viirus.DNA
QPCR No unit GSK 
Biologicals*
HZ lesion sample Herpes Simplex 
Virus.DNA
QPCR No unit GSK 
Biologicals*
HZ lesion sample Actin 
Gene.DNA
QPCR No unit GSK 
Biologicals*
*GSK Biologicals laboratory or validated laboratory designated by GSK Biologicals.
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Collected samples will be used for purposes related to the quality assurance of data 
generated within the scope of this protocol, such as for maintenance of assays described 
in this protocol and comparison between analytical methods and/or laboratories.
The GSK Biologicals’ clinical laboratories have established a Quality System supported 
by procedures. The activities of GSK Biologicals’ clinical laboratories are audited 
regularly for quality assessment by an internal (sponsor-dependent) but laboratory-
independent Quality Department.
5.8.4. Biological samples evaluation
5.8.4.1. Immunological read-outs
The plan for immunogenicity testing on samples obtained is shown in Table 10. In case 
of insufficient blood sample volume to perform the assays, the samples will be analysed 
according to priority ranking provided in Table 10.
 For subjects included in the Immunogenicity subset (humoral immunity), anti-
gE and anti-VZV Abs will be measured at specified timepoints. An anti-VZV 
neutralizing Ab assay may also be performed on the serum blood samples from a 
subgroup of subjects of the Immunogenicity subset.
 For a subgroup of subjects included in the CMI component of the 
Immunogenicity subset, CMI response will be measured at specified timepoints.
 For the correlates of protection analysis, analysis of the humoral immune 
responses at Month 3 will be performed on samples collected from vaccinated 
subjects who develop confirmed HZ and compared with the humoral immune 
responses at Month 3 from matched subjects that did not develop HZ. Additional 
blood samples may be analysed from other subjects to match more exactly with 
characteristics of those that developed HZ. 
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Table 10 Immunological read-outs
Blood sampling timepoint
Visit no Timing Month
Subset* Name Marker Components 
priority rank 
Visit 1 Pre-Vacc 1 0 Immunogenicity subset Ab gE ELISA 1
Immunogenicity subset Ab VZV ELISA 2
Immunogenicity subset** anti-VZV 
neutralizing Ab
3
CMI component of Immunogenicity 
subset
ICS gE 1
CMI component of Immunogenicity 
subset
ICS VZV 2
Correlate of protection analysis‡ Ab gE ELISA 1
Correlate of protection analysis‡ Ab VZV ELISA 2
Visit 3 Post-Vacc 2 Immunogenicity subset Ab gE ELISA 13
Immunogenicity subset Ab VZV ELISA 2
Immunogenicity subset** anti-VZV 
neutralizing Ab
3
CMI component of Immunogenicity 
subset
ICS gE 1
CMI component of Immunogenicity 
subset
ICS VZV 2
Correlate of protection analysis‡ Ab gE ELISA 1
Correlate of protection analysis‡ Ab VZV ELISA 2
Visit 4 Post-Vacc 2 14 Immunogenicity subset Ab gE ELISA 1
Immunogenicity subset Ab VZV ELISA 2
Immunogenicity subset** anti-VZV 
neutralizing Ab
3
CMI component of Immunogenicity 
subset
ICS gE 1
CMI component of Immunogenicity 
subset
ICS VZV 2
Visit 5 Post-Vacc 2 26 Immunogenicity subset Ab gE ELISA 1
Immunogenicity subset Ab VZV ELISA 2
Immunogenicity subset** anti-VZV 
neutralizing Ab
3
CMI component of Immunogenicity 
subset
ICS gE 1
CMI component of Immunogenicity 
subset
ICS VZV 2
Visit 6 Post-Vacc 2 38 Immunogenicity subset Ab gE ELISA 1
Immunogenicity subset Ab VZV ELISA 2
Immunogenicity subset** anti-VZV 
neutralizing Ab
3
CMI component of Immunogenicity 
subset
ICS gE 1
CMI component of Immunogenicity 
subset
ICS VZV 2
* Refer to Section 4.1 for description of subsets.
** Anti-VZV neutralizing Ab assay may be performed in a subgroup of the Immunogenicity subset.
‡ Refer also to Section 10.8.3.4 for details regarding correlate of protection analysis
Note: Test results obtained for the anti-gE and anti-VZV Ab ELISA assays will be used for correlate of protection 
analysis, if applicable.
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Additional testing may be performed if deemed appropriate by GSK Biologicals should 
any findings in the present study, or in other studies, indicate that further investigation of 
the immunogenicity of the vaccine is warranted. In this case, the rankings above may also 
change.
5.8.4.2. Test for laboratory diagnosis of HZ
In case of a suspected HZ case diagnosis in any of the subjects, clinical specimens from 
HZ lesions will be collected to confirm the diagnosis of HZ by PCR. Please refer to 
Appendix A for or a detailed description of the PCR.
5.8.5. Immunological correlates of protection
No correlate of protection has been demonstrated so far for the antigen used as part of the 
candidate vaccine.
Study ZOSTER-006 will attempt to correlate humoral immune responses at Month 3 with 
protection. Additional evaluations to add precision to this assessment may be performed
(see Section 10.8.3.4). 
6. STUDY VACCINE AND ADMINISTRATION
6.1. Description of study vaccine
The Quality Control Standards and Requirements for the candidate vaccine are described 
in separate Quality Assurance documents (e.g. release protocols, certificate of analysis) 
and the required approvals have been obtained. 
The vaccine is labelled and packed according to applicable regulatory requirements. 
The study vaccine will be supplied in 2 vials, one containing the VZV gE antigen, and the 
other containing Adjuvant System AS01B.
 The VZV gE antigen is provided in a lyophilized form in monodose vials. Each 
vial contains 62.5 g of recombinant purified gE and formulation excipients. 
Therefore, when the 62.5 g of VZV gE in each vial is reconstituted with the 
full volume of adjuvant, each vaccine dose will contain 50 g of the VZV gE 
antigen per 0.5 mL of reconstituted vaccine.
 The AS01B Adjuvant System is provided as a liquid formulation in monodose 
vials, each vial containing at least 0.5 mL of adjuvant. One 0.5 mL dose of 
AS01B formulation contains 50 g of MPL and 50 g of QS21 mixed with 
liposomes.
When the VZV gE antigen is reconstituted in AS01B it appears as an opalescent, 
colourless liquid, free from visible particles.
 
 ( - )
i l
14f52be5fd11c61d592d2b59e6184d3d
CONFIDENTIAL
110390 (ZOSTER-006)
Final
07-APR-2010 68
After reconstitution, each 0.5 mL dose of study vaccine contains 50 g of gE 
recombinant protein, 50 g of MPL, 50 g of QS21, and liposomes. 
The NaCl solution is provided in monodose vials (0.5 mL/dose) containing 150 mM 
NaCl per 0.5 mL dose. The NaCl solution used as the placebo appears clear and 
colourless and is free from visible particles.
The method of preparation of the gE/AS01B study vaccine (reconstitution required) 
differs from that of the placebo (no reconstitution required for the NaCl solution 
placebo). The reconstituted gE/AS01B study vaccine differs in appearance from the NaCl 
solution placebo. To conduct the study in an observer-blind manner, the gE/AS01B
vaccine and NaCl solution placebo doses will be prepared and administered by study staff 
not involved in the clinical evaluation of the subjects. In this way, neither the subject nor 
the investigator (or other study personnel) will know which treatment was administered. 
The method of blinding and the responsibilities of the study personnel in this regard will 
be documented by the investigator at each study site.
The SPM will include details of vaccine supplies.
6.2. Storage and handling of study vaccine
All study vaccines to be administered to the subjects must be stored in a safe and locked 
place with no access by unauthorised personnel. 
The study vaccines will be stored at the defined temperature range (i.e. +2 to +8°C/36F 
to 46F) and must not be frozen. Please refer to the Module on Clinical Trial Supplies in 
the SPM for more details on storage of the study vaccine. The storage temperature of the 
vaccine will be monitored daily with validated temperature monitoring device(s) and will 
be recorded as specified in the SPM. 
The storage conditions will be assessed during pre-study activities under the 
responsibility of the sponsor study contact.
Any temperature deviation, i.e. temperature outside the defined range (+2 to +8°C/36F 
to 46F of storage) , must be reported to the sponsor as soon as detected. Following an 
exposure to a temperature deviation, vaccines will not be used until written approval has 
been given by the Sponsor.
Refer to the Module on Clinical Trial Supplies in the SPM for details and instructions on 
the packaging and accountability of the study vaccine.
6.3. Dosage and administration of study vaccine
The vaccine should be reconstituted shortly after the vials are taken out of the 
refrigerator. The reconstituted vaccine is stable for up to two hours when kept at a
temperature range of +2°C (36°F) to 30°C (86°F). .Therefore, reconstituted vaccines 
should be administered within a maximum of two hours after reconstitution.
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To reconstitute gE/AS01B study vaccine, the entire content of one diluent vial (i.e. 
AS01B) is aspirated into a syringe and injected into one vial of lyophilized gE antigen. 
The pellet is dissolved by gentle shaking of the vial (for a few seconds) until complete 
dissolution of the lyophilized cake.
Table 11 summarises how vaccine will be administered.
The entire volume of the reconstituted vaccine should be withdrawn, the needle can be 
replaced, and any solution in excess of 0.5mL should be expelled. After confirming that 
the needle is not in a blood vessel, the reconstituted vaccine should be administered by 
IM injection, preferably into the deltoid muscle of the non-dominant arm, using a 
standard aseptic technique. A 0.5 mL dose of the NaCl solution placebo should be 
injected IM. The injection site should be on the same arm for all injections for an 
individual subject. In rare situations when there is no other alternative, the second 
injection may be given on the different arm.
Table 11 Dosage and administration
Group Visit Vaccination Treatment Route Site Side
Vaccine 1, 2 1, 2 gE/AS01B IM D Non-dominant arm
Placebo 1, 2 1, 2 NaCl solution placebo IM D Non-dominant arm
gE/AS01B: lyophilized gE reconstituted in liquid AS01B Adjuvant System
Intramuscular (IM)
Deltoid (D) muscle of non-dominant arm
6.4. Replacement of unusable vaccine
Additional vaccine doses will be provided to replace those that are unusable (see the 
Module on Clinical Trial Supplies in the SPM for details).
In addition to the vaccine doses provided for the planned number of subjects (including 
over-randomization when applicable), at least 5% additional doses will be supplied to 
replace those that are unusable. 
The investigator will use the central randomization system (SBIR) to obtain the 
replacement vial number. The system will ensure, in a blinded manner, that the 
replacement vial is of the same formulation as the randomized vaccine.
6.5. Contraindications to subsequent vaccination
The following events constitute absolute contraindications to further administration of 
gE/AS01B. If any of these events occur during the study, the subject must not receive 
additional doses of vaccine but may continue other study procedures at the discretion of 
the investigator (see Section 8.4.4). 
 Anaphylaxis following the administration of vaccine(s);
 Pregnancy (Section 8.2.2);
 Any confirmed or suspected immunosuppressive or immunodeficient condition 
resulting from disease (e.g., malignancy, HIV infection) or 
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immunosuppressive/cytotoxic therapy (e.g., medications used during cancer 
chemotherapy, organ transplantation or to treat autoimmune disorders). 
However subjects who have received less than 15 days of immunosuppressants 
or other immune modifying drugs should not be contraindicated from receiving 
subsequent vaccinations. Also, for corticosteroids, prednisone < 20 mg/day, or 
equivalent, is allowed. Inhaled and topical steroids are allowed. 
The following events constitute contraindications to administration of the gE/AS01B HZ 
vaccine at that point in time; if any one of these events occurs at the time scheduled for 
vaccination, the subject may be vaccinated at a later date, within the time window 
specified in the protocol (Section 5.6), or withdrawn at the discretion of the investigator 
(Section 8.4.4).
 Acute disease and/or fever at the time of vaccination. 
 Fever is defined as temperature ≥ 37.5°C (99.5°F) on oral, axillary or tympanic 
setting, or  38.0°C (100.4°F) on rectal setting. The preferred route for recording 
temperature in this study will be oral.
Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory 
infection) without fever can be administered all vaccines. 
See Section 5.7.3.7 for an additional criterion to be checked prior to administration of the 
second vaccination dose.
6.6. Concomitant medication/vaccination
At each study visit/contact, the investigator should question the subject about any 
medication taken and vaccination received by the subject.
Concomitant medication administered for the treatment of NOADs or other immune 
mediated inflammatory disorders at any time during the study must be recorded in the 
eCRF. Refer to Section 8.3.2.5 for information regarding NOADs and other immune 
mediated inflammatory disorders.
Any concomitant medication administered for the treatment of confirmed or suspected 
HZ or any HZ-related complications (including pain) at any time during the study must 
be recorded in the eCRF and coded as ‘Treatment for HZ’.
Administration of any medications/vaccinations/products listed in Section 6.6.1 must be 
recorded in the eCRF respecting the time window as detailed in Section 6.6.2.
All concomitant medications, with the exception of vitamins and/or dietary supplements, 
administered at ANY time during the 30 days (Days 0 -29) after each vaccination are to 
be recorded in the eCRF. This also applies to concomitant medication administered 
prophylactically in anticipation of reaction to the vaccination and any medication 
intended to treat an AE.
A prophylactic medication is a medication administered in the absence of ANY symptom 
and in anticipation of a reaction to the vaccination (e.g. an anti-pyretic is considered to be 
prophylactic when it is given in the absence of fever [oral/tympanic on oral 
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setting/axillary temperature < 37.5°C (99.5°F), or < 38.0°C (100.4°F) on rectal setting] 
and any other symptom, to prevent fever from occurring).
Similarly, concomitant medication administered for the treatment of a SAE must be 
recorded on the SAE screens in the eCRF, as applicable. Refer to Section 8.1.2 for the 
definition of a SAE and Section 8.3.1 for SAE reporting periods.
6.6.1. Medications/products that may lead to the elimination of a 
subject from ATP analyses
The following criteria should be checked at each visit subsequent to the first vaccination. 
If any become applicable during the study, it will not require withdrawal of the subject 
from the study but may determine a subject’s evaluability in the ATP analysis. See 
Section 10.5 for definition of study cohorts to be evaluated.
 Use of any investigational or non-registered product (drug or vaccine) other than 
the study vaccine during the study period;
 Administration of a vaccine not foreseen by the study protocol within 30 days 
prior to dose 2 of vaccine and/or within 30 days after any dose. However, 
licensed non-replicating vaccines (i.e., inactivated and subunit vaccines, 
including inactivated and subunit influenza vaccines, with or without adjuvant
for seasonal or pandemic flu) may be administered up to 8 days prior to dose 2 
and/or at least 14 days after any dose of study vaccine;
 Receipt of a vaccine against HZ other than the study vaccine during the study 
period;
 Prolonged use (> 14 consecutive days) of oral and/or parenteral antiviral agents 
that are active against VZV (acyclovir, valacyclovir, famciclovir etc.) during the 
study period for an indication other than to treat suspected or confirmed HZ or 
an HZ-related complication (topical use of these antiviral agents is allowed);
 Receipt of immunoglobulins and/or any blood products during the study period;
 Chronic administration (defined as > 15 consecutive days) of 
immunosuppressants or other immune-modifying drugs during the study period. 
For corticosteroids, this will mean prednisone < 20 mg/day, or equivalent, is 
allowed. Inhaled and topical steroids are allowed.
A detailed, comprehensive list of reasons for elimination from ATP analyses will be 
established at the time of data cleaning.
6.6.2. Time window for recording concomitant medication/vaccination
in the eCRF
All concomitant medications administered for the treatment of all SAEs from Day 0 until
Month 14, are to be recorded in the eCRF.
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Concomitant medication, administered for the treatment of SAEs related to study 
participation or to a concurrent GSK medication/vaccine or any fatal SAE, from Day 0 
until Study conclusion contact, must be recorded in the eCRF.
Concomitant medication, administered for the treatment of HZ or any related HZ-
complications, or for the treatment of NOADs or other immune-mediated inflammatory 
disorders, from Day 0 until Study conclusion contact, must be recorded in the eCRF.
Oral and/or parenteral antiviral agents that are active against VZV (acyclovir, 
valacyclovir, famciclovir etc.) administered for > 14 consecutive days for an indication 
other than to treat suspected or confirmed HZ or an HZ-related complication from Day 0 
until Study conclusion contact, are to be recorded in the eCRF;
Any vaccine not foreseen in the study protocol, administered from Day 0 until Month 3, 
is to be recorded in the eCRF.
Any investigational medication or investigational vaccine, administered from Day 0 
through Study conclusion contact, must be recorded in the eCRF.
Any vaccine against HZ other than the study vaccine, administered from Day 0 until 
Study conclusion contact, is to be recorded in the eCRF.
Immunoglobulins and/or any blood products, administered from Day 0 until Study 
conclusion contact, are to be recorded in the eCRF;
Immunosuppressants or other immune-modifying drugs administered during the study 
period for > 15 consecutive days, are to be recorded in the eCRF. For corticosteroids, this 
will mean prednisone  20 mg/day, or equivalent.
All concomitant medications, with the exception of vitamins and/or dietary supplements, 
administered at ANY time during the 30 days (Days 0 -29) after each vaccination are to 
be recorded in the eCRF.
6.7. Intercurrent medical conditions that may lead to elimination
from an ATP cohort
Subjects may be eliminated from the ATP cohort for immunogenicity if, during the study, 
they incur a condition that has the capability of confounding their immune response to the 
study vaccine (i.e. a confirmed case of HZ prior to one month after the second 
vaccination); or they have any confirmed or suspected immunosuppressive or 
immunodeficient condition resulting from disease (e.g. malignancy, HIV infection). 
Intercurrent conditions except HZ prior to one month after the second vaccination should 
be reported in the AE section of the eCRF.
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7. HEALTH ECONOMICS
The following questionnaires will be administered to the subjects:
 EQ-5D questionnaire
The EQ-5D is a generic multi-attribute health classification system. The EQ-5D uses 
a 5-dimension (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) descriptive system, with each consisting of 3 response options 
(no problems, moderate problems or extreme problems). The EQ-5D also includes a 
Visual Analogue Scale (VAS) ranging from 0 to 100, with 100 representing the best 
imaginable health state and 0 representing the worst imaginable health state.
 SF-36 health survey
The SF-36® is a multi-purpose health survey with 36 questions. It yields an 8-scale 
profile of scores (physical functioning, role physical, bodily pain, general health 
perceptions, vitality, social functioning, role emotional, and mental health) as well as 
a reported health transition score.
Both the EQ-5D and SF-36 questionnaires are international standards and have been 
extensively validated. They will generate Quality-Adjusted Life Years (QALY) weights 
in order to estimate the cost-effectiveness of an HZ vaccination strategy.
A standard algorithm has been developed for processing subjects’ answers and producing 
QALY weights. These QALY weights will be generated for each age group: 50-59 YOA, 
60-69 YOA and  70 YOA.
EQ-5D and SF-36 will be completed at Visit 1 for all subjects in order to generate a 
baseline measurement.
For subjects with clinically diagnosed suspected HZ, both questionnaires will be 
completed weekly from Day HZ-0 onwards until the case of clinically diagnosed 
suspected HZ is disproved, OR until a 4-week pain-free period is documented, OR until 
the cut-off date for final analysis. For all subjects with HZ-associated pain, data will be 
collected until at least Day HZ-90, regardless of the cut-off date for final analysis. For all 
subjects, the EQ-5D and SF-36 questionnaires will be completed at Visits 4, 5 and 6
(subjects with an ongoing HZ episode will follow the weekly schedule and do not need to 
additionally complete the questionnaires at these visits).
QALY weights measured for HZ cases in vaccine and placebo recipients will be 
compared and adjusted for their respective baseline values.
8. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
The investigator or site staff is/are responsible during the study for the detection and 
documentation of events meeting the criteria and definition of an adverse event (AE) or 
serious adverse event (SAE) as provided in this protocol.
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Each subject will be instructed to contact the investigator immediately should they/the 
subject manifest any signs or symptoms they perceive as serious.
8.1. Safety definitions
8.1.1. Definition of an adverse event
An AE is any untoward medical occurrence in a clinical investigation subject, temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with 
the use of a medicinal product. For marketed medicinal products, this also includes 
failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. 
Examples of an AE include:
 Significant or unexpected worsening or exacerbation of the condition/indication 
under study. 
 Exacerbation of a chronic or intermittent pre-existing condition including either 
an increase in frequency and/or intensity of the condition.
 New conditions detected or diagnosed after investigational product 
administration even though they may have been present prior to the start of the 
study.
 Signs, symptoms, or the clinical sequelae of a suspected interaction.
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concurrent medication (overdose per se should not 
be reported as an AE/SAE).
Examples of an AE DO NOT include:
 Medical or surgical procedures (e.g. endoscopy, appendectomy); the condition 
that leads to the procedure is an AE.
 Situations where an untoward medical occurrence did not occur (e.g. social 
and/or convenience admission to a hospital, admission for routine examination).
 Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen. 
AEs may include pre- or post-treatment events that occur as a result of protocol-
mandated procedures (i.e. invasive procedures, modification of subject’s previous 
therapeutic regimen).
NB: AEs to be recorded as endpoints (solicited AEs) are described in Section 8.1.3. All 
other AEs will be recorded as UNSOLICITED AEs. (For subjects not included in the 7-
day diary card subset, all AEs will be recorded as UNSOLICITED AEs.) 
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Example of events to be recorded in the medical history section of the eCRF:
 Pre-existing conditions or signs and/or symptoms present in a subject prior to 
the start of the study (i.e. prior to the first study vaccination).
The occurrence of HZ or PHN will not constitute an AE or SAE. However, complications 
or presentations of HZ or PHN that, in the opinion of the investigator, are not typical of 
these diseases may be AEs or SAEs. 
8.1.2. Definition of a serious adverse event 
A serious adverse event (SAE) is any untoward medical occurrence that:
a. Results in death.
b. Is life-threatening.
NB: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in 
which the subject was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, had it been more severe.
c. Requires hospitalisation or prolongation of existing hospitalisation.
NB: In general, hospitalisation signifies that the subject has been admitted at the 
hospital or emergency ward for observation and/or treatment that would not have 
been appropriate in the physician’s office or out-patient setting. Complications that 
occur during hospitalisation are also considered AEs. If a complication prolongs 
hospitalisation or fulfils any other serious criteria, the event will also be considered 
serious. When in doubt as to whether ‘hospitalisation’ occurred or was necessary, the 
AE should be considered serious.
Hospitalisation for elective treatment of a pre-existing condition (known/diagnosed 
prior to informed consent signature) that did not worsen from baseline is NOT
considered an AE.
d. Results in disability/incapacity, or
NB: The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions. This definition is not intended to include experiences 
of relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhoea, influenza like illness, and accidental trauma (e.g. sprained 
ankle) which may interfere or prevent everyday life functions but do not constitute a 
substantial disruption.
e. Is a congenital anomaly/birth defect in the offspring of a study subject.
Medical or scientific judgement should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalisation but may jeopardise the 
subject or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These should also be considered serious. 
Examples of such events are invasive or malignant cancers, intensive treatment in an 
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emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions 
that do not result in hospitalisation.
8.1.3. Solicited adverse events
Subjects in the 7-day diary card subset will be asked to report daily, from Day 0 to Day 6 
(7-day follow-up period) after each dose, the occurrence of local or general solicited 
adverse experiences on a safety diary card provided by the sponsor. All clinical signs and 
symptoms will be recorded by the investigator on the appropriate section of the eCRF.
The following local (injection-site) AEs will be solicited (Table 12):
Table 12 Solicited local adverse events
Pain at injection site
Redness at injection site
Swelling at injection site
The following general AEs will be solicited (Table 13):
General AEs are any experiences, which do not occur at the site of injection of a vaccine. 
They will be recorded as ‘general’ and include those events.
Table 13 Solicited general adverse events
Fatigue
Fever
Gastrointestinal symptoms †
Headache
Myalgia
Shivering
†Gastrointestinal symptoms include nausea, vomiting, diarrhoea and/or abdominal pain
NB: Temperature will be recorded in the evening. Should additional temperature 
measurements be performed at other times of day, the highest temperature will be 
recorded in the eCRF.
8.1.4. Clinical laboratory parameters and other abnormal assessments
qualifying as adverse events or serious adverse events 
Safety laboratories are not collected in this study. Abnormal laboratory findings (e.g. 
clinical chemistry, haematology, urinalysis) or other abnormal assessments that come to 
the attention of, and are judged by, the investigator to be clinically significant will be 
recorded as AEs or SAEs if they meet the definition of an AE, as defined in Section 8.1.1
or of a SAE, as defined in Section 8.1.2. Clinically significant abnormal laboratory 
findings or other abnormal assessments that are detected during the study or are present at 
baseline and significantly worsen following the start of the study will be reported as AEs 
or SAEs. 
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The investigator will exercise his or her medical and scientific judgement in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant.
8.2. Events or outcomes not qualifying as adverse events or 
serious adverse events
8.2.1. Disease-related events or outcomes not qualifying as serious 
adverse events
The occurrence of HZ or PHN will not constitute an SAE. However, complications or 
presentations of HZ or PHN that, in the opinion of the investigator, are not typical of 
these diseases may be SAEs.
8.2.2. Pregnancy
Any female subjects that are pregnant or lactating at the time of vaccination must not 
receive additional doses of study vaccine/placebo but may continue other study 
procedures at the discretion of the investigator.
While pregnancy itself is not considered an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be recorded as an AE or a 
SAE, as described in Section 8.1.1 and 8.1.2, and will be followed as described in Section
8.4.4.
A spontaneous abortion is always considered to be a SAE and will be reported as 
described in Section 8.4. Furthermore, any SAE occurring as a result of a post-study 
pregnancy AND considered by the investigator to be reasonably related in time to the 
receipt of the investigational product will be reported to GSK Biologicals as described in 
Section 8.4. While the investigator is not obligated to actively seek this information from 
former study participants, he/she may learn of a pregnancy through spontaneous 
reporting.
Information on pregnancies identified during screening/prior to vaccine administration is 
not required to be collected and communicated to safety.
8.3. Detecting and recording adverse events, serious adverse 
events and pregnancies
8.3.1. Time period for detecting and recording adverse events, serious 
adverse events and pregnancies
Solicited AEs will be evaluated only in subjects who are part of the 7-day diary card 
subset. Unsolicited AEs will be evaluated in all subjects from Day 0 to Day 29 after each 
vaccination.
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All AEs occurring from Day 0 to Day 29 after each vaccination must be recorded into the 
Adverse Event screen in the subject’s eCRF, irrespective of intensity or whether or not 
they are considered vaccination-related. 
SAEs will be evaluated in all subjects. The standard time period for collecting and 
recording SAEs will begin at Day 0 and continue until Month 14 for each subject. See 
Section 8.4 for instructions on reporting and recording SAEs.
In addition to the above-mentioned reporting requirements and in order to fulfil 
international reporting obligations, SAEs that are related to study participation (e.g. 
protocol-mandated procedures, invasive tests, a change from existing therapy) or are 
related to a concurrent GSK medication/vaccine or any fatal SAE will be collected and 
recorded from the time the subject consents to participate in the study until she/he is 
discharged.
NOADs and other immune mediated inflammatory disorders will be evaluated in all 
subjects during the entire study period (Section 8.3.2.5).
Medically attended visits will be evaluated in all subjects from Day 0 until Month 8 
(Section 8.3.2.4).
Intercurrent medical conditions (Section 6.7) will be recorded in all subjects throughout 
the entire study period. 
An overview of the protocol-required reporting periods for AEs and SAEs, NOADs and 
other immune mediated inflammatory disorders, medically attended visits, pregnancies, 
and intercurrent medical conditions in study ZOSTER-006 is shown in Table 14.
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Table 14 Reporting periods for AEs, SAEs, new onset of autoimmune diseases, medically attended visits, pregnancies and 
intercurrent medical conditions in study ZOSTER-006 
CONTACT (monthly after Visit 3 until study conclusion, except at 
months that coincide with the subject’s scheduled visits)
Study activity VISIT 1
DOSE 1
VISIT 2
DOSE 2
VISIT 3 CONTACT VISIT 4 VISIT 5 VISIT 6 Study 
conclusion 
contact
Timing of reporting Day 0/
Month 0
Day 6 
post 
Dose 1
Day 29 
post 
Dose 1
Day 0/
Month 2
Day 6 
post 
Dose 2
Day 29 
post 
Dose 2
 Month 3 Month 8 Month 14 Month 26 Month 38
Reporting of solicited AEs (only in 7-
day diary card subset)
Reporting of unsolicited AEs 
Reporting of all SAEs until Month 14
Reporting of SAEs related to study 
participation or GSK concomitant 
medication/vaccine or any fatal SAE
after Month 14 until study conclusion
Reporting of NOADs and other 
immune mediated inflammatory 
disorders
Reporting of medically attended visits
until Month 8
Reporting of pregnancies
Recording of intercurrent medical 
conditions 
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A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
reporting period defined in Table 14. Investigators are not obligated to actively seek AEs 
or SAEs in former study participants. However, if the investigator learns of any SAE, 
including a death, at any time after a subject has been discharged from the study, and 
he/she considers the event reasonably related to the investigational product, the 
investigator will promptly notify the Study Contact for Reporting SAEs.
8.3.2. Evaluation of adverse events and serious adverse events
8.3.2.1. Active questioning to detect adverse events and serious adverse 
events
As a consistent method of soliciting AEs, the subject should be asked a non-leading 
question such as:
‘Have you felt different in any way since receiving the vaccine or since the previous 
visit?’
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospital progress notes, laboratory, and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE on the eCRF or SAE Report screens as applicable. It is not acceptable for the 
investigator to send photocopies of the subject’s medical records to GSK Biologicals 
instead of the appropriate completed AE/SAE screens in the eCRF. However, there may 
be instances when copies of medical records for certain cases are requested by GSK 
Biologicals. In this instance, all subject identifiers will be blinded on the copies of the 
medical records prior to submission to GSK Biologicals.
The investigator will attempt to establish a diagnosis pertaining to the event based on 
signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs/symptoms.
8.3.2.2. Assessment of adverse events
8.3.2.2.1. Assessment of intensity
Intensity of the following AEs will be assessed as described:
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Table 15 Intensity scales for solicited symptoms 
Adverse Event Intensity grade Parameter
Pain at injection site 0 None
1 Mild: Any pain neither interfering with nor preventing 
normal every day activities.
2 Moderate: Painful when limb is moved and interferes with 
every day activities.
3 Severe: Significant pain at rest. Prevents normal every 
day activities.
Redness at injection site Record greatest surface diameter in mm
Swelling at injection site Record greatest surface diameter in mm
Fever* Record temperature in °C/°F
Headache 0 Normal
1 Mild: Headache that is easily tolerated
2 Moderate: Headache that interferes with normal activity
3 Severe: Headache that prevents normal activity
Fatigue 0 Normal
1 Mild: Fatigue that is easily tolerated
2 Moderate: Fatigue that interferes with normal activity
3 Severe: Fatigue that prevents normal activity
Gastrointestinal symptoms 0 Gastrointestinal symptoms normal
(nausea, vomiting, diarrhoea and/or 
abdominal pain)
1 Mild: Gastrointestinal symptoms that are easily tolerated
2 Moderate: Gastrointestinal symptoms that interfere with 
normal activity
3 Severe: Gastrointestinal symptoms that prevent normal 
activity
Myalgia 0 Normal 
1 Mild: Myalgia that is easily tolerated
2 Moderate: Myalgia that interferes with normal activity
3 Severe: Myalgia that prevents normal activity
0 None
1 Shivering that is easily tolerated
2 Shivering that interferes with normal activity
Shivering
3 Shivering that prevents normal activity
*Fever is defined as: rectal temperature 38°C (100.4°F)/axillary temperature 37.5°C (99.5°F)/oral temperature 
37.5°C (99.5°F)/tympanic temperature on oral setting 37.5°C (99.5°F)/tympanic temperature on rectal setting 
38°C (100.4°F).The preferred route for recording temperature in this study will be oral. 
The maximum intensity of local injection site redness/swelling will be scored at GSK 
Biologicals using GSK Biologicals’ standard grading scale based on the US Food and 
Drug Administration (FDA) guidelines for Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers enrolled in Preventive Vaccine Clinical Trials” [FDA, 2007].
0 : < 20 mm diameter
1 :  20 mm to  50 mm diameter
2 : > 50 mm to  100 mm diameter
3 : > 100 mm diameter
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Temperature (measured by oral, axillary or tympanic route) will be scored at GSK 
Biologicals as follows:
0 : < 37.5°C 
1 : 37.5°C to 38.0°C 
2 : 38.1°C to 39.0°C
3 : > 39.0°C
The investigator will assess of the maximum intensity that occurred over the duration of 
the event for all other AEs, i.e. unsolicited symptoms, including SAEs reported during 
the study. The assessment will be based on the investigator’s clinical judgement.
The intensity of each AE and SAE recorded in the eCRF or SAE screens, as applicable, 
should be assigned to one of the following categories:
1 (mild) = An AE which is easily tolerated by the subject, causing minimal 
discomfort and not interfering with everyday activities.
2 (moderate) = An AE which is sufficiently discomforting to interfere with 
normal everyday activities.
3 (severe) = An AE which prevents normal, everyday activities. Such an AE 
would, for example prevent attendance at work and would 
necessitate the administration of corrective therapy.
An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. Grade 
3 is a category utilised for rating the intensity of an event; and both AEs and SAEs can 
be assessed as Grade 3. An event is defined as ‘serious’ when it meets one of the pre-
defined outcomes as described in Section 8.1.2.
8.3.2.2.2. Assessment of causality
The investigator is obligated to assess the relationship between investigational vaccine 
and the occurrence of each AE/SAE. The investigator will use clinical judgement to 
determine the relationship. Alternative plausible causes, based on natural history of the 
underlying diseases, concomitant therapy, other risk factors and the temporal relationship 
of the event to the investigational vaccine will be considered and investigated. The 
investigator will also consult the IB in the determination of his/her assessment.
There may be situations when a SAE has occurred and the investigator has minimal 
information to include in the initial report to GSK Biologicals. However, it is very 
important that the investigator always makes an assessment of causality for every event 
prior to submission of the SAE to GSK Biologicals. The investigator may change his/her 
opinion of causality in light of follow-up information, amending the SAE information 
accordingly. The causality assessment is one of the criteria used when determining 
regulatory reporting requirements.
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In case of concomitant administration of multiple vaccines, it may not be possible to 
determine the causal relationship of general AEs to the individual vaccines administered. 
The investigator should, therefore, assess whether the AE could be causally related to 
vaccination rather than to the individual vaccines.
All solicited local (injection site) reactions will be considered causally related to 
vaccination. Causality of all other AEs should be assessed by the investigator using the 
following question:
Is there a reasonable possibility that the AE may have been caused by the investigational
vaccine?
NO : The AE is not causally related to administration of the study 
vaccine(s). There are other, more likely causes and administration 
of the study vaccine(s) is not suspected to have contributed to the 
AE.
YES : There is a reasonable possibility that the vaccine(s) contributed to 
the AE. 
Non-serious and serious AEs will be evaluated as two distinct events. If an event meets 
criteria to be determined ‘serious’ (Section 8.1.2 for definition of serious adverse event), 
additional examinations/tests will be performed by the investigator in order to determine 
ALL possible contributing factors applicable to each SAE.
Possible contributing factors include:
 Medical history.
 Other medication.
 Protocol required procedure.
 Other procedure not required by the protocol.
 Lack of efficacy of the vaccine, if applicable.
 Erroneous administration.
 Other cause (specify).
8.3.2.3. Assessment of outcomes
Outcome of any non-serious AE (i.e. unsolicited AE) occurring from Day 0 to Day 29 
after each vaccination or any SAE reported during the entire study will be assessed as:
 Recovered/resolved.
 Not recovered/not resolved.
 Recovering/resolving.
 Recovered with sequelae/resolved with sequelae.
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 Fatal (SAEs only).
8.3.2.4. Medically attended visits
The subject will be asked if the subject received medical attention defined as 
hospitalization, an emergency room visit or a visit to or from medical personnel (medical 
doctor) for any reason, other than routine health care visits, from the first vaccination
until Month 8, and this information will be recorded in the eCRF.
8.3.2.5. AEs of specific interest
Adverse events of specific interest for safety monitoring include the NOADs and other 
immune mediated inflammatory disorders, such as those listed below.
Occurrences of AEs of specific interest will be reported throughout the entire study 
period, whether or not they are considered to be possibly related to the treatment 
administration. Medical documentation of the events will be reported in appropriate 
targeted follow-up forms included in the eCRF. These events have also to be reported as 
AE or SAE as appropriate in the eCRF.
AEs of interest to be reported and documented are the following:
 Neuroinflammatory disorders: cranial nerve disorders, multiple sclerosis, 
demyelinating disease, transverse myelitis, Guillain-Barré syndrome, 
myasthenia gravis, encephalitis, neuritis.
 Musculoskeletal disorders: systemic lupus erythematosus, cutaneous lupus, 
Sjogren’s syndrome, scleroderma, dermatomyositis, polymyositis, rheumatoid
arthritis, polymyalgia rheumatica, reactive arthritis, psoriatic arthropathy, 
ankylosing spondylitis, undifferentiated spondyloarthropathy.
 Gastrointestinal disorders: Crohn’s disease, ulcerative colitis, ulcerative 
proctitis, celiac disease.
 Metabolic diseases: autoimmune thyroiditis, Grave’s or Basedow’s disease, 
Hashimoto thyroiditis, insulin-dependent diabetes mellitus (IDDM), Addison’s 
disease.
 Skin disorders: psoriasis, vitiligo, Raynaud’s phenomenon, erythema nodosum, 
autoimmune bullous skin diseases.
 Other: autoimmune haemolytic anemia, thrombocytopenias, antiphospholipid 
syndrome, vasculitis, pernicious anemia, autoimmune hepatitis, primary biliary 
cirrhosis, primary sclerosing cholangitis, autoimmune glomerulonephritis, 
autoimmune uveitis, autoimmune myocarditis, sarcoidosis, Stevens-Johnson 
syndrome.
Medical or scientific judgment should be exercised in deciding whether other 
disorders/diseases have autoimmune origin and should be reported as appropriate.
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8.4. Reporting and follow-up of adverse events, serious adverse 
events and pregnancies
8.4.1. Prompt reporting of serious adverse events and other events to 
GSK Biologicals
SAEs will be reported promptly to GSK as described in Table 16 once the investigator 
determines that the event meets the protocol definition of an SAE.
Pregnancies will be reported promptly to GSK as described in Table 16 once the 
investigator becomes aware of a pregnancy in the time period defined in Section 8.3. The 
subject will be followed to determine the outcome of the pregnancy. At the end of the 
pregnancy, whether that be full-term or premature, information on the status of the 
mother and child will be forwarded to GSK. Generally, follow-up should be no longer 
than 6 to 8 weeks following the estimated delivery date.
Table 16 Time frames for submitting SAEs and other events reports to GSK 
Biologicals
Initial Reports Follow-up Information 
on a Previous Report
Type of 
Event
Time Frame Documents Time Frame Documents
All SAEs 24 hours* SAE screen 24 hours* SAE screen
Pregnancy 24 hours* Pregnancy Report Form 24 hours* Pregnancy Report Form
* Time frame allowed after receipt or awareness of the information.
In case the electronic reporting system is temporarily unavailable, a back up system is in 
place. Please refer to Section 8.4.3 for a detailed description.
Please see the Sponsor Information Sheet for details on study contact for reporting SAEs. 
Back-up Study Contact for Reporting SAEs
GSK Biologicals Clinical Safety & Pharmacovigilance
Fax:  or 
24/24 hour and 7/7 day availability
8.4.2. Regulatory reporting requirements for serious adverse events
The investigator will promptly report all SAEs to GSK in accordance with the procedures 
detailed in Section 8.4.1. GSK Biologicals has a legal responsibility to promptly notify, 
as appropriate, both the local regulatory authority and other regulatory agencies about the 
safety of a product under clinical investigation. Prompt notification of SAEs by the 
investigator to the Study Contact for Reporting SAEs is essential so that legal obligations 
and ethical responsibilities towards the safety of other subjects are met.
Investigator safety reports are prepared according to the current GSK policy and are 
forwarded to investigators as necessary. An investigator safety report is prepared for a 
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SAE(s) that is both attributable to the investigational product and unexpected. The 
purpose of the report is to fulfil specific regulatory and Good Clinical Practice (GCP) 
requirements, regarding the product under investigation.
8.4.3. Completion and transmission of SAEs reports to GSK Biologicals
Once an investigator becomes aware that a SAE has occurred in a study subject, the 
investigator will complete and submit the information in the SAE screens in eCRF within 
24 hours. The SAE screens in eCRF will always be completed as thoroughly as possible 
with all available details of the event and will be submitted by the investigator. If the 
investigator does not have all information regarding an SAE, he/she will not wait to 
receive additional information before notifying GSK of the event and completing the 
SAE screens in eCRF. The SAE screens in eCRF should be updated when additional 
relevant information is received WITHIN 24 HOURS.
The investigator will always provide an assessment of causality at the time of the initial 
report.
8.4.3.1. Back-up system in case the electronic SAE reporting system does not 
work
If the SAE reporting system has been down for 24 hours, the investigator or his/her 
delegate should fax an SAE report form directly to the GSK Central Safety department 
(please refer to Section 8.4.1) within 24 hours. The maximum timeline for reporting 
SAEs to central safety is therefore 48 hours. 
NB. This back-up system should only be used if the electronic reporting system is not 
working and NOT if the system is slow.
As soon as the electronic reporting system is working again, the investigator or delegate 
must update the SAE screens in the eCRF within 24 hours. 
The final valid information for regulatory reporting will be the information reported 
through the electronic system. 
When additional information is received on a SAE after freezing of the subject’s eCRF, 
new or updated information is to be recorded on the paper SAE Report Form, with all 
changes signed and dated by the investigator. The updated SAE Report Form should be 
sent to GSK Biologicals WITHIN 24 HOURS of receipt of the follow-up information.
In rare circumstances, if the electronic system for reporting SAEs does not work and in 
the absence of facsimile equipment, notification by telephone is acceptable, with a copy 
of the SAE Report Form sent by email or by mail. Initial notification via the telephone 
does not replace the need for the investigator to complete and submit SAE screens in the 
eCRF (or complete and sign the SAE Report Form if back-up system need to be used).
In the event of a death determined by the investigator to be related to vaccination, 
completion of SAE screens in the eCRF/sending of the fax (if electronic SAE reporting 
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system does not work or after freezing of the subject’s eCRF) must be accompanied by 
telephone call to the Study Contact for Reporting SAEs.
8.4.4. Follow-up of adverse events and serious adverse events
After the initial AE/SAE report, the investigator is required to proactively follow each 
subject and provide further information to GSK Biologicals on the subject’s condition.
All SAEs documented at a previous visit/contact and designated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until study 
conclusion.
All AEs documented at a previous visit/contact and designated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until 30 
days after the last vaccination.
Cases of new onset of autoimmune diseases and other immune-mediated inflammatory 
disorders documented at a previous visit/contact and designated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until study 
conclusion. 
Investigators will follow-up subjects:
 With SAEs or subjects withdrawn from the study as a result of an AE, until the 
event has resolved, subsided, stabilised, disappeared, or until the event is 
otherwise explained, or the subject is lost to follow-up. 
 Or, in the case of other non-serious AEs, cases of new onset of autoimmune 
diseases, until study conclusion or they are lost to follow-up.
Clinically significant laboratory abnormalities will be followed up until they have 
returned to normal, or a satisfactory explanation has been provided. Additional 
information (including but not limited to laboratory results) relative to the subsequent 
course of such abnormalities noted for any subject must be made available to the Site 
Monitor.
GSK Biologicals may request that the investigator perform or arrange for the conduct of 
additional clinical examinations/tests and/or evaluations to elucidate as fully as possible 
the nature and/or causality of the AE or SAE. The investigator is obliged to assist. If a 
subject dies during participation in the study or during a recognised follow-up period, 
GSK Biologicals will be provided with a copy of any available post-mortem findings, 
including histopathology.
8.5. Treatment of adverse events
Treatment of any adverse event is at the sole discretion of the investigator and according 
to current good medical practice. Any medication administered for the treatment of an 
AE should be recorded in the subject’s eCRF. Refer to Section 6.6.
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8.6. Unblinding
GSK Biologicals’ policy (incorporating ICH E2A guidance, EU Clinical Trial Directive 
and Federal Regulations) is to unblind any serious adverse event (SAE) report associated 
with the use of the investigational product, which is unexpected and 
attributable/suspected, prior to regulatory reporting. The GSK Biologicals’ Central Safety 
physician is responsible for unblinding the treatment assignment in accordance with 
specified time frames for expedited reporting of SAEs (refer to Section 8.4.1).
8.7. Emergency unblinding
The investigator, or other physician managing the subject, should contact GSK 
Biologicals’ Central Safety Physician to discuss the need for emergency unblinding. 
Alternatively the investigator may contact the local contact who will contact the GSK 
Central Safety Physician. 
An investigator should request for unblinding of the subject’s treatment code only in the 
case of a medical emergency, or in the event of a serious medical condition, when 
knowledge of the investigational study vaccine(s)/product(s) is essential for the clinical 
management or welfare of the subject. 
The GSK Biologicals’ Central Safety Office will be allowed to access the individual 
randomisation code. The code will be broken by the GSK Biologicals’ Central Safety 
physician (see below and Study Contact for Emergency Code Break in Sponsor 
Information) only in the case of medical events that the investigator/physician in charge 
of the subject feels cannot be treated without knowing the identity of the study 
vaccine(s)/product(s).
GSK Biologicals Central Safety Physician 
(Study Contact for Emergency Code Break)
Mobile phones for 7/7 day availability:
Outside US/Canada:
 (GSK Biologicals Central Safety Physician)
For US/Canada only:
 (Head Safety Evaluation and Risk Management North America)
Back-up mobile phone contact (all countries):
8.8. Subject card
Study subjects must be provided with the address and telephone number of the main 
contact for information about the trial.
Investigator/delegate should therefore provide a “subject card” to each subject. The aim 
of this card is to inform any physician having to deal with a subject in an emergency 
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situation that the subject is in a clinical trial and that he/she can contact the trial 
investigator for more relevant information.
Subjects must be instructed to keep these cards in their possession at all times.
9. SUBJECT COMPLETION AND WITHDRAWAL
9.1. Subject completion
A subject who returns for the concluding visit/is available for the concluding contact 
foreseen in the protocol is considered to have completed the study.
9.2. Subject withdrawal
Subjects who are withdrawn because of SAEs/AEs must be clearly distinguished from 
subjects who are withdrawn for other reasons. Investigators will follow subjects who are 
withdrawn as result of a SAE/AE until resolution of the event (Section 8.4).
Withdrawals will not be replaced.
9.2.1. Subject withdrawal from the study
From an analysis perspective, a ‘withdrawal’ from the study refers to any subject who did 
not come back for the concluding visit/was not available for the concluding contact 
foreseen in the protocol. 
All data collected until the date of withdrawal/last contact of the subject will be used for 
the analysis.
A subject is considered a ‘withdrawal’ from the study when no study procedure has 
occurred, no follow-up has been performed and no further information has been collected 
for this subject from the date of withdrawal/last contact.
Investigators will make an attempt to contact those subjects who do not return for 
scheduled visits or follow-up. 
Information relative to the withdrawal will be documented in the eCRF. The investigator 
will document whether the decision to withdraw a subject from the study was made by 
the subject himself/herself, or by the investigator, as well as which of the following 
possible reasons was responsible for withdrawal:
 Serious adverse event.
 Non-serious adverse event.
 Protocol violation (specify).
 Consent withdrawal, not due to an adverse event.
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 Moved from the study area.
 Lost to follow-up.
 Death.
 Other (specify).
9.2.2. Subject withdrawal from investigational vaccine
A ‘withdrawal’ from the investigational vaccine refers to any subject who does not 
receive the complete treatment, i.e. when no further planned dose is administered from 
the date of withdrawal. A subject withdrawn from the investigational vaccine may not 
necessarily be withdrawn from the study as further study procedures or follow-up may be 
performed (safety or immunogenicity) if planned in the study protocol. 
Information relative to premature discontinuation of the investigational vaccine will be 
documented on the Vaccine Administration screen of the eCRF. The investigator will 
document whether the decision to discontinue further vaccination/treatment was made by 
the subject himself/herself, or by the investigator, as well as which of the following 
possible reasons was responsible for withdrawal:
 Serious adverse event.
 Non-serious adverse event.
 Other (specify).
10. DATA EVALUATION: CRITERIA FOR EVALUATION OF 
OBJECTIVES
10.1. Primary endpoint
 Confirmed HZ cases
 Confirmed HZ cases during the study in the modified total vaccinated cohort 
(mTVc).
10.2. Secondary endpoints
 Occurrence of overall PHN
 Incidence of PHN calculated using the mTVc;
 Duration of severe ‘worst’ HZ-associated pain
 Duration of severe ‘worst’ HZ-associated pain following the onset of a 
confirmed HZ rash over the entire pain reporting period as measured by the 
ZBPI in subjects with confirmed HZ;
 Incidence of overall and HZ-related mortality
 Incidence of overall and HZ-related mortality during the study;
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 Incidence of HZ complications
 Incidence of HZ complications during the study in subjects with confirmed HZ;
 Incidence of overall and HZ-related hospitalizations
 Incidence of overall and HZ-related hospitalizations during the study;
 Duration of pain medication administered for HZ
 Duration of pain medication administered for HZ during the study in subjects 
with confirmed HZ;
 Solicited local and general symptoms in a subset of subjects
 Occurrence, intensity of each solicited local symptom within 7 days (Days 0 
6) after each vaccination, in subjects included in the 7-day diary card subset;
 Occurrence, intensity and relationship to vaccination of each solicited general 
symptom within 7 days (Days 0  6) after each vaccination, in subjects included 
in the 7-day diary card subset;
 Unsolicited AEs 
 Occurrence, intensity and relationship to vaccination of unsolicited AEs during 
30 days (Days 0  29) after each vaccination, according to the Medical 
Dictionary for Regulatory Activities (MedDRA) classification, in all subjects;
 Serious AEs
 Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 
14 in all subjects;
 Occurrence of SAEs related to study participation or to a concurrent GSK 
medication/vaccine during the entire study period in all subjects;
 Occurrence of any fatal SAEs during the entire study period in all subjects;
 Occurrence of pre-defined AEs
 Occurrence and relationship to vaccination of any NOADs and other immune 
mediated inflammatory disorders during the entire study period in all subjects; 
 Occurrence of medically attended visits
 Occurrence and relationship to vaccination of medically attended visits (defined 
as hospitalizations, emergency room visits or visits to or from medical 
personnel), other than routine health care visits, from Month 0 to Month 8 in all 
subjects.
10.3. Exploratory endpoints
 Acute HZ severity
 Acute HZ severity as determined by the mean Area Under Curve (AUC) of the
severity-by-duration of HZ-associated pain as measured by the ZBPI during a 4-
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week period following the onset of confirmed HZ in subjects with confirmed 
HZ;
 Interference of HZ with QoL
 Interference of HZ with QoL as measured by ZBPI in subjects with confirmed 
HZ;
 Interference of HZ with QoL as measured by EQ-5D in subjects with confirmed 
HZ;
 Interference of HZ with QoL as measured by SF-36 in subjects with confirmed 
HZ;
 HZ BOI
 HZ BOI as determined by the mean AUC of the severity-by-duration HZ-
associated pain during a 26 week period following the onset of the HZ rash in 
the mTVc;
 CMI in terms of frequencies of antigen-specific CD4 T cells at Months 0, 3, 14, 
26 and 38
 Frequencies of CD4 T cells with antigen-specific Interferon gamma (IFN-) 
and/or Interleukin-2 (IL-2) and/or Tumour Necrosis Factor alpha (TNF-) 
and/or CD40 Ligand (CD40L) secretion/expression to gE and VZV as 
determined by ICS in a subset of subjects at Months 0, 3, 14, 26 and 38;
 Antigen-specific Ab concentrations at Months 0, 3, 14, 26 and 38
 Anti-gE and anti-VZV Ab concentrations as determined by ELISA, in a subset 
of subjects at Months 0, 3, 14, 26 and 38;
 Anti-VZV neutralizing Ab titres at Months 0, 3, 14, 26 and 38
 Anti-VZV neutralizing Ab titres as determined by the neutralization assay in a 
subset of subjects at Months 0, 3, 14, 26 and 38.
10.4. Estimated sample size
10.4.1. Sample size assumptions
Table 17 presents the assumptions used for the sample size calculations for both studies 
ZOSTER -006 and ZOSTER-022. Simulations were performed to estimate the sample 
size required as a consequence of unequal VE estimates by age strata. A drop-out rate of 
5% per year and an incidence of 5% for non-compliance to vaccine schedule were taken 
into account for sample size calculations.
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Table 17 Assumptions for incidences under placebo, and VE used for trial 
simulations
Age
HZ Incidence
(% / Year) HZ VE
PHN Incidence 
in HZ subjects
(% /Year)
On top PHN 
VE in HZ 
subjects (2)
Overall PHN 
VE in HZ 
subjects
Overall(1) ~0.7 ~68% ~11% NA ~71%
50-59 0.5 82% 5% 5% 83%
60-69 0.8 72% 9.5% 5% 73%
70-79 1.1 58% 17% 35% 73%
≥80 1.1 36% 28% 25% 52%
70 (1) 1.1 ~53% ~19% NA ~71%
1 The overall HZ incidence and the incidence in the  70YOA age strata depends on the age-stratification considered
2 VE against PHN in people with HZ, i.e., a comparison of VE between placebo recipients with HZ who got PHN versus 
vaccine recipients with HZ who got PHN.
10.4.2. Significance level
The overall efficacy analyses will be performed at the 5% 2-sided significance level. No 
significance adjustment is planned in ZOSTER-006 or ZOSTER-022 for the efficacy 
analyses due to the futility analyses, since GSK has no current intention to submit the 
data to Regulatory Authorities for registration.
The scope of the statistical testing of ZOSTER-006, ZOSTER-022 and the pooling of the 
data from both studies are described in Section 10.4.4 and summarised in Table 18. The 
pooled analysis of studies ZOSTER-006 and ZOSTER-022 is planned provided the 
following conditions are met, as defined in Section 10.4.4:
1. Clinically meaningful overall HZ VE in subjects  50 YOA is reached in ZOSTER-
006;
2. Clinically meaningful HZ VE is reached in subjects  70 YOA in ZOSTER-022;
3. Statistically significant PHN VE is reached in subjects  70 YOA in ZOSTER-022.
The pooled analysis of data in subjects  50 YOA accrued in study ZOSTER-006 and 
data in subjects  70 YOA collected in study ZOSTER-022 allows a more robust 
estimation of overall PHN VE, HZ VE in subjects  70 YOA and PHN VE in subjects 
70 YOA. Both objectives, HZ VE in subjects  70 YOA and PHN VE in subjects  70 
YOA, will be assessed in study ZOSTER-022. An estimation of the confidence interval
(CI), based on pooled data will be provided in addition. The statistical evaluation of the 
other objectives of the pooled analysis, including the overall PHN VE primary objective 
and the PHN VE in subjects with HZ secondary objective, will only be performed on the 
pooled data from both studies. According to these restrictions in the testing sequence, the 
type 1 error is maintained at 2.5% (1-sided). Each statistical evaluation in the pooled 
analysis is either preceded by an evaluation in ZOSTER-006, ZOSTER-022, or both; or 
is only performed on the pooled database during the pooled analysis. As a consequence, 
there is no increase in the significance level of each objective due to a possible multiple 
testing problem.
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Table 18 Summary of statistical evaluations of primary and secondary 
objectives for studies ZOSTER-006, ZOSTER-022 and the pooled 
analysis
Analysis Endpoint 50-59 YOA 60-69 YOA 70 YOA All age strata
ZOSTER-006 HZ VE S S O P
PHN VE - - - -
PHN VE in HZ subjects - - - -
ZOSTER-022 HZ VE - - P -
PHN VE - - P -
PHN VE in HZ subjects - - - -
Pooled analysis HZ VE - - R -
PHN VE - - R P
PHN VE in HZ subjects - - - S*
P: Primary objective, well powered
R: Re-estimation of VE for an objective already demonstrated previously in ZOSTER-006 or ZOSTER-022.
S: Secondary objective, appropriately powered
S*: Secondary objective, low power
O: Study not well powered under current assumptions although may lead to significance
- : Estimates not relevant or not considered for a statistical evaluation
10.4.3. Success criteria
The ZOSTER-006 study is designed to demonstrate clinically meaningful overall HZ VE 
in subjects of  50 YOA. Clinically meaningful overall HZ VE will be demonstrated if 
the lower limit of the 95% CI is above 25%; however, the study has been powered for the 
more robust lower limit of 40%. That primary analysis will be supported by sensitivity 
analyses of the HZ VE in the 50-59 YOA and 60-69 YOA strata. Clinically meaningful 
HZ VE by age strata will be demonstrated if the lower limit of the 95% CI is above 10%. 
The ZOSTER-006 study is not powered to demonstrate significant HZ VE within the 
70 YOA stratum. That objective is not within the scope of this study and is deferred to 
the analysis of ZOSTER-022 study data. 
The ZOSTER-022 study is designed to demonstrate clinically meaningful HZ VE in 
subjects  70 YOA. Clinically meaningful HZ VE will be demonstrated in that age range 
if the lower limit of the 95% CI is above 10%. The ZOSTER-022 study is also powered 
to demonstrate statistical significant PHN VE. Statistical significance of PHN VE in  70 
YOA randomized subjects will be demonstrated if the lower limit of the 95% CI is above 
0%. The PHN VE co-primary objective will be tested provided the primary HZ VE is 
demonstrated and no adjustment of significance level will be made.
Both studies ZOSTER-006 and ZOSTER-022 will be performed in parallel, in similar 
centres and using essentially identical study designs (aside from the age distribution of 
the enrolled population). The pooled analysis of those 2 studies is therefore deemed 
acceptable and will provide additional precision in estimating VE. Homogeneity of 
relative risk between the 2 studies will be demonstrated. The pooled analysis of studies 
ZOSTER-006 and ZOSTER-022 is intended to provide consolidated estimations of the 
clinically meaningful HZ VE in all subjects  70 YOA and clinically meaningful overall 
PHN VE in mTVc subjects randomized to studies ZOSTER-006 and ZOSTER-022. 
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Clinically meaningful HZ VE in subjects  70 YOA will be demonstrated if the lower 
limit of the 95% CI is above 10% and clinically meaningful overall PHN VE will be 
demonstrated if the lower limit of the 95% CI is above 25%.
10.4.4. Gatekeeping strategy
The statistical testing for each study will proceed sequentially using an order for the 
gatekeeping families defined prospectively (see below). If more than one test is involved 
within the same family, the Hochberg’s set up method [Hochberg, 1988] will be used to 
adjust the p-values for the multiple test schemes. All secondary objectives mentioned in 
protocols ZOSTER-006 and ZOSTER-022 will be evaluated within each report. 
However, the overall type 1 error of 5% two-sided can only be fully controlled for those 
objectives that are mentioned sequentially in the gatekeeping strategy presented below. If 
a gatekeeping family fails to be demonstrated, the remaining planned tests will be 
performed, but the type 1 error of the following families may not be fully controlled. 
The enrolment of subjects  70 YOA in both studies and the need to provide an 
estimation of the HZ VE and PHN VE across the two studies, requires the gatekeeping 
strategy to be defined across the two studies and the pooling. The following pathway is 
proposed and will be confirmed prior to unblinding of the treatment assignment.
The primary objective of ZOSTER-006 and both co-primary objectives of ZOSTER-022 
should be demonstrated prior to testing the primary objective of the pooling. The second 
co-primary of ZOSTER-022 will be tested at 5% 2-sided following demonstration of the 
first co-primary, also at 5%. Sensitivity analyses will be performed by age strata for each 
of the primary or co-primary objectives. 
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Zoster-006
Sensitivity Primary
Zoster-022
SensitivityPrimary
Demonstrate statistically 
significant VE against HZ in 
subjects ≥50 YOA
Demonstrate statistically 
significant VE against HZ 
in subjects ≥70 YOA
Demonstrate statistical 
significance of VE against 
HZ in subjects 50-59 YOA 
and subjects 60-69 YOA
Demonstrate statistically 
significant VE against HZ+ 
in subjects 70-79 YOA and 
≥80 YOA
Demonstrate statistically 
significant VE against 
PHN in all randomized 
subjects ≥70 YOA
Demonstrate statistically 
significant VE against PHN 
in all randomized subjects 
70-79 YOA and ≥80 YOA
Re-estimation Primary Sensitivity
VE estimates against HZ  in 
subjects ≥70 YOA and 
confidence intervals
VE estimates against HZ  
in subjects 70-79 YOA 
and ≥80 YOA and 
confidence intervals
VE estimates against PHN  
in subjects 70-79 YOA and 
≥80 YOA and confidence 
intervals
VE estimates against PHN  in 
subjects ≥70 YOA and 
confidence intervals
Demonstrate statistically significant VE 
against PHN  in subjects ≥50 YOA
Demonstrate statistically significant 
reduction of duration of pain 
following HZ in subjects with HZ
Demonstrate statistically significant 
VE against PHN  in subjects with HZ
Pooling
Secondary
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The primary objectives of the pooling include the re-estimation of HZ VE and PHN VE 
in subjects  70 YOA. Both hypotheses are planned to be already demonstrated in 
ZOSTER-022 and, as a consequence, do not affect the overall type 1 error and are not 
considered within the main path of the gatekeeping strategy. 
The first hypothesis to be tested from the pooled dataset consists in the overall PHN VE 
in subjects  50 YOA. Further secondary objectives are then sequentially tested 
following demonstration of overall PHN VE.   
1. Demonstrate statistically significant reduction in incidence of  PHN (90 days or 
more) in subjects with HZ
2. Demonstrate statistically significant reduction of duration of severe ‘worst’ pain
following HZ in subjects with HZ. 
10.4.5. Sample sizes
The sections below describe the estimated number of subjects required to achieve the 
objectives of studies ZOSTER-006, ZOSTER-022 and the pooling of data from both 
studies. The country allocation and various subsets are also described. For operational 
reasons, the same subjects may be randomized to the more than one subset.
10.4.5.1. Primary objective
The final analysis of the ZOSTER-006 study is planned after the accumulation of at least 
196 confirmed HZ cases across all age strata (primary condition) in the primary cohort 
for efficacy. Other conditions for triggering the analyses are described in Section 
10.4.5.6. It is estimated that 196 confirmed HZ cases would provide ~97% power to 
demonstrate an overall HZ VE of at least 40% assuming a true HZ VE of 68% (including 
essential sensitivity analyses in 50-59 and 60-69 YOA strata). Table 19 presents the 
sample sizes overall and according to the age-stratification ratio 8:5:3:1 (50-59, 60-69, 
70-79 and  80 YOA) using a randomization ratio 1:1 for vaccine or placebo. The sample 
size was selected in order to provide the required number of HZ cases within a follow-up 
time of ~3 years. The stratification ratios were selected in order to achieve similar 
numbers of HZ cases in the three main age strata. If large disparities in the total number 
of HZ cases (placebo and vaccine groups combined) are observed during the trial 
between the age strata, sample size reassessment or modification of the stratification 
ratios may be considered.
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Table 19 Expected median number of HZ and PHN cases in ZOSTER-006
Age strata Sample 
size
Median number of HZ 
cases
Median number of PHN 
cases
Placebo All Placebo All
50-59 YOA 7520 48 57 3 3
60-69 YOA 4700 48 62 4 6
70-79 YOA 2820 40 56 6 8
 80 YOA 940 13 22 4 5
All 15980 149 196 17 23
Median number of cases calculated based on 1000 trial simulations.
The final analysis of the ZOSTER-022 study is planned after the accumulation at least 65 
PHN cases (expected median are approximately 40 PHN cases in 70-79 YOA and 
approximately 26 PHN cases in  80 YOA strata) are accrued from study ZOSTER-022 
(primary condition for triggering analysis), and at least 278 confirmed HZ cases 
(expected median number of cases is 310 HZ cases) across both 70-79 YOA (median of 
222 HZ cases) and  80 YOA (median of 87 HZ cases) strata. All PHN or HZ cases 
should be accrued in the primary cohort for efficacy. Other conditions for triggering the 
analyses are described in Section 10.4.5.6. This number of HZ cases would provide 
~99% power to demonstrate HZ VE of at least 10% under the assumptions described 
above in subjects  70 YOA. This number of PHN cases would provide ~97% to 
demonstrate statistically significant PHN VE in all randomized subjects, in addition to 
the HZ objective above. Table 20 presents the sample sizes overall and according to the 
age-stratification ratio 3:1 (70-79 and  80 YOA) and a randomization ratio 1:1. The 
sample size was selected in order to provide the required number of HZ cases within a 
follow-up time of ~3 years. If the accrual rate of HZ or PHN cases is much lower than 
expected, a blinded sample size reassessment may be considered for which the details 
would be available prior to the first interim analysis.
Table 20 Expected median number of HZ and PHN cases in ZOSTER-022
Age strata Sample 
size
Median number of HZ 
cases
Median number of PHN 
cases
Placebo All Placebo All
70-79 YOA 10884 157 222 32 40
 80 YOA 3628 54 87 17 26
All 14512 210 310 49 65
Median number of cases calculated based on 1000 trial simulations.
The number of HZ cases, PHN cases and the total sample size for each age strata for the 
pooled analysis are driven by the number of the cases and sample size in both the 
ZOSTER-006 and ZOSTER-022 studies (see Table 21). The total number of PHN cases 
and the number of PHN cases in subjects  70 YOA that each study (ZOSTER-006 and 
ZOSTER-022) will contribute to the pooled analysis may vary from what has been 
described above. It is estimated however that the median total number of PHN cases in 
50 YOA subjects is approximately 88, among which at least ~79 PHN cases would be 
accrued in the  70 YOA age strata. A total of at least 88 PHN cases provide 93% power 
to demonstrate an overall PHN VE of at least 25%.
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Table 21 Expected median number of HZ and PHN cases in pooled ZOSTER-
006 and ZOSTER-022
Age strata Sample 
size
Median number of HZ 
cases
Median number of PHN 
cases
Placebo All Placebo All
50-59 YOA 7520 48 57 2 3
60-69 YOA 4700 48 61 4 6
70-79 YOA 13704 196 278 32 48
 80 YOA 4568 57 110 17 31
All 30492 360 506 57 88
Median number of cases calculated based on 1000 trial simulations. 
10.4.5.2. Secondary objectives
The ZOSTER-006 sample size is sufficient to demonstrate a HZ VE of at least 10% for 
the 50-59 YOA and 60-69 YOA age strata with powers of 99% and 98%, respectively.
The ZOSTER-022 sample size is sufficient to demonstrate a HZ VE of at least 10% for 
the  70 YOA stratum with a power of 99%.
The sample size of the pooled studies ZOSTER-006 and ZOSTER-022 provide 22% 
chance to demonstrate statistically significant PHN VE (LL above 0%) in those subjects 
presenting with an HZ episode.
10.4.5.3. Futility analyses and sample size re-assessment
The study may involve one (or more) unblinded futility analyses performed by the 
IDMC. One futility analysis is planned after approximately 25% of the total HZ cases are 
observed and/or when at least 20% of the total HZ cases are observed in each age 
stratum. The precise timing of that analysis may be triggered by a blinded review of the 
HZ accrual in ZOSTER-006 and/or ZOSTER-022. The futility decision rules will be 
described in the IDMC Charter and statistical analysis plan. Essentially, no increase in 
the type 1 error of the final analysis is incurred as no decision of early termination for 
efficacy will be made by GSK at any of those analyses. Adequate trial duration is 
required to accumulate enough PHN information and safety information necessary for 
regulatory purposes. Conversely, a slight reduction in the power of the study can be 
caused due to the futility rules. A conservative futility boundary or a predictive power 
threshold [Proschan, 2006] in the range of ~30% is anticipated but the actual functional 
form of the beta-spending function or the predictive power threshold used for the trial 
will be defined in the IDMC Charter. Information collected in both trials may be 
combined to calculate the predictive power for each trial separately and together.
Table 22 below provides information about the ZOSTER-006 conditional power with 
respect to the overall HZ VE LL 40% (i.e. without consideration for by-age HZ VE LL 
10%) calculated following 25% of accrual and for different values of the observed HZ 
VE or futility boundaries. Irrespective to the futility boundary considered, the conditional 
power calculated under the sample size (alternative) assumptions remains very high 
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although the conditional power calculated under the observed HZ VE is close to zero. A 
more reasonable prediction for the power at the final analysis that will be implemented is 
the expected conditional power or Bayesian predictive power, following integration of 
the conditional power on the posterior distribution of the VE in each age strata and 
accounting for the proportion density of each stratum in the total number of HZ cases at 
the final analysis.
Table 22 Observed HZ VE at ZOSTER-006 Interim to trigger futility stopping 
and conditional power at the final analysis calculated under 
alternative hypothesis and current observed VE
VE Confidence 
Intervale
Futility 
analysis Rhoa
# HZ 
cases
Observed 
VEb
CP under 
alternativec
CP under 
observed VEd
Lower 
Limit
Upper 
Limit
1 1 49 33.6% 87.2% 0.0% -102.6% 70.8%
2 1 98 46.9% 78.8% 1.8% 0.2% 69.5%
1 2 49 24.7% 81.5% 0.0% -137.4% 71.8%
2 2 98 44.6% 71.5% 0.6% -4.2% 69.7%
1 3 49 17.0% 76.1% 0.0% -168.1% 72.5%
2 3 98 42.5% 64.3% 0.2% -8.2% 69.9%
1 4 49 9.7% 69.7% 0.0% -201.7% 73.2%
2 4 98 40.4% 56.5% 0.0% -12.3% 70.1%
a: Rho defines the form of the futility boundary. A conservative (O’Brian-Fleming) boundary is defined for Rho=3 and 
a more aggressive (Pocock) boundary is defined for Rho = 1.
b: Observed HZ VE that triggers futility conditions at each futility analysis.
c: Conditional power at the final analysis calculated under the sample size (alternative) assumptions
d: Conditional power at the final analysis calculated under the observed HZ VE at the interim
e: HZ VE repeated confidence interval and approximate VE posterior distribution at the interim over which the mean 
(expected) conditional power may be calculated.
Table 23 below provides information about the ZOSTER-022 conditional power with 
respect to the HZ VE LL 40% in subjects of  70 YOA (i.e., without consideration for 
statistically significant PHN VE in subjects of  70 YOA) calculated following 25% of 
accrual and for different values of the observed HZ VE or futility boundaries. Irrespective 
to the futility boundary considered, the conditional power calculated under the sample 
size (alternative) assumptions remains very high although the conditional power 
calculated under the observed HZ VE is close to zero. A more reasonable prediction for 
the power at the final analysis that will be implemented is the expected conditional power 
or Bayesian predictive power, following integration of the conditional power on the 
posterior distribution of the VE in each age strata and accounting for the proportion 
density of each stratum in the total number of HZ cases at the final analysis.
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Table 23 Observed HZ VE at ZOSTER-022 Interim to trigger futility stopping 
and conditional power at the final analysis calculated under 
alternative hypothesis and current observed VE
VE Confidence 
Intervale
Futility 
analysis Rhoa
# HZ 
cases
Observed 
VEb
CP under 
alternativec
CP under 
observed VEd
Lower 
Limit
Upper 
Limit
1 1 77 18.7% 79.6% 0.1% -85.7% 53.2%
2 1 155 31.3% 71.4% 3.4% -9.6% 52.7%
1 2 77 8.5% 71.7% 0.0% -112.6% 53.7%
2 2 155 28.5% 62.1% 1.0% -14.1% 52.8%
1 3 77 -0.2% 64.1% 0.0% -136.3% 54.0%
2 3 155 26.0% 53.2% 0.3% -18.1% 52.9%
1 4 77 -8.4% 56.3% 0.0% -160.8% 54.3%
2 4 155 23.5% 44.5% 0.1% -22.3% 53.0%
a. Rho defines the form of the futility boundary. A conservative (O’Brian-Fleming) boundary is defined for Rho=3 and 
a more aggressive (Pocock) boundary is defined for Rho = 1.
b. Observed HZ VE that triggers futility conditions at each futility analysis.
c. Conditional power at the final analysis calculated under the sample size (alternative) assumptions
d. Conditional power at the final analysis calculated under the observed HZ VE at the interim
e. HZ VE repeated confidence interval and approximate VE posterior distribution at the interim over which the mean 
(expected) conditional power may be calculated.  
The futility approach, whether by futility boundary or conditional or predictive power 
implemented is not-bounding with regards to the decision actually taken at the time of the 
analysis. The IDMC recommendations with regards to futility of the study may not be 
endorsed by GSK Steering Committee without affecting the overall significance level. 
Blinded sample size reassessment may be performed by GSK in one or more age strata in 
order to keep the same trial duration if accrual is much lower than expected. The sample 
size re-evaluation will be done independently from the data provided to the IDMC. 
Conditions for the sample size reassessment need to be defined further.
10.4.5.4. Provisional region and sub-population allocations
The provisional region allocation for study ZOSTER-006 is presented in Table 24. In 
study ZOSTER-006, eligible subjects will be randomized to investigational 
vaccine/placebo according to a 1:1 ratio. 
Subjects will be stratified by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and  80 YOA
in an 8:5:3:1 ratio. The main  70 YOA stratum used for sample size calculation is 
subdivided into 70-79 and  80 YOA strata in order to demonstrate efficacy  80 YOA or 
in any of these 2 sub-strata taken separately. The study is however not powered to 
demonstrate efficacy in any of these 2 sub-strata taken separately. In addition, some small 
percentages of the sample will include frail elderly subjects. 
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Table 24 Provisional region allocation for study ZOSTER-006
Australasia Europe Latin America North America
Country Sample 
Size
Country Sample 
Size
Country Sample 
Size
Country Sample 
Size
Australia
Hong Kong
Japan
S. Korea
Taiwan
3200 Czech Republic
Estonia
Finland
France
Germany
Italy
Spain
Sweden
United Kingdom
7560 Brazil
Mexico
2620 Canada
US
~2620
10.4.5.5. 7-day diary card subset  
The number of subjects in this subset was defined based on the empirical rules that, in 
absence of a specific AE in a cohort of N subjects, the probability is 95% that the 
incidence of that AE is less than 1 / (N/3) [Hanley, 1983].
The provisional number of subjects in the 7-day diary card subset in study ZOSTER-006 
is shown in Table 25.
Table 25 Provisional number of subjects in the 7-day diary card subset in 
study ZOSTER-006 
Age 
cohort
50-59 YOA 60-69 YOA 70-79 YOA  80 YOA All
Treatment 
group Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo
ZOSTER-
006 1410 1410 1410 1410 1410 1410 470 470 4880 4880
Note: In addition, study ZOSTER-022 will include a 7-day diary card subset of 1000 subjects (in each 70-79 YOA and 
 80 YOA strata, 250 subjects in each treatment group).
10.4.5.6. Immunogenicity Subset
10.4.5.6.1. Assumptions and background information for humoral immunity
Assumptions to estimate the number of subjects to be included in the immunogenicity 
subset in study ZOSTER-006 and ZOSTER-022 were based on gE-specific humoral 
immunogenicity data obtained in study ZOSTER-003 for subjects who received two 
doses of gE 50 µg/AS01B. 
10.4.5.6.2. Humoral immune response vaccine take
The humoral vaccine take is assessed in comparison to placebo group using anti-gE or 
anti-VZV Ab concentrations. The increase observed post dose 2 in study ZOSTER-003 in 
the gE 50µg/AS01B group as compared with placebo is about 10-fold for anti-gE Abs. 
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The CV is about 100% (or In-based variance = 0.693 = 0.832²), accounting for higher 
variability in the current study as compared to study ZOSTER-003 due to, but not limited 
to, inter-country variations. A 4-fold increase in geometric mean over placebo as a lower 
bound for clinical relevance, in absence of other justification, adjusted for pre-
vaccination level, is considered as a threshold for clinical relevance, and will be used as 
criteria to demonstrate vaccine take.
When expressed on the log-scale, the effect size for clinical significance is Ln(10) / 0.832 
= 2.76. When accounting for the superiority requirement of a 4-fold increase over NaCl 
solution, the effect size is 2.76 – Ln(4) / 0.832= 1.10. Despite the number of blood 
samplings that should be administered in vaccine and placebo according to the study 
randomization ratio, it is also reasonable to analyze twice as much vaccine samples than 
placebo samples. The overall power of the test is conventionally set to ~95% and the type 
1 error to 2.5%. Since we may be required to demonstrate that success criteria in all 
countries involved in the trial, accounting for ~15 countries, the power of the test in each 
country should be 0.95^(1/15) = 0.996.
Table 26 presents the number of subjects under vaccine (N1) and placebo (N2) required 
to demonstrate a 4-fold increase in anti-gE Ab concentration geometric means over 
saline. The number of evaluable blood samples required in each country at post dose 2 is 
~55 for vaccine and ~28 for placebo for an overall power of 0.996^15 = 0.95. A slight 
increase in that number of subjects may be needed as the sample size should be a multiple 
of 3 for the age stratification. Overall, accounting for the same number of subjects to be 
sampled in vaccine and placebo groups in each of the 15 to 18 countries in order to 
maintain the blind, and to have a sufficiently large number of evaluable blood samples, 
the total number of subjects enrolled into the subset should be 18 x 60 x 2 = ~2160. No 
comparisons are planned within each age strata at the country level.
Table 26 Power calculations for a T-test for Relevant Superiority 
Significance level Standard deviationPower N1/N2 Equivalence 
margin (E)
Actual 
difference (D) alpha beta SD1 SD2
0.99839 61/32 13.90 23.00 0.02500 0.00161 8.32 8.32
0.99648 55/28 13.90 23.00 0.02500 0.00352 8.32 8.32
0.99413 51/26 13.90 23.00 0.02500 0.00587 8.32 8.32
0.99245 49/26 13.90 23.00 0.02500 0.00755 8.32 8.32
0.99031 47/24 13.90 23.00 0.02500 0.00969 8.32 8.32
0.95043 34/17 13.90 23.00 0.02500 0.04957 8.32 8.32
0.90324 28/14 13.90 23.00 0.02500 0.09676 8.32 8.32
Means & SD were multiplied by a 10-fold coefficient in order to allow more precision in the outputs.
N1, N2: number of subjects receiving vaccine (N1) and placebo (N2) 
10.4.5.6.3. Humoral immune response inter-region variability
Following the objective of vaccine take, the vaccine geometric mean responses between 
countries can be compared. This comparison consists of selecting two countries, or group 
of countries and comparing their means in order to demonstrate equivalence since 
defining the success criteria in terms of “statistical significance” is not meaningful in this
situation. The absence of statistical significance would not support the absence of clinical 
relevance between regions or countries.  
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Using Ratio of Geometric Means – Region-wise
An equivalence criteria of 2-fold is considered acceptable when referring to the ratio of 
geometric means between regions. This threshold ensures that any differences between 
countries are not clinically relevant as it corresponds to half of the 4-fold increase over 
placebo, considered as the minimally clinically relevant difference.    
The same assumptions as above are used for the calculations. ZOSTER-010 data showed 
a ratio of geometric means equal to 1.26 between EU and US. A pairwise comparison 
between each of the 4 main regions may be considered, leading to 6 comparisons. The 
power of each test should be ~99% for a global power of ~95%. 
Table 27 presents the sample size for each individual comparison, assuming absence of 
true difference between regions, assuming ratio of geometric means equal to 0, 90% (Ln 
= -0.10) and 75% (Ln = -0.29). A sample size of  approximately 60 subjects under 
vaccine within each region would allow demonstrating equivalence of the two geometric 
means within a non-clinically relevant range of 2-fold, provided absence of difference in 
means (true difference = 0). Since each region includes several countries, a pool of at 
least 3 countries is sufficient within each region to allow the comparison when the ratios 
of geometric means reach 75%.
Table 27 Power Testing Equivalence Using a Parallel-Group Design (Region)
Reference 
Group
Treatment 
Group
Power Sample 
Size
(N1)
Sample
Size
(N2)
Lower
Equiv
Limit
Upper 
Equiv
Limit
True
Difference
Standard
Deviation
Alpha Beta
0.7490 60 60 -6.93 6.93 -2.90 8.32 0.0250 0.2510
0.9630 120 120 -6.93 6.93 -2.90 8.32 0.0250 0.0370
0.9957 180 180 -6.93 6.93 -2.90 8.32 0.0250 0.0043
0.9996 240 240 -6.93 6.93 -2.90 8.32 0.0250 0.0004
0.9714 60 60 -6.93 6.93 -1.00 8.32 0.0250 0.0286
0.9998 120 120 -6.93 6.93 -1.00 8.32 0.0250 0.0002
1.0000 180 180 -6.93 6.93 -1.00 8.32 0.0250 0.0000
1.0000 240 240 -6.93 6.93 -1.00 8.32 0.0250 0.0000
0.9897 60 60 -6.93 6.93 0.00 8.32 0.0250 0.0103
1.0000 120 120 -6.93 6.93 0.00 8.32 0.0250 0.0000
1.0000 180 180 -6.93 6.93 0.00 8.32 0.0250 0.0000
1.0000 240 240 -6.93 6.93 0.00 8.32 0.0250 0.0000
Note: Means and Standard Deviation were multiplied by 10 to achieve sufficient precision
If those comparisons should be made within each age strata, leading to a total of 3*6 
comparisons, the power of each comparison should be closer to 99.7% in order to 
maintain the overall power to 0.997^18 = 0.95. The number of countries to be involved in 
the comparisons should then be at least 4.
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Using Ratio of Geometric Means – Country-wise
The same calculations may be performed on a country basis. The table below provides 
the power for a comparison of one country versus the rest of the world, assuming 15 
countries and a ratio of geometric mean equal to 0.90 (LN = -0.10) and 75% (LN = -
0.29). A sample of 60 subjects in the country selected is sufficient to allow the 
comparison versus 900 subjects with a power of at least 95%.
Table 28 Power Testing Equivalence Using a Parallel-Group Design (Country)
Reference 
Group
Treatment 
Group
Power Sample 
Size
(N1)
Sample
Size
(N2)
Lower
Equiv
Limit
Upper 
Equiv
Limit
True
Difference
Standard
Deviation
Alpha Beta
0.9553 60 900 -6.93 6.93 -2.87 8.32 0.0250 0.0447
0.9757 70 900 -6.93 6.93 -2.87 8.32 0.0250 0.0243
0.9868 80 900 -6.93 6.93 -2.87 8.32 0.0250 0.0132
0.9929 90 900 -6.93 6.93 -2.87 8.32 0.0250 0.0071
0.9962 100 900 -6.93 6.93 -2.87 8.32 0.0250 0.0038
0.9996 60 900 -6.93 6.93 -1.00 8.32 0.0250 0.0004
0.9999 70 900 -6.93 6.93 -1.00 8.32 0.0250 0.0001
1.0000 80 900 -6.93 6.93 -1.00 8.32 0.0250 0.0000
1.0000 90 900 -6.93 6.93 -1.00 8.32 0.0250 0.0000
1.0000 100 900 -6.93 6.93 -1.00 8.32 0.0250 0.0000
Note: Means and Standard Deviation were multiplied by 10 to achieve sufficient precision
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Using Ratio of responder Rates – Country-wise
When comparing responder rate, a non-inferiority limit of 15% may be considered. Based 
on ZOSTER-010 data, the responder rates were ~97% in EU (N=95) and 100% in US 
(N=37) and a value of 97% will be used as the reference value worldwide. A ~3% - 4% 
difference in point estimate may be observe between countries [eq. 96% in CZ (N=49) 
and 100% in SP (N=46)], as observed between EU and US.
Table 29 provides power for a sample of 60 - 100 subjects from one country in 
comparison with the rest of the world, assuming 15 countries. When considering a 
difference of 4%, the sample should be at least equal to 100 to achieve a power of 90%.
Table 29 Sample Sizes for Non-Inferiority Tests (Responder Rates)
Sample
Size
Sample
Size
Grp 2 Equiv 
Grp 1
Actual
Grp 1
Equiv
Margin
Actual
Margin
Grp 1 Grp 2 Prop Prop Prop Diff Diff Target
Power N1 N2 P2 P1.0 P1.1 D0 D1 Alpha
0.6449 60 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250
0.7364 70 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250
0.8088 80 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250
0.8641 90 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250
0.9050 100 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250
0.7642 60 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250
0.8471 70 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250
0.9041 80 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250
0.9415 90 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250
0.9652 100 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250
Score test [Miettinen ,1985]
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10.4.5.6.4. Number of subjects in the Immunogenicity subset 
Table 30 provides the provisional number of subjects in the Immunogenicity subset in 
study ZOSTER-006. CMI analysis will be performed in the Immunogenicity subset of 
three countries (Czech Republic, Japan and United States). These countries will have 
approximately 156 subjects per country enrolled in the immunogenicity subset. Other 
countries will have approximately 138 subjects per country enrolled in the 
immunogenicity subset.
Subjects will be randomized to be part of the Immunogenicity subset (Section 5.3.4). 
Blood samples obtained from subjects included in the Immunogenicity subset will be 
used to assess humoral immune responses. The number of placebo subjects and vaccine 
subjects that will have their blood sampled will be equal in order to maintain the blind. 
However, only a fraction of the placebo samples will be analyzed as a reduced sample is 
sufficient to characterise the background gE or VZV-specific immunogenicity levels in 
the placebo group.
Table 30 Provisional number of subjects in the Immunogenicity subset in 
study ZOSTER-006
Age 
cohort
50-59 YOA 60-69 YOA  70 YOA All
Treatment group Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo
CMI countries1 26 26 26 26 26 26 78 78
Non-CMI countries2 23 23 23 23 23 23 69 69
1 Czech Republic, Japan, United States
2 Australia, Hong Kong, S. Korea, Taiwan, Estonia, Finland, Germany, Italy, Spain, Sweden, United Kingdom, France, 
Brazil, Mexico, Canada
10.4.5.7. CMI Subset
10.4.5.7.1. Assumptions and background information for CMI
Assumptions to estimate the number of subjects to be included in the CMI subset in study 
ZOSTER-006 were based on gE-specific CMI data obtained in study ZOSTER-003 for 
subjects who received two doses of gE 50 µg/AS01B. 
The cellular proportion of subjects achieving a cellular immune response to vaccination 
with gE/AS01B  (cellular immunity take rate) will be compared to that of subjects in the 
Placebo group based on the frequency of gE specific CD4 cells, after adjustment for 
background and prevaccination gE-specific CD4 responses. The increase in CMI 
response observed post dose 2 following 50 µg gE/AS01B compared with saline is about 
5.5 fold, and the coefficient of variation  is about 100%. These figures were used for the 
sample size calculation.
When expressed on the log-scale, the effect size for clinical significance is Ln(5.5)/ 0.832 
= 2.05. When accounting for a target of a 1.5-fold increase over saline, the effect size is 
2.05 – Ln(1.5) /0.832 = 1.562. While the number of blood samplings will be collected in 
vaccine and placebo recipients according to the study randomization ratio, it is 
appropriate to analyze twice as many vaccine samples than placebo samples using an
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immunogenicity sample-randomization ratio of 2. Although this endpoint is purely 
exploratory, the overall power of this test is set to ~95% and the type 1 error to 2.5% per 
convention.    
Table 31 presents the number of subjects under vaccine (N1) and placebo (N2) required 
to demonstrate a 1.5-fold increase over saline in frequency of gE-specific CD4 cells 
producing at least 2 cytokines. If  the test is performed for each of the 3 age-ranges, the 
power of each test should be 98.1% in order to maintain the overall power at 0.981^3 = 
0.94 (i.e., 94%). Twenty-one subjects in each of the 3 main age strata equals will have 
received vaccine or  placebo, respectively, for a total number of 3 * 21 * 2 = 126 
subjects. For this exploratory objective, the comparison is based upon one country only 
and, for instance, does not account for comparison across multiple countries and regions.  
Table 31 Power Calculations for CMI subset
Significance level Standard deviationPower N1/N2 Equivalence 
margin (E)
Actual 
difference (D) Alpha beta SD1 SD2
0.99320 25/14 4.05 17.00 0.02500 0.00680 8.32 8.32
0.98871 23/12 4.05 17.00 0.02500 0.01129 8.32 8.32
0.98145 21/12 4.05 17.00 0.02500 0.01855 8.32 8.32
0.97242 20/10 4.05 17.00 0.02500 0.02758 8.32 8.32
0.95163 17/10 4.05 17.00 0.02500 0.04837 8.32 8.32
10.4.5.7.2. Number of subjects in the CMI subset
The CMI analyses will be performed in the Immunogenicity subset in three countries 
(Czech Republic, Japan and United States) at designated sites that have access to a 
PBMC processing facility within the acceptable time window from sample collection to 
PBMC processing. The CMI subset in these countries will include 156 subjects to 
account for anticipated lost or non-evaluable samples, see Table 32. 
Table 32 Provisional number of subjects in the CMI subset in study ZOSTER-
006
Age 
cohort
50-59 YOA 60-69 YOA  70 YOA All
Treatment group Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo
Each  participating country 26 26 26 26 26 26 78 78
10.4.6. Conditions for triggering analyses
A comprehensive understanding of the extent to which the candidate vaccine prevents HZ 
in the various age strata involves the availability of results from both studies (ZOSTER-
006 and ZOSTER-022). The database freeze and statistical analyses would then be 
triggered when both studies have achieved their conditions for triggering analyses. 
However, if one of the studies reached the conditions required for triggering the analyses 
and a delay of more than approximately 6 months is predicted prior to those conditions 
are reached for the second study, then GSK may decide to proceed with the analysis of 
the study that reaches its conclusion first. The conditions described below are minimum 
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requirements prior to unblinding. Additional HZ cases and/or PHN cases may be accrued 
as a result of the decision to wait for both studies to achieve the requirements 
simultaneously.
The following conditions are planned prior to final HZ analyses of study ZOSTER-006.
The number of HZ and PHN cases mentioned refers to the cases in the primary cohort for 
efficacy.
1. At least 196 HZ cases across all age group for the overall HZ analysis;
2. ~75% of the initial sample size (not accounting for any sample-size reassessment) in 
each strata with at least 36 months follow-up and the remaining subjects have 
completed at least 30 months follow-up after Dose 2 in order to ensure enough safety 
data;
3. Approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ cases 
in subjects 60-69 YOA for the HZ analysis by-age in 50-59 and 60-69 YOA age 
strata respectively;
4. A total of at least 88 PHN cases when pooled with ZOSTER-022 PHN cases 
accrued.
The following conditions are planned prior to final HZ analyses of study ZOSTER-022. 
The number of HZ and PHN cases mentioned refers to the cases in the primary cohort for 
efficacy.
1. At least 65 PHN cases over both 70-79 and  80 YOA strata;
2. A total of at least 88 PHN cases when pooled with ZOSTER-006 PHN cases 
accrued; 
3. At least 278 HZ cases accrue over both 70-79 and  80 YOA strata; 
4. ~75% of the initial sample size (not accounting for any sample-size reassessment) in 
each stratum with at least 36 months of follow-up and the remaining subjects have 
completed at least 30 months follow-up after Dose 2 in order to ensure enough safety 
data.
10.5. Study cohorts to be evaluated
10.5.1. Total Vaccinated cohort
The Total Vaccinated cohort (TVc) will include all vaccinated subjects with respect to 
the vaccine actually administered.
The TVc for analysis of efficacy and immunogenicity will include vaccinated subjects for 
whom data related to efficacy and immunogenicity endpoints are available.
The TVc for analysis of safety will include all subjects with at least one vaccine 
administration documented.
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10.5.2. Modified Total Vaccinated cohort
The mTVc will be the primary population for efficacy analysis, which excludes subjects 
in the TVc for efficacy analysis who were not administered with the second vaccination 
or who develop a confirmed case of HZ prior to 1 month after the second vaccination.
Rationale for using mTVc for primary analysis:
Although the TVc (Intent-to-treat [ITT] population) analysis of efficacy is the one 
recommended according to ICH, the true assessment of the VE, according to the 
recommended schedule, can only be performed based on the mTVc, where subjects not 
completing the vaccination schedule due to an HZ episode or withdrawal will be 
excluded, as was done in an earlier HZ vaccine efficacy study [Oxman, 2005]. The 
analysis on the TVc is planned for sensitivity analyses and is expected to provide 
consistent results with the primary analyses. A delay of 1 month was selected prior to 
which any subject with confirmed HZ would be excluded from mTVc.
For those reasons, GSK Biologicals believes that the VE estimate for registration 
purposes should be based on mTVc, provided there is no essential VE difference between 
the mTVc and TVc analyses. Our proposal is to compare VE analyses on mTVc and 
TVc, and review the frequency for exclusion from mTVc. If the results are consistent 
between both cohorts then the VE estimate based on mTVc would be considered for 
registration purposes.
10.5.3. According To Protocol cohort for analysis of efficacy
The According To Protocol cohort (ATPc) for analysis of efficacy will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures defined in the protocol, with no elimination criteria during the study) for 
whom efficacy data concerning endpoint measures are available, i.e., excluding all 
subjects who developed a confirmed case of HZ prior to 1 month after the second 
vaccination. The list of criteria used to exclude subjects from ATP will be defined 
prospectively in the Reporting and Analysis Plan (RAP) prior to database freeze.
The ATPc will be the analysis set for supportive efficacy analysis, only including 
subjects who developed a confirmed case of HZ during the follow-up period starting 
from 1 month after the second vaccination (Month 3).
10.5.4. According To Protocol cohort for analysis of safety
The ATPc for analysis of safety will include all subjects:
 who have received at least one dose of study vaccine/placebo according to their 
random assignment;
 with sufficient data to perform an analysis of safety (at least one dose with 
safety follow-up);
 for whom administration site of study vaccine/placebo is known;
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 who have not received other medication/vaccine forbidden in the protocol 
(Section 6.6.1);
 for whom the randomization code has not been broken. 
10.5.5. According To Protocol cohort for analysis of immunogenicity 
For study ZOSTER-006, the ATPc for analysis of immunogenicity will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures and intervals defined in the protocol, with no elimination criteria during the 
study) for whom data concerning immunogenicity endpoint measures are available. This 
will include subjects for whom immunogenicity results are available at Month 3 for CMI 
and/or humoral immunogenicity.
10.6. Derived and transformed data
10.6.1. Handling of missing data
For a given subject and a given efficacy measurement, missing or non-evaluable 
measurements will not be imputed for the primary analysis. The missing endpoint and 
censoring are supposed to occur independently, and the pattern of the missingness being 
either Completely At Random (MCAR) or Missing At Random (MAR) only.
For the analysis of solicited symptoms, missing or non-evaluable measurements will not 
be replaced. Therefore the analysis of the solicited symptoms based on the TVc will 
include only subjects/doses with documented safety data (i.e., symptom screen/sheet 
completed). 
For the analysis of unsolicited AEs/SAEs/concomitant medication, all vaccinated subjects
will be considered and subjects who did not report an event will be considered as subjects 
without an event.
For a given subject and a given immunogenicity measurement, missing or non-evaluable 
measurements will not be replaced. Therefore, an analysis will exclude subjects with 
missing or non-evaluable measurements.
The reasons for and timings of missing data will be reviewed and discussed. The likely 
patterns for missing data will be assessed and compared with the actual missing data 
pattern in light of CHMP /EWP/1776/99 and implementation recommendations. 
Sensitivity analyses will be pre-specified prior to unblinding for each main efficacy 
endpoint in order to assess the sensitivity of the conclusions to missing-data pattern. 
When repeated measurements are planned, primary methodology will include mixed 
effect model for repeated measurement analysis [Mallinckrodt, 2008].
10.6.2. Efficacy
The HZ incidence rate is determined with reference to the first confirmed HZ case 
observed in the patient, should several HZ cases occur in the same subject.
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The HZ-free period for a subject is calculated from HZ onset to time zero relative to the 
cohort considered: first vaccination for TVc and beyond the HZ-case exclusion period 
following the second injection for mTVc and ATP.
The number of Person-Years at risk over an interval of time is the sum of the confirmed 
HZ-free episodes over all subjects at risk during that interval, either up to the cut-off date 
for the analysis, the censoring date or the occurrence of the first HZ case for a subject.
The following outputs will be derived from the efficacy data recorded using the ZBPI:
HZ burden-of-illness score
For each confirmed case of HZ, responses to the “worst pain” question in the ZBPI are 
used to calculate a “HZ severity-of-illness” score, defined as the area under the curve 
(AUC) of HZ-associated pain plotted against time during the 182-day period after the 
onset of rash. Subjects developing HZ will present “severity-of-illness” scores ranging 
from 0 up to, theoretically, 1820. A score of 0 is recorded for subjects in whom HZ did 
not develop during the study period.
HZ severity score 
The methodology described for the HZ burden-of-illness score will be applied to the 4 
weeks during which a daily measure is taken and provide the HZ severity score. The HZ 
severity score will apply only to subjects with HZ. Subjects not infected with HZ will not 
take part in this analysis.
10.6.3. Humoral immune response
 The current cut-off values that apply for gE and VZV Ab responses are 
described in Table 7 of Section 5.8.3. Those values may changes as 
improvements are introduced to the analytical methods. The final cut-off values 
that are used for the analyses will be stated in the study report.
 A seronegative subject is a subject whose Ab concentration is below the cut-off 
value.
 A seropositive subject is a subject whose Ab concentration is greater than or 
equal to the cut-off value.
 The seropositivity rate is defined as the percentage of seropositive subjects.
 The VZV gE-specific humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as a 4-fold increase in the anti-gE Ab 
concentration at the endpoint as compared to the pre-vaccination anti-gE 
antibody concentration. The VZV gE-specific humoral immune response to 
vaccine for subjects who are seronegative at baseline is defined as a 4-fold 
increase in the anti-gE Ab concentration at the endpoint as compared to the anti-
gE Ab cut-off value for seropositivity.
 The VZV-specific humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as a 4-fold increase in the anti-VZV Ab 
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concentration at the endpoint as compared to the pre-vaccination anti-VZV Ab 
concentration. The VZV-specific humoral immune response to vaccine for 
subjects who are seronegative at baseline is defined as a 4-fold increase in the 
anti-VZV Ab concentration at the endpoint as compared to the anti-VZV Ab 
cut-off value for seropositivity.
 The Geometric Mean Concentrations (GMCs) calculations are performed by 
taking the anti-log of the mean of the log concentration transformations. For 
descriptive statistics only, Ab concentrations below the cut-off of the assay will 
be given an arbitrary value equal to half the cut-off for the purpose of GMC 
calculation. For inferential analyses, those concentrations below the cut-off will 
be considered as missing to avoid potential influential data.
10.6.4. Cellular-mediated immune response 
 The frequency of CD4 T cells producing at least 2 activation markers 
(cytokines: IFN-, IL-2, TNF- and/or CD40L, termed “all doubles” or 
CD4[2+]) upon in vitro stimulation with the antigen (induction condition) is 
calculated by adding an offset of 0.5 to the number of activated CD4 T cells 
(numerator) divided by the total number of CD4 T cells involved (denominator). 
A similar calculation will be made for the frequency of CD4 T cells producing at 
least 2 cytokines (“all doubles”, CD4[2+]) upon in vitro stimulation in medium 
only (background condition). 
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 The frequency of antigen-specific (gE or VZV) CD4 T cells for each individual 
subject is calculated as the difference between the frequency of CD4 T cells 
producing at least 2 cytokines among IFN-, IL-2, TNF- and/or CD40L, 
termed “all doubles” or CD4[2+], upon in vitro stimulation with the antigen 
(induction condition) minus the frequency of CD4 T cells producing at least 2 
cytokines (“all doubles”, CD4[2+]) upon in vitro stimulation in medium only 
(background condition). When the log-transformation is applied to that variable 
prior to analysis, differences less or equal to zero (0) are imputed to 1 gE or 
VZV-specific cytokine secreting CD4 T cell per 106 CD4 T cells. 
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 The Geometric Mean (GM) frequency calculations are performed by taking the 
anti-log of the mean of the log frequency transformations;
 The CMI vaccine response against gE is defined for all subjects as a 1.5 to 2-
fold increase (see RAP for final threshold) in background-adjusted frequency of 
CD4 following induction with gE measured at endpoint as compared to pre-
vaccination.
 The CMI vaccine response against VZV is defined for all subjects as a 1.5 to 2-
fold increase (see RAP for final threshold) in background-adjusted frequency of 
CD4 following induction with VZV measured at endpoint as compared to pre-
vaccination.
 A CMI responder is a subject with a CMI response greater than or equal to the 
cut-off value.
10.7. Conduct of analyses
Any deviation(s) or change(s) from the original statistical plan outlined in the protocol 
will be described and justified in the final study report.
10.7.1. Prior to Final Analysis
Blinded review of safety and efficacy data will be performed in order to anticipate any 
data issues and rate of accrual of HZ and PHN events within each age strata.
Unblinded evaluation of safety, efficacy and risk-benefit for the subjects will be 
performed by the IDMC on an ongoing basis. Operational details for IDMC will be 
provided in the IDMC Charter. 
10.7.2. Statistical considerations for the interim futility analyses
The IDMC may be also involved in evaluation of VE at specified interim timepoints 
(futility analysis) and may recommend discontinuation of a clinical study that has 
demonstrated its inability to achieve its primary and main secondary endpoints. The 
futility rules will be described in the IDMC Charter.
GSK has no plan to proceed with early registration for efficacy (i.e., following an interim 
analysis) due to the expected low accrual rate of PHN cases and the need to collect a 
sufficient number of events to achieve robust estimation of PHN VE. If a futility analysis 
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occurs and leads to a recommendation by the IDMC to filing prior to study end for ethical 
reasons, it is mandated that, prior to final analysis, the significance level required during 
the course of the trial for considering early analysis by IDMC for all primary objectives 
but also key secondary objectives is 0.0001 for both HZ and PHN. As a consequence, the 
significance level of the final analysis will be adjusted to 4.9998% 2-sided. Practically 
speaking, however, that adjustment makes no essential difference as using a significance 
level of 5% 2-sided that will be referred to in other part of this document.
10.7.3. Final analysis
When the conditions for triggering the final analysis of efficacy have been reached, the 
final analysis cut-off date will be defined. Any HZ episode occurring prior to the final 
analysis cut-off data will be followed for a minimal duration of 90 days, as described in 
the RAP, in order to document potential PHN episodes. 
Prior to unblinding, the third party responsible for generating immunogenicity data will 
communicate the results to the SDAC for review and consistency checks with the 
remaining database. SDAC will make sure than any feedback to that third party does not 
unblind the laboratory. Data issues on immunogenicity identified by the SDAC and that 
cannot be resolved beforehand unless unblinding a treatment assignment blind party, will 
be reviewed after efficacy and safety database lock. 
Following achievement of criteria triggering analyses, final data collection and data 
cleaning, the write access to the clinical database will be removed and all eCRF data will 
become available for final analysis. The merging of immunogenicity data to the eCRF 
data will occur after that database lock. A first report will document efficacy and safety 
results and provide immunogenicity results using descriptive methodology. Analysis of 
correlate of protection may require extensive exploratory analyses and may be available 
as an annex report after completion of the primary report. Persistency data may be also 
provided in annex reports. 
10.8. Statistical methods
All analyses will be presented overall and by age strata. The main age strata for reporting
purposes are 50-59, 60-69 and 70 YOA. In addition, the results for the  70 YOA 
stratum will also be presented separately for 70-79 and  80 YOA subjects. The study is 
not powered prospectively to demonstrate efficacy in these 2 sub-strata taken separately.
Another set of analyses in subjects  60 YOA will also be presented.
Any exploratory or sensitivity analysis may be performed in addition to the analyses 
described below on an ad-hoc basis. The significance level of those analyses may not 
however be fully controlled.
10.8.1. Analysis of demographics/baseline characteristics
Demographic characteristics (age, gender, geographic ancestry and ethnicity) of each 
study cohort will be tabulated overall and by region.
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The mean age (plus range and standard deviation) of the enrolled subjects, as a whole, 
and per treatment group and stratified by age group will be calculated. 
The distribution of subjects enrolled among the study sites will be tabulated as a whole 
and per vaccine group.
No inferential analyses of demographic data or baseline characteristics are planned.
10.8.2. Analysis of efficacy
All efficacy analyses will be presented overall and by age strata. 
When overall VE is presented, the age stratification factor will include the 3 main age 
levels. When VE by age is presented, the same model will be run using only the data 
pertaining to the strata under consideration.
Additional tables will present the overall VE by region and overall VE by time (e.g., 
using 1-year interval). The methodology will be described in the RAP.
All p-values reported are related to the null hypothesis test VE = 0 or absence of effect of 
the vaccine and will account for p-value adjustment for multiple testing scheme when 
applicable. Both raw-confidence intervals and confidence intervals adjusted for multiple 
testing or other kind of significance adjustment will be produced.
10.8.2.1. Reduction in HZ risk
Descriptive statistics
For each treatment group, the number of subjects at risk, person-time, number of 
confirmed events (HZ) and incidence rate, and incidence of confirmed HZ cases will be 
tabulated overall and by age strata. The results will be presented over the whole study and 
by visit interval. Similar tables will describe the median time-to-event and hazard rate.
Survival curves for each vaccine group will be calculated non-parametrically, tabulated 
and presented graphically overall and by age strata using the Kaplan-Meier (i.e., Product-
Limit) method. 
Primary Inferential Analyses
When the disease incidence is very low, large sample size is required together with 
longer trial duration. As a consequence, all participants cannot be expected to be 
followed for the same duration throughout the end of the trial. For sufficiently large 
sample size and small incidence of disease, the number of cases in the vaccine and 
placebo groups may be approximated by independent Poisson distributions. For such low 
incidence rates, both binomial and Poisson distribution are equivalent. Under that model, 
it can be demonstrated that the number of vaccine group, given the total number of cases, 
follows a binomial distribution and resolves into a single-parameter estimation problem 
[Chan, 2003].
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Under that model, the primary analysis method of the vaccine VE will consider the exact 
inference on the relative risk stratified for age strata and regions conditionally to the total 
number of HZ cases observed and time at risk. The method is implemented in the Poisson 
procedure of the StatXact package provided by Cytel. Relative risks will be calculated 
overall and by age-strata. Stratification will include age and regions for the overall 
analysis and region alone when analysis by age strata. The stratification will account for 
possible differences in HZ incidence across strata and/or regions.
These analyses will adjust for the number of person-time in each vaccine group and strata 
when applicable. Similarity of the relative risks across the strata analyzed will be 
assessed graphically and by means of exact tests for homogeneity of the relative risks. 
Absence of clinically meaningful difference in relative risks across strata and p-values 
larger than 5% (2-sided) will justify assuming the relative risks are similar across the 
strata. In other situations, the impact of potential heterogeneity on the study conclusions 
will be assessed using sensitivity analyses.
Sensitivity analysis of the VE will be provided by region to support registration and for 
visual inspection of the consistency of the VE across regions. The study is not powered to 
demonstrate significance of VE in any of those regions using only the data of that region 
in isolation.
Sensitivity analysis of the overall VE after each multiple of 12 months following last 
vaccination will be provided in order to assess consistency of VE over time.
Secondary Inferential Analyses
The elapsed time following the HZ-case exclusion period after the second vaccination to 
the first HZ episode may be analyzed using Cox’s proportional hazard regression 
stratified for age strata and region with vaccine groups as covariates. Wald test and CIs 
will be produced.
Ties will be handled using the Efron method. Cox adjusted survival curves will be 
produced for each combination of vaccine group and age category.
10.8.2.2. Reduction in overall PHN risk
The overall reduction in PHN risk will be evaluated similarly to the HZ risk using the 
exact inference on the relative risk stratified for age strata and regions conditionally to the 
total number of HZ cases observed and time at risk. Similarly to the HZ VE, a Poisson 
distribution for the number of PHN cases under placebo and vaccine groups is assumed. 
Since the incidence of PHN is approximately 10% to 25% of the incidence of HZ, the 
Poisson approximation of the overall number of PHN cases with regards to the mTVc is 
similarly valid. The inference of the PHN VE is partially confounded with the analysis of 
HZ risk as it includes the efficacy of the vaccine against HZ in all subjects randomized 
and the efficacy of the vaccine against PHN in those subjects that presented with HZ. 
However, the overall PHN analysis is deemed relevant for the following reasons:
1. An analysis performed on randomized cohort ensures comparability of the vaccine 
groups under evaluations. An analysis performed on the subset of subjects who 
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presented with HZ may be biased due to the selection of that subset due to the 
disease.
2. It matters to provide Health Authorities with overall benefit on PHN risk, whether 
the primary efficacy is against HZ or against PHN.
10.8.2.3. Reduction in Burden-of-Illness
The “Chop-lump” test [Follmann, 2009] for the overall reduction in Burden-of-Illness 
scores in all subjects between vaccine and placebo will be implemented and compared to 
the original analysis of the Burden-of-Illness proposed by Chang, 1994. That analysis is 
exploratory and will be described in the RAP. The purpose of this analysis is to compare 
with results published elsewhere [Oxman, 2005] and no further change to the 
methodology is this considered appropriate.
The HZ “Burden-Of-Illness (BOI) score” represents the average severity of illness among 
all subjects in the vaccine or placebo groups. It is calculated according to the “modified” 
scale described by Coplan [Coplan, 2004] as the sum of the HZ “severity-of-illness” 
scores of all members of the treatment group divided by the total number of subjects in 
the group.
The pain experienced by the subjects over the period that precedes a 24 hour window 
prior to the visit to the investigator will be captured in a single measure. VE with respect 
to the BOI due to HZ (VE BOI ) is defined as the relative reduction in the BOI score in 
the vaccine group as compared with that in the placebo group and calculated as 1 -
relative risk (i.e., 1- the HZ BOI score in the vaccine group divided by the HZ BOI score 
in the placebo group).
The same definition of clinically relevant improvement as given for HZ severity applies 
to BOI.
10.8.2.4. Reduction in HZ severity score
Based on Rowbotham [Rowbotham, 2001] and Farrar et al. [Farrar, 2001], a reduction of  
1.74 units or 28% on pain score between baseline and endpoint were best associated with 
clinically relevant improvement, according to the Patient’s Global Impression of Change 
(PGIC) category of “much improved” or better. The authors also concluded that, in 
studies with no minimum baseline requirement, the relationship between percentage 
changes and PGIC is more consistent than with the raw change. Dworkin et al, [Dworkin, 
2008] reach a similar conclusion. Therefore, a percentage reduction in pain between 
vaccine and placebo of ~28% may be considered as clinically relevant in this study.
Additional implementation details will be provided in the RAP.
The statistical methodology for the analysis of HZ severity will be described in the RAP 
and is similar to the methodology described previously for BOI assessment in [Chang, 
1994]. The method for accounting for the potential differential in use of antiviral 
treatment or pain medications between the vaccine and placebo groups will be pre-
specified. Contrary to the BOI analysis, the HZ severity analysis only applies to subjects 
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with HZ (i.e., a score of zero is not assigned to subjects who do not present with HZ) and 
only includes the first 4 weeks following the HZ episode. 
Additional analyses may be performed using partial AUC, calculated from 0 to specific 
elapsed time after HZ onset. That approach accounts partially for any difference in pain 
score profiles or pattern (e.g., long duration with low scores versus short score with high 
scores) even though subjects may have the same overall AUC.
10.8.2.5. Reduction in incidence of HZ associated complications
At the end of the trial, it is reasonable to assume that a final assessment of the presence or 
absence of HZ associated complication will be made for most patients with confirmed
HZ. As a consequence, the number HZ associated complications in subjects with HZ 
under placebo or vaccine may be considered as a binomial distribution rather than a 
Poisson distribution.
The overall incidence of HZ associated complications, in subjects with an HZ episode, 
overall and by sub-categories will be presented and compared with placebo using 
asymptotic standardized unconditional binomial test [Miettinen, 1985]. The analysis will 
be stratified by age group and weights associated to each stratum will be pre-specified. 
The statistical methodology will be further described in the RAP.
10.8.2.6. Reduction of duration of severe ‘worst’ pain in subjects with an HZ 
episode
This analysis aims at demonstrating the effect of the vaccine on the reduction of the 
duration of pain, irrespective of whether the pain is acute or chronic. Similarly to the 
approach taken for the analysis of incidence of PHN, this analysis will involve any 
subject reporting ZBPI pain scores of 3 or more at any time during the study. 
The time-to-cessation of severe ‘worst’ pain will be analyzed using a survival 
methodology. The primary analysis will consist in a Cox-proportional model to assess the 
hazard rate reduction in ZBPI worst pain duration due to the vaccine in those subjects 
that presented HZ.
A change-point piecewise exponential model [Arani, 2001; Desmond, 2002] may be used 
as sensitivity analysis to compare hazard rates related to acute (0-30 days), sub-acute (30-
120 days) and chronic (120+ days) pain between vaccine group and placebo. The cut-off 
points 30 days and 120 days were suggested according to Desmond [Desmond, 2002]. 
Those cut-off points may additionally be estimated using the data. The comparisons 
across both sub-acute pain and chronic pain will be combined using a likelihood-ratio 
test. 
Both methodologies will be further detailed in the RAP.
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10.8.2.7. Reduction in PHN incidence in subjects with an HZ episode
At the end of the trial, it is reasonable to assume that a final assessment of the presence or 
absence of PHN will be made for most patients who experienced an HZ episode. As a 
consequence, the number of PHN cases in subjects with HZ under placebo and vaccine 
maybe considered as a binomial distribution rather than a Poisson distribution.
The incidence of PHN in subjects with an HZ episode, overall and by sub-categories will 
be presented and compared with placebo using asymptotic standardized unconditional 
binomial test [Miettinen, 1985]. The analysis will be stratified by age group and weights 
associated to each stratum will be pre-specified. The statistical methodology will be 
further described in the RAP.
10.8.2.8. Improvement of subject’s quality of life by ZBPI
Descriptive statistics and inferential analysis of QoL subscale of ZBPI (item 9: questions 
A to G) total scores and scores per item over time will be provided overall and by age 
group. 
10.8.3. Analysis of immunogenicity 
The primary analysis will be based on the ATPc for analysis of immunogenicity (Section 
10.5.5). If the percentage of enrolled subjects excluded from this ATPc is more than 5%, 
a second analysis based on the TVc will be performed to complement the ATP analysis.
10.8.3.1. Cell-mediated immune response
CMI response will only be assessed and analyzed in the CMI component of the 
Immunogenicity subset as defined in Section 4.1.
Descriptive statistics
For CMI response, the following parameters will be tabulated by treatment group, overall 
and by age group at Months 0, 3, 14, 26 and 38:
 descriptive statistics of the frequency of CD4 T cell secreting at least two 
different cytokines (IFN-, IL-2, TNF-,CD40L) to both VZV and gE antigens;
 descriptive statistics of the frequency of CD4 T cell secreting at least IFN- and 
another cytokine (IL-2, TNF-,CD40L) to both VZV and gE antigens;
 descriptive statistics of the frequency of CD4 T cell secreting at least IL-2 and 
another cytokine (IFN-, TNF-,CD40L) to both VZV and gE antigens;
 descriptive statistics of the frequency of CD4 T cell secreting at least TNF- and 
another cytokine (IFN-, IL-2,CD40L) to both VZV and gE antigens;
 descriptive statistics of the frequency of CD4 T cell secreting at least CD40L 
and another cytokine (IFN-, IL-2, TNF-) to both VZV and gE antigens;
 proportion of responders with exact 95% CI.
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Inferential Analyses
If the data allows, inferential analysis on the log-transformed frequency of CD4 T cells 
producing at least two different cytokines following induction with antigen will be
performed overall and by age strata or sub-strata, in subjects infected with HZ and 
healthy subjects. Least-squares means and 95% CI are back-transformed to provide 
geometric means and ratios. Covariates will include the log-transformed pre-vaccination 
frequency following induction with the antigen and the non-specific background log-
transformed frequency. Sensitivity analyses may include additional effects for 
appropriate interactions in the model in order to provide estimations and 95% CI by 
region.
10.8.3.2. Humoral immune response
Humoral immune response will be assessed and analyzed in the Humoral 
Immunogenicity subset as defined in Section 4.1.
Descriptive statistics
The following parameters will be tabulated by treatment group, overall and by age group 
at Month 0, Month 3, Month 14, Month 26 and Month 38:
 Geometric mean concentrations (GMCs) of anti-gE Ab with 95% CIs;
 Humoral seropositivity rates with exact 95% CIs;
 Vaccine response rates with 95% CIs;
 Tabulations will be presented overall and by region.
Inferential Analyses
If the data allows, inferential analysis on the log-transformed Ab concentrations will be
performed overall and by age strata or sub-strata, in subjects infected with HZ and 
healthy subjects. Least-squares means and 95% CI are back-transformed to provide 
geometric means and ratios. Covariates will include the log-transformed pre-vaccination 
concentrations. Sensitivity analyses may include additional effects for regions and 
appropriate interactions in the model in order to provide estimations and 95% CI by 
region.
The analysis for immunogenicity will be performed on the pooled data of both ZOSTER-
006 and ZOSTER-022 and the results will be provided in an annex report.
10.8.3.3. VZV neutralizing antibody response
Descriptive statistics
The following parameters will be tabulated by treatment group, overall and by age group 
at Month 0, Month 3, Month 14, Month 26 and Month 38:
 Geometric mean titres (GMTs) of anti-VZV neutralizing Abs with 95% CIs;
 Tabulations will be presented overall and by region.
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10.8.3.4. Correlate of protection
An exploratory analysis will be implemented in an attempt to correlate humoral immune 
responses to vaccination and subsequent HZ risk [Dunning, 2006]. A specific RAP will 
describe the methodologies to be used for that purpose. The exploratory analyses may be 
initiated during the course of the trial by SDAC to support IDMC.
Serum blood samples will be collected from all subjects at Month 0 (pre-vaccination) and 
Month 3, and may be used for correlate of protection analysis. Additional subject samples 
may be retrieved and analyzed based on some demographics and baseline characteristics 
to match more exactly with characteristics of those who developed HZ.
The analysis for correlate of protection will be performed on the pooled data of both 
ZOSTER-006 and ZOSTER-022 and provided in an annex report.
10.8.4. Quality of life
10.8.4.1. SF-36 health survey
The methodology used for the analysis of the SF-36® questionnaire is detailed by Ware 
et al. [Ware, 2000]. Table 33 presents the SF-36® items that were to be taken into 
account for each score.
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A Minimal Important Difference (MID) for EQ-5D is defined as a change of ~0.07 to 
~0.08 [Walters, 2005]. However, when the ultimate objective is to influence resource 
allocation decisions, the difference in cost-effectiveness is more relevant and a difference 
of 0.03 is considered the minimum clinically important difference for QALY sample size 
calculations [Drummond, 2001].
10.8.5. Analysis of safety
The primary analysis for safety will be based on the TVc. A second analysis based on this 
ATPc will be performed to complement the TVc analysis.
When appropriate, tabulations will be presented overall and by time of occurrence 
relative to last vaccination (e.g., using windows such as Days 0  6, Days 0  29 and 
more than 30 days post-vaccination).
10.8.5.1. Within groups assessment
For each treatment group, the following results will be tabulated overall and by age strata.  
 The percentage of subjects with at least one local AE (solicited and unsolicited), 
with at least one general adverse event (solicited and unsolicited) and with any 
AE during the solicited follow-up period will be tabulated with exact 95% CI 
after each vaccine dose and overall. 
 The percentage of doses followed by at least one local AE (solicited and 
unsolicited), by at least one general AE (solicited and unsolicited) and by any 
AE will be tabulated, overall vaccination course, with exact 95% CI.
 The percentage of subjects reporting each individual solicited local and general 
AE during the solicited 7-day (Days 0-6) follow-up period will be tabulated with 
exact 95% CI. 
 The percentage of doses followed by each individual solicited local and general 
AE during the solicited 7 day (Days 0-6) follow-up period will be tabulated, 
overall vaccination course, with exact 95% CI. 
 For all solicited symptoms, the same tabulation will be performed for grade 3 
solicited AEs and for solicited general AEs with relationship to vaccination.
 Duration and prevalence of fever will be presented.
 The proportion of subjects with at least one report of unsolicited AE during the 
30-day (Days 0  29) follow-up period after each vaccination classified 
according to the MedDRA System Organ Class and Preferred Terms will be 
tabulated, with exact 95% CI.
 The distribution of the number of unsolicited AEs per subject will be tabulated.
 The same tabulation will be performed for grade 3 unsolicited AEs and for 
unsolicited AEs with a relationship to vaccination. The proportion of AEs 
resulting in a medically attended visit (other than routine health maintenance 
visits) will also be tabulated.
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 Incidences of SAEs during the 30-day (Days 0  29) follow-up period after each 
vaccination, up to 8 months and during any time during the study classified 
according to the MedDRA System Organ Class and Preferred Terms will be 
tabulated, with exact 95% CI.
 A separate tabulation will report major categories of SAEs that occur with 
higher frequencies in elderly subjects including: cardiac, vascular, respiratory, 
neurological, congestive heart failure, myocardial infarction, varicella or HZ-
like rash, cerebral or vascular events. 
 Incidences of SAEs by major categories including: cardiac, vascular, respiratory, 
neurological, congestive heart failure, myocardial infarction, varicella or HZ-
like rash, cerebral vascular. Listing will also be provided, sorted by patients and 
sorted by preferred term.
 Incidence of withdrawal due to AEs. Listing will also be provided, sorted by 
subjects and sorted by MedDRA Preferred Term.
 The proportion of subjects with at least one report of NOADs and other immune 
mediated inflammatory disorders during the entire study period will be tabulated 
overall and by time window. Listing will also be provided, sorted by subjects 
and sorted by MedDRA Preferred Term.
 The proportion of subjects with concomitant medication will be tabulated, until 
30 days after each vaccine dose and overall, with exact 95% CI.
 Proportion and incidence rate of subjects with fatal outcome, HZ-related 
complications and overall and HZ-related hospitalizations, will be tabulated 
overall and by time window.
 Proportion of subjects experiencing an HZ episode using pain medications by 
type (opiods, non-narcotics, antidepressants, miscellaneous) will be tabulated.
10.8.5.2. Additional exploratory safety comparisons 
The standardized asymptotic 95% CI for the difference between the two groups and the 
associated 2-sided p-value to detect group difference will be computed for the following 
endpoints.
 The proportion of subjects with at least one report of unsolicited AE classified 
by the MedDRA presented by System Organ Class and Preferred Term.
 Incidences of SAEs classified according to the MedDRA System Organ Class 
and Preferred Terms.
The objective of these analyses is to identify a safety signal as defined by the Council for 
the International Organization of Medical Sciences (CIOMS) VI working group, i.e., a 
report or reports of an event with an unknown causal relationship to treatment that is 
recognized as worthy of further exploration and continues surveillance. It is recognized 
that the use of any method to identify safety signals has the potential to identify a large 
number of events which may or may not have a causal relationship to drug treatment due 
to multiplicity of endpoints. In order to put any safety signal in perspective a permutation 
test will be conducted to quantify the probability to observe at least one false safety 
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signal according to the threshold p-value defining a signal. In addition, clinical 
significance and biological plausibility will need to be accounted before establishing 
causality.
Other exploratory safety analyses may be described in the RAP.
11. ADMINISTRATIVE MATTERS
To comply with ICH GCP administrative obligations relating to data collection, 
monitoring, archiving data, audits, confidentiality and publications must be fulfilled. 
11.1. Case Report Form/Remote Data Entry instructions
Remote Data Entry (RDE), a validated computer application, will be used as the method 
for data collection. 
In all cases, subject initials will not be collected nor transmitted to GSK. Subject data 
necessary for analysis and reporting will be entered/transmitted into a validated database 
or data system. Clinical data management will be performed in accordance with 
applicable GSK standards and data cleaning procedures.
While completed eCRFs are reviewed by a GSK Biologicals’ Site Monitor at the study 
site, omissions or inconsistencies detected by subsequent eCRF review may necessitate 
clarification or correction of omissions or inconsistencies with documentation and 
approval by the investigator or appropriately qualified designee. In all cases, the 
investigator remains accountable for the study data. 
The investigator will be provided with a CD-ROM of the final version of the data 
generated at the investigational site once the database is archived and the study report is 
complete and approved by all parties.
11.2. Monitoring by GSK Biologicals
Monitoring visits by a GSK Site Monitor are for the purpose of confirming that GSK 
Biologicals’ sponsored studies are being conducted in accordance with the ethical 
principles that have their origins in the Declaration of Helsinki and that are consistent 
with Good Clinical practice (GCP) and the applicable regulatory requirement(s) 
(verifying continuing compliance with the protocol, amendment(s), reviewing the 
investigational product accountability records, verifying that the site staff and facilities 
continue to be adequate to conduct the study). 
The investigator must ensure provision of reasonable time, space and qualified personnel 
for monitoring visits.
Direct access to all study-site related and source data is mandatory for the purpose of 
monitoring review. The monitor will perform a RDE review and a Source Document 
Verification (SDV). By SDV we understand verifying RDE entries by comparing them 
with the source data that will be made available by the investigator for this purpose. 
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The Source Documentation Agreement Form describes the source data for the different 
data in the RDE. This document should be completed and signed by the site monitor and 
investigator and should be filed in the monitor’s and investigator’s study file. Any data 
item for which the RDE will serve as the source must be identified, agreed and 
documented in the source documentation agreement form. 
For RDE, the monitor will mark completed and approved screens at each visit.
In accordance with applicable regulations, GCP, and GSK procedures, GSK monitors 
will contact the site prior to the start of the study to review with the site staff the protocol, 
study requirements, and their responsibilities to satisfy regulatory, ethical, and GSK 
requirements. When reviewing data collection procedures, the discussion will also 
include identification, agreement and documentation of data items for which the eCRF
entries will serve as the source document.
GSK will monitor the study to verify that, amongst others, the: 
 Data are authentic, accurate, and complete.
 Safety and rights of subjects are being protected.
 Study is conducted in accordance with the currently approved protocol and any 
amendments, any other study agreements, GCP and all applicable regulatory 
requirements. 
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents.
Upon completion or premature discontinuation of the study, the monitor will conduct site 
closure activities with the investigator or site staff, as appropriate, in accordance with 
applicable regulations, GCP, and GSK procedures.
11.3. Archiving of data at study sites
Following closure of the study, the investigator must maintain all site study records in a 
safe and secure location. The records must be maintained to allow easy and timely 
retrieval, when needed (e.g. audit or inspection), and, whenever feasible, to allow any 
subsequent review of data in conjunction with assessment of the facility, supporting 
systems, and staff. Where permitted by applicable laws/regulations or institutional policy, 
some or all of these records can be maintained in a validated format other than hard copy 
(e.g. microfiche, scanned, electronic for studies with an eCRF); however, caution needs 
to be exercised before such action is taken. The investigator must assure that all 
reproductions are legible and are a true and accurate copy of the original and meet 
accessibility and retrieval standards, including re-generating a hard copy, if required. 
Furthermore, the investigator must ensure there is an acceptable back-up of these 
reproductions and that an acceptable quality control process exists for making these 
reproductions.
GSK will inform the investigator/institution of the time period for retaining these records 
to comply with all applicable regulatory requirements. However, the 
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investigator/institution should seek the written approval of the sponsor before proceeding 
with the disposal of these records. The minimum retention time will meet the strictest 
standard applicable to that site for the study, as dictated by ICH GCP, any institutional
requirements or applicable laws or regulations, or GSK standards/procedures; otherwise, 
the minimum retention period will default to 15 years. 
The investigator/institution must notify GSK of any changes in the archival 
arrangements, including, but not limited to, the following: archival at an off-site facility, 
transfer of ownership of the records in the event the investigator leaves the site. 
11.4. Audits
To ensure compliance with GCP and all applicable regulatory requirements, GSK may 
conduct a quality assurance audit. Regulatory agencies may also conduct a regulatory 
inspection of this study. Such audits/inspections can occur at any time during or after 
completion of the study. If an audit or inspection occurs, the investigator and institution 
agree to allow the auditor/inspector direct access to all relevant documents and to allocate 
his/her time and the time of his/her staff to the auditor/inspector to discuss findings and 
any relevant issues.
11.5. Posting of information on Clinicaltrials.gov
Study information from this protocol will be posted on clinicaltrials.gov before enrolment 
of subjects begins.
11.6. Ownership, confidentiality and publication
11.6.1. Ownership
All information provided by GSK and all data and information generated by the site as 
part of the study (other than a subject’s medical records) are the sole property of GSK.
All rights, title, and interests in any inventions, know-how or other intellectual or 
industrial property rights which are conceived or reduced to practice by site staff during 
the course of or as a result of the study are the sole property of GSK, and are hereby 
assigned to GSK.
If a written contract for the conduct of the study which includes ownership provisions 
inconsistent with this statement is executed between GSK and the study site, that 
contract’s ownership provisions shall apply rather than this statement.
11.6.2. Confidentiality
Documented evidence that a potential investigator is aware and agrees to the confidential 
nature of the information related to the study must be obtained by means of a 
confidentiality agreement.
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All information provided by GSK and all data and information generated by the site as 
part of the study (other than a subject’s medical records) will be kept confidential by the 
investigator and other site staff. This information and data will not be used by the 
investigator or other site personnel for any purpose other than conducting the study. 
These restrictions do not apply to: (i) information which becomes publicly available 
through no fault of the investigator or site staff; (ii) information which it is necessary to 
disclose in confidence to an IEC or IRB solely for the evaluation of the study; (iii) 
information which it is necessary to disclose in order to provide appropriate medical care 
to a study subject; or (iv) study results which may be published as described in the next 
paragraph. If a written contract for the conduct of the study which includes 
confidentiality provisions inconsistent with this statement is executed, that contract’s 
confidentiality provisions shall apply rather than this statement.
11.6.3. Publication
For multicentre studies, the first publication or disclosure of study results shall be a 
complete, joint multicentre publication or disclosure coordinated by GSK. Thereafter, 
any secondary publications will reference the original publication(s).
Prior to submitting for publication, presentation, use for instructional purposes, or 
otherwise disclosing the study results generated by the site (collectively, a ‘Publication’), 
the investigator shall provide GSK with a copy of the proposed Publication and allow 
GSK a period to review the proposed Publication (at least twenty-one working days, or at 
least fifteen working days for abstracts/posters/presentations). Proposed Publications 
shall not include either GSK confidential information other than the study results or 
personal data on any subject, such as name or initials.
At GSK’s request, the submission or other disclosure of a proposed Publication will be 
delayed a sufficient time to allow GSK to seek patent or similar protection of any 
inventions, know-how or other intellectual or industrial property rights disclosed in the 
proposed Publication.
If a written contract for the conduct of the study, which includes publication provisions 
inconsistent with this statement is executed, that contract’s publication provisions shall 
apply rather than this statement.
11.6.4. Provision of study results to investigators, posting to the clinical 
trials registers and publication
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results at a GSK site or other mutually-
agreeable location.
GSK will also provide the investigator with the full summary of the study results. The 
investigator is encouraged to share the summary results with the study subjects, as 
appropriate.
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The results summary will be posted to the GSK Clinical Study Register at the time of the 
first regulatory approval or within 12 months of any decision to terminate development. 
In addition, a manuscript will be submitted to a peer-reviewed journal for publication 
within 12 months of the first approval or within 12 months of any decision to terminate 
development. When manuscript publication in a peer-reviewed journal is not feasible, 
further study information will be posted to the GSK Clinical Study Register to 
supplement the results summary.
12. COUNTRY SPECIFIC REQUIREMENTS
12.1. Requirements for France
This section includes all the requirements of the French law (n 2004-806 of 09 August 
2004), and identifies, item per item, the mandatory modifications or additional 
information to the study protocol.
Concerning the « STUDY POPULATION» 
 In line with the local regulatory requirements, the following text about 
«PAYMENT TO SUBJECTS » is added: 
If the subjects will be paid for the inconvenience of participating in the study. The 
amount of payment is stated in the informed consent form. Subjects not completing 
the study for whatever reason could be paid at the discretion of the Investigator, 
generally on a pro rata basis.
 In line with the local regulatory requirements, the following text about  
« NATIONAL FILE » is added:
All subjects participating in studies could be identified and monitored under the 
« Fichier national ».
The following details will be described:
 first 3 letters of name and first 2 letters of surname,
 date of birth,
 reference of the study and dates of beginning and termination,
 exclusion period,
 the total amount of honorarium.
 In line with the local regulatory requirements, the following text in section  
«OTHER STUDY ELIGIBILITY CRITERIA CONSIDERATIONS » is added:
A subject will be eligible for inclusion in this study if he /she is either affiliated to or 
beneficiary of a social security category.
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It is the investigator’s responsibility to ensure and to document (in source document -
patient notes) that the patient is either affiliated to or beneficiary of a social security 
category.
Concerning the “DATA ANALYSIS AND STATISTICAL CONSIDERATIONS” 
and specially in the “SAMPLE SIZE ASSUMPTION”
 The expected number of patients to be recruited in France is declared to the 
French regulatory authority.
Concerning the “STUDY CONDUCT CONSIDERATIONS”
 In section “Regulatory and Ethical Considerations, Including the Informed 
Consent Process”
Concerning the process for informing the patient or his/her legally 
authorized representative, the following text is added: 
 French Patient Informed Consent form is a document in triplicate which 
summarizes the main features of the study and allows collection of the patient's 
written consent. It also contains a reference to the authorisation of Afssaps and 
the approval from the French Ethics committee and the maintenance of 
confidentiality of the returned consent form by GSK France.
Concerning the process for obtaining subject informed consent:
 When biomedical research is carried out on an adult in the care of a 
“tutelle” guardian, consent is given by their legal representative and, if the 
committee mentioned in article L. 1123-1 considers that the research in question, 
because of the gravity of the restraints or the specificity of the medical acts 
involved, entails a serious risk of affecting their private life or the integrity of 
their body, by the family council if it has been instated, or by the judge of 
“tutelle” guardians.
 When biomedical research is carried out on an adult in the care of a "curatelle" 
guardian, consent is given by the subject assisted by his guardian.
However, if the adult in the care of a "curatelle" guardian is invited to participate in 
research which the committee mentioned in article L. 1123-1 considers, because of 
the gravity of the restraints or the specificity of the medical acts involved, to entail a 
serious risk of affecting their private life or the integrity of their body, the matter is 
submitted to the judge of guardians who decides whether the adult is capable of 
giving his consent. In the case of incapacity, the judge will decide whether or not to 
authorise the biomedical research.
 When biomedical research, which complies with the conditions laid down in 
article L. 1121-8, is considered for an adult incapable of expressing his consent 
and not under a legal protection order, consent is given by a person of 
confidance as defined in article L. 1111-6 and, failing this, by a person who 
maintains close and stable links with the subject. However, if the committee 
mentioned in article L. 1123-1 considers that the research in question, because 
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of the gravity of the restraints or the specificity of the medical acts involved, 
entails a serious risk of affecting their private life or the integrity of their body, 
consent is given by the judge of guardians.
Concerning the management of the Patient Informed Consent forms, the 
following text is added:
 The first copy of the Patient Informed Consent form is kept by the investigator. 
The second copy is kept by the Director of the Medical Department of 
GlaxoSmithKline France and the last copy is given to the patient or his/her 
legally authorized representative.
 The second copy of all the consent forms will be collected by the investigator at 
the end of the trial under the Clinical Research Assistant’s (CRA's) control, and 
placed in a sealed envelope bearing only:
 the study number, 
 the identification of the Centre : name of the principal investigator and number 
of centre),
 the number of informed consents,
 the date, 
 and the principal investigator’s signing.
Then, the CRA hands the sealed envelope over to the Director of the Medical 
Department, for confidential recording, under his responsibility.
In section concerning the “ NOTIFICATION TO THE HOSPITAL DIRECTOR ” 
the following text is added (if applicable)
 In accordance with Article L1123-13 of the Public Health Code, the Hospital 
Director is informed of the commitment to the trial in his establishment. The 
Hospital Director is supplied with the protocol and any information needed for 
the financial disposition, the name of the investigator(s), the number of sites 
involved in his establishment and the estimated time schedule of the trial 
(R.1123-63).
In section concerning the “ INFORMATION TO THE HOSPITAL 
PHARMACIST ” the following text is added (if applicable)
 In accordance with Article R.1123-64 of the Public Health Code, the Hospital 
Pharmacist is informed of the commitment to the trial in his establishment. The 
Pharmacist is supplied with a copy of the protocol (which allows him to 
dispense the drug(s) of the trial according to the trial methodology), all 
information concerning the product(s) of the trial (e.g. included in the CIB), the 
name of the investigator(s), the number of sites involved in his establishment 
and the estimated time schedule of the trial.
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In section  “ DATA MANAGEMENT ” the following text is added
 " within the framework of this clinical trial, data regarding the identity of the 
investigators and/or co-investigators and/or the pharmacist if applicable, 
involved in this clinical trial, and data regarding the patients recruited in this 
clinical trial (patient number, treatment number, patient status with respect to the 
clinical trial, dates of visit, medical data) will be collected and computerized in 
GSK data bases by Laboratoire GlaxoSmithKline or on its behalf, for reasons of 
follow up, clinical trial management and using the results of said clinical trial. 
According to the Act n° 78-17 of 6th January 1978 further modified, each of 
these people aforesaid has a right of access, correction and opposition on their 
own data through Laboratoire GlaxoSmithKline (Clinical Operations 
Department)."
12.2. Requirements for Germany
EXPLANATORY STATEMENT CONCERNING GENDER DISTRIBUTION 
(ARTICLE 7, PARAGRAPH 2 (12) OF THE GERMAN GCP ORDER)
 There is no intention to conduct specific analyses investigating the relationship 
between the gender of the subjects and the efficacy, immunogenicity or safety of 
the GSK Biologicals’ gE/AS01B vaccine. The ratio of male to female subjects 
recruited into the study ZOSTER-006 is expected to be in line with the 
demographics of the population aged  50 YOA in the Member State.
12.3. Requirements for Japan
Regulatory and Ethical Considerations
The study will be conducted in accordance with Good Clinical Practice (GCP), Article 
14-3 and 80-2 of the Pharmaceutical Affairs Law, all applicable subject privacy 
requirements, and the guiding principles of the declaration of Helsinki.
Clinical Trial Notification to Regulatory Authority
GSK will submit the CTN to the regulatory authorities in accordance with Article 80-2 of 
the Pharmaceutical Affairs Law before conclusion of any contract for the conduct of the 
study with study sites.
Informed Consent of Subjects 
Informed consent will be obtained before the subject can participate in the study. The 
contents and process of obtaining informed consent will be in accordance with all 
applicable regulatory requirements.
Informed Consent
Prior to the start of the study, the investigator (or subinvestigator) should fully inform the 
potential subject of the study including the written information given approval by the 
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IRB. The investigator (or subinvestigator) should provide the subject ample time and 
opportunity to inquire about details of the study and to decide whether or not to 
participate in the study. After giving informed consent based on his/her free will, the 
subject should sign and personally date the consent form. If the subject wishes to 
consider the content of the written information at home, he/she may sign the consent 
form at home. The person who conducted the informed consent discussion should sign 
and personally date the consent form. If the subject is unable to read, an impartial witness 
should be present during the entire informed consent discussion, and the witness should 
sign and personally date the consent form. The investigator (or subinvestigator) should 
retain this signed and dated form (and other written information) together with the source 
medical records, such as clinical charts (in accordance with the rules for records 
retention, if any, at each medical institution) and give a copy to the subject.
If information becomes available that may be relevant to the subject's 
willingness to continue participation in the study (revision of informed 
consent form and other written information)
If information becomes available that may be relevant to the subject's willingness to 
continue participation in the study, the investigator (or subinvestigator) should 
immediately inform the subject of it to confirm the willingness to continue participation 
in the study, and document the communication of this information (in medical records). If 
necessary, the investigator should revise the written information to be provided to 
subjects, promptly report it to the sponsor, and obtain approval from the IRB. The 
investigator should not enroll any new subject in the study before the IRB’s approval. 
After the IRB approves the revision of the written information to be provided to subjects, 
the investigator (or subinvestigator) should inform each subject participating in the study 
of the revised written information, and obtain written informed consent.
Study Monitoring
By monitoring the parties involved in the study including medical institutions, 
investigators, subinvestigators, study collaborators, and storage managers, monitors will:
1. Oversee the process of obtaining written informed consent, the control of 
investigational products and the progress of the study (including withdrawals and 
adverse events, and ensure that the conduct of the study is in compliance with GCP, 
Revised GCP, this protocol, and any other written agreement between the sponsor 
and the investigator/institution.
2. Collect and provide information that is necessary to conduct the study properly 
(information on investigational products’ safety, efficacy and quality).
3. Verify that the investigator/institution has adequate qualifications and resources and 
remain adequate throughout the study period, and that facilities, including 
laboratories, equipment, and staff, are adequate to safely and properly conduct the 
study and remain adequate throughout the study period.
4. Verify that source documents and other study records are accurate, complete, kept 
up-to-date and maintained.
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5. Determine whether the person responsible for retaining records is maintaining the 
essential documents at each medical institution.
6. Check the accuracy and completeness of the CRF entries, source documents and 
other study-related records against each other.
The investigator and institution should agree to allow the monitor direct access to 
essential documents and other relevant documents.
Direct access to essential documents by monitors and the scope of those documents will 
be specified separately in the written procedures for monitoring prepared for this study.
The monitor will also review EQ-5D, SF-36 and ZBPI questionnaires for extraneous 
written comments that could indicate possible AEs. Information collected in the CRF,
and in EQ-5D, SF-36 and ZBPI questionnaires will be handled as independent 
components of this study. Except for header section information (e.g., subject 
identification code (subject number), treatment number, visit date), neither the monitor 
nor the investigator (or subinvestigator) will attempt to reconcile responses to individual 
questions/items recorded on EQ-5D, SF-36 and ZBPI questionnaires or health outcomes 
portions of diary cards (if applicable) with other data recorded in the CRFs. EQ-5D, SF-
36 and ZBPI questionnaires itself generally serve as the source document; therefore, 
unless otherwise specified elsewhere, no other source document is available for data 
validation.
Source Data Recorded Directly on CRF
The following data may be recorded directly on the CRFs and considered to be source 
data.
1. Assessment of causality between adverse events and the investigational product.
Deviations from and Changes of Protocol
Deviations from Protocol
The investigator (or subinvestigator) may implement a deviation from, or a change of, the 
protocol to eliminate an immediate hazard(s) to subjects without agreement by the 
sponsor or prior IRB approval. As soon as possible, the implemented deviation or change 
and the reasons for it should be submitted to the head of the medical institution and the 
IRB for approval, and via the head of the medical institution to the sponsor for 
agreement.
The investigator (or subinvestigator) should document all deviations from the approved 
protocol. The investigator should document the reason only for the deviation from, or the
change of, the protocol to eliminate an immediate hazard(s) to subjects, and submit it to 
the sponsor and the head of the medical institution, and retain its copy.
Changes of Protocol
1. If it becomes necessary to make any changes significantly affecting the conduct of 
the study, and/or increasing the risk to subjects, the sponsor should promptly 
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document the changes and reasons for them and amend the protocol after discussion 
with the [coordinating [investigator, committee members] and] investigators, and 
notify the heads of the medical institutions and investigators of the changes of the 
protocol [sample informed consent form and other written information, if necessary]. 
The investigator should not implement any significant changes without approval 
from the IRB.
2. For changes other than the above 1), the sponsor should document the changes and 
reasons for them and inform the heads of the medical institutions and investigators of 
the changes of the protocol. Such changes require prior approval from the IRB, 
except where necessary to eliminate an immediate hazard(s), or when the change(s) 
involves only logistical or administrative aspects of the study. The investigator 
should promptly report the changes implemented without prior approval to the IRB 
for approval.
Study Period
June, 2010 ~ August, 2014
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Appendix A LABORATORY ASSAYS
Specific Ab (anti-VZV and anti-gE) measurements
Anti-VZV ELISA: Anti-VZV Ab concentrations will be measured using a commercial 
ELISA kit (Enzygnost/Dade Behring), which is based on a single point quantification Ab 
method (sera tested at a 1:231 dilution). The assay cut-off is 25 milli-international units 
(mIU)/mL. The assay will be performed on human serum at GSK Biologicals’ laboratory 
or another laboratory designated by GSK Biologicals.
Anti-gE ELISA: Anti-gE Ab concentrations will be measured using an anti-gE ELISA. 
Diluted blood serum samples of study subjects will be added to microtitre wells pre-
coated with gE antigen. Secondary peroxidase-conjugated anti-human Abs will be added, 
which bind to the primary human anti-gE Abs. After incubation of the microtitre wells 
with a chromogen substrate solution, the enzymatic reaction will be stopped. Optical 
densities will be recorded and anti-gE Ab concentrations are calculated from a standard 
curve. The assay cut-off is 18 mIU/mL. The assay will be performed on human serum at 
GSK Biologicals’ laboratory or another laboratory designated by GSK Biologicals.
Intracellular cytokine staining (ICS) 
CMI responses will be performed by GSK Biologicals (or designated laboratory) on 
thawed Peripheral Blood Mononuclear Cells (PBMCs) by ICS. The assay will be 
performed on samples collected during the course of the study. This assay provides 
information on the frequency of CD4 T cells responding to culture medium or antigens 
(gE peptide pool or VZV lysate) by secreting cytokine molecules involved in immunity 
such as IFN-, IL-2, TNF-, and CD40L.
Briefly, PBMC collected from the subjects are stimulated for two hours using culture 
medium (for evaluation of the non-specific response), a pool of overlapping peptides 
covering the entire sequence of the vaccine antigen gE or a VZV lysate. Then, an 
intracellular block (brefeldin A) is added to inhibit cytokine secretion for a subsequent 
overnight incubation. Cells are then harvested, stained for surface markers (CD3, CD4 
and CD8) and fixed. The fixed cells are then permeabilised and stained with anti-cytokine 
Abs, washed and analyzed by cytofluorometry.
The results of ICS assays are expressed as the frequency of specific CD4 T cells per 
million total CD4 T cells.
Anti-VZV neutralizing antibody assay
Anti-VZV neutralizing Abs will be quantified using a plaque reduction neutralization test 
(PRNT). Briefly, two-fold serum serial dilutions are incubated with a fixed amount of 
VZV. The mixture is then added to a monolayer of Vero cells in a 96-well plate and 
incubated for 2 days. The cells are then fixed, and viral replication is detected using a 
mixture of murine anti-VZV monoclonal Abs and anti-mouse Abs conjugated to 
horseradish peroxidase (HRPO). The HRPO activity is detected using a precipitated 
peroxidase substrate resulting in a brown coloration of VZV-infected cells. The plaques, 
visualized as collections of stained cells, are counted, and the ratio of the number of 
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plaques for each serum dilution to the number of plaques when no serum is added 
(control wells) is calculated. The neutralizing Ab titre is reported as the reciprocal of the 
serum dilution that reduces the number of plaques by 50% (ED50).
PCR Assay for Confirmation of suspected case of HZ 
HZ cases will be confirmed by a Polymerase Chain Reaction (PCR) based algorithm that 
assesses the presence of VZV DNA in samples, the adequacy of the samples (by 
assessing the presence of β-actin DNA) and, finally, the potential presence of Herpes 
Simplex Virus (HSV) -1 and -2 DNA.
VZV, HSV1/2 and β-actin DNA in HZ clinical specimens will be assessed using real-
time PCR detection by the 5’ nuclease assay based on the Taqman probe technology 
[Heid, 1996]. If the VZV PCR is negative, β-actin PCR will be performed to assess 
adequacy of the sample and if a specimen is found to be VZV–PCR negative and β-actin–
PCR negative, it is considered to be inadequate. If VZV PCR is negative and β-actin PCR 
is positive, a generic PCR for HSV1/2 will be performed. 
In the Taqman-based PCR experiments, the formation of a PCR product is monitored in 
real-time during amplification by means of fluorogenic probes that bind specifically to 
the amplified product. The reporter fluorophore is at the 5’ end of the Taqman probe and 
the quencher is at the 3’ end. As long as the probe is intact, no fluorescence is produced 
by the fluorophore. During the PCR polymerization step, the Taq DNA polymerase 
displaces the Taqman probe by 3-4 nucleotides, and the 5’ nuclease activity of the DNA 
polymerase separates the fluorophore from the quencher, and a measurable fluorescent 
signal proportional to the DNA copy number is produced.
As mentioned above, the 5' nuclease-based PCR assay allows the determination of the 
DNA copy number within samples, but in the present study the VZV, HSV1/2 and β-
actin DNA PCR data on samples from suspected HZ lesions (swabs of vesicles, papules 
and crusts, and crusts themselves) will be used qualitatively only according to the above 
mentioned algorithm.
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Appendix B ASCERTAINMENT OF HZ CASES INCLUDING PCR TESTING 
ALGORITHM TO CLASSIFY HZ SUSPECTED CASES 
A suspected case of HZ is defined as new unilateral rash accompanied by pain (broadly 
defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. 
This suspected case will be documented by digital photography of the rash and by 
collecting any relevant information as described in the clinical protocol.
To classify the suspected case of HZ, the samples from the rash lesions will be collected 
for laboratory testing by PCR (minimum 3 samples, collected on the same day, per 
subject). Each rash lesion will be tested using standardized and validated molecular 
assays according to the PCR testing algorithm described below.
A hierarchical case definition algorithm, similar to the algorithm used by Merck in their 
Shingle Prevention Study (Zostavax efficacy study) [Oxman, 2005] will be used to 
classify each suspected case of HZ as a confirmed HZ case or not.
1. If at least 1 sample coming from a given subject is “VZV positive” by PCR, this 
“suspected HZ case” will be classified as a “confirmed case of HZ”.
2. If all the samples coming from a given subject are “VZV negative” and “β-actin 
positive”, this means that the sampling procedure is validated and that the “suspected 
HZ case” will be classified as “not a case of HZ”. Regarding the testing algorithm, 
the HSV qPCR assay will assess if the rash lesions were due to HSV and not to 
VZV.
3. If all the PCR results for a particular subject could not confirm or exclude a 
“suspected HZ case” (i.e. samples coming from a given subject are considered as 
“inadequate” as both VZV and β-actin PCR results are negative, or the samples are 
missing), this case will be referred to the HZ Ascertainment Committee (HZAC) to 
be classified. The HZAC will consist of five physicians with HZ expertise. For every 
such case, each HZAC member will be asked to make a clinical determination of 
whether the case is HZ based on the review of the available clinical information. A 
“suspected HZ case” will be considered as a “confirmed HZ case” if at least 3 HZAC 
members concur (majority vote); otherwise, it will be classified as “not a case of 
HZ”.
This algorithm includes the following steps (see Figure 1):
1. DNA extraction from the rash lesion.
2. VZV real-time PCR assay (qPCR) targeting the orf62 gene is performed to detect 
VZV in the rash lesion:
1. If the VZV qPCR signal is above the cut-off of positivity corresponding to the 
technical limit of detection of the assay, the sample will be considered as “VZV 
positive”.
2. If the VZV qPCR signal is included between 1 copy/qPCR and the cut-off of 
positivity, it will be considered as “VZV borderline” and will be re-tested twice 
in order to obtain 3 results per sample. The sample will be considered as “VZV 
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positive” if at least 2 results out of the three obtained are above the cut-off of 
positivity.
3. If the VZV qPCR signal is equal to 0 copies/PCR, the sample will be considered 
as “VZV negative” and the extracted DNA will be assessed for the presence of 
β-actin housekeeping gene to validate the rash lesion sampling procedure (see 
item 3).
1. As described here above, the β-actin qPCR will be performed only on “VZV 
negative” samples to validate the sampling procedure:
1. If the β-actin qPCR signal is below the cut-off of positivity of this assay, the 
sample will be considered as “inadequate” as no DNA coming from human cells 
is detected within the rash lesion sample.
2. If the β-actin qPCR signal is above the cut-off of positivity of this assay, the 
sample will be considered as “valid” but it does not contain any VZV DNA. 
According to the testing algorithm, the extracted DNA will be assessed for the 
presence of HSV-1/2 within the rash lesion (see item 4.). 
2. As described here above the HSV qPCR assay will be performed on “VZV negative/ 
β-actin positive samples:
1. If the HSV qPCR signal is below the cut-off of positivity of this assay, the 
sample will be considered as “HSV negative”.
2. If the HSV qPCR signal is above the cut-off of positivity of this assay, the 
sample will be considered as “HSV positive”. 
Figure 1 Algorithm for HZ case definition by PCR
Rash lesion
DNA extraction
VZV Q-PCR (ORF62)
VZV Positive
VZV Negative
Actin Q-PCR
Actin Negative
Inadequate sample
Actin Positive
HSV Q-PCR
HSV Positive HSV Negative
VZV Borderline (below Positivity cut-off)
Re-test twice from rash lesion
VZV Pos if at least 2 results above Positivity cut-off
VZV: Varicella Zoster Virus; Q-PCR: real-time (quantitative) PCR; HSV: Herpes Simplex Virus
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Protocol Amendment 4 Rationale 
Amendment number: Amendment 4 
Rationale/background for changes:  
• It is predicted that study ZOSTER-006 will reach the conditions required for 
triggering final analysis of herpes zoster (HZ) primary endpoint about one year 
before those conditions being reached for study ZOSTER-022. Therefore GSK 
decided, as originally planned in these circumstances, to dissociate the two studies 
in terms of timing of the analysis of each study. Moreover, a two-step approach is 
allowed for the analysis of each study. Both studies will end concurrently . 
(Synopsis, Sections 3, 10.4.6) 
• In study ZOSTER-022, postherpetic neuralgia (PHN) is demoted from co-primary 
endpoint to a descriptive secondary endpoint and the overall PHN co-primary 
endpoint in subjects ≥ 70 YOA for pooled analyses of ZOSTER 006 and 
ZOSTER-022 will be considered as primary analysis for PHN. Overall PHN in 
subjects ≥ 50 YOA has become a secondary endpoint for pooled analyses of 
ZOSTER-006 and ZOSTER-022. The applicable objectives and endpoints have 
been updated accordingly in the ZOSTER-022 protocol. Pooled analyses of 
ZOSTER-006 and ZOSTER-022 will only be conducted if the primary objective 
[HZ vaccine efficacy (VE)] is demonstrated in both ZOSTER-006 and ZOSTER-
022 separately. The gatekeeping strategy has been updated accordingly and 
aligned with the objectives (Synopsis, Sections 1.2, 10.4.2, Table 19, 10.4.3, 
10.4.4); the gatekeeping strategy diagram has been numbered (Fig. 1). 
• The expected number of PHN cases is projected based on current accrual rates. 
The target number of PHN cases required to trigger pooled PHN analysis has been 
reduced, while maintaining statistical robustness. A total of at least 35 PHN cases 
in subjects ≥ 70YOA provides 90% power to demonstrate an overall PHN VE of at 
least 0% (previously a total of at least 88 PHN cases provided 93% power to 
demonstrate an overall PHN VE in subjects ≥ 50YOA of at least 25%). In the 
pooled analysis of studies ZOSTER-006 and ZOSTER-022 clinically meaningful 
overall PHN VE (PHN VE in ≥ 70 YOA randomized subjects) will be 
demonstrated if the lower limit of the 95% CI is above 0%.  The sample size of the 
pooled studies ZOSTER-006 and ZOSTER-022 provides 10% chance (previously 
22%) to demonstrate statistically significant PHN VE (LL above 0%) in those 
subjects presenting with a HZ episode.  (Sections 10.4.5.1, Table 20, 21, 22, 
Section 10.4.5.2)  
• The analysis steps, i.e. final HZ efficacy analysis (step 1) and end of study analysis 
(step 2) are defined. The conditions determining the cut-off dates of the 2 analysis 
steps are detailed.  
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The cut-off date for final HZ efficacy analysis will occur given the following 
conditions: 
− at least 196 confirmed HZ cases are accrued in the primary cohort for analysis 
of efficacy;   
− approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ 
cases in subjects 60-69 YOA are accrued in the mTVc; 
− approximately 75% of subjects in each stratum have completed at least 36 
months follow-up after Dose 2, and the remaining subjects have completed at 
least 30 months follow-up after Dose 2. 
The cut-off date for end of study analysis will occur given the following: 
− all previous conditions are met for final HZ analyses in study ZOSTER-022; 
− at least 35 PHN cases in subjects  ≥ 70YOA are accrued in the in the primary 
cohort for analysis of efficacy when pooling the studies ZOSTER-006 and 
ZOSTER-022.  
The end of study analysis cannot be performed before the final HZ efficacy 
analysis. Details regarding study duration are described. 
(Synopsis, Sections 3, 10.4.5.1, 10.4.6) 
• An overview of the analyses performed at each analysis step is given. Step 1 will 
include analyses of the following objectives of ZOSTER-006: all  HZ VE 
objectives and all reactogenicity/safety and immunogenicity objectives. At step 2,  
all objectives of study ZOSTER-006 will be analyzed. Objectives already analyzed 
at step 1 will be re-analyzed (confirmatory descriptive in case of inferential 
analysis at step 1 or descriptive analysis otherwise). At step 2, pooled analyses of 
studies ZOSTER-006 and ZOSTER-022 are planned; overall PHN VE in subjects 
≥ 70 YOA, and other pre-specified endpoints will be analyzed. (Synopsis, Sections 
3, 10.4.9, Table 33) 
• Each inferential objective in study ZOSTER-006 will be assessed only one time, 
therefore no alpha adjustment will be applied. For all inferential objectives 
assessed at first step analysis, a second descriptive analysis will be performed at 
the end of each study and will serve as confirmatory analysis (Sections 10.4.4, 
10.4.7). 
• It has been detailed that depending on the further evolution of the case accrual rate, 
the generated data may be presented in one or more study reports per study 
(ZOSTER-006 and ZOSTER-022). The final study report for each study will be a 
comprehensive report containing the results of the two analysis steps (Sections 
10.7.4, 10.8.3.2). Wording in Section 10.8.3.4 has been aligned with Section 
10.7.4. 
• The same blinding level (i.e. observer-blind) remains to be kept throughout the 
study. Measures taken to ensure the blinding, including the installation of a 
firewall, are described in a separate charter. Pending the outcome of the final HZ 
efficacy analysis of studies ZOSTER-006 and ZOSTER-022, a long-term follow-
up study might be planned enrolling subjects who participated in the primary 
studies ZOSTER-006 and ZOSTER-022 and are willing to participate in the 
follow-up study.  The design of the follow-up study remains to be confirmed. 
(Sections 5.4, 10.4.6, 10.4.8, 10.7.3) 
18-APR-2014 5 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
• Given the two-step analyses, in accordance with GSK procedures, in the List of 
study procedures the final HZ efficacy analysis trigger has been specified, with 
transcription in the eCRF of the date of the last visit or contact with the subject and 
addition of the investigator signature (Section 5.6, Table 2). This has also been 
detailed in a new Section 5.7.3.15; the numbering of subsequent sections has been 
updated accordingly (i.e., Sections 5.7.3.16 and 5.7.3.17). 
• It is anticipated that all subjects will have completed Visit 6 at the time of study 
conclusion; updates have been made accordingly (Sections 3 and 5.6, Table 2 and 
Table 4). 
• Given the two-step analyses, reference is made to the cut-off date for end of study 
analysis (instead of cut-off date for final analysis) when describing follow-up of 
HZ up to or close to study end (Sections 5.5.1, 5.5.2.2, 5.5.2.4, 5.6 Table 3, 
5.7.3.11, 5.7.3.17, 7, 10.7.3).  
• The description of the process for follow up of HZ has been aligned throughout the 
Table 3 footnotes (Section 5.6) reflecting that if HZ-associated pain ceases 
(defined as a 28-day [or 4-week] pain free period) and the HZ rash resolves, 
subsequent HZ follow-up visits or contacts will be cancelled. 
• Given the two-step analyses, reference is made to ‘final HZ efficacy analysis’ 
instead of ‘final analysis’, when applicable (Sections 10.4.5.3, 10.7.1 and 10.7.2, 
Table 23 and Table 24). 
• It has been detailed that in case of unblinding upon the subject’s request to allow 
the subject to decide if he/ she will consider immunization with a licensed HZ 
vaccine, the subject will be withdrawn from the study (Sections 5.7.3, 9.2.1) 
• The cut-off of the gE-specific ELISA assay has been changed from 18 to 97 
mIU/mL. Background signal has been measured with the anti-gE ELISA on 
samples from Varicella Zoster Virus (VZV) naïve paediatric subjects. This 
observation of background signal on VZV naïve samples was not part of the 
original validation of the assay and establishment of the assay cut-off. Background 
signal measured with the anti-gE ELISA has no impact on Zoster project clinical 
conclusions as the vast majority of the samples (at all timepoints) have high titers 
well above the unspecific response level measured on VZV naïve samples from 
Measles, Mumps, Rubella and Varicella (MMRV) studies and Zoster vaccine 
responses are very robust. However this finding triggered re-evaluation of the 
assay cut-off. Based on complementary validation experiments performed in line 
with Clinical and Laboratory Standards Institute (CLSI) guidelines and taking into 
account internal company guidelines the technical and seropositivity cut-off has 
been set at 97mIU/mL. (Section 5.8.3, Table 7, Appendix A) 
• Regarding the reporting of SAEs that are related to study participation (e.g. 
protocol-mandated procedures, invasive tests, a change from existing therapy) or 
are related to a concurrent GSK medication/vaccine or any fatal SAE, it has been 
clarified that this includes SAEs that are considered by the investigator  to be 
related to the investigational vaccine and are to be reported until study end 
(Section 8.3.1; Table 14). 
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• The section on derived and transformed data for cell-mediated immunogenicity 
vaccine responses  (gE- and VZV-specific) including the definition of vaccine 
response has been updated in alignment with the harmonised definitions within the 
ZOSTER project (Section 10.6.4). 
• For clarity, the total number of subjects included in the Immunogenicity subset and 
the CMI subset has been detailed (Section 10.4.5.6.4, Table 30; Section 10.4.5.7.2, 
Table 32). 
• A process related to review of immunogenicity data as described in the protocol is 
not applicable for the study, therefore any related wording has been removed 
(Section 10.7.3). 
• In accordance with current GSK procedures, where applicable the name of the plan 
previously referred to as ‘reporting analysis plan’ has been updated to ‘statistical 
analysis plan’ (List of abbreviations, Sections 10.5.3, 10.7.3, 10.8.2, 10.8.2.3, 
10.8.2.4, 10.8.2.5, 10.8.2.6, 10.8.2.7, 10.8.3.4, 10.8.4.1, 10.8.4.2, 10.8.5.2). 
• For clarity, it has been detailed that the subject will be reminded that the current 
study has yearly follow-up visits planned until Month 38 (Visit 6) (Section 
5.7.3.14). 
• The estimated study period has been updated in the section with country specific 
requirements for Japan (Section 12.3). 
• A reference has been further detailed and references which are not applicable 
anymore have been removed (Section 13).  
• The list of contributing authors and the sponsor signatory have been updated 
(cover page, sponsor signatory approval page). 
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Protocol Amendment 4 Investigator Agreement 
I agree: 
To conduct the study in compliance with this protocol, any mutually agreed future 
protocol amendments or protocol administrative changes, and with any other study 
conduct procedures and/or study conduct documents provided by GlaxoSmithKline 
Biologicals (GSK Biologicals). 
• To assume responsibility for the proper conduct of the study at this site. 
• That I am aware of, and will comply with, ‘Good Clinical Practice’ (GCP) and all 
applicable regulatory requirements.  
• To ensure that all persons assisting me with the study are adequately informed about 
the GSK Biologicals’ investigational product(s) and other study-related duties and 
functions as described in the protocol. 
• To acquire the reference ranges for laboratory tests performed locally and, if required 
by local regulations, obtain the laboratory’s current certification or Quality 
Assurance procedure manual. 
• To ensure that no clinical samples (including serum samples) are retained onsite or 
elsewhere without the approval of GSK Biologicals and the express written informed 
consent of the subject and/or the subject’s legally authorised representative.  
• To perform no other biological assays on the clinical samples except those described 
in the protocol or its amendment(s).  
• To co-operate with a representative of GSK Biologicals in the monitoring process of 
the study and in resolution of queries about the data. 
• That I have been informed that certain regulatory authorities require the sponsor to 
obtain and supply, as necessary, details about the investigator’s ownership interest in 
the sponsor or the investigational product, and more generally about his/her financial 
ties with the sponsor. GSK Biologicals will use and disclose the information solely 
for the purpose of complying with regulatory requirements. 
Hence I: 
• Agree to supply GSK Biologicals with any necessary information regarding 
ownership interest and financial ties (including those of my spouse and dependent 
children). 
• Agree to promptly update this information if any relevant changes occur during the 
course of the study and for 1 year following completion of the study.  
• Agree that GSK Biologicals may disclose any information it has about such 
ownership interests and financial ties to regulatory authorities. 
• Agree to provide GSK Biologicals with an updated Curriculum Vitae and other 
documents required by regulatory agencies for this study. 
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SYNOPSIS 
Detailed Title A phase III, randomized, observer-blind, placebo-controlled, 
multicentre, clinical vaccination trial to assess the 
prophylactic efficacy, safety, and immunogenicity of GSK 
Biologicals’ gE/AS01B vaccine when administered 
intramuscularly on a 0, 2-month schedule in adults 
aged 50 years and older. 
Indication Primary immunization of subjects ≥ 50 years of age (YOA) 
against Herpes Zoster (HZ). The study population includes 
males and females without severely immunocompromising 
conditions in the age ranges 50-59 YOA, 60-69 YOA, 70-79 
YOA and ≥ 80 YOA. The 70-79 YOA and ≥ 80 YOA strata 
will be combined for primary analyses. 
Rationale for the 
study and study 
design 
Two studies (ZOSTER-006 enrolling subjects ≥ 50 YOA and 
ZOSTER-022 enrolling subjects ≥ 70 YOA) will be 
conducted concurrently to evaluate efficacy of 
GlaxoSmithKline (GSK) Biologicals’ gE/AS01B vaccine. 
Study ZOSTER-006 will provide pivotal data on the overall 
efficacy in prevention of HZ in subjects ≥ 50 YOA. The 
primary endpoint of this study will be overall HZ vaccine 
efficacy (VE) across all age cohorts. To this end, ZOSTER-
006 will evaluate VE of the gE/AS01B vaccine compared to 
placebo in reducing the risk of developing HZ in subjects 
≥ 50 YOA. This study will enrol subjects in the age ranges 50-
59 YOA, 60-69 YOA, 70-79 YOA and ≥ 80 YOA in 
approximately an 8:5:3:1 ratio to achieve comparable numbers 
of HZ in the 3 main age strata (50-59 YOA, 60-69 YOA and 
≥ 70 YOA) so that a balanced estimate of the overall VE in 
persons ≥ 50 YOA can be determined.  
Apportionment of approximately 20-25% of the ≥ 70 YOA 
cohort to persons ≥ 80 YOA in both ZOSTER-006 and 
ZOSTER-022 ensures that this particularly vulnerable 
population is adequately represented. 
Assessment of Postherpetic Neuralgia (PHN) VE would 
require a large sample size of subjects ≥ 70 YOA due to a 
relatively lower incidence of PHN in younger adults. This 
cannot be achieved in study ZOSTER-006 without impacting 
the intent of the study, since a large overrepresentation of 
subjects ≥ 70 YOA in the ZOSTER-006 study would not 
allow an accurate assessment of HZ VE across the entire 
≥ 50 YOA age range enrolled in the trial and may potentially 
underestimate overall efficacy of the gE/AS01B vaccine, since 
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HZ VE may diminish with age. 
Study ZOSTER-022 will address VE against HZ in subjects 
≥ 70 YOA.  At the end of studies ZOSTER-006 and 
ZOSTER-022, a pooled analysis of HZ and PHN data from 
both studies combined is planned and will be described 
prospectively. The analysis of pooled data from both studies 
for overall PHN in subjects ≥ 70 YOA is positioned as 
primary analysis for PHN. (Amended 18 April 2014) 
A saline solution is included as a negative control (placebo) in 
this study to evaluate the efficacy and safety profile of the 
candidate HZ vaccine. Use of the placebo control and the 
observer-blind, randomized study design, will allow to control 
for potential biases in the conduct of the study. 
Objectives Primary 
• To evaluate VE in the prevention of HZ compared to 
placebo in adults ≥ 50 YOA, as measured by the 
reduction in HZ risk. 
 Secondary 
• To evaluate VE in the prevention of HZ compared to 
placebo in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, as 
measured by the reduction in HZ risk; 
• To evaluate VE in the prevention of overall PHN 
compared to placebo in subjects ≥ 50 YOA and in 
subjects within each of the following age ranges: 50-59 
YOA, 60-69 YOA and ≥ 70 YOA; 
• To evaluate VE in reducing the total duration of severe 
‘worst’ HZ-associated pain over the entire pain reporting 
period compared to placebo in subjects ≥ 50 YOA and in 
subjects within each of the following age ranges: 50-59 
YOA, 60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
• To evaluate VE in the reduction of overall and HZ-related 
mortality and hospitalizations compared to placebo in 
subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 
YOA; 
• To evaluate VE in the reduction in incidence of HZ-
associated complications compared to placebo in subjects 
≥ 50 YOA and in subjects within each of the following 
age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, with 
confirmed HZ; 
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• To evaluate VE in the reduction in use of pain 
medications compared to placebo in subjects ≥ 50 YOA 
and in subjects within each of the following age ranges: 
50-59 YOA, 60-69 YOA and ≥ 70 YOA, with confirmed 
HZ; 
• To evaluate vaccine safety and reactogenicity. 
 Exploratory objectives 
• To evaluate VE in reducing the severity of acute HZ-
associated pain compared to placebo in subjects ≥ 50 
YOA and in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, with 
confirmed HZ; 
• To evaluate VE in improving Quality of Life (QoL) 
compared to placebo in subjects ≥ 50 YOA and in 
subjects within each of the following age ranges: 50-59 
YOA, 60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
• To evaluate VE in the mitigation of Burden-Of-Illness 
(BOI) caused by HZ compared to placebo in subjects ≥ 
50 YOA and in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA; 
• To evaluate vaccine induced cell mediated and humoral 
immune responses and the persistence of each type of 
response after two injections of study vaccine in subjects 
≥ 50 YOA, and by age strata; 
• To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 
(pre-vaccination), and at Months 3, 14, 26 and 38, in 
subjects ≥ 50 YOA, and by age strata.  
Study design • Experimental design: multicentre, parallel group 
• Control: placebo (NaCl solution) 
• Vaccination schedule: 0, 2 months 
• Treatment groups: 2 groups of subjects  
− Vaccine group (gE/AS01B vaccine) 
− Placebo group (NaCl solution as control) 
• Study allocation: Eligible subjects 70-79 YOA and ≥ 80 
YOA will be randomly assigned to ZOSTER-006 or 
ZOSTER-022 at Visit 1. 
• Treatment allocation: Eligible subjects will be 
randomized to investigational vaccine/placebo according 
to a 1:1 ratio (vaccine:placebo). Subjects will be stratified 
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by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and ≥ 80 
YOA in approximately an 8:5:3:1 ratio. The 70-79 YOA 
and ≥ 80 YOA strata will be combined for primary 
analyses.  
• Blinding: observer-blind 
• Biological samples to be collected: 
− Blood samples will be collected from all subjects at 
Visit 1 and 3 to contribute to the correlate of 
protection assessment should the subject experience 
a HZ episode or be selected as a case control.  
− Blood samples will be collected from a subset of 
subjects at Visit 4, 5 and 6 to assess persistence of 
humoral immune response. In these subjects, the 
blood samples from Visit 1 and 3 will also be 
assessed for humoral immune response. 
− Blood samples will be collected from a subset of 
subjects at Visit 1, 3, 4, 5  and 6  to assess cell-
mediated immunogenicity (CMI) response.  
− Clinical specimens of HZ lesions will be collected 
from subjects clinically diagnosed as having a 
suspected case of HZ. 
• Type of study: Self-contained, and will be combined with 
study ZOSTER-022 for some analyses. 
• Data collection: Remote Data Entry (RDE) on electronic 
Case Report Form (eCRF). 
• Planned analysis steps:  
It is predicted that study ZOSTER-006 will reach the 
conditions required for triggering final analysis of HZ 
primary endpoint about one year before those 
conditions being reached for study ZOSTER-022. 
Therefore GSK decided, as originally planned in these 
circumstances, to dissociate the two studies in terms of 
timing of the analysis of each study. Moreover, a two-
step approach is allowed for the analysis of each study. 
Both studies will end concurrently. 
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 In study ZOSTER-006, the planned analysis steps are 
the following:  
1. Final HZ efficacy analysis (step 1). Final analysis of 
HZ primary endpoint:  
The cut-off date for final HZ efficacy analysis will 
occur when the following conditions are met: 
− at least 196 confirmed HZ cases are accrued in the 
modified Total Vaccinated cohort (mTVc)1;   
− approximately 60 HZ cases in subjects 50-59 YOA 
and approximately 60 HZ cases in subjects 60-69 
YOA are accrued in the mTVc; 
− approximately 75% of subjects in each stratum have 
completed at least 36 months follow-up after Dose 
2, and the remaining subjects have completed at 
least 30 months follow-up after Dose 2. 
Step 1 will include analyses of the following objectives: 
− all  HZ VE objectives; 
−  all reactogenicity/safety and immunogenicity 
objectives.  
2. End of study analysis (step 2).  
The cut-off date for end of study analysis will occur 
given the following:  
− all conditions (as detailed in ZOSTER-022 
protocol) are met for final HZ efficacy analysis in 
study ZOSTER-022; 
− at least 35 PHN cases in subjects ≥ 70YOA are 
accrued in the mTVc when pooling the studies 
ZOSTER-006 and ZOSTER-022.  
The end of study analysis (step 2) cannot be performed 
before the final HZ efficacy analysis (step 1). 
At step 2 all objectives of study ZOSTER-006 will be 
analyzed. Objectives already analyzed at step 1 will be 
re-analyzed (confirmatory descriptive in case of 
inferential analysis at step 1 or descriptive analysis 
otherwise).  
Pooled analyses of studies ZOSTER-006 and ZOSTER-
 
1 The modified Total Vaccinated cohort (mTVc) is the primary cohort for analysis of efficacy which 
excludes subjects in the TVc for efficacy analysis who were not administered with the second 
vaccination or who develop a confirmed case of HZ prior to 1 month after the second vaccination. 
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022 are planned if the primary objective of study 
ZOSTER-006 and the primary objective of study 
ZOSTER-022 are demonstrated. Overall PHN VE in 
subjects ≥ 70 YOA, and other pre-specified endpoints 
will be analyzed in the pooled analyses, as specified in 
ZOSTER-022 protocol. 
(Amended 18 April 2014) 
• Duration of the study: Each subject will be followed for 
at least 30 months after Dose 2.  
All subjects will continue in the study at least until the 
cut-off date for end of study analysis regardless of their 
date of enrolment. Study end will take place when the 
conditions for end of study analysis are met and a 
minimum 90 days follow-up is completed for each HZ 
case that occurs  up to the cut-off date for end of study 
analysis.  
The exact duration of the study for individual subjects 
will vary. The maximum total study duration for each 
subject is expected to be approximately 4 to 5 years. 
(Amended 18 April 2014) 
Number of subjects Target enrolment will be 15,980 eligible subjects (7,990 in the 
vaccine group and 7,990 in the placebo group). 
Endpoints Primary 
• Confirmed HZ cases. 
− Confirmed HZ cases during the study in the mTVc. 
 Secondary 
• Occurrence of overall PHN 
− Incidence of PHN calculated using the mTVc; 
• Duration of severe ‘worst’ HZ-associated pain 
− Duration of severe ‘worst’ HZ-associated pain 
following the onset of a confirmed HZ rash over the 
entire pain reporting period as measured by the 
Zoster Brief Pain Inventory (ZBPI) in subjects with 
confirmed HZ; 
• Incidence of overall and HZ-related mortality 
− Incidence of overall and HZ-related mortality during 
the study; 
• Incidence of HZ complications 
− Incidence of HZ complications during the study in 
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subjects with confirmed HZ; 
• Incidence of overall and HZ-related hospitalizations 
− Incidence of overall and HZ-related hospitalizations 
during the study; 
• Duration of pain medication administered for HZ 
− Duration of pain medication administered for HZ 
during the study in subjects with confirmed HZ; 
• Solicited local and general symptoms in a subset of 
subjects 
− Occurrence, intensity of each solicited local 
symptom within 7 days (Days 0-6) after each 
vaccination, in subjects included in the 7-day diary 
card subset; 
− Occurrence, intensity and relationship to vaccination 
of each solicited general symptom within 7 days 
(Days 0-6) after each vaccination, in subjects 
included in the 7-day diary card subset; 
• Unsolicited adverse events (AEs)  
− Occurrence, intensity and relationship to vaccination 
of unsolicited AEs during 30 days (Days 0 − 29) 
after each vaccination, according to the Medical 
Dictionary for Regulatory Activities (MedDRA) 
classification in all subjects; 
• Serious Adverse Events (SAEs) 
− Occurrence and relationship to vaccination of all 
SAEs from Month 0 to Month 14 in all subjects; 
− Occurrence of SAEs related to study participation or 
to a concurrent GSK medication/vaccine during the 
entire study period in all subjects; 
− Occurrence of any fatal SAEs during the entire study 
period in all subjects; 
• Occurrence of pre-defined AEs 
− Occurrence and relationship to vaccination of any 
potential immune-mediated diseases (pIMDs)2 
during the entire study period in all subjects;  
 
2 Formerly referred to as new onset of autoimmune diseases (NOADs) and other immune mediated 
inflammatory disorders. 
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• Occurrence of medically attended visits 
− Occurrence and relationship to vaccination of 
medically attended visits (defined as hospitalizations, 
emergency room visits or visits to or from medical 
personnel), other than routine health care visits, from 
Month 0 to Month 8 in all subjects. 
 Exploratory endpoints 
• Acute HZ severity 
− Acute HZ severity as determined by the mean Area 
Under Curve (AUC) of the severity-by-duration of 
HZ-associated pain as measured by the ZBPI during 
a 4-week period following the onset of confirmed HZ 
in subjects with confirmed HZ; 
• Interference of HZ with QoL 
− Interference of HZ with QoL as measured by ZBPI in 
subjects with confirmed HZ; 
− Interference of HZ with QoL as measured by EQ-5D 
in subjects with confirmed HZ; 
− Interference of HZ with QoL as measured by SF-36 
in subjects with confirmed HZ; 
• HZ BOI 
− HZ BOI as determined by the mean AUC of the 
severity-by-duration HZ-associated pain during a 26 
week period following the onset of the HZ rash in the 
mTVc; 
• CMI in terms of frequencies of antigen-specific CD4 T 
cells at Months 0, 3, 14, 26 and 38 
− Frequencies of CD4 T cells with antigen-specific 
Interferon gamma (IFN-γ) and/or Interleukin-2 (IL-2) 
and/or Tumour Necrosis Factor alpha (TNF-α) 
and/or CD40 Ligand (CD40L) secretion/expression 
to glycoprotein E (gE) and VZV as determined by 
intracellular cytokine staining (ICS) in a subset of 
subjects at Months 0, 3, 14, 26 and 38;  
• Antigen-specific Ab concentrations at Months 0, 3, 14, 26 
and 38 
− Anti-gE and anti-VZV Ab concentrations as 
determined by Enzyme-linked Immunosorbent Assay 
(ELISA), in a subset of subjects at Months 0, 3, 14, 
26 and 38; 
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• Anti-VZV neutralizing Ab titres at Months 0, 3, 14, 26 
and 38 
− Anti-VZV neutralizing Ab titres as determined by the 
neutralization assay in a subset of subjects at Months 
0, 3, 14, 26 and 38.  
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LIST OF ABBREVIATIONS 
Ab Antibody 
AE Adverse Event 
AS01B MPL, QS21, liposome based Adjuvant System (50 μg MPL and 50 
μg QS21) 
AS01E MPL, QS21, liposome based Adjuvant System (25 μg MPL and 25 
μg QS21) 
ATPc According To Protocol cohort 
AUC Area Under Curve 
BOI Burden-Of-Illness 
CD40 L CD40 Ligand 
CI Confidence Interval 
CMI Cell-Mediated Immunogenicity/immunity 
eCRF Electronic Case Report Form 
ELISA Enzyme-linked Immunosorbent Assay 
FDA Food and Drug Administration, United States 
GCP Good Clinical Practice 
gE Glycoprotein E 
GMC/T Geometric Mean Concentration/Titres 
GM Geometric Mean 
GSK GlaxoSmithKline  
HRPO Horseradish Peroxidase 
HSV Herpes Simplex Virus 
HZ Herpes Zoster 
HZAC HZ Ascertainment Committee  
IB Investigator Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonisation 
ICS Intracellular Cytokine Staining 
IDMC Independent Data Monitoring Committee 
IEC Independent Ethics Committee 
IFN-γ Interferon Gamma 
IL-2 Interleukin-2 
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IM Intramuscular/Intramuscularly 
IND Investigational New Drug 
IRB Institutional Review Board 
IUD Intrauterine Device 
IUS Intrauterine System 
LOD Limit Of Detection 
MedDRA Medical Dictionary for Regulatory Activities 
MID Minimal Important Difference 
mIU Milli-International Unit 
MPL 3-O-desacyl-4’-Monophosphoryl Lipid A 
mTVc Modified Total Vaccinated Cohort 
NOAD New Onset of Autoimmune Disease 
PBMC Peripheral Blood Mononuclear Cell 
PCR Polymerase Chain Reaction 
PHN Postherpetic Neuralgia 
PIMD Potential Immune-Mediated Disease 
PRNT Plaque Reduction Neutralization Test  
QALY Quality Adjusted Life Years  
QoL Quality of Life 
QS21 Quillaja saponaria Molina, fraction 21 (Antigenics, New York, NY, 
US) 
RAP Reporting and Analysis Plan 
RDE Remote Data Entry 
SAE Serious Adverse event 
SAP Statistical Analysis Plan (Amended 18 April 2014) 
SAS Statistical Analysis System 
SBIR Simply Better Internet Randomisation 
SD Standard Deviation  
SDAC Statistical Data Analysis Centre  
SDRRA Study Determination (Recruitment/Randomisation) Agreement 
SDV Source Data Verification 
SOP Standard Operating Procedure 
SPM  Study Procedures Manual  
18-APR-2014 29 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
TNF-α Tumour Necrosis Factor Alpha 
TVc Total Vaccinated Cohort 
US United States 
VAS Visual Analog Scale 
VE Vaccine Efficacy 
VZV Varicella-Zoster Virus 
YOA Years Of Age 
ZBPI Zoster Brief Pain Inventory 
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GLOSSARY OF TERMS 
Adequate contraception: Adequate contraception is defined as a contraceptive 
method with failure rate of less than 1% per year when 
used consistently and correctly (when applicable, as 
mentioned in the product label) for example abstinence, 
combined or progestogen oral contraceptives, injectable 
progestogen, implants of levonorgestrel, oestrogenic 
vaginal ring, percutaneous contraceptive patches or 
intrauterine device (IUD) or intrauterine system (IUS), 
vasectomy with documented azoospermia of the sole 
male partner or male condom combined with a vaginal 
spermicide (foam, gel, film, cream or suppository) or 
male condom combined with a female diaphragm, either 
with or without a vaginal spermicide (foam, gel, film, 
cream, or suppository).  
For azoospermia, ‘documented’ refers to the laboratory 
report of azoospermia, required for acceptable 
documentation of successful vasectomy in the subject’s 
male partner. 
Adverse event: Any untoward medical occurrence in a patient or clinical 
investigation subject, temporally associated with the use 
of a medicinal product, whether or not considered related 
to the medicinal product.  
An AE can therefore be any unfavourable and unintended 
sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally 
associated with the use of a medicinal product. For 
marketed medicinal products, this also includes failure to 
produce expected benefits (i.e. lack of efficacy), abuse or 
misuse. 
Blinding: A procedure in which one or more parties to the trial are 
kept unaware of the treatment assignment in order to 
reduce the risk of biased study outcomes. The level of 
blinding is maintained throughout the conduct of the trial, 
and only when the data are cleaned to an acceptable level 
of quality will appropriate personnel be unblinded or 
when required in case of a serious adverse event. In an 
observer-blind study, the subject and the site and sponsor 
personnel involved in the clinical evaluation of the 
subjects are blinded while other study personnel may be 
aware of the treatment allocation (see Section 5.4 for 
details on observer-blinded studies).  
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Burden-of-illness score: The HZ “Burden-Of-Illness (BOI) score” represents the 
average severity of illness among all subjects in the 
vaccine or placebo groups. It is calculated according to 
the “modified” scale described by Coplan [Coplan, 2004] 
as the sum of the HZ “severity-of-illness” scores of all 
members of the treatment group divided by the total 
number of subjects in the group. 
Eligible: Qualified for enrolment into the study based upon strict 
adherence to inclusion/exclusion criteria. 
eTrack: GSK’s tracking tool for clinical trials. 
Evaluable: Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, 
included in the according-to-protocol (ATP) analysis (see 
Sections 6.6.1 and 10.5 for details on criteria for 
evaluability). 
Investigational 
vaccine/product: 
(Synonym of 
Investigational Medicinal 
Product) 
A pharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, 
including a product with a marketing authorisation when 
used in a way different from the approved form, or when 
used for an unapproved indication, or when used to gain 
further information about an approved use.  
A NaCl solution, also referred to as saline is used as 
placebo in this study. 
Menopause: Menopause is the age associated with complete cessation 
of menstrual cycles, menses, and implies the loss of 
reproductive potential by ovarian failure. A practical 
definition accepts menopause after 1 year without menses 
with an appropriate clinical profile at the appropriate age 
e.g. > 45 years. 
Protocol amendment: ICH defines a protocol amendment as: ‘A written 
description of a change(s) to or formal clarification of a 
protocol.’ GSK Biologicals further details this to include 
a change to an approved protocol that affects the safety of 
subjects, scope of the investigation, study design, or 
scientific integrity of the study. 
Protocol administrative 
change: 
A protocol administrative change addresses changes to 
only logistical or administrative aspects of the study.  
NB Any change that falls under the definition of a 
protocol amendment (e.g. a change that affects the safety 
of subjects, scope of the investigation, study design, or 
scientific integrity of the study) MUST be prepared as an 
amendment to the protocol.  
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Quality of Life  Quality of Life is measured, using three questionnaires 
(ZBPI, EQ-5D and SF-36) to be completed by the subject. 
ZBPI specifically assesses HZ-associated pain and 
discomfort during an HZ episode. EQ-5D and SF-36 
provide multi-dimensional evaluation of the health status. 
Randomisation: Process of random attribution of treatment to subjects in 
order to reduce bias of selection. 
Site Monitor: An individual assigned by the sponsor who is responsible 
for assuring proper conduct of clinical studies at one or 
more investigational sites. 
Solicited adverse event: Adverse events (AEs) to be recorded as endpoints in the 
clinical study. The presence/occurrence/intensity of these 
events is actively solicited from the subject or an observer 
during a specified post-vaccination follow-up period. 
Study determination 
number: 
A unique number that assigns subjects aged 70 years and 
older to either study ZOSTER-006 or ZOSTER-022. 
Subject: Term used throughout the protocol to denote an 
individual who has been contacted in order to participate 
or participates in the clinical study, either as a recipient of 
the product(s) or as a control. 
Subject number: A unique number identifying a subject, assigned to each 
subject consenting to participate in the study. 
Treatment: Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject, 
identified by a unique number, according to the study 
randomisation or treatment allocation. 
Treatment number: A number identifying a treatment to a subject, according 
to the study randomisation or treatment allocation. 
Unsolicited adverse 
event: 
Any adverse event (AE) reported in addition to those 
solicited during the clinical study. Also any ‘solicited’ 
symptom with onset outside the specified period of 
follow-up for solicited symptoms will be reported as an 
unsolicited adverse event. 
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TRADEMARKS 
The following trademarks are used in the present protocol. 
Note: In the body of the Protocol (including the synopsis), the names of the 
vaccines/products and/or medications will be written in italic font and without the 
subscript symbol ™ or ®. 
Trademarks of the GlaxoSmithKline 
group of companies 
 Generic description 
VarilrixTM  Varicella vaccine consisting of live 
attenuated Varicella-zoster virus (Oka 
strain) 
 
Trademarks not owned by the 
GlaxoSmithKline group of companies 
 Generic descriptions 
Varivax® (Merck & Co)  Varicella vaccine consisting of live 
attenuated varicella-zoster virus (Oka strain) 
Zostavax® (Merck & Co )  Herpes zoster vaccine consisting of high-
titre live attenuated Varicella-zoster virus 
(Oka strain) 
Enzygnost® (Dade Behring)  ELISA kit 
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1. INTRODUCTION 
1.1. Background 
Varicella-zoster Virus (VZV) causes two distinct diseases. Varicella (chickenpox) shortly 
occurs after primary VZV infection and is characterised by systemic illness and a widely 
disseminated rash. Herpes zoster (shingles) occurs when VZV reactivates from latency 
and typically manifests as a localised, dermatomal rash. 
The typical herpes zoster (HZ) rash usually lasts 2 to 4 weeks and is usually accompanied 
by pain that is often described as burning, shooting, or stabbing. In some patients, even 
touching the affected area lightly may cause pain, a phenomenon known as allodynia. 
This HZ-associated pain may be severe, and pruritus, which can also be severe, may be as 
common as pain.  
The most common complication of HZ is postherpetic neuralgia (PHN). PHN is defined 
as pain that persists after the resolution of the HZ rash. Affected patients typically report 
constant burning, throbbing, intermittent sharp or electric shock-like pain, or allodynia. 
Older age is a clear risk factor for PHN. Other risk factors may include a severe HZ rash 
and a painful HZ prodrome. PHN tends to improve over a period of months. About 70-
80% of cases resolve within 1 year, however, in some persons PHN persists for many 
years [Dworkin, 2007]. 
Other complications of HZ include ophthalmologic, neurological, cutaneous and visceral 
disease, which can result in severe disability. The most common ocular complications of 
HZ are keratitis and uveitis; other ophthalmologic complications include ptosis, 
episcleritis/scleritis, retinitis, secondary glaucoma and cataract [Schmader, 2008; Carter, 
2008]. Neurologic complications associated with HZ include myelitis, motor neuropathy, 
ischaemic infarction of the brain and spinal cord, aneurysm, and subarachnoid and 
cerebral haemorrhage [Gilden, 2009; Schmader, 2008]. 
Age is the most common risk factor for developing HZ. The incidence of HZ is relatively 
constant at 2-3 cases per 1000 persons per year until age 40, and then increases 
progressively with age: At 50-59 years of age (YOA) the incidence is about 5 cases per 
1000 persons per year, and it increases to 10 cases per 1000 persons per year in people ≥ 
60 YOA [CDC, 2008; Oxman, 2005]. While most HZ incidence data come from the 
United States (US) and Europe, available data indicate similar incidences of HZ in other 
parts of the world including Japan, Korea, Australia and Latin America [Araújo, 2007; 
Garcia Cenoz, 2008; Kang, 2008; Toyama, 2009]. 
Half of all HZ cases occur in patients over the age of 60, and individuals who reach 85 
years old have a 50% chance of having HZ during their lifetime [Oxman, 2005]. The risk 
for PHN is also highest in older people with HZ, occurring in 18-50% of those aged 70 
years and older [Oxman, 2005; Scott, 2006]. Patients with impaired cell-mediated 
immunity (CMI) due to disease, drug treatment, medical interventions or advanced age 
are at increased risk for the development of HZ [Cohen, 2007]. Since the loss of VZV-
specific T cell responses as a result of aging or immunosuppression leads to heightened 
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susceptibility to HZ, vaccination is considered as a means to reduce the risk of HZ in 
older adults and immunocompromised persons [Oxman, 2005; Sperber, 1992]. 
The potential of vaccination to protect against HZ was evaluated in a large efficacy study 
in which Zostavax (a live attenuated HZ vaccine that is a high titre preparation of the 
varicella vaccine, Varivax [both manufactured by Merck & Co]) partially protected 
immunocompetent older adults against HZ [Oxman, 2005]. In the overall population (≥ 
60 YOA), Zostavax reduced the incidence of HZ by 51.3% (p-value < 0.001), although its 
effectiveness decreased with the age of the vaccinee. In particular, vaccine efficacy (VE) 
diminished to 37.6% among persons in older age groups (≥ 70 years of age) [Oxman, 
2005]. Based on the data from this study, Zostavax was licensed in the US and other 
countries. In the US, Zostavax is indicated for prevention of HZ in individuals ≥ 50 YOA 
and older [Zostavax Prescribing information, 2011]. In Australia, Zostavax is indicated 
for the prevention of HZ, PHN and for reduction of acute and chronic HZ-associated pain 
in individuals ≥ 60 YOA, and for the prevention of HZ in individuals 50-59 YOA [TGA, 
2009]. In Europe, Zostavax is indicated for prevention of HZ and PHN in individuals ≥ 
50 YOA [EMEA, 2009]. Zostavax is contraindicated in persons with immunodeficiency 
due to malignancy, human immunodeficiency virus (HIV) infection or 
immunosuppressive medical therapy. 
Although no immunological correlate for protection against HZ has been identified, 
current knowledge suggests that VZV-specific CMI is of primary importance in 
preventing HZ [CDC, 2008]. The role of humoral immune responses in preventing HZ is 
less clear. However, VZV-specific antibodies (Abs) may help control viral dissemination 
in immunocompromised persons and may thereby help limiting the severity of HZ. 
Furthermore, a correlation between post-vaccination anti-VZV Ab concentrations and 
protection against HZ was observed in the Zostavax efficacy study [Levin, 2008]. While 
VZV-specific Abs may not be directly protective against HZ, they may represent a 
“downstream” measure of the CMI response to vaccination. 
GlaxoSmithKline (GSK) Biologicals is developing a candidate HZ vaccine consisting of 
VZV glycoprotein E (gE) and an adjuvant. The VZV gE was chosen as the subunit 
vaccine antigen because of both its prominence as a target for host immune responses 
[Cohen, 2007] and its functional significance during viral infection. Since the vaccine 
does not contain live virus, it is expected that this vaccine will prove safe in all 
populations including highly immunocompromised persons. Adjuvant System AS01B 
used in combination with the gE antigen was developed at GSK Biologicals, and contains 
the immunostimulants MPL (3-O-desacyl-4’-monophosphoryl lipid A) and QS21 
(Quillaja saponaria Molina, fraction 21; Antigenics, New York, NY, US) formulated in 
combination with liposomes. MPL is a chemically detoxified form of the parent 
lipopolysaccharide from the gram negative bacterium Salmonella minnesota. QS21 is a 
natural saponin molecule (triterpene glycoside) obtained from the tree bark of Quillaja 
saponaria Molina. 
Three recently completed trials in healthy older adults have provided clinical evidence for 
the immunogenicity and tolerability of GSK Biologicals’ candidate HZ vaccine, 
gE/AS01B.  
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In a phase I/II exploratory trial (Explo CRD-004), 155 subjects received two doses of 
either gE/AS01B, gE/AS01B and Varilrix (a live attenuated varicella vaccine similar to 
Zostavax), or Varilrix alone. Of the 110 subjects who received gE/AS01B, 90 were 50-
70 YOA (the other 20 subjects were 18-30 YOA). Subjects in the gE/AS01B groups 
developed significantly higher CD4 T cell responses to gE and VZV than those in the 
Varilrix alone group. Immune responses persisted up to 40 months after administration of 
the second vaccination in older adults receiving gE/AS01B alone (the latest timepoint 
evaluated). Reactogenicity was higher in the gE/AS01B groups than in the group that 
received Varilrix alone; however, the incidences of grade 3 local and general symptoms 
were low. Based on the results of this study, gE/AS01B, without Varilrix, was selected for 
further clinical evaluation. 
In a phase II dose finding trial (ZOSTER-003), gE/AS01B was administered to 714 adults 
≥ 60 YOA. Subjects received either 2 doses of either 25 µg, 50 µg or 100 µg gE 
adjuvanted with AS01B, one dose of 100 µg gE adjuvanted with AS01B and one of NaCl 
solution [Saline], or 2 doses of 100 µg gE/Saline (no adjuvant). Subjects in all gE/AS01B 
dose groups (660 total) developed significantly higher CD4 T cell and humoral immune 
responses to gE than did those who received unadjuvanted gE. Also, 2 vaccinations with 
any of the gE/AS01B vaccine formulations elicited higher immunological responses than 
a single dose. Comparison between the 25 µg, 50 µg and 100 µg gE/AS01B vaccine 
formulations administered in a 2 dose schedule demonstrated that humoral immune 
responses to 50 μg gE/AS01B were significantly greater than those induced by 25 μg 
gE/AS01B, whereas 100 μg gE/AS01B was not superior to 50 μg gE/AS01B. In addition, 
cellular immune responses to gE/AS01B vaccines exhibited slight dose dependence in 
favour of higher gE doses. Reactogenicity was similar for 25 μg, 50 μg, and 100 μg 
gE/AS01B formulations, but greater than that induced by 100 μg gE/Saline. Overall, 
vaccine safety and tolerability were acceptable in all gE/AS01B vaccine groups. Based on 
these data, the antigen dose of 50 μg gE combined with AS01B and administered as two 
doses was selected for use in future trials. 
In a phase II adjuvant dose comparison trial (ZOSTER-010), 410 adults ≥ 50 YOA 
received two doses of 50 μg gE adjuvanted with AS01B, AS01E (½ dose of AS01B) or no 
adjuvant (gE/Saline), or saline alone, administered on a 2-dose schedule at months 0 and 
2. The objective of this study was to compare the immunogenicity and safety of 
gE/AS01B and gE/AS01E groups. Analysis of data obtained up to Month 14 is currently 
available for this study. Subjects in the gE/AS01B group had 30% superior cellular 
immune responses and 40% superior antigen-specific humoral immune responses 
compared to the gE/AS01E group, which were both statistically significant differences. 
Local and general reactogenicity were common in both the gE/AS01B and gE/AS01E 
groups; however, approximately 11% more doses of gE/AS01B were associated with 
local or general reactogenicity than gE/AS01E doses. The overall incidence of grade 3 
local and general reactions was low for both vaccines, and similar between the gE/AS01B 
and gE/AS01E groups. No related serious adverse events (SAEs) were reported in either 
the gE/AS01B or gE/AS01E groups. Based on these results, AS01B was chosen for the 
final vaccine formulation, in combination with 50 μg gE, to be used in future studies. 
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Please refer to the current Investigator Brochure (IB) for a review of the pre-clinical and 
clinical studies, and the potential risks and benefits of GSK Biologicals’ candidate HZ 
vaccine. 
1.2. Rationale for the study and study design 
Two studies (ZOSTER-006 enrolling subjects ≥ 50 YOA and ZOSTER-022 enrolling 
subjects ≥ 70 YOA) will be conducted concurrently to evaluate efficacy of GSK 
Biologicals’ gE/AS01B vaccine. 
Study ZOSTER-006 will provide pivotal data on the overall HZ VE. The primary 
endpoint of this study will be overall HZ VE across all age cohorts. To this end, 
ZOSTER-006 will evaluate VE of the gE/AS01B vaccine compared to placebo in 
reducing the risk of developing HZ in subjects ≥ 50 YOA. This study will enrol subjects 
in the age ranges 50-59 YOA, 60-69 YOA, 70-79 YOA and ≥ 80 YOA in approximately 
an 8:5:3:1 ratio to achieve comparable numbers of HZ cases in the 3 main age strata (50-
59 YOA, 60-69 YOA and ≥ 70 YOA; the 70-79 YOA and ≥ 80 YOA strata will be 
combined for primary analyses) so that a balanced estimate of the overall VE in persons 
≥ 50 YOA can be determined. Apportionment of approximately 20-25% of the ≥ 70 YOA 
cohort to persons ≥ 80 YOA ensures that this particularly vulnerable population is 
adequately represented.  
Assessment of PHN VE would require a large sample size of subjects ≥ 70 YOA due to a 
relatively lower incidence of PHN in younger adults. This cannot be achieved in 
ZOSTER-006 without impacting the intent of the study, since a large overrepresentation 
of subjects ≥ 70 YOA in the ZOSTER-006 study would not allow an accurate assessment 
of HZ VE across the entire ≥ 50 YOA age range enrolled in the trial and may potentially 
underestimate overall efficacy of the gE/AS01B vaccine, since HZ VE may diminish with 
age. Study ZOSTER-022 will address VE against HZ in subjects ≥ 70 YOA. At the end 
of studies ZOSTER-006 and ZOSTER-022, a pooled analysis of HZ and PHN data from 
both studies combined is planned and will be described prospectively. The analysis of 
pooled data from both studies for overall PHN in subjects ≥ 70 YOA is positioned as 
primary analysis for PHN. (Amended 18 April 2014) Detailed information regarding 
study ZOSTER-022 and the pooled analysis of data of both studies combined will be 
included in the protocol of study ZOSTER-022. 
A saline solution is included as a negative control (placebo) in this study and provides an 
objective baseline for the evaluation of the efficacy and safety profile of the candidate HZ 
vaccine. Use of the placebo control and the observer-blind, randomized study design, will 
allow to control for potential biases in the conduct of the study. 
2. OBJECTIVES 
2.1. Primary objective 
• To evaluate VE in the prevention of HZ compared to placebo in adults ≥ 50 YOA, as 
measured by the reduction in HZ risk. 
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Refer to Section 10.1 for the definition of the primary endpoint. 
2.2. Secondary objectives 
• To evaluate VE in the prevention of HZ compared to placebo in subjects within each 
of the following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, as measured 
by the reduction in HZ risk; 
• To evaluate VE in the prevention of overall PHN compared to placebo in subjects ≥ 
50 YOA and in subjects within each of the following age ranges: 50-59 YOA, 60-69 
YOA and ≥ 70 YOA; 
• To evaluate VE in reducing the total duration of severe ‘worst’ HZ-associated pain 
over the entire pain reporting period compared to placebo in subjects ≥ 50 YOA and 
in subjects within each of the following age ranges: 50-59 YOA, 60-69 YOA and ≥ 
70 YOA, with confirmed HZ; 
• To evaluate VE in the reduction of overall and HZ-related mortality and 
hospitalizations compared to placebo in subjects ≥ 50 YOA and in subjects within 
each of the following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA; 
• To evaluate VE in the reduction in incidence of HZ-associated complications 
compared to placebo in subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
• To evaluate VE in the reduction in use of pain medications compared to placebo in 
subjects ≥ 50 YOA and in subjects within each of the following age ranges: 50-59 
YOA, 60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
• To evaluate vaccine safety and reactogenicity. 
Refer to Section 10.2 for the definition of the secondary endpoints. 
2.3. Exploratory objectives 
• To evaluate VE in reducing the severity of acute HZ-associated pain compared to 
placebo in subjects ≥ 50 YOA and in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
• To evaluate VE in improving Quality of Life (QoL) compared to placebo in subjects 
≥ 50 YOA and in subjects within each of the following age ranges: 50-59 YOA, 60-
69 YOA and ≥ 70 YOA, with confirmed HZ; 
• To evaluate VE in the mitigation of Burden-Of-Illness (BOI) caused by HZ 
compared to placebo in subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA; 
• To evaluate vaccine induced cell mediated and humoral immune responses and the 
persistence of each type of response after two injections of study vaccine in subjects 
≥ 50 YOA, and by age strata; 
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• To evaluate anti-VZV neutralizing Ab titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects ≥ 50 YOA, and by age 
strata. 
Refer to Section 10.3 for the definition of the exploratory endpoints. 
3. STUDY DESIGN OVERVIEW  
(Amended 18 April 2014) 
* Blood samples will be collected from all subjects at Visit 1 and Visit 3, and from subsets of subjects additionally at the 
other visits to assess immune responses. 
 (Amended 18 April 2014) 
Note: In case of suspected HZ, the subject will have additional visits and contacts for follow-up of HZ (see Table 3). 
• Experimental design: multicentre, parallel group 
• Control: placebo (NaCl solution) 
• Vaccination schedule: 0, 2 months 
• Treatment groups: Treatment groups: 2 groups of subjects  
− Vaccine group (gE/AS01B vaccine) 
− Placebo group (NaCl solution as control) 
• Study allocation: Eligible subjects 70-79 YOA and ≥ 80 YOA will be randomly 
assigned to ZOSTER-006 or ZOSTER-022 at Visit 1. 
18-APR-2014 40 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
                                                
• Treatment allocation: Eligible subjects will be randomized to investigational 
vaccine/placebo according to a 1:1 ratio (vaccine:placebo). Subjects will be stratified 
by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and ≥ 80 YOA in approximately an 
8:5:3:1 ratio. The 70-79 YOA and ≥ 80 YOA strata will be combined for primary 
analyses.  
• Blinding: observer-blind 
• Biological samples to be collected: 
− Blood samples will be collected from all subjects at Visit 1 and 3 to contribute to 
the correlate of protection assessment should the subject experience a HZ 
episode or be selected as a case control. 
− Blood samples will be collected from a subset of subjects at Visit 4, 5 and 6 to 
assess persistence of humoral immune response. In these subjects, the blood 
samples from Visit 1 and 3 will also be assessed for humoral immune response. 
− Blood samples will be collected from a subset of subjects at Visit 1, 3, 4, 5 and 6 
to assess CMI response. 
− Clinical specimens of HZ lesions will be collected from subjects clinically 
diagnosed as having a suspected case of HZ. 
• Type of study: Self-contained, and will be combined with study ZOSTER-022 for 
some analyses. 
• Data collection: Remote Data Entry (RDE) on electronic Case Report Form (eCRF). 
• Planned analysis steps : 
It is predicted that study ZOSTER-006 will reach the conditions required for 
triggering final analysis of HZ primary endpoint about one year before those 
conditions being reached for study ZOSTER-022. Therefore GSK decided, as 
originally planned in these circumstances, to dissociate the two studies in terms of 
timing of the analysis of each study. Moreover, a two-step approach is allowed for 
the analysis of each study. Both studies will end concurrently. 
In study ZOSTER-006, the planned analysis steps are the following:  
1. Final HZ efficacy analysis (step 1). Final analysis of HZ primary endpoint:  
The cut-off date for final HZ efficacy analysis will occur when the following 
conditions are met: 
− at least 196 confirmed HZ cases are accrued in the modified Total Vaccinated 
cohort (mTVc)3;   
− approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ 
cases in subjects 60-69 YOA are accrued in the mTVc; 
 
3 The modified Total Vaccinated cohort (mTVc) is the primary cohort for analysis of efficacy which 
excludes subjects in the TVc for efficacy analysis who were not administered with the second 
vaccination or who develop a confirmed case of HZ prior to 1 month after the second vaccination. 
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− approximately 75% of subjects in each stratum have completed at least 36 
months follow-up after Dose 2, and the remaining subjects have completed at 
least 30 months follow-up after Dose 2. 
Step 1 will include analyses of the following objectives: 
− all  HZ VE objectives; 
−  all reactogenicity/safety and immunogenicity objectives.  
2. End of study analysis (step 2).  
The cut-off date for end of study analysis will occur given the following:  
− all conditions (as detailed in ZOSTER-022 protocol) are met for final HZ 
efficacy analysis in study ZOSTER-022; 
− at least 35 PHN cases in subjects ≥ 70 YOA are accrued in the mTVc when 
pooling the studies ZOSTER-006 and ZOSTER-022.  
The end of study analysis (step 2) cannot be performed before the final HZ efficacy 
analysis (step 1). 
At step 2 all objectives of study ZOSTER-006 will be analyzed. Objectives already 
analyzed at step 1 will be re-analyzed (confirmatory descriptive in case of 
inferential analysis at step 1 or descriptive analysis otherwise).  
Pooled analyses of studies ZOSTER-006 and ZOSTER-022 are planned if the 
primary objective of study ZOSTER-006 and the primary objective of study 
ZOSTER-022 are demonstrated. Overall PHN VE in subjects ≥ 70 YOA, and other 
pre-specified endpoints will be analyzed in the pooled analyses, as specified in 
ZOSTER-022 protocol. 
(Amended 18 April 2014) 
• Duration of the study: Each subject will be followed for at least 30 months after 
Dose 2.  
All subjects will continue in the study at least until the cut-off date for end of study 
analysis regardless of their date of enrolment. Study end will take place when the 
conditions for end of study analysis are met and a minimum 90 days follow-up is 
completed for each HZ case that occurs  up to the cut-off date for end of study 
analysis.  
The exact duration of the study for individual subjects will vary. The maximum total 
study duration for each subject is expected to be approximately 4 to 5 years. 
(Amended 18 April 2014) 
Throughout the protocol, visit numbers are referred to interchangeably with their month 
designations (Month 0 refers to Visit 1, Month 2 refers to Visit 2, etc). 
4. STUDY COHORT 
4.1. Number of subjects/centres  
Study ZOSTER-006 will be an international multicentre trial.  
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Target enrolment is approximately 15,980 eligible subjects using a 1:1 randomization 
ratio (vaccine:placebo). 
Refer to Section 10.4 for a detailed description of the criteria used in the estimation of 
sample size. 
The following subsets of subjects will be included in this study (see Table 1). Details 
regarding the number of subjects included in each of the subsets are described in Sections 
10.4.5.5 and 10.4.5.6. The randomization of subjects to subsets is described in Section 
5.3.4. 
Table 1 Subsets in study ZOSTER-006 
Subset name Description 
7-day diary card Diary card completion for recording of solicited adverse events (AEs) (from Day 
0 to Day 6 after each vaccination)  
Immunogenicity Blood samples (approximately 10 mL) collected at Visit 1, 3, 4, 5 and 6 will be 
analyzed to assess humoral immune response 
CMI component of the 
Immunogenicity subset 
Blood samples (approximately 20 mL) collected at Visit 1, 3, 4, 5  and 6 will be 
analyzed to assess CMI response 
Note: Blood samples (approximately 10 mL) will be collected from all subjects at Visits 1 and 3, and will be used to 
assess correlate of protection. 
Overview of the recruitment plan 
Study ZOSTER-006 is planned to be conducted at sites in multiple countries in North 
America, Europe, Latin America and Australasia.  
The recruitment rate will be monitored using a study specific central randomization 
system on internet (SBIR). Prior to randomization within each study, a SBIR distribution 
application will be used to assign subjects 70-79 YOA and ≥ 80 YOA to either ZOSTER-
006 or ZOSTER-022.  
Transfer of supplies will be tracked by the central randomization system. Monitoring 
visits frequency will be adapted to the pace of enrolment. Enrolment is estimated to last 
for approximately 12 months. 
Vaccine doses will be distributed to each study site respecting the randomization block 
size. In addition, SBIR will account for the number of subjects in each age stratum 
(Section 5.3.3.2). 
In case any countries would fall behind in subject recruitment (in a specific age group or 
overall), a redistribution of the enrolment target per country may be made to allow other 
participating countries to enrol additional subjects in an effort to ensure full and timely 
enrolment of the overall targeted number of subjects specified in this protocol. 
Furthermore, enrolment target numbers per region (see Section 10.4.5.4) are approximate 
and may change depending on the enrolment.  
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4.2. Inclusion criteria for enrolment 
All subjects must satisfy ALL the following criteria at study entry: 
• Subjects who the investigator believes will comply with the requirements of the 
protocol (e.g. completion of the diary cards/questionnaires, return for follow-up 
visits, have regular contact to allow evaluation during the study);  
• Written informed consent obtained from the subject; 
• A male or female aged 50 years or older at the time of the first vaccination; 
• Female subjects of non-childbearing potential may be enrolled in the study; 
For this study population, non-childbearing potential is defined as current tubal 
ligation, hysterectomy, ovariectomy or post-menopause. 
Please refer to the glossary of terms for the definition of menopause. 
OR 
Female subjects of childbearing potential may be enrolled in the study, if the subject 
has practiced adequate contraception for 30 days prior to vaccination, and has a 
negative urine pregnancy test on the day of vaccination, and has agreed to continue 
adequate contraception during the entire treatment period and for 2 months after 
completion of the vaccination series.  
Please refer to the glossary of terms for the definition of adequate contraception. 
4.3. Exclusion criteria for enrolment 
The following criteria should be checked at the time of study entry. If ANY exclusion 
criterion applies, the subject must not be included in the study: 
• Use of any investigational or non-registered product (drug or vaccine) other than the 
study vaccine within 30 days preceding the first dose of study vaccine, or planned 
use during the study period; 
• Concurrently participating in another clinical study, at any time during the study 
period, in which the subject has been or will be exposed to an investigational or a 
non-investigational product (pharmaceutical product or device); 
• Any confirmed or suspected immunosuppressive or immunodeficient condition 
resulting from disease (e.g., malignancy, HIV infection) or 
immunosuppressive/cytotoxic therapy (e.g., medications used during cancer 
chemotherapy, organ transplantation or to treat autoimmune disorders); 
• History of HZ; 
• Previous vaccination against varicella or HZ (either registered product or 
participation in a previous vaccine study, and including previous vaccination with 
childhood varicella vaccine);  
• History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine. Additionally, consider allergic reactions to other material or equipment 
18-APR-2014 44 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
related to study participation (such as materials that may possibly contain latex -
gloves, syringes, etc). Please note, the vaccine and vials in this study do not contain 
latex; 
• Significant underlying illness that in the opinion of the investigator would be 
expected to prevent completion of the study (e.g., life-threatening disease likely to 
limit survival to less than 4 years); 
• Receipt of immunoglobulins and/or any blood products within the 90 days preceding 
the first dose of study vaccine or planned administration during the study period; 
• Administration or planned administration of any other immunizations within 30 days 
before the first or second study vaccination or scheduled within 30 days after study 
vaccination. However, licensed non-replicating vaccines (i.e., inactivated and subunit 
vaccines, including inactivated and subunit influenza vaccines for seasonal or 
pandemic flu, with or without adjuvant) may be administered up to 8 days prior to 
each dose and/or at least 14 days after any dose of study vaccine; 
• Any other condition (e.g., extensive psoriasis, chronic pain syndrome, cognitive 
impairment, severe hearing loss) that, in the opinion of the investigator, might 
interfere with the evaluations required by the study; 
• Acute disease and/or fever at the time of enrolment;  
− Fever is defined as temperature ≥ 37.5°C (99.5°F) on oral, axillary or tympanic 
setting, or ≥ 38.0°C (100.4°F) on rectal setting. The preferred route for recording 
temperature in this study will be oral. 
− Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory 
infection) without fever may, be enrolled at the discretion of the investigator.  
• Chronic administration (defined as > 15 consecutive days) of immunosuppressants or 
other immune-modifying drugs within six months prior to the first vaccine dose. For 
corticosteroids, this will mean prednisone < 20 mg/day, or equivalent, is allowed. 
Inhaled and topical steroids are allowed.  
• Pregnant or lactating female; 
• Female planning to become pregnant or planning to discontinue contraceptive 
precautions (if of childbearing potential); 
A list of criteria that will eliminate subjects from According To Protocol (ATP) analyses 
can be found in Section 6.6.1, Section 6.7 and Section 10.5. 
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5. CONDUCT OF THE STUDY 
5.1. Regulatory and ethical considerations, including the 
informed consent process 
The study will be conducted in accordance with all applicable regulatory requirements. 
The study will also be conducted in accordance with the International conference on 
harmonisation (ICH) Guideline for Good Clinical Practice (GCP), all applicable subject 
privacy requirements and the guiding principles of the Declaration of Helsinki.  
GSK will obtain favourable opinion/approval to conduct the study from the appropriate 
regulatory agency, in accordance with applicable regulatory requirements, prior to a site 
initiating the study in that country. 
Conduct of the study includes, but is not limited to, the following: 
• Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review and 
favourable opinion/approval of study protocol and any subsequent amendments. 
• Subject informed consent. 
• Investigator reporting requirements as stated in the protocol. 
GSK will provide full details of the above procedures to the investigator, either verbally, 
in writing, or both. 
Freely given and written (or witnessed thumb printed consent in case of an illiterate 
subject) informed consent must be obtained from each subject prior to participation in the 
study.  
GSK Biologicals will prepare a model ICF which will embody the ICH GCP and GSK 
Biologicals required elements. While it is strongly recommended that this model ICF is to 
be followed as closely as possible, the informed consent requirements given in this 
document are not intended to pre-empt any local regulations which require additional 
information to be disclosed for informed consent to be legally effective. Clinical 
judgement, local regulations and requirements should guide the final structure and 
content of the local version of the ICF. 
The investigator has the final responsibility for the final presentation of the ICF, 
respecting the mandatory requirements of local regulations. The ICF generated by the 
investigator with the assistance of the sponsor’s representative must be acceptable to 
GSK Biologicals and be approved (along with the protocol, and any other necessary 
documentation) by the IRB/IEC. 
5.2. Study Determination (Recruitment/Randomisation) 
Agreement 
Eligible subjects 70-79 YOA and ≥ 80 YOA will be randomly assigned to ZOSTER-006 
or ZOSTER-022 at Visit 1. Prior to study assignment, these subjects must sign a Study 
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Determination (Recruitment/Randomisation) Agreement (SDRRA). The signing of the 
SDRRA is not a consent or confirmation of the subject’s participation in either study. The 
SDRRA allows the sponsor/study staff to collect limited personal information about a 
subject who has been contacted to participate in a clinical study. By signing the SDRRA, 
the subject enables the study staff to input age information into the SBIR system. The 
SBIR system will review current enrolment in the two age strata in both ZOSTER-006 
and ZOSTER-022 and determine the study assignment for the subject. The subject will 
then be provided with the study specific informed consent to review and determine if they 
wish to participate in the assigned study. The first study related activity/procedure other 
than the study determination randomisation procedure may only be carried out after the 
subject has confirmed willingness to participate in the assigned study and signed an 
informed consent form. 
5.3. Subject identification and randomization of treatment 
All subjects 50-69 YOA will be randomized to vaccine or placebo in ZOSTER-006. 
Subjects 70-79 YOA and ≥ 80 YOA will be randomized to either ZOSTER-006 or 
ZOSTER-022, and then randomized to vaccine or placebo. This procedure ensures the 
compatibility of the ≥ 70 YOA subjects between the two studies and facilitates the pooled 
evaluation of both studies for HZ and PHN episodes. All subjects in ZOSTER-006 will 
be randomly assigned to two treatment groups in a 1: 1 ratio. 
5.3.1.  Study identification 
ZOSTER-006 and ZOSTER-022 are similar studies, differing essentially in the age strata 
recruited. A SBIR study determination application will use a study determination number 
to assign subjects 70-79 YOA and ≥ 80 YOA to either ZOSTER-006 or ZOSTER-022. 
Subjects 50-69 YOA can only be assigned to ZOSTER-006. 
5.3.2. Subject identification 
Subject numbers will be assigned sequentially to subjects consenting to participate in the 
study, according to the range of subject numbers allocated to each study centre. 
5.3.3. Randomization of treatment 
5.3.3.1. Randomization of supplies 
The randomisation will be performed at GSK Biologicals, Belgium, using MATEX, a 
program developed for use in SAS® (Cary, NC, US) by GSK Biologicals.  
To allow GSK Biologicals to take advantage of greater rates of recruitment than 
anticipated at individual centres in this multicentre study, and to thus reduce the overall 
study recruitment period, an over-randomization of supplies will be prepared. 
The vaccine doses will be distributed to each study centre, respecting the randomization 
block size. 
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5.3.3.2. Treatment allocation to the subject 
The treatment allocation at the investigator site will be performed using a central 
randomization system on the internet (SBIR). The treatment numbers will be allocated by 
kit. Within ZOSTER-006, the randomization algorithm will use stratification (preventing 
further randomization when a stratum is complete) and weighted minimization techniques 
for each parameter, below: 
• By region: Stratification 
• By age cohort within each region: Stratification  
• By country within each region: Minimization  
• By site within each country: Minimization  
Note that as soon as the target number of subjects in a specific stratification group has 
been reached the recruitment will be frozen for that age group. 
When SBIR is not available, please refer to SBIR user guide or Study Procedures Manual 
(SPM) for specific instructions. 
After having checked the eligibility of the subject and obtaining the signed ICF, the site 
staff in charge of the vaccination will access SBIR.  
Upon providing the subject identification number, the randomization system will use 
stratification and minimization algorithms to determine the treatment number to be used 
for the subject. The treatment number must be recorded in the eCRF on the Vaccine 
Administration screen (Randomization/Treatment Allocation Section). 
5.3.4. Randomization of subjects to assay subsets  
Subjects from 50-59 YOA and 60-69 YOA strata will be randomly allocated to be part of 
the 7-day diary card subset (note: all subjects from ≥ 70 YOA strata will be included in 
the 7-day diary card subset) according to criteria defined in Section 10.4.5.5. Subjects 
will be randomly allocated to be part of the Immunogenicity subset according to criteria 
defined in Section 10.4.5.6. For operational reasons, the same subjects may be 
randomized to the various subsets.  
The CMI analyses will be performed in the randomly selected Immunogenicity subset in 
three countries (Czech Republic, Japan and United States) at designated sites that have 
access to a Peripheral Blood Mononuclear Cells (PBMC) processing facility within the 
acceptable time window from sample collection to PBMC processing. 
5.4. Method of blinding  
Because the reconstituted gE/AS01B study vaccine differs in appearance from the NaCl 
solution placebo, the study will be conducted in an observer-blind manner. 
Data will be collected in an observer-blind manner. By observer-blind, it is meant that 
during the course of the study, the vaccine/placebo recipient and those responsible for the 
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evaluation of any study endpoint (e.g., safety, reactogenicity, and efficacy) will all be 
unaware of which vaccine/placebo was administered. To do so, vaccine/placebo 
preparation and administration will be done by authorised medical personnel who will not 
participate in the clinical evaluation of the subjects. Immunological data, which could 
lead to the unblinding of the treatment groups, will not be available during the course of 
the trial to any investigator or any person involved in the clinical conduct of the study 
(including data cleaning). (Amended 18 April 2014) Immunological data may however 
be available to the Statistical Data Analysis Centre (SDAC) and Independent Data 
Monitoring Committee (IDMC) in order to answer potential questions related to safety, 
efficacy or presence of correlate of protection during the interim analysis. 
The laboratory in charge of the laboratory testing will be blinded to the treatment, and 
codes will be used to link the subject and study (without any link to the treatment 
attributed to the subject) to each sample. 
Refer to Section 10.4.8 for more details regarding aspects of blinding in the study. 
(Amended 18 April 2014) 
5.5. General study aspects 
Supplementary study conduct information not mandated to be present in this protocol is 
provided in the accompanying SPM. The SPM provides the investigator and the site 
personnel with administrative and detailed technical information that does not impact the 
safety of the subjects. 
5.5.1. Data collection 
After Visit 3 monthly contacts between the subjects and the investigator and/or his 
delegate will take place to collect information on any event of interest that may have 
occurred [see Table 2 and Section 5.7.3.14 for details]. The contacts will not take place at 
months that coincide with the subject’s scheduled study visits. Also, subjects with 
suspected HZ will be contacted periodically as outlined in Table 3. The contacts will take 
place using the most convenient method suited for the sites (e.g., telephone calls by site 
staff or designee, or SMS text messages through a call centre, or visit by the study staff to 
the subject's home). A guidance document outlining the information that needs to be 
collected at each contact will be provided to each country, and will serve as a guidance to 
develop the local script. The logistic details on the set-up of the contacts will be 
documented by each site/country. At each contact, the subjects will respond to a standard 
set of questions in a language that is understandable to them. The investigator and/or his 
delegate will transcribe the relevant information on any event of interest in the 
appropriate section of the subject’s eCRF, in English. In case of ongoing HZ, subjects 
will also be reminded to complete Zoster Brief Pain Inventory (ZBPI), EQ-5D and SF-36 
questionnaires.  
The diary cards and/or questionnaires to be completed will be distributed and explained 
by the investigator or his/her delegate. Any supplied diary cards or questionnaires should 
be preferably completed by the subject themselves. In case of difficulty in self-
completion of the diary cards or questionnaires, an aide (such as a family member or care 
provider who is not involved in the study) may provide assistance with reading the 
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questions (verbatim) and/or transcribing the subject’s responses on the questionnaires 
and/or diary cards. When the completed diary cards and/or questionnaires are returned to 
the study staff, the study staff will ask the subject (at the time of return or at subsequent 
contact) if he/she received any assistance in completing diary cards or questionnaires. If 
the subject had assistance completing the diary card and/or questionnaires, it should be 
noted in the eCRF. In case questionnaires are completed at the study site, study staff can 
assist in reading the questions (verbatim).  
For all subjects: 
• 30-day diary cards: To be completed by all subjects for unsolicited AEs (from Day 
0 to Day 29 after each vaccination) and any concomitant medication and vaccination 
taken from Day 0 to Day 29 after each vaccination. 
• EQ-5D and SF-36 questionnaires: To be completed by all subjects at study entry. 
Also, to be completed by all subjects at Visits 4, 5 and 6 (subjects with an ongoing 
suspected HZ episode will follow a weekly schedule and do not need to additionally 
complete the questionnaires at these visits).  
EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed into the eCRF for subjects who have suspected 
HZ during the study. 
For subjects in the 7-day diary card subset (in addition to the above):  
• 7-day diary card: To be completed by subjects to record solicited AEs (from Day 0 
to Day 6 after each vaccination). 
For all subjects in case of a suspected or confirmed case of HZ: 
• HZ-specific diary card: To be completed by subjects who develop symptoms 
suggestive of HZ beginning immediately upon development of these symptoms and 
prior to visiting the study site for evaluation of the suspected HZ. 
• Zoster Brief Pain Inventory (ZBPI) questionnaire: To be completed by subjects 
with suspected HZ on Day HZ-0 (Visit HZ-1) and daily from Day HZ-1 (day after 
the Visit HZ-1) up to Day HZ-28, and weekly from Day HZ-29 onwards until a 4-
week pain-free period is documented OR until the cut-off date for end of study 
analysis. For all subjects with ongoing HZ-associated pain at the time of cut-off date 
for end of study analysis, ZBPI data will be collected until a 4-week pain-free period 
is documented OR until at least Day HZ-90 (Refer to Section 5.5.2.2 for more 
details). (Amended 18 April 2014) 
• EQ-5D and SF-36 questionnaires: To be completed weekly by the subjects with  
suspected HZ from Day HZ-0 onwards until a 4-week pain-free period is 
documented OR until the cut-off date for end of study analysis. For all subjects with 
ongoing HZ-associated pain at the time of the cut-off date for end of study analysis, 
EQ-5D and SF-36 data will be collected until a 4-week pain-free period is 
documented OR until at least Day HZ-90 (Refer to Section 5.5.2.2 for more details). 
(Amended 18 April 2014) 
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5.5.2. Evaluation and confirmation of suspected HZ cases 
5.5.2.1. Definitions 
A suspected case of HZ is defined as new unilateral rash accompanied by pain (broadly 
defined to include allodynia, pruritus or other sensations) and no alternative diagnosis.  
Subjects clinically diagnosed as having a suspected case of HZ by the investigator will be 
referred to as a case of ‘suspected HZ’, and followed up. If a case is not clinically 
diagnosed as suspected HZ, the investigator should not progress further with evaluation 
of the case. Also refer to Section 5.5.2.2.  
Determination of confirmed cases of HZ for efficacy analyses is provided in Section 
5.5.2.3. 
The HZ onset date is the earlier of the following two events: 1) the HZ rash start date; or 
2) the date on which pain at the site of a subsequent HZ rash is first noted. 
The end date of a HZ episode is defined as the first time at which a subject had no rash 
(papules, vesicles, ulcers or crusts) present. This end date will be recorded in the eCRF.  
PHN is defined by the presence of HZ-associated severe ‘worst’ pain persisting or 
appearing more than 90 days after onset of the HZ rash. Severe ‘worst’ pain is defined as 
HZ-associated pain rated as 3 or greater on the “worst pain” ZBPI question. Alternative 
definitions of PHN, based on duration of pain of 30, 60, 120 and 180 days will also be 
used for reporting purposes. 
Cessation of pain to assess duration of HZ-associated pain: A 28-day pain-free period is 
used to confirm cessation of HZ-associated pain. If that pain-free period is not achieved 
or if pain did not cease, the time-to-event will be censored at the last day of HZ-
associated pain. 
Acute pain is defined as pain measured during the 4-week period following the onset of 
confirmed HZ. 
5.5.2.2. Evaluation of suspected case of HZ 
All HZ cases that occur during the study period up to the cut-off date for end of study 
analysis will be followed and evaluated. Please refer to the SPM for information about 
recording HZ cases that occur after the cut-off date for end of study analysis. Such cases 
will be referred to the local physician for follow-up. (Amended 18 April 2014) 
Any symptom/sign suggestive of HZ must be evaluated. At Visit 1, all subjects will be 
educated with regard to the signs and symptoms of HZ. The subjects are also given a HZ-
specific diary card that they would complete with the date that rash and/or pain began. 
Subjects will be instructed to contact their study site immediately, and start completing 
the HZ-specific diary card if he/she develops any symptoms suggestive of HZ. The 
subjects will be asked to visit the study site (within 48 hours if possible) for evaluation of 
the “suspected case of HZ”. The subject will be asked to bring the completed HZ-specific 
diary card when he/she visits the study site for evaluation of the suspected HZ. The 
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investigator will perform a clinical examination when the subject visits the study site for 
the first evaluation of the suspected case of HZ [Visit HZ-1 at Day HZ-0]. If not 
considered a suspected HZ diagnosis, the investigator should not progress further with 
evaluation of this event as a HZ case for the purpose of this study. However, if meeting 
the definition of an AE/SAE (Section 8.1), the case should be handled as applicable 
(Section 8.3).  
The schedule of visits/contacts that will take place for follow-up of suspected HZ cases is 
presented in Table 3. 
For clinically diagnosed suspected HZ cases, the following will take place at Visit HZ-1: 
• The investigator or his delegate will verify the completed HZ-specific diary card 
returned by the subject. The information from the diary card will be transcribed into 
the eCRF. The investigator or his delegate will record relevant information regarding 
the HZ episode in the eCRF (such as date of onset of pain and rash, date of clinical 
diagnosis of HZ, location and nature of HZ lesions, HZ-related complications if any); 
• The study staff/investigator will ask the subject to complete a ZBPI questionnaire at 
Visit HZ-1 to rate HZ-associated pain within the last 24 hours. If the time between 
the HZ onset and clinical evaluation at Visit HZ-1 is greater than 24 hours, the 
subject will be asked to complete a second ZBPI also for the elapsed time between 
the HZ onset and 24 hours before Visit HZ-1; 
• The rash will be documented by digital photography;  
• The study staff/investigator will record concomitant medication/vaccination, 
including concomitant medication for HZ treatment or any HZ-related complications 
(Section 6.6), and record intercurrent medical conditions (Section 6.7). If antiviral 
therapy is needed, it is recommended to use valacyclovir, acyclovir or famciclovir. 
Concomitant medication the subject has already received and/or will receive for HZ 
treatment will be recorded in the eCRF. The study staff/investigator will check if the 
subject received any medical attention [hospitalization, emergency room visit, or a 
visit to or from medical personnel (medical doctor)] for HZ or any HZ-related 
complication. 
• Rash lesion samples (three replicate samples on the same day) will be collected from 
subjects clinically diagnosed as having a suspected case of HZ (Section 5.7.3.11);  
• The subject will be given a supply of ZBPI, EQ-5D and SF-36 questionnaires. The 
ZBPI questionnaires will be used to collect information on the severity of HZ-
associated pain, the duration of HZ-associated pain, and the impact of the HZ 
episode on the subject’s QoL. The impact of HZ on subject’s QoL will also be 
measured using the EQ-5D and SF-36 questionnaires (Section 7). The study 
staff/investigator will provide instructions to the subjects for completing the ZBPI, 
EQ-5D and SF-36 questionnaires and explain the importance of completing and 
returning the questionnaires to the site in order to provide more information on HZ.  
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• The subject will be asked to complete the ZBPI questionnaires daily from Day HZ-1 
(day after the Visit HZ-1) up to Day 28 (ZBPI must be completed to Day HZ-28 at 
minimum) and weekly from Day HZ-29 onwards until: 
− 28 days after HZ-associated pain ceases. The subject should continue to 
complete the ZBPI questionnaires weekly until a 28-day (or 4-week) pain free 
period is documented (a ‘No’ answer to the ZBPI question: ‘Have you had any 
pain caused by your shingles in the last 24 hours’ (item 1) at each assessment 
during that entire period); OR 
− The cut-off date for end of study analysis. (Amended 18 April 2014) 
For all subjects with ongoing HZ-associated pain at the time of cut-off date for 
end of study analysis, completion of ZBPI questionnaires will continue until a 4-
week pain-free period is documented OR until at least Day HZ-90. (Amended 
18 April 2014) 
• The subjects will be asked to complete the EQ-5D and SF-36 questionnaires from 
Day HZ-0 and continued weekly during the entire period that the ZBPI 
questionnaires are completed. Therefore, these questionnaires should be completed 
until Day HZ-28 at minimum. 
After Visit HZ-1 until Visit HZ-7, visits/contacts will take place for follow-up of the HZ 
episode according to the schedule presented in Table 3. Follow-up of HZ-associated pain 
and complications will continue irrespective of whether the rash has ended in some cases. 
Follow-up of HZ-associated pain persisting beyond Visit HZ-7 or other complications 
will be done at monthly contacts between the subjects and the investigator and/or his 
delegate that are planned after Visit 3. When a case initially clinically diagnosed as 
suspected HZ is subsequently not considered anymore by the investigator as suspected 
HZ, this will be noted in the eCRF. However study procedures to be performed during the 
follow-up period for a suspected HZ case (see Table 3) should be continued. 
If HZ-associated pain ceases (defined as a 28-day [or 4-week] pain free period), the study 
staff/investigator will inform the subjects to stop completing the ZBPI, EQ-5D and SF-36 
questionnaires and will provide instructions for the subject to return the completed 
questionnaires to the study site. If a 4-week pain-free period is achieved and the HZ rash 
resolves, subsequent follow-up visits or contacts related to this case of HZ will be 
cancelled. Collection of subsequent HZ episode-related information will be stopped and 
no further information on that suspected HZ episode will be encoded in the clinical 
database.   
The following will take place at each visit or contact that occurs after Visit HZ-1: 
• The study staff/investigator will: 1) record relevant information regarding the 
suspected HZ case (such as the location and nature of HZ lesions, the end date of the 
rash, HZ-related complications, if any); 2) record concomitant 
medications/vaccinations, including concomitant medication the subject has already 
received and/or will receive for HZ treatment or treatment of any HZ-related 
complications (Section 6.6); 3) record intercurrent medical conditions (Section 6.7); 
and 4) check if the subject received any medical attention [hospitalization, 
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emergency room visit, or a visit to or from medical personnel (medical doctor)] for 
HZ or any HZ-related complication. 
• Additional photographs of HZ lesions may be taken after Visit HZ-1 to help note the 
progression of the rash. 
• If the investigator determines that adequate rash samples are not present at Visit HZ-
1 (i.e., <3 lesions present or only papules present), the investigator has the option of 
collecting three additional samples prior to or at Visit HZ-2 (see Section 5.7.3.11). 
• The study staff/investigator will remind subjects to complete the ZBPI, EQ-5D and 
SF-36 questionnaires, and return the completed ZBPI, EQ-5D and SF-36 
questionnaires to the study site according to the instructions given by the study 
staff/investigator. Once the completed ZBPI, EQ-5D and SF-36 questionnaires are 
available, the investigator will transcribe the information into the subject’s eCRF. A 
new supply of ZBPI, EQ-5D and SF-36 questionnaires will be provided to the 
subjects as necessary.  
5.5.2.3. Confirmation of a suspected case of HZ 
A suspected case of HZ can be confirmed in two ways: 
• By Polymerase Chain Reaction (PCR):  
Rash lesion samples will be collected from subjects clinically diagnosed as having a 
suspected case of HZ. The samples will be transferred to GSK Biologicals or a 
validated laboratory designated by GSK Biologicals using standardised and validated 
procedures for laboratory diagnosis of HZ by PCR. Refer to Appendix A for details 
of PCR assay to be performed on HZ lesion samples. Refer to Appendix B for details 
of the PCR testing algorithm to classify suspected cases of HZ.  
In addition, if based on qPCR test results the diagnosis of HZ can be excluded, 
Herpes Simplex Virus (HSV) qPCR may be performed to assess if the rash lesions 
are due to HSV (1 or 2). This exploratory testing is not part of the process for HZ 
case confirmation (see Appendix A and Appendix B). This exploratory testing is 
optional and requires specific consent from the individual subjects. 
• By the HZ Ascertainment Committee: 
All suspected HZ cases will be referred to the HZ Ascertainment Committee 
(HZAC). The HZAC will classify all referred cases as either “HZ” or “not HZ”. 
However, the HZAC classification will serve as the final case definition only when 
the case cannot be confirmed or excluded by PCR, e.g., when all samples from a 
given subject are inadequate (as when both VZV and β-actin PCR results are 
negative), or when no samples are available for a given subject. Therefore, definitive 
PCR results, when available, will determine the final HZ case assignment. In such 
cases, the HZAC classification will not contribute to HZ case determination decision. 
The HZAC will consist of three to five physicians with HZ expertise. HZAC 
members, participating as investigator in this study, will not evaluate cases from their 
own study site. HZAC members will be blinded to treatment assignments. For every 
such case, each reviewing HZAC member will be asked to make a clinical 
determination of whether the case is HZ based on review of the available clinical 
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information (e.g., summary of the rash and pain evaluations, digital photographs of 
the subject's rash, and clinical progress notes). A suspected case of HZ will be 
considered as “HZ” if the HZAC members concur unanimously; otherwise, it will be 
classified as “not HZ”. As described above, the HZAC case assignment will only be 
considered as the final case assignment if definitive PCR results are not available. 
Further details will be provided in the HZAC charter. 
5.5.2.4. Evaluation of severity of HZ-associated pain using the Zoster Brief Pain 
Inventory 
The ZBPI is an assessment tool in the form of a questionnaire completed by the subject 
that is specifically designed to assess HZ-associated pain and discomfort during an HZ 
episode. The ZBPI also takes into account the effect of HZ treatment on subject’s pain 
and the interference of HZ-associated pain with subject’s QoL, and general health status. 
Previous studies have been shown that increasing HZ-associated pain scores are highly 
correlated with worsening of subject’s QoL [Coplan, 2004; Schmader, 2007].  
In each case of suspected HZ, the subjects will be asked to assess their HZ-associated 
pain and interference of HZ with their QoL by completing the ZBPI questionnaire either 
themselves or assisted, by an aide (Section 5.5.1) until HZ-associated pain ceases 
(defined as a 28-day [or 4-week] pain free period) or until the cut-off date for end of 
study analysis (see further details in Section 5.5.2.2). (Amended 18 April 2014) 
Information on HZ-associated pain is derived from the ZBPI question: “Please rate your 
pain by circling the one number that best describes your pain at its worst in the last 24 
hours” (item 3), so called “worst pain” in this protocol. 
The following outputs will be derived from the data recorded in the ZBPI: HZ Burden-
Of-Illness (BOI) score and HZ severity score (Section 10.6.2). 
5.5.2.5. HZ complications 
The presence of HZ complications listed below will be documented in the eCRF, 
independently from the AE reporting of those HZ complications (see Section 8.3.1 and 
refer to the SPM for details). Any HZ complications, according to the definitions below, 
will be recorded by the investigator. If a recorded complication is associated with a case 
of suspected HZ, and that case is finally not considered to be a confirmed case, the 
associated complication will not be considered a complication of HZ. 
HZ vasculitis  Vasculopathy or vasculitis (based on clinical, laboratory or 
radiologic findings) that is temporally associated with an 
episode of HZ and, in the opinion of the investigator, was caused 
directly by the VZV infection arising from the HZ episode. 
Disseminated disease Defined as ≥ 6 HZ lesions outside the primary dermatome as per 
the investigator’s judgment. 
Ophthalmic disease Defined as HZ affecting any eye structure as per investigator’s 
judgment. 
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Neurologic disease Defined as cranial or peripheral nerve palsies, myelitis, 
meningoencephalitis, stroke, etc. that is temporally associated 
with an episode of HZ and, in the opinion of the investigator, 
was caused directly by VZV infection arising from the HZ 
episode. 
Visceral disease Defined as an abnormality of one or more internal organs (e.g., 
hepatitis, pneumonitis, gastroenteritis, etc.) that is temporally 
associated with an episode of HZ and, in the opinion of the 
investigator, was caused directly by VZV infection arising from 
the HZ episode. 
Stroke A diagnosis of stroke requires that criteria 1, 2 and 3 are fulfilled 
or criteria 1 and 4 and in the opinion of the investigator is 
temporally associated with an episode of HZ  
 Criterion 1: Rapid onset of localising neurological deficit and/or 
change in level of consciousness; 
 Criterion 2: Localising neurological deficit or change in level of 
consciousness that lasts greater than 24 hours; 
 Criterion 3: No other cerebral process, peripheral lesion, or other 
disorder is the cause of the localising neurological deficit or 
change in level of consciousness; 
 Criterion 4: CT scan or MRI scan evidence of an acute 
thrombotic or hemorrhagic lesion. 
5.5.3. Independent Data Monitoring Committee 
In order to ensure the safety of the subjects during the entire study period, an IDMC will 
be appointed to 1) monitor and follow-up the safety and tolerability of the subjects 
enrolled in the trial and 2) make recommendations to the sponsors concerning the 
continuation, modification, or termination of the trial.  
An independent statistical team (i.e., not GSK employees), appointed by GSK Biologicals 
and not involved in the study management, will be unblinded to treatment assignment and 
provide all necessary tables, listings, figures and individual subject data to the IDMC. 
The IDMC will consist of four to six clinical experts, who are not participating in the 
study and an independent statistician.  
The role of the IDMC will be to review the progress of the trial and the accumulating data 
to detect evidence of safety issues for the subjects while the trial is ongoing. The IDMC 
will be held to evaluate the safety assessments (e.g., AEs, SAEs, fatal events and 
withdrawals due to AEs) during the trial and make recommendations regarding 
continuation, modification or discontinuation of the study to the sponsor following each 
meeting.  
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The frequency of IDMC sessions and other operational details are described in the IDMC 
charter. The IDMC meetings will consist of an open session in which the conduct, 
recruitment and general baseline characteristics of the trial are presented, and a closed 
session in which the safety assessments by treatment group will be presented. One or 
more members of the Zoster vaccine program will attend the IDMC meeting open 
sessions to immediately reply to any questions from the IDMC members. No GSK staff 
will participate in the closed sessions. 
The IDMC may be also involved in evaluation of VE for futility analyses and prevent the 
continuation of a clinical study that already showed its inability to demonstrate the 
primary and main secondary endpoints.  
Vaccine efficacy for futility analysis, and other analyses described in the protocol to be 
done in preparation of IDMC review, will be further detailed in the Reporting and 
Analysis Plan (RAP).  
The IDMC will review all safety parameters and efficacy data together before making a 
final recommendation. In case of a serious safety issue during the study, the sponsor will 
inform the IDMC expeditiously. 
5.6. Outline of study procedures 
Table 2 summarises the list of study procedures to be followed during the study visits and 
at the study conclusion contact. Table 3 summarises study procedures to be performed for 
the follow-up of each suspected HZ case. 
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Table 2 List of study procedures (Amended 18 April 2014) 
Type of contact/trigger 
(Amended 18 April 2014) 
VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse 
VISIT 4 Monthly 
contactse 
VISIT 5 Monthly 
contactse 
VISIT 6 Monthly 
contactse 
Final HZ 
efficacy 
analysis 
trigger 
(Amended 18 
April 2014) 
Study 
conclusion 
contact 
Timepoints  Day 0*/ 
Month0 
Month 2 Month 3  Month 14  Month 26  Month 38    
Sampling timepoints Pre-Vacc Post-Vacc 
1 
Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
   
SDRRAa ●            
Informed consent ●            
Check inclusion criteria ●            
Check exclusion criteria ●            
Check contraindications ● ●           
Medical history ●            
Physical examination  ○            
Record demographic data ●            
Training on self-reporting by 
subjectsb  ○ ○ ○  ○ 
 ○  ○    
Urine pregnancy testc ● ●           
Pre-vaccination body 
temperature ● ●    
       
Blood sampling (approximately 
10 mL) for Ab determination in 
all subjects 
●  ●   
 
 
 
 
  
 
Blood sampling (approximately 
10 mL) for Ab determination in 
Immunogenicity subset subjects 
only 
   
 
● 
 
● 
 
● 
  
 
Blood sampling (approximately 
20 mL) for CMI response in CMI 
subset subjects only 
●  ● 
 
● 
 
● 
 
● 
  
 
Randomization ○            
18-APR-2014 58 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
Type of contact/trigger 
(Amended 18 April 2014) 
VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6 Monthly 
contactse
Final HZ 
efficacy 
analysis 
trigger 
(Amended 18
    
 
April 2014) 
Study 
conclusion 
contact 
Timepoints  Day 0*/ 
Month0 
Month 2 Month 3  Month 14  Month 26  Month 38    
Sampling timepoints Pre-Vacc Post-Vacc 
1 
Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
   
Recording of treatment number  ● ●           
Vaccination ● ●           
Dispensing of HZ-specific diary 
cards to all subjects  ○     
       
Recording of intercurrent 
medical conditions according to 
guidelines in Section 6.7 
●d ● ● ● ● ● ● ● ● ● 
 
● 
Reporting of all SAEs  until 
Month 14 ●
 d ● ● ● ●        
Reporting of SAEs related to 
study participation or to a 
concurrent GSK 
medication/vaccine, or any fatal 
SAE, after Month 14 until study 
conclusion 
     ● ● ● ● ● 
 
● 
Reporting of potential immune-
mediated diseases (pIMDs) † 
according to guidelines In 
Section 8.3.2.5. 
● d ● ● ● ● ● ● ● ● ● 
 
● 
Follow-up of HZ  ● d ● ● ● ● ● ● ● ● ●  ● 
Reporting of medically attended 
visits until Month 8 ●
 d ● ● ●         
Recording of concomitant 
medication/vaccination by study 
staff/investigator according to 
guidelines in Section 6.6 
● ● ● ● ● ● ● ● ● ● 
 
● 
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Type of contact/trigger 
(Amended 18 April 2014) 
VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6 Monthly 
contactse
Final HZ 
efficacy 
analysis 
trigger 
(Amended 18
    
 
April 2014) 
Study 
conclusion 
contact 
Timepoints  Day 0*/ 
Month0 
Month 2 Month 3  Month 14  Month 26  Month 38    
Sampling timepoints Pre-Vacc Post-Vacc 
1 
Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
   
Reporting of pregnancy  ● d ● ● ● ● ● ● ● ● ●  ● 
Completion of EQ-5D and SF-36 
questionnaires 
-by all subjects  (subjects with 
an ongoing HZ episode will 
follow the weekly schedule and 
do not need to additionally 
complete the questionnaires at 
these visits) 
○    ○  ○  ○  
 
 
Transcription f by study 
staff/investigator of EQ-5D and 
SF-36 questionnaires completed 
●    ●  ●  ●  
 
 
Dispensing of 7-day diary cards 
for solicited AEs to the 7-day 
diary card subset only and 30-
day diary cards for unsolicited 
AEs and concomitant 
medication/vaccination to all 
subjects  
○ ○  
 
 
 
 
    
 
Daily post-vaccination recording 
by subjects of solicited 
symptoms (Days 0 − 6 after 
each vaccination) on the 7-day 
diary card by the 7-day diary 
card subset subjects  
○ ○  
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Type of contact/trigger 
(Amended 18 April 2014) 
VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6 Monthly 
contactse
Final HZ 
efficacy 
analysis 
trigger 
(Amended 18
    
 
April 2014) 
Study 
conclusion 
contact 
Timepoints  Day 0*/ 
Month0 
Month 2 Month 3  Month 14  Month 26  Month 38    
Sampling timepoints Pre-Vacc Post-Vacc 
1 
Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
   
Daily post-vaccination recording 
by subjects of unsolicited 
symptoms (Days 0 − 29 after 
each vaccination), and 
concomitant medication/ 
vaccination (Days 0 − 29 after 
each vaccination) on 30-day 
diary card by all subjects  
○ ○  
 
 
 
 
 
 
  
 
Returning by subjects of 7-day 
diary cards diary cards for 
solicited symptoms and 30-day 
diary cards for unsolicited AEs 
and concomitant medication and 
vaccination  
 ○ ○ 
 
 
 
 
 
 
  
 
Transcription of 7-day diary 
cards for solicited symptoms 
and 30-day dairy cards for 
unsolicited AEs and concomitant 
medication and vaccination by 
study staff/investigator 
 ● ● 
 
 
 
 
 
 
  
 
Transcription in eCRF of date 
of last visit or contact with 
subject 
(Amended 18 April 2014) 
   
 
 
 
 
 
 
 
●  
Investigator signature in eCRF 
(Amended 18 April 2014)    
       ●  
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Type of contact/trigger 
(Amended 18 April 2014) 
VISIT 1 VISIT 2 VISIT 3 Monthly 
contactse
VISIT 4 Monthly 
contactse
VISIT 5 Monthly 
contactse
VISIT 6 Monthly 
contactse
Final HZ 
efficacy 
analysis 
trigger 
(Amended 18
    
 
April 2014) 
Study 
conclusion 
contact 
Timepoints  Day 0*/ 
Month0 
Month 2 Month 3  Month 14  Month 26  Month 38    
Sampling timepoints Pre-Vacc Post-Vacc 
1 
Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
 Post-Vacc 
2 
   
Study Conclusion             ● 
Note: After Visit 3, monthly contacts between the subjects and the investigator and/or his delegate will be scheduled for the subject to respond to a standard set of questions, in a 
language that is understandable to the subject, to collect information on safety and the occurrence of HZ, and to follow-up ongoing HZ cases (Section 5.5.1). 
Note: Futility analysis may occur (Section 10.4.5.3)  
Note: The double-line border indicates the analyses which will be performed on data (i.e., data that are as clean as possible) obtained at the cut-off date for final HZ 
efficacy analysis. The possibility of data changes after the final HZ efficacy analysis exists because data collection and data entry may continue until study end.  Indicated 
by the dotted line, pending subjects’ advancement in the study, the cut-off date for final HZ efficacy analysis may occur at Visit 6 or some time  prior or after this visit. 
(Amended 18 April 2014) 
* Day of first vaccination 
† formerly referred to as new onset of autoimmune diseases (NOADs) and other immune mediated inflammatory disorders 
n is used to indicate a study procedure that requires documentation in the individual eCRF.  
O  is used to indicate a study procedure that does not require documentation in the individual eCRF. 
a Subjects 70-79 YOA and ≥ 80 YOA will be randomly assigned to ZOSTER-006 or ZOSTER-022 at Visit 1. These subjects must sign a Study Determination 
(Recruitment/Randomization) Agreement (SDRRA) prior to study assignment, and will receive a study determination number to be recorded in the eCRF. Study assignment can be 
done prior to Visit 1 if needed. 
b Subjects will be instructed to contact their study site immediately if he/she develops any symptoms suggestive of HZ, if he/she manifests any symptoms he/she perceive as serious 
and, in case of pregnancy for women of childbearing potential. 
c Only for women of child-bearing potential.  
d Study procedure to be assessed only after administration of vaccine at Visit 1. 
e Monthly contact after Visit 3 until study conclusion, except at months that coincide with the subject’s scheduled visits 
(Amended 18 April 2014) 
f  EQ-5D and SF-36 will remain as source documents. The information from these questionnaires will only be transcribed in the eCRF for subjects who have a suspected HZ event 
during the study. 
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Table 3 Study procedures to be performed during the follow-up period for each suspected HZ case 
 VISITS/CONTACTS IN CASE OF HZ 
Type of contact Visit HZ-1 Visit HZ-2 Contact HZ-3 Contact HZ-4 Visit HZ-5 Contact HZ-6 Visit HZ-7 
Timepoints Day HZ-0 Day HZ-7 Day HZ-14 Day HZ-21 Day HZ-28 Day HZ-56 Day HZ-91 
Perform clinical examination ○       
Return HZ-specific diary cards to study staff/investigator ○       
Transcription of the HZ-specific diary card by study 
staff/investigator  ●       
Take digital photographs of HZ rash α ●       
Recording of the HZ onset date by study staff/investigator ●       
Collect HZ lesion samples (3 replicate samples) for 
confirmation by PCR of a case of clinically diagnosed 
suspected HZ as specified in Section 5.7.3.11*, and for 
exploratory HSV qPCR** 
●       
Record relevant information regarding HZ in eCRF by 
study staff/investigator ● ● ● ● ● ● ● 
Record concomitant medication/vaccination according to 
guidelines in Section 6.6  ● ● ● ● ● ● ● 
Record intercurrent medical conditions according to 
guidelines in Section 6.7 ● ● ● ● ● ● ● 
Record any medical attention received for HZ or any HZ-
related complication ● ● ● ● ● ● ● 
Dispense ZBPI questionnaires to subjects ○       
Completion† of ZBPI questionnaires by the subjects until 
pain ceases or the cut-off date for end of study  analysis 
(ZBPI pain data will be collected until at least Day HZ-90) 
(Amended 18 April 2014) 
○ ○ ○ ○ ○ ○ ○ 
Return completed ZBPI questionnaires to study 
staff/investigator according to instructions provided by the 
investigator/study staff to subjects 
 ○ ○ ○ ○ ○ ○ 
Transcription of ZBPI questionnaires by study 
staff/investigator ● ● ● ● ● ● ● 
Dispense EQ-5D and SF-36 questionnaires to subjects 
○       
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 VISITS/CONTACTS IN CASE OF HZ 
Type of contact Visit HZ-1 Visit HZ-2 Contact HZ-3 Contact HZ-4 Visit HZ-5 Contact HZ-6 Visit HZ-7 
Timepoints Day HZ-0 Day HZ-7 Day HZ-14 Day HZ-21 Day HZ-28 Day HZ-56 Day HZ-91 
Completion‡ of EQ-5D and SF-36 questionnaires by the 
subjects until pain ceases or the cut-off date for end of 
study  analysis (EQ-5D and SF-36 data will be collected 
until at least Day HZ-90) (Amended 18 April 2014) 
○ ○ ○ ○ ○ ○ ○ 
Return completed EQ-5D and SF-36 questionnaires to 
study staff/investigator according to instructions provided 
by the investigator/study staff to subjects  
 ○ ○ ○ ○ ○ ○ 
Transcription of EQ-5D and SF-36 questionnaires by 
study staff/investigator ● ● ● ● ● ● ● 
Note: If HZ-associated pain ceases (defined as a 28-day [or 4-week] pain free period) and the HZ rash resolves, subsequent HZ follow-up visits or contacts will be cancelled. If pain 
reappears in the same area after a 4-week pain-free period and is not accompanied by a new HZ rash, it will be assigned to the previous HZ-episode. Visits/contacts will restart with 
Day HZ-0 defined as the first visit of the assigned episode, prior to the pain free period. 
α Additional photographs of HZ lesions may be taken after Visit HZ-1 to help note the progression of the rash 
* If during clinical evaluation at Visit HZ-1, the investigator determines that adequate rash samples are not present at Visit HZ-1 (i.e., <3 lesions present or only papules present), the 
investigator has the option of collecting three additional samples prior to or at Visit HZ-2. See the SPM for further details on PCR sample collection. ** If based on qPCR test results the 
diagnosis of HZ can be excluded, Herpes Simplex Virus (HSV) qPCR may be performed to assess if the rash lesions are due to HSV (1 or 2). This exploratory testing is not part of the 
decision making process for HZ case confirmation (see Appendix A and Appendix B). This testing is optional and requires specific consent from the individual subjects. 
† Subjects with suspected HZ will be asked to complete the ZBPI questionnaire at Day HZ-0 (Visit HZ-1) to rate HZ-associated pain within the last 24 hours (If the time between the HZ 
onset and clinical evaluation at Visit HZ-1 is greater than 24 hours, the subject will be asked to complete a second ZBPI also for the elapsed time between the HZ onset and 24 hours 
before Visit HZ-1); daily from Day HZ- 1 to Day HZ-28, and weekly from Day HZ-29 onwards until a 4-week pain-free period is documented or until the cut-off date for end of study  
analysis. (Amended 18 April 2014) If pain reappears in the same area after a 4-week pain-free period and is not accompanied by a new HZ rash, it will be assigned to the previous 
HZ-episode. The completion of ZBPI questionnaires will resume based upon the weekly schedule established at the start of the assigned episode. For all subjects with ongoing HZ-
associated pain at the time of cut-off date for end of study analysis, ZBPI data will be collected until a 4-week pain-free period is documented OR until at least Day HZ-90 (See Section 
5.5.2.2). (Amended 18 April 2014) 
‡Subjects with suspected HZ will be asked to complete the EQ-5D and SF-36 questionnaire weekly from Day HZ-0 to Day HZ-28, and weekly onwards until a 4-week pain-free period 
is documented or until the cut-off date for end of study analysis. (Amended 18 April 2014) If pain reappears in the same area after a 4-week pain-free period and is not accompanied 
by a new HZ rash, it will be assigned to the previous HZ-episode. The completion of EQ-5D and SF-36 questionnaires will resume based upon the weekly schedule established at the 
start of the assigned episode. For all subjects with ongoing HZ-associated pain at the time of cut-off date for end of study analysis, EQ-5D and SF-36 data will be collected until a 4-
week pain-free period is documented OR until at least Day HZ-90. Each suspected HZ that occurs up to the cut-off date for end of study analysis will be followed at least until Visit HZ-
7 (the study visit at Day HZ-91) (or sooner if the subject has no HZ-associated pain for 4 consecutive weeks and the HZ rash resolves). (Amended 18 April 2014) Follow-up of 
HZ-associated pain and complications will continue irrespective of whether the rash has ended in some cases. (See Section 5.5.2.2).  
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It is the investigator’s responsibility to ensure that the intervals between study 
visits/contacts are strictly followed. These intervals determine each subject’s evaluability 
in the ATP analyses. 
Time intervals between study visits/contacts related to study procedures performed in 
subjects participating in the study are presented in Table 4. In addition; after Visit 3, 
monthly contacts between the subjects and the investigator and/or his delegate will be 
scheduled. 
Follow-up for the occurrence of any SAEs will begin at Day 0 and continue until Month 
14. Follow-up for the occurrence of SAEs related to an HZ complication as defined in 
Section 5.5.2.5, related to study participation, related to a concurrent GSK 
medication/vaccine or any fatal SAE will continue until study conclusion. Follow-up for 
the occurrence of potential immune-mediated diseases (pIMDs), formerly referred to as 
new onset of autoimmune diseases and other immune mediated inflammatory disorders, 
will begin at Day 0 and continue until study conclusion. 
Table 4 Intervals between study visits/contacts (Amended 18 April 2014) 
Interval Length of interval Range (days) 
Visit 1 → Visit 2 2 months 49-83 
Visit 2 → Visit 3 1 month 30-48 
Visit 2 → Visit 4 12 months 335-395 
Visit 2 → Visit 5 24 months 700-760 
Visit 2 → Visit 6 36 months 1065-1125 
Visit 2 → Study 
conclusion contact Not fixed Not fixed  
Note: The date of Dose 1 (Visit 1) or Dose 2 (Visit 2), respectively, is used as reference date to define the interval 
between study visits/contacts. 
(Amended 18 April 2014) 
Time intervals between study visits/contacts to be performed for follow-up of HZ are 
presented in Table 5. Refer to the SPM for further guidance on data collection during 
follow-up of HZ. 
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Table 5 Intervals between contacts with subjects in case of suspected HZ  
Interval between visits/contacts Length of 
interval 
Optimal Timing of contact 
(range of days) 
Visit HZ-1 (Day HZ-0) → Visit HZ-2 (Day HZ-7) 7 days Day HZ-7 (+/- 3 days)* 
Visit HZ-2 (Day HZ-7) → Contact HZ-3 (Day HZ-14) 7 days Day HZ--14 (+/- 3 days)* 
Contact HZ-3 (Day HZ-14) → Contact HZ-4 (Day HZ-21) 7 days Day HZ-21 (+/- 3 days)* 
Contact HZ-4 (Day HZ-21) → Visit HZ-5 (Day HZ-28)  7 days  Day HZ-28 (+/- 3 days)* 
Visit HZ-5 (Day HZ-28) → Contact HZ-6 (Day HZ-56) 28 days  Day HZ-56 (+/- 7 days)* 
Visit HZ-1 (Day HZ-0) → Visit HZ-7 (Day HZ-91) 91 days  Day HZ-91 (+ 7 days) 
Note: The date of the previous visit/contact is used as reference date to define the interval between the subsequent 
study visits/contacts 
Note: If HZ-associated pain ceases (i.e., after a 4-week pain-free period is documented) and the HZ rash resolves, 
subsequent follow-up HZ visits or contacts will be cancelled (see Section 5.5.2.2). Follow-up of HZ-associated pain 
persisting beyond Visit HZ-7 (Day HZ-91) or other complications will be done at monthly contacts between the subjects 
and the investigator and/or his delegate that are planned after Visit 3  
* If contacted early in the window, then remaining days in the interval will need to be captured with the next contact. 
5.7. Detailed description of study procedures 
5.7.1. Procedures prior to study participation 
5.7.1.1. Study Determination (Recruitment/Randomization) Agreement 
Eligible subjects 70-79 YOA and ≥ 80 YOA will be randomly assigned to ZOSTER-006 
or ZOSTER-022 at Visit 1. Prior to study assignment, subjects need to provide their 
signature/thumb print on the Study Determination (Recruitment/Randomisation) 
Agreement. Subjects will receive a study determination number to be recorded in the 
eCRF. Study assignment can be done prior to Visit 1 if needed. 
5.7.1.2. Informed consent 
Before performing any other study procedure, subjects need to provide their 
signature/thumb print on the study specific informed consent. Refer to Section 5.1 for the 
requirements on how to obtain informed consent, as appropriate.  
5.7.2. Procedures prior to the first vaccination 
5.7.2.1. Check inclusion and exclusion criteria 
Check all applicable inclusion and exclusion criteria as described in Sections 4.2 and 4.3 
before enrolment.  
If a subject is enrolled while not meeting all inclusion criteria or while meeting any of the 
exclusion criteria, this must be reported in the eCRF.  
5.7.2.2. Collect demographic data 
Record demographic data such as information regarding date of birth, gender, geographic 
ancestry and ethnicity in the subject’s eCRF.  
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5.7.2.3. Medical history 
Review and record any pre-existing conditions or signs and/or symptoms present in a 
subject prior to the start of the study in the eCRF. 
Treatment of any abnormality observed during this examination has to be performed 
according to local medical practice outside this study or by referral to an appropriate 
health care provider. 
5.7.2.4. Physical examination 
A history-directed physical examination according to local practice should be performed 
to ensure the subject is in good physical condition. 
5.7.2.5. Urine pregnancy test  
Female subjects of childbearing potential are to have a urine pregnancy test prior to any 
study vaccine administration. The study vaccine/placebo may only be administered if the 
pregnancy test is negative. 
5.7.3. Procedures during the study  
Note that the urine pregnancy test is performed prior to vaccination and is described in 
Section 5.7.2. 
Note that subjects may decide at any time to end their participation in the study or 
request unblinding of the treatment received. In case of non-emergency unblinding, 
e.g., to receive a licensed HZ vaccine, subjects will be withdrawn from the study. An 
internal operating procedure that describes the process for non-emergency unblinding 
will be followed. (Amended 18 April 2014) 
5.7.3.1. Check and record concomitant medication/vaccination and intercurrent 
medical conditions  
Concomitant medication/vaccination must be recorded in the eCRF as described in 
Section 6.6. Refer to Section 6.6 for details on the medications/vaccinations that are 
forbidden or allowed during the study. 
At each study visit or contact subsequent to the first vaccination, it must be verified if the 
subject has experienced or is experiencing any intercurrent medical condition listed in 
Section 6.7. If it is the case, the condition(s) must be recorded in the eCRF. 
Intercurrent medical conditions except HZ prior to one month after the second 
vaccination should be reported in the AE section of the eCRF. 
Any subject with a clinically diagnosed suspected HZ episode between Visit 1 and Visit 2 
should not receive the second vaccination. 
Antiviral and/or pain medications administered to subjects with a suspected or confirmed 
case of HZ for the purpose of treating the HZ or the associated pain will be recorded in 
order to establish the link between the medications and the indication. 
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In addition, any medication/vaccination taken from Day 0 to Day 29 after each 
vaccination will be recorded by the subjects on a 30-day diary card (Section 5.7.3.8).  
5.7.3.2. Check contraindications to vaccination 
Contraindications to vaccination are to be checked at the beginning of each vaccination 
visit. Refer to Section 6.5. 
See Section 5.7.3.7 for additional criteria to be checked prior to administration of the 
second vaccination dose.  
5.7.3.3. Assess pre-vaccination body temperature 
The axillary, rectal, oral or tympanic body temperature of all subjects will be measured 
prior to any study vaccine administration. The preferred route for recording temperature 
in this study will be oral. All vaccines may be administered to persons with low-grade 
fevers, i.e., oral, tympanic on oral setting, or axillary temperature < 37.5°C/99.5°F, or 
< 38.0°C (100.4°F) on rectal setting (Section 4.3). If a subject has an 
axillary/oral/tympanic on oral setting temperature ≥ 37.5°C/99.5°F, or ≥ 38.0°C 
(100.4°F) on rectal setting, it will constitute a contraindication to administration of 
vaccine or placebo at that point in time (Section 6.5). 
5.7.3.4. Randomization 
At the first vaccination visit, randomization will occur as explained in Section 5.3. 
5.7.3.5. Blood sampling for safety or immune response assessments  
As specified in Table 2, blood samples will be taken during certain study visits. Refer to 
the Module on Biospecimen Management in the SPM for general handling of blood 
samples. 
• A volume of approximately 10 mL of whole blood should be drawn from all subjects 
at Visits 1 and 3, and, from all subjects included in the Immunogenicity subset, at 
Visits 4, 5 and 6. 
• An additional volume of approximately 20 mL of whole blood should be drawn from 
all subjects included in the CMI component of the Immunogenicity subset at Visits 
1, 3, 4, 5 and 6. 
5.7.3.6. Treatment number assignment  
At the first vaccination visit, the subject will be assigned a treatment number defining the 
treatment he/she will be receiving. The treatment number must be recorded in the eCRF 
at each vaccination visit. 
If there is a need for a site to use a replacement vaccine, then that treatment number needs 
to be transcribed into the eCRF (see Section 6.4). 
18-APR-2014 69 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
5.7.3.7. Vaccination 
• After completing the prerequisite procedures prior to each vaccination, one dose of 
study vaccine/placebo will be administered intramuscularly (IM) in the deltoid of the 
non-dominant arm (refer to Section 6.3 for detailed description of the vaccine 
administration procedure). If the Investigator or delegate determines that the 
subject’s health on the day of vaccination temporarily precludes vaccination, the visit 
will be rescheduled within the interval for this visit.  
• The vaccinees will be observed closely for at least 30 minutes, with appropriate 
medical treatment readily available in case of anaphylaxis following the 
administration of vaccine. 
• Any subject with clinically diagnosed suspected HZ episode between Visit 1 and 
Visit 2 should not receive the second dose. 
• Any subject with an SAE related to the first dose of vaccine (as judged by the 
investigator) should not receive the second dose (Section 6.5).  
5.7.3.8. Recording of non-serious AEs and SAEs 
Refer to Section 8.3 for procedures for the Investigator to record AEs and SAEs and to 
Section 8.4 for guidelines on how to report these AEs/SAEs to GSK Biologicals. 
• The subjects will be instructed to contact the investigator immediately should the 
subject manifest any signs or symptoms they perceive as serious or in case of 
pregnancy for women of childbearing potential. 
• After each vaccination, 30-day diary cards will be provided to all subjects by study 
staff/investigator for daily recording by the subjects of: 
− unsolicited symptoms from Days 0 to 29 after each vaccination 
− any medication/vaccination taken from Days 0 to 29 after each vaccination. 
• After each vaccination, 7-day diary cards will be provided to subjects who are part of 
the 7-day diary card subset by study staff/investigator for daily recording by the 
subjects of solicited symptoms from Days 0 to 6 after each vaccination  
• The subjects will be instructed to return the completed diary cards to the investigator 
at Visit 2 and Visit 3, respectively. 
• Collection and verification of completed diary cards will occur during discussion 
with the subject at Visit 2 and Visit 3. The investigator will transcribe the collected 
information into the eCRF in English. 
5.7.3.9. Recording of potential immune-mediated diseases (pIMDs)  
As specified in the List of Study Procedures (Table 2, Section 5.6), potential immune-
mediated diseases (pIMDs), formerly referred to as NOADs and other immune mediated 
inflammatory disorders, occurring from administration of the first dose of 
vaccine/placebo onwards until end of the trial will be recorded. 
Refer to Section 8.3.2.5 for information on recording of pIMDs. 
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5.7.3.10. Recording of data from completed EQ-5D and SF-36 questionnaires 
EQ-5D and SF-36 questionnaires will be completed by all subjects at Visit 1. 
• EQ-5D and SF-36 questionnaires: To be completed by all subjects at study entry. 
Also, to be completed by all subjects at Visits 4, 5 and 6 (subjects with an ongoing 
suspected HZ episode will follow a weekly schedule and do not need to additionally 
complete the questionnaires at these visits). 
EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed into the eCRF for subjects who have suspected 
HZ during the study. 
5.7.3.11. Follow up of suspected HZ cases and HZ-associated pain 
Data will be collected on all suspected HZ cases that occur from administration of the 
first dose of vaccine/placebo until the cut-off date for end of study analysis (Section 
5.7.3.17). (Amended 18 April 2014) For each suspected case of HZ that the investigator 
concludes is clinically consistent with HZ, data on HZ-associated pain (using ZBPI 
questionnaires completed by the subject) will be collected until Day-HZ-28, and from 
Day HZ-29 until:1) the subject has no HZ-associated pain for 4 consecutive weeks; or, 2) 
the cut-off date for end of study analysis. For all subjects with ongoing HZ-associated 
pain at the time of cut-off date for end of study analysis, ZBPI data will be collected until 
a 4-week pain-free period is documented OR until at least Day HZ-90. (Amended 18 
April 2014) In addition, subjects with suspected HZ will be asked to complete EQ-5D 
and SF-36 questionnaires weekly. If pain reappears in the same area after a 4-week pain-
free period and is not accompanied by a new HZ rash, it will be assigned to the previous 
HZ-episode. The completion of ZBPI, EQ-5D and SF-36 questionnaires will resume 
based upon the weekly schedule established at the start of the assigned episode. 
Visits/contacts will also restart according to the schedule in Table 3 with Day HZ-0 
defined as the first visit of the assigned episode, prior to the pain free period. Refer to 
Section 5.5.2.2 for more details. 
At the first HZ evaluation visit (Visit HZ-1 at Day HZ-0 – The visit at which the 
suspected case of HZ is first evaluated by the investigator), rash lesion samples will be 
collected from the subject if the investigator considers the symptoms/signs to be 
consistent with HZ. Three replicate rash lesion samples (see Table 6) should be collected 
on the same day. If during clinical evaluation at Visit HZ-1, the investigator determines 
that adequate rash lesion samples cannot be collected (i.e., less than three lesions present, 
or if only papules are present), the subject should be asked to return to the study site for 
collection of additional samples prior to or at the Visit HZ-2 if there is rash progression 
(i.e., appearance of new/additional lesions if originally less than three lesions present, or 
appearance of vesicles if originally only papules present). When the subject returns for 
repeat sample collection, three samples from separate lesions should be collected. See the 
SPM for further details on sample collection. 
At Visit HZ-1, the rash will be documented by digital photography. Additional 
photographs of HZ lesions may be taken after Visit HZ-1 to help note the progression of 
the rash. 
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Refer to Section 5.5.2 for details on follow-up of HZ cases and HZ-associated pain. 
5.7.3.12. Recording of medically attended visits  
Refer to Section 8.3.2.4 for detailed information on recording of medically attended visits 
occurring up until Month 8.  
5.7.3.13. Reminder for self-reporting by subjects 
Subjects will be instructed at Visit 1 (and will be reminded at each subsequent visit) to 
contact their study site immediately  
• should the subject develop any symptoms suggestive of HZ, and to start completion 
of the HZ-specific diary card immediately upon development of these symptoms 
prior to visiting the study site for evaluation of the suspected HZ; 
• should the subject manifest any signs or symptoms he/she perceive as serious; 
• should the subject become pregnant (for women of childbearing potential).  
5.7.3.14. Reminder for monthly follow-up contacts/yearly follow-up visits 
The subject will be reminded that, after Visit 3, monthly contacts between the subjects 
and the investigator and/or his delegate will take place (except at months that coincide 
with the subject’s scheduled visits) in order to collect all relevant information on any 
event of interest that may have occurred [including SAEs (Section 8.3), pIMDs (Section 
8.3.2.5), occurrence or follow up of a suspected episode of HZ (Section 5.5.2), 
intercurrent medical conditions (Section 6.7), medically attended visits (up to Month 8 
only, Section 8.3.2.4), the use of concomitant medications and/or vaccinations (Section 
6.6) or pregnancy (Section 8.3)], and that information will be recorded in the appropriate 
section of the subject’s eCRF. 
The subject will be reminded that the current study still has yearly follow-up visits 
planned until Month 38 (Visit 6). (Amended 18 April 2014) 
5.7.3.15. Final HZ efficacy analysis trigger (Amended 18 April 2014) 
When the cut-off date for final HZ efficacy analysis has been reached and 
communicated to the sites, the following actions need to take place:  
• Transcription in eCRF of date of last visit or contact with the subject  
• Addition of Investigator signature in eCRF (signing of data) 
(Amended 18 April 2014) 
5.7.3.16. Invitation for a planned follow-up study  
If study ZOSTER-006 is extended to include an additional long-term follow-up period 
beyond that currently mandated by the protocol, the investigator/study staff will ask all or 
a subset of subjects at the study conclusion contact if the subject would be willing to 
participate to a long-term follow-up study. If a subject declines to participate in a long-
term follow-up study, refusal will be documented in the individual eCRF.  
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5.7.3.17. Study conclusion  
Study end will take place when the conditions for end of study analysis are met and a 
minimum 90 days follow-up is completed for each case of suspected HZ that occurs prior 
to the cut-off date for end of study analysis. (Amended 18 April 2014) 
Refer to Section 3 for more details regarding end of study analysis (Amended 18 April 
2014)  
When the cut-off date for end of study analysis is established, the study sites will contact 
the subjects for the study conclusion contact as soon as possible. If a subject with 
suspected HZ has not completed follow-up until at least Day HZ-90 at the cut-off date for 
end of study analysis, follow-up for such a subject will continue until Day HZ-90 (or 
sooner if the subject has no HZ-associated pain for 4 consecutive weeks and the HZ rash 
resolves). (Amended 18 April 2014) The study conclusion contact for such a subject will 
thus occur after he/she completes follow-up as described above.  
At the study conclusion contact, the study sites will provide instructions to the subjects 
for returning any outstanding ZBPI questionnaires. 
At the study conclusion contact, the following procedures will take place: 
• Follow-up of any cases of suspected HZ and HZ-associated pain (Sections 5.5.2 and 
5.7.3.10) 
• Recording of any SAEs related to study participation or to a concurrent GSK 
medication/vaccine, or any fatal SAE (Section 5.7.3.8); 
• Recording of pIMDs (Section 5.7.3.9); 
• Check and record specific concomitant medication/vaccination and intercurrent 
medical conditions (Section 5.7.3.1); 
• Study conclusion will be recorded in the eCRF. 
After study conclusion, if the study vaccine demonstrates sufficient evidence of efficacy 
and safety such that a clinically important benefit may be reasonably expected, placebo 
recipients may be offered cross-over immunization with the study vaccine. 
5.8. Biological sample handling and analysis 
Please refer to the SPM for details of biospecimen management (handling, storage and 
shipment). 
Samples will not be labelled with information that directly identifies the subjects but will 
be coded with the identification number for the subject (subject number). 
Collected samples may be used in other assays, for test improvement or test development 
of analytical methods related to the study vaccine and its constituents or the disease under 
study to allow to achieve a more reliable measurement of the vaccine response. Under 
these circumstances, additional testing on the samples may be performed by GSK 
Biologicals outside the scope of this protocol.  
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Information on further investigations and their rationale can be obtained from GSK 
Biologicals.  
Any sample testing will be done in line with the consent of the individual subject.  
Herpes Simplex Virus (HSV) qPCR (see Section 5.8.2) may be performed on Varicella 
Zoster Virus (VZV) negative β-actin positive samples for exploratory purpose to assess if 
the rash lesions are due to HSV (1 or 2) and not to VZV; it is not part of the decision 
making process for HZ case confirmation. This testing is optional and requires specific 
consent from the individual subjects (see Appendix A and Appendix B).  
Any human pharmacogenetic testing will require specific consent from the individual 
subjects and the ethics committee approval. Any anti-HIV testing will also require 
specific consent and ethics committee approval.  
Refer also to the Investigator Agreement, where it is noted that the Investigator cannot 
perform any other biological assays except those described in the protocol or its 
amendment(s).  
If additional testing is performed, the marker priority ranking given in Section 5.8.4 may 
be changed. 
Collected samples will be stored for up to 15 years (counting from when the last subject 
performed the last study visit), unless local rules, regulations or guidelines require 
different timeframes or different procedures, which will then be in line with the subject 
consent. These extra requirements need to be communicated formally to and discussed 
and agreed with GSK Biologicals. 
5.8.1. Use of specified study materials 
When materials are provided by GSK Biologicals, it is MANDATORY that all clinical 
samples (including serum samples) be collected and stored exclusively using those 
materials in the appropriate manner. The use of other materials could result in the 
exclusion of the subject from the ATP analysis (see Section 10.5 for the definition of 
study cohorts to be evaluated). The investigator must ensure that his/her personnel and 
the laboratory(ies) under his/her supervision comply with this requirement. However, 
when GSK Biologicals does not provide material for collecting and storing clinical 
samples, then appropriate materials from the investigator’s site are to be used. Refer to 
the Module on Clinical Trial Supplies in the SPM. 
5.8.2. Biological samples 
The different biological samples collected in the study, the quantities needed, the units 
and the timepoints are described in Table 6.  
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Table 6 Biological samples  
Sample type Quantity (approximate volume) Unit Timepoint Subset Name* 
Blood (Cell-mediated 
immunology )  
20  mL Visit 1, 3, 4, 5, 6 CMI component of 
Immunogenicity subset 
Blood (Humoral 
immunology)  
10  mL  Visit 1, 3 All subjects  
 10  mL  Visit 4, 5, 6 Immunogenicity subset 
Clinical specimens of 
HZ lesions 
 
3 replicate samples, taken on 
the same day, of the highest 
priority lesion type available (1) 
vesicle fluid; 2) crust; 3) crust 
swab; 4) papule swab)† 
NA Scheduled in 
case of suspected 
HZ for diagnosis  
Subjects clinically 
diagnosed as having a 
suspected case of HZ  
* Refer to Section 4.1 for description of the subsets 
†If during clinical evaluation at Visit HZ-1, the investigator determines that adequate rash samples are not present at 
Visit HZ-1 (i.e., <3 lesions present or only papules present), the investigator has the option of collecting three additional 
samples prior to or at Visit HZ-2. See the SPM for further details on sample collection. 
5.8.3. Laboratory assays 
Please refer to Appendix A for a detailed description of the assays performed in the 
study. 
Laboratory assays, which will be used in this study, are summarised in respectively Table 
7 (Humoral Immunity), Table 8 (CMI) and Table 9 (Molecular Biology). 
Table 7 Humoral Immunity (Antibody determination) (Amended 18 April 
2014) 
System Component Method Kit / Manufacturer Unit Cut-off Laboratory 
Serum Varicella Zoster 
Virus Ab.IgG 
ELISA Enzygnost 
Dade Behring 
mIU/mL 25 GSK 
Biologicals* 
Serum  gE Ab.IgG ELISA NA mIU/mL 97 GSK 
Biologicals* 
Serum Varicella Zoster 
Virus Neutralizing 
Ab.IgG 
PRNT NA ED50 TBD GSK 
Biologicals* 
*GSK Biologicals laboratory or validated laboratory designated by GSK Biologicals. 
ELISA = Enzyme-linked Immunosorbent Assay; PRNT = Plaque Reduction Neutralization Test 
mIU = milli international unit; ED50 = endpoint dilution 50% 
NA = Not applicable; TBD = to be determined; Ab = antibody 
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Table 8 Cell-Mediated Immunity (CMI) 
System Component Challenge Method Unit Laboratory 
Peripheral 
Blood 
Mononuclear 
Cells 
Cells CD4.All double 
CD40 Ligand or 
Interleukin-2 or 
Tumor Necrosis 
Factor alpha or 
Interferon gamma  
gE ICS Events/10E6 GSK 
Biologicals* 
Peripheral 
Blood 
Mononuclear 
Cells 
Cells CD4.All double 
CD40 Ligand or 
Interleukin-2 or 
Tumor Necrosis 
Factor alpha or 
Interferon gamma  
VZV ICS Events/10E6 GSK 
Biologicals* 
*GSK Biologicals laboratory or validated laboratory designated by GSK Biologicals. 
ICS = Intracellular cytokine staining 
Table 9 Molecular Biology (PCR tests)  
System Component Method Unit Laboratory 
HZ lesion sample Varicella Zoster 
Virus.DNA 
QPCR No unit GSK 
Biologicals* 
HZ lesion sample Herpes Simplex 
Virus.DNA** 
QPCR No unit GSK 
Biologicals* 
HZ lesion sample Actin 
Gene.DNA 
QPCR No unit GSK 
Biologicals* 
*GSK Biologicals laboratory or validated laboratory designated by GSK Biologicals. 
** Herpes Simplex Virus (HSV) qPCR may be performed on VZV negative/β-actin positive samples for exploratory 
purpose to assess if the rash lesions are due to HSV (1 or 2) and not to VZV; it is not part of the decion making 
process for HZ case confirmation (see Appendix A  and Appendix B). This exploratory testing is optional and requires 
specific consent from the individual subjects. 
Collected samples will be used for purposes related to the quality assurance of data 
generated within the scope of this protocol, such as for maintenance of assays described 
in this protocol and comparison between analytical methods and/or laboratories. 
The GSK Biologicals’ clinical laboratories have established a Quality System supported 
by procedures. The activities of GSK Biologicals’ clinical laboratories are audited 
regularly for quality assessment by an internal (sponsor-dependent) but laboratory-
independent Quality Department. 
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5.8.4. Biological samples evaluation 
5.8.4.1. Immunological read-outs 
The plan for immunogenicity testing on samples obtained is shown in Table 10. In case 
of insufficient blood sample volume to perform the assays, the samples will be analysed 
according to priority ranking provided in Table 10. 
• For subjects included in the Immunogenicity subset (humoral immunity), anti-gE and 
anti-VZV Abs will be measured at specified timepoints. An anti-VZV neutralizing 
Ab assay may also be performed on the serum blood samples from a subgroup of 
subjects of the Immunogenicity subset. 
• For a subgroup of subjects included in the CMI component of the Immunogenicity 
subset, gE and VZV specific CMI response will be measured at specified timepoints. 
• For the correlates of protection analysis, analysis of the humoral immune responses 
at prevaccination and Month 3 will be performed on samples collected from 
vaccinated subjects who develop confirmed HZ and compared with the humoral 
immune responses at prevaccination and Month 3 from matched subjects that did not 
develop HZ. Additional blood samples may be analysed from other subjects to match 
more exactly with characteristics of those that developed HZ.  
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Table 10 Immunological read-outs  
Blood sampling timepoint Subset* Name Marker Components 
priority rank Visit no Timing Month 
Visit 1 Pre-Vacc 1  0 Immunogenicity subset  Ab gE ELISA 1 
   Immunogenicity subset Ab VZV ELISA 2 
   Immunogenicity subset** anti-VZV 
neutralizing Ab 
3 
   CMI component of Immunogenicity 
subset 
ICS gE  1 
   CMI component of Immunogenicity 
subset 
ICS VZV 2 
   Correlate of protection analysis‡ Ab gE ELISA 1 
   Correlate of protection analysis‡ Ab VZV ELISA 2 
Visit 3 Post-Vacc 2  3 Immunogenicity subset Ab gE ELISA 1 
  Immunogenicity subset Ab VZV ELISA 2 
   Immunogenicity subset** anti-VZV 
neutralizing Ab 
3 
   CMI component of Immunogenicity 
subset 
ICS gE  1 
   CMI component of Immunogenicity 
subset 
ICS VZV 2 
   Correlate of protection analysis‡ Ab gE ELISA 1 
   Correlate of protection analysis‡ Ab VZV ELISA 2 
Visit 4 Post-Vacc 2  14 Immunogenicity subset Ab gE ELISA 1 
   Immunogenicity subset Ab VZV ELISA 2 
   Immunogenicity subset** anti-VZV 
neutralizing Ab 
3 
   CMI component of Immunogenicity 
subset 
ICS gE  1 
   CMI component of Immunogenicity 
subset 
ICS VZV 2 
Visit 5 Post-Vacc 2  26 Immunogenicity subset Ab gE ELISA 1 
   Immunogenicity subset Ab VZV ELISA 2 
   Immunogenicity subset** anti-VZV 
neutralizing Ab 
3 
   CMI component of Immunogenicity 
subset 
ICS gE  1 
   CMI component of Immunogenicity 
subset 
ICS VZV 2 
Visit 6 Post-Vacc 2  38 Immunogenicity subset Ab gE ELISA 1 
   Immunogenicity subset Ab VZV ELISA 2 
   Immunogenicity subset** anti-VZV 
neutralizing Ab 
3 
   CMI component of Immunogenicity 
subset 
ICS gE  1 
   CMI component of Immunogenicity 
subset 
ICS VZV 2 
* Refer to Section 4.1 for description of subsets. 
** Anti-VZV neutralizing Ab assay may be performed in a subgroup of the Immunogenicity subset. 
‡ Refer also to Section 10.8.3.4 for details regarding correlate of protection analysis 
Note: Test results obtained for the anti-gE and anti-VZV Ab ELISA assays will be used for correlate of protection 
analysis, if applicable. 
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Additional testing may be performed if deemed appropriate by GSK Biologicals should 
any findings in the present study, or in other studies, indicate that further investigation of 
the immunogenicity of the vaccine is warranted. In this case, the rankings above may also 
change.  
5.8.4.2. Test for laboratory diagnosis of HZ 
In case of a suspected HZ case diagnosis in any of the subjects, clinical specimens from 
HZ lesions will be collected to confirm the diagnosis of HZ by PCR. Please refer to 
Appendix A for or a detailed description of the PCR. 
5.8.5. Immunological correlates of protection 
No correlate of protection has been demonstrated so far for the antigen used as part of the 
candidate vaccine. 
Study ZOSTER-006 will attempt to correlate humoral immune responses at Month 3 with 
protection. Additional evaluations to add precision to this assessment may be performed 
(see Section 10.8.3.4).  
6. STUDY VACCINE AND ADMINISTRATION 
6.1. Description of study vaccine 
The Quality Control Standards and Requirements for the candidate vaccine are described 
in separate Quality Assurance documents (e.g. release protocols, certificate of analysis) 
and the required approvals have been obtained.  
The vaccine is labelled and packed according to applicable regulatory requirements.  
The study vaccine will be supplied in 2 vials, one containing the VZV gE antigen, and the 
other containing Adjuvant System AS01B. 
• The VZV gE antigen is provided in a lyophilized form in monodose vials. Each vial 
contains 62.5 μg of recombinant purified gE and formulation excipients. Therefore, 
when the 62.5 μg of VZV gE in each vial is reconstituted with the full volume of 
adjuvant, each vaccine dose will contain 50 μg of the VZV gE antigen per 0.5 mL of 
reconstituted vaccine. 
• The AS01B Adjuvant System is provided as a liquid formulation in monodose vials, 
each vial containing at least 0.5 mL of adjuvant. One 0.5 mL dose of AS01B 
formulation contains 50 μg of MPL and 50 μg of QS21 mixed with liposomes. 
When the VZV gE antigen is reconstituted in AS01B it appears as an opalescent, 
colourless liquid, free from visible particles. 
After reconstitution, each 0.5 mL dose of study vaccine contains 50 μg of gE 
recombinant protein, 50 μg of MPL, 50 μg of QS21, and liposomes.  
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The NaCl solution is provided in monodose vials (0.5 mL/dose) containing 150 mM 
NaCl per 0.5 mL dose. The NaCl solution used as the placebo appears clear and 
colourless and is free from visible particles. 
The method of preparation of the gE/AS01B study vaccine (reconstitution required) 
differs from that of the placebo (no reconstitution required for the NaCl solution 
placebo). The reconstituted gE/AS01B study vaccine differs in appearance from the NaCl 
solution placebo. To conduct the study in an observer-blind manner, the gE/AS01B 
vaccine and NaCl solution placebo doses will be prepared and administered by study staff 
not involved in the clinical evaluation of the subjects. In this way, neither the subject nor 
the investigator (or other study personnel) will know which treatment was administered. 
The method of blinding and the responsibilities of the study personnel in this regard will 
be documented by the investigator at each study site. 
The SPM will include details of vaccine supplies. 
6.2. Storage and handling of study vaccine  
All study vaccines to be administered to the subjects must be stored in a safe and locked 
place with no access by unauthorised personnel.  
The study vaccines must be stored at the defined temperature range (i.e. +2 to +8°C/36°F 
to 46°F) and must not be frozen. Please refer to the Module on Clinical Trial Supplies in 
the SPM for more details on storage of the study vaccine. The storage temperature of the 
vaccine will be monitored daily with temperature monitoring device(s) (at the minimum 
calibrated) and will be recorded as specified in the SPM.  
The storage conditions will be assessed during pre-study activities under the 
responsibility of the sponsor study contact. 
Any temperature deviation outside the range 0°C to +8°C/32°F to 46°F, must be reported 
to the sponsor as soon as detected. Following an exposure to such a temperature 
deviation, vaccines will not be used until approval has been given by the Sponsor. 
In case of temperature deviation between 0 and +2°C/32 and 36°F, the impacted study 
vaccine can still be administered, but the site must take adequate actions to go back to the 
defined range +2 to +8°C/36 to 46°F and avoid re-occurrence of such a temperature 
deviation. 
Please refer to the Module on Clinical Trial Supplies in the SPM for details and 
instructions on the Temperature deviation process, packaging and accountability of the 
study vaccine. 
6.3. Dosage and administration of study vaccine 
The vaccine should be reconstituted shortly after the vials are taken out of the 
refrigerator. The reconstituted vaccine is stable for up to two hours when kept at a 
temperature range of +2°C (36°F) to 30°C (86°F). Therefore, reconstituted vaccines 
should be administered within a maximum of two hours after reconstitution. 
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To reconstitute gE/AS01B study vaccine, the entire content of one diluent vial (i.e. 
AS01B) is aspirated into a syringe and injected into one vial of lyophilized gE antigen. 
The pellet is dissolved by gentle shaking of the vial (for a few seconds) until complete 
dissolution of the lyophilized cake. 
Table 11 summarises how vaccine will be administered. 
The entire volume of the reconstituted vaccine should be withdrawn, the needle can be 
replaced, and any solution in excess of 0.5mL should be expelled. The reconstituted 
vaccine or a 0.5mL dose of the NaCl solution placebo should be administered by IM 
injection into the deltoid muscle using a standard aseptic technique, preferably in the non-
dominant arm. In rare situations when there is no other alternative, the injection may be 
given in the dominant arm. 
Table 11 Dosage and administration 
Group Visit Vaccination Treatment Route Site Side 
Vaccine 1, 2 1, 2 gE/AS01B IM D Non-dominant arm 
Placebo 1, 2 1, 2 NaCl solution placebo IM D Non-dominant arm 
gE/AS01B: lyophilized gE reconstituted in liquid AS01B Adjuvant System 
Intramuscular (IM) 
Deltoid (D) muscle of non-dominant arm 
6.4. Replacement of unusable vaccine 
Additional vaccine doses will be provided to replace those that are unusable (see the 
Module on Clinical Trial Supplies in the SPM for details). 
In addition to the vaccine doses provided for the planned number of subjects (including 
over-randomization when applicable), at least 5% additional doses will be supplied to 
replace those that are unusable.  
The investigator will use the central randomization system (SBIR) to obtain the 
replacement vial number. The system will ensure, in a blinded manner, that the 
replacement vial is of the same formulation as the randomized vaccine. 
6.5. Contraindications to subsequent vaccination  
The following events constitute absolute contraindications to further administration of 
gE/AS01B. If any of these events occur during the study, the subject must not receive 
additional doses of vaccine but may continue other study procedures at the discretion of 
the investigator (see Section 8.4.4).  
• Anaphylaxis following the administration of vaccine(s); 
• Pregnancy (Section 8.2.2); 
• If the subject experiences an SAE judged to be vaccine-related by the investigator 
(Sections 8.1.2 and 8.3.2.2.2); 
• Any confirmed or suspected immunosuppressive or immunodeficient condition 
resulting from disease (e.g., malignancy, HIV infection) or 
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immunosuppressive/cytotoxic therapy (e.g., medications used during cancer 
chemotherapy, organ transplantation or to treat autoimmune disorders). However 
subjects who have received less than 15 days of immunosuppressants or other 
immune modifying drugs should not be contraindicated from receiving subsequent 
vaccinations. Also, for corticosteroids, prednisone < 20 mg/day, or equivalent, is 
allowed. Inhaled and topical steroids are allowed.  
The following events constitute contraindications to administration of the gE/AS01B HZ 
vaccine at that point in time; if any one of these events occurs at the time scheduled for 
vaccination, the subject may be vaccinated at a later date, within the time window 
specified in the protocol (Section 5.6), or withdrawn at the discretion of the investigator 
(Section 8.4.4). 
• Acute disease and/or fever at the time of vaccination.  
− Fever is defined as temperature ≥ 37.5°C (99.5°F) on oral, axillary or tympanic 
setting, or ≥ 38.0°C (100.4°F) on rectal setting. The preferred route for recording 
temperature in this study will be oral. 
Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory 
infection) without fever can be administered all vaccines.  
See Section 5.7.3.7 for an additional criterion to be checked prior to administration of the 
second vaccination dose. 
6.6. Concomitant medication/vaccination 
At each study visit/contact, the investigator should question the subject about any 
medication taken and vaccination received by the subject. 
Concomitant medication administered for the treatment of pIMDs at any time during the 
study must be recorded in the eCRF. Refer to Section 8.3.2.5 for information regarding 
pIMDs. 
Any concomitant medication administered for the treatment of confirmed or suspected 
HZ or any HZ-related complications (including pain) at any time during the study must 
be recorded in the eCRF and coded as ‘Treatment for HZ’. 
Administration of any medications/vaccinations/products listed in Section 6.6.1 must be 
recorded in the eCRF respecting the time window as detailed in Section 6.6.2. 
All concomitant medications, with the exception of vitamins and/or dietary supplements, 
administered at ANY time during the 30 days (Days 0 -29) after each vaccination are to 
be recorded in the eCRF. This also applies to concomitant medication administered 
prophylactically in anticipation of reaction to the vaccination and any medication 
intended to treat an AE. 
A prophylactic medication is a medication administered in the absence of ANY symptom 
and in anticipation of a reaction to the vaccination (e.g. an anti-pyretic is considered to be 
prophylactic when it is given in the absence of fever [oral/tympanic on oral 
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setting/axillary temperature < 37.5°C (99.5°F), or < 38.0°C (100.4°F) on rectal setting] 
and any other symptom, to prevent fever from occurring). 
Similarly, concomitant medication administered for the treatment of a SAE must be 
recorded on the SAE screens in the eCRF, as applicable. Refer to Section 8.1.2 for the 
definition of a SAE and Section 8.3.1 for SAE reporting periods. 
6.6.1. Medications/products that may lead to the elimination of a 
subject from ATP analyses 
The following criteria should be checked at each visit subsequent to the first vaccination. 
If any become applicable during the study, it will not require withdrawal of the subject 
from the study but may determine a subject’s evaluability in the ATP analysis. See 
Section 10.5 for definition of study cohorts to be evaluated. 
• Use of any investigational or non-registered product (drug or vaccine) other than the 
study vaccine during the study period; 
• Administration of a vaccine not foreseen by the study protocol within 30 days prior 
to dose 2 of vaccine and/or within 30 days after any dose. However, licensed non-
replicating vaccines (i.e., inactivated and subunit vaccines, including inactivated and 
subunit influenza vaccines, with or without adjuvant for seasonal or pandemic flu) 
may be administered up to 8 days prior to dose 2 and/or at least 14 days after any 
dose of study vaccine; 
• Receipt of a vaccine against HZ other than the study vaccine during the study period; 
• Prolonged use (> 14 consecutive days) of oral and/or parenteral antiviral agents that 
are active against VZV (acyclovir, valacyclovir, famciclovir etc.) during the study 
period for an indication other than to treat suspected or confirmed HZ or an HZ-
related complication (topical use of these antiviral agents is allowed); 
• Receipt of immunoglobulins and/or any blood products during the study period; 
• Chronic administration (defined as > 15 consecutive days) of immunosuppressants or 
other immune-modifying drugs during the study period. For corticosteroids, this will 
mean prednisone < 20 mg/day, or equivalent, is allowed. Inhaled and topical steroids 
are allowed.  
A detailed, comprehensive list of reasons for elimination from ATP analyses will be 
established at the time of data cleaning. 
6.6.2. Time window for recording concomitant medication/vaccination 
in the eCRF 
All concomitant medications administered for the treatment of all SAEs from Day 0 until 
Month 14, are to be recorded in the eCRF. 
Concomitant medication, administered for the treatment of SAEs related to study 
participation or to a concurrent GSK medication/vaccine or any fatal SAE, from Day 0 
until Study conclusion contact, must be recorded in the eCRF. 
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Concomitant medication, administered for the treatment of HZ or any related HZ-
complications, or for the treatment of pIMDs, from Day 0 until Study conclusion contact, 
must be recorded in the eCRF. 
Oral and/or parenteral antiviral agents that are active against VZV (acyclovir, 
valacyclovir, famciclovir etc.) administered for > 14 consecutive days for an indication 
other than to treat suspected or confirmed HZ or an HZ-related complication from Day 0 
until Study conclusion contact, are to be recorded in the eCRF. 
Any vaccine not foreseen in the study protocol, administered from Day 0 until Month 3, 
is to be recorded in the eCRF. 
Any investigational medication or investigational vaccine, administered from Day 0 
through Study conclusion contact, must be recorded in the eCRF. 
Any vaccine against HZ other than the study vaccine, administered from Day 0 until 
Study conclusion contact, is to be recorded in the eCRF. 
Immunoglobulins and/or any blood products, administered from Day 0 until Study 
conclusion contact, are to be recorded in the eCRF. 
Immunosuppressants or other immune-modifying drugs administered during the study 
period for > 15 consecutive days, are to be recorded in the eCRF. For corticosteroids, this 
will mean prednisone ≥ 20 mg/day, or equivalent.  
All concomitant medications, with the exception of vitamins and/or dietary supplements, 
administered at ANY time during the 30 days (Days 0 -29) after each vaccination are to 
be recorded in the eCRF. 
6.7. Intercurrent medical conditions that may lead to elimination 
from an ATP cohort 
Subjects may be eliminated from the ATP cohort for immunogenicity if, during the study, 
they incur a condition that has the capability of confounding their immune response to the 
study vaccine (i.e. a confirmed case of HZ prior to one month after the second 
vaccination); or they have any confirmed or suspected immunosuppressive or 
immunodeficient condition resulting from disease (e.g. malignancy, HIV infection). 
Intercurrent conditions except HZ prior to one month after the second vaccination should 
be reported in the AE section of the eCRF. 
7. HEALTH ECONOMICS 
The following questionnaires will be administered to the subjects: 
• EQ-5D questionnaire 
The EQ-5D is a generic multi-attribute health classification system. The EQ-5D uses 
a 5-dimension (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) descriptive system, with each consisting of 3 response options 
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(no problems, moderate problems or extreme problems). The EQ-5D also includes a 
Visual Analogue Scale (VAS) ranging from 0 to 100, with 100 representing the best 
imaginable health state and 0 representing the worst imaginable health state. 
• SF-36 health survey 
The SF-36® is a multi-purpose health survey with 36 questions. It yields an 8-scale 
profile of scores (physical functioning, role physical, bodily pain, general health 
perceptions, vitality, social functioning, role emotional, and mental health) as well as 
a reported health transition score. 
Both the EQ-5D and SF-36 questionnaires are international standards and have been 
extensively validated. They will generate Quality-Adjusted Life Years (QALY) weights 
in order to estimate the cost-effectiveness of an HZ vaccination strategy. 
A standard algorithm has been developed for processing subjects’ answers and producing 
QALY weights. These QALY weights will be generated for each age group: 50-59 YOA, 
60-69 YOA and ≥ 70 YOA. 
EQ-5D and SF-36 will be completed at Visit 1 for all subjects in order to generate a 
baseline measurement. 
For subjects with suspected HZ, both questionnaires will be completed weekly from Day 
HZ-0 onwards until a 4-week pain-free period is documented OR until the cut-off date for 
end of study analysis. For all subjects with ongoing HZ-associated pain at the time of the 
cut-off date for end of study analysis, EQ-5D and SF-36 data will be collected until a 4-
week pain-free period is documented OR until at least Day HZ-90. (Amended 18 April 
2014) Refer to Section 5.5.2.2 for more details. For all subjects, the EQ-5D and SF-36 
questionnaires will be completed at Visits 4, 5 and 6 (subjects with an ongoing HZ 
episode will follow the weekly schedule and do not need to additionally complete the 
questionnaires at these visits).  
QALY weights measured for HZ cases in vaccine and placebo recipients will be 
compared and adjusted for their respective baseline values. 
8. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The investigator or site staff is/are responsible during the study for the detection and 
documentation of events meeting the criteria and definition of an adverse event (AE) or 
serious adverse event (SAE) as provided in this protocol.  
Each subject will be instructed to contact the investigator immediately should they/the 
subject manifest any signs or symptoms they perceive as serious. 
18-APR-2014 85 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
8.1. Safety definitions 
8.1.1. Definition of an adverse event 
An AE is any untoward medical occurrence in a clinical investigation subject, temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with 
the use of a medicinal product. For marketed medicinal products, this also includes 
failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.  
Examples of an AE include: 
• Significant or unexpected worsening or exacerbation of the condition/indication 
under study.  
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after investigational product administration 
even though they may have been present prior to the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concurrent medication (overdose per se should not be 
reported as an AE/SAE). 
Examples of an AE DO NOT include: 
• Medical or surgical procedures (e.g. endoscopy, appendectomy); the condition that 
leads to the procedure is an AE. 
• Situations where an untoward medical occurrence did not occur (e.g. social and/or 
convenience admission to a hospital, admission for routine examination). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
AEs may include pre- or post-treatment events that occur as a result of protocol-
mandated procedures (i.e. invasive procedures, modification of subject’s previous 
therapeutic regimen). 
NB: AEs to be recorded as endpoints (solicited AEs) are described in Section 8.1.3. All 
other AEs will be recorded as UNSOLICITED AEs. (For subjects not included in the 7-
day diary card subset, all AEs will be recorded as UNSOLICITED AEs.)  
Example of events to be recorded in the medical history section of the eCRF: 
• Pre-existing conditions or signs and/or symptoms present in a subject prior to the 
start of the study (i.e. prior to the first study vaccination). 
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The occurrence of HZ or PHN will not constitute an AE or SAE. However, HZ 
complications other than PHN (see Section 5.5.2.5) will be considered as AEs or SAEs. 
8.1.2. Definition of a serious adverse event  
A serious adverse event (SAE) is any untoward medical occurrence that: 
a. Results in death. 
b. Is life-threatening. 
NB: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, had it been more severe. 
c. Requires hospitalisation or prolongation of existing hospitalisation. 
NB: In general, hospitalisation signifies that the subject has been admitted at the hospital 
or emergency ward for observation and/or treatment that would not have been appropriate 
in the physician’s office or out-patient setting. Complications that occur during 
hospitalisation are also considered AEs. If a complication prolongs hospitalisation or 
fulfils any other serious criteria, the event will also be considered serious. When in doubt 
as to whether ‘hospitalisation’ occurred or was necessary, the AE should be considered 
serious. 
Hospitalisation for elective treatment of a pre-existing condition (known/diagnosed prior 
to informed consent signature) that did not worsen from baseline is NOT considered an 
AE. 
d. Results in disability/incapacity, or 
NB: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of relatively 
minor medical significance such as uncomplicated headache, nausea, vomiting, 
diarrhoea, influenza like illness, and accidental trauma (e.g. sprained ankle) which may 
interfere or prevent everyday life functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect in the offspring of a study subject. 
Medical or scientific judgement should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalisation but may jeopardise the 
subject or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These should also be considered serious. 
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions 
that do not result in hospitalisation. 
8.1.3. Solicited adverse events 
Subjects in the 7-day diary card subset will be asked to report daily, from Day 0 to Day 6 
(7-day follow-up period) after each dose, the occurrence of local or general solicited 
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adverse experiences on a safety diary card provided by the sponsor. All clinical signs and 
symptoms will be recorded by the investigator on the appropriate section of the eCRF. 
The following local (injection-site) AEs will be solicited (Table 12): 
Table 12 Solicited local adverse events 
Pain at injection site 
Redness at injection site 
Swelling at injection site 
The following general AEs will be solicited (Table 13): 
General AEs are any experiences, which do not occur at the site of injection of a vaccine. 
They will be recorded as ‘general’ and include those events. 
Table 13 Solicited general adverse events 
Fatigue 
Fever 
Gastrointestinal symptoms † 
Headache 
Myalgia 
Shivering 
†Gastrointestinal symptoms include nausea, vomiting, diarrhoea and/or abdominal pain 
NB: Temperature will be recorded in the evening. Should additional temperature 
measurements be performed at other times of day, the highest temperature will be 
recorded in the eCRF. 
8.1.4. Clinical laboratory parameters and other abnormal assessments 
qualifying as adverse events or serious adverse events  
Safety laboratories are not collected in this study. Abnormal laboratory findings (e.g. 
clinical chemistry, haematology, urinalysis) or other abnormal assessments that come to 
the attention of, and are judged by, the investigator to be clinically significant will be 
recorded as AEs or SAEs if they meet the definition of an AE, as defined in Section 8.1.1 
or of a SAE, as defined in Section 8.1.2. Clinically significant abnormal laboratory 
findings or other abnormal assessments that are detected during the study or are present at 
baseline and significantly worsen following the start of the study will be reported as AEs 
or SAEs.  
The investigator will exercise his or her medical and scientific judgement in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant. 
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8.2. Events or outcomes not qualifying as adverse events or 
serious adverse events 
8.2.1. Disease-related events or outcomes not qualifying as serious 
adverse events 
The occurrence of HZ or PHN will not constitute an AE or SAE. However, HZ 
complications other than PHN (see Section 5.5.2.5) will be considered as AEs or SAEs. 
8.2.2. Pregnancy 
Any female subjects that are pregnant or lactating at the time of vaccination must not 
receive additional doses of study vaccine/placebo but may continue other study 
procedures at the discretion of the investigator. 
While pregnancy itself is not considered an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be recorded as an AE or a 
SAE, as described in Section 8.1.1 and 8.1.2, and will be followed as described in Section 
8.4.4. 
A spontaneous abortion is always considered to be a SAE and will be reported as 
described in Section 8.4. Furthermore, any SAE occurring as a result of a post-study 
pregnancy AND considered by the investigator to be reasonably related in time to the 
receipt of the investigational product will be reported to GSK Biologicals as described in 
Section 8.4. While the investigator is not obligated to actively seek this information from 
former study participants, he/she may learn of a pregnancy through spontaneous 
reporting. 
Information on pregnancies identified during screening/prior to vaccine administration is 
not required to be collected and communicated to safety. 
8.3. Detecting and recording adverse events, serious adverse 
events and pregnancies 
8.3.1. Time period for detecting and recording adverse events, serious 
adverse events and pregnancies  
Solicited AEs will be evaluated only in subjects who are part of the 7-day diary card 
subset. Unsolicited AEs will be evaluated in all subjects from Day 0 to Day 29 after each 
vaccination. 
All AEs occurring from Day 0 to Day 29 after each vaccination must be recorded into the 
Adverse Event screen in the subject’s eCRF, irrespective of intensity or whether or not 
they are considered vaccination-related.  
SAEs will be evaluated in all subjects. The standard time period for collecting and 
recording SAEs will begin at Day 0 and continue until Month 14 for each subject. See 
Section 8.4 for instructions on reporting and recording SAEs. 
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In addition to the above-mentioned reporting requirements and in order to fulfil 
international reporting obligations, SAEs that are related to study participation (e.g. 
protocol-mandated procedures, invasive tests, a change from existing therapy) or are 
related to a concurrent GSK medication/vaccine or any fatal SAE will be collected and 
recorded from the time the subject consents to participate in the study until she/he is 
discharged. This is including SAEs that are considered by the investigator to be related 
to the investigational vaccine and are to be collected and recorded from the time of the 
first receipt of study vaccine/placebo until the subject is discharged from the 
study.(Amended 18 April 2014) 
pIMDs will be evaluated in all subjects during the entire study period (Section 8.3.2.5)  
Medically attended visits will be evaluated in all subjects from Day 0 until Month 8 
(Section 8.3.2.4). 
Intercurrent medical conditions (Section 6.7) will be recorded in all subjects throughout 
the entire study period.  
All HZ complications as defined in Section 5.5.2.5 (including AE/SAE information) will 
be reported throughout the entire study period. 
An overview of the protocol-required reporting periods for AEs and SAEs, pIMDs, 
medically attended visits, pregnancies, intercurrent medical conditions and HZ 
complications in study ZOSTER-006 is shown in Table 14. 
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Table 14 Reporting periods for AEs, SAEs, pIMDs, medically attended visits, pregnancies, intercurrent medical conditions 
and HZ complications in study ZOSTER-006 (Amended 18 April 2014) 
  CONTACT (monthly after Visit 3 until study conclusion, 
except at months that coincide with the subject’s 
scheduled visits) 
Study activity VISIT 1 
DOSE 1 
   VISIT 2 
DOSE 2 
  VISIT 3 CONTACT VISIT 4 VISIT 5 VISIT 6 Study 
conclusion 
contact 
Timing of reporting Day 0/ 
Month 0 
Day 6 
post 
Dose 1 
Day 29 
post 
Dose 1 
 Day 0/ 
Month 2 
Day 6 
post 
Dose 2 
Day 29 
post 
Dose 2 
Month 3 Month 8 Month 14 Month 26 Month 38  
Reporting of solicited AEs (only in 7-day 
diary card subset) 
             
             
             
Reporting of unsolicited AEs  
             
             
             
Reporting of all SAEs until Month 14 
             
             
             
Reporting of SAEs related to study 
participation or GSK concomitant 
medication/vaccine or any fatal SAE, 
including SAEs that are considered by the 
investigator to be related to the 
investigational vaccine, after Month 14 until 
study conclusion (Amended 18 April 2014) 
             
             
             
Reporting of pIMDs 
             
             
             
Reporting of medically attended visits until 
Month 8 
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  CONTACT (monthly after Visit 3 until study conclusion, 
except at months that coincide with the subject’s 
scheduled visits) 
Study activity VISIT 1 
DOSE 1 
   VISIT 2 
DOSE 2 
  VISIT 3 CONTACT VISIT 4 VISIT 5 VISIT 6 Study 
conclusion 
contact 
Timing of reporting Day 0/ 
Month 0 
Day 6 
post 
Dose 1 
Day 29 
post 
Dose 1 
 Day 0/ 
Month 2 
Day 6 
post 
Dose 2 
Day 29 
post 
Dose 2 
Month 3 Month 8 Month 14 Month 26 Month 38  
Reporting of pregnancies 
             
             
             
Recording of intercurrent medical conditions  
             
             
             
              
Recording of HZ Complications*  (including 
AE/SAE information) 
             
              
* HZ complications are defined in Section 5.5.2.5 
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A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
reporting period defined in Table 14. Investigators are not obligated to actively seek AEs 
or SAEs in former study participants. However, if the investigator learns of any SAE, 
including a death, at any time after a subject has been discharged from the study, and 
he/she considers the event reasonably related to the investigational product, the 
investigator will promptly notify the Study Contact for Reporting SAEs. 
8.3.2. Evaluation of adverse events and serious adverse events 
8.3.2.1. Active questioning to detect adverse events and serious adverse 
events 
As a consistent method of soliciting AEs, the subject should be asked a non-leading 
question such as: 
‘Have you felt different in any way since receiving the vaccine or since the previous 
visit?’  
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospital progress notes, laboratory, and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE on the eCRF or SAE Report screens as applicable. It is not acceptable for the 
investigator to send photocopies of the subject’s medical records to GSK Biologicals 
instead of the appropriate completed AE/SAE screens in the eCRF. However, there may 
be instances when copies of medical records for certain cases are requested by GSK 
Biologicals. In this instance, all subject identifiers will be blinded on the copies of the 
medical records prior to submission to GSK Biologicals. 
The investigator will attempt to establish a diagnosis pertaining to the event based on 
signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs/symptoms. 
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8.3.2.2. Assessment of adverse events 
8.3.2.2.1. Assessment of intensity 
Intensity of the following AEs will be assessed as described: 
Table 15 Intensity scales for solicited symptoms  
Adverse Event Intensity grade Parameter 
Pain at injection site 0 None 
 1 Mild: Any pain neither interfering with nor preventing 
normal every day activities. 
 2 Moderate: Painful when limb is moved and interferes with 
every day activities. 
 3 Severe: Significant pain at rest. Prevents normal every 
day activities. 
Redness at injection site Record greatest surface diameter in mm 
Swelling at injection site Record greatest surface diameter in mm 
Fever*  Record temperature in °C/°F 
Headache 0 Normal 
 1 Mild: Headache that is easily tolerated 
 2 Moderate: Headache that interferes with normal activity 
 3 Severe: Headache that prevents normal activity 
Fatigue 0 Normal 
 1 Mild: Fatigue that is easily tolerated 
 2 Moderate: Fatigue that interferes with normal activity 
 3 Severe: Fatigue that prevents normal activity 
Gastrointestinal symptoms 0 Gastrointestinal symptoms normal 
(nausea, vomiting, diarrhoea and/or 
abdominal pain) 
1 Mild: Gastrointestinal symptoms that are easily tolerated 
 2 Moderate: Gastrointestinal symptoms that interfere with 
normal activity 
 3 Severe: Gastrointestinal symptoms that prevent normal 
activity 
Myalgia 0 Normal  
 1 Mild: Myalgia that is easily tolerated 
 2 Moderate: Myalgia that interferes with normal activity 
 3 Severe: Myalgia that prevents normal activity 
Shivering 0 None 
1 Shivering that is easily tolerated 
2 Shivering that interferes with normal activity 
3 Shivering that prevents normal activity 
*Fever is defined as: rectal temperature ≥38°C (100.4°F)/axillary temperature ≥37.5°C (99.5°F)/oral temperature 
≥37.5°C (99.5°F)/tympanic temperature on oral setting ≥37.5°C (99.5°F)/tympanic temperature on rectal setting 
≥38°C (100.4°F).The preferred route for recording temperature in this study will be oral.  
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The maximum intensity of local injection site redness/swelling will be scored at GSK 
Biologicals using GSK Biologicals’ standard grading scale based on the US Food and 
Drug Administration (FDA) guidelines for Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers enrolled in Preventive Vaccine Clinical Trials” [FDA, 2007]. 
0 : < 20 mm diameter 
1 : ≥ 20 mm to ≤ 50 mm diameter 
2 : > 50 mm to ≤ 100 mm diameter 
3 : > 100 mm diameter 
Temperature (measured by oral, axillary or tympanic route) will be scored at GSK 
Biologicals as follows: 
0 : < 37.5°C  
1 : 37.5°C to 38.0°C  
2 : 38.1°C to 39.0°C 
3 : > 39.0°C 
The investigator will assess the maximum intensity that occurred over the duration of the 
event for all other AEs, i.e. unsolicited symptoms, including SAEs reported during the 
study. The assessment will be based on the investigator’s clinical judgement.  
The intensity of each AE and SAE recorded in the eCRF or SAE screens, as applicable, 
should be assigned to one of the following categories: 
1 (mild) = An AE which is easily tolerated by the subject, causing minimal 
discomfort and not interfering with everyday activities. 
2 (moderate) = An AE which is sufficiently discomforting to interfere with 
normal everyday activities. 
3 (severe) = An AE which prevents normal, everyday activities. Such an AE 
would, for example prevent attendance at work and would 
necessitate the administration of corrective therapy.  
An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. Grade 
3 is a category utilised for rating the intensity of an event; and both AEs and SAEs can 
be assessed as Grade 3. An event is defined as ‘serious’ when it meets one of the pre-
defined outcomes as described in Section 8.1.2. 
8.3.2.2.2. Assessment of causality 
The investigator is obligated to assess the relationship between investigational vaccine 
and the occurrence of each AE/SAE. The investigator will use clinical judgement to 
determine the relationship. Alternative plausible causes, based on natural history of the 
underlying diseases, concomitant therapy, other risk factors and the temporal relationship 
of the event to the investigational vaccine will be considered and investigated. The 
investigator will also consult the IB in the determination of his/her assessment. 
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There may be situations when a SAE has occurred and the investigator has minimal 
information to include in the initial report to GSK Biologicals. However, it is very 
important that the investigator always makes an assessment of causality for every event 
prior to submission of the SAE to GSK Biologicals. The investigator may change his/her 
opinion of causality in light of follow-up information, amending the SAE information 
accordingly. The causality assessment is one of the criteria used when determining 
regulatory reporting requirements. 
In case of concomitant administration of multiple vaccines, it may not be possible to 
determine the causal relationship of general AEs to the individual vaccines administered. 
The investigator should, therefore, assess whether the AE could be causally related to 
vaccination rather than to the individual vaccines. 
All solicited local (injection site) reactions will be considered causally related to 
vaccination. Causality of all other AEs should be assessed by the investigator using the 
following question: 
Is there a reasonable possibility that the AE may have been caused by the investigational 
vaccine? 
NO : The AE is not causally related to administration of the study 
vaccine(s). There are other, more likely causes and administration 
of the study vaccine(s) is not suspected to have contributed to the 
AE. 
YES : There is a reasonable possibility that the vaccine(s) contributed to 
the AE.  
Non-serious and serious AEs will be evaluated as two distinct events. If an event meets 
criteria to be determined ‘serious’ (Section 8.1.2 for definition of serious adverse event), 
additional examinations/tests will be performed by the investigator in order to determine 
ALL possible contributing factors applicable to each SAE. 
Possible contributing factors include: 
• Medical history. 
• Other medication. 
• Protocol required procedure. 
• Other procedure not required by the protocol. 
• Lack of efficacy of the vaccine, if applicable. 
• Erroneous administration. 
• Other cause (specify). 
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8.3.2.3. Assessment of outcomes 
Outcome of any non-serious AE (i.e. unsolicited AE) occurring from Day 0 to Day 29 
after each vaccination or any SAE reported during the entire study will be assessed as: 
• Recovered/resolved. 
• Not recovered/not resolved. 
• Recovering/resolving. 
• Recovered with sequelae/resolved with sequelae. 
• Fatal (SAEs only). 
8.3.2.4. Medically attended visits 
The subject will be asked if the subject received medical attention defined as 
hospitalization, an emergency room visit or a visit to or from medical personnel (medical 
doctor) for any reason, other than routine health care visits, from the first vaccination 
until Month 8, and this information will be recorded in the eCRF. 
8.3.2.5. AEs of specific interest  
Potential immune-mediated diseases (pIMDs) (formerly referred to as NOADs and other 
immune mediated inflammatory disorders) are a subset of AEs that include autoimmune 
diseases and other inflammatory and/or neurologic disorders of interest which may or 
may not have an autoimmune aetiology. AEs that need to be recorded and reported as 
pIMDs include those listed in the table below. 
However, the investigator will exercise his/her medical and scientific judgement in 
deciding whether other immune-mediated diseases have an autoimmune origin (i.e. 
pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and 
should also be recorded as a pIMD. 
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Table 16 List of Potential immune-mediated diseases 
Neuroinflammatory disorders Musculoskeletal disorders Skin disorders 
Cranial nerve disorders, including 
paralyses/paresis (e.g. Bell’s palsy), 
and neuritis (e.g. optic neuritis) 
Multiple sclerosis (including 
variants) 
Transverse myelitis 
Guillain-Barré syndrome, (including 
Miller Fisher syndrome and other 
variants) 
Other demyelinating diseases 
(including acute disseminated 
encephalomyelitis) 
Myasthenia gravis (including 
Lambert-Eaton myasthenic 
syndrome)  
Non-infectious encephalitis/ 
encephalomyelitis  
Neuritis (including peripheral 
neuropathies) 
Narcolepsy 
Systemic lupus erythematosus  
Scleroderma (including, CREST 
syndrome and morphoea) 
Systemic sclerosis 
Dermatomyositis  
Polymyositis  
Antisynthetase syndrome 
Rheumatoid arthritis,  
Juvenile chronic arthritis, (including 
Still’s disease) 
Polymyalgia rheumatica  
Reactive arthritis 
Psoriatic arthropathy 
Ankylosing spondylitis 
Relapsing polychondritis 
Mixed connective tissue disorder 
Psoriasis 
Vitiligo 
Raynaud’s phenomenon 
Erythema nodosum 
Autoimmune bullous skin diseases 
(including pemphigus, pemphigoid 
and dermatitis herpetiformis) 
Cutaneous lupus erythematosus 
Alopecia areata 
Lichen planus 
Sweet’s syndrome 
Liver disorders Gastrointestinal disorders Metabolic diseases 
Autoimmune hepatitis 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Autoimmune cholangitis. 
Crohn’s disease  
Ulcerative colitis  
Ulcerative proctitis  
Celiac disease 
Autoimmune thyroiditis (including 
Hashimoto thyroiditis) 
Grave's or Basedow’s disease 
Diabetes mellitus type I 
Addison’s disease 
Vasculitides Others 
Large vessels vasculitis including: giant cell arteritis 
such as Takayasu's arteritis and temporal arteritis.  
Medium sized and/or small vessels vasculitis including: 
polyarteritis nodosa, Kawasaki's disease, microscopic 
polyangiitis, Wegener's granulomatosis, Churg–Strauss 
syndrome, thromboangiitis obliterans (Buerger’s 
disease), necrotizing vasculitis, allergic granulomatous 
angiitis, Henoch-Schonlein purpura, anti-neutrophil 
cytoplasmic antibody positive vasculitis, Behcet's 
syndrome, leukocytoclastic vasculitis.  
Vasculitides secondary to other immune mediated 
diseases such as lupus vasculitis and rheumatoid 
vasculitis. 
Autoimmune hemolytic anemia 
Autoimmune thrombocytopenias 
Antiphospholipid syndrome 
Pernicious anemia 
Autoimmune glomerulonephritis (including IgA 
nephropathy, glomerulonephritis rapidly progressive, 
membranous glomerulonephritis, membranoproliferative 
glomerulonephritis, and mesangioproliferative 
glomerulonephritis) 
Uveitis 
Autoimmune myocarditis/cardiomyopathy 
Sarcoidosis 
Stevens-johnson syndrome 
Sjögren’s syndrome 
Idiopathic pulmonary fibrosis 
Goodpasture syndrome 
 
When there is enough evidence to make any of the above diagnoses, the AE must be 
reported as a pIMD. Symptoms, signs or conditions which might (or might not) represent 
the above diagnoses, should be recorded and reported as AEs but not as pIMDs until the 
final or definitive diagnosis has been determined, and alternative diagnoses have been 
eliminated or shown to be less likely. 
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In order to facilitate the documentation of pIMDs in the eCRF a pIMD standard 
questionnaire and a list of preferred terms (PTs) and PT codes corresponding to the above 
diagnoses will be available to investigators. 
pIMDs that occur during the study (see also Section 8.3.1 for reporting period) will be 
reported promptly to GSK within the timeframes described in Table 17, once the 
investigator becomes aware of the pIMD. 
Once onset of a new pIMD or exacerbation of a pre-existing pIMD is diagnosed (serious 
or non-serious) in a study subject, the investigator (or designate) must complete the 
information in the SAE screens of the eCRF WITHIN 24 HOURS after the he/she 
becomes aware of the diagnosis. A field on the SAE screen allows to specify that the 
event is a pIMD and whether it is serious or non serious. The SAE screens will always be 
completed as thoroughly as possible with all available details of the event, in accordance 
with the pIMD standard questionnaire provided. Even if the investigator does not have all 
information regarding a pIMD, the SAE screens should still be completed within 24 
hours. Once additional relevant information is received, the SAE screens in the eCRF 
should be updated WITHIN 24 HOURS. 
The investigator will always provide an assessment of causality at the time of the initial 
report. 
Refer to Section 8.4.3 for back-up system and updating of SAE information after freezing 
of the subject’s eCRF. 
8.4. Reporting and follow-up of adverse events, serious adverse 
events and pregnancies 
8.4.1. Prompt reporting of serious adverse events and other events to 
GSK Biologicals  
SAEs will be reported promptly to GSK as described in Table 17 once the investigator 
determines that the event meets the protocol definition of an SAE. 
Pregnancies will be reported promptly to GSK as described in Table 17 once the 
investigator becomes aware of a pregnancy in the time period defined in Section 8.3. The 
subject will be followed to determine the outcome of the pregnancy. At the end of the 
pregnancy, whether that be full-term or premature, information on the status of the 
mother and child will be forwarded to GSK. Generally, follow-up should be no longer 
than 6 to 8 weeks following the estimated delivery date. 
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Table 17 Time frames for submitting SAEs and other events reports to GSK 
Biologicals 
 Initial Reports Follow-up Information 
on a Previous Report 
Type of 
Event 
Time Frame Documents Time Frame Documents 
All SAEs 24 hours* SAE screen 24 hours* SAE screen 
Pregnancy 24 hours* Pregnancy Report Form 24 hours* Pregnancy Report Form 
pIMDs 24 hours** SAE screen  24 hours** SAE screen 
* Time frame allowed after receipt or awareness of the information. 
**Timeframe allowed after the diagnosis is established and known to the investigator 
 
In case the electronic reporting system is temporarily unavailable, a back up system is in 
place. Please refer to Section 8.4.3 for a detailed description. 
Please see the Sponsor Information Sheet for details on study contact for reporting SAEs.  
Back-up Study Contact for Reporting SAEs 
 
GSK Biologicals Clinical Safety & Pharmacovigilance 
Fax:  or  
24/24 hour and 7/7 day availability
 
8.4.2. Regulatory reporting requirements for serious adverse events 
The investigator will promptly report all SAEs to GSK in accordance with the procedures 
detailed in Section 8.4.1. GSK Biologicals has a legal responsibility to promptly notify, 
as appropriate, both the local regulatory authority and other regulatory agencies about the 
safety of a product under clinical investigation. Prompt notification of SAEs by the 
investigator to the Study Contact for Reporting SAEs is essential so that legal obligations 
and ethical responsibilities towards the safety of other subjects are met. 
Investigator safety reports are prepared according to the current GSK policy and are 
forwarded to investigators as necessary. An investigator safety report is prepared for a 
SAE(s) that is both attributable to the investigational product and unexpected. The 
purpose of the report is to fulfil specific regulatory and Good Clinical Practice (GCP) 
requirements, regarding the product under investigation. 
8.4.3. Completion and transmission of SAEs reports to GSK Biologicals 
Once an investigator becomes aware that a SAE has occurred in a study subject, the 
investigator will complete and submit the information in the SAE screens in eCRF within 
24 hours. The SAE screens in eCRF will always be completed as thoroughly as possible 
with all available details of the event and will be submitted by the investigator. If the 
investigator does not have all information regarding an SAE, he/she will not wait to 
receive additional information before notifying GSK of the event and completing the 
SAE screens in eCRF. The SAE screens in eCRF should be updated when additional 
relevant information is received WITHIN 24 HOURS. 
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The investigator will always provide an assessment of causality at the time of the initial 
report. 
8.4.3.1. Back-up system in case the electronic SAE reporting system does not 
work 
If the SAE reporting system has been down for 24 hours, the investigator or his/her 
delegate should fax an SAE report form directly to the GSK Central Safety department 
(please refer to Section 8.4.1) within 24 hours. The maximum timeline for reporting 
SAEs to central safety is therefore 48 hours.  
NB. This back-up system should only be used if the electronic reporting system is not 
working and NOT if the system is slow. 
As soon as the electronic reporting system is working again, the investigator or delegate 
must update the SAE screens in the eCRF within 24 hours.  
The final valid information for regulatory reporting will be the information reported 
through the electronic system.  
When additional information is received on a SAE after freezing of the subject’s eCRF, 
new or updated information is to be recorded on the paper SAE Report Form, with all 
changes signed and dated by the investigator. The updated SAE Report Form should be 
sent to GSK Biologicals WITHIN 24 HOURS of receipt of the follow-up information. 
In rare circumstances, if the electronic system for reporting SAEs does not work and in 
the absence of facsimile equipment, notification by telephone is acceptable, with a copy 
of the SAE Report Form sent by email or by mail. Initial notification via the telephone 
does not replace the need for the investigator to complete and submit SAE screens in the 
eCRF (or complete and sign the SAE Report Form if back-up system need to be used). 
In the event of a death determined by the investigator to be related to vaccination, 
completion of SAE screens in the eCRF/sending of the fax (if electronic SAE reporting 
system does not work or after freezing of the subject’s eCRF) must be accompanied by 
telephone call to the Study Contact for Reporting SAEs. 
8.4.4. Follow-up of adverse events and serious adverse events 
After the initial AE/SAE report, the investigator is required to proactively follow each 
subject and provide further information to GSK Biologicals on the subject’s condition. 
All SAEs documented at a previous visit/contact and designated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until study 
conclusion. 
All AEs documented at a previous visit/contact and designated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until 30 
days after the last vaccination. 
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Cases of new onset of autoimmune diseases and other immune-mediated inflammatory 
disorders documented at a previous visit/contact and designated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until study 
conclusion.  
Investigators will follow-up subjects: 
• With SAEs or subjects withdrawn from the study as a result of an AE, until the event 
has resolved, subsided, stabilised, disappeared, or until the event is otherwise 
explained, or the subject is lost to follow-up.  
• Or, in the case of other non-serious AEs, cases of new onset of autoimmune diseases, 
until study conclusion or they are lost to follow-up. 
Clinically significant laboratory abnormalities will be followed up until they have 
returned to normal, or a satisfactory explanation has been provided. Additional 
information (including but not limited to laboratory results) relative to the subsequent 
course of such abnormalities noted for any subject must be made available to the Site 
Monitor. 
GSK Biologicals may request that the investigator perform or arrange for the conduct of 
additional clinical examinations/tests and/or evaluations to elucidate as fully as possible 
the nature and/or causality of the AE or SAE. The investigator is obliged to assist. If a 
subject dies during participation in the study or during a recognised follow-up period, 
GSK Biologicals will be provided with a copy of any available post-mortem findings, 
including histopathology. 
8.5. Treatment of adverse events 
Treatment of any adverse event is at the sole discretion of the investigator and according 
to current good medical practice. Any medication administered for the treatment of an 
AE should be recorded in the subject’s eCRF. Refer to Section 6.6. 
8.6. Unblinding 
GSK Biologicals’ policy (incorporating ICH E2A guidance, EU Clinical Trial Directive 
and Federal Regulations) is to unblind any serious adverse event (SAE) report associated 
with the use of the investigational product, which is unexpected and 
attributable/suspected, prior to regulatory reporting. The GSK Biologicals’ Central Safety 
physician is responsible for unblinding the treatment assignment in accordance with 
specified time frames for expedited reporting of SAEs (refer to Section 8.4.1). 
8.7. Emergency unblinding  
Unblinding of a subject’s individual treatment code should occur only in the case of a 
medical emergency, or in the event of a serious medical condition, when knowledge of 
the study treatment is essential for the clinical management or welfare of the subject, as 
judged by the investigator. 
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The emergency unblinding process consists of the automated system (SBIR) that allows 
the investigator to have unrestricted, immediate and direct access to the subject’s 
individual study treatment. 
The investigator has the option of contacting a GSK Biologicals’ On-call Central Safety 
Physician (or Backup) if he/she needs medical advice or needs the support of GSK to 
perform the unblinding (i.e. he/she cannot access the automated Internet-based system). 
Any emergency unblinding must be fully documented by using the Emergency 
Unblinding Documentation Form, which must be appropriately completed by the 
investigator and sent within 24 hours to GSK Biologicals. 
GSK Biologicals’ Contact information for Emergency Unblinding 
24/24 hour and 7/7 day availability 
GSK Biologicals’ Central Safety Physician: 
Outside US/Canada: 
 (GSK Biologicals Central Safety Physician on-call) 
US/Canada only: 
 (GSK Biologicals Central Safety Physician on-call) 
GSK Biologicals’ Central Safety Physician Back-up: 
Outside US/Canada: 
 
US/Canada only: 
 
Emergency Unblinding Documentation Form transmission: 
Outside US & Canada: 
Fax:  or  
US/Canada only: 
Fax:  
8.8. Subject card 
Study subjects must be provided with the address and telephone number of the main 
contact for information about the trial. 
Investigator/delegate should therefore provide a “subject card” to each subject. The aim 
of this card is to inform any physician having to deal with a subject in an emergency 
situation that the subject is in a clinical trial and that he/she can contact the trial 
investigator for more relevant information. 
Subjects must be instructed to keep these cards in their possession at all times. 
9. SUBJECT COMPLETION AND WITHDRAWAL 
9.1. Subject completion 
A subject who returns for the concluding visit/is available for the concluding contact 
foreseen in the protocol is considered to have completed the study. 
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9.2. Subject withdrawal 
Subjects who are withdrawn because of SAEs/AEs must be clearly distinguished from 
subjects who are withdrawn for other reasons. Investigators will follow subjects who are 
withdrawn as result of a SAE/AE until resolution of the event (Section 8.4). 
Withdrawals will not be replaced. 
9.2.1. Subject withdrawal from the study 
From an analysis perspective, a ‘withdrawal’ from the study refers to any subject who did 
not come back for the concluding visit/was not available for the concluding contact 
foreseen in the protocol.  
All data collected until the date of withdrawal/last contact of the subject will be used for 
the analysis. 
A subject is considered a ‘withdrawal’ from the study when no study procedure has 
occurred, no follow-up has been performed and no further information has been collected 
for this subject from the date of withdrawal/last contact. 
Investigators will make an attempt to contact those subjects who do not return for 
scheduled visits or follow-up.  
Information relative to the withdrawal will be documented in the eCRF. The investigator 
will document whether the decision to withdraw a subject from the study was made by 
the subject himself/herself, or by the investigator, as well as which of the following 
possible reasons was responsible for withdrawal: 
• Serious adverse event. 
• Non-serious adverse event. 
• Protocol violation (specify). 
• Consent withdrawal, not due to an adverse event. 
• Moved from the study area. 
• Lost to follow-up. 
• Death. 
• Unblinding upon the subject’s request to allow the subject to decide if he/she will 
consider immunization with a licensed HZ vaccine. 
(Amended 18 April 2014) 
• Other (specify). 
9.2.2. Subject withdrawal from investigational vaccine 
A ‘withdrawal’ from the investigational vaccine refers to any subject who does not 
receive the complete treatment, i.e. when no further planned dose is administered from 
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the date of withdrawal. A subject withdrawn from the investigational vaccine may not 
necessarily be withdrawn from the study as further study procedures or follow-up may be 
performed (safety or immunogenicity) if planned in the study protocol.  
Information relative to premature discontinuation of the investigational vaccine will be 
documented on the Vaccine Administration screen of the eCRF. The investigator will 
document whether the decision to discontinue further vaccination/treatment was made by 
the subject himself/herself, or by the investigator, as well as which of the following 
possible reasons was responsible for withdrawal: 
• Serious adverse event. 
• Non-serious adverse event. 
• Other (specify). 
10. DATA EVALUATION: CRITERIA FOR EVALUATION OF 
OBJECTIVES 
10.1. Primary endpoint 
• Confirmed HZ cases 
− Confirmed HZ cases during the study in the modified total vaccinated cohort 
(mTVc). 
10.2. Secondary endpoints 
• Occurrence of overall PHN  
− Incidence of PHN calculated using the mTVc; 
• Duration of severe ‘worst’ HZ-associated pain 
− Duration of severe ‘worst’ HZ-associated pain following the onset of a 
confirmed HZ rash over the entire pain reporting period as measured by the 
ZBPI in subjects with confirmed HZ; 
• Incidence of overall and HZ-related mortality 
− Incidence of overall and HZ-related mortality during the study; 
• Incidence of HZ complications 
− Incidence of HZ complications during the study in subjects with confirmed HZ; 
• Incidence of overall and HZ-related hospitalizations 
− Incidence of overall and HZ-related hospitalizations during the study; 
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• Duration of pain medication administered for HZ 
− Duration of pain medication administered for HZ during the study in subjects 
with confirmed HZ; 
• Solicited local and general symptoms in a subset of subjects 
− Occurrence, intensity of each solicited local symptom within 7 days (Days 0 − 
6) after each vaccination, in subjects included in the 7-day diary card subset; 
− Occurrence, intensity and relationship to vaccination of each solicited general 
symptom within 7 days (Days 0 − 6) after each vaccination, in subjects included 
in the 7-day diary card subset; 
• Unsolicited AEs  
− Occurrence, intensity and relationship to vaccination of unsolicited AEs during 
30 days (Days 0 − 29) after each vaccination, according to the Medical 
Dictionary for Regulatory Activities (MedDRA) classification, in all subjects; 
• Serious AEs 
− Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 
14 in all subjects; 
− Occurrence of SAEs related to study participation or to a concurrent GSK 
medication/vaccine during the entire study period in all subjects; 
− Occurrence of any fatal SAEs during the entire study period in all subjects; 
• Occurrence of pre-defined AEs 
− Occurrence and relationship to vaccination of any pIMDs during the entire study 
period in all subjects;  
• Occurrence of medically attended visits 
− Occurrence and relationship to vaccination of medically attended visits (defined 
as hospitalizations, emergency room visits or visits to or from medical 
personnel), other than routine health care visits, from Month 0 to Month 8 in all 
subjects. 
10.3. Exploratory endpoints 
• Acute HZ severity 
− Acute HZ severity as determined by the mean Area Under Curve (AUC) of the 
severity-by-duration of HZ-associated pain as measured by the ZBPI during a 4-
week period following the onset of confirmed HZ in subjects with confirmed 
HZ; 
• Interference of HZ with QoL 
− Interference of HZ with QoL as measured by ZBPI in subjects with confirmed 
HZ; 
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− Interference of HZ with QoL as measured by EQ-5D in subjects with confirmed 
HZ; 
− Interference of HZ with QoL as measured by SF-36 in subjects with confirmed 
HZ; 
• HZ BOI 
− HZ BOI as determined by the mean AUC of the severity-by-duration HZ-
associated pain during a 26 week period following the onset of the HZ rash in 
the mTVc; 
• CMI in terms of frequencies of antigen-specific CD4 T cells at Months 0, 3, 14, 26  
and 38  
− Frequencies of CD4 T cells with antigen-specific Interferon gamma (IFN-γ) 
and/or Interleukin-2 (IL-2) and/or Tumour Necrosis Factor alpha (TNF-α) 
and/or CD40 Ligand (CD40L) secretion/expression to gE and VZV as 
determined by ICS in a subset of subjects at Months 0, 3, 14, 26  and 38; 
• Antigen-specific Ab concentrations at Months 0, 3, 14, 26  and 38  
− Anti-gE and anti-VZV Ab concentrations as determined by ELISA, in a subset 
of subjects at Months 0, 3, 14, 26 and 38; 
• Anti-VZV neutralizing Ab titres at Months 0, 3, 14, 26 and 38 
− Anti-VZV neutralizing Ab titres as determined by the neutralization assay in a 
subset of subjects at Months 0, 3, 14, 26 and 38 
10.4. Estimated sample size 
10.4.1. Sample size assumptions 
Table 18 presents the assumptions used for the sample size calculations for both studies 
ZOSTER -006 and ZOSTER-022. Simulations were performed to estimate the sample 
size required as a consequence of unequal VE estimates by age strata. A drop-out rate of 
5% per year and an incidence of 5% for non-compliance to vaccine schedule were taken 
into account for sample size calculations. 
Table 18 Assumptions for incidences under placebo, and VE used for trial 
simulations  
Age 
HZ Incidence 
(% / Year) HZ VE 
PHN Incidence 
in HZ subjects 
(% /Year) 
On top PHN 
VE in HZ 
subjects (2) 
Overall PHN 
VE 
Overall(1) ~0.7 ~68% ~11% NA ~71% 
50-59 0.5 82% 5% 5% 83% 
60-69 0.8 72% 9.5% 5% 73% 
70-79 1.1 58% 17% 35% 73% 
≥80 1.1 36% 28% 25% 52% 
≥70 (1) 1.1 ~53% ~19% NA ~71% 
1 The overall HZ incidence and the incidence in the ≥ 70YOA age strata depends on the age-stratification considered 
2 VE against PHN in people with HZ, i.e., a comparison of VE between placebo recipients with HZ who got PHN versus 
vaccine recipients with HZ who got PHN. 
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10.4.2. Significance level 
The overall efficacy analyses will be performed at the 5% 2-sided significance level. No 
significance adjustment is planned in ZOSTER-006 or ZOSTER-022 for the efficacy 
analyses due to the futility analyses, since GSK has no current intention to submit the 
data to Regulatory Authorities for registration. 
The scope of the statistical testing of ZOSTER-006, ZOSTER-022 and the pooling of the 
data from both studies are described in Section 10.4.4 and summarised in Table 19. The 
pooled analysis of studies ZOSTER-006 and ZOSTER-022 is planned provided the 
following conditions are met, as defined in Section 10.4.4: 
1. Clinically meaningful overall HZ VE in subjects ≥ 50 YOA is reached in 
ZOSTER-006; 
2. Clinically meaningful HZ VE is reached in subjects ≥ 70 YOA in ZOSTER-
022. 
(Amended 18 April 2014) 
The pooled analysis of data in subjects ≥ 50 YOA accrued in study ZOSTER-006 and 
data in subjects ≥ 70 YOA collected in study ZOSTER-022 allows for the estimation of 
overall PHN VE (subjects ≥ 50 YOA), PHN VE in subjects ≥ 70 YOA and a more robust 
estimation of HZ VE in subjects ≥ 70 YOA (as HZ VE in subjects ≥ 70 YOA will be 
assessed in study ZOSTER-022). (Amended 18 April 2014) An estimation of the 
confidence interval (CI), based on pooled data will be provided in addition. The statistical 
evaluation of the other objectives of the pooled analysis, including the overall PHN VE 
primary objective and the PHN VE in subjects with HZ secondary objective, will only be 
performed on the pooled data from both studies. According to these restrictions in the 
testing sequence, the type 1 error is maintained at 2.5% (1-sided). Each statistical 
evaluation in the pooled analysis is either preceded by an evaluation in ZOSTER-006, 
ZOSTER-022, or both; or is only performed on the pooled database during the pooled 
analysis. As a consequence, there is no increase in the significance level of each objective 
due to a possible multiple testing problem. 
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Table 19 Summary of statistical inferential evaluations of primary and 
secondary objectives for studies ZOSTER-006, ZOSTER-022 and the 
pooled analysis (Amended 18 April 2014) 
Analysis Endpoint 50-59 YOA 60-69 YOA ≥70 YOA All age strata 
ZOSTER-006 HZ VE S S O P 
 PHN VE - - - - 
 PHN VE in HZ subjects - - - - 
ZOSTER-022 HZ VE - - P - 
 PHN VE - - -  - 
 PHN VE in HZ subjects - - - - 
Pooled analysis HZ VE - - R - 
 PHN VE - - P S 
 PHN VE in HZ subjects - - - S* 
P: Primary objective, well powered 
R: Re-estimation of VE for an objective already demonstrated previously in ZOSTER-006 or ZOSTER-022. 
S: Secondary objective, appropriately powered 
S*: Secondary objective, low power 
O: Study not well powered under current assumptions although may lead to significance 
- : Estimates not relevant or not considered for a statistical evaluation 
10.4.3. Success criteria 
The ZOSTER-006 study is designed to demonstrate clinically meaningful overall HZ VE 
in subjects of ≥ 50 YOA. Clinically meaningful overall HZ VE will be demonstrated if 
the lower limit of the 95% CI is above 25%; however, the study has been powered for the 
more robust lower limit of 40%. That primary analysis will be supported by sensitivity 
analyses of the HZ VE in the 50-59 YOA and 60-69 YOA strata. Clinically meaningful 
HZ VE by age strata will be demonstrated if the lower limit of the 95% CI is above 10%. 
The ZOSTER-006 study is not powered to demonstrate significant HZ VE within the ≥ 
70 YOA stratum. That objective is not within the scope of this study and is deferred to 
the analysis of ZOSTER-022 study data.  
The ZOSTER-022 study is designed to demonstrate clinically meaningful HZ VE in 
subjects ≥ 70 YOA. Clinically meaningful HZ VE will be demonstrated in that age range 
if the lower limit of the 95% CI is above 10%. The pooled analysis of the ZOSTER-006 
and ZOSTER-022 studies is powered to demonstrate statistically significant PHN VE in 
subjects ≥ 70 YOA. Statistical significance of PHN VE in ≥ 70 YOA randomized subjects 
will be demonstrated if the lower limit of the 95% CI is above 0%. The PHN VE co-
primary objective of the pooled ZOSTER-006 and ZOSTER-022 studies will be tested 
provided the primary HZ VE is demonstrated in each study and no adjustment of 
significance level will be made. (Amended 18 April 2014) 
Both studies ZOSTER-006 and ZOSTER-022 will be performed in parallel, in similar 
centres and using essentially identical study designs (aside from the age distribution of 
the enrolled population). The pooled analysis of those 2 studies is therefore deemed 
acceptable and will provide additional precision in estimating VE. Homogeneity of 
relative risk between the 2 studies will be demonstrated. The primary analysis to 
demonstrate efficacy for overall PHN in subjects ≥ 70 YOA will be performed on the 
pooled studies ZOSTER-006 and ZOSTER-022.  In addition, the pooled analysis of 
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studies ZOSTER-006 and ZOSTER-022 is intended to provide consolidated estimations 
of the clinically meaningful HZ VE in all subjects ≥ 70 YOA in mTVc subjects 
randomized to studies ZOSTER-006 and ZOSTER-022. Clinically meaningful HZ VE in 
subjects ≥ 70 YOA will be demonstrated if the lower limit of the 95% CI is above 10% 
and clinically meaningful overall PHN VE in all subjects ≥ 70 YOA will be demonstrated 
if the lower limit of the 95% CI is above 0%. (Amended 18 April 2014) 
10.4.4. Gatekeeping strategy 
The statistical testing for each study will proceed sequentially using an order for the 
gatekeeping families defined prospectively (see below). If more than one test is involved 
within the same family, the Hochberg’s set up method [Hochberg, 1988] will be used to 
adjust the p-values for the multiple test schemes. All secondary objectives mentioned in 
protocols ZOSTER-006 and ZOSTER-022 will be evaluated within each report. 
However, the overall type 1 error of 5% two-sided can only be fully controlled for those 
objectives that are mentioned sequentially in the gatekeeping strategy presented below. If 
a gatekeeping family fails to be demonstrated, the remaining planned tests will be 
performed, but the type 1 error of the following families may not be fully controlled.  
The enrolment of subjects ≥ 70 YOA in both studies and the need to provide an 
estimation of the HZ VE and PHN VE across the two studies, requires the gatekeeping 
strategy to be defined across the two studies and the pooling (see Figure 1) (Amended 
18 April 2014). The following pathway is proposed and will be confirmed prior to 
unblinding of the treatment assignment. 
The primary objective of ZOSTER-006 and the primary objective of ZOSTER-022 
should be demonstrated prior to testing the primary objective of the pooling. Sensitivity 
analyses will be performed by age strata for each of the primary objectives. (Amended 
18 April 2014) 
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Figure 1 Gatekeeping strategy (Amended 18 April 2014) 
Zoster-006
Sensitivity Primary
Zoster-022
SensitivityPrimary
Demonstrate statistically 
significant VE against HZ in 
subjects ≥50 YOA
Demonstrate statistically 
significant VE against HZ 
in subjects ≥70 YOA
Demonstrate statistical 
significance of VE against 
HZ in subjects 50-59 YOA 
and subjects 60-69 YOA
Demonstrate statistically 
significant VE against HZ in 
subjects 70-79 YOA and 
≥80 YOA
Re-estimation Primary Sensitivity
VE estimates against HZ  in 
subjects ≥70 YOA and 
confidence intervals
VE estimates against HZ  
in subjects 70-79 YOA 
and ≥80 YOA and 
confidence intervals
Demonstrate statistically significant VE 
against PHN  in subjects ≥70 YOA
Demonstrate statistically significant 
reduction of duration of pain 
following HZ in subjects with HZ
(in subjects ≥ 70 YOA)
Demonstrate statistically significant 
VE against PHN  in subjects with HZ
(in subjects ≥ 50 YOA)
Pooling
Secondary
Demonstrate statistically 
significant VE against PHN  
in subjects ≥50 YOA
 
The primary objectives of the pooling include the re-estimation of HZ VE in subjects ≥ 
70 YOA and estimation of PHN VE in subjects ≥ 70 YOA. The HZ VE is planned to be 
already demonstrated in ZOSTER-022 and the pooled PHN VE will be the primary 
analysis of PHN; as a consequence, they do not affect the overall type 1 error and are 
not considered within the main path of the gatekeeping strategy.  
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The first hypothesis to be tested from the pooled dataset consists in the overall PHN VE 
in subjects ≥ 70 YOA. Further secondary objectives are then sequentially tested 
following demonstration of overall PHN VE in subjects ≥ 70 YOA.    
1. Demonstrate statistically significant reduction in incidence of  PHN (90 days or 
more) in subjects ≥ 50 YOA  
2. Demonstrate statistically significant reduction in incidence of  PHN (90 days or 
more) in subjects with HZ (in subjects ≥ 50 YOA) 
3. Demonstrate statistically significant reduction of duration of severe ‘worst’ pain 
following HZ in subjects with HZ (in subjects ≥ 70 YOA).  
(Amended 18 April 2014) 
10.4.5. Sample sizes 
The sections below describe the estimated number of subjects required to achieve the 
objectives of studies ZOSTER-006, ZOSTER-022 and the pooling of data from both 
studies. The provisional country allocation and various subsets are also described. For 
operational reasons, the same subjects may be randomized to the more than one subset. 
10.4.5.1. Primary objective  
The final HZ efficacy analysis of the ZOSTER-006 study is planned after the 
accumulation of at least 196 confirmed HZ cases across all age strata (primary condition) 
in the primary cohort for efficacy. (Amended 18 April 2014) Other conditions for 
triggering the analyses are described in Section 10.4.5.6. It is estimated that 196 
confirmed HZ cases would provide ~97% power to demonstrate an overall HZ VE of at 
least 40% assuming a true HZ VE of 68% (including essential sensitivity analyses in 50-
59 and 60-69 YOA strata). Table 20 presents the sample sizes overall and according to 
the age-stratification ratio 8:5:3:1 (50-59, 60-69, 70-79 and ≥ 80 YOA) using a 
randomization ratio 1:1 for vaccine or placebo. The sample size was selected in order to 
provide the required number of HZ cases within a follow-up time of ~3 years. The 
stratification ratios were selected in order to achieve similar numbers of HZ cases in the 
three main age strata. If large disparities in the total number of HZ cases (placebo and 
vaccine groups combined) are observed during the trial between the age strata, sample 
size reassessment or modification of the stratification ratios may be considered.  
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Table 20 Expected number of HZ and PHN cases in ZOSTER-006 (Amended 
18 April 2014) 
Age strata Sample 
size 
Median number of 
HZ cases 
Median number of 
PHN cases (initial 
assumptions) 
Expected number of PHN cases 
(projection based on current 
accrual rates) 
  Placebo All Placebo All Placebo All 
50-59 YOA 7520 48 57 3 3 4 5 
60-69 YOA 4700 48 62 4 6 5 7 
70-79 YOA 2820 40 56 6 8 4 5 
≥ 80 YOA 940 13 22 4 5 1 2 
All 15980 149 196 17 23 14 19 
Median number of cases calculated based on 1000 trial simulations.  
 
The final HZ efficacy analysis of the ZOSTER-022 study is planned after the 
accumulation of at least 278 confirmed HZ cases (expected median number of cases is 
310 HZ cases) across both 70-79 YOA (expected median of 222 HZ cases) and ≥ 80 
YOA (expected median of 87 HZ cases) strata. All HZ cases should be accrued in the 
primary cohort for efficacy. (Amended 18 April 2014) Other conditions for triggering 
the analyses are described in Section 10.4.5.6. This number of HZ cases would provide 
~99% power to demonstrate HZ VE of at least 10% under the assumptions described 
above in subjects ≥ 70 YOA.  
The end of study analyses of the ZOSTER-006 and the ZOSTER-022 studies are 
planned after the accumulation at least 35 PHN cases in subjects ≥ 70 YOA in the 
pooled ZOSTER-006 and ZOSTER-022.  All PHN cases should be accrued in the 
primary cohort for efficacy. Other conditions for triggering the analyses are described 
in Section 10.4.5.6. This number of PHN cases would provide ~90% power to 
demonstrate PHN VE with Lower Limit (LL) above 0%. (Amended 18 April 2014) 
 Table 21 presents the sample sizes overall and according to the age-stratification ratio 
3:1 (70-79 and ≥ 80 YOA) and a randomization ratio 1:1. The sample size was selected in 
order to provide the required number of HZ cases within a follow-up time of ~3 years. If 
the accrual rate of HZ or PHN cases is much lower than expected, a blinded sample size 
reassessment may be considered for which the details would be available prior to the first 
interim analysis. 
Table 21 Expected number of HZ and PHN cases in ZOSTER-022 (Amended 
18 April 2014) 
Age strata Sample 
size 
Median number of 
HZ cases 
Median number of 
PHN cases 
(initial assumptions) 
Expected number of PHN cases 
(projection based on current 
accrual rates) 
  Placebo All Placebo All Placebo All 
70-79 YOA 10884 157 222 32 40 15 20 
≥ 80 YOA 3628 54 87 17 26 5 8 
All 14512 210 310 49 65 20 28 
Median number of cases calculated based on 1000 trial simulations.  
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The number of HZ cases, PHN cases and the total sample size for each age strata for the 
pooled analysis are driven by the number of the cases and sample size in both the 
ZOSTER-006 and ZOSTER-022 studies (see Table 22). The total number of PHN cases 
and the number of PHN cases in subjects ≥ 70 YOA that each study (ZOSTER-006 and 
ZOSTER-022) will contribute to the pooled analysis may vary from what has been 
described above. It is estimated however that the total number of PHN cases in ≥ 50 
YOA subjects is approximately 47, among which at least ~35 PHN cases would be 
accrued in the ≥ 70 YOA age strata. A total of at least 35 PHN cases provide 90% power 
to demonstrate in subjects ≥ 70 YOA an overall PHN VE of at least 0%. (Amended 18 
April 2014) 
Table 22 Expected number of HZ and PHN cases in pooled ZOSTER-006 and 
ZOSTER-022 (Amended 18 April 2014) 
Age strata Sample 
size 
Median number of HZ 
cases 
Median number of 
PHN cases 
(initial assumptions) 
Expected number of PHN cases 
(projection based on current 
accrual rates) 
  Placebo All Placebo All Placebo All 
50-59 YOA 7520 48 57 2 3 4 5 
60-69 YOA 4700 48 61 4 6 5 7 
70-79 YOA 13704 196 278 32 48 19 25 
≥ 80 YOA  4568 57 110 17 31 6 10 
All 30492 360 506 57 88 34 47 
Median number of cases calculated based on 1000 trial simulations.  
 
10.4.5.2. Secondary objectives 
The ZOSTER-006 sample size is sufficient to demonstrate a HZ VE of at least 10% for 
the 50-59 YOA and 60-69 YOA age strata with powers of 99% and 98%, respectively. 
The ZOSTER-022 sample size is sufficient to demonstrate a HZ VE of at least 10% for 
the ≥ 70 YOA stratum with a power of 99%. 
The sample size of the pooled studies ZOSTER-006 and ZOSTER-022 provide 10% 
chance to demonstrate statistically significant PHN VE (LL above 0%) in those subjects 
presenting with an HZ episode. (Amended 18 April 2014) 
10.4.5.3. Futility analyses and sample size re-assessment 
The study may involve one (or more) unblinded futility analyses performed by the 
IDMC. One futility analysis is planned after at least 25% of the total number of HZ cases 
anticipated at final HZ efficacy analysis are observed in Zoster-006 (see Table 20), and 
when at least 20% of the total number of HZ cases anticipated at final HZ efficacy 
analysis within each age stratum (50-59 YOA, 60-69 YOA and 70+ YOA) are observed 
(see Table 20). (Amended 18 April 2014) Note that HZ cases from ZOSTER-022 may 
be used to meet the required number of 70+ YOA cases. The precise timing of that 
analysis will be determined by a blinded review of the HZ case accrual in ZOSTER-006 
and/or ZOSTER-022. The futility decision rules will be described in the RAP. 
Essentially, no increase in the type 1 error of the final HZ efficacy analysis is incurred as 
no decision of early termination for efficacy will be made by GSK at any of those 
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analyses. (Amended 18 April 2014) Adequate trial duration is required to accumulate 
enough PHN information and safety information necessary for regulatory purposes. 
Conversely, a slight reduction in the power of the study can be caused due to the futility 
rules. A conservative futility boundary or a predictive power threshold [Proschan, 2006] 
in the range of ~30% is anticipated but the actual functional form of the beta-spending 
function or the predictive power threshold used for the trial will be defined in the RAP. 
Information collected in both trials may be combined to calculate the predictive power 
for each trial separately and together. 
Table 23 below provides information about the ZOSTER-006 conditional power with 
respect to the overall HZ VE LL 40% (i.e. without consideration for by-age HZ VE LL 
10%) calculated following 25% of accrual and for different values of the observed HZ 
VE or futility boundaries. Irrespective to the futility boundary considered, the conditional 
power calculated under the sample size (alternative) assumptions remains very high 
although the conditional power calculated under the observed HZ VE is close to zero. A 
more reasonable prediction for the power at the final HZ efficacy analysis that will be 
implemented is the expected conditional power or Bayesian predictive power, following 
integration of the conditional power on the posterior distribution of the VE in each age 
strata and accounting for the proportion density of each stratum in the total number of HZ 
cases at the final HZ efficacy analysis. (Amended 18 April 2014) 
Table 23 Observed HZ VE at ZOSTER-006 Interim to trigger futility stopping 
and conditional power at the final HZ efficacy analysis calculated 
under alternative hypothesis and current observed VE (Amended 18 
April 2014) 
      
VE Confidence 
Intervale 
Futility 
analysis Rhoa 
# HZ 
cases 
Observed 
VEb 
CP under 
alternativec 
CP under 
observed VEd 
Lower 
Limit 
Upper 
Limit 
1 1 49 33.6% 87.2% 0.0% -102.6% 70.8% 
2 1 98 46.9% 78.8% 1.8% 0.2% 69.5% 
1 2 49 24.7% 81.5% 0.0% -137.4% 71.8% 
2 2 98 44.6% 71.5% 0.6% -4.2% 69.7% 
1 3 49 17.0% 76.1% 0.0% -168.1% 72.5% 
2 3 98 42.5% 64.3% 0.2% -8.2% 69.9% 
1 4 49 9.7% 69.7% 0.0% -201.7% 73.2% 
2 4 98 40.4% 56.5% 0.0% -12.3% 70.1% 
a:  Rho defines the form of the futility boundary. A conservative (O’Brian-Fleming) boundary is defined for Rho=3 and 
a more aggressive (Pocock) boundary is defined for Rho = 1. 
b: Observed HZ VE that triggers futility conditions at each futility analysis. 
c: Conditional power at the final HZ efficacy analysis calculated under the sample size (alternative) assumptions 
d: Conditional power at the final HZ efficacy analysis calculated under the observed HZ VE at the interim 
(Amended 18 April 2014) 
e: HZ VE repeated confidence interval and approximate VE posterior distribution at the interim over which the mean 
(expected) conditional power may be calculated. 
 
Table 24 below provides information about the ZOSTER-022 conditional power with 
respect to the HZ VE LL 40% in subjects of ≥ 70 YOA (i.e., without consideration for 
statistically significant PHN VE in subjects of ≥ 70 YOA) calculated following 25% of 
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accrual and for different values of the observed HZ VE or futility boundaries. Irrespective 
to the futility boundary considered, the conditional power calculated under the sample 
size (alternative) assumptions remains very high although the conditional power 
calculated under the observed HZ VE is close to zero. A more reasonable prediction for 
the power at the final HZ efficacy analysis that will be implemented is the expected 
conditional power or Bayesian predictive power, following integration of the conditional 
power on the posterior distribution of the VE in each age strata and accounting for the 
proportion density of each stratum in the total number of HZ cases at the final HZ 
efficacy analysis. (Amended 18 April 2014) 
Table 24 Observed HZ VE at ZOSTER-022 Interim to trigger futility stopping 
and conditional power at the final HZ efficacy analysis calculated 
under alternative hypothesis and current observed VE (Amended 18 
April 2014) 
      
VE Confidence 
Intervale 
Futility 
analysis Rhoa 
# HZ 
cases 
Observed 
VEb 
CP under 
alternativec 
CP under 
observed VEd 
Lower 
Limit 
Upper 
Limit 
1 1 77 18.7% 79.6% 0.1% -85.7% 53.2% 
2 1 155 31.3% 71.4% 3.4% -9.6% 52.7% 
1 2 77 8.5% 71.7% 0.0% -112.6% 53.7% 
2 2 155 28.5% 62.1% 1.0% -14.1% 52.8% 
1 3 77 -0.2% 64.1% 0.0% -136.3% 54.0% 
2 3 155 26.0% 53.2% 0.3% -18.1% 52.9% 
1 4 77 -8.4% 56.3% 0.0% -160.8% 54.3% 
2 4 155 23.5% 44.5% 0.1% -22.3% 53.0% 
a. Rho defines the form of the futility boundary. A conservative (O’Brian-Fleming) boundary is defined for Rho=3 and 
a more aggressive (Pocock) boundary is defined for Rho = 1. 
b. Observed HZ VE that triggers futility conditions at each futility analysis. 
c. Conditional power at the final HZ efficacy analysis calculated under the sample size (alternative) assumptions 
d. Conditional power at the final HZ efficacy analysis calculated under the observed HZ VE at the interim 
(Amended 18 April 2014) 
HZ VE repeated confidence interval and approximate VE posterior distribution at the 
interim over which the mean (expected) conditional power may be calculated.   
The futility approach, whether by futility boundary or conditional or predictive power 
implemented is not-bounding with regards to the decision actually taken at the time of the 
analysis. The IDMC recommendations with regards to futility of the study may not be 
endorsed by GSK Steering Committee without affecting the overall significance level.  
Blinded sample size reassessment may be performed by GSK in one or more age strata in 
order to keep the same trial duration if accrual is much lower than expected. The sample 
size re-evaluation will be done independently from the data provided to the IDMC. 
Conditions for the sample size reassessment need to be defined further. 
10.4.5.4. Provisional region and sub-population allocations 
The provisional region allocation for study ZOSTER-006 is presented in Table 25. 
Enrolment target numbers per region are approximate and may change depending on the 
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enrolment. In study ZOSTER-006, eligible subjects will be randomized to investigational 
vaccine/placebo according to a 1:1 ratio.  
Subjects will be stratified by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and ≥ 80 YOA 
in approximately an 8:5:3:1 ratio. The main ≥ 70 YOA stratum used for sample size 
calculation is subdivided into 70-79 and ≥ 80 YOA strata in order to demonstrate efficacy 
≥ 80 YOA or in any of these 2 sub-strata taken separately. The study is however not 
powered to demonstrate efficacy in any of these 2 sub-strata taken separately. In addition, 
some small percentages of the sample will include frail elderly subjects.  
Table 25 Provisional region allocation for study ZOSTER-006  
Australasia Europe Latin America North America 
Country Sample 
Size 
Country Sample 
Size 
Country Sample 
Size 
Country Sample 
Size 
Australia 
Hong Kong 
Japan 
S. Korea 
Taiwan 
∼3410 Czech Republic 
Estonia 
Finland 
France 
Germany 
Italy 
Spain 
Sweden 
United Kingdom 
∼7345 Brazil 
Mexico 
∼2615 Canada 
US 
~2610 
 
10.4.5.5. 7-day diary card subset   
The number of subjects in this subset was defined based on the empirical rules that, in 
absence of a specific AE in a cohort of N subjects, the probability is 95% that the 
incidence of that AE is less than 1 / (N/3) [Hanley, 1983]. 
The provisional number of subjects in the 7-day diary card subset in study ZOSTER-006 
is shown in Table 26. 
Table 26 Provisional number of subjects in the 7-day diary card subset in 
study ZOSTER-006 
Age 
cohort 
50-59 YOA 60-69 YOA 70-79 YOA ≥ 80 YOA All 
Treatment 
group Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo 
ZOSTER-
006 1410 1410 1410 1410 1410 1410 470 470 4700 4700 
Note: In addition, study ZOSTER-022 will include a 7-day diary card subset of 1008 subjects (in respectively the 70-79 
YOA and ≥ 80 YOA strata, there are 252 subjects in each treatment group). 
10.4.5.6. Immunogenicity Subset 
10.4.5.6.1. Assumptions and background information for humoral immunity 
Assumptions to estimate the number of subjects to be included in the immunogenicity 
subset in study ZOSTER-006 and ZOSTER-022 were based on gE-specific humoral 
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immunogenicity data obtained in study ZOSTER-003 for subjects who received two 
doses of gE 50 µg/AS01B.  
10.4.5.6.2. Humoral immune response vaccine take 
The humoral vaccine take is assessed in comparison to placebo group using anti-gE or 
anti-VZV Ab concentrations. The increase observed post dose 2 in study ZOSTER-003 in 
the gE 50µg/AS01B group as compared with placebo is about 10-fold for anti-gE Abs. 
The CV is about 100% (or In-based variance = 0.693 = 0.832²), accounting for higher 
variability in the current study as compared to study ZOSTER-003 due to, but not limited 
to, inter-country variations. A 4-fold increase in geometric mean over placebo as a lower 
bound for clinical relevance, in absence of other justification, adjusted for pre-
vaccination level, is considered as a threshold for clinical relevance, and will be used as 
criteria to demonstrate vaccine take. 
When expressed on the log-scale, the effect size for clinical significance is Ln(10) / 0.832 
= 2.76. When accounting for the superiority requirement of a 4-fold increase over NaCl 
solution, the effect size is 2.76 – Ln(4) / 0.832= 1.10. Despite the number of blood 
samplings that should be administered in vaccine and placebo according to the study 
randomization ratio, it is also reasonable to analyze twice as much vaccine samples than 
placebo samples. The overall power of the test is conventionally set to ~95% and the type 
1 error to 2.5%. Since we may be required to demonstrate that success criteria in all 
countries involved in the trial, accounting for ~15 countries, the power of the test in each 
country should be 0.95^(1/15) = 0.996. 
Table 27 presents the number of subjects under vaccine (N1) and placebo (N2) required 
to demonstrate a 4-fold increase in anti-gE Ab concentration geometric means over 
saline. The number of evaluable blood samples required in each country at post dose 2 is 
~55 for vaccine and ~28 for placebo for an overall power of 0.996^15 = 0.95. A slight 
increase in that number of subjects may be needed as the sample size should be a multiple 
of 3 for the age stratification. Overall, accounting for the same number of subjects to be 
sampled in vaccine and placebo groups in each of the 15 to 18 countries in order to 
maintain the blind, and to have a sufficiently large number of evaluable blood samples, 
the total number of subjects enrolled into the subset should approximately be 18 x 60 x 2 
= ~2160. No comparisons are planned within each age strata at the country level. 
Table 27 Power calculations for a T-test for Relevant Superiority  
Power N1/N2 Equivalence 
margin (E) 
Actual 
difference (D) 
Significance level Standard deviation 
alpha beta SD1 SD2 
0.99839 61/32 13.90 23.00 0.02500 0.00161 8.32 8.32 
0.99648 55/28 13.90 23.00 0.02500 0.00352 8.32 8.32 
0.99413 51/26 13.90 23.00 0.02500 0.00587 8.32 8.32 
0.99245 49/26 13.90 23.00 0.02500 0.00755 8.32 8.32 
0.99031 47/24 13.90 23.00 0.02500 0.00969 8.32 8.32 
0.95043 34/17 13.90 23.00 0.02500 0.04957 8.32 8.32 
0.90324 28/14 13.90 23.00 0.02500 0.09676 8.32 8.32 
Means & SD were multiplied by a 10-fold coefficient in order to allow more precision in the outputs. 
N1, N2: number of subjects receiving vaccine (N1) and placebo (N2)  
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10.4.5.6.3. Humoral immune response inter-region variability  
Following the objective of vaccine take, the vaccine geometric mean responses between 
countries can be compared. This comparison consists of selecting two countries, or group 
of countries and comparing their means in order to demonstrate equivalence since 
defining the success criteria in terms of “statistical significance” is not meaningful in this 
situation. The absence of statistical significance would not support the absence of clinical 
relevance between regions or countries.   
Using Ratio of Geometric Means – Region-wise 
An equivalence criteria of 2-fold is considered acceptable when referring to the ratio of 
geometric means between regions. This threshold ensures that any differences between 
countries are not clinically relevant as it corresponds to half of the 4-fold increase over 
placebo, considered as the minimally clinically relevant difference.     
The same assumptions as above are used for the calculations. ZOSTER-010 data showed 
a ratio of geometric means equal to 1.26 between EU and US. A pairwise comparison 
between each of the 4 main regions may be considered, leading to 6 comparisons. The 
power of each test should be ~99% for a global power of ~95%.  
Table 28 presents the sample size for each individual comparison, assuming absence of 
true difference between regions, assuming ratio of geometric means equal to 0, 90% (Ln 
= -0.10) and 75% (Ln = -0.29). A sample size of approximately 60 subjects under vaccine 
within each region would allow demonstrating equivalence of the two geometric means 
within a non-clinically relevant range of 2-fold, provided absence of difference in means 
(true difference = 0). Since each region includes several countries, a pool of at least 3 
countries is sufficient within each region to allow the comparison when the ratios of 
geometric means reach 75%. 
Table 28 Power Testing Equivalence Using a Parallel-Group Design (Region) 
 Reference 
Group 
Treatment 
Group 
      
Power Sample Size 
(N1) 
Sample Size 
(N2) 
Lower 
Equiv Limit 
Upper 
Equiv Limit 
True 
Difference 
Standard 
Deviation 
Alpha Beta 
0.7490 60 60 -6.93 6.93 -2.90 8.32 0.0250 0.2510 
0.9630 120 120 -6.93 6.93 -2.90 8.32 0.0250 0.0370 
0.9957 180 180 -6.93 6.93 -2.90 8.32 0.0250 0.0043 
0.9996 240 240 -6.93 6.93 -2.90 8.32 0.0250 0.0004 
0.9714 60 60 -6.93 6.93 -1.00 8.32 0.0250 0.0286 
0.9998 120 120 -6.93 6.93 -1.00 8.32 0.0250 0.0002 
1.0000 180 180 -6.93 6.93 -1.00 8.32 0.0250 0.0000 
1.0000 240 240 -6.93 6.93 -1.00 8.32 0.0250 0.0000 
0.9897 60 60 -6.93 6.93 0.00 8.32 0.0250 0.0103 
1.0000 120 120 -6.93 6.93 0.00 8.32 0.0250 0.0000 
1.0000 180 180 -6.93 6.93 0.00 8.32 0.0250 0.0000 
1.0000 240 240 -6.93 6.93 0.00 8.32 0.0250 0.0000 
Note: Means and Standard Deviation were multiplied by 10 to achieve sufficient precision 
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If those comparisons should be made within each age strata, leading to a total of 3*6 
comparisons, the power of each comparison should be closer to 99.7% in order to 
maintain the overall power to 0.997^18 = 0.95. The number of countries to be involved in 
the comparisons should then be at least 4. 
Using Ratio of Geometric Means – Country-wise 
The same calculations may be performed on a country basis. The table below provides 
the power for a comparison of one country versus the rest of the world, assuming 15 
countries and a ratio of geometric mean equal to 0.90 (LN = -0.10) and 75% (LN = -
0.29). A sample of 60 subjects in the country selected is sufficient to allow the 
comparison versus 900 subjects with a power of at least 95%. 
Table 29 Power Testing Equivalence Using a Parallel-Group Design (Country) 
 Reference 
Group 
Treatment 
Group 
      
Power Sample Size 
(N1) 
Sample Size 
(N2) 
Lower Equiv 
Limit 
Upper Equiv 
Limit 
True 
Difference 
Standard 
Deviation 
Alpha Beta 
0.9553 60 900 -6.93 6.93 -2.87 8.32 0.02500.0447
0.9757 70 900 -6.93 6.93 -2.87 8.32 0.02500.0243
0.9868 80 900 -6.93 6.93 -2.87 8.32 0.02500.0132
0.9929 90 900 -6.93 6.93 -2.87 8.32 0.02500.0071
0.9962 100 900 -6.93 6.93 -2.87 8.32 0.02500.0038
0.9996 60 900 -6.93 6.93 -1.00 8.32 0.02500.0004
0.9999 70 900 -6.93 6.93 -1.00 8.32 0.02500.0001
1.0000 80 900 -6.93 6.93 -1.00 8.32 0.02500.0000
1.0000 90 900 -6.93 6.93 -1.00 8.32 0.02500.0000
1.0000 100 900 -6.93 6.93 -1.00 8.32 0.02500.0000
Note: Means and Standard Deviation were multiplied by 10 to achieve sufficient precision 
 
10.4.5.6.4. Number of subjects in the Immunogenicity subset  
Table 30 provides the provisional number of subjects in the Immunogenicity subset in 
study ZOSTER-006. CMI analysis will be performed in the Immunogenicity subset of 
three countries (Czech Republic, Japan and United States). These countries will have 
approximately 156 subjects per country enrolled in the immunogenicity subset. Other 
countries will have approximately 138 subjects per country enrolled in the 
immunogenicity subset.  
Subjects will be randomized to be part of the Immunogenicity subset (Section 5.3.4). 
Blood samples obtained from subjects included in the Immunogenicity subset will be 
used to assess humoral immune responses. The number of placebo subjects and vaccine 
subjects that will have their blood sampled will be equal in order to maintain the blind. 
However, only a fraction of the placebo samples will be analyzed as a reduced sample is 
sufficient to characterise the background gE or VZV-specific immunogenicity levels in 
the placebo group. 
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Table 30 Provisional number of subjects in the Immunogenicity subset in 
study ZOSTER-006 (Amended 18 April 2014) 
Age 
cohort 
50-59 YOA 60-69 YOA ≥ 70 YOA All  
Treatment group Vaccine Placebo Vaccine Placebo Vaccin
e 
Placebo Vaccine Placebo Total 
CMI countries1 26 26 26 26 26 26 78 78 156  
Non-CMI countries2 23 23 23 23 23 23 69 69 138  
All countries 1+2 (Total of 18 
countries) 
      1269 1269 2538 
1 Czech Republic, Japan, United States 
2 Australia, Hong Kong, S. Korea, Taiwan, Estonia, Finland, Germany, Italy, Spain, Sweden, United Kingdom, France, 
Brazil, Mexico, Canada 
10.4.5.7. CMI Subset 
10.4.5.7.1. Assumptions and background information for CMI 
Assumptions to estimate the number of subjects to be included in the CMI subset in study 
ZOSTER-006 were based on gE-specific CMI data obtained in study ZOSTER-003 for 
subjects who received two doses of gE 50 µg/AS01B.  
The frequency of CD4 T-cells producing at least 2 cytokines following induction with 
gE/AS01B will be estimated in both placebo and vaccine recipients, after adjustment for 
background CD4 T-cell frequency and pre-vaccination CD4 T-cell responses. The 
increase in CMI responses observed previously following administration of 2 doses of 
gE[50 μg] /AS01B compared with saline is about 5.5-fold, and the coefficient of variation is 
about 100%. Therefore, a 1.5-fold increase over placebo in the frequency of activated 
CD4 T-cells is considered as a minimum target for vaccine take and was used as 
threshold for immunologic superiority. These figures were used for the sample size 
calculation. 
When expressed on the log-scale, the effect size for clinical significance is Ln(5.5)/ 0.832 
= 2.05. When accounting for a target of a 1.5-fold increase over saline, the effect size is 
2.05 – Ln(1.5) /0.832 = 1.562. While the number of blood samplings will be collected in 
vaccine and placebo recipients according to the study randomization ratio, it is 
appropriate to analyze twice as many vaccine samples than placebo samples using an 
immunogenicity sample-randomization ratio of 2. Although this endpoint is purely 
exploratory, the overall power of this test is set to ~95% and the type 1 error to 2.5% per 
convention. 
Table 31 presents the number of subjects under vaccine (N1) and placebo (N2) required 
to demonstrate a 1.5-fold increase over saline in frequency of gE-specific CD4 cells 
producing at least 2 cytokines. If  the test is performed for each of the 3 age-ranges, the 
power of each test should be 98.1% in order to maintain the overall power at 0.981^3 = 
0.94 (i.e., 94%). Twenty-one subjects in each of the 3 main age strata equals will have 
received vaccine or  placebo, respectively, for a total number of 3 * 21 * 2 = 126 
subjects. For this exploratory objective, the comparison is based upon one country only 
and, for instance, does not account for comparison across multiple countries and regions. 
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Table 31 Power Calculations for CMI subset 
Power N1/N2 Equivalence 
margin (E) 
Actual 
difference (D) 
Significance level Standard deviation 
Alpha beta SD1 SD2 
0.99320 25/14 4.05 17.00 0.02500 0.00680 8.32 8.32 
0.98871 23/12 4.05 17.00 0.02500 0.01129 8.32 8.32 
0.98145 21/12 4.05 17.00 0.02500 0.01855 8.32 8.32 
0.97242 20/10 4.05 17.00 0.02500 0.02758 8.32 8.32 
0.95163 17/10 4.05 17.00 0.02500 0.04837 8.32 8.32 
 
10.4.5.7.2. Number of subjects in the CMI subset 
The CMI analyses will be performed in the Immunogenicity subset in three countries 
(Czech Republic, Japan and United States) at designated sites that have access to a 
PBMC processing facility within the acceptable time window from sample collection to 
PBMC processing. The CMI subset in these countries is expected to include 156 subjects 
to account for anticipated lost or non-evaluable samples, see Table 32. 
Table 32 Provisional number of subjects in the CMI subset in study ZOSTER-
006 (Amended 18 April 2014) 
Age  
cohort 
50-59 YOA 60-69 YOA ≥ 70 YOA All 
Treatment group Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo Total 
Each  participating country  26 26 26 26 26 26 78 78 156 
All countries (Total of 3 
countries) 
      234 234 468 
10.4.6. Conditions for triggering analyses 
A comprehensive understanding of the extent to which the candidate vaccine prevents HZ 
in the various age strata involves the availability of results from both studies (ZOSTER-
006 and ZOSTER-022). The database freeze and statistical analyses would then be 
triggered when both studies have achieved their conditions for triggering analyses. 
However, if one of the studies reached the conditions required for triggering the analyses 
and a delay of more than approximately 6 months is predicted prior to those conditions 
are reached for the second study, then GSK may decide to proceed with the analysis of 
the study that reaches its conclusion first. The conditions described below are minimum 
requirements prior to the specified analyses. (Amended 18 April 2014) Additional HZ 
cases and/or PHN cases may be accrued as a result of the decision to wait for both 
studies to achieve the requirements simultaneously. 
The following conditions are planned prior to final HZ efficacy analyses of study 
ZOSTER-006. The number of HZ and PHN cases mentioned refers to the cases in the 
primary cohort for efficacy. 
1. At least 196 HZ cases across all age group for the overall HZ analysis; 
2. ~75% of the initial sample size (not accounting for any sample-size reassessment) in 
each strata with at least 36 months follow-up and the remaining subjects have 
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completed at least 30 months follow-up after Dose 2 in order to ensure enough safety 
data; 
3. Approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ cases 
in subjects 60-69 YOA for the HZ analysis by-age in 50-59 and 60-69 YOA age 
strata respectively; 
(Amended 18 April 2014) 
The ZOSTER-006 study will continue until an adequate number of HZ cases will be 
accrued in ZOSTER-022 and an adequate number of PHN cases will be accrued in 
both ZOSTER-006 and ZOSTER-022. 
The end of study analysis of ZOSTER-006 will occur when the following conditions 
are met: 
1. All previous conditions are met for final HZ efficacy analysis in study 
ZOSTER-022; 
2. A total of at least 35 PHN cases in subjects ≥ 70 YOA when pooled with 
ZOSTER-022 PHN cases are accrued. 
The end of study analysis cannot be performed before the final HZ efficacy analysis. 
(Amended 18 April 2014) 
The following conditions are planned prior to final HZ  efficacy analyses of study 
ZOSTER-022. The number of HZ and PHN cases mentioned refers to the cases in the 
primary cohort for efficacy. 
(Amended 18 April 2014) 
1. At least 278 HZ cases accrue over both 70-79 and ≥ 80 YOA strata;  
2. ~75% of the initial sample size (not accounting for any sample-size reassessment) in 
each stratum with at least 36 months of follow-up and the remaining subjects have 
completed at least 30 months follow-up after Dose 2 in order to ensure enough safety 
data. 
The end of study analysis of ZOSTER-022 will occur when the following condition is 
met: 
1. A total of at least 35 PHN cases in subjects≥ 70 YOA when pooled with ZOSTER-
006 PHN cases are accrued.  
The end of study analysis cannot be performed before the final HZ efficacy analysis. 
In study ZOSTER-022, depending on accrual of HZ and PHN cases, final HZ efficacy 
analysis may occur at the same time as the end of study analysis. 
(Amended 18 April 2014) 
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10.4.7. Control of type I error for the two-steps analyses (Amended 18 
April 2014) 
Although, the analyses of ZOSTER-006 will be performed in two steps. Each objective 
will be assessed only once. Therefore no adjustment of type I error is needed. 
(Amended 18 April 2014) 
10.4.8. Maintaining the blind (Amended 18 April 2014) 
It is planned to maintain the whole team (Central, Local, Investigators) and subjects 
blinded up to end of study.  
A firewall team will be set up in order to allow the planned analyses to be performed 
and results reported to the relevant authorities while the study blind is maintained to 
the whole team and subjects. All details of this approach can be found in the firewall 
charter.  
(Amended 18 April 2014) 
10.4.9. List of objectives assessed at each analysis step (Amended 18 
April 2014) 
Table 33 provides, for studies ZOSTER-006 and ZOSTER-022,  an overview of the 
analyses which will be performed at final HZ efficacy analysis (step 1) and end of study 
analysis (step 2), respectively. 
For ZOSTER-006, step 1 will include analyses of the following objectives: 
• all  HZ VE objectives; 
•  all reactogenicity/safety and immunogenicity objectives.  
At step 2 all objectives of study ZOSTER-006 will be analyzed. Objectives already 
analyzed at step 1 will be re-analyzed (confirmatory descriptive in case of inferential 
analysis at step 1 or descriptive analysis otherwise).  
At step 2, overall PHN VE in subjects ≥ 70 YOA, and other pre-specified endpoints will 
be analyzed in the pooled analyses of studies ZOSTER-006 and ZOSTER-022. 
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Table 33 Overview of analyses performed at each analysis step (ZOSTER-006, ZOSTER-022, pooled analysis of ZOSTER-
006 and ZOSTER-022) (Amended 18 April 2014) 
 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
ZOSTER-006 
Primary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to placebo in 
adults ≥ 50 YOA, as measured by the reduction in HZ risk. 
Y I Y CD 
Secondary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to placebo in 
subjects within each of the following age ranges: 50-59 YOA, 
60-69 YOA and ≥ 70 YOA, as measured by the reduction in HZ 
risk;  
Y I Y CD 
  To evaluate VE in the prevention of overall PHN compared to 
placebo in subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA; 
N - Y D 
  To evaluate VE in reducing the total duration of severe ‘worst’ 
HZ-associated pain over the entire pain reporting period 
compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 YOA 
and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in the reduction of overall and HZ-related 
mortality and hospitalizations compared to placebo in subjects 
≥ 50 YOA and in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA; 
N - Y I 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
  To evaluate VE in the reduction in incidence of HZ-associated 
complications compared to placebo in subjects ≥ 50 YOA and 
in subjects within each of the following age ranges: 50-59 YOA, 
60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in the reduction in use of pain medications 
compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 YOA 
and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
 Safety       
  To evaluate vaccine safety and reactogenicity. Y D Y D 
Exploratory       
 Efficacy       
  To evaluate VE in reducing the severity of acute HZ-associated 
pain compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 YOA 
and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in improving Quality of Life (QoL) compared to 
placebo in subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, 
with confirmed HZ; 
N - Y I 
  To evaluate VE in the mitigation of Burden-Of-Illness (BOI) 
caused by HZ compared to placebo in subjects ≥ 50 YOA and 
in subjects within each of the following age ranges: 50-59 YOA, 
60-69 YOA and ≥ 70 YOA. 
N - Y I 
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 First  step* Second step** 
Final HZ efficacy analysis End of study analysis  
Type of analysis  Analysis of 
objective 
Type of 
analysis  
Analysis of 
objective I: inferential  
D: descriptive  Yes (Y)  I: inferential  Yes (Y)  
CD; confirmatory 
descriptive  
No (N) D: descriptive  
CD; 
confirmatory 
descriptive 
No (N) 
Not applicable 
(NA)  
 Immunogenicity      
  To evaluate vaccine induced cell mediated and humoral 
immune responses and the persistence of each type of 
response after two injections of study vaccine in subjects ≥ 50 
YOA, and by age strata; 
Y I, D Y CD, D 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects ≥ 50 
YOA, and by age strata. 
Y I, D Y CD, D 
       
ZOSTER-022*** 
Primary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to placebo in 
adults ≥ 70 YOA, as measured by the reduction in HZ risk. 
Y I Y CD 
Secondary       
 Efficacy      
  To evaluate VE in the prevention of overall PHN compared to 
placebo in subjects ≥ 70 YOA;  
N - Y D 
  To evaluate VE in reducing the total duration of severe ‘worst’ 
HZ-associated pain over the entire pain reporting period 
compared to placebo in subjects ≥ 70 YOA, with confirmed HZ 
N - Y I 
  To evaluate VE in the reduction of overall and HZ-related 
mortality and hospitalizations compared to placebo in subjects 
≥ 70 YOA 
N - Y I 
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 First  step* Second step** 
Final HZ efficacy analysis End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
I: inferential  
CD; confirmatory 
descriptive  
Type of analysis  Analysis of 
objective 
Type of 
analysis  
D: descriptive  Yes (Y)  I: inferential  
No (N) D: descriptive  
CD; 
confirmatory 
descriptive 
  To evaluate VE in the reduction in incidence of HZ-associated 
complications compared to placebo in subjects ≥ 70 YOA, with 
confirmed HZ; 
N - Y I 
  To evaluate VE in the reduction in use of pain medications 
compared to placebo in subjects ≥ 70 YOA, with confirmed HZ; 
N - Y I 
 Safety       
  To evaluate vaccine safety and reactogenicity. Y D Y D 
Exploratory       
 Efficacy      
  To evaluate VE in reducing the severity of acute HZ-associated 
pain compared to placebo in subjects ≥ 70 YOA, with confirmed 
HZ; 
N - Y I 
  To evaluate VE in improving Quality of Life (QoL) compared to 
placebo in subjects ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in the mitigation of BOI caused by HZ 
compared to placebo in subjects ≥ 70 YOA; 
N - Y I 
 Immunogenicity      
  To evaluate vaccine induced humoral immune responses and 
the persistence of each type of response after two injections of 
study vaccine in subjects ≥ 70 YOA and by age strata; 
Y I, D Y CD, D 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects  ≥ 70 
YOA and by age strata. 
Y I, D Y CD, D 
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 First  step* Second step** 
Final HZ efficacy analysis End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
I: inferential  
CD; confirmatory 
descriptive  
Type of analysis  Analysis of 
objective 
Type of 
analysis  
D: descriptive  Yes (Y)  I: inferential  
No (N) D: descriptive  
CD; 
confirmatory 
descriptive 
Pooled analysis of ZOSTER-006 and ZOSTER-022 
Co-primary       
 Efficacy      
  To evaluate VE in the prevention of PHN compared to placebo 
in subjects ≥ 70 YOA across both phase III studies. 
NA  Y I 
  To consolidate VE estimation in the prevention of HZ compared 
to placebo in subjects ≥ 70 YOA across both phase III studies; 
NA Y CD 
      
Secondary      
 Efficacy     
  To evaluate VE in the prevention of overall PHN compared to 
placebo in subjects ≥ 50 YOA; 
NA Y I 
  To evaluate VE in the prevention of PHN compared to placebo 
in subjects ≥ 50 YOA with confirmed HZ; 
 
NA Y I 
  To evaluate VE in reducing the total duration of severe ‘worst’ 
HZ-associated pain over the entire pain reporting period 
compared to placebo in subjects ≥ 70 YOA, with confirmed HZ; 
 
NA Y CD 
 Safety     
  To evaluate vaccine safety and reactogenicity in subjects ≥ 70 
YOA. 
NA Y D 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
I: inferential  
CD; confirmatory 
descriptive  
Type of analysis  
D: descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
Exploratory      
 Efficacy     
  To evaluate VE in reducing the severity of acute HZ-associated 
pain compared to placebo in subjects ≥ 70 YOA, with confirmed 
HZ; 
 
NA Y CD 
  To evaluate VE in improving QoL compared to placebo in 
subjects ≥ 70 YOA, with confirmed HZ; 
NA Y CD 
 Immunogenicity     
  To evaluate vaccine induced humoral immune responses and 
the persistence of each type of response after two injections of 
study vaccine in subjects ≥ 50 YOA and by age cohort; 
 
NA Y CD 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects ≥ 50 
YOA and by age strata; 
 
NA Y CD 
  To assess correlation of the humoral immune responses at 
Month 3 with protection against HZ. 
NA Y D 
       
* It is predicted that the first step for Zoster-006 will occur about one year before the first step for Zoster-022. 
** The second analysis step for both studies will occur at the same time. 
*** Depending on accrual of HZ and PHN cases, in study ZOSTER-022, step 1 may occur at the same time as step 2. 
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10.5. Study cohorts to be evaluated 
10.5.1. Total Vaccinated cohort 
The Total Vaccinated cohort (TVc) will include all vaccinated subjects with respect to 
the vaccine actually administered. 
The TVc for analysis of efficacy and immunogenicity will include vaccinated subjects for 
whom data related to efficacy and immunogenicity endpoints are available. 
The TVc for analysis of safety will include all subjects with at least one vaccine 
administration documented. 
10.5.2. Modified Total Vaccinated cohort 
The mTVc will be the primary population for efficacy analysis, which excludes subjects 
in the TVc for efficacy analysis who were not administered with the second vaccination 
or who develop a confirmed case of HZ prior to 1 month after the second vaccination. 
Rationale for using mTVc for primary analysis: 
Although the TVc (Intent-to-treat [ITT] population) analysis of efficacy is the one 
recommended according to ICH, the true assessment of the VE, according to the 
recommended schedule, can only be performed based on the mTVc, where subjects not 
completing the vaccination schedule due to an HZ episode or withdrawal will be 
excluded, as was done in an earlier HZ vaccine efficacy study [Oxman, 2005]. The 
analysis on the TVc is planned for sensitivity analyses and is expected to provide 
consistent results with the primary analyses. A delay of 1 month was selected prior to 
which any subject with confirmed HZ would be excluded from mTVc. 
For those reasons, GSK Biologicals believes that the VE estimate for registration 
purposes should be based on mTVc, provided there is no essential VE difference between 
the mTVc and TVc analyses. Our proposal is to compare VE analyses on mTVc and 
TVc, and review the frequency for exclusion from mTVc. If the results are consistent 
between both cohorts then the VE estimate based on mTVc would be considered for 
registration purposes. 
10.5.3. According To Protocol cohort for analysis of efficacy 
The According To Protocol cohort (ATPc) for analysis of efficacy will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures defined in the protocol, with no elimination criteria during the study) for 
whom efficacy data concerning endpoint measures are available, i.e., excluding all 
subjects who developed a confirmed case of HZ prior to 1 month after the second 
vaccination. The list of criteria used to exclude subjects from ATP will be defined 
prospectively in the Statistical Analysis Plan (SAP) prior to database freeze. (Amended 
18 April 2014) 
The ATPc will be the analysis set for supportive efficacy analysis, only including 
subjects who developed a confirmed case of HZ during the follow-up period starting 
from 1 month after the second vaccination (Month 3). 
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10.5.4. According To Protocol cohort for analysis of safety 
The ATPc for analysis of safety will include all subjects: 
• who have received at least one dose of study vaccine/placebo according to their 
random assignment; 
• with sufficient data to perform an analysis of safety (at least one dose with safety 
follow-up); 
• for whom administration site of study vaccine/placebo is known; 
• who have not received other medication/vaccine forbidden in the protocol (Section 
6.6.1); 
• for whom the randomization code has not been broken.  
10.5.5. According To Protocol cohort for analysis of immunogenicity  
For study ZOSTER-006, the ATPc for analysis of immunogenicity will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures and intervals defined in the protocol, with no elimination criteria during the 
study) for whom data concerning immunogenicity endpoint measures are available. This 
will include subjects for whom immunogenicity results are available at Month 3 for CMI 
and/or humoral immunogenicity. 
10.6. Derived and transformed data 
10.6.1. Handling of missing data 
For a given subject and a given efficacy measurement, missing or non-evaluable 
measurements will not be imputed for the primary analysis. The missing endpoint and 
censoring are supposed to occur independently, and the pattern of the missingness being 
either Completely At Random (MCAR) or Missing At Random (MAR) only. 
For the analysis of solicited symptoms, missing or non-evaluable measurements will not 
be replaced. Therefore the analysis of the solicited symptoms based on the TVc will 
include only subjects/doses with documented safety data (i.e., symptom screen/sheet 
completed).  
For the analysis of unsolicited AEs/SAEs/concomitant medication, all vaccinated subjects 
will be considered and subjects who did not report an event will be considered as subjects 
without an event. 
For a given subject and a given immunogenicity measurement, missing or non-evaluable 
measurements will not be replaced. Therefore, an analysis will exclude subjects with 
missing or non-evaluable measurements. 
The reasons for and timings of missing data will be reviewed and discussed. The likely 
patterns for missing data will be assessed and compared with the actual missing data 
pattern in light of CHMP /EWP/1776/99 and implementation recommendations.  
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Sensitivity analyses will be pre-specified prior to unblinding for each main efficacy 
endpoint in order to assess the sensitivity of the conclusions to missing-data pattern. 
When repeated measurements are planned, primary methodology will include mixed 
effect model for repeated measurement analysis [Mallinckrodt, 2008]. 
10.6.2. Efficacy 
The HZ incidence rate is determined with reference to the first confirmed HZ case 
observed in the patient, should several HZ cases occur in the same subject. 
The HZ-free period for a subject is calculated from HZ onset to time zero relative to the 
cohort considered: first vaccination for TVc and beyond the HZ-case exclusion period 
following the second injection for mTVc and ATP. 
The number of Person-Years at risk over an interval of time is the sum of the confirmed 
HZ-free episodes over all subjects at risk during that interval, either up to the cut-off date 
for the analysis, the censoring date or the occurrence of the first HZ case for a subject. 
The following outputs will be derived from the efficacy data recorded using the ZBPI: 
HZ burden-of-illness score 
For each confirmed case of HZ, responses to the “worst pain” question in the ZBPI are 
used to calculate a “HZ severity-of-illness” score, defined as the area under the curve 
(AUC) of HZ-associated pain plotted against time during the 182-day period after the 
onset of the case. Subjects developing HZ will present “severity-of-illness” scores 
ranging from 0 up to, theoretically, 1820. A score of 0 is recorded for subjects in whom 
HZ did not develop during the study period. 
HZ severity score  
The methodology described for the HZ burden-of-illness score will be applied to the 4 
weeks during which a daily measure is taken and provide the HZ severity score. The HZ 
severity score will apply only to subjects with HZ. Subjects not infected with HZ will not 
take part in this analysis. 
10.6.3. Humoral immune response 
The current cut-off values that apply for gE and VZV Ab responses are described in 
Table 7 of Section 5.8.3. Those values may changes as improvements are introduced to 
the analytical methods. The final cut-off values that are used for the analyses will be 
stated in the study report. 
• A seronegative subject is a subject whose Ab concentration is below the cut-off 
value. 
• A seropositive subject is a subject whose Ab concentration is greater than or equal to 
the cut-off value. 
• The seropositivity rate is defined as the percentage of seropositive subjects. 
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• The VZV gE-specific humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as a 4-fold increase in the anti-gE Ab 
concentration at the endpoint as compared to the pre-vaccination anti-gE antibody 
concentration. The VZV gE-specific humoral immune response to vaccine for 
subjects who are seronegative at baseline is defined as a 4-fold increase in the anti-
gE Ab concentration at the endpoint as compared to the anti-gE Ab cut-off value for 
seropositivity. 
• The VZV-specific humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as a 4-fold increase in the anti-VZV Ab 
concentration at the endpoint as compared to the pre-vaccination anti-VZV Ab 
concentration. The VZV-specific humoral immune response to vaccine for subjects 
who are seronegative at baseline is defined as a 4-fold increase in the anti-VZV Ab 
concentration at the endpoint as compared to the anti-VZV Ab cut-off value for 
seropositivity. 
• The Geometric Mean Concentrations (GMCs) calculations are performed by taking 
the anti-log of the mean of the log concentration transformations. For descriptive 
statistics only, Ab concentrations below the cut-off of the assay will be given an 
arbitrary value equal to half the cut-off for the purpose of GMC calculation. For 
inferential analyses, those concentrations below the cut-off will be considered as 
missing to avoid potential influential data. 
10.6.4. Cellular-mediated immune response  
• For the inferential analysis, the frequency of CD4 [2+] T cells, i.e., CD4 T cells 
producing at least 2 activation markers among IFN-γ, IL-2, TNF-α and/or CD40L, 
upon in vitro stimulation with the antigen (induction condition) is calculated by 
adding an offset of 0.5 to the number of activated CD4[2+] T cells (numerator) 
divided by the total number of CD4 T cells involved (denominator). A similar 
calculation will be made for the frequency of CD4 [2+] T cells upon in vitro 
stimulation in medium only (background condition).  
(Amended 18 April 2014) 
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(Amended 18 April 2014) 
• For the descriptive analyses, the frequency of CD4[2+] T cells upon in vitro 
stimulation with the antigen (induction condition) is calculated by dividing the 
number of activated CD4[2+] Tcells (numerator) over the total number of CD4 T 
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cells involved (denominator). The same calculation will be performed for the 
frequency computation for any kinds of cells and for each individual activation 
marker as appropriate. (Amended 18 April 2014) 
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(Amended 18 April 2014) 
• The frequency of antigen-specific (gE or VZV) CD4[2+] T cells for each individual 
subject is calculated as the difference between the frequency of CD4[2+] T cells, 
upon in vitro stimulation with the antigen (induction condition), minus the frequency 
of CD4[2+] T cells, upon in vitro stimulation in medium only (background 
condition). The differences less or equal to one (1) are imputed to 1 antigen-
specific CD4[2+] T cell per 106 CD4 T cells. The same calculation will be 
performed for the frequency computation for any kinds of cells and for each 
individual activation marker as appropriate. (Amended 18 April 2014) 
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(Amended 18 April 2014) 
• The Geometric Mean (GM) frequency calculations are performed by taking the anti-
log of the mean of the log frequency transformations; 
• The CMI vaccine response to gE will be based on the gE-specific data as computed 
above.  The cut-off for the assay (320 positive events/106 CD4  T cells) will be used 
for vaccine response assessment. The vaccine response is defined as the 
percentage of subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the cut-off. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, 
for subjects with pre-vaccination T cell frequencies above the cut-off. 
(Amended 18 April 2014) 
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• The CMI vaccine response to VZV will be based on the VZV-specific data as 
computed above.  The cut-off for the assay (320 positive events/106 CD4 T cells) 
will be used for vaccine response assessment. The vaccine response is defined as 
the percentage of subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the cut-off. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, 
for subjects with pre-vaccination T cell frequencies above the cut-off. 
(Amended 18 April 2014) 
• A CMI responder is a subject with a CMI response greater than or equal to the cut-
off value. 
 
10.7. Conduct of analyses 
Any deviation(s) or change(s) from the original statistical plan outlined in the protocol 
will be described and justified in the final study report. 
10.7.1. Prior to Final HZ efficacy Analysis (Amended 18 April 2014) 
Blinded review of safety and efficacy data will be performed in order to anticipate any 
data issues and rate of accrual of HZ and PHN events within each age strata. 
Unblinded evaluation of safety, efficacy and risk-benefit for the subjects will be 
performed by the IDMC on an ongoing basis. Operational details for IDMC will be 
provided in the IDMC Charter.  
10.7.2. Statistical considerations for the interim futility analyses 
The IDMC may be also involved in evaluation of VE at specified interim timepoints 
(futility analysis) and may recommend discontinuation of a clinical study that has 
demonstrated its inability to achieve its primary and main secondary endpoints. The 
futility rules will be described in the RAP. 
GSK has no plan to proceed with early registration for efficacy (i.e., following an interim 
analysis) due to the expected low accrual rate of PHN cases and the need to collect a 
sufficient number of events to achieve robust estimation of PHN VE. If a futility analysis 
occurs and leads to a recommendation by the IDMC to filing prior to study end for ethical 
reasons, it is mandated that, prior to final HZ efficacy analysis, the significance level for 
all primary objectives but also key secondary objectives is set to 0.0001 for both HZ and 
overall PHN, considering the alternative hypotheses of true vaccine efficacies above 
40%. As a consequence, the significance level of the final HZ efficacy analysis will be 
adjusted to 4.9998% 2-sided. Practically speaking, however, that adjustment makes no 
essential difference as using a significance level of 5% 2-sided that will be referred to in 
other part of this document. (Amended 18 April 2014) 
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10.7.3. End of study analysis (Amended 18 April 2014) 
When the conditions for triggering the end of analysis of efficacy have been reached, the 
end of study analysis cut-off date will be defined. Any HZ episode occurring prior to the 
end of study analysis cut-off date will be followed, as described in the SAP, until a 4-
week pain-free period is documented and the HZ rash resolves OR until the cut-off date 
for end of study analysis. For all subjects with ongoing HZ-associated pain at the time of 
cut-off date for end of study analysis, questionnaire data will be collected until a 4-week 
pain-free period is documented OR until at least Day HZ-90 in order to document 
potential PHN episodes. (Amended 18 April 2014) 
Following achievement of criteria triggering analyses, final data collection and data 
cleaning, the write access to the clinical database will be removed and all eCRF data will 
become available for end of study analysis. (Amended 18 April 2014) The merging of 
immunogenicity data to the eCRF data will occur after that database lock.  
10.7.4. Study reports (Amended 18 April 2014) 
Depending on the further evolution of the case accrual rate, the generated data may be 
presented in one or more study reports per study (ZOSTER-006 and ZOSTER-022).  
• The first study report for each study will contain assessment of the HZ 
VE objectives (ZOSTER-006) or the HZ VE objective (ZOSTER-022) and of 
safety, reactogenicity and immunogenicity objectives. 
• A final study report for each study will contain the assessment of remaining 
objectives not assessed at the first step, and in addition, but not limited to, the 
confirmatory descriptive re-analysis of the previously assessed objectives. The final 
study report for each study will also contain the results presented in the first report 
(to provide a comprehensive all in one report).  Assessment of the objectives of the 
pooled analyses of both studies will be included in the final ZOSTER-022 study 
report. Analysis of correlate of protection may require extensive exploratory 
analyses and therefore may be available as an annex report after completion of 
this final ZOSTER-022 study report. 
(Amended 18 April 2014) 
10.8. Statistical methods 
All analyses will be presented overall and by age strata. The main age strata for reporting 
purposes are 50-59, 60-69 and ≥70 YOA. In addition, the results for the ≥ 70 YOA 
stratum will also be presented separately for 70-79 and ≥ 80 YOA subjects. The study is 
not powered prospectively to demonstrate efficacy in these 2 sub-strata taken separately. 
Another set of analyses in subjects ≥ 60 YOA will also be presented. 
Any exploratory or sensitivity analysis may be performed in addition to the analyses 
described below on an ad-hoc basis. The significance level of those analyses may not 
however be fully controlled. 
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10.8.1. Analysis of demographics/baseline characteristics 
Demographic characteristics (age, gender, geographic ancestry and ethnicity) of each 
study cohort will be tabulated overall and by region. 
The mean age (plus range and standard deviation) of the enrolled subjects, as a whole, 
and per treatment group and stratified by age group will be calculated.  
The distribution of subjects enrolled among the study sites will be tabulated as a whole 
and per vaccine group. 
No inferential analyses of demographic data or baseline characteristics are planned. 
10.8.2. Analysis of efficacy 
All efficacy analyses will be presented overall and by age strata.  
When overall VE is presented, the age stratification factor will include the 3 main age 
levels. When VE by age is presented, the same model will be run using only the data 
pertaining to the strata under consideration. 
Additional tables will present the overall VE by region and overall VE by time (e.g., 
using 1-year interval). The methodology will be described in the SAP. (Amended 18 
April 2014) 
All p-values reported are related to the null hypothesis test VE = 0 or absence of effect of 
the vaccine and will account for p-value adjustment for multiple testing scheme when 
applicable. Both raw-confidence intervals and confidence intervals adjusted for multiple 
testing or other kind of significance adjustment will be produced. 
10.8.2.1. Reduction in HZ risk 
Descriptive statistics 
For each treatment group, the number of subjects at risk, person-time, number of 
confirmed events (HZ) and incidence rate, and incidence of confirmed HZ cases will be 
tabulated overall and by age strata. The results will be presented over the whole study and 
by visit interval. Similar tables will describe the median time-to-event and hazard rate. 
Survival curves for each vaccine group will be calculated non-parametrically, tabulated 
and presented graphically overall and by age strata using the Kaplan-Meier (i.e., Product-
Limit) method.  
Primary Inferential Analyses 
When the disease incidence is very low, large sample size is required together with 
longer trial duration. As a consequence, all participants cannot be expected to be 
followed for the same duration throughout the end of the trial. For sufficiently large 
sample size and small incidence of disease, the number of cases in the vaccine and 
placebo groups may be approximated by independent Poisson distributions. For such low 
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incidence rates, both binomial and Poisson distribution are equivalent. Under that model, 
it can be demonstrated that the number of vaccine group, given the total number of cases, 
follows a binomial distribution and resolves into a single-parameter estimation problem 
[Chan, 2003]. 
Under that model, the primary analysis method of the vaccine VE will consider the exact 
inference on the relative risk stratified for age strata and regions conditionally to the total 
number of HZ cases observed and time at risk. The method is implemented in the Poisson 
procedure of the StatXact package provided by Cytel. Relative risks will be calculated 
overall and by age-strata. Stratification will include age and regions for the overall 
analysis and region alone when analysis by age strata. The stratification will account for 
possible differences in HZ incidence across strata and/or regions. 
These analyses will adjust for the number of person-time in each vaccine group and strata 
when applicable. Similarity of the relative risks across the strata analyzed will be 
assessed graphically and by means of exact tests for homogeneity of the relative risks. 
Absence of clinically meaningful difference in relative risks across strata and p-values 
larger than 5% (2-sided) will justify assuming the relative risks are similar across the 
strata. In other situations, the impact of potential heterogeneity on the study conclusions 
will be assessed using sensitivity analyses. 
Sensitivity analysis of the VE will be provided by region to support registration and for 
visual inspection of the consistency of the VE across regions. The study is not powered to 
demonstrate significance of VE in any of those regions using only the data of that region 
in isolation. 
Sensitivity analysis of the overall VE after each multiple of 12 months following last 
vaccination will be provided in order to assess consistency of VE over time. 
Secondary Inferential Analyses 
The elapsed time following the HZ-case exclusion period after the second vaccination to 
the first HZ episode may be analyzed using Cox’s proportional hazard regression 
stratified for age strata and region with vaccine groups as covariates. Wald test and CIs 
will be produced. 
Ties will be handled using the Efron method. Cox adjusted survival curves will be 
produced for each combination of vaccine group and age category. 
10.8.2.2. Reduction in overall PHN risk 
The overall reduction in PHN risk will be evaluated similarly to the HZ risk using the 
exact inference on the relative risk stratified for age strata and regions conditionally to the 
total number of HZ cases observed and time at risk. Similarly to the HZ VE, a Poisson 
distribution for the number of PHN cases under placebo and vaccine groups is assumed. 
Since the incidence of PHN is approximately 10% to 25% of the incidence of HZ, the 
Poisson approximation of the overall number of PHN cases with regards to the mTVc is 
similarly valid. The inference of the PHN VE is partially confounded with the analysis of 
HZ risk as it includes the efficacy of the vaccine against HZ in all subjects randomized 
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and the efficacy of the vaccine against PHN in those subjects that presented with HZ. 
However, the overall PHN analysis is deemed relevant for the following reasons: 
1. An analysis performed on randomized cohort ensures comparability of the vaccine 
groups under evaluations. An analysis performed on the subset of subjects who 
presented with HZ may be biased due to the selection of that subset due to the 
disease. 
2. It matters to provide Health Authorities with overall benefit on PHN risk, whether 
the primary efficacy is against HZ or against PHN. 
10.8.2.3. Reduction in Burden-of-Illness 
The “Chop-lump” test [Follmann, 2009] for the overall reduction in Burden-of-Illness 
scores in all subjects between vaccine and placebo will be implemented and compared to 
the original analysis of the Burden-of-Illness proposed by Chang [Chang,1994]. That 
analysis is exploratory and will be described in the SAP.  (Amended 18 April 2014) The 
purpose of this analysis is to compare with results published elsewhere [Oxman, 2005] 
and no further change to the methodology is this considered appropriate. 
The HZ “Burden-Of-Illness (BOI) score” represents the average severity of illness among 
all subjects in the vaccine or placebo groups. It is calculated according to the “modified” 
scale described by Coplan [Coplan, 2004] as the sum of the HZ “severity-of-illness” 
scores of all members of the treatment group divided by the total number of subjects in 
the group. 
The pain experienced by the subjects over the period that precedes a 24 hour window 
prior to the visit to the investigator will be captured in a single measure. VE with respect 
to the BOI due to HZ (VE BOI ) is defined as the relative reduction in the BOI score in 
the vaccine group as compared with that in the placebo group and calculated as 1 - 
relative risk (i.e., 1- the HZ BOI score in the vaccine group divided by the HZ BOI score 
in the placebo group). 
The same definition of clinically relevant improvement as given for HZ severity applies 
to BOI. 
10.8.2.4. Reduction in HZ severity score 
Based on Rowbotham [Rowbotham, 2001] and Farrar et al. [Farrar, 2001], a reduction of  
1.74 units or 28% on pain score between baseline and endpoint were best associated with 
clinically relevant improvement, according to the Patient’s Global Impression of Change 
(PGIC) category of “much improved” or better. The authors also concluded that, in 
studies with no minimum baseline requirement, the relationship between percentage 
changes and PGIC is more consistent than with the raw change. Dworkin et al, [Dworkin, 
2008] reach a similar conclusion. Therefore, a percentage reduction in pain between 
vaccine and placebo of ~28% may be considered as clinically relevant in this study. 
Additional implementation details will be provided in the SAP. (Amended 18 April 
2014) 
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The statistical methodology for the analysis of HZ severity will be described in the SAP 
and is similar to the methodology described previously for BOI assessment in [Chang, 
1994]. (Amended 18 April 2014) The method for accounting for the potential 
differential in use of antiviral treatment or pain medications between the vaccine and 
placebo groups will be pre-specified. Contrary to the BOI analysis, the HZ severity 
analysis only applies to subjects with HZ (i.e., a score of zero is not assigned to subjects 
who do not present with HZ) and only includes the first 4 weeks following the HZ 
episode.  
Additional analyses may be performed using partial AUC, calculated from 0 to specific 
elapsed time after HZ onset. That approach accounts partially for any difference in pain 
score profiles or pattern (e.g., long duration with low scores versus short score with high 
scores) even though subjects may have the same overall AUC. 
10.8.2.5. Reduction in incidence of HZ associated complications 
At the end of the trial, it is reasonable to assume that a final assessment of the presence or 
absence of HZ associated complication will be made for most patients with confirmed 
HZ. As a consequence, the number HZ associated complications in subjects with HZ 
under placebo or vaccine may be considered as a binomial distribution rather than a 
Poisson distribution. 
The overall incidence of HZ associated complications, in subjects with an HZ episode, 
overall and by sub-categories will be presented and compared with placebo using 
asymptotic standardized unconditional binomial test [Miettinen, 1985]. The analysis will 
be stratified by age group and weights associated to each stratum will be pre-specified. 
The statistical methodology will be further described in the SAP. (Amended 18 April 
2014) 
10.8.2.6. Reduction of duration of severe ‘worst’ pain in subjects with an HZ 
episode 
This analysis aims at demonstrating the effect of the vaccine on the reduction of the 
duration of pain, irrespective of whether the pain is acute or chronic. Similarly to the 
approach taken for the analysis of incidence of PHN, this analysis will involve any 
subject reporting ZBPI pain scores of 3 or more at any time during the study.  
The time-to-cessation of severe ‘worst’ pain will be analyzed using a survival 
methodology. The primary analysis will consist in a Cox-proportional model to assess the 
hazard rate reduction in ZBPI worst pain duration due to the vaccine in those subjects 
that presented HZ. 
A change-point piecewise exponential model [Arani, 2001; Desmond, 2002] may be used 
as sensitivity analysis to compare hazard rates related to acute (0-30 days), sub-acute (30-
120 days) and chronic (120+ days) pain between vaccine group and placebo. The cut-off 
points 30 days and 120 days were suggested according to Desmond [Desmond, 2002]. 
Those cut-off points may additionally be estimated using the data. The comparisons 
across both sub-acute pain and chronic pain will be combined using a likelihood-ratio 
test.  
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Both methodologies will be further detailed in the SAP. (Amended 18 April 2014) 
10.8.2.7. Reduction in PHN incidence in subjects with an HZ episode 
At the end of the trial, it is reasonable to assume that a final assessment of the presence or 
absence of PHN will be made for most patients who experienced an HZ episode. As a 
consequence, the number of PHN cases in subjects with HZ under placebo and vaccine 
maybe considered as a binomial distribution rather than a Poisson distribution. 
The incidence of PHN in subjects with an HZ episode, overall and by sub-categories will 
be presented and compared with placebo using asymptotic standardized unconditional 
binomial test [Miettinen, 1985]. The analysis will be stratified by age group and weights 
associated to each stratum will be pre-specified. The statistical methodology will be 
further described in the SAP. (Amended 18 April 2014)  
10.8.2.8. Improvement of subject’s quality of life by ZBPI 
Descriptive statistics and inferential analysis of QoL subscale of ZBPI (item 9: questions 
A to G) total scores and scores per item over time will be provided overall and by age 
group.  
10.8.3. Analysis of immunogenicity  
The primary analysis will be based on the ATPc for analysis of immunogenicity (Section 
10.5.5). If the percentage of enrolled subjects excluded from this ATPc is more than 5%, 
a second analysis based on the TVc will be performed to complement the ATP analysis. 
10.8.3.1. Cell-mediated immune response 
CMI response will only be assessed and analyzed in the CMI component of the 
Immunogenicity subset as defined in Section 4.1. 
Descriptive statistics 
• For CMI response, the following parameters will be tabulated by treatment group, 
overall and by age group at Months 0, 3, 14, 26 and 38: 
• descriptive statistics of the frequency of CD4 T cell secreting at least two different 
cytokines (IFN-γ, IL-2, TNF-α,CD40L) to both VZV and gE antigens; 
• descriptive statistics of the frequency of CD4 T cell secreting at least IFN-γ and 
another cytokine (IL-2, TNF-α,CD40L) to both VZV and gE antigens; 
• descriptive statistics of the frequency of CD4 T cell secreting at least IL-2 and 
another cytokine (IFN-γ, TNF-α,CD40L) to both VZV and gE antigens; 
• descriptive statistics of the frequency of CD4 T cell secreting at least TNF-α and 
another cytokine (IFN-γ, IL-2,CD40L) to both VZV and gE antigens; 
• descriptive statistics of the frequency of CD4 T cell secreting at least CD40L and 
another cytokine (IFN-γ, IL-2, TNF-α) to both VZV and gE antigens; 
• proportion of responders with exact 95% CI. 
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Inferential Analyses 
If the data allows, inferential analysis on the log-transformed frequency of CD4 T cells 
producing at least two different cytokines following induction with antigen will be 
performed overall and by age strata or sub-strata, in subjects infected with HZ and 
healthy subjects. Least-squares means and 95% CI are back-transformed to provide 
geometric means and ratios. Covariates will include the log-transformed pre-vaccination 
frequency following induction with the antigen and the non-specific background log-
transformed frequency. Sensitivity analyses may include additional effects for 
appropriate interactions in the model in order to provide estimations and 95% CI by 
region. 
10.8.3.2. Humoral immune response 
Humoral immune response will be assessed and analyzed in the Humoral 
Immunogenicity subset as defined in Section 4.1. 
Descriptive statistics 
The following parameters will be tabulated by treatment group, overall and by age group 
at Month 0, Month 3, Month 14, Month 26 and Month 38: 
• Geometric mean concentrations (GMCs) of anti-gE Ab with 95% CIs; 
• Humoral seropositivity rates with exact 95% CIs; 
• Vaccine response rates with 95% CIs; 
• Tabulations will be presented overall and by region. 
Inferential Analyses 
If the data allows, inferential analysis on the log-transformed Ab concentrations will be 
performed overall and by age strata or sub-strata, in subjects infected with HZ and 
healthy subjects. Least-squares means and 95% CI are back-transformed to provide 
geometric means and ratios. Covariates will include the log-transformed pre-vaccination 
concentrations. Sensitivity analyses may include additional effects for regions and 
appropriate interactions in the model in order to provide estimations and 95% CI by 
region. 
The analysis for immunogenicity will be performed at final HZ efficacy analysis. A 
confirmatory descriptive analysis for immunogenicity will be performed  at end of study 
analysis.  
An additional humoral immunogenicity analysis will be performed on the pooled data 
of both ZOSTER-006 and ZOSTER-022 and the results will be provided in the final 
study report for ZOSTER-022. 
(Amended 18 April 2014) 
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10.8.3.3. VZV neutralizing antibody response 
Descriptive statistics 
The following parameters will be tabulated by treatment group, overall and by age group 
at Month 0, Month 3, Month 14, Month 26 and Month 38: 
• Geometric mean titres (GMTs) of anti-VZV neutralizing Abs with 95% CIs; 
• Tabulations will be presented overall and by region. 
10.8.3.4. Correlate of protection 
An exploratory analysis will be implemented in an attempt to correlate humoral immune 
responses to vaccination and subsequent HZ risk [Dunning, 2006]. A specific SAP will 
describe the methodologies to be used for that purpose. (Amended 18 April 2014) The 
exploratory analyses may be initiated during the course of the trial by SDAC to support 
IDMC.  
Serum blood samples will be collected from all subjects at Month 0 (pre-vaccination) and 
Month 3, and may be used for correlate of protection analysis. Additional subject samples 
may be retrieved and analyzed based on some demographics and baseline characteristics 
to match more exactly with characteristics of those who developed HZ. 
The analysis for correlate of protection will be performed on the pooled data of both 
ZOSTER-006 and ZOSTER-022 and may be available as an annex report. (Amended 18 
April 2014) 
10.8.4. Quality of life 
10.8.4.1. SF-36 health survey 
The methodology used for the analysis of the SF-36® questionnaire is detailed by Ware 
et al. [Ware, 2000]. The SF-36® yields an 8-scale profile of scores (physical functioning, 
role physical, bodily pain, general health perceptions, vitality, social functioning, role 
emotional, and mental health) as well as a reported health transition score. 
Details on descriptive statistics and statistical analysis of the effect of the vaccine on the 
difference over pre-vaccination scores will be provided in the SAP. (Amended 18 April 
2014) 
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10.8.4.2. EQ-5D questionnaire  
The EQ-5D questionnaire is analyzed based on three different types of scores: 
• 5-dimensional descriptive system: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression, 
• A weighted health state index computed by applying scores from EQ5D “value sets” 
elicited from general population samples in United Kingdom [Dolan, 1995] 
• A Visual Analog Scale (VAS) ranging from 0 to 100, with 100 representing the best 
imaginable health state and 0 representing the worst imaginable health state. 
Details on contingency tables for each of the 5-dimension and descriptive statistics for 
weighted health state index and VAS will be provided in the SAP. (Amended 18 April 
2014) Similar details will be provided for the change from pre-vaccination. Further 
specifications of statistical analyses will also be provided.   
10.8.5. Analysis of safety 
The primary analysis for safety will be based on the TVc. A second analysis based on this 
ATPc will be performed to complement the TVc analysis. 
When appropriate, tabulations will be presented overall and by time of occurrence 
relative to last vaccination (e.g., using windows such as Days 0 − 6, Days 0 − 29 and 
more than 30 days post-vaccination). 
10.8.5.1. Within groups assessment 
For each treatment group, the following results will be tabulated overall and by age strata.   
• The percentage of subjects with at least one local AE (solicited and unsolicited), with 
at least one general adverse event (solicited and unsolicited) and with any AE during 
the solicited follow-up period will be tabulated with exact 95% CI after each vaccine 
dose and overall.  
• The percentage of doses followed by at least one local AE (solicited and unsolicited), 
by at least one general AE (solicited and unsolicited) and by any AE will be 
tabulated, overall vaccination course, with exact 95% CI. 
• The percentage of subjects reporting each individual solicited local and general AE 
during the solicited 7-day (Days 0-6) follow-up period will be tabulated with exact 
95% CI.  
• The percentage of doses followed by each individual solicited local and general AE 
during the solicited 7 day (Days 0-6) follow-up period will be tabulated, overall 
vaccination course, with exact 95% CI.  
• For all solicited symptoms, the same tabulation will be performed for grade 3 
solicited AEs and for solicited general AEs with relationship to vaccination. 
• Duration and prevalence of fever will be presented. 
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• The proportion of subjects with at least one report of unsolicited AE during the 30-
day (Days 0 − 29) follow-up period after each vaccination classified according to the 
MedDRA System Organ Class and Preferred Terms will be tabulated, with exact 
95% CI. 
• The distribution of the number of unsolicited AEs per subject will be tabulated. 
• The same tabulation will be performed for grade 3 unsolicited AEs and for 
unsolicited AEs with a relationship to vaccination. The proportion of AEs resulting 
in a medically attended visit (other than routine health maintenance visits) will also 
be tabulated. 
• Incidences of SAEs during the 30-day (Days 0 − 29) follow-up period after each 
vaccination, up to 8 months and during any time during the study classified 
according to the MedDRA System Organ Class and Preferred Terms will be 
tabulated, with exact 95% CI. 
• A separate tabulation will report major categories of SAEs that occur with higher 
frequencies in elderly subjects including: cardiac, vascular, respiratory, neurological, 
congestive heart failure, myocardial infarction, varicella or HZ-like rash, cerebral or 
vascular events.  
• Incidences of SAEs by major categories including: cardiac, vascular, respiratory, 
neurological, congestive heart failure, myocardial infarction, varicella or HZ-like 
rash, cerebral vascular. Listing will also be provided, sorted by patients and sorted by 
preferred term. 
• Incidence of withdrawal due to AEs. Listing will also be provided, sorted by subjects 
and sorted by MedDRA Preferred Term. 
• The proportion of subjects with at least one report of pIMDs during the entire study 
period will be tabulated overall and by time window. Listing will also be provided, 
sorted by subjects and sorted by MedDRA Preferred Term. 
• The proportion of subjects with concomitant medication will be tabulated, until 
30 days after each vaccine dose and overall, with exact 95% CI. 
• Proportion and incidence rate of subjects with fatal outcome, HZ-related 
complications and overall and HZ-related hospitalizations, will be tabulated overall 
and by time window. 
• Proportion of subjects experiencing an HZ episode using pain medications by type 
(opiods, non-narcotics, antidepressants, miscellaneous) will be tabulated. 
10.8.5.2. Additional exploratory safety comparisons  
The standardized asymptotic 95% CI for the difference between the two groups and the 
associated 2-sided p-value to detect group difference will be computed for the following 
endpoints. 
• The proportion of subjects with at least one report of unsolicited AE classified by the 
MedDRA presented by System Organ Class and Preferred Term. 
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• Incidences of SAEs classified according to the MedDRA System Organ Class and 
Preferred Terms. 
The objective of these analyses is to identify a safety signal as defined by the Council for 
the International Organization of Medical Sciences (CIOMS) VI working group, i.e., a 
report or reports of an event with an unknown causal relationship to treatment that is 
recognized as worthy of further exploration and continues surveillance. It is recognized 
that the use of any method to identify safety signals has the potential to identify a large 
number of events which may or may not have a causal relationship to drug treatment due 
to multiplicity of endpoints. In order to put any safety signal in perspective a permutation 
test will be conducted to quantify the probability to observe at least one false safety 
signal according to the threshold p-value defining a signal. In addition, clinical 
significance and biological plausibility will need to be accounted before establishing 
causality. 
Other exploratory safety analyses may be described in the SAP. (Amended 18 April 
2014) 
11. ADMINISTRATIVE MATTERS 
To comply with ICH GCP administrative obligations relating to data collection, 
monitoring, archiving data, audits, confidentiality and publications must be fulfilled.  
11.1. Case Report Form/Remote Data Entry instructions 
Remote Data Entry (RDE), a validated computer application, will be used as the method 
for data collection.  
In all cases, subject initials will not be collected nor transmitted to GSK. Subject data 
necessary for analysis and reporting will be entered/transmitted into a validated database 
or data system. Clinical data management will be performed in accordance with 
applicable GSK standards and data cleaning procedures. 
While completed eCRFs are reviewed by a GSK Biologicals’ Site Monitor at the study 
site, omissions or inconsistencies detected by subsequent eCRF review may necessitate 
clarification or correction of omissions or inconsistencies with documentation and 
approval by the investigator or appropriately qualified designee. In all cases, the 
investigator remains accountable for the study data.  
The investigator will be provided with a CD-ROM of the final version of the data 
generated at the investigational site once the database is archived and the study report is 
complete and approved by all parties. 
11.2. Monitoring by GSK Biologicals 
Monitoring visits by a GSK Site Monitor are for the purpose of confirming that GSK 
Biologicals’ sponsored studies are being conducted in accordance with the ethical 
principles that have their origins in the Declaration of Helsinki and that are consistent 
with Good Clinical practice (GCP) and the applicable regulatory requirement(s) 
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(verifying continuing compliance with the protocol, amendment(s), reviewing the 
investigational product accountability records, verifying that the site staff and facilities 
continue to be adequate to conduct the study).  
The investigator must ensure provision of reasonable time, space and qualified personnel 
for monitoring visits. 
Direct access to all study-site related and source data is mandatory for the purpose of 
monitoring review. The monitor will perform a RDE review and a Source Document 
Verification (SDV). By SDV we understand verifying RDE entries by comparing them 
with the source data that will be made available by the investigator for this purpose.  
The Source Documentation Agreement Form describes the source data for the different 
data in the RDE. This document should be completed and signed by the site monitor and 
investigator and should be filed in the monitor’s and investigator’s study file. Any data 
item for which the RDE will serve as the source must be identified, agreed and 
documented in the source documentation agreement form.  
For RDE, the monitor will mark completed and approved screens at each visit. 
In accordance with applicable regulations, GCP, and GSK procedures, GSK monitors 
will contact the site prior to the start of the study to review with the site staff the protocol, 
study requirements, and their responsibilities to satisfy regulatory, ethical, and GSK 
requirements. When reviewing data collection procedures, the discussion will also 
include identification, agreement and documentation of data items for which the eCRF 
entries will serve as the source document. 
GSK will monitor the study to verify that, amongst others, the:  
• Data are authentic, accurate, and complete. 
• Safety and rights of subjects are being protected. 
• Study is conducted in accordance with the currently approved protocol and any 
amendments, any other study agreements, GCP and all applicable regulatory 
requirements.  
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents. 
Upon completion or premature discontinuation of the study, the monitor will conduct site 
closure activities with the investigator or site staff, as appropriate, in accordance with 
applicable regulations, GCP, and GSK procedures. 
11.3. Archiving of data at study sites 
Following closure of the study, the investigator must maintain all site study records in a 
safe and secure location. The records must be maintained to allow easy and timely 
retrieval, when needed (e.g. audit or inspection), and, whenever feasible, to allow any 
subsequent review of data in conjunction with assessment of the facility, supporting 
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systems, and staff. Where permitted by applicable laws/regulations or institutional policy, 
some or all of these records can be maintained in a validated format other than hard copy 
(e.g. microfiche, scanned, electronic for studies with an eCRF); however, caution needs 
to be exercised before such action is taken. The investigator must assure that all 
reproductions are legible and are a true and accurate copy of the original and meet 
accessibility and retrieval standards, including re-generating a hard copy, if required. 
Furthermore, the investigator must ensure there is an acceptable back-up of these 
reproductions and that an acceptable quality control process exists for making these 
reproductions. 
GSK will inform the investigator/institution of the time period for retaining these records 
to comply with all applicable regulatory requirements. However, the 
investigator/institution should seek the written approval of the sponsor before proceeding 
with the disposal of these records. The minimum retention time will meet the strictest 
standard applicable to that site for the study, as dictated by ICH GCP, any institutional 
requirements or applicable laws or regulations, or GSK standards/procedures; otherwise, 
the minimum retention period will default to 15 years.  
The investigator/institution must notify GSK of any changes in the archival 
arrangements, including, but not limited to, the following: archival at an off-site facility, 
transfer of ownership of the records in the event the investigator leaves the site.  
11.4. Audits 
To ensure compliance with GCP and all applicable regulatory requirements, GSK may 
conduct a quality assurance audit. Regulatory agencies may also conduct a regulatory 
inspection of this study. Such audits/inspections can occur at any time during or after 
completion of the study. If an audit or inspection occurs, the investigator and institution 
agree to allow the auditor/inspector direct access to all relevant documents and to allocate 
his/her time and the time of his/her staff to the auditor/inspector to discuss findings and 
any relevant issues. 
11.5. Posting of information on Clinicaltrials.gov 
Study information from this protocol will be posted on clinicaltrials.gov before enrolment 
of subjects begins. 
11.6. Ownership, confidentiality and publication 
11.6.1. Ownership 
All information provided by GSK and all data and information generated by the site as 
part of the study (other than a subject’s medical records) are the sole property of GSK. 
All rights, title, and interests in any inventions, know-how or other intellectual or 
industrial property rights which are conceived or reduced to practice by site staff during 
the course of or as a result of the study are the sole property of GSK, and are hereby 
assigned to GSK. 
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If a written contract for the conduct of the study which includes ownership provisions 
inconsistent with this statement is executed between GSK and the study site, that 
contract’s ownership provisions shall apply rather than this statement. 
11.6.2. Confidentiality 
Documented evidence that a potential investigator is aware and agrees to the confidential 
nature of the information related to the study must be obtained by means of a 
confidentiality agreement. 
All information provided by GSK and all data and information generated by the site as 
part of the study (other than a subject’s medical records) will be kept confidential by the 
investigator and other site staff. This information and data will not be used by the 
investigator or other site personnel for any purpose other than conducting the study. 
These restrictions do not apply to: (i) information which becomes publicly available 
through no fault of the investigator or site staff; (ii) information which it is necessary to 
disclose in confidence to an IEC or IRB solely for the evaluation of the study; (iii) 
information which it is necessary to disclose in order to provide appropriate medical care 
to a study subject; or (iv) study results which may be published as described in the next 
paragraph. If a written contract for the conduct of the study which includes 
confidentiality provisions inconsistent with this statement is executed, that contract’s 
confidentiality provisions shall apply rather than this statement. 
11.6.3. Publication 
For multicentre studies, the first publication or disclosure of study results shall be a 
complete, joint multicentre publication or disclosure coordinated by GSK. Thereafter, 
any secondary publications will reference the original publication(s). 
Prior to submitting for publication, presentation, use for instructional purposes, or 
otherwise disclosing the study results generated by the site (collectively, a ‘Publication’), 
the investigator shall provide GSK with a copy of the proposed Publication and allow 
GSK a period to review the proposed Publication (at least twenty-one working days, or at 
least fifteen working days for abstracts/posters/presentations). Proposed Publications 
shall not include either GSK confidential information other than the study results or 
personal data on any subject, such as name or initials. 
At GSK’s request, the submission or other disclosure of a proposed Publication will be 
delayed a sufficient time to allow GSK to seek patent or similar protection of any 
inventions, know-how or other intellectual or industrial property rights disclosed in the 
proposed Publication. 
If a written contract for the conduct of the study, which includes publication provisions 
inconsistent with this statement is executed, that contract’s publication provisions shall 
apply rather than this statement. 
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11.6.4. Provision of study results to investigators, posting to the clinical 
trials registers and publication 
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results at a GSK site or other mutually-
agreeable location. 
GSK will also provide the investigator with the full summary of the study results. The 
investigator is encouraged to share the summary results with the study subjects, as 
appropriate. 
The results summary will be posted to the GSK Clinical Study Register at the time of the 
first regulatory approval or within 12 months of any decision to terminate development. 
In addition, a manuscript will be submitted to a peer-reviewed journal for publication 
within 12 months of the first approval or within 12 months of any decision to terminate 
development. When manuscript publication in a peer-reviewed journal is not feasible, 
further study information will be posted to the GSK Clinical Study Register to 
supplement the results summary. 
12. COUNTRY SPECIFIC REQUIREMENTS 
All countries will comply with AE and SAE reporting as described in Section 8 of the 
protocol. Additionally, countries and sites will follow all applicable local regulations and 
guidelines for AE and SAE reporting as required by their respective healthcare authorities 
and ethics committees.  
12.1. Requirements for France 
This section includes all the requirements of the French law (n° 2004-806 of 09 August 
2004), and identifies, item per item, the mandatory modifications or additional 
information to the study protocol. 
Concerning the « STUDY POPULATION»  
• In line with the local regulatory requirements, the following text about «PAYMENT 
TO SUBJECTS » is added:  
If the subjects will be paid for the inconvenience of participating in the study. The 
amount of payment is stated in the informed consent form. Subjects not completing 
the study for whatever reason could be paid at the discretion of the Investigator, 
generally on a pro rata basis. 
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• In line with the local regulatory requirements, the following text about  
« NATIONAL FILE » is added: 
All subjects participating in studies could be identified and monitored under the 
« Fichier national ». 
The following details will be described: 
− first 3 letters of name and first 2 letters of surname, 
− date of birth, 
− reference of the study and dates of beginning and termination, 
− exclusion period, 
− the total amount of honorarium. 
• In line with the local regulatory requirements, the following text in section  «OTHER 
STUDY ELIGIBILITY CRITERIA CONSIDERATIONS » is added: 
A subject will be eligible for inclusion in this study if he /she is either affiliated to or 
beneficiary of a social security category. 
It is the investigator’s responsibility to ensure and to document (in source document - 
patient notes) that the patient is either affiliated to or beneficiary of a social security 
category. 
Concerning the “DATA ANALYSIS AND STATISTICAL CONSIDERATIONS” 
and specially in the “SAMPLE SIZE ASSUMPTION” 
• The expected number of patients to be recruited in France is declared to the French 
regulatory authority. 
Concerning the “STUDY CONDUCT CONSIDERATIONS” 
• In section “Regulatory and Ethical Considerations, Including the Informed Consent 
Process” 
Concerning the process for informing the patient or his/her legally 
authorized representative, the following text is added:  
• French Patient Informed Consent form is a document in triplicate which summarizes 
the main features of the study and allows collection of the patient's written consent. It 
also contains a reference to the authorisation of Afssaps and the approval from the 
French Ethics committee and the maintenance of confidentiality of the returned 
consent form by GSK France. 
Concerning the process for obtaining subject informed consent: 
• When biomedical research is carried out on an adult in the care of a “tutelle” 
guardian, consent is given by their legal representative and, if the committee 
mentioned in article L. 1123-1 considers that the research in question, because of the 
gravity of the restraints or the specificity of the medical acts involved, entails a 
serious risk of affecting their private life or the integrity of their body, by the family 
council if it has been instated, or by the judge of “tutelle” guardians. 
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• When biomedical research is carried out on an adult in the care of a "curatelle" 
guardian, consent is given by the subject assisted by his guardian. 
However, if the adult in the care of a "curatelle" guardian is invited to participate in 
research which the committee mentioned in article L. 1123-1 considers, because of 
the gravity of the restraints or the specificity of the medical acts involved, to entail a 
serious risk of affecting their private life or the integrity of their body, the matter is 
submitted to the judge of guardians who decides whether the adult is capable of 
giving his consent. In the case of incapacity, the judge will decide whether or not to 
authorise the biomedical research. 
• When biomedical research, which complies with the conditions laid down in article 
L. 1121-8, is considered for an adult incapable of expressing his consent and not 
under a legal protection order, consent is given by a person of confidance as defined 
in article L. 1111-6 and, failing this, by a person who maintains close and stable 
links with the subject. However, if the committee mentioned in article L. 1123-1 
considers that the research in question, because of the gravity of the restraints or the 
specificity of the medical acts involved, entails a serious risk of affecting their 
private life or the integrity of their body, consent is given by the judge of guardians. 
Concerning the management of the Patient Informed Consent forms, the 
following text is added: 
• The first copy of the Patient Informed Consent form is kept by the investigator. The 
second copy is kept by the Director of the Medical Department of GlaxoSmithKline 
France and the last copy is given to the patient or his/her legally authorized 
representative. 
• The second copy of all the consent forms will be collected by the investigator at the 
end of the trial under the Clinical Research Assistant’s (CRA's) control, and placed 
in a sealed envelope bearing only: 
the study number,  
the identification of the Centre : name of the principal investigator and number of 
centre), 
the number of informed consents, 
the date,  
and the principal investigator’s signing. 
Then, the CRA hands the sealed envelope over to the Director of the Medical 
Department, for confidential recording, under his responsibility. 
In section concerning the “ NOTIFICATION TO THE HOSPITAL DIRECTOR ” 
the following text is added (if applicable) 
• In accordance with Article L1123-13 of the Public Health Code, the Hospital 
Director is informed of the commitment to the trial in his establishment. The 
Hospital Director is supplied with the protocol and any information needed for the 
financial disposition, the name of the investigator(s), the number of sites involved in 
his establishment and the estimated time schedule of the trial (R.1123-63). 
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In section concerning the “ INFORMATION TO THE HOSPITAL 
PHARMACIST ” the following text is added (if applicable) 
• In accordance with Article R.1123-64 of the Public Health Code, the Hospital 
Pharmacist is informed of the commitment to the trial in his establishment. The 
Pharmacist is supplied with a copy of the protocol (which allows him to dispense the 
drug(s) of the trial according to the trial methodology), all information concerning 
the product(s) of the trial (e.g. included in the CIB), the name of the investigator(s), 
the number of sites involved in his establishment and the estimated time schedule of 
the trial. 
In section  “ DATA MANAGEMENT ” the following text is added 
• " within the framework of this clinical trial, data regarding the identity of the 
investigators and/or co-investigators and/or the pharmacist if applicable, involved in 
this clinical trial, and data regarding the patients recruited in this clinical trial (patient 
number, treatment number, patient status with respect to the clinical trial, dates of 
visit, medical data) will be collected and computerized in GSK data bases by 
Laboratoire GlaxoSmithKline or on its behalf, for reasons of follow up, clinical trial 
management and using the results of said clinical trial. According to the Act n° 78-17 
of 6th January 1978 further modified, each of these people aforesaid has a right of 
access, correction and opposition on their own data through Laboratoire 
GlaxoSmithKline (Clinical Operations Department)." 
12.2. Requirements for Germany 
EXPLANATORY STATEMENT CONCERNING GENDER DISTRIBUTION 
(ARTICLE 7, PARAGRAPH 2 (12) OF THE GERMAN GCP ORDER) 
• There is no intention to conduct specific analyses investigating the relationship 
between the gender of the subjects and the efficacy, immunogenicity or safety of the 
GSK Biologicals’ gE/AS01B vaccine. The ratio of male to female subjects recruited 
into the study ZOSTER-006 is expected to be in line with the demographics of the 
population aged ≥ 50 YOA in the Member State. 
12.3. Requirements for Japan 
Regulatory and Ethical Considerations  
The study will be conducted in accordance with Good Clinical Practice (GCP), Article 
14-3 and 80-2 of the Pharmaceutical Affairs Law, all applicable subject privacy 
requirements, and the guiding principles of the declaration of Helsinki. 
Clinical Trial Notification to Regulatory Authority 
GSK will submit the CTN to the regulatory authorities in accordance with Article 80-2 of 
the Pharmaceutical Affairs Law before conclusion of any contract for the conduct of the 
study with study sites. 
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Informed Consent of Subjects  
Informed consent will be obtained before the subject can participate in the study. The 
contents and process of obtaining informed consent will be in accordance with all 
applicable regulatory requirements. 
Informed Consent 
Prior to the start of the study, the investigator (or subinvestigator) should fully inform the 
potential subject of the study including the written information given approval by the 
IRB. The investigator (or subinvestigator) should provide the subject ample time and 
opportunity to inquire about details of the study and to decide whether or not to 
participate in the study. After giving informed consent based on his/her free will, the 
subject should sign and personally date the consent form. If the subject wishes to 
consider the content of the written information at home, he/she may sign the consent 
form at home. The person who conducted the informed consent discussion should sign 
and personally date the consent form. If the subject is unable to read, an impartial witness 
should be present during the entire informed consent discussion, and the witness should 
sign and personally date the consent form. The investigator (or subinvestigator) should 
retain this signed and dated form (and other written information) together with the source 
medical records, such as clinical charts (in accordance with the rules for records 
retention, if any, at each medical institution) and give a copy to the subject. 
If information becomes available that may be relevant to the subject's 
willingness to continue participation in the study (revision of informed 
consent form and other written information)  
If information becomes available that may be relevant to the subject's willingness to 
continue participation in the study, the investigator (or subinvestigator) should 
immediately inform the subject of it to confirm the willingness to continue participation 
in the study, and document the communication of this information (in medical records). If 
necessary, the investigator should revise the written information to be provided to 
subjects, promptly report it to the sponsor, and obtain approval from the IRB. The 
investigator should not enroll any new subject in the study before the IRB’s approval. 
After the IRB approves the revision of the written information to be provided to subjects, 
the investigator (or subinvestigator) should inform each subject participating in the study 
of the revised written information, and obtain written informed consent. 
Study Monitoring 
By monitoring the parties involved in the study including medical institutions, 
investigators, subinvestigators, study collaborators, and storage managers, monitors will: 
1. Oversee the process of obtaining written informed consent, the control of 
investigational products and the progress of the study (including withdrawals and 
adverse events, and ensure that the conduct of the study is in compliance with GCP, 
Revised GCP, this protocol, and any other written agreement between the sponsor 
and the investigator/institution. 
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2. Collect and provide information that is necessary to conduct the study properly 
(information on investigational products’ safety, efficacy and quality). 
3. Verify that the investigator/institution has adequate qualifications and resources and 
remain adequate throughout the study period, and that facilities, including 
laboratories, equipment, and staff, are adequate to safely and properly conduct the 
study and remain adequate throughout the study period. 
4. Verify that source documents and other study records are accurate, complete, kept 
up-to-date and maintained. 
5. Determine whether the person responsible for retaining records is maintaining the 
essential documents at each medical institution. 
6. Check the accuracy and completeness of the CRF entries, source documents and 
other study-related records against each other. 
The investigator and institution should agree to allow the monitor direct access to 
essential documents and other relevant documents. 
Direct access to essential documents by monitors and the scope of those documents will 
be specified separately in the written procedures for monitoring prepared for this study. 
The monitor will also review EQ-5D, SF-36 and ZBPI questionnaires for extraneous 
written comments that could indicate possible AEs. Information collected in the CRF, 
and in EQ-5D, SF-36 and ZBPI questionnaires will be handled as independent 
components of this study. Except for header section information (e.g., subject 
identification code (subject number), treatment number, visit date), neither the monitor 
nor the investigator (or subinvestigator) will attempt to reconcile responses to individual 
questions/items recorded on EQ-5D, SF-36 and ZBPI questionnaires or health outcomes 
portions of diary cards (if applicable) with other data recorded in the CRFs. EQ-5D, SF-
36 and ZBPI questionnaires itself generally serve as the source document; therefore, 
unless otherwise specified elsewhere, no other source document is available for data 
validation. 
Source Data Recorded Directly on CRF 
The following data may be recorded directly on the CRFs and considered to be source 
data. 
1. Assessment of causality between adverse events and the investigational product. 
Deviations from and Changes of Protocol  
Deviations from Protocol  
The investigator (or subinvestigator) may implement a deviation from, or a change of, the 
protocol to eliminate an immediate hazard(s) to subjects without agreement by the 
sponsor or prior IRB approval. As soon as possible, the implemented deviation or change 
and the reasons for it should be submitted to the head of the medical institution and the 
IRB for approval, and via the head of the medical institution to the sponsor for 
agreement. 
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The investigator (or subinvestigator) should document all deviations from the approved 
protocol. The investigator should document the reason only for the deviation from, or the 
change of, the protocol to eliminate an immediate hazard(s) to subjects, and submit it to 
the sponsor and the head of the medical institution, and retain its copy. 
Changes of Protocol 
1. If it becomes necessary to make any changes significantly affecting the conduct of 
the study, and/or increasing the risk to subjects, the sponsor should promptly 
document the changes and reasons for them and amend the protocol after discussion 
with the [coordinating [investigator, committee members] and] investigators, and 
notify the heads of the medical institutions and investigators of the changes of the 
protocol [sample informed consent form and other written information, if necessary]. 
The investigator should not implement any significant changes without approval 
from the IRB. 
2. For changes other than the above 1), the sponsor should document the changes and 
reasons for them and inform the heads of the medical institutions and investigators of 
the changes of the protocol. Such changes require prior approval from the IRB, 
except where necessary to eliminate an immediate hazard(s), or when the change(s) 
involves only logistical or administrative aspects of the study. The investigator 
should promptly report the changes implemented without prior approval to the IRB 
for approval. 
Study Period 
June, 2010 ~ December, 2015 (estimation at the time of protocol amendment 4) 
(Amended 18 April 2014) 
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Appendix A LABORATORY ASSAYS 
Specific Ab (anti-VZV and anti-gE) measurements 
Anti-VZV ELISA: Anti-VZV Ab concentrations will be measured using a commercial 
ELISA kit (Enzygnost/Dade Behring), which is based on a single point quantification Ab 
method (sera tested at a 1:231 dilution). The assay cut-off is 25 milli-international units 
(mIU)/mL. The assay will be performed on human serum at GSK Biologicals’ laboratory 
or another laboratory designated by GSK Biologicals. 
Anti-gE ELISA: Anti-gE Ab concentrations will be measured using an anti-gE ELISA. 
Diluted blood serum samples of study subjects will be added to microtitre wells pre-
coated with gE antigen. Secondary peroxidase-conjugated anti-human Abs will be added, 
which bind to the primary human anti-gE Abs. After incubation of the microtitre wells 
with a chromogen substrate solution, the enzymatic reaction will be stopped. Optical 
densities will be recorded and anti-gE Ab concentrations are calculated from a standard 
curve. The assay cut-off is 97 mIU/mL. (Amended 18 April 2014) The assay will be 
performed on human serum at GSK Biologicals’ laboratory or another laboratory 
designated by GSK Biologicals. 
Intracellular cytokine staining (ICS)  
CMI responses will be performed by GSK Biologicals (or designated laboratory) on 
thawed Peripheral Blood Mononuclear Cells (PBMCs) by ICS. The assay will be 
performed on samples collected during the course of the study. This assay provides 
information on the frequency of CD4 T cells responding to culture medium or antigens 
(gE peptide pool or VZV lysate) by secreting cytokine molecules involved in immunity 
such as IFN-γ, IL-2, TNF-α, and CD40L. 
Briefly, PBMC collected from the subjects are stimulated for two hours using culture 
medium (for evaluation of the non-specific response), a pool of overlapping peptides 
covering the entire sequence of the vaccine antigen gE or a VZV lysate. Then, an 
intracellular block (brefeldin A) is added to inhibit cytokine secretion for a subsequent 
overnight incubation. Cells are then harvested, stained for surface markers (CD3, CD4 
and CD8) and fixed. The fixed cells are then permeabilised and stained with anti-cytokine 
Abs, washed and analyzed by cytofluorometry. 
The results of ICS assays are expressed as the frequency of specific CD4 T cells per 
million total CD4 T cells. 
Anti-VZV neutralizing antibody assay 
Anti-VZV neutralizing Abs will be quantified using a plaque reduction neutralization test 
(PRNT). Briefly, two-fold serum serial dilutions are incubated with a fixed amount of 
VZV. The mixture is then added to a monolayer of Vero cells in a 96-well plate and 
incubated for 2 days. The cells are then fixed, and viral replication is detected using a 
mixture of murine anti-VZV monoclonal Abs and anti-mouse Abs conjugated to 
horseradish peroxidase (HRPO). The HRPO activity is detected using a precipitated 
peroxidase substrate resulting in a brown coloration of VZV-infected cells. The plaques, 
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visualized as collections of stained cells, are counted, and the ratio of the number of 
plaques for each serum dilution to the number of plaques when no serum is added 
(control wells) is calculated. The neutralizing Ab titre is reported as the reciprocal of the 
serum dilution that reduces the number of plaques by 50% (ED50). 
PCR Assay for Confirmation of suspected case of HZ  
HZ cases will be confirmed by a Polymerase Chain Reaction (PCR) based algorithm that 
assesses the presence of VZV DNA in samples, and the adequacy of the samples (by 
assessing the presence of β-actin DNA). Herpes Simplex Virus (HSV) qPCR will be 
performed on VZV negative/ β -actin positive samples for exploratory purpose to assess 
if the rash lesions are due to HSV(1 or 2) and not to VZV; it is not part of the decision 
making process for HZ case confirmation. HSV qPCR testing is optional and requires 
specific consent from the individual subjects. 
VZV, HSV1/2 and β-actin DNA in HZ clinical specimens will be assessed using real-
time PCR detection by the 5’ nuclease assay based on the Taqman probe technology 
[Heid, 1996]. If the VZV PCR is negative, β-actin PCR will be performed to assess 
adequacy of the sample and if a specimen is found to be VZV–PCR negative and β-actin–
PCR negative, it is considered to be inadequate. If VZV PCR is negative and β-actin PCR 
is positive, a generic PCR for HSV1/2 will be performed.  
In the Taqman-based PCR experiments, the formation of a PCR product is monitored in 
real-time during amplification by means of fluorogenic probes that bind specifically to 
the amplified product. The reporter fluorophore is at the 5’ end of the Taqman probe and 
the quencher is at the 3’ end. As long as the probe is intact, no fluorescence is produced 
by the fluorophore. During the PCR polymerization step, the Taq DNA polymerase 
displaces the Taqman probe by 3-4 nucleotides, and the 5’ nuclease activity of the DNA 
polymerase separates the fluorophore from the quencher, and a measurable fluorescent 
signal proportional to the DNA copy number is produced. 
As mentioned above, the 5' nuclease-based PCR assay allows the determination of the 
DNA copy number within samples, but in the present study the VZV, HSV1/2 and β-
actin DNA PCR data on samples from suspected HZ lesions (swabs of vesicles, papules 
and crusts, and crusts themselves) will be used qualitatively only according to the above 
mentioned approach. 
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Appendix B ASCERTAINMENT OF HZ CASES INCLUDING PCR TESTING  
ALGORITHM TO CLASSIFY HZ SUSPECTED CASES  
A suspected case of HZ is defined as new unilateral rash accompanied by pain (broadly 
defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. 
This suspected case will be documented by digital photography of the rash and by 
collecting any relevant information as described in the clinical protocol. 
To classify the suspected case of HZ, the samples from the rash lesions will be collected 
for laboratory testing by PCR (3 samples, collected on the same day, per subject). If 
during clinical evaluation at Visit HZ-1, the investigator determines that adequate rash 
lesion samples cannot be collected (i.e., less than three lesions present, or if only papules 
are present), the subject should be asked to return to the study site for collection of 
additional samples prior to or at the Visit HZ-2 if there is rash progression (i.e., 
appearance of new/additional lesions if originally less than three lesions present, or 
appearance of vesicles if originally only papules present). When the subject returns for 
repeat sample collection, three samples from separate lesions should be collected. See the 
Study Procedures Manual for further details on sample collection. 
Each rash lesion will be tested using standardized and validated molecular assays 
according to the PCR testing algorithm described below. 
A hierarchical case definition algorithm, similar to the algorithm used by Merck in their 
Shingle Prevention Study (Zostavax efficacy study) [Oxman, 2005] will be used to 
classify each suspected case of HZ as a confirmed HZ case or not. 
• If at least 1 sample coming from a given subject is “VZV positive” by PCR (as 
defined below), the PCR algorithm will classify the “suspected HZ case” as a 
“confirmed case of HZ”. 
• If all the samples coming from a given subject are “VZV negative” (as defined 
below), then β-actin PCR will be performed. If one or more “VZV negative” samples 
are “β-actin positive”, this means that the sampling procedure is valid and that the 
“suspected HZ case” will be classified as “not a case of HZ”. HSV qPCR will be 
performed on VZV negative/ β-actin positive samples for exploratory purpose to 
assess if the rash lesions are due to HSV and not to VZV; it is not part of the decision 
making process for HZ case confirmation. HSV qPCR testing is optional and 
requires specific consent from the individual subjects. 
• If PCR results for a particular subject do not confirm or exclude a “suspected HZ 
case” (i.e. samples coming from a given subject are considered as “inadequate” as 
both VZV and β-actin PCR results are negative, or no samples are available for the 
subject), only then will the classification by the HZAC be used to confirm or exclude 
the suspected HZ case. The HZAC will consist of three to five physicians with HZ 
expertise. For every suspected HZ case, each HZAC member will be asked to make a 
clinical determination of whether the case is HZ based on review of the available 
clinical information. A “suspected HZ case” will be considered as “HZ” if all HZAC 
members concur (unanimous decision); otherwise, it will be classified as “not HZ”.  
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This algorithm includes the following steps (see Figure 2): 
1. DNA extraction from the rash lesion. 
VZV real-time PCR assay (qPCR) targeting the orf62 gene is performed to detect VZV in 
the rash lesion: 
1. If the VZV qPCR signal is ≥ the cut-off level, i.e. the technical limit of 
detection (LOD) of the assay (10 VZV DNA copies), the sample will be 
considered as “VZV positive”. 
2. If the VZV qPCR signal is above 0 copy/qPCR but below the cut-off 
level of the assay, it will be considered as “VZV borderline” and will be 
re-tested twice in order to obtain 3 results per sample. The sample will be 
considered as “VZV positive” if at least 2 results out of the three 
obtained are ≥ the cut-off level of the assay and it will be considered 
“VZV negative” if fewer than 2 samples are ≥ the cut-off level of the 
assay.  
3. If the VZV qPCR signal is equal to 0 copies/qPCR, the sample will be 
considered as “VZV negative”. If every sample is VZV negative, then 
extracted DNA from the samples will be assessed for the presence of β-
actin DNA to confirm the validity of the rash lesion sampling procedure 
(see step 3). 
As described above, if all the samples are VZV negative for a given subject, then β-actin 
qPCR will be performed on “VZV negative” samples to confirm the validity of the 
sampling procedure. 
1. If the β-actin qPCR signal is below the cut-off level of the assay (β-actin 
Negative), the sample will be considered as “inadequate” as no β-actin 
DNA from human cells is detected within the rash lesion sample. If all 
samples are β-actin Negative, then the classification by the HZAC will 
be used to confirm or exclude the HZ case. 
2. If the β-actin qPCR signal is ≥ the cut-off level of the assay (β-actin 
Positive), the sample will be considered as “valid” but without any VZV 
DNA. The extracted DNA may then be assessed for the presence of 
HSV-1/2 within the rash lesion (see below). If at least one sample is β-
actin Positive, then the HZAC classification of a suspected HZ case, will 
not be part of the decision-making process for HZ case confirmation. 
As described above the HSV qPCR assay may be performed for exploratory purpose on 
“VZV negative/ β-actin positive samples: 
1. If the HSV qPCR signal is below the cut-off level of this assay, the sample 
will be considered as “HSV negative”. 
If the HSV qPCR signal is ≥ the cut-off level of this assay, the sample will be considered 
as “HSV positive”.  
Note: The cut-off level of the VZV qPCR, β-actin qPCR and HSV qPCR assays is 
defined as the technical limit of detection of these assays (LOD; i.e. lowest concentration 
that can be detected by PCR in at least 95% of the tests). 
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Figure 2 Algorithm for HZ case definition by PCR 
 
 
VZV Positive 
if at least 2 results 
≥ cut-off level
Re-testing twice from rash lesion in 
order to obtain 3 results
VZV above 0 copy/qPCR but below cut-off level 
Rash lesion
VZV qPCR (ORF62)
If all samples are 
VZV Negative
β-actin-qPCR
If ≥ 1 sample is VZV 
Postive at or above 
the cut-off level
β-actin Positive 
(≥ 1 sample positive; 
Adequate Sample)
DNA extraction
β-actin Negative 
(all samples negative; 
Inadequate Sample)
All samples 
are VZV 
Negative 
Confirmed Case See Below
Case classified based on HZAC 
diagnosis
Classified as Not a Zoster case
Confirmed Case
VZV Negative 
if fewer than 2 results 
≥ cut-off level
See Below*
 
VZV: Varicella Zoster Virus; Q-PCR: real-time (quantitative) PCR; HSV: Herpes Simplex Virus  
* If the VZV qPCR signal is above 0 copy/qPCR but below the cut-off level of the assay, it will be considered as “VZV 
borderline” and will be re-tested twice in order to obtain 3 results per sample. The sample will be considered as “VZV 
positive” if at least 2 results out of the three obtained are ≥ the cut-off level of the assay and it will be considered “VZV 
negative” if fewer than 2 samples are ≥ the cut-off level of the assay. See then below ‘All samples are VZV Negative’. 
Note: The cut-off level of the VZV qPCR assay is defined as the technical limit of detection of the assay (LOD of 10 
VZV DNA copies; i.e. lowest concentration that can be detected by PCR in at least 95% of the tests) 
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Appendix C AMENDMENTS AND ADMINISTRATIVE CHANGES TO THE 
PROTOCOL 
GlaxoSmithKline Biologicals 
Clinical Research & Development 
Protocol Administrative Change 1 
eTrack study number 
and Abbreviated Title 
110390 (ZOSTER-006) 
IND number BB-IND 13857 
EudraCT number 2008-000367-42  
Administrative change 
number: 
Administrative Change 1 
Administrative change 
date: 
20-APR-2010 
Co-ordinating author:  Scientific Writer 
Rationale/background for changes: 
• The original protocol (7 April 2010) had an incorrect EudraCT number (2008-
00367-42), which was missing a zero. The correct number 2008-000367-42 has 
been included (instead of 2008-00367-42 as stated in the original protocol). 
• The title of the sponsor signatory has been updated. 
Title Page 
EudraCT number   2008-000367-42  
Protocol Sponsor Signatory Approval Page 
EudraCT number   2008-000367-42  
  
Vice President and Director 
Global Clinical Development 
Late Clinical Development 
GlaxoSmithKline Biologicals 
 
Protocol Investigator Agreement Page 
EudraCT number   2008-000367-42  
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GlaxoSmithKline Biologicals 
Clinical Research & Development 
Protocol Amendment 1 
eTrack study number 
and Abbreviated Title(s) 
110390 (ZOSTER-006) 
IND number BB-IND 13857 
EudraCT number 2008-000367-42  
Amendment number: Amendment 1 
Amendment date: 16-DEC-2010 
Co-ordinating author:  Scientific Writer 
Rationale/background for changes: 
• At the request of GSK Japan, signature lines were included for the GSK Japan 
Representative on the Investigator Agreement Page. 
• A clarification has been added regarding the completion of the ZBPI beyond 24hrs 
prior to clinical evaluation at Visit HZ-1 (Sections 5.5.2.2 and 5.6). 
• The process for ascertainment of HZ cases including the PCR testing algorithm to 
confirm or exclude suspected HZ cases and the circumstances under which 
suspected HZ cases will be referred to the HZ Ascertainment Committee (HZAC) 
has been updated and further clarified (Sections 5.5.2.3, Appendix A and 
Appendix B) (Figure 1 has been updated and both the original and amended 
versions are presented). It has been further clarified that, if based on qPCR test 
results the diagnosis of HZ can be excluded, exploratory testing may be performed 
to assess if the rash lesions are due to Herpes Simplex Virus (HSV); and that this 
testing is optional (Sections 5.5.2.3, 5.6, 5.8, 5.8.2, Appendix A and Appendix B).. 
• Section 5.5.3 has been updated to maintain consistency with the current IDMC 
charter. 
• Sections 5.6 and 5.7.3.6. have been updated to state that the treatment number 
must be recorded in the eCRF at each vaccination visit, rather than the first 
vaccination visit only. 
• The procedures in case of temperature deviation during vaccine storage have been 
updated to reflect the most current standards for GSK Biologicals in Section 6.2. 
• Section 6.3 was updated to clarify that the non-dominant arm is the preferred 
injection site for every dose. 
• At the request of the US FDA, Sections 5.7.3.7 and 6.5 were updated to specify 
that subjects with a  SAE (as judged by the investigator) related to the first dose of 
the vaccine should not receive a second dose. 
• To reflect the most current standards for GSK Biologicals, wording regarding the 
description of potential immune-mediated diseases (pIMDs) [formerly referred to 
as new onset of autoimmune diseases (NOADs) and other immune mediated 
inflammatory disorders] has been updated, and the procedure has been added to 
report pIMDs to GSK Biologicals within 24 hrs of awareness using SAE screens 
(Sections 8.3.2.5 and 8.4.1; and Synopsis, List of Abbreviations, Sections 5.6, 
5.7.3.9, 5.7.3.14, 5.7.3.16, 6.6, 6.6.2, 8.3.1, 10.2 and 10.8.5.1). 
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• The contact details for reporting of emergency code break have been updated in 
Section 8.7. 
• The provisional regional allocation has been updated to reflect the most recent 
estimates for the study in Section 10.4.5.4. A clarification has been added that 
enrolment target numbers per region are approximate and may change depending 
on the enrolment (Sections 4.1 and 10.4.5.4). 
• In Section 10.4.5.6.3, the subsection 'Using the Ratio of Responder Rates - 
Country-wise' has been deleted, as the responder rate will not be used to compare 
vaccine responses between countries.  
• Clarification has been added to Section 10.4.5.7.1 with regards to the 1.5-fold 
increase used for the sample size calculation. 
• Details in Sections 10.8.4.1 and 10.8.4.2 regarding the analysis of quality of life 
questionnaires (SF-36 and EQ-5D) have been removed from the protocol as they 
will be presented in the RAP. 
• At the request of GSK Taiwan, additional wording was added to Section 12 
(Country Specific Requirements) that countries should follow local regulations and 
guidelines for AE and SAE reporting as required by their respective healthcare 
authorities and ethics committees. 
• Inconsistencies, redundancies and typographical errors have been corrected or 
clarifications have been added in the following Sections: Title page, List of 
Abbreviations; 3, 4.1, 4.3, 5.5.1, 5.5.2.1, 5.5.2.2, 5.5.2.5, 5.6, 5.7.2.2, 5.7.3, 
5.7.3.1, 5.7.3.2, 5.7.3.6, 5.7.3.10, 5.7.3.11, 5.7.3.14, 5.7.3.16, 5.8.2, 5.8.3, 5.8.4.1, 
7, 8.1.1 , 8.2.1, 8.3.2.2.1, 10.4.1, 10.4.5.3, 10.4.5.5, 10.6.2, 10.7.2, 10.7.3, and 
Appendix B. 
The numbering of protocol sections and tables has been updated, as applicable. 
Amended text has been indicated in bold italics and deleted text has been indicated 
in strikethrough (e.g. text) in the following sections: 
 
Title Page 
Contributing authors   
• , Biostatistician 
• , Project Manager Clinical Laboratory  
Protocol Amendment Investigator Agreement 
Study Representative   
(Japan)  
  
Signature  
  
Date  
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Synopsis  
• Occurrence of pre-defined AEs 
− Occurrence and relationship to vaccination of any potential immune-mediated 
diseases (pIMDs)1 new onset of autoimmune diseases (NOADs) and other 
immune mediated inflammatory disorders during the entire study period in all 
subjects;  
Footnote 1: Formerly referred to as new onset of autoimmune diseases (NOADs) and 
other immune mediated inflammatory disorders. 
 
LIST OF ABBREVIATIONS 
LOD Limit Of Detection 
PIMD Potential Immune-Mediated Disease 
 
3 Study Design Overview  
Randomization
1:1
Group Vaccine (gE/AS01B) (N=7990)
Group Placebo (NaCl solution) (N=7990)
Visit  3 
Month 3
Vis it 6‡
Month 38
Scheduled monthly contacts  from after V isit 3 to s tudy concl usi on. 
Contacts will  not be performed at months that coincide with the 
subject ’s scheduled v isits .
Blood 
sampling*
Visit  5
Month 26
B lood 
sampl ing*
Vis it 4
Month 14
Study 
conclus ion 
contact
Vaccinat ion visit s Follow-up contact s/vi sits
Blood 
sampling* Blood sampling*
Visit  2
Month 2
Blood 
sampling*
Vi sit 1
Month 0
 
4.1 Number of subjects/centres 
 
Target enrolment is approximately 15,980 16,000 eligible subjects using a 1:1 
randomization ratio (vaccine:placebo). 
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Table 1 Subsets in study ZOSTER-006 
Subset name Description 
7-day diary card Diary card completion for recording of solicited adverse events (AEs) (from Day 
0 to Day 6 after each vaccination)  
Immunogenicity Blood samples (approximately 10 mL) collected at Visit 1, 3, 4, 5 and 6 will be 
analyzed to assess humoral immune response 
CMI  component of the 
Immunogenicity subset 
Blood samples (approximately 20 mL) collected at Visit 1, 3, 4, 5 and 6 will be 
analyzed to assess CMI response 
Note: Blood samples (approximately 10 mL) will be collected from all subjects at Visits 1 and 3, and will be used to 
assess correlate of protection. 
 
Overview of the recruitment plan 
Furthermore, enrolment target numbers per region (see Section 10.4.5.4) are 
approximate and may change depending on the enrolment. 
4.3 Exclusion criteria for enrolment 
• Administration or planned administration of any other immunizations within 30 days 
before the first or second study vaccination or scheduled within 30 days after study 
vaccination. However, licensed non-replicating vaccines (i.e., inactivated and subunit 
vaccines, including inactivated and subunit influenza vaccines for seasonal or 
pandemic flu, with or without adjuvant for seasonal or pandemic flu) may be 
administered up to 8 days prior to each dose and/or at least 14 days after any dose of 
study vaccine; 
• Chronic administration (defined as > 15 consecutive 15 days) of 
immunosuppressants or other immune-modifying drugs within six months prior to 
the first vaccine dose.  
5.5.1  Data collection 
Starting at After Visit 3 monthly contacts between the subjects and the investigator 
and/or his delegate will take place to collect information on any event of interest that may 
have occurred [see Table 2 and Section 5.7.4.14 for details]. 
For all subjects: 
• EQ-5D and SF-36 questionnaires: To be completed by all subjects at study entry. 
Also, to be completed by all subjects at Visits 4, 5 and 6 (subjects with an ongoing 
clinically diagnosed suspected HZ episode will follow a weekly schedule and do not 
need to additionally complete the questionnaires at these visits). 
EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed into the eCRF for subjects who have clinically 
diagnosed suspected confirmed HZ during the study. 
For all subjects in case of a suspected or confirmed case of HZ: 
• Zoster Brief Pain Inventory (ZBPI) questionnaire: To be completed by subjects 
with clinically diagnosed suspected HZ on Day HZ-0 (Visit HZ-1) and daily from 
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Day HZ-1 (day after the Visit HZ-1) up to Day HZ-28, and weekly from Day HZ-29 
onwards until the case of suspected HZ is disproved, OR until a 4-week pain-free 
period is documented, OR until the cut-off date for final analysis. For all subjects 
with ongoing HZ-associated pain at the time of the cut-off date for final analysis, 
ZBPI data will be collected until suspected HZ is disproved, OR until a 4-week 
pain-free period is documented OR until at least Day HZ-90 regardless of the cut-
off date for final analysis . (see Section 5.5.2.2 for more details) 
• EQ-5D and SF-36 questionnaires: To be completed weekly by the subjects with 
clinically diagnosed suspected HZ from Day HZ-0 onwards until the case of 
clinically diagnosed suspected HZ is disproved, OR until a 4-week pain-free period 
is documented, OR until the cut-off date for final analysis. For all subjects with 
ongoing HZ-associated pain at the time of the cut-off date for final analysis, EQ-5D 
and SF-36 data will be collected until suspected HZ is disproved, OR until a 4-week 
pain-free period is documented OR until at least Day HZ-90 regardless of the cut-
off date for final analysis.. (see Section 5.5.2.2 for more details) 
5.5.2 Evaluation and confirmation of suspected and confirmed HZ 
cases 
5.5.2.1 Definitions 
The end date of a HZ episode is defined as the first time at  which a subject had no 
rash (papules, vesicles, ulcers or crusts) and after which he/she did not develop a rash 
at the same location at any later visit/contact. This end date will be recorded in the 
eCRF. 
5.5.2.2. Evaluation of suspected case of HZ 
All HZ cases that occur during the study period up to the cut-off date for final analysis 
will be followed and evaluated. Please refer to the SPM for information about 
recording Any HZ cases that occur after the cut-off date for final analysis. will be 
recorded in the study database and Such cases will be referred to the local physician for 
follow-up. 
• The study staff/investigator will ask the subject to complete a ZBPI questionnaire at 
Visit HZ-1 to rate HZ-associated pain within the last 24 hours. If the time between 
the HZ onset and clinical evaluation at Visit HZ-1 is greater than 24 hours, the 
subject will be asked to complete a second ZBPI also for the elapsed time between 
the HZ onset and 24 hours before Visit HZ-1; 
 
• The subject will be given a supply of ZBPI, EQ-5D and SF-36 questionnaires. The 
ZBPI questionnaires will be used to collect information on the severity of HZ-
associated pain, the duration of HZ-associated pain and rash, and the impact of the 
HZ episode on subject’s QoL.  
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• The subject will be asked to complete the ZBPI questionnaires daily from Day HZ-1 
(day after the Visit HZ-1) up to Day 28, and weekly from Day HZ-29 onwards until: 
− The cut-off date for final analysis. For all subjects with HZ-associated pain, 
ZBPI pain data will be collected until at least Day HZ-90, regardless of the cut-
off date for final analysis;  
For all subjects with ongoing HZ-associated pain at the time of cut-off date for 
final analysis, If a subject with clinically diagnosed suspected HZ has not completed 
follow-up until at least Day HZ-90 at the cut-off date for final analysis, and the case 
is not disproved, follow-up for such a subject will continue until suspected HZ is 
disproved, OR until a 4-week pain-free period is documented OR until at least  the 
Day HZ-90. follow-up is completed. The study conclusion contact for such a subject 
will thus occur after he/she completes Day HZ-90 follow-up as descrived above. 
After Visit HZ-1 until Visit HZ-7, visits/contacts will take place for follow-up of the HZ 
episode according to the schedule presented in Table 3. Follow-up of HZ-associated 
pain and complications will continue irrespective of whether the rash has ended in 
some cases. Follow-up of HZ-associated pain persisting beyond Visit HZ-7 or other 
complications will be done at monthly contacts between the subjects and the investigator 
and/or his delegate that are planned starting at after Visit 3.  
Collection of subsequent HZ episode-related information will be stopped and no further 
information on that suspected HZ episode will be encoded in the clinical database. 
• The study staff/investigator will: 1) record relevant information regarding the  
clinically diagnosed suspected HZ case (such as the location and nature of HZ 
lesions, the end date of the rash, HZ-related complications, if any); 2) record 
concomitant medications/vaccinations, including concomitant medication the subject 
has already received and/or will receive for HZ treatment or treatment of any HZ-
related complications (Section 6.6); 3) record intercurrent medical conditions 
(Section 6.7); and 4) check if the subject received any medical attention 
[hospitalization, emergency room visit, or a visit to or from medical personnel 
(medical doctor)] for HZ or any HZ-related complication. Concomitant medication 
the subject has already received and/or will receive for HZ treatment will be 
recorded in the eCRF. 
5.5.2.3 Confirmation of clinically diagnosed suspected case of HZ  
A clinically diagnosed suspected case of HZ can be confirmed in two ways: 
• By Polymerase Chain Reaction (PCR):  
In addition, if based on qPCR test results the diagnosis of HZ can be excluded, 
Herpes Simplex Virus (HSV) qPCR may be performed to assess if the rash lesions 
are due to HSV (1 or 2). This exploratory testing is not part of the process for HZ 
case confirmation (see Appendix A and Appendix B). This testing is optional and 
requires specific consent from the individual subjects. 
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• By the HZ Ascertainment Committee: 
All clinically diagnosed suspected HZ cases will be referred to the HZ 
Ascertainment Committee (HZAC). The HZAC will classify all referred cases as 
either “HZ” or “not HZ”. However, the HZAC classification will serve as the final 
case definition only when the case cannot be confirmed or excluded by PCR, e.g., 
when all samples from a given subject are inadequate (as when both VZV and β-
actin PCR results are negative), or when no samples are available for a given 
subject. Therefore, definitive PCR results, when available, will determine the final 
HZ case assignment. In such cases, the HZAC classification will not contribute to 
HZ case determination decision. 
All cases of clinically diagnosed suspected HZ that cannot be confirmed or excluded 
by PCR [if the PCR specimen is inadequate (i.e., negative for both virus and β-actin 
DNA) or is missing] will be reviewed by the HZ Ascertainment Committee (HZAC). 
The HZAC will consist of three to five physicians with HZ expertise. HZAC 
members, participating as investigator in this study, will not evaluate cases from 
their own study site. HZAC members will be blinded to treatment assignments. For 
every such case, each reviewing HZAC member will be asked to make a clinical 
determination of whether the case is HZ based on review of the available clinical 
information (e.g., summary of the rash and pain evaluations, digital photographs of 
the subject's rash, and clinical progress notes). A unanimous diagnosis of "a 
confirmed case of HZ" or "not a case of HZ" will constitute a confirmed clinical 
diagnosis. HZAC members will discuss each non-unanimous case. A clinically 
diagnosed suspected case of HZ will be considered as a “clinically confirmed case of 
HZ” if the majority of the HZAC members concur unanimously; otherwise, it will 
be classified as “not a case of HZ”. As described above, the HZAC case assignment 
will only be considered as the final case assignment if definitive PCR results are 
not available. Further details will be provided in the HZAC charter. 
5.5.2.4 Evaluation of severity of HZ-associated pain using the 
Zoster Brief Pain Inventory 
In each case of clinically diagnosed suspected HZ, the subjects will be asked to assess 
their HZ-associated pain and interference of HZ with their QoL by completing the ZBPI 
questionnaire either themselves or assisted, by an aide (Section 5.5.1) until the suspected 
case of HZ diagnosed is disproved, HZ-associated pain ceases (defined as a 28-day [or 4-
week] pain free period) or until the cut-off date for final analysis (for all subjects with 
HZ-associated pain, ZBPI pain data will be collected until at least Day HZ-90, regardless 
of the cut-off date for final analysis) (see further details in Section 5.5.2.2). 
5.5.2.5  HZ complications  
The presence of HZ complications listed below will be documented in the eCRF at each 
contact/study visit, independently from the AE reporting of those HZ complications 
(refer to the SPM for details). 
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5.5.3  Independent Data Monitoring Committee 
The GSK Biologicals biostatistician and a member One or more members of the Zoster 
vaccine program will attend the IDMC meeting open sessions to immediately reply to 
any questions from the IDMC members.  
The futility rules will be described in the IDMC Charter. 
Vaccine efficacy for futility analysis, and other analyses described in the protocol to be 
done in preparation of IDMC review, will be further detailed in the IDMC Reporting 
and Analysis Plan (RAP). 
5.6 Outline of study procedures 
Table 2 List of study procedures  
(Bullet added at Visit 2 for Recording of treatment number) 
Type of contact VISIT 1 VISIT 2 
Timepoints  Day 0*/ 
Month0 
Month 2 
Sampling timepoints Pre-Vacc Post-Vacc 1 
Randomizationd ○  
Recording of treatment number  ● ● 
Reporting of potential immune-mediated diseases (pIMDs)† 
new onset of autoimmune diseases (NOADs) and other immune 
mediated inflammatory disorders according to guidelines In 
Section  8.3.2.5 
● d ● 
Transcriptiong by study staff/investigator of EQ-5D and SF-36 
questionnaires completed 
- by all subjects  ● 
 
- by subjects who do not have an ongoing HZ episode   
Note: Starting at After Visit 3, monthly contacts between the subjects and the investigator and/or his delegate will be 
scheduled for the subject to respond to a standard set of questions, in a language that is understandable to the 
subject, to collect information on safety and the occurrence of HZ, and to follow-up ongoing HZ cases (Section 5.5.1). 
† formerly referred to as new onset of autoimmune diseases (NOADs) and other immune mediated 
inflammatory disorders. 
g EQ-5D and SF-36 will remain as source documents. The information from these questionnaires will only be 
transcribed in the eCRF for subjects who have a clinically diagnosed suspected HZ  zoster event during the study. 
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Table 3 Study procedures to be performed during the follow-up period for 
each suspected HZ case  
(Asterisk added after 'Section 5.7.3.11' for the listed study procedure) 
Type of contact 
Timepoints 
Collect HZ lesion samples (3 replicate 
samples) for confirmation by PCR of a 
case of clinically diagnosed suspected 
HZ as specified in Section 5.7.3.11*, and 
for exploratory HSV qPCR ** 
Note: If the case of clinically diagnosed suspected HZ is disproved, or if HZ-associated pain ceases (defined as a 28-
day [or 4-week] pain free period), subsequent HZ follow-up visits or contacts will be cancelled. When case of clinically 
diagnosed suspected HZ is disproved, collection of HZ-related information will be stopped and no further information 
on that suspected HZ episode will be encoded in the clinical database.  
* If during clinical evaluation at Visit HZ-1, the investigator determines that only papules are present, three 
samples should be collected (if possible). The investigator has the option of collecting three additional 
samples if the rash progresses to vesicles or crusts are present prior to or at the Visit HZ-2.. See the SPM for 
further details on PCR sample collection. ** If based on qPCR test results the diagnosis of HZ can be excluded, 
Herpes Simplex Virus (HSV) qPCR may be performed to assess if the rash lesions are due to HSV (1 or 2). This 
exploratory testing is not part of the decision making process for HZ case confirmation (see Appendix A and 
Appendix B). This testing is optional and requires specific consent from the individual subjects. 
† Subjects with clinically diagnosed suspected HZ will be asked to complete the ZBPI questionnaire at Day HZ-0 (Visit 
HZ-1) to rate HZ-associated pain within the last 24 hours (If the time between the HZ onset and clinical 
evaluation at Visit HZ-1 is greater than 24 hours, the subject will be asked to complete a second ZBPI also for 
the elapsed time between the HZ onset and 24 hours before Visit HZ-1); daily from Day HZ- 1 to Day HZ-28, and 
weekly from Day HZ-29 onwards until suspected HZ is disproved,  a 4-week pain-free period is documented or until 
the cut-off date for final analysis. For all subjects with ongoing HZ-associated pain at the time of cut-off date for 
final analysis, ZBPI data will be collected until suspected HZ is disproved, OR until a 4-week pain-free period is 
documented OR until at least Day HZ-90. (ZBPI pain data will be collected until at least Day HZ-90) (See Section 
5.5.2.2) 
‡Subjects with clinically diagnosed suspected HZ will be asked to complete the EQ-5D and SF-36 questionnaire 
weekly from Day HZ-0 onwards until suspected HZ is disproved,  a 4-week pain-free period is documented or until 
the cut-off date for final analysis. For all subjects with ongoing HZ-associated pain at the time of cut-off date for 
final analysis,  EQ-5D and SF-36 data will be collected until suspected HZ is disproved, OR until a 4-week pain-
free period is documented OR until at least Day HZ-90. (EQ-5D and SF-36 data will be collected until at least Day 
HZ-90).(See Section 5.5.2.2). 
Each clinically diagnosed suspected HZ that occurs up to the cut-off date for final analysis will be followed at least until 
Visit HZ-7 (the study visit at Day HZ-91). Follow-up of HZ-associated pain and complications will continue 
irrespective of whether the rash has ended in some cases. (See Section 5.5.2.2). 
The study staff/investigator will dispense additional questionnaires and provide instructions for the subject to return the 
completed questionnaires to the study site. The subjects will be given a new supply of questionnaires as necessary. 
Follow-up of HZ-associated pain persisting beyond Visit HZ-7 (Day HZ-91) or other complications will be done at 
monthly contacts that are planned starting at after Visit 3 between the subjects and the investigator and/or his 
delegate. 
 
Time intervals between study visits/contacts related to study procedures performed in 
subjects participating in the study are presented in Table 4. In addition; starting at after 
Visit 3, monthly contacts between the subjects and the investigator and/or his delegate 
will be scheduled. 
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Follow-up for the occurrence of any SAEs will begin at Day 0 and continue until Month 
14. Follow-up for the occurrence of SAEs related to study participation, or related to a 
concurrent GSK medication/vaccine or any fatal SAE, will continue until study 
conclusion. Follow-up for the occurrence of potential immune-mediated diseases 
(pIMDs), formerly referred to as new onset of autoimmune diseases and other immune 
mediated inflammatory disorders, will begin at Day 0 and continue until study 
conclusion. 
Table 5 Intervals between contacts with subjects in case of suspected HZ  
Table Footnotes  
Note: If a case of clinically diagnosed suspected HZ is disproved or if pain ceases (i.e., after a 4-week pain-free period 
is documented), subsequent follow-up HZ visits or contacts may be cancelled. Follow-up of HZ-associated pain 
persisting beyond Visit HZ-7 (Day HZ-91) or other complications will be done at monthly contacts between the 
subjects and the investigator and/or his delegate that are planned starting at after Visit 3  
 
5.7.2.2. Collect demographic data 
Record demographic data such as information regarding date of birth, gender, 
geographic ancestry and ethnicity in the subject’s eCRF.  
5.7.2.3 Medical history 
Perform a history-directed medical examination Review and record any pre-existing 
conditions or signs and/or symptoms present in a subject prior to the start of the study in 
the eCRF  
5.7.3. Procedures during the study  
Note that the urine pregnancy test some of the procedures to be performed during the 
vaccination visits, i.e., Visits 1 and 2, (such as history directed physical examination and 
urine pregnancy test) are is performed prior to the first vaccination and are is described in 
Section 5.7.2. 
5.7.3.1 Check and record concomitant medication/vaccination and 
intercurrent medical conditions  
Any subject with a clinically diagnosed suspected HZ episode between Visit 1 and Visit 
2 should not receive the second vaccination. 
5.7.3.2. Check contraindications to vaccination 
See Section 5.7.3.7 for an additional criteria criterion to be checked prior to 
administration of the second vaccination dose.  
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5.7.3.6. Treatment number assignment 
At the first vaccination visit, the subject will be assigned a treatment number defining the 
treatment he/she will be receiving. The treatment number must be recorded in the eCRF 
at the first each vaccination visit. 
If there is a need for a site to use a replacement vaccine at the subsequent visit, then that 
treatment number needs to be transcribed into the eCRF (see Section 6.4). 
5.7.3.7. Vaccination 
• Any subject with clinically diagnosed suspected HZ episode between Visit 1 and 
Visit 2 should not receive the second dose. 
• Any subject with an SAE related to the first dose of vaccine (as judged by the 
investigator) should not receive the second dose (Section 6.5). 
5.7.3.9 Recording of potential immune-mediated diseases (pIMDs) 
new onset of autoimmune diseases (NOADs) and other immune 
mediated inflammatory disorders 
As specified in the List of Study Procedures (Table 2, Section 5.6), potential immune-
mediated diseases (pIMDs), formerly referred to as NOADs and other immune mediated 
inflammatory disorders, occurring from administration of the first dose of 
vaccine/placebo onwards until end of the trial will be recorded. 
Refer to Section8.3.2.5 for information on recording of pIMDs NOADs and other 
immune mediated inflammatory disorders. 
5.7.3.10 Recording of data from completed EQ-5D and SF-36 
questionnaires 
EQ-5D and SF-36 questionnaires: To be completed by all subjects at study entry. Also, 
to be completed by all subjects at Visits 4, 5 and 6 (subjects with an ongoing clinically 
diagnosed suspected HZ episode will follow a weekly schedule and do not need to 
additionally complete the questionnaires at these visits). 
EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed into the eCRF for subjects who have clinically 
diagnosed suspected confirmed HZ during the study. 
5.7.3.11. Follow up of suspected HZ cases and HZ-associated pain 
For all subjects with ongoing HZ-associated pain at the time of cut-off date for final 
analysis, ZBPI data will be collected until suspected HZ is disproved, OR until a 4-
week pain-free period is documented OR until at least Day HZ-90. For all subjects with 
HZ-associated pain, ZBPI pain data will be collected until at least Day HZ-90, regardless 
of the cut-off date for final analysis. In addition, subjects with clinically diagnosed 
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suspected HZ will be asked to complete EQ-5D and SF-36 questionnaires weekly. Refer 
to Section 5.5.2.2 for more details. 
Three replicate rash lesion samples (see Table 6) should be collected on the same day 
according to the guidelines provided in the SPM. If during clinical evaluation at Visit 
HZ-1, the investigator determines that only papules are present, three samples should 
be collected (if possible). The investigator has the option of collecting three additional 
samples if the rash progresses to vesicles or crusts are present prior to or at the Visit 
HZ-2. See the SPM for further details on sample collection. 
5.7.3.14 Reminder for monthly follow-up contacts/yearly follow-up 
visits 
The subject will be reminded that, starting at after Visit 3, monthly contacts between the 
subjects and the investigator and/or his delegate will take place (except at months that 
coincide with the subject’s scheduled visits) in order to collect all relevant information on 
any event of interest that may have occurred [including SAEs (Section 8.3), pIMDs 
NOADs and other immune mediated inflammatory disorders (Section 8.3.2.5), 
occurrence or follow up of a suspected episode of HZ (Section 5.5.2), intercurrent 
medical conditions (Section 6.7), medically attended visits (up to Month 8 only, Section 
8.3.2.4), the use of concomitant medications and/or vaccinations (Section 6.6) or 
pregnancy (Section 8.3)], and that information will be recorded in the appropriate section 
of the subject’s eCRF. 
5.7.3.16 Study conclusion 
When the cut-off date for final analysis is established, the study sites will contact the 
subjects for the study conclusion contact as soon as possible. If a subject with clinically 
diagnosed suspected HZ has not completed follow-up until at least Day HZ-90 at the cut-
off date for final analysis, and the case is not disproved, follow-up for such a subject will 
continue until the Day HZ-90 (or sooner (1) if the case is disproved or (2) if the subject 
has no HZ-associated pain for 4 consecutive weeks) follow-up is completed. The study 
conclusion contact for such a subject will thus occur after he/she completes Day HZ-90 
follow-up as described above. 
• Recording of pIMDs NOADs and other immune mediated inflammatory disorders 
(Section 5.7.3.9). 
After At study conclusion, if the study vaccine demonstrates sufficient evidence of 
efficacy and safety such that a clinically important benefit may be reasonably expected, 
placebo recipients may will be offered cross-over immunization with the study vaccine. 
5.8  Biological sampling handling and analyis 
Herpes Simplex Virus (HSV) qPCR (see Section 5.8.2) may be performed on Varicella 
Zoster Virus (VZV) negative β-actin positive samples for exploratory purpose to assess 
if the rash lesions are due to HSV (1 or 2) and not toVZV; it is not part of the decision 
making process for HZ case confirmation. This testing is optional and requires specific 
consent from the individual subjects (see Appendix A and Appendix B).  
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5.8.2 Biological samples 
Table 6 Biological samples 
Sample type Quantity (approximate volume) Unit Timepoint Subset Name* 
Clinical specimens of 
HZ lesions 
 
3 replicate samples, taken on 
the same day, of the highest 
priority lesion type available (1) 
vesicle fluid; 2) crust; 3) crust 
swab; 4) papule swab) † 
NA Sscheduled in 
case of suspected 
HZ for diagnosis 
Subjects clinically 
diagnosed as having a 
suspected case of HZ 
† If during clinical evaluation at Visit HZ-1, the investigator determines that only papules are present, three 
samples should be collected (if possible). The investigator has the option of collecting three additional 
samples if the rash progresses to vesicles or crusts are present prior to or at the Visit HZ-2.  See the SPM for 
further details on sample collection   
 
5.8.3 Laboratory assays  
Table 9 Molecular Biology (PCR tests) 
System Component 
HZ lesion sample Varicella Zoster 
Viirus.DNA 
HZ lesion sample Herpes Simplex 
Virus.DNA** 
** Herpes Simplex Virus (HSV) qPCR may be performed on VZV negative/β-actin positive samples for 
exploratory purpose to assess if the rash lesions are due to HSV (1 or 2) and not to VZV; it is not part of the 
decion making process for HZ case confirmation (see Appendix A  and Appendix B). This exploratory testing 
is optional and requires specific consent from the individual subjects. 
 
5.8.4.1 Immunological read-outs 
• For a subgroup of subjects included in the CMI component of the Immunogenicity 
subset, gE and VZV specific CMI response will be measured at specified timepoints. 
• For the correlates of protection analysis, analysis of the humoral immune responses 
at prevaccination and Month 3 will be performed on samples collected from 
vaccinated subjects who develop confirmed HZ and compared with the humoral 
immune responses at prevaccination and Month 3 from matched subjects that did 
not develop HZ.  
 
6.2 Storage and handling of study vaccine  
The study vaccines will must be stored at the defined temperature range (i.e. +2 to 
+8°C/36°F to 46°F) and must not be frozen. Please refer to the Module on Clinical Trial 
Supplies in the SPM for more details on storage of the study vaccine. The storage 
temperature of the vaccine will be monitored daily with validated temperature monitoring 
device(s) (at the minimum calibrated) and will be recorded as specified in the SPM.  
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The storage conditions will be assessed during pre-study activities under the 
responsibility of the sponsor study contact. 
Any temperature deviation, i.e. temperature outside the defined range (0+2°C to 
+8°C/3236°F to 46°F), must be reported to the sponsor as soon as detected. Following an 
exposure to such a temperature deviation, vaccines will not be used until written approval 
has been given by the Sponsor. 
In case of temperature deviation between 0 and +2°C/32 and 36°F, the impacted study 
vaccine can still be administered, but the site must take adequate actions to go back to 
the defined range +2 to +8°C/36 to 46°F and avoid re-occurrence of such a 
temperature deviation. 
Please Rrefer to the Module on Clinical Trial Supplies in the SPM for details and 
instructions on the Temperature deviation process, packaging and accountability of the 
study vaccine. 
6.3 Dosage and administration of study vaccine 
The entire volume of the reconstituted vaccine should be withdrawn, the needle can be 
replaced, and any solution in excess of 0.5mL should be expelled. After confirming that 
the needle is not in a blood vessel, tThe reconstituted vaccine or a 0.5mL dose of the 
NaCl solution placebo should be administered by IM injection into the deltoid muscle 
using a standard aseptic technique, preferably into the deltoid muscle of in the non-
dominant arm, using a standard aseptic technique. A 0.5 mL dose of the NaCl solution 
placebo should be injected IM. The injection site should be on the same arm for all 
injections for an individual subject. In rare situations when there is no other alternative, 
the second injection may be given in the dominant armon the different arm. 
6.5 Contraindications to subsequent vaccination 
The following events constitute absolute contraindications to further administration of 
gE/AS01B. If any of these events occur during the study, the subject must not receive 
additional doses of vaccine but may continue other study procedures at the discretion of 
the investigator (see Section 8.4.4).  
• If the subject experiences an SAE judged to be vaccine-related by the investigator 
(Sections 8.1.2 and 8.3.2.2.2); 
See Section 5.7.3.7 for an additional criterion to be checked prior to administration of 
the second vaccination dose. 
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6.6 Concomitant medication/vaccination 
Concomitant medication administered for the treatment of pIMDs NOADs or other 
immune mediated inflammatory disorders at any time during the study must be recorded 
in the eCRF. Refer to Section 8.3.2.5 for information regarding pIMDs NOADs and other 
immune mediated inflammatory disorders . 
6.6.2 Time window for recording concomitant medication/vaccination 
in the eCRF 
Concomitant medication, administered for the treatment of HZ or any related HZ-
complications, or for the treatment of pIMDs NOADs or other immune-mediated 
inflammatory disorders, from Day 0 until Study conclusion contact, must be recorded in 
the eCRF. 
7 Health economics 
For subjects with clinically diagnosed suspected HZ, both questionnaires will be 
completed weekly from Day HZ-0 onwards until the case of clinically diagnosed 
suspected HZ is disproved, OR until a 4-week pain-free period is documented, OR until 
the cut-off date for final analysis. For all subjects with ongoing HZ-associated pain at the 
time of the cut-off date for final analysis, EQ-5D and SF-36 data will be collected until 
suspected HZ is disproved, OR until a 4-week pain-free period is documented OR until 
at least Day HZ-90 regardless of the cut-off date for final analysis.. 
8.1.1 Definition of an adverse event  
The occurrence of HZ or PHN will not constitute an AE or SAE. However, HZ 
complications other than PHN (see Section 5.5.2.5) or presentations of HZ or PHN that, 
in the opinion of the investigator, are not typical of these diseases may will be considered 
as AEs or SAEs. 
8.2.1 Disease-related events or outcomes not qualifying as serious 
adverse events 
The occurrence of HZ or PHN will not constitute an AE or SAE. However, HZ 
complications other than PHN(see Section 5.5.2.5) or presentations of HZ or PHN that, 
in the opinion of the investigator, are not typical of these diseases may will be considered 
as AEs or SAEs. 
8.3.1 Time period for detecting and recording adverse events, serious 
adverse events and pregnancies  
pIMDs NOADs and other immune mediated inflammatory disorders will be evaluated in 
all subjects during the entire study period (Section 8.3.2.5)  
An overview of the protocol-required reporting periods for AEs and SAEs, pIMDs 
NOADs and other immune mediated inflammatory disorders, medically attended visits, 
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pregnancies, and intercurrent medical conditions in study ZOSTER-006 is shown in 
Table 14. 
Table 14 Reporting periods for AEs, SAEs, pIMDs new onset of autoimmune 
diseases, medically attended visits, pregnancies and intercurrent medical conditions 
in study ZOSTER-006 
Study activity 
Timing of reporting 
Reporting of pIMDs NOADs and other immune 
mediated inflammatory disorders 
 
8.3.2.2.1 Assessment of intensity 
The investigator will assess of the maximum intensity that occurred over the duration of 
the event for all other AEs, i.e. unsolicited symptoms, including SAEs reported during 
the study. The assessment will be based on the investigator’s clinical judgement.  
8.3.2.5 AEs of specific interest  
Potential immune-mediated diseases (pIMDs) (formerly referred to as NOADs and 
other immune mediated inflammatory disorders) are a subset of AEs that include 
autoimmune diseases and other inflammatory and/or neurologic disorders of interest 
which may or may not have an autoimmune aetiology. AEs that need to be recorded 
and reported as pIMDs include those listed in the table below. 
However, the investigator will exercise his/her medical and scientific judgement in 
deciding whether other immune-mediated diseases have an autoimmune origin (i.e. 
pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and 
should also be recorded as a pIMD. 
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Table 16 List of potential immune-mediated diseases 
Neuroinflammatory disorders Musculoskeletal disorders Skin disorders 
Cranial nerve disorders, including 
paralyses/paresis (e.g. Bell’s palsy), 
and neuritis (e.g. optic neuritis) 
Multiple sclerosis (including 
variants) 
Transverse myelitis 
Guillain-Barré syndrome, (including 
Miller Fisher syndrome and other 
variants) 
Other demyelinating diseases 
(including acute disseminated 
encephalomyelitis) 
Myasthenia gravis (including 
Lambert-Eaton myasthenic 
syndrome) 
Non-infectious encephalitis/ 
encephalomyelitis 
Neuritis (including peripheral 
neuropathies) 
Systemic lupus erythematosus 
Scleroderma (including, CREST 
syndrome and morphoea) 
Systemic sclerosis 
Dermatomyositis 
Polymyositis 
Antisynthetase syndrome 
Rheumatoid arthritis, 
Juvenile chronic arthritis, (including 
Still’s disease) 
Polymyalgia rheumatica 
Reactive arthritis 
Psoriatic arthropathy 
Ankylosing spondylitis 
Relapsing polychondritis 
Mixed connective tissue disorder 
Psoriasis 
Vitiligo 
Raynaud’s phenomenon 
Erythema nodosum 
Autoimmune bullous skin diseases 
(including pemphigus, pemphigoid 
and dermatitis herpetiformis) 
Cutaneous lupus erythematosus 
Alopecia areata 
Lichen planus 
Sweet’s syndrome 
Liver disorders Gastrointestinal disorders Metabolic diseases 
Autoimmune hepatitis 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Autoimmune cholangitis. 
Crohn’s disease 
Ulcerative colitis 
Ulcerative proctitis 
Celiac disease 
Autoimmune thyroiditis (including 
Hashimoto thyroiditis) 
Grave's or Basedow’s disease 
Diabetes mellitus type I 
Addison’s disease 
Vasculitides Others 
Large vessels vasculitis including: giant cell arteritis 
such as Takayasu's arteritis and temporal arteritis. 
Medium sized and/or small vessels vasculitis including: 
polyarteritis nodosa, Kawasaki's disease, microscopic 
polyangiitis, Wegener's granulomatosis, Churg–Strauss 
syndrome, thromboangiitis obliterans (Buerger’s 
disease), necrotizing vasculitis, allergic granulomatous 
angiitis, Henoch-Schonlein purpura, anti-neutrophil 
cytoplasmic antibody positive vasculitis, Behcet's 
syndrome, leukocytoclastic vasculitis. 
Vasculitides secondary to other immune mediated 
diseases such as lupus vasculitis and rheumatoid 
vasculitis. 
Autoimmune hemolytic anemia 
Autoimmune thrombocytopenias 
Antiphospholipid syndrome 
Pernicious anemia 
Autoimmune glomerulonephritis (including IgA 
nephropathy, glomerulonephritis rapidly progressive, 
membranous glomerulonephritis, membranoproliferative 
glomerulonephritis, and mesangioproliferative 
glomerulonephritis) 
Uveitis 
Autoimmune myocarditis/cardiomyopathy 
Sarcoidosis 
Stevens-johnson syndrome 
Sjögren’s syndrome 
Idiopathic pulmonary fibrosis 
Goodpasture syndrome 
 
When there is enough evidence to make any of the above diagnoses, the AE must be 
reported as a pIMD. Symptoms, signs or conditions which might (or might not) 
represent the above diagnoses, should be recorded and reported as AEs but not as 
pIMDs until the final or definitive diagnosis has been determined, and alternative 
diagnoses have been eliminated or shown to be less likely. 
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In order to facilitate the documentation of pIMDs in the eCRF a pIMD standard 
questionnaire and a list of preferred terms (PTs) and PT codes corresponding to the 
above diagnoses will be available to investigators. 
pIMDs that occur during the study (see also Section 8.3.1 for reporting period) will be 
reported promptly to GSK within the timeframes described in Table 17, once the 
investigator becomes aware of the pIMD. 
Once onset of a new pIMD or exacerbation of a pre-existing pIMD is diagnosed 
(serious or non-serious) in a study subject, the investigator (or designate) must 
complete the information in the SAE screens of the eCRF WITHIN 24 HOURS after 
the he/she becomes aware of the diagnosis. A field on the SAE screen allows to specify 
that the event is a pIMD and whether it is serious or non serious. The SAE screens will 
always be completed as thoroughly as possible with all available details of the event, in 
accordance with the pIMD standard questionnaire provided. Even if the investigator 
does not have all information regarding a pIMD, the SAE screens should still be 
completed within 24 hours. Once additional relevant information is received, the SAE 
screens in the eCRF should be updated WITHIN 24 HOURS. 
The investigator will always provide an assessment of causality at the time of the initial 
report. 
Refer to Section 8.4.3 for back-up system and updating of SAE information after 
freezing of the subject’s eCRF. 
Adverse events of specific interest for safety monitoring include the NOADs and other 
immune mediated inflammatory disorders, such as those listed below. 
Occurrences of AEs of specific interest will be reported throughout the entire study 
period, whether or not they are considered to be possibly related to the treatment 
administration. Medical documentation of the events will be reported in appropriate 
targeted follow-up forms included in the eCRF. These events have also to be reported as 
AE or SAE as appropriate in the eCRF. 
AEs of interest to be reported and documented are the following: 
Neuroinflammatory disorders: cranial nerve disorders, multiple sclerosis, demyelinating 
disease, transverse myelitis, Guillain-Barré syndrome, myasthenia gravis, encephalitis, 
neuritis. 
Musculoskeletal disorders: systemic lupus erythematosus, cutaneous lupus, Sjogren’s 
syndrome, scleroderma, dermatomyositis, polymyositis, rheumatoid arthritis, 
polymyalgia rheumatica, reactive arthritis, psoriatic arthropathy, ankylosing spondylitis, 
undifferentiated spondyloarthropathy. 
Gastrointestinal disorders: Crohn’s disease, ulcerative colitis, ulcerative proctitis, celiac 
disease. 
Metabolic diseases: autoimmune thyroiditis, Grave’s or Basedow’s disease, Hashimoto 
thyroiditis, insulin-dependent diabetes mellitus (IDDM), Addison’s disease. 
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Skin disorders: psoriasis, vitiligo, Raynaud’s phenomenon, erythema nodosum, 
autoimmune bullous skin diseases. 
Other: autoimmune haemolytic anemia, thrombocytopenias, antiphospholipid syndrome, 
vasculitis, pernicious anemia, autoimmune hepatitis, primary biliary cirrhosis, primary 
sclerosing cholangitis, autoimmune glomerulonephritis, autoimmune uveitis, autoimmune 
myocarditis, sarcoidosis, Stevens-Johnson syndrome. 
Medical or scientific judgment should be exercised in deciding whether other 
disorders/diseases have autoimmune origin and should be reported as appropriate. 
Section 8.4.1. Prompt reporting of serious adverse events and other 
events to GSK Biologicals  
Table 17 Time frames for submitting SAEs and other events reports to GSK 
Biologicals 
 Initial Reports Follow-up Information 
on a Previous Report 
Type of 
Event 
Time Frame Documents Time Frame Documents 
All SAEs 24 hours* SAE screen 24 hours* SAE screen 
Pregnancy 24 hours* Pregnancy Report Form 24 hours* Pregnancy Report Form 
pIMDs 24 hours** SAE screen 24 hours** SAE screen 
* Time frame allowed after receipt or awareness of the information. 
**Timeframe allowed after the diagnosis is established and known to the investigator 
 
8.7 Emergency unblinding 
GSK Biologicals Central Safety Physician  
(Study Contact for Emergency Code Break) 
Mobile pPhones for 7/7 day availability: 
Outside US/Canada: 
  (GSK Biologicals Central Safety Physician on call)  
For US/Canada only: 
  (Head Safety Evaluation and Risk Management 
North America GSK Biologicals Central Safety Physician on call) 
Back-up mobile phone contact (all countries): 
  
Outside US/Canada: 
 
For US/Canada only: 
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10.2 Secondary endpoints 
• Occurrence of pre-defined AEs 
− Occurrence and relationship to vaccination of any pIMDs NOADs and other 
immune mediated inflammatory disorders during the entire study period in all 
subjects; 
10.4.1. Sample size assumptions 
Table 18 Assumptions for incidences under placebo, and VE used for trial 
simulations  
Age HZ Incidence (% / Year) HZ VE 
PHN Incidence 
in HZ subjects 
(% /Year) 
On top PHN 
VE in HZ 
subjects (2) 
Overall PHN 
VE in HZ 
subjects 
 
10.4.5.3 Futility analyses and sample size re-assessment 
The study may involve one (or more) unblinded futility analyses performed by the 
IDMC. One futility analysis is planned after approximately 25% of the total HZ cases are 
observed and/or when at least 20% of the total HZ cases are observed in each age 
stratum.  
A conservative futility boundary or a predictive power threshold [Proschan, 2006] in the 
range of ~30% is anticipated but the actual functional form of the beta-spending function 
or the predictive power threshold used for the trial will be defined in the IDMC 
Charter/IDMC RAP. 
10.4.5.4. Provisional region and sub-population allocations 
Enrolment target numbers per region are approximate and may change depending on 
the enrolment. 
Table 25 Provisional region allocation for study ZOSTER-006  
Australasia Europe Latin America North America 
Country Sample 
Size 
Country Sample 
Size 
Country Sample 
Size 
Country Sample 
Size 
Australia 
Hong Kong 
Japan 
S. Korea 
Taiwan 
∼3200 
∼3410 
Czech Republic 
Estonia 
Finland 
France 
Germany 
Italy 
Spain 
Sweden 
United Kingdom 
∼7560 
∼7345 
Brazil 
Mexico 
∼2620 
∼2615 
Canada 
US 
~2620 
~2610 
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10.4.5.5. 7-day diary card subset   
Table 26 Provisional number of subjects in the 7-day diary card subset in study 
ZOSTER-006  
Age  
cohort 
50-59 YOA 60-69 YOA 70-79 YOA ≥ 80 YOA All 
Treatment 
group Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo 
ZOSTER-
006 1410 1410 1410 1410 1410 1410 470 470 
 
4880 
4700 
 
4880 
4700 
Note: In addition, study ZOSTER-022 will include a 7-day diary card subset of 1000 1008 subjects (in each 
respectively the 70-79 YOA and ≥ 80 YOA strata, 250  there are 252 subjects in each treatment group). 
 
10.4.5.6.3. Humoral immune response inter-region variability  
Using Ratio of responder Rates – Country-wise 
When comparing responder rate, a non-inferiority limit of 15% may be considered. Based 
on ZOSTER-010 data, the responder rates were ~97% in EU (N=95) and 100% in US 
(N=37) and a value of 97% will be used as the reference value worldwide. A ~3% - 4% 
difference in point estimate may be observe between countries [eq. 96% in CZ (N=49) 
and 100% in SP (N=46)], as observed between EU and US. 
Table 30 provides power for a sample of 60 - 100 subjects from one country in 
comparison with the rest of the world, assuming 15 countries. When considering a 
difference of 4%, the sample should be at least equal to 100 to achieve a power of 90%. 
Table 30 Sample Sizes for Non-Inferiority Tests (Responder Rates) 
 Sample 
Size 
Sample 
Size 
Grp 2 Equiv  
Grp 1 
Actual 
Grp 1 
Equiv 
Margin 
Actual 
Margin 
 
 Grp 1 Grp 2 Prop Prop Prop Diff Diff Target 
Power N1 N2 P2 P1.0 P1.1 D0 D1 Alpha 
0.6449 60 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250 
0.7364 70 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250 
0.8088 80 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250 
0.8641 90 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250 
0.9050 100 900 0.9700 0.8200 0.9300 -0.1500 -0.0400 0.0250 
0.7642 60 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250 
0.8471 70 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250 
0.9041 80 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250 
0.9415 90 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250 
0.9652 100 900 0.9700 0.8200 0.9400 -0.1500 -0.0300 0.0250 
Score test [Miettinen,1985] 
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10.4.5.7.1. Assumptions and background information for CMI 
The frequency of CD4 T-cells producing at least 2 cytokines following induction with 
gE/AS01B will be estimated in both placebo and vaccine recipients, The cellular 
proportion of subjects achieving a cellular immune response to vaccination with 
gE/AS01B (cellular immunity take rate) will be compared to that of subjects in the 
Placebo group based on the frequency of gE specific CD4 cells, after adjustment for 
background CD4 T-cell frequency and pre-vaccination gE-specific CD4 T-cell responses. 
The increase in CMI responses observed previously post dose 2 following administration 
of 2 doses of 50 μg gE[50 μg] /AS01B compared with saline is about 5.5-fold, and the 
coefficient of variation is about 100%. Therefore, a 1.5-fold increase over placebo in the 
frequency of activated CD4 T-cells is considered as a minimum target for vaccine take 
and was used as threshold for immunologic superiority. These figures were used for the 
sample size calculation. 
 
10.6.2 Efficacy 
HZ burden-of-illness score 
For each confirmed case of HZ, responses to the “worst pain” question in the ZBPI are 
used to calculate a “HZ severity-of-illness” score, defined as the area under the curve 
(AUC) of HZ-associated pain plotted against time during the 182-day period after the 
onset of the case rash.  
10.7.2. Statistical considerations for the interim futility analyses 
The futility rules will be described in the IDMC Charter/IDMC RAP. 
If a futility analysis occurs and leads to a recommendation by the IDMC to filing prior to 
study end for ethical reasons, it is mandated that, prior to final analysis, the significance 
level required during the course of the trial for considering early analysis by IDMC for all 
primary objectives but also key secondary objectives is set to 0.0001 for both HZ and 
overall PHN, considering the alternative hypotheses of true vaccine efficacies above 
40%. 
10.7.3. Final analysis 
When the conditions for triggering the final analysis of efficacy have been reached, the 
final analysis cut-off date will be defined. Any HZ episode occurring prior to the final 
analysis cut-off datae will be followed for a minimal duration of 90 days, as described in 
the RAP, until the case of suspected HZ is disproved, OR until a 4-week pain-free 
period is documented, OR until the cut-off date for final analysis. For all subjects with 
ongoing HZ-associated pain at the time of cut-off date for final analysis, ZBPI data 
will be collected until suspected HZ is disproved, OR until a 4-week pain-free period is 
documented OR until at least Day HZ-90 in order to document potential PHN episodes. 
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10.8.4 Quality of life 
10.8.4.1. SF-36 health survey 
The methodology used for the analysis of the SF-36® questionnaire is detailed by Ware 
et al. [Ware, 2000]. The SF-36® yields an 8-scale profile of scores (physical 
functioning, role physical, bodily pain, general health perceptions, vitality, social 
functioning, role emotional, and mental health) as well as a reported health transition 
score. 
Table 33 presents the SF-36® items that were to be taken into account for each score. 
The SF-36 evaluates the following items: physical functioning, role-physical, bodily pain, 
general health, vitality, social functioning, role-emotional, mental health, reported health 
transition. 
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10.8.5 Analysis of safety 
10.8.5.1 Within groups assessment 
• The proportion of subjects with at least one report of pIMDs NOADs and other 
immune mediated inflammatory disorders during the entire study period will be 
tabulated overall and by time window. Listing will also be provided, sorted by 
subjects and sorted by MedDRA Preferred Term. 
12 Country specific requirements 
All countries will comply with AE and SAE reporting as described in Section 8 of the 
protocol. Additionally, countries and sites will follow all applicable local regulations 
and guidelines for AE and SAE reporting as required by their respective healthcare 
authorities and ethics committees.  
 
Appendix A Laboratory Assays 
PCR Assay for Confirmation of suspected case of HZ  
HZ cases will be confirmed by a Polymerase Chain Reaction (PCR) based algorithm that 
assesses the presence of VZV DNA in samples, and the adequacy of the samples (by 
assessing the presence of β-actin DNA) and, finally, the potential presence of Herpes 
Simplex Virus (HSV) -1 and -2 DNA. Herpes Simplex Virus (HSV) qPCR will be 
performed on VZV negative/ β -actin positive samples for exploratory purpose to assess 
if the rash lesions are due to HSV(1 or 2) and not to VZV; it is not part of the decision 
making process for HZ case confirmation. HSV qPCR testing is optional and requires 
specific consent from the individual subjects. 
As mentioned above, the 5' nuclease-based PCR assay allows the determination of the 
DNA copy number within samples, but in the present study the VZV, HSV1/2 and β-
actin DNA PCR data on samples from suspected HZ lesions (swabs of vesicles, papules 
and crusts, and crusts themselves) will be used qualitatively only according to the above 
mentioned algorithm approach. 
Appendix B Ascertainment of HZ cases including PCR testing 
algorithm to classify HZ suspected cases 
To classify the suspected case of HZ, the samples from the rash lesions will be collected 
for laboratory testing by PCR (minimum 3 samples, collected on the same day, per 
subject). If during clinical evaluation at Visit HZ-1, the investigator determines that 
only papules are present, three samples should be collected (if possible). The 
investigator has the option of collecting three additional samples if the rash progresses 
to vesicles or crust are present prior to or at the Visit HZ-2. See the Study Procedures 
Manual for further details on sample collection. 
Each rash lesion will be tested using standardized and validated molecular assays 
according to the PCR testing algorithm described below. 
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A hierarchical case definition algorithm, similar to the algorithm used by Merck in their 
Shingle Prevention Study (Zostavax efficacy study) [Oxman, 2005] will be used to 
classify each suspected case of HZ as a confirmed HZ case or not. 
• If at least 1 sample coming from a given subject is “VZV positive” by PCR (as 
defined below), the PCR algorithm will classify the this “suspected HZ case” will be 
classified as a “confirmed case of HZ”. 
• If all the samples coming from a given subject are “VZV negative” (as defined 
below), then β-actin PCR will be performed. If one or more “VZV negative” 
samples are and “β-actin positive”, this means that the sampling procedure is 
validated and that the “suspected HZ case” will be classified as “not a case of HZ”. 
HSV qPCR will be performed on VZV negative/ β-actin positive samples for 
exploratory purpose to assess if the rash lesions are due to HSV and not to VZV; it 
is not part of the decision making process for HZ case confirmation. Regarding the 
testing algorithm, the HSV qPCR assay will assess if the rash lesions were due to 
HSV and not to VZV. HSV qPCR testing is optional and requires specific consent 
from the individual subjects. 
• If all the PCR results for a particular subject could do not confirm or exclude a 
“suspected HZ case” (i.e. samples coming from a given subject are considered as 
“inadequate” as both VZV and β-actin PCR results are negative, or no samples are 
available for the subject or the samples are missing), this case will be referred to the 
HZ Ascertainment Committee (HZAC) to be classified, only then will the 
classification by the HZAC be used to confirm or exclude the suspected HZ case. 
The HZAC will consist of three to five physicians with HZ expertise. For every such 
case suspected HZ case, each HZAC member will be asked to make a clinical 
determination of whether the case is HZ based on the review of the available clinical 
information. A “suspected HZ case” will be considered as a “confirmed HZ case” if 
at least 3 all HZAC members concur (majority vote unanimous decision); 
otherwise, it will be classified as “not a case of HZ”.  
This algorithm includes the following steps (see Figure 1): 
1. DNA extraction from the rash lesion. 
2. VZV real-time PCR assay (qPCR) targeting the orf62 gene is performed to detect 
VZV in the rash lesion: 
1. If the VZV qPCR signal is ≥ the cut-off level above the cut-off of positivity 
corresponding to, i.e. the technical limit of detection (LOD) of the assay (10 
VZV DNA copies), the sample will be considered as “VZV positive”. 
If the VZV qPCR signal is above 0 copy/qPCR but below the cut-off level of the assay, 
included between 1 copy/qPCR and the cut-off of positivity, it will be considered as 
“VZV borderline” and will be re-tested twice in order to obtain 3 results per sample. The 
sample will be considered as “VZV positive” if at least 2 results out of the three obtained 
are ≥ the cut-off level of the assay and it will be considered “VZV negative” if fewer 
than 2 samples are ≥ the cut-off level of the assay above the cut-off of positivity.  
If the VZV qPCR signal is equal to 0 copies/qPCR, the sample will be considered as 
“VZV negative”. If every sample is VZV negative, then and the extracted DNA from the 
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samples will be assessed for the presence of β-actin DNA housekeeping gene to validate 
confirm the validity of the rash lesion sampling procedure (see item step 3). 
3. As described here above, if all the samples are VZV negative for a given subject, 
then β-actin qPCR will be performed only on “VZV negative” samples to validate 
confirm the validity of the sampling procedure. 
1. If the β-actin qPCR signal is below the cut-off level of the assay cut-off of 
positivity of this assay (β-actin Negative), the sample will be considered as 
“inadequate” as no β-actin DNA coming from human cells is detected within 
the rash lesion sample. If all samples are β-actin Negative, then the 
classification by the HZAC will be used to confirm or exclude the HZ case. 
If the β-actin qPCR signal is ≥ the cut-off level of the assay above the cut-off of 
positivity of this assay (β-actin Positive), the sample will be considered as “valid” but it 
does not contain without any VZV DNA. According to the testing algorithm, tThe 
extracted DNA will may then be assessed for the presence of HSV-1/2 within the rash 
lesion (see below item 4). If at least one sample is β-actin Positive, then the HZAC 
classification of a suspected HZ case, will not be part of the decision-making process 
for HZ case confirmation. 
As described here above the HSV qPCR assay will may be performed for exploratory 
purpose on “VZV negative/ β-actin positive samples: 
1. If the HSV qPCR signal is below the cut-off level cut-off of positivity of this 
assay, the sample will be considered as “HSV negative”. 
2. If the HSV qPCR signal is ≥ the cut-off level above the cut-off of positivity 
of this assay, the sample will be considered as “HSV positive”.  
Note: The cut-off level of the VZV qPCR, β-actin qPCR and HSV qPCR assays is 
defined as the technical limit of detection of these assays (LOD; i.e. lowest 
concentration that can be detected by PCR in at least 95% of the tests). 
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Figure 1 Algorithm for HZ case definition by PCR 
ORIGINAL 
 
VZV: Varicella Zoster Virus; Q-PCR: real-time (quantitative) PCR; HSV: Herpes Simplex Virus  
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UPDATED 
 
VZV Positive 
if at least 2 results 
≥ cut-off level
Re-testing twice from rash lesion in 
order to obtain 3 results
VZV above 0 copy/qPCR but below cut-off level 
Rash lesion
VZV qPCR (ORF62)
If all samples are 
VZV Negative
β-actin-qPCR
If ≥ 1 sample is VZV 
Postive at or above 
the cut-off level
β-actin Positive 
(≥ 1 sample positive; 
Adequate Sample)
DNA extraction
β-actin Negative 
(all samples negative; 
Inadequate Sample)
All samples 
are VZV 
Negative 
Confirmed Case See Below
Case classified based on HZAC 
diagnosis
Classified as Not a Zoster case
Confirmed Case
VZV Negative 
if fewer than 2 results 
≥ cut-off level
See Below*
 
VZV: Varicella Zoster Virus; Q-PCR: real-time (quantitative) PCR; HSV: Herpes Simplex Virus  
* If the VZV qPCR signal is above 0 copy/qPCR but below the cut-off level of the assay, it will be considered as 
“VZV borderline” and will be re-tested twice in order to obtain 3 results per sample. The sample will be 
considered as “VZV positive” if at least 2 results out of the three obtained are ≥ the cut-off level of the assay 
and it will be considered “VZV negative” if fewer than 2 samples are ≥ the cut-off level of the assay. See then 
below ‘All samples are VZV Negative’. 
Note: The cut-off level of the VZV qPCR assay is defined as the technical limit of detection of the assay (LOD 
of 10 VZV DNA copies; i.e. lowest concentration that can be detected by PCR in at least 95% of the tests) 
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110390 (ZOSTER-006) 
IND number BB-IND 13857 
EudraCT number 2008-000367-42  
Amendment number: Amendment 2 
Amendment date: 16-MAR-2012 
Co-ordinating author:  Scientific Writer 
Rationale/background for changes: 
• To provide further guidance and clarification the following updates have been 
made:  
− In this amendment, the term ‘disproved case’ has been removed. (Previously, 
follow-up could be discontinued for disproved cases of HZ.) Currently, 
standard follow-up is to be conducted for all cases initially clinically 
diagnosed as suspected HZ, even if the case is subsequently not considered as 
suspected. Although this situation will be noted in the eCRF. Therefore, all 
cases initially clinically diagnosed as suspected HZ will be followed for a 
minimum of 28 days. The term ‘clinically diagnosed suspected’ has been 
replaced with ‘suspected’ where applicable to be in alignment with the 
aforementioned change. Sections 5.5.1, 5.5.2, 5.5.2.1, 5.5.2.2, 5.5.2.3, 5.5.2.4, 
5.5.2.5, 5.6, 5.7.3.10, 5.7.3.11, 5.7.3.16, 7 and 10.7.3 have been updated 
accordingly. 
− Details have been added regarding follow-up of suspected HZ cases and 
completion of questionnaires if pain reappears in the same area after a 4-week 
pain-free period and is not accompanied by a new HZ rash. Sections 5.5.1, 
5.6, 5.7.3.11 and 7 have been updated accordingly. 
− Additional photographs of HZ lesions may be taken after Visit HZ-1 to help 
note the progression of the rash. Sections 5.5.2.2, 5.6 and 5.7.3.11 have been 
updated accordingly. 
− The circumstances where the investigator has the option to collect up to three 
additional rash samples after Visit HZ-1 and prior to or at Visit HZ-2 (i.e., <3 
lesions present or only papules present) has been clarified in Sections 5.5.2.2, 
5.6, 5.7.3.11, 5.8.2 and Appendix B and harmonized with the SPM. 
− The HZ date of onset is not recorded in the eCRF, although date of rash onset 
and pain are recorded in the eCRF. Sections 5.5.2.1 and 5.5.2.2 have been 
updated accordingly. 
− Guidance has been provided that HZ complications as defined in Section 
5.5.2.5 (including AE/SAE information) should be recorded throughout the 
duration of the study. Sections 5.5.2.5, 5.6 and 8.3.1 have been updated 
accordingly.  
− The definition of the end date of a suspected case of HZ has been clarified in 
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Section 5.5.2.1. 
− Clarification has been added that if a 4-week pain free period is achieved, 
subjects can stop completing questionnaires. If a 4-week pain free period is 
achieved and additionally the HZ rash resolves, subsequent visit/contacts 
related to the case of HZ can be cancelled. Sections 5.5.2.2, 5.6, 5.7.3.16 and 
10.7.3 have been updated accordingly. 
− The definition of pain free period is based upon item 1 of the ZBPI 
questionnaire and has been updated accordingly in Section 5.5.2.2. 
− The ZBPI, EQ-5D and SF-36 questionnaires must be completed until Day HZ-
28 at minimum. Sections 5.5.2.2, 5.6 and 5.7.3.11 have been updated 
accordingly. 
− In case questionnaires are completed at the study site, study staff can assist in 
reading the questions. Questions should be read verbatim to the subject. 
Family members and care providers who provide assistance should also read 
questions verbatim. Section 5.5.1 has been updated accordingly. 
− The clarification has been added in Section 3 that visit numbers are referred to 
interchangeably with their month designations throughout the protocol (Month 
0 refers to Visit 1, Month 2 refers to Visit 2, etc). For example, all SAEs are to 
be reported until Visit 4 (Month 14). Visit 4 is used to indicate 12 months post 
2nd vaccination. (SAEs related to an HZ complication, related to study 
participation, related to a concurrent GSK medication/vaccine or any fatal 
SAE will be reported throughout the study.)  
− Zostavax has recently been approved for the prevention of herpes zoster 
(shingles) in individuals 50 to 59 years of age in the United States. Sections 
1.1 and 13 have been updated accordingly. 
− Background (Section 1.1) has been updated to reflect that data up to Month 14 
is now available from phase II adjuvant dose comparison study Zoster-010. 
− Small adjustments in the age ratio of 8:5:3:1 (50-59 YOA; 60-69 YOA; 70-79 
YOA and ≥ 80 YOA) and country and subset allocation were necessary to 
complete enrollment of the study in a timely manner. As a result, text in the 
synopsis as well as Sections 1.2, 3, 10.4.5, 10.4.5.1, 10.4.5.4, 10.4.5.6.2 and 
10.4.5.7.2 were updated accordingly. 
− The list of potential immune-mediated diseases (Table 16 in Section 8.3.2.5) 
has been updated to include narcolepsy. 
− Section 10.4.5.3 has been updated to reflect current criteria that are planned to 
trigger the futility analysis.  
− Further information regarding the interim futility analyses will be detailed in 
the RAP, and Sections 5.5.3, 10.4.5.3 and 10.7.2 have been updated 
accordingly. 
− The list of contributing authors has been updated in the title page. 
− The sponsor signatory has been updated in the Protocol Amendment 2 
Sponsor Signatory Approval Page. 
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Amended text has been indicated in bold italics and deleted text has been indicated 
in strikethrough (e.g. text) in the following sections: 
 
Title page  
Contributing authors • , Director, Global Clinical 
Development, Herpesvirus Vaccines 
, Scientific Writer,  
contractor for GSK Biologicals  
• , Director Clinical Regulatory 
Affairs 
• , US Regulatory Affairs 
• , Health Economics 
• , Global Study 
Manager 
• , Safety Physician 
 
Protocol Amendment 2 Sponsor Signatory Approval page 
Sponsor signatory 
 
 Vice President, and Director 
Late Clinical Development 
GlaxoSmithKline Biologicals 
, Director, Global Clinical 
Development, Vaccines
Synopsis  
Rationale for the 
study and study 
design 
This study will enrol subjects in the age ranges 50-59 YOA, 
60-69 YOA, 70-79 YOA and ≥ 80 YOA in approximately an 
8:5:3:1 ratio to achieve comparable numbers of HZ in the 3 
main age strata (50-59 YOA, 60-69 YOA and ≥ 70 YOA) so 
that a balanced estimate of the overall VE in persons 
≥ 50 YOA can be determined.  
Apportionment of approximately 20-25% of the ≥ 70 YOA 
cohort to persons ≥ 80 YOA in both ZOSTER-006 and 
ZOSTER-022 ensures that this particularly vulnerable 
population is adequately represented. 
Study design • Treatment allocation: Eligible subjects will be 
randomized to investigational vaccine/placebo according 
to a 1:1 ratio (vaccine:placebo). Subjects will be stratified 
by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and ≥ 80 
YOA in approximately an 8:5:3:1 ratio. The 70-79 YOA 
and ≥ 80 YOA strata will be combined for primary 
analyses.  
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1.1 Background  
In the US, Zostavax is indicated for prevention of HZ in individuals ≥ 50 60 YOA and 
older [Zostavax Prescribing Information, 2011] [CDC, 2008]. 
Analysis of data obtained up to Month 14 Month 3 (one month after dose 2) is currently 
available for this study; an extended safety follow-up is ongoing. 
1.2 Rationale for the study and study design  
This study will enrol subjects in the age ranges 50-59 YOA, 60-69 YOA, 70-79 YOA and 
≥ 80 YOA in approximately an 8:5:3:1 ratio to achieve comparable numbers of HZ cases 
in the 3 main age strata (50-59 YOA, 60-69 YOA and ≥ 70 YOA; the 70-79 YOA and 
≥ 80 YOA strata will be combined for primary analyses) so that a balanced estimate of 
the overall VE in persons ≥ 50 YOA can be determined. Apportionment of 
approximately 20-25% of the ≥ 70 YOA cohort to persons ≥ 80 YOA ensures that this 
particularly vulnerable population is adequately represented.  
3 Study design overview 
• Treatment allocation: Eligible subjects will be randomized to investigational 
vaccine/placebo according to a 1:1 ratio (vaccine:placebo). Subjects will be stratified 
by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and ≥ 80 YOA in approximately an 
8:5:3:1 ratio. The 70-79 YOA and ≥ 80 YOA strata will be combined for primary 
analyses.  
Throughout the protocol, visit numbers are referred to interchangeably with their 
month designations (Month 0 refers to Visit 1, Month 2 refers to Visit 2, etc). 
5.5.1 Data collection  
Also, subjects with clinically diagnosed suspected HZ will be contacted periodically as 
outlined in Table 3. 
In case of difficulty in self-completion of the diary cards or questionnaires, an aide (such 
as a family member or care provider who is not involved in the study) may provide 
assistance with reading the questions (verbatim) and/or transcribing the subject’s 
responses on the questionnaires and/or diary cards. 
In case questionnaires are completed at the study site, study staff can assist in reading 
the questions (verbatim). 
For all subjects: 
• EQ-5D and SF-36 questionnaires: To be completed by all subjects at study entry. 
Also, to be completed by all subjects at Visits 4, 5 and 6 (subjects with an ongoing 
clinically diagnosed suspected HZ episode will follow a weekly schedule and do not 
need to additionally complete the questionnaires at these visits). 
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EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed into the eCRF for subjects who have clinically 
diagnosed suspected HZ during the study. 
For all subjects in case of a suspected or confirmed case of HZ: 
• Zoster Brief Pain Inventory (ZBPI) questionnaire: To be completed by subjects 
with clinically diagnosed suspected HZ on Day HZ-0 (Visit HZ-1) and daily from 
Day HZ-1 (day after the Visit HZ-1) up to Day HZ-28, and weekly from Day HZ-29 
onwards until the case of suspected HZ is disproved, OR until a 4-week pain-free 
period is documented, OR until the cut-off date for final analysis. For all subjects 
with ongoing HZ-associated pain at the time of cut-off date for final analysis, ZBPI 
data will be collected until suspected HZ is disproved, OR until a 4-week pain-free 
period is documented OR until at least Day HZ-90 (seeRefer to Section 5.5.2.2 for 
more details).  
• EQ-5D and SF-36 questionnaires: To be completed weekly by the subjects with 
clinically diagnosed suspected HZ from Day HZ-0 onwards until the case of 
clinically diagnosed suspected HZ is disproved, OR until a 4-week pain-free period 
is documented, OR until the cut-off date for final analysis. For all subjects with 
ongoing HZ-associated pain at the time of the cut-off date for final analysis, EQ-5D 
and SF-36 data will be collected until suspected HZ is disproved, OR until a 4-week 
pain-free period is documented OR until at least Day HZ-90 (seeRefer to Section 
5.5.2.2 for more details). 
5.5.2 Evaluation and confirmation of suspected and confirmed HZ cases 
5.5.2.1 Definitions 
Subjects clinically diagnosed as having a suspected case of HZ by the investigator will be 
referred to as a case of ‘clinically diagnosed suspected HZ’, and followed up. If a case is 
not clinically diagnosed as suspected HZ, the investigator should not progress further 
with evaluation of the case. 
The HZ onset date is the earlier of the following two events: 1) the HZ rash start date; or 
2) the date on which pain at the site of a subsequent HZ rash is first noted. The HZ onset 
date will be confirmed by the investigator and recorded in the eCRF.  
The end date of a HZ episode is defined as the first time at which a subject had no rash 
(papules, vesicles, ulcers or crusts) presentand after which he/she did not develop a rash 
at the same location at any later visit/contact. This end date will be recorded in the eCRF. 
18-APR-2014 202 
CONFIDENTIAL 
110390 (ZOSTER-006) 
Protocol Amendment 4 Final 
5.5.2.2 Evaluation of suspected case of HZ 
The schedule of visits/contacts that will take place for follow-up of clinically diagnosed 
suspected HZ cases is presented in Table 3. 
• The investigator or his delegate will verify the completed HZ-specific diary card 
returned by the subject. The information from the diary card will be transcribed into 
the eCRF. The investigator or his delegate will record relevant information regarding 
the HZ episode in the eCRF (such as date of onset of pain and rash, date of clinical 
diagnosis of HZ, location and nature of HZ lesions, HZ-related complications if any). 
The HZ onset date will be confirmed by the investigator and recorded in the eCRF; 
• The subject will be asked to complete the ZBPI questionnaires daily from Day HZ-1 
(day after the Visit HZ-1) up to Day 28 (ZBPI must be completed to Day HZ-28 at 
minimum), and weekly from Day HZ-29 onwards until: 
− The case of clinically diagnosed suspected HZ is disproved; OR  
− 28 days after HZ-associated pain ceases. The subject should continue to 
complete the ZBPI questionnaires weekly until a 28-day (or 4-week) pain free 
period is documented (i.e., '0' circled for item 3 of the ZBPI questionnaire at 
each assessment during that entire period a ‘No’ answer to the ZBPI question: 
’Have you had any pain caused by your shingles in the last 24 hours’ (item 1) 
at each assessment during that entire period); OR 
− The cut-off date for final analysis.  
For all subjects with ongoing HZ-associated pain at the time of cut-off date for 
final analysis, follow-up for such a subject completion of ZBPI questionnaires 
will continue until suspected HZ is disproved, OR until a 4-week pain-free 
period is documented OR until at least Day HZ-90. The study conclusion 
contact for such a subject will thus occur after he/she completes follow-up as 
described above. 
• The subjects will be asked to complete the EQ-5D and SF-36 questionnaires from 
Day HZ-0 and continued weekly during the entire period that the ZBPI 
questionnaires are completed. Therefore, these questionnaires should be completed 
until Day HZ-28 at minimum. 
When a case initially clinically diagnosed as suspected HZ is subsequently not 
considered anymore by the investigator as suspected HZ, this will be noted in the 
eCRF. However study procedures to be performed during the follow-up period for a 
suspected HZ case (seeTable 3)should be continued. If the case of clinically diagnosed 
suspected HZ is disproved, or i 
If HZ-associated pain ceases (defined as a 28-day [or 4-week] pain free period), the study 
staff/investigator will inform the subjects to stop completing the ZBPI, EQ-5D and SF-
36 questionnaires and will provide instructions for the subject to return the completed 
questionnaires to the study site. If a 4-week pain-free period is achieved and the HZ 
rash resolves, subsequent follow-up visits or contacts related to this case of HZ will be 
cancelled. The study staff/investigator will inform the subjects to stop completing the 
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ZBPI, EQ-5D and SF-36 questionnaires and will provide instructions for the subject to 
return the completed questionnaires to the study site.  
• The study staff/investigator will: 1) record relevant information regarding the 
clinically diagnosed suspected HZ case (such as the location and nature of HZ 
lesions, the end date of the rash, HZ-related complications, if any); 2) record 
concomitant medications/vaccinations, including concomitant medication the subject 
has already received and/or will receive for HZ treatment or treatment of any HZ-
related complications (Section 6.6); 3) record intercurrent medical conditions 
(Section 6.7); and 4) check if the subject received any medical attention 
[hospitalization, emergency room visit, or a visit to or from medical personnel 
(medical doctor)] for HZ or any HZ-related complication. 
• Additional photographs of HZ lesions may be taken after Visit HZ-1 to help note 
the progression of the rash.  
• If the investigator determines that adequate rash samples are not present at Visit 
HZ-1 (i.e., <3 lesions present or only papules present), the investigator has the 
option of collecting three additional samples prior to or at Visit HZ-2 (see Section 
5.7.3.11).  
5.5.2.3 Confirmation of clinically diagnosed a suspected case of HZ 
A clinically diagnosed suspected case of HZ can be confirmed in two ways: 
 
• By the HZ Ascertainment Committee: 
All clinically diagnosed suspected HZ cases will be referred to the HZ 
Ascertainment Committee (HZAC). The HZAC will classify all referred cases as 
either “HZ” or “not HZ”. 
A clinically diagnosed suspected case of HZ will be considered as “HZ” if the 
HZAC members concur unanimously; otherwise, it will be classified as “not HZ”.  
5.5.2.4 Evaluation of severity of HZ-associated pain using the Zoster 
Brief Pain Inventory 
In each case of clinically diagnosed suspected HZ, the subjects will be asked to assess 
their HZ-associated pain and interference of HZ with their QoL by completing the ZBPI 
questionnaire either themselves or assisted, by an aide (Section 5.5.1) until the suspected 
case of HZ diagnosed is disproved, HZ-associated pain ceases (defined as a 28-day [or 4-
week] pain free period) or until the cut-off date for final analysis (see further details in 
Section 5.5.2.2). 
5.5.2.5 HZ complications 
The presence of HZ complications listed below will be documented in the eCRF, 
independently from the AE reporting of those HZ complications (see Section 8.3.1 and 
refer to the SPM for details). Any HZ complications, according to the definitions below, 
will be recorded by the investigator only in subjects with clinically diagnosed suspected 
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HZ or confirmed HZ. If a recorded complication is associated with a case of suspected 
HZ, and that case is finally not considered to be a confirmed case, the associated 
complication will not be considered a complication of HZ. If a recorded complication is 
associated with a case of clinically diagnosed suspected HZ, and that case of HZ is 
subsequently disproved, the associated complication will not be considered a 
complication of HZ. 
5.5.3 Independent Data Monitoring Committee 
Vaccine efficacy for futility analysis, and other analyses described in the protocol to be 
done in preparation of IDMC review, will be further detailed in the IDMC Reporting and 
Analysis Plan (RAP). 
5.6 Outline of study procedures 
Table 2 List of study procedures 
Footnote:  
f EQ-5D and SF-36 will remain as source documents. The information from these questionnaires will only be 
transcribed in the eCRF for subjects who have a clinically diagnosed suspected HZ  event during the study. 
 
Table 3 Study procedures to be performed during the follow-up period for each 
suspected HZ case 
 
Type of contact 
Timepoints 
 
Take digital photographs of HZ rashα 
Completion† of ZBPI questionnaires by the subjects until HZ 
is disproved, pain ceases or the cut-off date for final analysis  
(ZBPI pain data will be collected until at least Day HZ-90) 
Completion‡ of EQ-5D and SF-36 questionnaires by the 
subjects until HZ is disproved, pain ceases  
or the cut-off date for final analysis (EQ-5D and SF-36 data 
will be collected until at least Day HZ-90) 
Note: If the case of clinically diagnosed suspected HZ is disproved, or if HZ-associated pain ceases (defined as a 28 
day [or 4-week] pain free period) and the HZ rash resolves, subsequent HZ follow-up visits or contacts will be 
cancelled. When a case of clinically diagnosed suspected HZ is disproved, collection of HZ-related information will be 
stopped and no further information on that suspected HZ episode will be encoded in the clinical database. If pain 
reappears in the same area after a 4-week pain-free period and is not accompanied by a new HZ rash, it will be 
assigned to the previous HZ-episode. Visits/contacts will restart with Day HZ-0 defined as the first visit of the 
assigned episode, prior to the pain free period. 
α Additional photographs of HZ lesions may be taken after Visit HZ-1 to help note the progression of the rash. 
* If during clinical evaluation at Visit HZ-1, the investigator determines that only papules are present, three samples 
should be collected (if possible). The investigator has the option of collecting three additional samples if the rash 
progresses to vesicles or crusts are present prior to or at the Visit HZ-2 adequate rash samples are not present at 
Visit HZ-1 (i.e., <3 lesions present or only papules present), the investigator has the option of collecting three 
additional samples prior to or at Visit HZ-2.  
 
† Subjects with clinically diagnosed suspected HZ will be asked to complete the ZBPI questionnaire at Day HZ-0 (Visit 
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HZ-1) to rate HZ-associated pain within the last 24 hours (If the time between the HZ onset and clinical evaluation at 
Visit HZ-1 is greater than 24 hours, the subject will be asked to complete a second ZBPI also for the elapsed time 
between the HZ onset and 24 hours before Visit HZ-1); daily from Day HZ- 1 to Day HZ-28, and weekly from Day HZ 
29 onwards until suspected HZ is disproved,  a 4-week pain-free period is documented or until the cut-off date for final 
analysis. If pain reappears in the same area after a 4-week pain-free period and is not accompanied by a new 
HZ rash, it will be assigned to the previous HZ-episode. The completion of ZBPI questionnaires will resume 
based upon the weekly schedule established at the start of the assigned episode. For all subjects with ongoing 
HZ-associated pain at the time of cut-off date for final analysis, ZBPI data will be collected until suspected HZ is 
disproved, OR until a 4-week pain-free period is documented OR until at least Day HZ-90. (See Section 5.5.2.2). 
‡Subjects with clinically diagnosed suspected HZ will be asked to complete the EQ-5D and SF-36 questionnaire 
weekly from Day HZ-0 to Day HZ-28, and weekly onwards until suspected HZ is disproved,  a 4-week pain-free period 
is documented or until the cut-off date for final analysis. If pain reappears in the same area after a 4-week pain-free 
period and is not accompanied by a new HZ rash, it will be assigned to the previous HZ-episode. The 
completion of EQ-5D and SF-36 questionnaires will resume based upon the weekly schedule established at the 
start of the assigned episode. For all subjects with ongoing HZ-associated pain at the time of cut-off date for final 
analysis,  EQ-5D and SF-36 data will be collected until suspected HZ is disproved, OR until a 4-week pain-free period 
is documented OR until at least Day HZ-90. (See Section 5.5.2.2)  
Each clinically diagnosed suspected HZ that occurs up to the cut-off date for final analysis will be followed at least until 
Visit HZ-7 (the study visit at Day HZ-91). 
Follow-up for the occurrence of any SAEs will begin at Day 0 and continue until Month 
14. Follow-up for the occurrence of SAEs related to an HZ complication as defined in 
Section 5.5.2.5, related to study participation, or related to a concurrent GSK 
medication/vaccine or any fatal SAE, will continue until study conclusion.  
Table 5 Intervals between contacts with subjects in case of suspected HZ 
Footnote: 
Note: If a case of clinically diagnosed suspected HZ is disproved or if HZ-associated pain ceases (i.e., after a 4-week 
pain-free period is documented) and the HZ rash resolves, subsequent follow-up HZ visits or contacts may will be 
cancelled (see Section 5.5.2.2). 
5.7.3.10 Recording of data from completed EQ-5D and SF-36 
questionnaires 
• EQ-5D and SF-36 questionnaires: To be completed by all subjects at study entry. 
Also, to be completed by all subjects at Visits 4, 5 and 6 (subjects with an ongoing 
clinically diagnosed suspected HZ episode will follow a weekly schedule and do not 
need to additionally complete the questionnaires at these visits). 
EQ-5D and SF-36 will remain as source documents. The information from these 
questionnaires will only be transcribed into the eCRF for subjects who have clinically 
diagnosed suspected HZ during the study. 
5.7.3.11 Follow up of suspected HZ cases and HZ-associated pain 
Data will be collected on all clinically diagnosed suspected HZ cases that occur from 
administration of the first dose of vaccine/placebo until the cut-off date for final analysis 
(Section 5.7.3.16). For each suspected case of HZ that the investigator concludes is 
clinically consistent with HZ, data on HZ-associated pain (using ZBPI questionnaires 
completed by the subject) will be collected until Day HZ-28, and from Day HZ-29 
until:1) The case is disproved; 2)  the subject has no HZ-associated pain for 4 
consecutive weeks; or, 23) the cut-off date for final analysis. For all subjects with 
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ongoing HZ-associated pain at the time of cut-off date for final analysis, ZBPI data will 
be collected until suspected HZ is disproved, OR until a 4-week pain-free period is 
documented OR until at least Day HZ-90. In addition, subjects with clinically diagnosed 
suspected HZ will be asked to complete EQ-5D and SF-36 questionnaires weekly. If pain 
reappears in the same area after a 4-week pain-free period and is not accompanied by 
a new HZ rash, it will be assigned to the previous HZ-episode. The completion of 
ZBPI, EQ-5D and SF-36 questionnaires will resume based upon the weekly schedule 
established at the start of the assigned episode. Visits/contacts will also restart 
according to the schedule in Table 3 with Day HZ-0 defined as the first visit of the 
assigned episode, prior to the pain free period. Refer to Section 5.5.2.2 for more details.  
If during clinical evaluation at Visit HZ-1, the investigator determines that adequate rash 
lesion samples cannot be collected, the subject may be asked to return to the study site for 
collection of suitable HZ lesion samples. Three replicate rash lesion samples (see Table 
6) should be collected on the same day. If during clinical evaluation at Visit HZ-1, the 
investigator determines that only papules are present, three samples should be collected 
(if possible). The investigator has the option of collecting three additional samples if the 
rash progresses to vesicles or crusts are present prior to or at the Visit HZ-2. If during 
clinical evaluation at Visit HZ-1, the investigator determines that adequate rash lesion 
samples cannot be collected (i.e., less than three lesions present, or if only papules are 
present), the subject should be asked to return to the study site for collection of 
additional samples prior to or at the Visit HZ-2 if there is rash progression (i.e., 
appearance of new/additional lesions if originally less than three lesions present, or 
appearance of vesicles if originally only papules present). When the subject returns for 
repeat sample collection, three samples from separate lesions should be collected.  
At Visit HZ-1, the rash will be documented by digital photography. Additional 
photographs of HZ lesions may be taken after Visit HZ-1 to help note the progression 
of the rash.  
5.7.3.16 Study conclusion 
Study end will take place when both conditions for final analysis are met and a minimum 
90 days follow-up is completed for each case of confirmed or clinically diagnosed 
suspected HZ that occurs prior to the cut-off date for final analysis. 
When the cut-off date for final analysis is established, the study sites will contact the 
subjects for the study conclusion contact as soon as possible. If a subject with clinically 
diagnosed suspected HZ has not completed follow-up until at least Day HZ-90 at the cut-
off date for final analysis, follow-up for such a subject will continue until Day HZ-90 (or 
sooner (1) if the case is disproved or (2) if the subject has no HZ-associated pain for 4 
consecutive weeks and the HZ rash resolves).  
At the study conclusion contact, the following procedures will take place: 
• Follow-up of any cases of confirmed or clinically diagnosed suspected HZ and HZ-
associated pain (Sections 5.5.2 and 5.7.3.10); 
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5.8.2 Biological samples 
Table 6 Biological samples 
Footnote: 
† If during clinical evaluation at Visit HZ-1, the investigator determines that only papules are present, three samples 
should be collected (if possible). The investigator has the option of collecting three additional samples if the rash 
progresses to vesicles or crusts are present prior to or at the Visit HZ-2 that adequate rash samples are not present 
at Visit HZ-1 (i.e., <3 lesions present or only papules present), the investigator has the option of collecting 
three additional samples prior to or at Visit HZ-2. See the SPM for further details on sample collection. 
 
7 Health economics 
For subjects with clinically diagnosed suspected HZ, both questionnaires will be 
completed weekly from Day HZ-0 onwards until the case of clinically diagnosed 
suspected HZ is disproved, OR until a 4-week pain-free period is documented, OR until 
the cut-off date for final analysis. For all subjects with ongoing HZ-associated pain at the 
time of the cut-off date for final analysis, EQ-5D and SF-36 data will be collected until 
suspected HZ is disproved, OR until a 4-week pain-free period is documented OR until at 
least Day HZ-90. Refer to Section 5.5.2.2 for more details.  
8.3.1 Time period for detecting and recording adverse events, serious 
adverse events  
All HZ complications as defined in Section 5.5.2.5 (including AE/SAE information) 
will be reported throughout the entire study period. 
An overview of the protocol-required reporting periods for AEs and SAEs, pIMDs, 
medically attended visits and, intercurrent medical conditions and HZ complications in 
study ZOSTER-022 is shown in Table 14. 
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Table 14 Reporting periods for AEs, SAEs, pIMDs, medically attended visits and, intercurrent medical conditions and HZ 
complications in study ZOSTER-006 
         CONTACT (monthly after Visit 3 until study conclusion, 
except at months that coincide with the subject’s 
scheduled visits) 
Study activity VISIT 1 
DOSE 1 
   VISIT 2 
DOSE 2 
  VISIT 3 CONTACT VISIT 4 VISIT 5 VISIT 6 Study 
conclusion 
contact 
Timing of reporting Day 0/ 
Month 0 
Day 6 
post 
Dose 1 
Day 29 
post 
Dose 1 
 Day 0/ 
Month 2 
Day 6 
post 
Dose 2 
Day 29 
post 
Dose 2 
Month 3 Month 8 Month 14 Month 26 Month 38  
              
              
Recording of HZ Complications*  
(including AE/SAE information) 
             
              
* HZ complications are defined in Section 5.5.2.5 
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Section 8.3.2.5 AEs of specific interest 
Table 16 List of Potential immune-mediated diseases 
Neuroinflammatory disorders 
Cranial nerve disorders, including 
paralyses/paresis (e.g. Bell’s palsy), 
and neuritis (e.g. optic neuritis) 
Multiple sclerosis (including 
variants) 
Transverse myelitis 
Guillain-Barré syndrome, (including 
Miller Fisher syndrome and other 
variants) 
Other demyelinating diseases 
(including acute disseminated 
encephalomyelitis) 
Myasthenia gravis (including 
Lambert-Eaton myasthenic 
syndrome)  
Non-infectious encephalitis/ 
encephalomyelitis  
Neuritis (including peripheral 
neuropathies) 
Narcolepsy  
 
10.4.5 Sample sizes  
The provisional country allocation and various subsets are also described.  
10.4.5.1 Primary objective  
The final analysis of the ZOSTER-022 study is planned after the accumulation at least 65 
PHN cases (expected median are approximately 40 PHN cases in 70-79 YOA and 
approximately 26 PHN cases in ≥ 80 YOA strata) are accrued from study ZOSTER-022 
(primary condition for triggering analysis), and at least 278 confirmed HZ cases 
(expected median number of cases is 310 HZ cases) across both 70-79 YOA (expected 
median of 222 HZ cases) and ≥ 80 YOA (expected median of 87 HZ cases) strata. 
10.4.5.3 Futility analyses and sample size re-assessment 
One futility analysis is planned after approximately at least 25% of the total number of 
HZ cases anticipated at final analysis are observed in Zoster-006 (see Table 20), and 
when at least 20% of the total number of HZ cases anticipated at final analysis within 
each age stratum (50-59 YOA, 60-69 YOA and 70+ YOA) are observed (seeTable 20) in 
each age stratum. Note that HZ cases from ZOSTER-022 may be used to meet the 
required number of 70+ YOA cases. The precise timing of that analysis maywill be 
triggereddetermined by a blinded review of the HZ case accrual in ZOSTER-006 and/or 
ZOSTER-022. The futility decision rules will be described in the IDMC Charter and 
statistical analysis plan RAP.  
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A conservative futility boundary or a predictive power threshold [Proschan, 2006] in the 
range of ~30% is anticipated but the actual functional form of the beta-spending function 
or the predictive power threshold used for the trial will be defined in the IDMC 
Charter/IDMC RAP. 
10.4.5.4 Provisional region and sub-population allocations 
Subjects will be stratified by age: 50-59 YOA; 60-69 YOA; 70-79 YOA and ≥ 80 YOA 
in approximately an 8:5:3:1 ratio. 
10.4.5.6.2 Humoral immune response vaccine take 
Overall, accounting for the same number of subjects to be sampled in vaccine and 
placebo groups in each of the 15 to 18 countries in order to maintain the blind, and to 
have a sufficiently large number of evaluable blood samples, the total number of subjects 
enrolled into the subset should approximately be 18 x 60 x 2 = ~2160. 
10.4.5.7.2 Number of subjects in the CMI subset 
The CMI analyses will be performed in the Immunogenicity subset in three countries 
(Czech Republic, Japan and United States) at designated sites that have access to a 
PBMC processing facility within the acceptable time window from sample collection to 
PBMC processing. The CMI subset in these countries will is expected to include 156 
subjects to account for anticipated lost or non-evaluable samples, see Table 32. 
10.7.2 Statistical considerations for the interim futility analyses 
The futility rules will be described in the IDMC Charter/IDMC RAP. 
10.7.3 Final analysis  
When the conditions for triggering the final analysis of efficacy have been reached, the 
final analysis cut-off date will be defined. Any HZ episode occurring prior to the final 
analysis cut-off date will be followed, as described in the RAP, until the case of 
suspected HZ is disproved, OR until a 4-week pain-free period is documented and the 
HZ rash resolves, OR until the cut-off date for final analysis. For all subjects with 
ongoing HZ-associated pain at the time of cut-off date for final analysis, ZBPI 
questionnaire data will be collected until suspected HZ is disproved, OR until a 4-week 
pain-free period is documented OR until at least Day HZ-90 in order to document 
potential PHN episodes. 
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Appendix B  ASCERTAINMENT OF HZ CASES INCLUDING 
PCR TESTING ALGORITHM TO CLASSIFY HZ SUSPECTED 
CASES  
To classify the suspected case of HZ, the samples from the rash lesions will be collected 
for laboratory testing by PCR (3 samples, collected on the same day, per subject). If 
during clinical evaluation at Visit HZ-1, the investigator determines that only papules are 
present, three samples should be collected (if possible). The investigator has the option of 
collecting three additional samples if the rash progresses to vesicles or crust are present 
prior to or at the Visit HZ-2. If during clinical evaluation at Visit HZ-1, the investigator 
determines that adequate rash lesion samples cannot be collected (i.e., less than three 
lesions present, or if only papules are present), the subject should be asked to return to 
the study site for collection of additional samples prior to or at the Visit HZ-2 if there is 
rash progression (i.e., appearance of new/additional lesions if originally less than three 
lesions present, or appearance of vesicles if originally only papules present). When the 
subject returns for repeat sample collection, three samples from separate lesions 
should be collected.  
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GlaxoSmithKline Biologicals 
Clinical Research & Development 
Protocol Amendment 3 
eTrack study number and 
Abbreviated Title(s) 
110390 (ZOSTER-006) 
IND number BB-IND 13857 
EudraCT number 2008-000367-42  
Amendment number: Amendment 3 
Amendment date: Final, 28 June 2012 
 
Co-ordinating author: , Scientific Writer,  contractor for 
GSK Biologicals 
Rationale/background for changes:  
• At the European Medicines Agency’s (EMA) request, GSK Biologicals has 
updated its procedure for emergency unblinding during the conduct of a clinical 
study. According to the revised procedure, the responsibility and the decision to 
break the treatment code in emergency situations resides solely with the 
investigator and consequently, the investigator will have full authority to break the 
treatment code. 
• To update the list of contributing authors (cover page) 
Amended text is indicated in bold italics and deleted text is shown with strikethrough in 
the following sections: 
Cover page 
Contributing authors • , Health Economics 
• , Project Data Manager 
Section 8.7 Emergency Unblinding 
Unblinding of a subject’s individual treatment code should occur only in the case of a 
medical emergency, or in the event of a serious medical condition, when knowledge of 
the study treatment is essential for the clinical management or welfare of the subject, 
as judged by the investigator. 
The emergency unblinding process consists of the automated system (SBIR) that allows 
the investigator to have unrestricted, immediate and direct access to the subject’s 
individual study treatment. 
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The investigator has the option of contacting a GSK Biologicals’ On-call Central 
Safety Physician (or Backup) if he/she needs medical advice or needs the support of 
GSK to perform the unblinding (i.e. he/she cannot access the automated Internet-based 
system). 
Any emergency unblinding must be fully documented by using the Emergency 
Unblinding Documentation Form, which must be appropriately completed by the 
investigator and sent within 24 hours to GSK Biologicals. 
GSK Biologicals’ Contact information for Emergency Unblinding 
24/24 hour and 7/7 day availability 
GSK Biologicals’ Central Safety Physician: 
Outside US/Canada: 
 (GSK Biologicals Central Safety Physician on-call) 
US/Canada only: 
 (GSK Biologicals Central Safety Physician on-call) 
GSK Biologicals’ Central Safety Physician Back-up: 
Outside US/Canada: 
 
US/Canada only: 
 
Emergency Unblinding Documentation Form transmission: 
Outside US & Canada: 
Fax:  or  
US/Canada only: 
Fax:  
The investigator, or other physician managing the subject, should contact GSK 
Biologicals’ Central Safety Physician to discuss the need for emergency unblinding. 
Alternatively the investigator may contact the local contact who will contact the GSK 
Central Safety Physician.  
An investigator should request for unblinding of the subject’s treatment code only in the 
case of a medical emergency, or in the event of a serious medical condition, when 
knowledge of the investigational study vaccine(s)/product(s) is essential for the clinical 
management or welfare of the subject.  
The GSK Biologicals’ Central Safety Office will be allowed to access the individual 
randomisation code. The code will be broken by the GSK Biologicals’ Central Safety 
physician (see below and Study Contact for Emergency Code Break in Sponsor 
Information) only in the case of medical events that the investigator/physician in charge 
of the subject feels cannot be treated without knowing the identity of the study 
vaccine(s)/product(s). 
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GSK Biologicals Central Safety Physician  
(Study Contact for Emergency Code Break) 
Phones for 7/7 day availability: 
Outside US/Canada: 
 (GSK Biologicals Central Safety Physician on call)  
For US/Canada only: 
 (GSK Biologicals Central Safety Physician on call) 
Back-up phone contact: 
Outside US/Canada: 
 
For US/Canada only: 
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GlaxoSmithKline Biologicals 
Clinical Research & Development 
Protocol Amendment 4 
eTrack study number and 
Abbreviated Title(s) 
110390 (ZOSTER-006) 
IND number BB-IND 13857 
EudraCT number 2008-000367-42  
Amendment number: Amendment 4 
Amendment date: Final, 18 April 2014 
Co-ordinating author: , Scientific Writer,  contractor for 
GSK Biologicals 
Rationale/background for changes:  
• It is predicted that study ZOSTER-006 will reach the conditions required for 
triggering final analysis of herpes zoster (HZ) primary endpoint about one year 
before those conditions being reached for study ZOSTER-022. Therefore GSK 
decided, as originally planned in these circumstances, to dissociate the two studies 
in terms of timing of the analysis of each study. Moreover, a two-step approach is 
allowed for the analysis of each study. Both studies will end concurrently. 
(Synopsis, Sections 3, 10.4.6) 
• In study ZOSTER-022, postherpetic neuralgia (PHN) is demoted from co-primary 
endpoint to a descriptive secondary endpoint and the overall PHN co-primary 
endpoint in subjects ≥ 70 YOA for pooled analyses of ZOSTER 006 and 
ZOSTER-022 will be considered as primary analysis for PHN. Overall PHN in 
subjects ≥ 50 YOA has become a secondary endpoint for pooled analyses of 
ZOSTER-006 and ZOSTER-022. The applicable objectives and endpoints have 
been updated accordingly in the ZOSTER-022 protocol. Pooled analyses of 
ZOSTER-006 and ZOSTER-022 will only be conducted if the primary objective 
[HZ vaccine efficacy (VE)] is demonstrated in both ZOSTER-006 and ZOSTER-
022 separately. The gatekeeping strategy has been updated accordingly and 
aligned with the objectives (Synopsis, Sections 1.2, 10.4.2, Table 19, 10.4.3, 
10.4.4) ; the gatekeeping strategy diagram has been numbered (Fig. 1). 
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• The expected number of PHN cases is projected based on current accrual rates. 
The target number of PHN cases required to trigger pooled PHN analysis has been 
reduced, while maintaining statistical robustness. A total of at least 35 PHN cases 
in subjects ≥ 70YOA provides 90% power to demonstrate an overall PHN VE of at 
least 0% (previously a total of at least 88 PHN cases provided 93% power to 
demonstrate an overall PHN VE in subjects ≥ 50YOA of at least 25%). In the 
pooled analysis of studies ZOSTER-006 and ZOSTER-022 clinically meaningful 
overall PHN VE (PHN VE in ≥ 70 YOA randomized subjects) will be 
demonstrated if the lower limit of the 95% CI is above 0%.  The sample size of the 
pooled studies ZOSTER-006 and ZOSTER-022 provides 10% chance (previously 
22%) to demonstrate statistically significant PHN VE (LL above 0%) in those 
subjects presenting with a HZ episode.  (Sections 10.4.5.1, Table 20, 21, 22, 
Section 10.4.5.2) 
• The analysis steps, i.e. final HZ efficacy analysis (step 1) and end of study analysis 
(step 2) are defined. The conditions determining the cut-off dates of the 2 analysis 
steps are detailed.  
The cut-off date for final HZ efficacy analysis will occur given the following 
conditions: 
− at least 196 confirmed HZ cases are accrued in the primary cohort for analysis 
of efficacy;   
− approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ 
cases in subjects 60-69 YOA are accrued in the mTVc; 
− approximately 75% of subjects in each stratum have completed at least 36 
months follow-up after Dose 2, and the remaining subjects have completed at 
least 30 months follow-up after Dose 2. 
The cut-off date for end of study analysis will occur given the following: 
− all previous conditions are met for final HZ analyses in study ZOSTER-022; 
− at least 35 PHN cases in subjects ≥ 70 YOA are accrued in the in the primary 
cohort for analysis of efficacy when pooling the studies ZOSTER-006 and 
ZOSTER-022.  
The end of study analysis cannot be performed before the final HZ efficacy 
analysis. Details regarding study duration are described. 
(Synopsis, Sections 3, 10.4.5.1, 10.4.6) 
• An overview of the analyses performed at each analysis step is given. Step 1 will 
include analyses of the following objectives of ZOSTER-006: all  HZ VE 
objectives and all reactogenicity/safety and immunogenicity objectives. At step 2,  
all objectives of study ZOSTER-006 will be analyzed. Objectives already analyzed 
at step 1 will be re-analyzed (confirmatory descriptive in case of inferential 
analysis at step 1 or descriptive analysis otherwise). At step 2, pooled analyses of 
studies ZOSTER-006 and ZOSTER-022 are planned; overall PHN VE in subjects 
≥ 70 YOA, and other pre-specified endpoints will be analyzed. (Synopsis, Sections 
3, 10.4.9, Table 33) 
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• Each inferential objective in study ZOSTER-006 will be assessed only one time, 
therefore no alpha adjustment will be applied. For all inferential objectives 
assessed at first step analysis, a second descriptive analysis will be performed at 
the end of each study and will serve as confirmatory analysis (Sections 10.4.4, 
10.4.7). 
• It has been detailed that depending on the further evolution of the case accrual rate, 
the generated data may be presented in one or more study reports per study 
(ZOSTER-006 and ZOSTER-022). The final study report for each study will be a 
comprehensive report containing the results of the two analysis steps (Sections 
10.7.4, 10.8.3.2). Wording in Section 10.8.3.4 has been aligned with Section 
10.7.4. 
• The same blinding level (i.e. observer-blind) remains to be kept throughout the 
study. Measures taken to ensure the blinding, including the installation of a 
firewall, are described in a separate charter. Pending the outcome of the final HZ 
efficacy analysis of studies ZOSTER-006 and ZOSTER-022, a long-term follow-
up study might be planned enrolling subjects who participated in the primary 
studies ZOSTER-006 and ZOSTER-022 and are willing to participate in the 
follow-up study.  The design of the follow-up study remains to be confirmed. 
(Sections 5.4, 10.4.6, 10.4.8, 10.7.3) 
• Given the two-step analyses, in accordance with GSK procedures, in the List of 
study procedures the final HZ efficacy analysis trigger has been specified, with 
transcription in the eCRF of the date of the last visit or contact with the subject and 
addition of the investigator signature (Section 5.6, Table 2). This has also been 
detailed in a new section 5.7.3.15; the numbering of subsequent sections has been 
updated accordingly (i.e., Sections 5.7.3.16 and 5.7.3.17). 
• It is anticipated that all subjects will have completed Visit 6 at the time of study 
conclusion; updates have been made accordingly (Sections 3 and 5.6, Table 2 and 
Table 4). 
• Given the two-step analyses, reference is made to the cut-off date for end of study 
analysis (instead of cut-off date for final analysis) when describing follow-up of 
HZ up to or close to study end (Sections 5.5.1, 5.5.2.2, 5.5.2.4, 5.6 Table 3, 
5.7.3.11, 5.7.3.17, 7, 10.7.3). 
• The description of the process for follow up of HZ has been aligned throughout the 
Table 3 footnotes (Section 5.6) reflecting that if HZ-associated pain ceases 
(defined as a 28-day [or 4-week] pain free period) and the HZ rash resolves, 
subsequent HZ follow-up visits or contacts will be cancelled. 
• Given the two-step analyses, reference is made to ‘final HZ efficacy analysis’ 
instead of ‘final analysis’, when applicable (Sections 10.4.5.3, 10.7.1 and 10.7.2, 
Table 23 and Table 24). 
• It has been detailed that in case of unblinding upon the subject’s request to allow 
the subject to decide if he/ she will consider immunization with a licensed HZ 
vaccine, the subject will be withdrawn from the study (Sections 5.7.3, 9.2.1). 
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• The cut-off of the gE-specific ELISA assay has been changed from 18 to 97 
mIU/mL. Background signal has been measured with the anti-gE ELISA on 
samples from Varicella Zoster Virus (VZV) naïve paediatric subjects. This 
observation of background signal on VZV naïve samples was not part of the 
original validation of the assay and establishment of the assay cut-off. Background 
signal measured with the anti-gE ELISA has no impact on Zoster project clinical 
conclusions as the vast majority of the samples (at all timepoints) have high 
titerswell above the unspecific response level measured on VZV naïve samples 
from Measles, Mumps, Rubella and Varicella (MMRV) studies and Zoster vaccine 
responses are very robust. However this finding triggered re-evaluation of the 
assay cut-off. Based on complementary validation experiments performed in line 
with Clinical and Laboratory Standards Institute (CLSI) guidelines and taking into 
account internal company guidelines the technical and seropositivity cut-off has 
been set at 97mIU/mL. (Section 5.8.3, Table 7, Appendix A) 
• Regarding the reporting of SAEs that are related to study participation (e.g. 
protocol-mandated procedures, invasive tests, a change from existing therapy) or 
are related to a concurrent GSK medication/vaccine or any fatal SAE, it has been 
clarified that this includes SAEs that are considered by the investigator  to be 
related to the investigational vaccine and are to be reported until study end 
(Section 8.3.1; Table 14). 
• The section on derived and transformed data for cell-mediated immunogenicity 
vaccine responses  (gE- and VZV-specific) including the definition of vaccine 
response has been updated in alignment with the harmonised definitions within the 
ZOSTER project (Section 10.6.4). 
• For clarity, the total number of subjects included in the Immunogenicity subset and 
the CMI subset has been detailed (Section 10.4.5.6.4, Table 30; Section 10.4.5.7.2, 
Table 32). 
• A process related to review of immunogenicity data as described in the protocol is 
not applicable for the study, therefore any related wording has been removed 
(Section 10.7.3). 
• In accordance with current GSK procedures, where applicable the name of the plan 
previously referred to as ‘reporting analysis plan’ has been updated to ‘statistical 
analysis plan’ (List of abbreviations, Sections 10.5.3, 10.7.3, 10.8.2, 10.8.2.3, 
10.8.2.4, 10.8.2.5, 10.8.2.6, 10.8.2.7, 10.8.3.4, 10.8.4.1, 10.8.4.2, 10.8.5.2). 
• For clarity, it has been detailed that the subject will be reminded that the current 
study has yearly follow-up visits planned until Month 38 (Visit 6) (Section 
5.7.3.14). 
• The estimated study period has been updated in the section with country specific 
requirements for Japan (Section 12.3). 
• A reference has been further detailed and references which are not applicable 
anymore have been removed (Section 13).  
• The list of contributing authors and the sponsor signatory have been updated 
(cover page, sponsor signatory approval page). 
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Amended text is indicated in bold italics and deleted text is shown with strikethrough in 
the following sections: 
Cover page 
Contributing authors   
•  Project Level Clinical Research & 
Development Lead,  Director, Global Clinical 
Development , Vaccines 
• , Clinical Research and 
Development Lead 
• , Biostatistician 
•  Biostatistician, Lead Statistician  
•  Manager Science Writing 
•  Scientific Writer 
•  Scientific Writer,  
contractor for GSK Biologicals  
•  Global Study Manager 
•  Clinical Immunology and Project 
Management 
•  Project Manager Clinical 
Laboratory  
•   Global Vaccine Clinical 
Laboratories Project Manager 
•  Global Vaccine 
Clinical Laboratories Project Director 
•  Data Management 
•  Project Data Manager 
•  Safety Physician 
•  Clinical Global Regulatory Affairs 
•  Global Regulatory Affairs 
•  Global Regulatory Affairs 
•  Director, US Regulatory 
Affairs  
•  Health Economics 
•  Director Clinical Global 
Regulatory Lead Regulatory Affairs, Director 
•  US Regulatory Affairs 
•  Health Economics 
•  Health Economics 
• , Health Economics  
•  Global Study Manager 
•  Project Data Manager, Study 
Delivery Lead
Copyright 2010- 20122014 the GlaxoSmithKline group of companies. All rights reserved. Unauthorized 
copying or use of this information is prohibited. 
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Protocol Amendment 4 Sponsor signatory approval page 
Sponsor signatory 
 
 Director, Global Clinical 
Development, Vaccines  Project Level 
Clinical Research & Development Lead, Director, 
Global Clinical Development, Vaccines 
Synopsis  
Rationale for the 
study and study 
design 
Study ZOSTER-022 will address VE against PHNHZ in 
subjects ≥ 70 YOA, in addition to providing a robust estimate 
of HZ VE in that age stratum. After each study (ZOSTER-006 
and ZOSTER-022) is analyzed separately At the end of 
studies ZOSTER-006 and ZOSTER-022, a pooled analysis of 
HZ and PHN data from both studies combined is planned and 
will be described prospectively. The analysis of pooled data 
from both studies for overall PHN in subjects ≥ 70 YOA is 
positioned as primary analysis for PHN. 
 
Study design  
• Planned analysis steps:  
It is predicted that study ZOSTER-006 will reach the 
conditions required for triggering final analysis of HZ 
primary endpoint about one year before those 
conditions being reached for study ZOSTER-022. 
Therefore GSK decided, as originally planned in these 
circumstances, to dissociate the two studies in terms of 
timing of the analysis of each study. Moreover, a two-
step approach is allowed for the analysis of each study. 
Both studies will end concurrently. 
In study ZOSTER-006, the planned analysis steps are 
the following:  
1. Final HZ efficacy analysis (step 1). Final analysis of 
HZ primary endpoint:  
The cut-off date for final HZ efficacy analysis will 
occur when the following conditions are met: 
− at least 196 confirmed HZ cases are accrued in the 
modified Total Vaccinated cohort (mTVc) (Footnote 1);  
− approximately 60 HZ cases in subjects 50-59 YOA 
and approximately 60 HZ cases in subjects 60-69 
YOA are accrued in the mTVc; 
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− approximately 75% of subjects in each stratum have 
completed at least 36 months follow-up after Dose 
2, and the remaining subjects have completed at 
least 30 months follow-up after Dose 2. 
Step 1 will include analyses of the following objectives: 
− all  HZ VE objectives; 
−  all reactogenicity/safety and immunogenicity 
objectives. 
2. End of study analysis (step 2).  
The cut-off date for end of study analysis will occur 
given the following:  
− all conditions (as detailed in ZOSTER-022 
protocol) are met for final HZ efficacy analysis in 
study ZOSTER-022; 
− at least 35 PHN cases in subjects ≥ 70YOA are 
accrued in the mTVc when pooling the studies 
ZOSTER-006 and ZOSTER-022.  
The end of study analysis (step 2) cannot be performed 
before the final HZ efficacy analysis (step 1). 
At step 2 all objectives of study ZOSTER-006 will be 
analyzed. Objectives already analyzed at step 1 will be 
re-analyzed (confirmatory descriptive in case of 
inferential analysis at step 1 or descriptive analysis 
otherwise).  
Pooled analyses of studies ZOSTER-006 and ZOSTER-
022 are planned if the primary objective of study 
ZOSTER-006 and the primary objective of study 
ZOSTER-022 are demonstrated. Overall PHN VE in 
subjects ≥ 70 YOA, and other pre-specified endpoints 
will be analyzed in the pooled analyses, as specified in 
ZOSTER-022 protocol. 
• Duration of the study: Each subject will be followed for 
at least 30 months after Dose 2.  
The cut-off date for final analysis will occur when both of 
the following conditions are met: 
− The prespecified number of confirmed HZ and PHN 
cases in the modified Total Vaccinated cohort 
(mTVc) required for final analyses of both ZOSTER-
006 and ZOSTER-022 are accrued;  
− 75% of subjects (for both ZOSTER-006 and 
ZOSTER-022) have completed at least 36 months 
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follow-up after Dose 2, and the remaining subjects 
have completed at least 30 months follow-up after 
Dose 2. 
All subjects will continue in the study at least until the 
cut-off date for final end of study analysis regardless of 
their date of enrolment. Study end will take place when 
the both conditions for final end of study analysis are met 
and a minimum 90 days follow-up is completed for each 
HZ case that occurs  up to the cut-off date for final end of 
study analysis.  
The exact duration of the study for individual subjects 
will vary. The maximum total study duration for each 
subject is expected to be approximately 4 to 5 years. 
If a delay of approximately 6 months or more is predicted 
prior to the simultaneous end dates for the two studies 
based on the rates of accumulation of HZ and PHN cases, 
then the first study that reaches the criteria for final 
analysis  may be continued until the second study reaches 
the criteria for final analysis so that the two studies end 
concurrently. 
 
Footnote 1: The modified Total Vaccinated cohort (mTVc) is the primary cohort for 
analysis of efficacy which excludes subjects in the TVc for efficacy analysis who were 
not administered with the second vaccination or who develop a confirmed case of HZ 
prior to 1 month after the second vaccination. 
 
List of abbreviations 
 
SAP Statistical Analysis Plan  
 
Section 1.2 Rationale for the study and study design 
 
Study ZOSTER-022 will address VE against PHNHZ in subjects ≥ 70 YOA, in addition 
to providing a robust estimate of HZ VE in that age stratum. (After each study (ZOSTER-
006 and ZOSTER-022) is analyzed separately At the end of studies ZOSTER-006 and 
ZOSTER-022, a pooled analysis of HZ and PHN data from both studies combined is 
planned and will be described prospectively. The analysis of pooled data from both 
studies for overall PHN in subjects ≥ 70 YOA is positioned as primary analysis for 
PHN. 
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Section 3 Study design overview 
 
Original figure:  
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Amended figure:  
‡ If the conditions for final analysis and study end are met before Visits 6 is completed by all subjects and it is decided 
to conclude the study, Visit 6 may not take place in some subjects. 
 
• Planned analysis steps : 
It is predicted that study ZOSTER-006 will reach the conditions required for 
triggering final analysis of HZ primary endpoint about one year before those 
conditions being reached for study ZOSTER-022. Therefore GSK decided, as 
originally planned in these circumstances, to dissociate the two studies in terms of 
timing of the analysis of each study. Moreover, a two-step approach is allowed for 
the analysis of each study. Both studies will end concurrently. 
In study ZOSTER-006, the planned analysis steps are the following:  
1. Final HZ efficacy analysis (step 1). Final analysis of HZ primary endpoint:  
The cut-off date for final HZ efficacy analysis will occur when the following 
conditions are met: 
− at least 196 confirmed HZ cases are accrued in the modified Total Vaccinated 
cohort (mTVc) (Footnote 3);   
− approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ 
cases in subjects 60-69 YOA are accrued in the mTVc; 
− approximately 75% of subjects in each stratum have completed at least 36 
months follow-up after Dose 2, and the remaining subjects have completed at 
least 30 months follow-up after Dose 2. 
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Step 1 will include analyses of the following objectives: 
− all  HZ VE objectives; 
−  all reactogenicity/safety and immunogenicity objectives.  
2. End of study analysis (step 2).  
The cut-off date for end of study analysis will occur given the following:  
− all conditions (as detailed in ZOSTER-022 protocol) are met for final HZ 
efficacy analysis in study ZOSTER-022; 
− at least 35 PHN cases in subjects ≥ 70 YOA are accrued in the mTVc when 
pooling the studies ZOSTER-006 and ZOSTER-022.  
The end of study analysis (step 2) cannot be performed before the final HZ 
efficacy analysis (step 1). 
At step 2 all objectives of study ZOSTER-006 will be analyzed. Objectives already 
analyzed at step 1 will be re-analyzed (confirmatory descriptive in case of 
inferential analysis at step 1 or descriptive analysis otherwise).  
Pooled analyses of studies ZOSTER-006 and ZOSTER-022 are planned if the 
primary objective of study ZOSTER-006 and the primary objective of study 
ZOSTER-022 are demonstrated. Overall PHN VE in subjects ≥ 70 YOA, and other 
pre-specified endpoints will be analyzed in the pooled analyses, as specified in 
ZOSTER-022 protocol. 
• Duration of the study: Each subject will be followed for at least 30 months after 
Dose 2.  
The cut-off date for final analysis will occur when both of the following conditions 
are met: 
− The prespecified number of confirmed HZ and PHN cases in modified Total 
Vaccinated cohort (mTVc) required for final analyses of both ZOSTER-006 and 
ZOSTER-022 are accrued;  
− 75% of subjects (for both ZOSTER-006 and ZOSTER-022) have completed at 
least 36 months follow-up after Dose 2, and the remaining subjects have 
completed at least 30 months follow-up after Dose 2. 
All subjects will continue in the study at least until the cut-off date for final end of 
study analysis regardless of their date of enrolment. Study end will take place when 
the both conditions for final end of study analysis are met and a minimum 90 days 
follow-up is completed for each HZ case that occurs  up to the cut-off date for final 
end of study analysis.  
The exact duration of the study for individual subjects will vary. The maximum total 
study duration for each subject is expected to be approximately 4 to 5 years. 
If a delay of approximately 6 months or more is predicted prior to the simultaneous 
end dates for the two studies based on the rates of accumulation of HZ and PHN 
cases, then the first study that reaches the criteria for final analysis may be continued 
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until the second study reaches the criteria for final analysis so that the two studies 
end concurrently. 
Footnote 3: The modified Total Vaccinated cohort (mTVc) is the primary cohort for 
analysis of efficacy which excludes subjects in the TVc for efficacy analysis who were 
not administered with the second vaccination or who develop a confirmed case of HZ 
prior to 1 month after the second vaccination. 
Section 5.4 Method of blinding 
 
Immunological data, which could lead to the unblinding of the treatment groups, will not 
be available during the course of the trial to any investigator or any person involved in 
the clinical conduct of the study (including data cleaning), until after the database is 
locked.  
 
Refer to Section 10.4.8 for more details regarding aspects of blinding in the study. 
 
Section 5.5.1 Data collection 
 
• Zoster Brief Pain Inventory (ZBPI) questionnaire: To be completed by subjects 
with suspected HZ on Day HZ-0 (Visit HZ-1) and daily from Day HZ-1 (day after 
the Visit HZ-1) up to Day HZ-28, and weekly from Day HZ-29 onwards until a 4-
week pain-free period is documented OR until the cut-off date for final end of study 
analysis. For all subjects with ongoing HZ-associated pain at the time of cut-off date 
for final end of study analysis, ZBPI data will be collected until a 4-week pain-free 
period is documented OR until at least Day HZ-90 (Refer to Section 5.5.2.2 for more 
details).  
• EQ-5D and SF-36 questionnaires: To be completed weekly by the subjects with  
suspected HZ from Day HZ-0 onwards until a 4-week pain-free period is 
documented OR until the cut-off date for final end of study analysis. For all subjects 
with ongoing HZ-associated pain at the time of the cut-off date for final end of study 
analysis, EQ-5D and SF-36 data will be collected until a 4-week pain-free period is 
documented OR until at least Day HZ-90 (Refer to Section 5.5.2.2 for more details).  
 
Section 5.5.2.2 Evaluation of suspected case of HZ 
All HZ cases that occur during the study period up to the cut-off date for final end of 
study analysis will be followed and evaluated. Please refer to the SPM for information 
about recording HZ cases that occur after the cut-off date for final end of study analysis. 
Such cases will be referred to the local physician for follow-up.  
• The subject will be asked to complete the ZBPI questionnaires daily from Day HZ-1 
(day after the Visit HZ-1) up to Day 28 (ZBPI must be completed to Day HZ-28 at 
minimum) and weekly from Day HZ-29 onwards until: 
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− The cut-off date for final end of study analysis.  
For all subjects with ongoing HZ-associated pain at the time of cut-off date for 
final end of study analysis, completion of ZBPI questionnaires will continue 
until a 4-week pain-free period is documented OR until at least Day HZ-90.  
 
Section 5.5.2.4 Evaluation of severity of HZ-associated pain using the 
Zoster Brief Pain Inventory 
In each case of suspected HZ, the subjects will be asked to assess their HZ-associated 
pain and interference of HZ with their QoL by completing the ZBPI questionnaire either 
themselves or assisted, by an aide (Section 5.5.1) until HZ-associated pain ceases 
(defined as a 28-day [or 4-week] pain free period) or until the cut-off date for final end of 
study analysis (see further details in Section 5.5.2.2).  
Section 5.6 Outline of study procedures 
Table 2 List of study procedures 
Type of 
contact/trigger  
        VISIT 6 f  Final HZ 
efficacy 
analysis 
trigger 
Study 
conclusion 
contact 
Timepoints              
Sampling 
timepoints 
            
             
Transcriptiongf by 
study 
staff/investigator of 
EQ-5D and SF-36 
questionnaires 
completed 
   
 
 
 
 
 
 
 
  
             
Transcription in 
eCRF of date of 
last visit or 
contact with 
subject 
 
   
 
 
 
 
 
 
 
●  
Investigator 
signature in eCRF 
 
   
 
 
 
 
 
 
 
●  
             
Note: The double-line border indicates the analyses which will be performed on data (i.e., data that are as 
clean as possible) obtained at the cut-off date for final HZ efficacy analysis. The possibility of data changes 
after the final HZ efficacy analysis exists because data collection and data entry may continue until study end.  
Indicated by the dotted line, pending subjects’ advancement in the study, the cut-off date for final HZ efficacy 
analysis may occur at Visit 6 or some time  prior or after this visit.  
f If the conditions for final analysis and study end are met before Visit 6 is completed by all subjects and it is decided to 
conclude the study, Visit 6 may not take place in some subjects.  
gf EQ-5D and SF-36 will remain as source documents. The information from these questionnaires will only be 
transcribed in the eCRF for subjects who have a suspected HZ  event during the study. 
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Table 3 Study procedures to be performed during the follow-up period for each 
suspected HZ case 
 
 
Type of contact 
Timepoints 
 
Completion† of ZBPI questionnaires by the subjects until 
pain ceases or the cut-off date for end of study final 
analysis (ZBPI pain data will be collected until at least Day 
HZ-90)  
 
Completion‡ of EQ-5D and SF-36 questionnaires by the 
subjects until pain ceases or the cut-off date for end of 
study  final analysis (EQ-5D and SF-36 data will be 
collected until at least Day HZ-90)  
 
† Subjects with suspected HZ will be asked to complete the ZBPI questionnaire at Day HZ-0 (Visit HZ-1) to rate HZ-
associated pain within the last 24 hours (If the time between the HZ onset and clinical evaluation at Visit HZ-1 is 
greater than 24 hours, the subject will be asked to complete a second ZBPI also for the elapsed time between the HZ 
onset and 24 hours before Visit HZ-1); daily from Day HZ- 1 to Day HZ-28, and weekly from Day HZ-29 onwards until a 
4-week pain-free period is documented or until the cut-off date for final end of study  analysis. If pain reappears in the 
same area after a 4-week pain-free period and is not accompanied by a new HZ rash, it will be assigned to the 
previous HZ-episode. The completion of ZBPI questionnaires will resume based upon the weekly schedule established 
at the start of the assigned episode. For all subjects with ongoing HZ-associated pain at the time of cut-off date for final 
end of study analysis, ZBPI data will be collected until a 4-week pain-free period is documented OR until at least Day 
HZ-90 (See Section 5.5.2.2).  
‡Subjects with suspected HZ will be asked to complete the EQ-5D and SF-36 questionnaire weekly from Day HZ-0 to 
Day HZ-28, and weekly onwards until a 4-week pain-free period is documented or until the cut-off date for final end of 
study analysis. If pain reappears in the same area after a 4-week pain-free period and is not accompanied by a new 
HZ rash, it will be assigned to the previous HZ-episode. The completion of EQ-5D and SF-36 questionnaires will 
resume based upon the weekly schedule established at the start of the assigned episode. For all subjects with ongoing 
HZ-associated pain at the time of cut-off date for final end of study analysis, EQ-5D and SF-36 data will be collected 
until a 4-week pain-free period is documented OR until at least Day HZ-90. Each suspected HZ that occurs up to the 
cut-off date for end of study final analysis will be followed at least until Visit HZ-7 (the study visit at Day HZ-91) (or 
sooner if the subject has no HZ-associated pain for 4 consecutive weeks and the HZ rash resolves). 
 
Table 4 Intervals between study visits/contacts 
Interval 
 
Visit 2 → Visit 6* 
 
* If the conditions for final analysis and study end are met before Visit 6 is completed by all subjects and it is decided to 
conclude the study, Visit 6 may not take place in some subjects.  
 
Section 5.7.3 Procedures during the study  
Note that subjects may decide at any time to end their participation in the study or 
request unblinding of the treatment received. In case of non-emergency unblinding, 
e.g., to receive a licensed HZ vaccine, subjects will be withdrawn from the study. An 
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internal operating procedure that describes the process for non-emergency unblinding 
will be followed.  
Section 5.7.3.11 Follow up of suspected HZ cases and HZ-associated 
pain 
Data will be collected on all suspected HZ cases that occur from administration of the 
first dose of vaccine/placebo until the cut-off date for final end of study analysis (Section 
5.7.3.17). For each suspected case of HZ that the investigator concludes is clinically 
consistent with HZ, data on HZ-associated pain (using ZBPI questionnaires completed by 
the subject) will be collected until Day-HZ-28, and from Day HZ-29 until:1) the subject 
has no HZ-associated pain for 4 consecutive weeks; or, 2) the cut-off date for final end of 
study analysis. For all subjects with ongoing HZ-associated pain at the time of cut-off 
date for final end of study analysis, ZBPI data will be collected until a 4-week pain-free 
period is documented OR until at least Day HZ-90.  
Section 5.7.3.14 Reminder for monthly follow-up contacts/yearly follow-up 
visits 
The subject will be reminded that the current study still has yearly follow-up visits 
planned until Month 38 (Visit 6).  
Section 5.7.3.15 Final HZ efficacy analysis trigger  
When the cut-off date for final HZ efficacy analysis has been reached and 
communicated to the sites, the following actions need to take place:  
• Transcription in eCRF of date of last visit or contact with the subject  
• Addition of Investigator signature in eCRF (signing of data) 
Section 5.7.3.15 16 Invitation for a planned follow-up study  
Section 5.7.3.16 17 Study conclusion  
Study end will take place when both  the conditions for final end of study analysis are 
met and a minimum 90 days follow-up is completed for each case of suspected HZ that 
occurs prior to the cut-off date for final end of study analysis.  
If it appears that there will be a large disparity in the study end date for study ZOSTER-
006 and ZOSTER-022, respectively, then the first study that meets the criteria for final 
analysis may be continued until the second study reaches the criteria for final analysis so 
that the two studies end concurrently.Refer to Section 3 for more details regarding end 
of study analysis. 
When the cut-off date for final end of study analysis is established, the study sites will 
contact the subjects for the study conclusion contact as soon as possible. If a subject with 
suspected HZ has not completed follow-up until at least Day HZ-90 at the cut-off date for 
final end of study analysis, follow-up for such a subject will continue until Day HZ-90 
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(or sooner if the subject has no HZ-associated pain for 4 consecutive weeks and the HZ 
rash resolves).  
Section 5.8.3 laboratory assays 
Table 7 Humoral Immunity (Antibody determination) 
System Component Method Kit / Manufacturer Unit Cut-off Laboratory 
       
Serum  gE Ab.IgG ELISA NA mIU/mL 18 97 GSK 
Biologicals* 
 
Section 7 Health economics  
For subjects with suspected HZ, both questionnaires will be completed weekly from Day 
HZ-0 onwards until a 4-week pain-free period is documented OR until the cut-off date for 
final end of study analysis. For all subjects with ongoing HZ-associated pain at the time 
of the cut-off date for final end of study analysis, EQ-5D and SF-36 data will be collected 
until a 4-week pain-free period is documented OR until at least Day HZ-90. 
Section 8.3.1 Time period for detecting and recording adverse events, 
serious adverse events and pregnancies  
In addition to the above-mentioned reporting requirements and in order to fulfil 
international reporting obligations, SAEs that are related to study participation (e.g. 
protocol-mandated procedures, invasive tests, a change from existing therapy) or are 
related to a concurrent GSK medication/vaccine or any fatal SAE will be collected and 
recorded from the time the subject consents to participate in the study until she/he is 
discharged. This is including SAEs that are considered by the investigator to be related 
to the investigational vaccine and are to be collected and recorded from the time of the 
first receipt of study vaccine/placebo until the subject is discharged from the study. 
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Table 14 Reporting periods for AEs, SAEs, pIMDs, medically attended visits, 
pregnancies, intercurrent medical conditions and HZ complications in study 
ZOSTER-006  
 
 
Reporting of SAEs related to study 
participation or GSK concomitant 
medication/vaccine or any fatal SAE, 
including SAEs that are considered by the 
investigator to be related to the 
investigational vaccine, after Month 14 until 
study conclusion  
 
Section 9.2.1 Subject withdrawal from the study 
• Unblinding upon the subject’s request to allow the subject to decide if he/she will 
consider immunization with a licensed HZ vaccine. 
 
Section 10.4.2 Significance level 
The pooled analysis of studies ZOSTER-006 and ZOSTER-022 is planned provided the 
following conditions are met, as defined in Section 10.4.4: 
1. Clinically meaningful overall HZ VE in subjects ≥ 50 YOA is reached in 
ZOSTER-006; 
2. Clinically meaningful HZ VE is reached in subjects ≥ 70 YOA in ZOSTER-
022;. 
3. Statistically significant PHN VE is reached in subjects ≥ 70 YOA in 
ZOSTER-022. 
 
The pooled analysis of data in subjects ≥ 50 YOA accrued in study ZOSTER-006 and 
data in subjects ≥ 70 YOA collected in study ZOSTER-022 allows for a more robust the 
estimation of overall PHN VE (subjects ≥ 50 YOA), HZ VE in subjects ≥ 70 YOA and 
PHN VE in subjects ≥ 70 YOA and a more robust estimation of HZ VE in subjects ≥ 70 
YOA . Both objectives, (as HZ VE in subjects ≥ 70 YOA and PHN VE in subjects ≥ 70 
YOA, will be assessed in study ZOSTER-022).  
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Table 19 Summary of statistical inferential evaluations of primary and secondary 
objectives for studies ZOSTER-006, ZOSTER-022 and the pooled analysis  
Analysis Endpoint 50-59 YOA 60-69 YOA ≥70 YOA All age strata 
ZOSTER-006 HZ VE S S O P 
 PHN VE - - - - 
 PHN VE in HZ subjects - - - - 
ZOSTER-022 HZ VE - - P - 
 PHN VE - - P-  - 
 PHN VE in HZ subjects - - - - 
Pooled analysis HZ VE - - R - 
 PHN VE - - RP PS 
 PHN VE in HZ subjects - - - S* 
 
Section 10.4.3 Success criteria 
The pooled analysis of the ZOSTER-006 and ZOSTER-022 studystudies is  also 
powered to demonstrate statistically significant PHN VE in subjects ≥ 70 YOA. Statistical 
significance of PHN VE in ≥ 70 YOA randomized subjects will be demonstrated if the 
lower limit of the 95% CI is above 0%. The PHN VE co-primary objective of the pooled 
ZOSTER-006 and ZOSTER-022 studies will be tested provided the primary HZ VE is 
demonstrated in each study and no adjustment of significance level will be made. 
The primary analysis to demonstrate efficacy for overall PHN in subjects ≥ 70 YOA 
will be performed on the pooled studies ZOSTER-006 and ZOSTER-022.  In addition, 
Tthe pooled analysis of studies ZOSTER-006 and ZOSTER-022 is intended to provide 
consolidated estimations of the clinically meaningful HZ VE in all subjects ≥ 70 YOA 
and clinically meaningful overall PHN VE in mTVc subjects randomized to studies 
ZOSTER-006 and ZOSTER-022. Clinically meaningful HZ VE in subjects ≥ 70 YOA 
will be demonstrated if the lower limit of the 95% CI is above 10% and clinically 
meaningful overall PHN VE in all subjects ≥ 70 YOA will be demonstrated if the lower 
limit of the 95% CI is above 250%. 
Section 10.4.4 Gatekeeping strategy 
The enrolment of subjects ≥ 70 YOA in both studies and the need to provide an 
estimation of the HZ VE and PHN VE across the two studies, requires the gatekeeping 
strategy to be defined across the two studies and the pooling (see Figure 1). 
The primary objective of ZOSTER-006 and the both coprimary objectives of ZOSTER-
022 should be demonstrated prior to testing the primary objective of the pooling. The 
second co-primary of ZOSTER-022 will be tested at 5% 2-sided following demonstration 
of the first co-primary, also at 5%. Sensitivity analyses will be performed by age strata 
for each of the primary or co-primary objectives.  
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Figure 1 Gatekeeping strategy 
Original figure: 
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Amended figure: 
 
Zoster-006
Sensitivity Primary
Zoster-022
SensitivityPrimary
Demonstrate statistically 
significant VE against HZ in 
subjects ≥50 YOA
Demonstrate statistically 
significant VE against HZ 
in subjects ≥70 YOA
Demonstrate statistical 
significance of VE against 
HZ in subjects 50-59 YOA 
and subjects 60-69 YOA
Demonstrate statistically 
significant VE against HZ in 
subjects 70-79 YOA and 
≥80 YOA
Re-estimation Primary Sensitivity
VE estimates against HZ  in 
subjects ≥70 YOA and 
confidence intervals
VE estimates against HZ  
in subjects 70-79 YOA 
and ≥80 YOA and 
confidence intervals
Demonstrate statistically significant VE 
against PHN  in subjects ≥70 YOA
Demonstrate statistically significant 
reduction of duration of pain 
following HZ in subjects with HZ
(in subjects ≥ 70 YOA)
Demonstrate statistically significant 
VE against PHN  in subjects with HZ
(in subjects ≥ 50 YOA)
Pooling
Secondary
Demonstrate statistically 
significant VE against PHN  
in subjects ≥50 YOA
 
The primary objectives of the pooling include the re-estimation of HZ VE in subjects ≥ 
70 YOA and estimation of PHN VE in subjects ≥ 70 YOA. Both hypotheses are planned 
to be already demonstrated in ZOSTER-022 and, as a consequence, do not affect the 
overall type 1 error and are not considered within the main path of the gatekeeping 
strategy. The HZ VE is planned to be already demonstrated in ZOSTER-022 and the 
pooled PHN VE will be the primary analysis of PHN; as a consequence, they do not 
affect the overall type 1 error and are not considered within the main path of the 
gatekeeping strategy.  
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The first hypothesis to be tested from the pooled dataset consists in the overall PHN VE 
in subjects ≥ 50 70 YOA. Further secondary objectives are then sequentially tested 
following demonstration of overall PHN VE in subjects ≥ 70 YOA .    
1. Demonstrate statistically significant reduction in incidence of  PHN (90 days or 
more) in subjects ≥ 50 YOA  
2. Demonstrate statistically significant reduction in incidence of  PHN (90 days or 
more) in subjects with HZ (in subjects ≥ 50 YOA) 
3. Demonstrate statistically significant reduction of duration of severe ‘worst’ pain 
following HZ in subjects with HZ (in subjects ≥ 70 YOA).  
 
Section 10.4.5.1 Primary objective  
 
The final HZ efficacy analysis of the ZOSTER-006 study is planned after the 
accumulation of at least 196 confirmed HZ cases across all age strata (primary condition) 
in the primary cohort for efficacy.  
 
Table 20 Expected median number of HZ and PHN cases in ZOSTER-006  
Age 
strata 
Sample 
size 
Median number of 
HZ cases 
Median number of 
PHN cases (initial 
assumptions) 
Expected number of PHN cases 
(projection based on current 
accrual rates) 
  Placebo All Placebo All Placebo All 
50-59 
YOA 
7520 48 57 3 3 4 5 
60-69 
YOA 
4700 48 62 4 6 5 7 
70-79 
YOA 
2820 40 56 6 8 4 5 
≥ 80 YOA 940 13 22 4 5 1 2 
All 15980 149 196 17 23 14 19 
Median number of cases calculated based on 1000 trial simulations.  
 
The final HZ efficacy analysis of the ZOSTER-022 study is planned after the 
accumulation at least 65 PHN cases (expected median are approximately 40 PHN cases 
in 70-79 YOA and approximately 26 PHN cases in ≥ 80 YOA strata) are accrued from 
study ZOSTER-022 (primary condition for triggering analysis), and of at least 278 
confirmed HZ cases (expected median number of cases is 310 HZ cases) across both 70-
79 YOA (expected median of 222 HZ cases) and ≥ 80 YOA (expected median of 87 HZ 
cases) strata. All PHN or HZ cases should be accrued in the primary cohort for efficacy.  
This number of PHN cases would provide ~97% to demonstrate statistically significant 
PHN VE in all randomized subjects, in addition to the HZ objective above. 
The end of study analyses of the ZOSTER-006 and the ZOSTER-022 studies are 
planned after the accumulation at least 35 PHN cases in subjects ≥ 70 YOA in the 
pooled ZOSTER-006 and ZOSTER-022.  All PHN cases should be accrued in the 
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primary cohort for efficacy. Other conditions for triggering the analyses are described 
in Section 10.4.5.6. This number of PHN cases would provide ~90% power to 
demonstrate PHN VE with Lower Limit (LL) above 0%.  
Table 21 Expected median number of HZ and PHN cases in ZOSTER-022  
Age strata Sample 
size 
Median number of 
HZ cases 
Median number of 
PHN cases 
(initial assumptions) 
Expected number of PHN cases 
(projection based on current 
accrual rates) 
  Placebo All Placebo All Placebo All 
70-79 YOA 10884 157 222 32 40 15 20 
≥ 80 YOA 3628 54 87 17 26 5 8 
All 14512 210 310 49 65 20 28 
Median number of cases calculated based on 1000 trial simulations.  
 
It is estimated however that the median total number of PHN cases in ≥ 50 YOA subjects 
is approximately 8847, among which at least ~79 35 PHN cases would be accrued in the 
≥ 70 YOA age strata. A total of at least 8835 PHN cases provide 9390% power to 
demonstrate in subjects ≥ 70 YOA an overall PHN VE of at least 250%.  
Table 22 Expected median number of HZ and PHN cases in pooled ZOSTER-
006 and ZOSTER-022  
Age strata Sample 
size 
Median number of HZ 
cases 
Median number of 
PHN cases 
(initial assumptions) 
Expected number of PHN cases 
(projection based on current 
accrual rates) 
  Placebo All Placebo All Placebo All 
50-59 YOA 7520 48 57 2 3 4 5 
60-69 YOA 4700 48 61 4 6 5 7 
70-79 YOA 13704 196 278 32 48 19 25 
≥ 80 YOA  4568 57 110 17 31 6 10 
All 30492 360 506 57 88 34 47 
Median number of cases calculated based on 1000 trial simulations.  
 
Section 10.4.5.2 Secondary objectives 
 
The sample size of the pooled studies ZOSTER-006 and ZOSTER-022 provide 2210% 
chance to demonstrate statistically significant PHN VE (LL above 0%) in those subjects 
presenting with an HZ episode. 
 
Section 10.4.5.3 Futility analyses and sample size re-assessment 
 
The study may involve one (or more) unblinded futility analyses performed by the 
IDMC. One futility analysis is planned after at least 25% of the total number of HZ cases 
anticipated at final HZ efficacy analysis are observed in Zoster-006 (see Table 20), and 
when at least 20% of the total number of HZ cases anticipated at final HZ efficacy 
analysis within each age stratum (50-59 YOA, 60-69 YOA and 70+ YOA) are observed 
(see Table 20).  
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Essentially, no increase in the type 1 error of the final HZ efficacy analysis is incurred as 
no decision of early termination for efficacy will be made by GSK at any of those 
analyses.  
A more reasonable prediction for the power at the final HZ efficacy analysis that will be 
implemented is the expected conditional power or Bayesian predictive power, following 
integration of the conditional power on the posterior distribution of the VE in each age 
strata and accounting for the proportion density of each stratum in the total number of HZ 
cases at the final HZ efficacy analysis.  
Table 23 Observed HZ VE at ZOSTER-006 Interim to trigger futility stopping 
and conditional power at the final HZ efficacy analysis calculated under alternative 
hypothesis and current observed VE  
c: Conditional power at the final HZ efficacy analysis calculated under the sample size (alternative) assumptions 
d: Conditional power at the final HZ efficacy analysis calculated under the observed HZ VE at the interim  
A more reasonable prediction for the power at the final HZ efficacy analysis that will be 
implemented is the expected conditional power or Bayesian predictive power, following 
integration of the conditional power on the posterior distribution of the VE in each age 
strata and accounting for the proportion density of each stratum in the total number of HZ 
cases at the final HZ efficacy analysis.  
Table 24 Observed HZ VE at ZOSTER-022 Interim to trigger futility stopping 
and conditional power at the final HZ efficacy analysis calculated under alternative 
hypothesis and current observed VE  
c.Conditional power at the final HZ efficacy analysis calculated under the sample size (alternative) assumptions 
d.Conditional power at the final HZ efficacy analysis calculated under the observed HZ VE at the interim  
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Section 10.4.5.6.4 Number of subjects in the Immunogenicity subset  
 
Table 30 Provisional number of subjects in the Immunogenicity subset in study 
ZOSTER-006 
 
Age 
cohort 
50-59 YOA 60-69 YOA ≥ 70 YOA All  
Treatment 
group 
Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo Total 
CMI countries1 26 26 26 26 26 26 78 78 156  
Non-CMI 
countries2 
23 23 23 23 23 23 69 69 138  
All countries 
1+2 (Total of 18 
countries) 
      1269 1269 2538 
 
Section 10.4.5.7.2 Number of subjects in the CMI subset 
Table 32 Provisional number of subjects in the CMI subset in study ZOSTER-006 
 
Age  
cohort 
50-59 YOA 60-69 YOA ≥ 70 YOA All 
Treatment 
group 
Vaccine Placebo Vaccine Placebo Vaccine Placebo Vaccine Placebo Total 
Each  
participating 
country  
26 26 26 26 26 26 78 78 156 
All countries 
(Total of 3 
countries) 
      234 234 468 
 
Section 10.4.6 Conditions for triggering analyses 
The conditions described below are minimum requirements prior to the specified 
analyses unblinding. 
The following conditions are planned prior to final HZ efficacy analyses of study 
ZOSTER-006. The number of HZ and PHN cases mentioned refers to the cases in the 
primary cohort for efficacy. 
4. A total of at least 88 PHN cases when pooled with ZOSTER-022 PHN cases 
accrued.  
The ZOSTER-006 study will continue until an adequate number of HZ cases will be 
accrued in ZOSTER-022 and an adequate number of PHN cases will be accrued in 
both ZOSTER-006 and ZOSTER-022. 
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The end of study analysis of ZOSTER-006 will occur when the following conditions 
are met: 
1. All previous conditions are met for final HZ efficacy analysis in study ZOSTER-
022; 
2. A total of at least 35 PHN cases in subjects ≥ 70 YOA when pooled with ZOSTER-
022 PHN cases are accrued. 
The end of study analysis cannot be performed before the final HZ efficacy analysis. 
The following conditions are planned prior to final HZ  efficacy analyses of study 
ZOSTER-022. The number of HZ and PHN cases mentioned refers to the cases in the 
primary cohort for efficacy. 
1. At least 65 PHN cases over both 70-79 and ≥ 80 YOA strata; 
2. A total of at least 88 PHN cases when pooled with ZOSTER-006 PHN cases 
accrued;  
 
The end of study analysis of ZOSTER-022 will occur when the following condition is 
met: 
1. A total of at least 35 PHN cases in subjects≥ 70 YOA when pooled with ZOSTER-
006 PHN cases are accrued.  
The end of study analysis cannot be performed before the final HZ efficacy analysis. 
In study ZOSTER-022, depending on accrual of HZ and PHN cases, final HZ efficacy 
analysis may occur at the same time as the end of study analysis. 
Section 10.4.7 Control of type I error for the two-steps analyses  
Although, the analyses of ZOSTER-006 will be performed in two steps. Each objective 
will be assessed only once. Therefore no adjustment of type I error is needed. 
Section 10.4.8 Maintaining the blind  
It is planned to maintain the whole team (Central, Local, Investigators) and subjects 
blinded up to end of study.  
A firewall team will be set up in order to allow the planned analyses to be performed 
and results reported to the relevant authorities while the study blind is maintained to 
the whole team and subjects. All details of this approach can be found in the firewall 
charter.  
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Section 10.4.9 List of objectives assessed at each analysis step  
Table 33 provides, for studies ZOSTER-006 and ZOSTER-022,  an overview of the 
analyses which will be performed at final HZ efficacy analysis (step 1) and end of study 
analysis (step 2), respectively. 
For ZOSTER-006, step 1 will include analyses of the following objectives: 
• all  HZ VE objectives; 
•  all reactogenicity/safety and immunogenicity objectives. 
At step 2 all objectives of study ZOSTER-006 will be analyzed. Objectives already 
analyzed at step 1 will be re-analyzed (confirmatory descriptive in case of inferential 
analysis at step 1 or descriptive analysis otherwise).  
At step 2, overall PHN VE in subjects ≥ 70 YOA, and other pre-specified endpoints will 
be analyzed in the pooled analyses of studies ZOSTER-006 and ZOSTER-022. 
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New table: 
Table 33 Overview of analyses performed at each analysis step (ZOSTER-006, ZOSTER-022, pooled analysis of ZOSTER-006 and 
ZOSTER-022) 
 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
ZOSTER-006 
Primary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to placebo in 
adults ≥ 50 YOA, as measured by the reduction in HZ risk. 
Y I Y CD 
Secondary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to placebo in 
subjects within each of the following age ranges: 50-59 YOA, 
60-69 YOA and ≥ 70 YOA, as measured by the reduction in HZ 
risk;  
Y I Y CD 
  To evaluate VE in the prevention of overall PHN compared to 
placebo in subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA; 
N - Y D 
  To evaluate VE in reducing the total duration of severe ‘worst’ 
HZ-associated pain over the entire pain reporting period 
compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 YOA 
and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
  To evaluate VE in the reduction of overall and HZ-related 
mortality and hospitalizations compared to placebo in subjects 
≥ 50 YOA and in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA; 
N - Y I 
  To evaluate VE in the reduction in incidence of HZ-associated 
complications compared to placebo in subjects ≥ 50 YOA and 
in subjects within each of the following age ranges: 50-59 YOA, 
60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in the reduction in use of pain medications 
compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 YOA 
and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
 Safety       
  To evaluate vaccine safety and reactogenicity. Y D Y D 
Exploratory       
 Efficacy       
  To evaluate VE in reducing the severity of acute HZ-associated 
pain compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 YOA 
and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in improving Quality of Life (QoL) compared to 
placebo in subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, 
with confirmed HZ; 
N - Y I 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
  To evaluate VE in the mitigation of Burden-Of-Illness (BOI) 
caused by HZ compared to placebo in subjects ≥ 50 YOA and 
in subjects within each of the following age ranges: 50-59 YOA, 
60-69 YOA and ≥ 70 YOA. 
N - Y I 
 Immunogenicity      
  To evaluate vaccine induced cell mediated and humoral 
immune responses and the persistence of each type of 
response after two injections of study vaccine in subjects ≥ 50 
YOA, and by age strata; 
Y I, D Y CD, D 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects ≥ 50 
YOA, and by age strata. 
Y I, D Y CD, D 
       
ZOSTER-022*** 
Primary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to placebo in 
adults ≥ 70 YOA, as measured by the reduction in HZ risk. 
Y I Y CD 
Secondary       
 Efficacy      
  To evaluate VE in the prevention of overall PHN compared to 
placebo in subjects ≥ 70 YOA;  
N - Y D 
  To evaluate VE in reducing the total duration of severe ‘worst’ 
HZ-associated pain over the entire pain reporting period 
compared to placebo in subjects ≥ 70 YOA, with confirmed HZ 
N - Y I 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
  To evaluate VE in the reduction of overall and HZ-related 
mortality and hospitalizations compared to placebo in subjects 
≥ 70 YOA 
N - Y I 
  To evaluate VE in the reduction in incidence of HZ-associated 
complications compared to placebo in subjects ≥ 70 YOA, with 
confirmed HZ; 
N - Y I 
  To evaluate VE in the reduction in use of pain medications 
compared to placebo in subjects ≥ 70 YOA, with confirmed HZ; 
N - Y I 
 Safety       
  To evaluate vaccine safety and reactogenicity. Y D Y D 
Exploratory       
 Efficacy      
  To evaluate VE in reducing the severity of acute HZ-associated 
pain compared to placebo in subjects ≥ 70 YOA, with confirmed 
HZ; 
N - Y I 
  To evaluate VE in improving Quality of Life (QoL) compared to 
placebo in subjects ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in the mitigation of BOI caused by HZ 
compared to placebo in subjects ≥ 70 YOA; 
N - Y I 
 Immunogenicity      
  To evaluate vaccine induced humoral immune responses and 
the persistence of each type of response after two injections of 
study vaccine in subjects ≥ 70 YOA and by age strata; 
Y I, D Y CD, D 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects  ≥ 70 
YOA and by age strata. 
Y I, D Y CD, D 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
Pooled analysis of ZOSTER-006 and ZOSTER-022 
Co-primary       
 Efficacy      
  To evaluate VE in the prevention of PHN compared to placebo 
in subjects ≥ 70 YOA across both phase III studies. 
NA  Y I 
  To consolidate VE estimation in the prevention of HZ compared 
to placebo in subjects ≥ 70 YOA across both phase III studies; 
NA Y CD 
Secondary      
 Efficacy     
  To evaluate VE in the prevention of overall PHN compared to 
placebo in subjects ≥ 50 YOA; 
NA Y I 
  To evaluate VE in the prevention of PHN compared to placebo 
in subjects ≥ 50 YOA with confirmed HZ; 
 
NA Y I 
  To evaluate VE in reducing the total duration of severe ‘worst’ 
HZ-associated pain over the entire pain reporting period 
compared to placebo in subjects ≥ 70 YOA, with confirmed HZ; 
 
NA Y CD 
 Safety     
  To evaluate vaccine safety and reactogenicity in subjects ≥ 70 
YOA. 
NA Y D 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable 
(NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis of 
objective 
Yes (Y)  
No (N) 
Type of 
analysis  
I: inferential  
D: descriptive  
CD; 
confirmatory 
descriptive 
Exploratory      
 Efficacy     
  To evaluate VE in reducing the severity of acute HZ-associated 
pain compared to placebo in subjects ≥ 70 YOA, with confirmed 
HZ; 
 
NA Y CD 
  To evaluate VE in improving QoL compared to placebo in 
subjects ≥ 70 YOA, with confirmed HZ; 
NA Y CD 
 Immunogenicity     
  To evaluate vaccine induced humoral immune responses and 
the persistence of each type of response after two injections of 
study vaccine in subjects ≥ 50 YOA and by age cohort; 
 
NA Y CD 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects ≥ 50 
YOA and by age strata; 
 
NA Y CD 
  To assess correlation of the humoral immune responses at 
Month 3 with protection against HZ. 
NA Y D 
       
* It is predicted that the first step for Zoster-006 will occur about one year before the first step for Zoster-022. 
** The second analysis step for both studies will occur at the same time. 
*** Depending on accrual of HZ and PHN cases, in study ZOSTER-022, step 1 may occur at the same time as step 2. 
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Section 10.5.3 According To Protocol cohort for analysis of efficacy 
The list of criteria used to exclude subjects from ATP will be defined prospectively in the 
Reporting andStatistical Analysis Plan (RSAP) prior to database freeze.  
Section 10.6.4 Cellular-mediated immune response 
• For the inferential analysis, Tthe frequency of CD4 [2+] T cells, i.e., CD4 T cells 
producing at least 2 activation markers among (cytokines: IFN-γ, IL-2, TNF-α 
and/or CD40L, termed “all doubles” or CD4[2+]) upon in vitro stimulation with the 
antigen (induction condition) is calculated by adding an offset of 0.5 to the number 
of activated CD4[2+] T cells (numerator) divided by the total number of CD4 T cells 
involved (denominator). A similar calculation will be made for the frequency of CD4 
[2+] T cells producing at least 2 cytokines (“all doubles”, CD4[2+]) upon in vitro 
stimulation in medium only (background condition).  
Original formula:  
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Amended formula: 
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• For the descriptive analyses, the frequency of CD4[2+] T cells upon in vitro 
stimulation with the antigen (induction condition) is calculated by dividing the 
number of activated CD4[2+] Tcells (numerator) over the total number of CD4 T 
cells involved (denominator). The same calculation will be performed for the 
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frequency computation for any kinds of cells and for each individual activation 
marker as appropriate.  
New formula 
  [ ]
)(inductionassay  in the involved cells T CD4 ofnumber  Total 
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• The frequency of antigen-specific (gE or VZV) CD4[2+] T cells for each individual 
subject is calculated as the difference between the frequency of CD4[2+] T cells 
producing at least 2 cytokines among IFN-γ, IL-2, TNF-α and/or CD40L, termed “all 
doubles” or CD4[2+], upon in vitro stimulation with the antigen (induction 
condition), minus the frequency of CD4[2+] T cells, producing at least 2 cytokines 
(“all doubles”, CD4[2+]) upon in vitro stimulation in medium only (background 
condition). When the log-transformation is applied to that variable prior to analysis, 
differences less or equal to zero (0) are imputed to 1 gE or VZV-specific cytokine 
secreting CD4 T cell per 106 CD4 T cells. The differences less or equal to one (1) 
are imputed to 1 antigen-specific CD4[2+] T cell per 106 CD4 T cells. The same 
calculation will be performed for the frequency computation for any kinds of cells 
and for each individual activation marker as appropriate.  
Original formula: 
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Amended formula: 
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• The Geometric Mean (GM) frequency calculations are performed by taking the anti-
log of the mean of the log frequency transformations; 
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• The CMI vaccine response against gE is defined for all subjects as a 1.5 to 2-fold 
increase (see RAP for final threshold) in background-adjusted frequency of CD4 
following induction with gE measured at endpoint as compared to pre-vaccination. 
• The CMI vaccine response to gE will be based on the gE-specific data as computed 
above.  The cut-off for the assay (320 positive events/106 CD4  T cells) will be used 
for vaccine response assessment. The vaccine response is defined as the 
percentage of subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the cut-off. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, 
for subjects with pre-vaccination T cell frequencies above the cut-off. 
• The CMI vaccine response against VZV is defined for all subjects as a 1.5 to 2-fold -
increase (see RAP for final threshold) in background-adjusted frequency of CD4 
following induction with VZV measured at endpoint as compared to pre-vaccination. 
• The CMI vaccine response to VZV will be based on the VZV-specific data as 
computed above.  The cut-off for the assay (320 positive events/106 CD4 T cells) 
will be used for vaccine response assessment. The vaccine response is defined as 
the percentage of subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the cut-off. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, 
for subjects with pre-vaccination T cell frequencies above the cut-off. 
• A CMI responder is a subject with a CMI response greater than or equal to the cut-
off value. 
Section 10.7.1 Prior to Final HZ efficacy Analysis 
Section 10.7.2 Statistical considerations for the interim futility analyses  
If a futility analysis occurs and leads to a recommendation by the IDMC to filing prior to 
study end for ethical reasons, it is mandated that, prior to final HZ efficacy analysis, the 
significance level for all primary objectives but also key secondary objectives is set to 
0.0001 for both HZ and overall PHN, considering the alternative hypotheses of true 
vaccine efficacies above 40%. As a consequence, the significance level of the final HZ 
efficacy analysis will be adjusted to 4.9998% 2-sided. Practically speaking, however, that 
adjustment makes no essential difference as using a significance level of 5% 2-sided that 
will be referred to in other part of this document.  
Section 10.7.3 Final End of study analysis  
When the conditions for triggering the final end of analysis of efficacy have been 
reached, the final end of study analysis cut-off date will be defined. Any HZ episode 
occurring prior to the final end of study analysis cut-off date will be followed, as 
described in the RSAP, until a 4-week pain-free period is documented and the HZ rash 
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resolves OR until the cut-off date for final end of study analysis. For all subjects with 
ongoing HZ-associated pain at the time of cut-off date for final end of study analysis, 
questionnaire data will be collected until a 4-week pain-free period is documented OR 
until at least Day HZ-90 in order to document potential PHN episodes.  
Prior to unblinding, the third party responsible for generating immunogenicity data will 
communicate the results to the SDAC for review and consistency checks with the 
remaining database. SDAC will make sure than any feedback to that third party does not 
unblind the laboratory. Data issues on immunogenicity identified by the SDAC and that 
cannot be resolved beforehand unless unblinding a treatment assignment blind party, will 
be reviewed after efficacy and safety database lock.  
Following achievement of criteria triggering analyses, final data collection and data 
cleaning, the write access to the clinical database will be removed and all eCRF data will 
become available for final end of study analysis. The merging of immunogenicity data to 
the eCRF data will occur after that database lock.  
A first report will document efficacy and safety results and provide immunogenicity 
results using descriptive methodology.  Analysis of correlate of protection may require 
extensive exploratory analyses and may be available as an annex report after completion 
of the primary report. Persistency data may be also provided in annex reports.  
Section 10.7.4 Study reports  
Depending on the further evolution of the case accrual rate, the generated data may be 
presented in one or more study reports per study (ZOSTER-006 and ZOSTER-022).  
• The first study report for each study will contain assessment of the HZ 
VE objectives (ZOSTER-006) or the HZ VE objective (ZOSTER-022) and of 
safety, reactogenicity and immunogenicity objectives. 
• A final study report for each study will contain the assessment of remaining 
objectives not assessed at the first step, and in addition, but not limited to, the 
confirmatory descriptive re-analysis of the previously assessed objectives. The final 
study report for each study will also contain the results presented in the first report 
(to provide a comprehensive all in one report).  Assessment of the objectives of the 
pooled analyses of both studies will be included in the final ZOSTER-022 study 
report. Analysis of correlate of protection may require extensive exploratory 
analyses and therefore may be available as an annex report after completion of 
this final ZOSTER-022 study report. 
Section 10.8.2 Analysis of efficacy 
 
Additional tables will present the overall VE by region and overall VE by time (e.g., 
using 1-year interval). The methodology will be described in the RSAP.  
Section 10.8.2.3 Reduction in Burden-of-Illness 
That analysis is exploratory and will be described in the RSAP.  
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Section 10.8.2.4 Reduction in HZ severity score 
Additional implementation details will be provided in the RSAP. 
The statistical methodology for the analysis of HZ severity will be described in the RSAP 
and is similar to the methodology described previously for BOI assessment in [Chang, 
1994]. 
Section 10.8.2.5 Reduction in incidence of HZ associated complications 
The statistical methodology will be further described in the RSAP. 
Section 10.8.2.6 Reduction of duration of severe ‘worst’ pain in subjects 
with an HZ episode 
Both methodologies will be further detailed in the RSAP. 
Section 10.8.2.7 Reduction in PHN incidence in subjects with an HZ 
episode 
The statistical methodology will be further described in the RSAP. 
Section 10.8.3.2 Humoral immune response 
The analysis for immunogenicity will be performed on the pooled data of both ZOSTER-
006 and ZOSTER-022 and the results will be provided in an annex report. 
The analysis for immunogenicity will be performed at final HZ efficacy analysis. A 
confirmatory descriptive analysis for immunogenicity will be performed  at end of study 
analysis.  
An additional humoral immunogenicity analysis will be performed on the pooled data 
of both ZOSTER-006 and ZOSTER-022 and the results will be provided in the final 
study report for ZOSTER-022. 
Section 10.8.3.4 Correlate of protection 
A specific RSAP will describe the methodologies to be used for that purpose.  
The analysis for correlate of protection will be performed on the pooled data of both 
ZOSTER-006 and ZOSTER-022 and may be available as provided in an annex report.  
Section 10.8.4.1 SF-36 health survey 
Details on descriptive statistics and statistical analysis of the effect of the vaccine on the 
difference over pre-vaccination scores will be provided in the RSAP.  
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Section 10.8.4.2 EQ-5D questionnaire  
Details on contingency tables for each of the 5-dimension and descriptive statistics for 
weighted health state index and VAS will be provided in the RSAP.  
Section 10.8.5.2 Additional exploratory safety comparisons  
Other exploratory safety analyses may be described in the RSAP. 
Section 12.3 Requirements for Japan  
Study Period 
June, 2010 ~ August, 2014 December, 2015 (estimation at the time of protocol 
amendment 4) 
Section 13 References 
Carter WP, Germann CA, Baumann MR. Ophthalmic diagnoses in the ED: herpes zoster 
ophthamicus. Am. J. Ophthalmol. 2008; 26(5): 612– 617.  
Drummond MF. Ann. Med. 2001;33;344–349. 
Walters S, Brazier J. Quality of  Life Research. 2005 14:1523–1532.  
Appendix A LABORATORY ASSAYS 
Specific Ab (anti-VZV and anti-gE) measurements 
Anti-gE ELISA:  
The assay cut-off is 18 97 mIU/mL. 
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The analysis plan is divided into 2 parts: the first part (called SAP) detailing the analyses 
to be performed (current document) and a second part, annexes (called TFL) describing 
the flow and format of tables, figures and listings to be annexed to the SR. two annexes 
will be prepared, one that describes the TFLs for the step 1 analysis of immunogenicity 
and safety and a second TFLs for the end of study analysis of immunogenicity and safety. 
Two separate SAPs and TFLs documents will describe efficacy analysis and Quality of 
life analysis. 
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1. DOCUMENT HISTORY 
Date  Version Description Protocol Version 
05-May-2014 First Version  Final analysis for 
demongraphy, Safety and 
immunogenicity  
Amendment 4 18 Apr 
2014 
 
2. STUDY DESIGN 
 
* Blood samples will be collected from all subjects at Visit 1 and Visit 3, and from subsets of subjects additionally at the 
other visits to assess immune responses. 
Note: In case of suspected HZ, the subject will have additional visits and contacts for follow-up of HZ. 
The following group names will be used for the statistical analyses: 
Group order 
in tables 
Group label in 
tables 
Group definition for 
footnote 
1 Placebo Placebo 
2 HZ/su Herpes Zoster subunit 
vaccine 
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The following sub-group names will be used for the statistical analyses: 
Analysis by age group 
Sub-group 
order in 
tables 
Sub-group 
label in 
tables 
Sub-group 
definition for 
footnote 
Pooled Groups 1 
label in tables 
Pooled Groups 2 
label in tables 
1 50-59Y 50-59 years old 
subjects 
50-59Y 50-59Y 
2 60-69Y 60-69 years old 
subjects 
60-69Y ≥ 60Y 
3 70-79Y 70-79 years old 
subjects 
≥ 70Y ≥ 60Y 
4 ≥ 80Y ≥ 80 years old 
subjects 
≥ 70Y ≥ 60Y 
 
Analysis by region 
Sub-group 
order in tables 
Sub-group label 
in tables 
Sub-group definition for 
footnote 
Pooled Groups label 
in tables 
1 CZ Czech Republic Europe 
2 EN Estonia Europe 
3 FI Finland Europe 
4 FR France Europe 
5 GE Germany Europe 
6 IT Italy Europe 
7 SP Spain Europe 
8 SW Sweden Europe 
9 UK United Kingdom Europe 
10 AS Australia Australasia 
11 HK Hong Kong Australasia 
12 JA Japan Australasia 
13 SK South Korea Australasia 
14 TW Taiwan Australasia 
15 BR Brazil Latin America 
16 MX Mexico Latin America 
17 US United States North America 
18 CA Canada North America 
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3. OBJECTIVES 
As per protocol. 
4. ENDPOINTS 
As per protocol. 
5. STUDY POPULATION 
As per protocol. 
5.1. Total Vaccinated cohort 
The Total Vaccinated cohort (TVc) will include all vaccinated subjects with respect to the 
vaccine actually administered. 
The TVc for analysis of efficacy will include vaccinated subjects for whom data related 
to efficacy endpoints are available. 
The TVc for analysis of immunogenicity will include vaccinated subjects in the 
immunogenicity sub-cohort for whom immunogenicity data are available. 
The TVc for analysis of safety will include all subjects with at least one vaccine 
administration documented. 
The TVc diary card for analysis of reactogenicity will include all TVC subjects belonging 
to the diary card subset. 
5.2. Modified Total Vaccinated cohort 
The mTVc will be the primary population for efficacy analysis, which excludes subjects 
in the TVc for efficacy analysis who were not administered with the second vaccination 
or who develop a confirmed case of HZ prior to 1 month after the second vaccination or 
who received vaccine doses /or replacement not according to their randomized group . 
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5.3. According To Protocol cohort for analysis of efficacy 
The According To Protocol cohort (ATPc) for analysis of efficacy will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures defined in the protocol, with no elimination criteria during the study) for 
whom efficacy data concerning endpoint measures are available, i.e., excluding all 
subjects who developed a confirmed case of HZ prior to 1 month after the second 
vaccination. The list of criteria used to exclude subjects from ATP cohort are:  
• Study vaccine dose not administered AT ALL but subject number allocated 
• Administration of concomitant vaccine(s) forbidden in the protocol 
• Randomisation failure (subject not randomized in the correct group) 
• Randomisation code broken at the investigator site or at GSK Safety department 
• Side, site or route of study vaccine administration wrong or unknown 
Administration not according to protocol for reason specified by the 
investigator, other than side, site and route 
Administered study vaccine reported as being the correct one but is not 
compatible with the vaccine regimen associated to the treatment number 
• Wrong replacement or study vaccine administered 
• Protocol violation linked to the inclusion/exclusion criteria including age and 
excluding codes mentioned below 
• Subjects not  received two doses 
• Subjects having an episode of HZ prior than 30 days after the dose 2 
The ATPc will be the analysis set for supportive efficacy analysis, only including 
subjects who developed a confirmed case of HZ during the follow-up period starting from 
1 month after the second vaccination (Month 3). 
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5.4. According To Protocol cohort for analysis of safety 
The According To Protocol (ATP) cohort for analysis of safety will include all subjects: 
• who have received at least one dose of study vaccine/placebo according to their 
random assignment;  
• with sufficient data to perform an analysis of safety (at least one dose with 
safety follow-up);  
• for whom administration site of study vaccine/placebo is known/correct;  
• who have not received other medication forbidden in the protocol;  
• for whom the randomization code has not been broken. 
The ATP safety diary card for analysis of reactogenicity will include all subjects in the 
ATP safety included in the diary card subset. 
5.5. According To Protocol cohort for analysis of 
immunogenicity 
For study ZOSTER-006, the ATPc for analysis of immunogenicity will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures and intervals defined in the protocol, with no elimination criteria during the 
study) for whom data concerning immunogenicity endpoint measures are available. This 
will include subjects for whom immunogenicity results are available at Month 3 for CMI 
and/or humoral immunogenicity. 
The list of applicable elimination codes for each cohort can be found in the study specific 
form FORM-BIO-CLIN-9004-05 Elim code specifications. 
Cohort Elimination codes Eli Type 
Total vaccinated cohort 900,1030 MA 
Total vaccinated cohort diary card 900,1030, 5130 MA 
Total vaccinated cohort Humoral 900,1030, 2500 MA 
Total vaccinated cohort CMI 900,1030, 2500, 4130 MA 
ATP cohort for analysis for safety 900,1030-1500 MA 
ATP diary card 900,1030-1500, 5130 MA 
mTVC 900,1030,1050,1070, 
1500, 2500, 3500 
MA 
ATP cohort for analysis for immunogenicity-Humoral 900,1030-2500 MA 
ATP cohort for analysis for immunogenicity-CMI 900,1030-2500 , 4130 MA 
ATP cohort for analysis of efficacy 900, 1030-1070, 1500-
2010, 2500,3500 
MA 
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6. STATISTICAL METHODS 
All analyses will be presented overall and by age strata. The main age strata for reporting 
purposes are 50-59, 60-69 and ≥ 70 YOA. Additional analysis will be presented in ≥ 60 
YOA.  
6.1. Analysis of demographics/baseline characteristics 
Demographic characteristics (age at first study vaccination, gender, geographic ancestry, 
race and ethnicity), cohort description and withdrawal status will be summarized overall 
and by region. 
The mean age (plus range and standard deviation) of the enrolled subjects, as a whole, 
and per treatment group and stratified by age group will be calculated. 
The distribution of subjects enrolled among the study sites will be tabulated as a whole 
and per vaccine group. 
Frequency tables will be generated for categorical variables such as gender. 
Mean, median and standard error will be provided for continuous data such as age. 
6.2. Analysis of safety 
The primary analysis will be based on the Total Vaccinated cohort. A second analysis 
based on this ATP cohort will be performed to complement the Total Vaccinated Cohort 
analysis. 
When appropriate, tabulations will be presented overall and by time of occurrence 
relative to last vaccination (e.g., using windows such as Days 0-6, Days 0-29 and more 
than 30 days post-vaccination). 
6.2.1. Within groups assessment 
For each treatment group, the following results will be tabulated overall and by age strata. 
The percentage of subjects with at least one local AE (solicited and unsolicited), with at 
least one general adverse event (solicited and unsolicited) and with any AE during the 
solicited follow-up period, i.e., the day of vaccination and six subsequent days after each 
vaccination will be tabulated with exact 95% CI after each vaccine dose and overall. 
The percentage of doses followed by at least one local AE (solicited and unsolicited), by 
at least one general AE (solicited and unsolicited) and by any AE will be tabulated, 
overall vaccination course, with exact 95% CI. The same tabulation will be done for 
grade 3 AEs, related AEs and grade 3 related AEs. 
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The percentage of subjects reporting each individual solicited local and general AE 
during the solicited 7-day (Days 0-6) follow-up period will be tabulated with exact 95% 
CI. 
The percentage of doses followed by each individual solicited local and general AE 
during the solicited 7 day (Days 0-6) follow-up period will be tabulated, overall 
vaccination course, with exact 95% CI. 
For all solicited symptoms, the same tabulation will be performed for grade 3 solicited 
AEs and for solicited general AEs with relationship to vaccination. 
The number and percentage of subjects with at least one local solicited AE, with at least 
one general solicited AEand with any solicited AE during the 7-day follow-up period 
with exact 95% CIs after each vaccine dose and overall by vaccination group will be 
provided 
Duration and prevalence of fever will be presented, analyses will be broken down by 
route. 
The proportion of subjects with at least one report of unsolicited AE during the 30-day 
(Days 0  29) follow-up period after each vaccination classified according to the MedDRA 
System Organ Class and Preferred Terms will be tabulated, with exact 95% CI. 
The distribution of the number of unsolicited AEs per subject will be tabulated. 
The same tabulation will be performed for grade 3 unsolicited AEs and for unsolicited 
AEs with a relationship to vaccination. The proportion of AEs resulting in a medically 
attended visit (other than routine health maintenance visits) will also be tabulated. 
Incidences of SAEs during the 30-day (Days 0 - 29) follow-up period after each 
vaccination, and during any time during the study classified according to the MedDRA 
System Organ Class and Preferred Terms will be tabulated, with exact 95% CI. 
A separate tabulation will report some of the major categories of SAEs that occur with 
higher frequencies in elderly subjects including: cardiac, vascular, respiratory, 
neurological, congestive heart failure, myocardial infarction, varicella or HZ-like rash, 
cerebral or vascular events. 
Incidences of SAEs by major categories including: cardiac, vascular, respiratory, 
neurological, congestive heart failure, myocardial infarction, varicella or HZ-like rash, 
cerebral vascular. Listing will also be provided, sorted by patients and sorted by preferred 
term. 
Incidence of withdrawal due to AEs will be tabulated. Listing will also be provided, 
sorted by subjects and sorted by MedDRA Preferred Term. 
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The proportion of subjects with at least one report of pIMDs during the entire study 
period will be tabulated overall and by time window (eg 0-6 month, 6-12 month and more 
than 12 month). Listing will also be provided, sorted by subjects and sorted by MedDRA 
Preferred Term. 
The proportion of subjects with concomitant medication will be tabulated, until 30 days 
after each vaccine dose and overall, with exact 95% CI. 
Proportion and incidence rate of subjects with fatal outcome will be tabulated overall and 
by time window (0-23 months, 23-6 months, 6-12 months and more then 12 months after 
dose 1. 
Proportion of subjects experiencing an HZ episode using pain medications by type 
(opioids, non-narcotics, antidepressants, miscellaneous) will be tabulated. 
6.2.2. Additional exploratory safety comparisons 
The standardized asymptotic 95% CI for the difference between the two groups and the 
associated 2-sided p-value to detect group difference will be computed for the following 
endpoints: 
• The proportion of subjects with at least one report of unsolicited AE classified 
by the MedDRA presented by System Organ Class.The proportion of subjects 
with at least one report of unsolicited AE classified by the MedDRA presented 
by System Organ Class and Preferred Term. 
• Incidences of SAEs classified according to the MedDRA System Organ Class 
and Preferred Terms. 
The objective of these analyses is to identify a safety signal as defined by the Council for 
the International Organization of Medical Sciences (CIOMS) VI working group, i.e., a 
report or reports of an event with an unknown causal relationship to treatment that is 
recognized as worthy of further exploration and continues surveillance. It is recognized 
that the use of any method to identify safety signals has the potential to identify a large 
number of events which may or may not have a causal relationship to drug treatment due 
to multiplicity of endpoints. In order to put any safety signal in perspective a permutation 
test will be conducted to quantify the probability to observe at least one false safety signal 
according to the threshold p-value defining a signal. In addition, clinical significance and 
biological plausibility will need to be accounted before establishing causality. 
In the following section, we will describe a proposed approach to help detection of SAE 
signal 
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6.2.3. AE signal method 
6.2.3.1. Analysis by System Organ Class (SOC) 
Three summary tables and one plot of probability of false signal will be provided: 
1. The first summary table will be the complete table with SOC only with ratio of 
proportion between both groups and exact non adjusted p-values. The second 
table will be a subset of the first with only SOC of interest. 
2. The plot of probability of false signal will be built on the whole data set used to
produce the summary of the first table. The plot will be zoomed to have in Y-
axis adjusted p-values between 0 and 0.15. An additional table of 
correspondence between unadjusted p-values and the adjusted p-value (i.e. 
probability of false signal) will be provided as annotation for the plot provided.   
SOC with adjusted p-value below 15% will be considered to identify SOC of 
interest for further review. 
 
 
est).  
 
3. The third summary table will be a subset of the first table containing the PT
associated to SOC of interest for further review. This table will be sorted by p-
values (lowest to highest) within each SOC. 
6.2.3.2. Analysis by SOC & PT 
Two summary tables and one plot of probability of false signal will be provided: 
1. The first summary table will be the complete table with SOC and PT with ratio 
of proportion between both groups and exact non adjusted p-values. This table 
will be sorted by SOC and PT. 
2. The second summary table will be a subset of the first containing only SOC & 
PT when the adjusted p-values are below 15%. This table will be sorted by p-
values (lowest to high
3. The plot of probability of false signal will be built on the whole data set used to
produce the summary of the first table. The plot will be zoomed to have in Y-
axis adjusted p-values between 0 and 0.15. An additional table of 
correspondence between unadjusted p-values and the adjusted p-value (i.e. 
probability of false signal) will be provided as annotation for the plot provided. 
6.3. Analysis of immunogenicity 
The primary analysis will be based on the ATP cohort for analysis of immunogenicity. If 
the percentage of subjects excluded from this ATPc is more than 5%, a second analysis 
based on the Total vaccinated cohort will be performed to complement the ATP analysis. 
The analysis for immunogenicity will be performed by treatment group, by age strata and 
by region/country. 
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6.3.1. Cell-mediated immune response 
CMI response will only be assessed and analyzed in the CMI component of the 
Immunogenicity subset as defined in Section 4.1 in the protocol. 
6.3.1.1. Descriptive statistics 
For CMI response, the following parameters (for gE and VZV specific CD4[2+] 
frequency and CD4[+2] T-cell following induction with gE and VZV) will be tabulated 
by treatment group, overall and by age group at Months 0, 3, 14, 26 and 38: 
• descriptive statistics of the frequency of CD4 T cell secreting at least two 
different cytokines (IFN-γ, IL-2, TNF-α,CD40L) to both VZV and gE antigens; 
• descriptive statistics of the frequency of CD4 T cell secreting at least IFN-γ and 
another cytokine (IL-2, TNF-α,CD40L) to both VZV and gE antigens;  
• descriptive statistics of the frequency of CD4 T cell secreting at least IL-2 and 
another cytokine (IFN-γ, TNF-α,CD40L) to both VZV and gE antigens;  
• descriptive statistics of the frequency of CD4 T cell secreting at least TNF-α and 
another cytokine (IFN-γ, IL-2,CD40L) to both VZV and gE antigens;  
• descriptive statistics of the frequency of CD4 T cell secreting at least CD40L 
and another cytokine (IFN-γ, IL-2, TNF-α) to both VZV and gE antigens;  
• descriptive statistics on the fold over pre-vaccination at months 3, 14, 26 and 38.  
• Vaccine response rate with exact 95% CI at Months 3, 14, 26 and 38 (only in the 
gE-specific CD4[2+] T-cell frequency at Month 3, 14, 26 and 38) 
6.3.1.2. Inferential Analyses 
The inferential analysis on CMI endpoint is performed using ‘a’ Treatment comparison of 
the Frequency of CD4[2+]” following induction and ‘b’ Treatment comparison of the 
Frequency of gE-specific CD4[2+]”. Analysis described in ‘b’ involves derivations of 
confidence intervals using the theorem of propagation of error (or delta-method) from 
estimates of means and variances calculated according to the methodology described in 
‘a’. 
a. The Frequency of CD4[2+] following gE-induction 
If the data allows, inferential analysis on the log-transformed frequency of CD4 T cells 
producing at least two different cytokines following induction with antigen will be 
performed overall and by age strata, in subjects with HZ and healthy subjects.  
A simple Analysis of Covariance (ANCOVA) model will be used to analyze the post-
vaccination (Month 3) log-transformed frequency of CD4 T cells secreting at least 2 
cytokines following induction with gE antigen.  
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The fixed-effect model will include the means for all levels of the treatment effect, all 
levels of age strata and interactions levels. Covariates will include the log-transformed 
pre-vaccination frequency following induction with the antigen and the non-specific 
background log-transformed frequency. Least-squares means and 95% CI are back-
transformed to provide geometric means and ratios.  
Sensitivity analyses will include additional effects for regions and appropriate 
interactions in the model in order to provide estimations and 95% CI by region. The same 
ANCOVA model as described above will be used for the sensitivity analyses. The fixed-
effect model will include the means for all levels of the treatment effect, all levels of age 
strata and all levels of region and interactions levels. The effects that are not significant at 
the 5% level will be removed from the model. 
Geometric means (GMs) of post-vaccination CD4[2+] T cell frequency following 
induction with gE, will be calculated conditionally to the means of the pre-vaccination 
log-transformed CD4[2+] T cell frequency following induction with gE and the post-
vaccination log-transformed CD4[2+] T cell frequency under background conditions. 
Difference of means between vaccines will be calculated together with 95% CIs and 
back-transformed to the original units to provide frequency GMs and frequency GM 
ratios. For each stratum, estimation of the fold-increase in frequencies following 
induction will be presented together with confidence intervals. 
b. Treatment comparison of the Frequency of gE-specific CD4[2+]  
The same ANCOVA model as described above will be used to analyze the log-
transformed ratio between induction frequency and background frequency of CD4[2+]. 
Least-square means and difference of least-squares means will then be back-transformed 
and used to provide estimates for the frequency difference divided by background 
([induction – background] / background). The log-transformed ratios of these estimates 
between treatments will be calculated together with confidence intervals according to the 
delta-method (error propagation method). These estimates better represent the net effect 
of the vaccines over the frequency of CD4[2+]as the nuisance background mean 
frequency is subtracted from the mean induction frequency. 
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6.3.2. Humoral immune response 
Humoral immune response will be assessed and analyzed in the Humoral 
Immunogenicity subset as defined in Section 4.1 in the protocol. 
Descriptive statistics 
For the humoral immune response, at each timepoint that a blood sample is available 
(Month 0, Month 3, Month 14, Month 26 and Month 38), the following parameters (with 
95% CIs) will be tabulated for each treatment group, by age group and by region/country: 
• Geometric mean concentrations (GMCs) of anti-gE Ab with 95% confidence 
interval (CIs);  
• Humoral seropositivity rates with exact 95% confidence interval (CIs);  
• Vaccine response rates with 95% confidence interval (CIs); 
• Descriptive statistics of the fold over pre-vaccination at months 3, 14, 26 and 38 
(Mean, Standard deviation, Min, Q1, Median, Q3, Max). 
Inferential Analyses 
If the data allows, inferential analysis on the log-transformed Antibody concentrations 
will be performed overall and by age strata or sub-strata, in subjects infected with HZ and 
healthy subjects.  
A simple ANCOVA model will be used to analyze post-vaccination (Month 3) log-
transformed anti-gE and anti-VZV ELISA antibody concentrations. The fixed-effect 
model will include the means for all levels of treatment effect and all levels of age strata. 
The pre-vaccination log-transformed antibody concentrations (Month 0) will be included 
as continuous covariate.  
Least-squares means and 95% CI are back-transformed to provide geometric means and 
ratios. Sensitivity analyses will include additional effects for regions and appropriate 
interactions in the model in order to provide estimations and 95% CI by region. The 
fixed-effect model will include the means for all levels of the treatment effect, all levels 
of age strata and all levels of region and interactions levels. The effects that are not 
significant at the 5% level will be removed from the final model.  
Geometric means of post-vaccination Ab concentrations will be calculated for month 3 
conditionally to the means of the log-transformed concentrations at pre-vaccination 
calculated across the treatment groups. The difference of means between vaccine and 
placebo will be calculated together with 95% CIs (2-sided) and back-transformed to the 
original units to provide GMCs and GM ratios 
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6.3.3. VZV neutralizing antibody response 
Descriptive statistics 
The following parameters will be tabulated by treatment group, overall and by age group 
at Month 0, Month 3, Month 14, Month 26 and Month 38: 
• Geometric mean titres (GMTs) of anti-VZV neutralizing Abs with 95% CIs; 
• Descriptive statistics on the fold over pre-vaccination; 
• Tabulations will be presented overall and by region.  
6.3.4. Correlate of protection 
An exploratory analysis will be implemented in an attempt to correlate humoral immune 
responses to vaccination and subsequent HZ risk [Dunning, 2006]. More details of the 
methodologies will be included in SAP of study Zoster-022.  
Serum blood samples have been collected from all subjects at Month 0 (pre-vaccination) 
and Month 3, and may be used for correlate of protection analysis. Additional subject 
samples may be retrieved and analyzed based on some demographics and baseline 
characteristics to match more exactly with characteristics of those who developed HZ. 
The analysis for correlate of protection will be performed on the pooled data of both 
ZOSTER-006 and ZOSTER-022 and may be provided in an annex report. Further details 
will be provided in SAP of ZOSTER-022. 
6.4. Quality of life 
A specific SAP will describe the methodologies to be used for the quality of life analysis. 
7. STATISTICAL CALCULATIONS 
7.1. Derived and transformed data 
7.1.1. Demography 
Age: Age at the reference activity, computed as the number of units between the date of 
birth and the reference activity. In case of partialcompletion of any of these 2 dates: 
15th of month, If only the day is missing 
30th of June, if day and months are missing. 
Statistical Analysis Plan 
 
Study alias & e-track number(s): ZOSTER-006 (110390) 
 
FORM-BIO-CLIN-8003-01 v1.1_SAP 
GSK SOP Reference: SOP-BIO-CLIN-8003 
Version: 05Apr2012 
Page 18 of 26 
 
7.1.2. Immunogenicity 
7.1.2.1. Humoral immune response 
The current cut-off values that apply for gE and VZV Ab responses are described in 
Table 7 of Section 5.8.3 in the protocol. Those values may changes as improvements are 
introduced to the analytical methods. The final cut-off values that are used for the 
analyses will be stated in the study report. 
• A seronegative subject is a subject whose Ab concentration is below the cut-off 
value.  
• A seropositive subject is a subject whose Ab concentration is greater than or 
equal to the cut-off value.  
• The seropositivity rate is defined as the percentage of seropositive subjects.  
• The anti-gE humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as at least 4-fold increase in the anti-gE Ab 
concentration at the endpoint as compared to the pre-vaccination anti-gE 
antibody concentration. The anti-gE humoral immune response to vaccine for 
subjects who are seronegative at baseline is defined as at least 4-fold increase in 
the antigE Ab concentration at the endpoint as compared to the anti-gE Ab cut-
off value for seropositivity.  
• The anti-VZV humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as at least 4-fold increase in the anti-VZV Ab 
concentration at the endpoint as compared to the pre-vaccination anti-VZV Ab 
concentration. The anti-VZV humoral immune response to vaccine for subjects 
who are seronegative at baseline is defined as at least 4-fold increase in the anti-
VZV Ab concentration at the endpoint as compared to the anti-VZV Ab cut-off 
value for seropositivity.  
• The Geometric Mean Concentrations (GMCs) calculations are performed by 
taking the anti-log of the mean of the log concentration transformations. For 
descriptive statistics only, Ab concentrations below the cut-off of the assay will 
be given an arbitrary value equal to half the cut-off for the purpose of GMC 
calculation. For inferential analyses, those concentrations below the cut-off will 
be considered as missing to avoid potential influential data. 
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7.1.2.2. Cellular-mediated immune (CMI) response 
• For the inferential analysis, the frequency of CD4 [2+] T cells, i.e., CD4 T cells 
producing at least 2 activation markers among IFN-γ, IL-2, TNF-α and/or CD40L, 
upon in vitro stimulation with the antigen (induction condition) is calculated by 
adding an offset of 0.5 to the number of activated CD4[2+] T cells (numerator) 
divided by the total number of CD4 T cells involved (denominator). A similar 
calculation will be made for the frequency of CD4 [2+] T cells upon in vitro 
stimulation in medium only (background condition).  
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• For the descriptive analyses, the frequency of CD4[2+] T cells upon in vitro 
stimulation with the antigen (induction condition) is calculated by dividing the 
number of activated CD4[2+] Tcells (numerator) over the total number of CD4 T 
cells involved (denominator). The same calculation will be performed for the 
frequency computation for any kinds of cells and for each individual activation 
marker as appropriate. (Amended 18 April 2014) 
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• The frequency of antigen-specific (gE or VZV) CD4[2+] T cells for each individual 
subject is calculated as the difference between the frequency of CD4[2+] T cells, 
upon in vitro stimulation with the antigen (induction condition), minus the frequency 
of CD4[2+] T cells, upon in vitro stimulation in medium only (background 
condition). The differences less or equal to one (1) are imputed to 1 antigen-specific 
CD4[2+] T cell per 106 CD4 T cells. The same calculation will be performed for the 
frequency computation for any kinds of cells and for each individual activation 
marker as appropriate. (Amended 18 April 2014) 
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• The Geometric Mean (GM) frequency calculations are performed by taking the anti-
log of the mean of the log frequency transformations; 
• The CMI vaccine response to gE will be based on the gE-specific data as computed 
above.  The cut-off for the assay (320 positive events/106 CD4  T cells) will be used 
for vaccine response assessment. The vaccine response is defined as the percentage 
of subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the cut-off. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, for 
subjects with pre-vaccination T cell frequencies above the cut-off. 
• The CMI vaccine response to VZV will be based on the VZV-specific data as 
computed above.  The lower limit of linearity (LLL) for the assay (320 positive 
events/106 CD4 T cells) will be used for vaccine response assessment. The vaccine 
response is defined as the percentage of subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the LLL. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, for 
subjects with pre-vaccination T cell frequencies above the LLL. 
• A CMI responder is a subject with a CMI response greater than or equal to the LLL 
value. 
Table 1 Cell-Mediated Immunogenicity (CMI) 
System Component Challenge Method Unit LLL Laboratory 
Peripheral 
Blood 
Mononuclear 
Cells 
Cells CD4.All double 
CD40 Ligand or 
Interleukin-2 or Tumor 
Necrosis Factor alpha or 
Interferon gamma 
Background Reduced  
gE ICS Events/10E6 
CD4+ T-cells 
320**  CEVAC* 
* University of Gent, Belgium or another validated laboratory designated by GSK Biologicals. 
** Corresponding to the lower limit of linearity. 
ICS = Intracellular cytokine staining 
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7.1.3. Number of decimals 
The following decimal description from the decision rules will be used for the 
demography, immunogenicity and safety/ reactogenicity. 
Display Table Parameters Number of 
decimal digits
Demographic characteristics Mean, median age 1 
Demographic characteristics SD (age) 2 
Immunogenicity Ratio of GMT/C 2 
Reactogenicity Mean, Min, Q1, Median, Q3, Max for duration 1 
All summaries % of count, including LL & UL of CI 1 
All summaries % of difference, including LL & UL of CI 2 
All summaries p-value 4 
 
7.2. Handling of missing data 
For the analysis of solicited symptoms, missing or non-evaluable measurements will not 
be replaced. Therefore the analysis of the solicited symptoms based on the TVc will 
include only subjects/doses with documented safety data (i.e., symptom screen/sheet 
completed). 
For the analysis of unsolicited AEs/SAEs/concomitant medication, all vaccinated subjects 
will be considered and subjects who did not report an event will be considered as subjects 
without an event. 
For a given subject and a given immunogenicity measurement, missing or non-evaluable 
measurements will not be replaced. Therefore, an analysis will exclude subjects with 
missing or non-evaluable measurements. 
The reasons for and timings of missing data will be reviewed and discussed. The likely 
patterns for missing data will be assessed and compared with the actual missing data 
pattern in light of CHMP /EWP/1776/99 and implementation recommendations. 
7.3. Methodology for computing CI 
Unless otherwise mentioned, the confidence intervals will be 2 sided 95% CI and 
calculated according to the following methods: 
7.3.1. Binomial Data 
The exact 95% CIs for a proportion within a group will be calculated according to 
Clopper & al. (1934). 
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7.3.2. Continuous Data 
The 95% CI for geometric mean titres/concentrations (GMTs/GMCs) in non-inferential 
analyses will be obtained within each group separately. The 95% CI for the mean of log-
transformed titre/concentration will be first obtained assuming that log-transformed 
values were normally distributed with unknown variance. The 95% CI for the GMCs will 
be then obtained by exponential-transformation of the 95% CI for the mean of log-
transformed titre/concentration.  
Refer to dedicated methods for inferential methods. 
7.4. Inferential analysis and statistical models 
7.4.1. Cellular-mediated immune response 
See section 6.3.1 for statistical method. 
A similar analysis as describe in section 6.3.1  and 7.1.2.1will be implemented on the 
post-vaccination frequency of CD4 T cells producing at least two different cytokines 
following induction. 
The model is defined as follow: 
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Example of SAS code 
1 - Overall analysis 
PROC GLM DATA=file; 
  BY    v_id; 
  CLASS pid treatment agecat; 
  MODEL Log(frequency of induction at month 3)] = agecat  
                       treatment 
               Log(frequency of induction at pre-vaccination)]  
               Log(frequency of background)] ; 
 
  LSMEANS treatment / AT MEANS CL DIFF=CONTROL("Placebo") ALPHA=0.05 
  ; 
 
  ODS OUTPUT LSMEANS=lsm; 
  ODS OUTPUT DIFFS=dif; 
RUN; 
  
2- By subgroup analysis 
The same model will be applied for each age strata and for each region 
7.4.2. Humoral immune response 
See section 6.3.2 for statistical method. 
A similar analysis as describe in section 6.3.2 and  7.1.2.1will be implemented on the 
post-vaccination anti-gE ELISA titers. 
The following SAS code will be used to perform this analysis. 
1 - Overall analysis 
PROC GLM DATA=file ; 
 CLASS pid treatment agecat; 
 MODEL log(antibody concentrations) = agecat treatment  
         Log(antibody concentration at pre-vaccination) ; 
  LSMEANS treatment / AT MEANS CL DIFF=CONTROL(“Placebo”) ALPHA=0.05 
  ; 
 ODS OUTPUT LSMEANS=lsm; 
 ODS OUTPUT DIFFS=diff; 
RUN;  
  
2- By subgroup analysis 
For each age strata and each region, a similar model will be used. 
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7.5. Sensitivity analyses 
Sensitivity analyses will include additional effects for region levels and appropriate 
interactions in the model in order to provide estimations and 95% CI by region. 
The following interactions below will be implemented. The effects that are not significant 
at the 5 % level will then be removed, provided it does not change the conclusion. 
MODEL Log(frequency of induction at month 3)]  =  
treatment  
agecat agecat*treatment 
region region*treatment 
region*agecat*treatment 
Log(frequency of induction at pre-vaccination)     
agecat*Log(frequency of induction at pre-vaccination)           
region*Log(frequency of induction at pre-vaccination)           
Log(frequency of background)  
agecat*Log(frequency of background) 
region*Log(frequency of background)  
8. CONDUCT OF ANALYSES 
8.1. Sequence of analyses 
Any deviation(s) or change(s) from the original statistical plan outlined in the protocol 
will be described and justified in the final study report. 
Description Analysis ID (SDD sub-folder) 
Final HZ efficacy Analysis Analysis_E1_35 
End-of-study Analysis Analysis_E1_XX 
 
8.2. Statistical considerations for interim analyses 
Not applicable. 
8.3. Final HZ efficacy and end-of-study analysis 
Two analyses are planned, in each analysis all objectives will be assessed.  The first 
analysis (final HZ efficacy analysis) will be considered as primary analysis for any 
inferential analysis. The end-of-study analysis will provided the complete analysis of the 
full data available at the end of study and serve as confirmatory analysis for the 
objectives demonstrated at previous steps. 
Blind will be maintained through the end-of-study analysis. Individual listings will only 
be provided to the Firewall Team / added to an unblinded report version if applicable 
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9. CHANGES FROM PLANNED ANALYSES 
The following criterion is not used to eliminate subjects from the ATP cohort for safety 
“with sufficient data to perform an analysis of safety (at least one dose with safety 
follow-up). The reactogenicity analyses will be performed on the subjects with diary 
cards returned, therefore the subjects without diary cards will not be included in the 
analysis. In the analysis of AEs, the subjects who did not report any event will be 
considered without event. 
The first time window (0-23 months) used for safety analyses (SAEs, PIMDs and fatal 
events) have been modified according to standard time window used in Zoster program 
(from dose 1 to one month post dose 2). 
The vaccine response rate (VRR) in CMI have been modified and adapted with the new 
definition included on protocol amendment. 
Additional descriptive immunogenicity analysis will be also provided by country.  
10. REFERENCES 
• Dunning A. A model for immunological correlates of protection. Statist. Med. 
2006, 25:1485–1497. 
• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in 
the case of binomial. Biometrika, 1934; 26: 404-413. 
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GSK GlaxoSmithKline 
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pIMD potential Immune Mediated Disease 
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The analysis plan is divided into 2 parts: the first part called statistical analysis plan 
(SAP) detailing the analyses to be performed (current document) and a second part, 
annexes (called TFL) describing the flow and format of tables, figures and listings to be 
annexed to the study report (SR). Two annexes will be prepared, one that describes the 
TFLs for the step 1 analysis of immunogenicity and safety and a second one that 
describes the TFLs for the analysis of end-of-study analysis of immunogenicity and 
safety. Each of the following analysis efficacy analysis, correlate of protection and 
Quality of Life analysis will be described in a Separate SAPs and TFLs documents.  
1. DOCUMENT HISTORY 
Date  Version Description Protocol Version 
05-May-2014 First Version  Final analysis for 
demongraphy, Safety 
and immunogenicity  
Amendment 4 18 Apr 2014 
20-October-2014 2.0  Amendment  Amendment 4 18 Apr 2014 
 
2. STUDY DESIGN 
 
* Blood samples will be collected from all subjects at Visit 1 and Visit 3, and from subsets of subjects additionally at the 
other visits to assess immune responses. 
Note: In case of suspected HZ, the subject will have additional visits and contacts for follow-up of HZ. 
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The following group names will be used for the statistical analyses: 
Group order 
in tables 
Group label in 
tables 
Group definition for footnote 
1 HZ/su Herpes Zoster subunit vaccine 
2 Placebo Placebo 
Amended October 20th ,2014 
The following sub-group names will be used for the statistical analyses: 
Analysis by age group 
Sub-group 
order in 
tables 
Sub-group 
label in 
tables 
Sub-group definition 
for footnote 
Pooled Groups 
1 label in 
tables 
Pooled Groups 2 
label in tables 
1 50-59Y 50-59 years old subjects 50-59Y 50-59Y 
2 60-69Y 60-69 years old subjects 60-69Y ≥ 60Y 
3 70-79Y 70-79 years old subjects ≥ 70Y ≥ 60Y 
4 ≥ 80Y ≥ 80 years old subjects ≥ 70Y ≥ 60Y 
 
Analysis by region 
Sub-group 
order in tables 
Sub-group label 
in tables 
Sub-group definition for 
footnote 
Pooled Groups label 
in tables 
1 CZ Czech Republic Europe 
2 EN Estonia Europe 
3 FI Finland Europe 
4 FR France Europe 
5 GE Germany Europe 
6 IT Italy Europe 
7 SP Spain Europe 
8 SW Sweden Europe 
9 UK United Kingdom Europe 
10 AS Australia Australasia 
11 HK Hong Kong Australasia 
12 JA Japan Australasia 
13 SK South Korea Australasia 
14 TW Taiwan Australasia 
15 BR Brazil Latin America 
16 MX Mexico Latin America 
17 US United States North America 
18 CA Canada North America 
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3. OBJECTIVES 
As per protocol. 
4. ENDPOINTS 
As per protocol. 
5. STUDY POPULATION 
As per protocol. 
5.1. Total Vaccinated cohort 
The Total Vaccinated Cohort (TVC) will include all vaccinated subjects with respect to 
the vaccine actually administered. 
The TVC for analysis of efficacy will include vaccinated subjects for whom data related 
to efficacy endpoints are available. 
The TVC for analysis of immunogenicity will include vaccinated subjects in the 
immunogenicity sub-cohort for whom immunogenicity data are available. 
The TVC for analysis of safety will include all subjects with at least one vaccine 
administration documented. 
The TVC diary card for analysis of reactogenicity will include all TVC subjects 
belonging to the diary card subset. 
The subjects from closed sites will be excluded from the TVC. 
5.2. Modified Total Vaccinated cohort 
The mTVC will be the primary population for efficacy analysis, which excludes subjects 
in the TVC for efficacy analysis who were not administered with the second vaccination 
or who developed a confirmed case of HZ prior to 1 month after the second vaccination 
or who received vaccine doses /or replacement not according to their randomized group . 
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5.3. According To Protocol cohort for analysis of efficacy 
The According To Protocol cohort (ATP) for analysis of efficacy will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures defined in the protocol, with no elimination criteria during the study) for 
whom efficacy data concerning endpoint measures are available, i.e., excluding all 
subjects who developed a confirmed case of HZ prior to 1 month after the second 
vaccination. The list of criteria used to exclude subjects from ATP cohort are:  
• Study vaccine dose not administered AT ALL but subject number allocated 
• Administration of concomitant vaccine(s) forbidden in the protocol 
• Randomisation failure (subject not randomized in the correct group) 
• Randomisation code broken at the investigator site or at GSK Safety department 
• Site or route of study vaccine administration wrong or unknown 
Administration not according to protocol for reason specified by the 
investigator, other than side, site and route 
Administered study vaccine reported as being the correct one but is not 
compatible with the vaccine regimen associated to the treatment number 
• Wrong replacement or study vaccine administered (not compatible with the 
vaccine regimen associated to the treatment number). 
• Protocol violation linked to the inclusion/exclusion criteria including age and 
excluding codes mentioned below 
• Subjects who did not  received two doses 
• Subjects having an episode of HZ prior than 30 days after the dose 2 
The ATP cohort for efficacy will be the analysis set for supportive efficacy analysis. 
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5.4. According To Protocol cohort for analysis of safety 
The According To Protocol (ATP) cohort for analysis of safety will include all subjects 
from TVC cohort: 
• who meet all eligibility criteria 
• who have received at least one dose of study vaccine/placebo according to their 
random assignment;  
• for whom administration site of study vaccine/placebo is known/correct;  
• who have not received other vaccine forbidden in the protocol (Section 6.6.1 
from protocol); 
• for whom the randomization code has not been broken. 
Amended October 20th, 2014 
The ATP safety diary card for analysis of reactogenicity will include all subjects in the 
ATP safety included in the diary card subset. 
5.5. According To Protocol cohort for analysis of 
immunogenicity 
For study ZOSTER-006, the ATPc for analysis of immunogenicity will include all 
evaluable subjects from the According To Protocol (ATP) cohort for analysis of safety 
(i.e., those meeting all eligibility criteria, complying with the procedures and intervals 
allowed for the analysis, with no elimination criteria during the study) for whom data 
concerning immunogenicity endpoint measures are available. This will include subjects 
for whom immunogenicity results are available at Month 3 for CMI and/or humoral 
immunogenicity. 
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The intervals allowed for the inclusion in the ATP cohort for analysis of 
immunogenicity are defined as follow 
 Group Interval Allowed interval for 
ATP cohort analysis 
of immunogenicity 
Interval between  
vaccinations 
HZ/su HZ/su (Dose 1) – HZ/su 
(Dose 2) 
49-83 Days 
 Placebo Placebo (Dose 1) – 
Placebo (Dose 2) 
49-83 Days 
Interval between 
vaccination and 
blood sample taken 
HZ/su HZ/su (Dose 2) – Visit 
Visit Month 3 for BS 
28-48 days 
 Placebo HZ/su (Dose 2) – Visit 
Month 3 for BS  
28-48 days 
BS= blood sampling taken 
Amended October 20th, 2014 
The list of applicable elimination codes for each cohort can be found in the study specific 
form FORM-BIO-CLIN-9004-05 Elim code specifications. 
Cohort Elimination codes Eli Type 
Total vaccinated cohort 900,1030 MA 
Total vaccinated cohort diary card 900,1030, 5130 MA 
Total vaccinated cohort Humoral 900,1030, 2500 MA 
Total vaccinated cohort CMI 900,1030, 2500, 4130 MA 
ATP cohort for analysis for safety 900,1030-1500 MA 
ATP diary card 900,1030-1500, 5130 MA 
mTVC 900,1030,1050,1070, 
1500, 2500, 3500 
MA 
ATP cohort for analysis for immunogenicity-Humoral 900,1030-2500 MA 
ATP cohort for analysis for immunogenicity-CMI 900,1030-2500 , 4130 MA 
ATP cohort for analysis of efficacy 900, 1030-1070, 1500-
2010, 2500,3500 
MA 
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6. STATISTICAL METHODS 
All analyses will be presented overall and by age strata. The main age strata for reporting 
purposes are 50-59, 60-69 and ≥ 70 YOA. Additional analysis will be presented in ≥ 60 
YOA.  
6.1. Analysis of demographics/baseline characteristics 
Demographic characteristics (age at first study vaccination, gender, geographic ancestry, 
race and ethnicity), cohort description and withdrawal status will be summarized overall 
and by region. 
The mean age (plus range and standard deviation) of the enrolled subjects, as a whole, 
and per treatment group and stratified by age group will be calculated. 
The distribution of subjects enrolled among the study sites will be tabulated as a whole 
and per vaccine group. 
Frequency tables will be generated for categorical variables such as gender. 
Mean, median and standard error will be provided for continuous data such as age. 
In addition, the following table will be performed for CTRS posting: 
• Percentage of Enrolled subjects by country will be tabulated by group, 
• Percentage of Enrolled subjects in the following age categories ≤64, 65-84, 
≥85 will be tabulated by group. 
Amended October 20th, 2014 
6.2. Analysis of safety 
The primary analysis will be based on the Total Vaccinated cohort. A second analysis 
based on the ATP cohort for safety will be performed to complement the Total 
Vaccinated Cohort analysis. 
When appropriate, tabulations will be presented overall and by time of occurrence 
relative to last vaccination (e.g., using windows such as Days 0-6, Days 0-29 and more 
than 30 days post-vaccination). 
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6.2.1. Within groups assessment 
For each treatment group, the following results will be tabulated overall and by age strata. 
The percentage of subjects with at least one local AE (solicited and unsolicited), with at 
least one general adverse event (solicited and unsolicited) and with any AE during the 
solicited follow-up period, i.e., the day of vaccination and six subsequent days after each 
vaccination will be tabulated with exact 95% CI after each vaccine dose and overall. 
The percentage of doses followed by at least one local AE (solicited and unsolicited), by 
at least one general AE (solicited and unsolicited) and by any AE will be tabulated, 
overall vaccination course, with exact 95% CI. The same tabulation will be done for 
grade 3 AEs, related AEs and grade 3 related AEs. 
The number and percentage of subjects with at least one local solicited AE, with at least 
one general solicited AE and with any solicited AE during the 7-day follow-up period 
with exact 95% CIs after each vaccine dose and overall by vaccination group will be 
provided 
The percentage of subjects reporting each individual solicited local and general AE 
during the solicited 7-day (Days 0-6) follow-up period will be tabulated with exact 95% 
CI. 
The percentage of doses followed by each individual solicited local and general AE 
during the solicited 7 day (Days 0-6) follow-up period will be tabulated, overall 
vaccination course, with exact 95% CI. 
For all solicited symptoms, the same tabulation will be performed for grade 3 solicited 
AEs and for solicited general AEs with relationship to vaccination. For fever, the 
summary will be presented by half cumulative degree increment. 
Duration of fever will be presented, analyses will be done overall and broken down by 
route. 
The proportion of subjects with at least one report of unsolicited AE during the 30-day 
(Days 0-29) follow-up period after each vaccination classified according to the MedDRA 
System Organ Class and Preferred Terms will be tabulated, with exact 95% CI. 
The distribution of the number of unsolicited AEs per subject will be tabulated. 
The same tabulation will be performed for grade 3 unsolicited AEs and for unsolicited 
AEs with a relationship to vaccination. The proportion of AEs resulting in a medically 
attended visit (other than routine health maintenance visits) will also be tabulated. 
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Proportion of subjects reporting at least one serious adverse events classified by 
MedDRA Primary System Organ Class and Preferred Term by time window and 
overall (eg 0-29 days, 0-3 months, 0-8 Months ,3-8 month, 8-14 month and more than 
14 month)   will be tabulated, with exact 95% CI. 
A separate tabulation will report some of the major categories of SAEs that occur with 
higher frequencies in elderly subjects including: cardiac, vascular, respiratory, 
neurological, congestive heart failure, myocardial infarction, varicella or HZ-like rash, 
cerebral or vascular events, stroke. Listing will also be provided, sorted by patients and 
sorted by preferred term. 
The proportion of subjects with at least one report of pIMDs during the entire study 
period will be tabulated overall and by time window (eg 0-3 month, 3-8 month, 8-14 
month and more than 14 month) will be tabulated, with exact 95% CI.  Listing will also 
be provided, sorted by subjects and sorted by MedDRA Preferred Term. 
The proportion of subjects with fatal outcome during the entire study period will be 
tabulated overall and by time window (eg 0-29 days, 0-3 month, 3-8 month, 8-14 month 
and more than 14 month) will be tabulated, with exact 95% CI.  
Proportion of subjects of subjects with, HZ-related complications and HZ-related 
hospitalizations, will be tabulated overall and by time window. (eg 0-29 days, 0-3 
month, 3-8 month, 8-14 month and more than 14 month) 
Incidence of withdrawal due to AEs will be tabulated. Listing will also be provided, 
sorted by subjects and sorted by MedDRA Preferred Term. 
The proportion of subjects with concomitant medication will be tabulated, until 30 days 
after each vaccine dose and overall, with exact 95% CI. 
Proportion of subjects experiencing an HZ episode using pain medications by type 
(Aspirin, Paracetamol, NSAIDs, Opioids, Topicals, Others (antiepileptics, 
antidepressants …)) will be tabulated. 
SAEs and pIMD for subjects from the closed centers will be described separately 
The following additional analysis will be performed  
• Summary of temperature value by half degree cumulative increment taken 
reported during the 7-day (Days 0-6) post-vaccination period following each dose 
and overall doses and subjects with no conversion rule 
• For each specified route of temperature measurement 
Number and percentage of subjects who reported fever (by half degree cumulative 
increment) measured via each route during the 7-day (Days 0-6) post-vaccination 
period following each dose and overall with no conversion rule.  
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The following additional analysis will be performed for CTRS 
• The number of occurrence of the 5% most frequent non-serious unsolicited AE  
classified by the MedDRA Preferred Terms and reported up to 30 days after each 
vaccination will be tabulated  
• The number of occurrence of SAE classified by the MedDRA Preferred Terms and 
reported up to 30 days after each vaccination will be tabulated  
Amended October 20th, 2014 
6.2.2. Additional exploratory safety comparisons 
The exact 95% CI for the relative risk between the two groups and the associated 2-sided 
p-value to detect group difference will be computed for the following endpoints: 
• The proportion of subjects with at least one report of unsolicited AE classified 
by the MedDRA presented by System Organ Class.The proportion of subjects 
with at least one report of unsolicited AE classified by the MedDRA presented 
by System Organ Class and Preferred Term. 
• Incidences of SAEs classified according to the MedDRA System Organ Class 
and Preferred Terms. 
The objective of these analyses is to identify a safety signal as defined by the Council for 
the International Organization of Medical Sciences (CIOMS) VI working group, i.e., a 
report or reports of an event with an unknown causal relationship to treatment that is 
recognized as worthy of further exploration and continues surveillance. It is recognized 
that the use of any method to identify safety signals has the potential to identify a large 
number of events which may or may not have a causal relationship to drug treatment due 
to multiplicity of endpoints. In order to put any safety signal in perspective a permutation 
test will be conducted to quantify the probability to observe at least one false safety signal 
according to the threshold p-value defining a signal. In addition, clinical significance and 
biological plausibility will need to be accounted before establishing causality. 
In the following section, we will describe a proposed approach to help detection of SAE 
signal 
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6.2.3. AE signal method 
6.2.3.1. Analysis by System Organ Class (SOC) 
Three summary tables and one plot of probability of false signal will be provided: 
1. The first summary table will be the complete table with SOC only with ratio of 
proportion between both groups and exact non adjusted p-values. The second 
table will be a subset of the first with only SOC of interest. 
2. The plot of probability of false signal will be built on the whole data set used to
produce the summary of the first table. The plot will be zoomed to have in Y-
axis adjusted p-values between 0 and 0.15. An additional table of 
correspondence between unadjusted p-values and the adjusted p-value (i.e. 
probability of false signal) will be provided as annotation for the plot provided.   
SOC with adjusted p-value below 15% will be considered to identify SOC of 
interest for further review. 
 
 
est).  
 
3. The third summary table will be a subset of the first table containing the PT
associated to SOC of interest for further review. This table will be sorted by p-
values (lowest to highest) within each SOC. 
6.2.3.2. Analysis by SOC & PT 
Two summary tables and one plot of probability of false signal will be provided: 
1. The first summary table will be the complete table with SOC and PT with ratio 
of proportion between both groups and exact non adjusted p-values. This table 
will be sorted by SOC and PT. 
2. The second summary table will be a subset of the first containing only SOC & 
PT when the adjusted p-values are below 15%. This table will be sorted by p-
values (lowest to high
3. The plot of probability of false signal will be built on the whole data set used to
produce the summary of the first table. The plot will be zoomed to have in Y-
axis adjusted p-values between 0 and 0.15. An additional table of 
correspondence between unadjusted p-values and the adjusted p-value (i.e. 
probability of false signal) will be provided as annotation for the plot provided. 
6.3. Analysis of immunogenicity 
The primary analysis will be based on the ATP cohort for analysis of immunogenicity. If 
the percentage of subjects excluded from this ATP cohort is more than 5%, a second 
analysis based on the Total vaccinated cohort will be performed to complement the ATP 
analysis. 
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The analysis for immunogenicity will be performed by treatment group, by age strata and 
by region/country. 
6.3.1. Cell-mediated immune response 
CMI response will only be assessed and analyzed in the CMI component of the 
Immunogenicity subset as defined in Section 4.1 in the protocol. 
6.3.1.1. Descriptive statistics 
For CMI response, the following parameters (for gE and VZV specific CD4[2+] 
frequency and CD4[+2] T-cell following induction with gE and VZV) will be tabulated 
by treatment group, overall and by age group at Months 0, 3, 14, 26 and 38: 
• descriptive statistics of the frequency of CD4 T cell secreting at least two 
different cytokines (IFN-γ, IL-2, TNF-α,CD40L) to both VZV and gE antigens; 
• descriptive statistics of the frequency of CD4 T cell secreting at least IFN-γ and 
another cytokine (IL-2, TNF-α,CD40L) to both VZV and gE antigens;  
• descriptive statistics of the frequency of CD4 T cell secreting at least IL-2 and 
another cytokine (IFN-γ, TNF-α,CD40L) to both VZV and gE antigens;  
• descriptive statistics of the frequency of CD4 T cell secreting at least TNF-α and 
another cytokine (IFN-γ, IL-2,CD40L) to both VZV and gE antigens;  
• descriptive statistics of the frequency of CD4 T cell secreting at least CD40L 
and another cytokine (IFN-γ, IL-2, TNF-α) to both VZV and gE antigens;  
• descriptive statistics on the fold over pre-vaccination at months 3, 14, 26 and 38.  
• Vaccine response rate with exact 95% CI at Months 3, 14, 26 and 38 (only in the 
gE-specific CD4[2+] T-cell frequency at Month 3, 14, 26 and 38) 
6.3.1.2. Inferential Analyses 
The inferential analysis on CMI endpoint is performed using ‘a’ Treatment comparison of 
the Frequency of CD4[2+]” following induction and ‘b’ Treatment comparison of the 
Frequency of gE-specific CD4[2+]”. Analysis described in ‘b’ involves derivations of 
confidence intervals using the theorem of propagation of error (or delta-method) from 
estimates of means and variances calculated according to the methodology described in 
‘a’. 
a. The Frequency of CD4[2+] following gE-induction 
If the data allows, inferential analysis on the log-transformed frequency of CD4 T cells 
producing at least two different cytokines following induction with antigen will be 
performed overall and by age strata, in subjects with HZ and healthy subjects.  
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A simple Analysis of Covariance (ANCOVA) model will be used to analyze the post-
vaccination (Month 3) log-transformed frequency of CD4 T cells secreting at least 2 
cytokines following induction with gE antigen.  
The fixed-effect model will include the means for all levels of the treatment effect, all 
levels of age strata and interactions levels. Covariates will include the log-transformed 
pre-vaccination frequency following induction with the antigen and the non-specific 
background log-transformed frequency. Least-squares means and 95% CI are back-
transformed to provide geometric means and ratios.  
Sensitivity analyses will include additional effects for regions and appropriate 
interactions in the model in order to provide estimations and 95% CI by region. The same 
ANCOVA model as described above will be used for the sensitivity analyses. The fixed-
effect model will include the means for all levels of the treatment effect, all levels of age 
strata and all levels of region and interactions levels. The effects that are not significant at 
the 5% level will be removed from the model. 
Geometric means (GMs) of post-vaccination CD4[2+] T cell frequency following 
induction with gE, will be calculated conditionally to the means of the pre-vaccination 
log-transformed CD4[2+] T cell frequency following induction with gE and the post-
vaccination log-transformed CD4[2+] T cell frequency under background conditions. 
Difference of means between vaccines will be calculated together with 95% CIs and 
back-transformed to the original units to provide frequency GMs and frequency GM 
ratios. For each stratum, estimation of the fold-increase in frequencies following 
induction will be presented together with confidence intervals. 
b. Treatment comparison of the Frequency of gE-specific CD4[2+]  
The same ANCOVA model as described above will be used to analyze the log-
transformed ratio between induction frequency and background frequency of CD4[2+]. 
Least-square means and difference of least-squares means will then be back-transformed 
and used to provide estimates for the frequency difference divided by background 
([induction – background] / background). The log-transformed ratios of these estimates 
between treatments will be calculated together with confidence intervals according to the 
delta-method (error propagation method). These estimates better represent the net effect 
of the vaccines over the frequency of CD4[2+]as the nuisance background mean 
frequency is subtracted from the mean induction frequency. 
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6.3.2. Humoral immune response 
Humoral immune response will be assessed and analyzed in the Humoral 
Immunogenicity subset as defined in Section 4.1 in the protocol. 
Descriptive statistics 
For the humoral immune response, at each timepoint that a blood sample is available 
(Month 0, Month 3, Month 14, Month 26 and Month 38), the following parameters (with 
95% CIs) will be tabulated for each treatment group, by age group and by region/country: 
• Geometric mean concentrations (GMCs) of anti-gE Ab with 95% confidence 
interval (CIs);  
• Humoral seropositivity rates with exact 95% confidence interval (CIs);  
• Vaccine response rates with 95% confidence interval (CIs); 
• Descriptive statistics of the fold over pre-vaccination at months 3, 14, 26 and 38 
(Mean, Standard deviation, Min, Q1, Median, Q3, Max). 
In addition, the following analysis will be done 
Mean Geometric Increase (MGI) with exact 95% CI for anti-gE 
Distribution of the fold increase i.e Percentage of subjects with a more than X-fold (e.g. 
>2, >4, >6,..-fold) increase will be tabulated per group with 95%CI. 
Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of fold increase over 
pre-vaccination for anti-gE 
Amended October 20th, 2014 
Inferential Analyses 
If the data allows, inferential analysis on the log-transformed Antibody concentrations 
will be performed overall and by age strata or sub-strata, in subjects infected with HZ and 
healthy subjects.  
A simple ANCOVA model will be used to analyze post-vaccination (Month 3) log-
transformed anti-gE and anti-VZV ELISA antibody concentrations. The fixed-effect 
model will include the treatment and age strata as fixed effect. The pre-vaccination log-
transformed antibody concentrations (Month 0) will be included as continuous covariate.  
Least-squares means and 95% CI are back-transformed to provide geometric means and 
ratios. Sensitivity analyses will include additional effects for regions and appropriate 
interactions in the model in order to provide estimations and 95% CI by region. The 
fixed-effect model will include the means for all levels of the treatment effect, all levels 
of age strata and all levels of region and interactions levels. The effects that are not 
significant at the 5% level will be removed from the final model.  
Statistical Analysis Plan 
 
Study alias & e-track number(s): ZOSTER-006 (110390) 
 
FORM-BIO-CLIN-8003-01 v1.1_SAP 
GSK SOP Reference: SOP-BIO-CLIN-8003 
Version: 20Oct2014 
Page 19 of 31 
 
Geometric means of post-vaccination Ab concentrations will be calculated for month 3 
conditionally to the means of the log-transformed concentrations at pre-vaccination 
calculated across the treatment groups. The difference of means between vaccine and 
placebo will be calculated together with 95% CIs (2-sided) and back-transformed to the 
original units to provide GMCs and GM ratios 
6.3.3. VZV neutralizing antibody response 
Descriptive statistics 
The following parameters will be tabulated by treatment group, overall and by age group 
at Month 0, Month 3, Month 14, Month 26 and Month 38: 
• Geometric mean titres (GMTs) of anti-VZV neutralizing Abs with 95% CIs; 
• Descriptive statistics on the fold over pre-vaccination; 
• Tabulations will be presented overall and by region.  
In addition, the following analysis will be done 
• Mean Geometric Increase (MGI) with exact 95% CI for anti-gE 
• Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of fold 
increase over pre-vaccination for anti-gE 
• Distribution of the fold increase i.e Percentage of subjects with a more than X-
fold (e.g. >2, >4, >6,..-fold) increase will be tabulated per group with 95%CI. 
Amended October 20th, 2014 
6.3.4. Correlate of protection 
An exploratory analysis will be implemented in an attempt to correlate humoral immune 
responses to vaccination and subsequent HZ risk [Dunning, 2006]. A specific SAP will 
describe the methodologies to be used for that purpose. 
Serum blood samples have been collected from all subjects at Month 0 (pre-vaccination) 
and Month 3, and may be used for correlate of protection analysis. Additional subject 
samples may be retrieved and analyzed based on some demographics and baseline 
characteristics to match more exactly with characteristics of those who developed HZ. 
The analysis for correlate of protection will be performed on the pooled data of both 
ZOSTER-006 and ZOSTER-022 and may be provided in an annex report.  
6.4. Quality of life 
A specific SAP will describe the methodologies to be used for the quality of life analysis. 
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7. STATISTICAL CALCULATIONS 
7.1. Derived and transformed data 
7.1.1. Demography 
Age: Age at the reference activity, computed as the number of units between the date of 
birth and the reference activity. In case of partialcompletion of any of these 2 dates: 
15th of month, If only the day is missing 
30th of June, if day and months are missing. 
7.1.2. Immunogenicity 
7.1.2.1. Humoral immune response 
The current cut-off values that apply for gE and VZV Ab responses are described in 
Table 7 of Section 5.8.3 in the protocol. Those values may changes as improvements are 
introduced to the analytical methods. The final cut-off values that are used for the 
analyses will be stated in the study report. 
• A seronegative subject is a subject whose Ab concentration is below the cut-off 
value.  
• A seropositive subject is a subject whose Ab concentration is greater than or 
equal to the cut-off value.  
• The seropositivity rate is defined as the percentage of seropositive subjects.  
• The anti-gE humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as at least 4-fold increase in the anti-gE Ab 
concentration at the endpoint as compared to the pre-vaccination anti-gE 
antibody concentration. The anti-gE humoral immune response to vaccine for 
subjects who are seronegative at baseline is defined as at least 4-fold increase in 
the antigE Ab concentration at the endpoint as compared to the anti-gE Ab cut-
off value for seropositivity.  
• The anti-VZV humoral immune response to vaccine for subjects who are 
seropositive at baseline is defined as at least 4-fold increase in the anti-VZV Ab 
concentration at the endpoint as compared to the pre-vaccination anti-VZV Ab 
concentration. The anti-VZV humoral immune response to vaccine for subjects 
who are seronegative at baseline is defined as at least 4-fold increase in the anti-
VZV Ab concentration at the endpoint as compared to the anti-VZV Ab cut-off 
value for seropositivity.  
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• The Geometric Mean Concentrations (GMCs) calculations are performed by 
taking the anti-log of the mean of the log concentration transformations. For 
descriptive statistics only, Ab concentrations below the cut-off of the assay will 
be given an arbitrary value equal to half the cut-off for the purpose of GMC 
calculation.  
7.1.2.2. Cellular-mediated immune (CMI) response 
For the inferential analysis, the frequency of CD4 [2+] T cells, i.e., CD4 T cells 
producing at least 2 activation markers among IFN-γ, IL-2, TNF-α and/or CD40L, upon 
in vitro stimulation with the antigen (induction condition) is calculated by adding an 
offset of 0.5 to the number of activated CD4[2+] T cells (numerator) divided by the total 
number of CD4 T cells involved (denominator). A similar calculation will be made for 
the frequency of CD4 [2+] T cells upon in vitro stimulation in medium only (background 
condition).  
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For the descriptive analyses, the frequency of CD4[2+] T cells upon in vitro stimulation 
with the antigen (induction condition) is calculated by dividing the number of activated 
CD4[2+] Tcells (numerator) over the total number of CD4 T cells involved 
(denominator). The same calculation will be performed for the frequency computation for 
any kinds of cells and for each individual activation marker as appropriate. (Amended 18 
April 2014) 
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The frequency of antigen-specific (gE or VZV) CD4[2+] T cells for each individual 
subject is calculated as the difference between the frequency of CD4[2+] T cells, upon in 
vitro stimulation with the antigen (induction condition), minus the frequency of CD4[2+] 
T cells, upon in vitro stimulation in medium only (background condition). The 
differences less or equal to one (1) are imputed to 1 antigen-specific CD4[2+] T cell per 
106 CD4 T cells. The same calculation will be performed for the frequency computation 
for any kinds of cells and for each individual activation marker as appropriate. (Amended 
18 April 2014) 
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The Geometric Mean (GM) frequency calculations are performed by taking the anti-log 
of the mean of the log frequency transformations; 
The CMI vaccine response to gE will be based on the gE-specific data as computed 
above.  The cut-off for the assay (320 positive events/106 CD4  T cells) will be used for 
vaccine response assessment. The vaccine response is defined as the percentage of 
subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the cut-off. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, for 
subjects with pre-vaccination T cell frequencies above the cut-off. 
The CMI vaccine response to VZV will be based on the VZV-specific data as computed 
above.  The lower limit of linearity (LLL) for the assay (320 positive events/106 CD4 T 
cells) will be used for vaccine response assessment. The vaccine response is defined as 
the percentage of subjects who have: 
− at least a 2-fold increase as compared to the cut-off, for subjects with pre-
vaccination T cell frequencies below the LLL. 
− at least a 2-fold increase as compared to pre-vaccination T cell frequencies, for 
subjects with pre-vaccination T cell frequencies above the LLL. 
A CMI responder is a subject with a CMI response greater than or equal to the LLL 
value. 
Table 1 Cell-Mediated Immunogenicity (CMI) 
System Component Challenge Method Unit LLL Laboratory 
Peripheral 
Blood 
Mononuclear 
Cells 
Cells CD4.All double 
CD40 Ligand or 
Interleukin-2 or Tumor 
Necrosis Factor alpha or 
Interferon gamma 
Background Reduced  
gE ICS Events/10E6 
CD4+ T-cells 
320**  CEVAC* 
* University of Gent, Belgium or another validated laboratory designated by GSK Biologicals. 
** Corresponding to the lower limit of linearity. 
ICS = Intracellular cytokine staining 
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7.1.3. Number of decimals 
The following decimal description from the decision rules will be used for the 
demography, immunogenicity and safety/ reactogenicity. 
Display Table Parameters Number of 
decimal digits
Demographic characteristics Mean, median age 1 
Demographic characteristics SD (age) 2 
Immunogenicity Ratio of GMT/C 2 
Reactogenicity Mean, Min, Q1, Median, Q3, Max for duration 1 
All summaries % of count, including LL & UL of CI 1 
All summaries % of difference, including LL & UL of CI 2 
All summaries p-value 4 
 
7.2. Handling of missing data 
For the analysis of solicited symptoms, missing or non-evaluable measurements will not 
be replaced. Therefore the analysis of the solicited symptoms based on the TVc will 
include only subjects/doses with documented safety data (i.e., symptom screen/sheet 
completed). 
For the analysis of unsolicited AEs/SAEs/concomitant medication, all vaccinated subjects 
will be considered and subjects who did not report an event will be considered as subjects 
without an event. 
For a given subject and a given immunogenicity measurement, missing or non-evaluable 
measurements will not be replaced. Therefore, an analysis will exclude subjects with 
missing or non-evaluable measurements. 
The reasons for and timings of missing data will be reviewed and discussed. The likely 
patterns for missing data will be assessed and compared with the actual missing data 
pattern in light of CHMP /EWP/1776/99 and implementation recommendations. 
7.3. Methodology for computing CI 
Unless otherwise mentioned, the confidence intervals will be 2 sided 95% CI and 
calculated according to the following methods: 
7.3.1. Binomial Data 
The exact 95% CIs for a proportion within a group will be calculated according to 
Clopper & al. (1934). 
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7.3.2. Continuous Data 
The 95% CI for geometric mean titres/concentrations (GMTs/GMCs) in non-inferential 
analyses will be obtained within each group separately. The 95% CI for the mean of log-
transformed titre/concentration will be first obtained assuming that log-transformed 
values were normally distributed with unknown variance. The 95% CI for the GMCs will 
be then obtained by exponential-transformation of the 95% CI for the mean of log-
transformed titre/concentration.  
Refer to dedicated methods for inferential methods. 
7.4. Inferential analysis and statistical models 
7.4.1. Cellular-mediated immune response 
See section 6.3.1 for statistical method. 
A similar analysis as describe in section 6.3.1  and 7.1.2.1will be implemented on the 
post-vaccination frequency of CD4 T cells producing at least two different cytokines 
following induction. 
The model is defined as follow: 
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Example of SAS code 
1 - Overall analysis 
PROC GLM DATA=file; 
  BY    v_id; 
  CLASS pid treatment agecat; 
  MODEL Log(frequency of induction at month 3)] = agecat  
                       treatment 
               Log(frequency of induction at pre-vaccination)]  
               Log(frequency of background)] ; 
 
  LSMEANS treatment / AT MEANS CL DIFF=CONTROL("Placebo") ALPHA=0.05 
  ; 
 
  ODS OUTPUT LSMEANS=lsm; 
  ODS OUTPUT DIFFS=dif; 
RUN; 
  
2- By subgroup analysis 
The same model will be applied for each age strata and for each region 
7.4.2. Humoral immune response 
See section 6.3.2 for statistical method. 
A similar analysis as describe in section 6.3.2 and  7.1.2.1will be implemented on the 
post-vaccination anti-gE ELISA titers. 
The following SAS code will be used to perform this analysis. 
1 - Overall analysis 
PROC GLM DATA=file ; 
 CLASS pid treatment agecat; 
 MODEL log(antibody concentrations) = agecat treatment  
         Log(antibody concentration at pre-vaccination) ; 
  LSMEANS treatment / AT MEANS CL DIFF=CONTROL(“Placebo”) ALPHA=0.05 
  ; 
 ODS OUTPUT LSMEANS=lsm; 
 ODS OUTPUT DIFFS=diff; 
RUN;  
  
2- By subgroup analysis 
For each age strata and each region, a similar model will be used. 
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7.5. Sensitivity analyses 
Sensitivity analyses will include additional effects for region levels and appropriate 
interactions in the model in order to provide estimations and 95% CI by region. 
The following interactions below will be implemented. The effects that are not significant 
at the 5 % level will then be removed, provided it does not change the conclusion. 
MODEL Log(frequency of induction at month 3)]  =  
treatment  
agecat agecat*treatment 
region region*treatment 
region*agecat*treatment 
Log(frequency of induction at pre-vaccination)     
agecat*Log(frequency of induction at pre-vaccination)           
region*Log(frequency of induction at pre-vaccination)           
Log(frequency of background)  
agecat*Log(frequency of background) 
region*Log(frequency of background)  
8. CONDUCT OF ANALYSES 
8.1. Sequence of analyses 
Any deviation(s) or change(s) from the original statistical plan outlined in the protocol 
will be described and justified in the final study report. 
Description Analysis ID (SDD sub-folder) 
Final HZ efficacy Analysis Analysis_E1_35 
End-of-study Analysis Analysis_E1_XX 
 
8.2. Statistical considerations for interim analyses 
Not applicable. 
8.3. Final HZ efficacy and end-of-study analysis 
Two analyses are planned, in each analysis all objectives will be assessed.  The first 
analysis (final HZ efficacy analysis) will be considered as primary analysis for any 
inferential analysis. The end-of-study analysis will provided the complete analysis of the 
full data available at the end of study and serve as confirmatory analysis for the 
objectives demonstrated at previous steps. 
Blind will be maintained through the end-of-study analysis. Individual listings will only 
be provided to the Firewall Team / added to an unblinded report version if applicable 
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9. CHANGES FROM PLANNED ANALYSES 
The following criterion is added to eliminate subjects from the ATP cohort for safety  
• Who meet all eligibility criteria 
• for whom administration site of study vaccine/placebo is known/correct; 
• who have not received other vaccine forbidden in the protocol (Section 6.6.1 from 
protocol); 
In addition, subjects who received medication forbidden in the protocol will be only 
excluded from the ATP cohort for immunogenicity but included in the ATP cohort for 
safety 
The following criterion is not used to eliminate subjects from the ATP cohort for safety 
“with sufficient data to perform an analysis of safety (at least one dose with safety 
follow-up). The reactogenicity analyses will be performed on the subjects with diary 
cards returned, therefore the subjects without diary cards will not be included in the 
analysis. In the analysis of AEs, the subjects who did not report any event will be 
considered without event. 
For the purpose of the ATP analysis of immunogenicity, the specific interval for blood 
sampling taken after the second dose of HZ/su has been set at 28-48 days instead the 
protocol-defined interval between study visits of 30-48 days. 
The first time window (0-3 months) used for safety analyses (SAEs, PIMDs and fatal 
events) have been modified according to standard time window used in Zoster program 
(from dose 1 to one month post dose 2). 
The vaccine response rate (VRR) in CMI have been modified and adapted with the new 
definition included on protocol amendment. 
Additional descriptive immunogenicity analysis will be also provided by country.  
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10. AMENDMENT 
A separate SAP will be written for the analysis of the correlate of protection. 
Section 2 
The order of the group in the table has been switch; the vaccine group will be first and 
placebo group at second position. 
Section 5.1 
The subjects from the closed site Genova will be excluded from the TVC. 
Section 5.3 
Wrong administration side is allowed 
And clarification has been made on the following bullet 
• Wrong replacement or study vaccine administered (not compatible with the 
vaccine regimen associated to the treatment number). 
Section 5.4 
The following criterion is added to eliminate subjects from the ATP cohort for safety  
• Who meet all eligibility criteria 
• who have not received other vaccine forbidden in the protocol (Section 6.6.1 from 
protocol); 
In addition, subjects who received medication forbidden in the protocol will be only 
excluded from the ATP cohort for immunogenicity but included in the ATP cohort for 
safety. Also, the administration site of the study vaccine/placebo should be correct. 
Section 5.5 
Interval allowed for the analysis has been enlarged as compared to the protocol defined 
interval and wording has been adjusted. 
Section 6.1 
Analysis for CTRS posting have been added  
Section 6.2.1 
For fever analysis, the summary will be presented by half cumulative degree increment. 
Statistical Analysis Plan 
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For SAE analysis, the following analysis has been added 
Proportion of subjects reporting at least one serious adverse events classified by 
MedDRA Primary System Organ Class and Preferred Term by time window and overall 
(eg 0-29 days, 0-3 months, 0-8 Months ,3-8 month, 8-14 month and more than 14 
month)   will be tabulated, with exact 95% CI. 
For pIMD analysis, different time windows have been revised to summarize the 
proportion of subjects with pIMDs. The following analysis  
The proportion of subjects with at least one report of pIMDs during the entire study 
period will be tabulated overall and by time window (eg 0-6 month, 6-12 month and more 
than 12 month).  
Has been replaced by  
The proportion of subjects with at least one report of pIMDs during the entire study 
period will be tabulated overall and by time window (eg 0-3 month, 3-8 month, 8-14 
month and more than 14 month) will be tabulated, with exact 95% CI.   
For fatal outcome analysis, different time windows have been revised to summarize the 
proportion of subjects with fatal outcome. The following analysis  
Proportion and incidence rate of subjects with fatal outcome will be tabulated overall and 
by time window (0-3 months, 3-6 months, 6-12 months and more then 12 months after 
dose 1. 
Has been replaced by  
The proportion of subjects with fatal outcome during the entire study period will be 
tabulated overall and by time window (eg 0-29 days, 0-3 month, 3-8 month, 8-14 month 
and more than 14 month) will be tabulated, with exact 95% CI.  
Proportion of subjects experiencing an HZ episode using pain medications by type 
(opioids, non-narcotics, antidepressants, miscellaneous) will be tabulated. 
Has been replaced by  
Proportion of subjects experiencing an HZ episode using pain medications by type 
(Aspirin, Paracetamol, NSAIDs, Opioids, Topicals, Others (antiepileptics, 
antidepressants, …)) will be tabulated. 
The following analysis has been added 
Proportion of subjects of subjects with, HZ-related complications and overall and HZ-
related hospitalizations, will be tabulated overall and by time window. (eg 0-29 days, 0-3 
month, 3-8 month, 8-14 month and more than 14 month) 
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Analysis for CTRS posting have been added  
Additional analysis on fever by route have been proposed 
SAEs and pIMD for subjects from the closed centers will be described in details 
Section 6.2.2 
The exact confidence interval for the relative risk between the two groups will be 
displayed instead of the standardized asymptotic confidence interval of the difference. 
Section 6.3.2 
The following analysis have been added 
Mean Geometric Increase (MGI) with exact 95% CI for anti-gE 
Distribution of the fold increase i.e Percentage of subjects with a more than X-fold (e.g. 
>2, >4, >6,..-fold) increase will be tabulated per group with 95%CI. 
Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of Mean Geometric 
Increase (MGI) for anti-gE 
Section 6.3.3 
The following analysis have been added 
Mean Geometric Increase (MGI) with exact 95% CI for anti-gE 
Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of Mean Geometric 
Increase (MGI) for anti-gE 
Distribution of the fold increase i.e Percentage of subjects with a more than X-fold (e.g. 
>2, >4, >6,..-fold) increase will be tabulated per group with 95%CI. 
Section 6.3.4 
Specific SAP will describe the methodologies will be used for the analysis of the 
correlate of protection 
And so, Further details will be provided in SAP of ZOSTER-022 has been removed from 
the text 
Section 7.2.1.2 
For the inference analysis, no data will be removed even for concentration below the cut 
off. And so, the following statement has been removed : 
For inferential analyses, those concentrations below the cut-off will be considered as 
missing to avoid potential influential data. 
Statistical Analysis Plan 
 
Study alias & e-track number(s): ZOSTER-006 (110390) 
 
FORM-BIO-CLIN-8003-01 v1.1_SAP 
GSK SOP Reference: SOP-BIO-CLIN-8003 
Version: 20Oct2014 
Page 31 of 31 
 
11. REFERENCES 
Dunning A. A model for immunological correlates of protection. Statist. Med. 2006, 
25:1485–1497. 
Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of 
binomial. Biometrika, 1934; 26: 404-413. 
CONFIDENTIAL 
110390 (ZOSTER-006) SAP 
 
 
 
Statistical Analysis Plan Approval 
Protocol Title: Efficacy, safety, and immunogenicity study of GSK 
Biologicals’ Herpes Zoster vaccine GSK1437173A in 
adults aged above 50 years. 
eTrack study number 110390  
eTrack abbreviated title ZOSTER-006 
Protocol version/date 
Scope: 
Amendment 2 (16 March 2012) 
All efficacy data pertaining to the above study  
Version: 
Date: 
Version 1  
23-Mar-2012 
Co-ordinating author:  
Other author(s):  
Approved by: 
Lead Clinical 
Development  Director 
   
 Name Signature dd-mmm-yyyy 
    
Clinical Development  
Director 
   
 Name Signature dd-mmm-yyyy 
    
    
Lead Statistician Name Signature dd-mmm-yyyy 
    
    
 
FORM-BIO-CLIN-8003-01 
GSK SOP Reference: SOP-BIO-CLIN-8003 
Version: 30Mar2011 
Page 1 of 24 
 
CONFIDENTIAL 
110390 (ZOSTER-006) SAP 
 
TABLE OF CONTENTS 
PAGE 
1. DOCUMENT HISTORY ............................................................................................. 4 
2. STUDY DESIGN ........................................................................................................ 4 
3. OBJECTIVES ............................................................................................................. 4 
4. ENDPOINTS .............................................................................................................. 4 
5. STUDY POPULATION ............................................................................................... 4 
5.1. Total Vaccinated cohort .................................................................................. 4 
5.2. Modified Total Vaccinated cohort ................................................................... 4 
5.3. According To Protocol cohort for analysis of efficacy ..................................... 5 
6. STATISTICAL METHODS ......................................................................................... 5 
6.1. Interim analysis for futility ............................................................................... 5 
6.1.1. Futility rules agreed by GSK Management ..................................... 5 
6.1.2. Statistical methodology for analysis of futility .................................. 6 
6.1.2.1. Frequentist approach .................................................... 6 
6.1.2.2. Bayesian approach ........................................................ 6 
6.1.2.3. Testing the futility rule ................................................... 6 
6.2. Final analysis for Efficacy ............................................................................... 7 
6.2.1. Reduction of HZ .............................................................................. 7 
6.2.2. Secondary objectives ...................................................................... 8 
6.2.2.1. Reduction in overall PHN risk ........................................ 8 
6.2.2.2. Reduction of duration of severe ‘worst’ pain in 
subjects with an HZ episode ......................................... 8 
6.2.2.3. Reduction of HZ-related mortality and 
hospitalizations .............................................................. 9 
6.2.2.4. Reduction in incidence of HZ associated 
complications ................................................................. 9 
6.2.2.5. Reduction in use of pain medications ............................ 9 
6.2.3. Exploratory objectives ................................................................... 10 
6.2.3.1. Reduction in Burden-of-Illness .................................... 10 
6.2.3.2. Reduction in HZ severity score ................................... 10 
6.2.3.3. Reduction in PHN incidence in subjects with an 
HZ episode .................................................................. 11 
6.2.3.4. Improvement of subject’s quality of life by ZBPI .......... 11 
7. STATISTICAL CALCULATIONS .............................................................................. 11 
7.1. Derived and transformed data ...................................................................... 11 
7.1.1. Handling of missing data ............................................................... 11 
7.1.2. Efficacy data ................................................................................. 11 
7.2. Number of decimals ..................................................................................... 12 
7.3. Primary method for Vaccine Efficacy: .......................................................... 13 
7.4. Vaccine Efficacy using Cox regression model ............................................. 13 
7.5. Time-to-first event methodology: follow-up time and status ......................... 14 
7.6. Methods for Confidence Intervals (CIs) ........................................................ 14 
7.6.1. CIs for Vaccine Efficacy ................................................................ 14 
FORM-BIO-CLIN-8003-01 
GSK SOP Reference: SOP-BIO-CLIN-8003 
Version: 30Mar2011 
Page 2 of 24 
 
CONFIDENTIAL 
110390 (ZOSTER-006) SAP 
 
7.6.1.1. Poisson distribution ..................................................... 14 
7.6.1.2. Binomial distribution .................................................... 14 
7.6.1.3. Cox regression ............................................................ 15 
8. CONDUCT OF ANALYSES ..................................................................................... 15 
8.1. Sequence of analyses .................................................................................. 15 
8.2. Prior to Final Analysis ................................................................................... 15 
8.3. Statistical considerations for interim analysis ............................................... 15 
8.3.1. Interim analysis for Benefit ............................................................ 16 
8.3.2. Interim analysis for Futility ............................................................ 16 
8.3.2.1. Frequentist approach .................................................. 16 
8.3.2.2. Bayesian approach ...................................................... 18 
8.3.2.3. Testing the futility rule ................................................. 19 
8.4. Final analysis ................................................................................................ 19 
9. CHANGES FROM PLANNED ANALYSES .............................................................. 20 
10. REFERENCES......................................................................................................... 20 
11. ABBREVIATIONS .................................................................................................... 22 
LIST OF FIGURES 
PAGE 
Figure 1 Predictive power to demonstrate the primary objective with lower 
limit of 95% CI ≥ 25% for different observed VEs with 49 cases ............. 18 
 
LIST OF APPENDICES 
PAGE 
APPENDIX 1 N-Weighted Vaccine efficacy ................................................................... 24 
 
FORM-BIO-CLIN-8003-01 
GSK SOP Reference: SOP-BIO-CLIN-8003 
Version: 30Mar2011 
Page 3 of 24 
 
CONFIDENTIAL 
110390 (ZOSTER-006) SAP 
 
The SAP is divided into 2 parts: the first part details the analyses to be performed (current 
document) and the second part, annex (-es) (called TFL) describes the flow and format of 
tables, figures and listings to be annexed to the SR. 
1. DOCUMENT HISTORY 
Date  Version Description 
23-Mar-2012 First Version  Futility analysis and Efficacy objectives 
 
2. STUDY DESIGN 
The following group names will be used for the statistical analyses: 
Group order 
in tables 
Group label in 
tables 
Group definition for 
footnote 
Pooled Groups label in 
tables 
1 gEAS01B gE/AS01B NA 
2 Placebo Placebo NA 
 
3. OBJECTIVES 
As per protocol 
4. ENDPOINTS 
As per protocol 
5. STUDY POPULATION 
5.1. Total Vaccinated cohort 
The Total Vaccinated cohort (TVc) will include all vaccinated subjects (at least one dose) 
with respect to the vaccine actually administered. 
5.2. Modified Total Vaccinated cohort 
The mTVc will be the primary population for efficacy analysis, which excludes subjects 
in the TVc from efficacy analysis who did not receive two doses of the planned vaccine 
or who develop a confirmed case of herpes zoster (HZ) prior to 1 month (30 days) after 
the second vaccination. 
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5.3. According To Protocol cohort for analysis of efficacy 
The According To Protocol cohort (ATPc) for analysis of efficacy will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures defined in the protocol, with no elimination criteria during the study) for 
whom efficacy data concerning endpoint measures are available, but excluding all 
subjects who developed a confirmed case of HZ prior to 1 month (30 days) after the 
second vaccination. The list of criteria used to exclude subjects from ATPc will be 
defined prospectively prior to database freeze. 
The ATPc will be the analysis set for supportive efficacy analysis, only including 
subjects who developed a confirmed case of HZ during the follow-up period starting from 
1 month after the second vaccination (Month 3). 
Cohort Elimination codes Eli Type 
ATP cohort for analysis of efficacy [3010 to 3500] MA 
mTVC 1050-1070-1500-1510 FU/MA 
TVC cohort  1030 (subjects not 
vaccinated) 
MA 
 
6. STATISTICAL METHODS 
6.1. Interim analysis for futility 
One futility analysis is planned. The following conditions are planned prior to futility 
analyses of vaccine efficacy against HZ in study ZOSTER-006. The number of HZ cases 
mentioned refers to the cases in the primary cohort for efficacy (mTVC). 
1. At least 49 HZ cases across all age group in ZOSTER-006; 
2. At least : 
a. 11 HZ cases in subjects in the 50-59 years of age (YOA) stratum in ZOSTER-
006; 
b. 12 HZ cases in subjects in the 60-69 YOA stratum in ZOSTER-006; 
c. 15 HZ cases in subjects in the 70+ YOA strata in both ZOSTER-006 and 
ZOSTER-022. 
6.1.1. Futility rules agreed by GSK Management 
The following futility rule has been agreed by GSK management (ref Futility rules 
document): 
A predictive power of 10% was selected as the threshold below which the ZOSTER-006 
study would be declared futile.  
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6.1.2. Statistical methodology for analysis of futility 
Two different approaches are proposed to evaluate futility, based on all observed HZ 
cases from ZOSTER-006 and ZOSTER-022 at futility analysis. The first approach will 
use a Frequentist approach. The second one will use a Bayesian approach.  The primary 
method will be the Frequentist approach.  
6.1.2.1. Frequentist approach 
This approach has three steps: 
1. Vaccine efficacy (VE) and relative risk (RR) for HZ will be tabulated for each 
age stratum (50-59, 60-69 and 70+ YOA); 
2. An N-weighted VE, using expected numbers of cases in each age stratum at 
final analysis in ZOSTER-006 as weight, will be calculated; 
3. Calculate the predictive power based on the calculated N-weighted VE and other 
parameters used when setting up the futility criteria (O’Brian-Fleming 
boundaries, assumed VE and criteria of success at final analysis). 
6.1.2.2. Bayesian approach 
Using all HZ cases accrued from ZOSTER-006 and ZOSTER-022, we will predict the 
accrual of further HZ cases using interim VE and incidence estimates (or distribution) 
and analyse both interim and predicted data with the planned method for Final analysis 
(stratified Poisson).  A non-informative Bayesian Poisson ratio model will be built for 
each of the 3 age-strata, and interim data will be used to estimate the posterior 
distribution of VE and incidence. The accrual of further HZ cases up to the final analysis 
will be simulated, using posterior predictive distribution, and the analysis of interim and 
simulated cases analysed. 
The proportion of simulated trials leading to success would be used as a proxy of the 
predictive power (probability of success) at final analysis. 
6.1.2.3. Testing the futility rule 
The predictive powers calculated by both the Frequentist and the Bayesian approachs will 
be compared to the futility rule. 
• If the calculated Predictive power is less than the futility boundary, the study will be 
declared futile, and the IDMC will provide this statement to the team. 
• If the calculated Predictive power is greater than the futility boundary, the study will 
be declared not futile, and the IDMC will provide this statement to the team. 
In case of disagreement between the Frequentist the Bayesian approaches, the Frequentist 
approach will be  considered as primary.  
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6.2. Final analysis for Efficacy 
The primary analysis will be based on the mTVC cohort for analysis of efficacy. A 
secondary analysis based on the Total Vaccinated Cohort (TVC) and the ATPc for 
efficacy will be performed to complement the mTVC analysis. 
When overall VE is presented, the age stratification factor will include the 3 main age 
strata. When VE by age is presented, the same model will be run using only the data 
pertaining to the strata under consideration. 
Additional tables will present the overall VE by region and overall VE by time (e.g., 
using 1-year intervals).  
All p-values reported are related to the null hypothesis test VE = 0, or absence of effect of 
the vaccine, and will account for p-value adjustment for multiple testing scheme when 
applicable.  
6.2.1. Reduction of HZ  
The following conditions are planned prior to final HZ analyses of study ZOSTER-006. 
The number of HZ and PHN cases mentioned refers to the cases in the primary cohort for 
efficacy. 
1. At least 196 HZ cases across all age groups for the overall HZ efficacy analysis; 
2. ~75% of the initial sample size (not accounting for any sample-size reassessment) in 
each strata with at least 36 months follow-up and the remaining subjects having 
completed at least 30 months follow-up after Dose 2 in order to ensure enough safety 
data; 
3. Approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ cases 
in subjects 60-69 YOA for the HZ analysis by age in the 50-59 and 60-69 YOA age 
strata, respectively; 
4. A total of at least 88 PHN cases when pooled with ZOSTER-022 PHN cases accrued. 
Primary Inferential Analyses 
The primary analysis method of the vaccine VE will consider the exact inference on the 
relative risk stratified for age strata and regions conditionally to the total number of HZ 
cases observed and time at risk. The method is implemented in the Poisson procedure of 
the StatXact package provided by Cytel. Relative risks will be calculated overall and by 
age-strata. Stratification will include age and regions for the overall analysis and region 
alone when analysis by age strata.  
Incidence rates and VE with 95% CI will be tabulated for primary efficacy endpoint. P-
value (to test H0 = [VE≤25%]) will be tabulated for the primary endpoint. 
The efficacy of ZOSTER vaccine against HZ will be demonstrated if the LL of the two-
sided 95% CI of VE is above 25%. 
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Secondary Inferential Analyses 
The elapsed time following the HZ-case exclusion period after the second vaccination to 
the first HZ episode may be analyzed using Cox’s proportional hazard regression 
stratified for age strata and region with vaccine groups as covariates. Wald test and CIs 
will be produced. 
Ties will be handled using the Efron method. Cox adjusted survival curves will be 
produced for each combination of vaccine group and age category. 
Descriptive statistics 
For each treatment group, the number of subjects at risk, person-time, number of 
confirmed events (HZ) and incidence rate, and incidence of confirmed HZ cases will be 
tabulated overall and by age strata. The results will be presented over the whole study and 
by visit interval. Similar tables will describe the median time-to-event and hazard rate. 
Survival curves for each vaccine group will be calculated non-parametrically, tabulated 
and presented graphically overall and by age strata using the Kaplan-Meier (i.e., Product-
Limit) method.  
Sensitivity analysis of the overall VE after each multiple of 12 months following last 
vaccination will be provided in order to assess consistency of VE over time. 
6.2.2. Secondary objectives 
6.2.2.1. Reduction in overall PHN risk 
The overall reduction in PHN risk will be evaluated similarly to the HZ risk using the 
exact inference on the relative risk stratified for age strata and regions conditionally to the 
total number of HZ cases observed and time at risk. Similarly to the HZ VE, a Poisson 
distribution for the number of PHN cases under placebo and vaccine groups is assumed. 
The efficacy of ZOSTER vaccine against PHN will be demonstrated if the LL of the two-
sided 95% CI of VE is above 0%. 
6.2.2.2. Reduction of duration of severe ‘worst’ pain in subjects with an HZ 
episode 
The time-to-cessation of severe ‘worst’ pain will be analyzed using a survival 
methodology. The primary analysis will consist in a Cox-proportional model to assess the 
hazard rate reduction in ZBPI worst pain duration due to the vaccine in those subjects that 
presented HZ. 
The efficacy of ZOSTER vaccine against duration of several worst pain will be 
demonstrated if  the LL of the two-sided 95% CI of VE derived from the Hasard ratio is 
above 0%. 
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A change-point piecewise exponential model [Arani, 2001; Desmond, 2002] may be used 
as sensitivity analysis to compare hazard rates related to acute (0-30 days), sub-acute (30-
120 days) and chronic (120+ days) pain between vaccine group and placebo. The cut-off 
points 30 days and 120 days were suggested according to Desmond [Desmond, 2002]. 
Those cut-off points may additionally be estimated using the data. The comparisons 
across both sub-acute pain and chronic pain will be combined using a likelihood-ratio 
test. 
For each treatment group, the number of subjects at risk (with confirmed HZ), number of 
subjects with severe “worst” pain and incidence rate will be tabulated overall and by age 
strata. Similar tables will describe the median, median, minimum and maximum duration 
of severe “worst” pain.  
Survival curves for each vaccine group will be calculated non-parametrically and 
presented graphically overall and by age strata using the Kaplan-Meier (i.e., Product-
Limit) method. 
6.2.2.3. Reduction of HZ-related mortality and hospitalizations 
The reduction of HZ-related mortality and hospitalizations will be evaluated through; 
• The vaccine VE will consider the exact inference on the relative risk stratified for 
age strata and regions conditionally to the total number of HZ cases observed and 
time at risk. The method is implemented in the Poisson procedure of the StatXact 
package provided by Cytel. Relative risks will be calculated overall and by age-
strata. Stratification will include age and regions for the overall analysis and region 
alone when analysis by age strata.  
The efficacy of ZOSTER vaccine against HZ-related mortality and hospitalizations will 
be demonstrated if the LL of the two-sided 95% CI of VE is above 0%. 
6.2.2.4. Reduction in incidence of HZ associated complications 
The overall incidence of HZ associated complications, in subjects with an HZ episode, 
overall and by age group will be presented and compared with placebo using asymptotic 
standardized unconditional binomial test [Miettinen, 1985]. The analysis will be stratified 
by age group and weights associated to each stratum will be pre-specified. 
The efficacy of ZOSTER vaccine against HZ associated complications will be 
demonstrated if the LL of the VE is above 0%. 
6.2.2.5. Reduction in use of pain medications 
The reduction in use of pain medication will be evaluated through; 
• The vaccine VE will consider the exact inference on the relative risk stratified for 
age strata and regions conditionally to the total number of HZ cases observed and 
time at risk. The method is implemented in the Poisson procedure of the StatXact 
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package provided by Cytel. Relative risks will be calculated overall and by age-
strata. Stratification will include age and regions for the overall analysis and region 
alone when analysis by age strata.  
The efficacy of ZOSTER vaccine in reduction in use of pain medications  will be 
demonstrated if the LL of the two-sided 95% CI of VE is above 0%. 
All analyses will be presented overall and by age strata. The main age strata for reporting 
purposes are 50-59, 60-69 and ≥70 YOA. In addition, the results for the ≥ 70 YOA 
stratum will also be presented separately for 70-79 and ≥ 80 YOA subjects. The study is 
not powered prospectively to demonstrate efficacy in these 2 sub-strata taken separately. 
Another set of analyses in subjects ≥ 60 YOA will also be presented. 
Any exploratory or sensitivity analysis may be performed in addition to the analyses 
described below on an ad-hoc basis. The significance level of those analyses may not 
however be fully controlled. 
6.2.3. Exploratory objectives 
6.2.3.1. Reduction in Burden-of-Illness 
The overall reduction in Burden-of-Illness will be evaluated through:  
• The “Chop-lump” test [Follmann, 2009] for the overall reduction in Burden-of-
Illness scores in all subjects between vaccine and placebo will be implemented 
and compared to the original analysis of the Burden-of-Illness proposed by 
Chang, 1994; 
• VE with respect to the BOI due to HZ (VE BOI ) is defined as the relative 
reduction in the BOI score in the vaccine group as compared with that in the 
placebo group and calculated as 1 - relative risk (i.e., 1- the HZ BOI score in the 
vaccine group divided by the HZ BOI score in the placebo group). 
6.2.3.2. Reduction in HZ severity score 
The reduction in HZ severity score will be evaluated through:  
• The “Chop-lump” test [Chang, 1994] for the reduction in HZ severity scores in 
subjects with HZ between vaccine and placebo will be implemented. 
The HZ severity analysis applies to subjects with HZ and includes the first 4 weeks 
following the HZ episode.  
Additional analyses may be performed using partial AUC, calculated from 0 to specific 
elapsed time after HZ onset. That approach accounts partially for any difference in pain 
score profiles or pattern (e.g., long duration with low scores versus short score with high 
scores) even though subjects may have the same overall AUC. 
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6.2.3.3. Reduction in PHN incidence in subjects with an HZ episode 
The reduction in PHN incidence in subjects with an HZ episode will be evaluated 
through: 
• The incidence of PHN in subjects with an HZ episode, overall and by age group 
will be presented and compared with placebo using asymptotic standardized 
unconditional binomial test [Miettinen, 1985]. The analysis will be stratified by 
age group and weights associated to each stratum will be pre-specified.  
6.2.3.4. Improvement of subject’s quality of life by ZBPI 
Descriptive statistics and inferential analysis of QoL subscale of ZBPI (item 9: questions 
A to G) total scores and scores per item over time will be provided overall and by age 
group.  
7. STATISTICAL CALCULATIONS 
7.1. Derived and transformed data 
7.1.1. Handling of missing data 
For a given subject and a given efficacy measurement, missing or non-evaluable 
measurements will not be imputed for the primary analysis. The missing endpoint and 
censoring are supposed to occur independently, and the pattern of the missingness being 
either Completely At Random (MCAR) or Missing At Random (MAR) only. 
Sensitivity analyses will be pre-specified prior to unblinding for each main efficacy 
endpoint in order to assess the sensitivity of the conclusions to missing-data pattern. 
When repeated measurements are planned, primary methodology will include mixed 
effect model for repeated measurement analysis [Mallinckrodt, 2008]. 
7.1.2. Efficacy data 
The HZ incidence rate is determined with reference to the first confirmed HZ case 
observed in the patient, should several HZ cases occur in the same subject. 
The HZ-free period for a subject is calculated from HZ onset to time zero relative to the 
cohort considered: first vaccination for TVc and beyond the HZ-case exclusion period 
following the second injection for mTVc and ATP. 
The number of Person-Years at risk over an interval of time is the sum of the confirmed 
HZ-free episodes over all subjects at risk during that interval, either up to the cut-off date 
for the analysis, the censoring date or the occurrence of the first HZ case for a subject. 
RR is defined as the ratio of the incidence rates of the vaccine group over the placebo 
group. 
VE is defined as the 1 – RR. 
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The following outputs will be derived from the efficacy data recorded using the ZBPI: 
Duration of severe worst pain 
For each confirmed HZ cases the follow up time is considered as starting from the date of 
HZ episode and ending the last day of ZBPI questionnaire period. The confirmed HZ 
cases without severe “worst” pain are considered as non-event cases. The cases with 
severe “worst” pain are considered as an event cases, their time to event is calculated as 
being the difference between their follow up time period and duration of pain. Those 
transformations allow computing vaccine efficacy in term of severe “worst” pain-free 
period. 
HZ burden-of-illness score 
For each confirmed case of HZ, responses to the “worst pain” question in the ZBPI are 
used to calculate a “HZ severity-of-illness” score, defined as the area under the curve 
(AUC) of HZ-associated pain plotted against time during the 182-day period after the 
onset of the case. Subjects developing HZ will present “severity-of-illness” scores 
ranging from 0 up to, theoretically, 1820. A score of 0 is recorded for subjects in whom 
HZ did not develop during the study period. 
HZ severity score  
The methodology described for the HZ burden-of-illness score will be applied to the 4 
weeks during which a daily measure is taken and provide the HZ severity score. The HZ 
severity score will apply only to subjects with HZ. Subjects not infected with HZ will not 
take part in this analysis. 
7.2. Number of decimals 
The following decimal description will be used for the efficacy analyses. 
Display Table Parameters Number of decimal digits 
All summaries % of count, including LL & UL 
of CI 
 
1 
All summaries % of difference, including LL & 
UL of CI 
2 
All summaries p-value 3 
Efficacy VE, including LL & UL of CI 2 
IR 2 
T, T/N 1 
p-value 3 
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7.3. Primary method for Vaccine Efficacy: 
VE will consider the exact inference on the relative risk stratified for age strata and 
regions conditionally to the total number of HZ cases observed and time at risk. 
Stratification will include age and regions for the overall analysis and region alone when 
analysis by age strata.  
This method computes an exact confidence interval (CI) around the rate ratio (ratio of the 
event rates in the vaccinated versus control group) and takes into account the follow-up 
time of the subjects within each group. VE is then defined as 1 minus the rate ratio. 
The follow-up time for each subject will start 
• at the day after first vaccination (Month 0) if analyses are done on the Total 
vaccinated cohort for efficacy, or 
• at 30 days after second vaccination (Month 3) if analyses are done on the mTVC or 
ATP cohort for efficacy.  
The follow-up time for each subject will end 
• at the time of the event; or,  
• at date of last visitfor subjects who completed the study and did not have an event; 
or,  
• at the latest visit for which data is available for subjects who did not yet complete the 
study at the time of the interim analysis or final analysis (if criteria to reach final 
analyses are met before all subjects complete their last visit) and did not have an 
event: 
• For HZ endpoints, we take the minimum date of the start of the rash or start of 
the pain to assess the HZ, whichever comes first. 
The follow-up time will be calculated in days as Date of end of follow-up period – Date 
of vaccination, and expressed in person-years at risk (number of days/365.25).  
7.4. Vaccine Efficacy using Cox regression model 
In addition to the primary analysis, VE and its CI will also be calculated using a Cox 
regression model. This methodology can take into account specific risk factors which 
might have been imbalanced, by chance, at the beginning of the trial between the 
vaccinated and control group. Risk factors that will be investigated are age strata and 
country. VE is then calculated as 1 minus the hazard ratio. 
Cox regression assumes proportional hazards throughout the follow-up period. This 
assumption will be checked by a test based on the Schoenfeld residuals. 
If there is strong evidence that the hazard rate is not constant over the surveillance period, 
then a non-parametric analysis will be performed. 
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7.5. Time-to-first event methodology: follow-up time and status 
The study participants will be actively followed for the occurrence of HZ, PHN and use 
of pain medications during entire study follow up. The events linked to primary and 
secondary efficacy outcomes (with onset time) will be identified and in case multiple 
events are observed for the same subject, only the first event will be considered.  
For primary and secondary endpoints, the follow-up time and the status will be 
recorded as follows: 
• If the subject gets his/her first event of corresponding primary or secondary 
endpoints during the study follow up period, the status will be 1 and the 
associated time will be the number of days between start date of the considered 
period (30 days after last study vaccination) and the date of the appearance of the 
event. If he/she gets the same event afterwards, it will not be considered in the 
analysis. 
• If a subject does not get the event of corresponding endpoint during the study 
follow up, the status will be 0 and the associated time will be the number of days 
the subject is followed (if a subject is dropped-out from the study, his/her date of 
last contact will be taken into account). 
• Subjects meeting censoring criteria will be included in the analysis. 
7.6. Methods for Confidence Intervals (CIs) 
7.6.1. CIs for Vaccine Efficacy 
7.6.1.1. Poisson distribution 
The CI for vaccine efficacy can then be derived from the exact CI from RR (Miettinen, 
1985). This method is implemented in the Poisson procedure of the StatXact package 
provided by Cytel. 
7.6.1.2. Binomial distribution 
The Vaccine Efficacy (VE) can be estimated by:  
2*
11
2/2
1/11
nr
n
Nn
NnVE −=−=
 
where  n1 = number of cases in the vaccinated group 
N1 = follow-up time the vaccinated group 
n2 = number of cases in the control group 
N2 = follow-up time in the control group 
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r = 
2
1
N
N
 
Conditionally to the total number of cases n = n1+ n2 and r, let p denote the proportion of 
cases in the vaccine group, 
)1(*)1(*)1(* prprnnrn −−− 1
1*1*11 ppnnVE −=−=−=
 
where p = n1/n is binomially distributed. 
Therefore, there is a monotonic link between VE, the true vaccine efficacy, and p, the 
true proportion of subjects in the vaccine group among the total cases in the two groups. 
The CI for vaccine efficacy can then be derived from the exact CI from p (Dragalin, 
Fedorov and Cheuvart, 2002). This method is implemented in the Binomial procedure of 
the StatXact package provided by Cytel. 
7.6.1.3. Cox regression 
The CI for vaccine efficacy can then be derived from the Wald CI from Hazard Ratio. 
This method is implemented in the PHREG procedure of the SAS/STAT package (SAS 
V9.2). 
8. CONDUCT OF ANALYSES 
8.1. Sequence of analyses 
Description Analysis ID (SDD sub-folder) TFL short title 
Futility analysis at 25% of 
HZ accrual 
2 Interim 
Final Analysis  1 Final 
End of study analysis EOS EOS 
 
8.2. Prior to Final Analysis 
Blinded review of efficacy data will be performed in order to anticipate rate of accrual of 
HZ events within each age strata. 
Unblinded evaluation of futility efficacy will be performed by the IDMC.  
8.3. Statistical considerations for interim analysis 
When 49 confirmed HZ cases have accrued in ZOSTER-006 and at least 20% of HZ 
cases are observed in each age strata [50-59 years], [60-69 years] and [70+ years] (see 
section 6.1), an interim analysis for futility will be performed. 
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8.3.1. Interim analysis for Benefit 
GSK has no plan to proceed with early registration for efficacy (i.e., following the interim 
analysis) due to the following reasons: 
− The expected low accrual rate of PHN cases and the need to collect a sufficient 
number of events to achieve a robust estimate of PHN VE; 
− The duration of protection conferred by the vaccine is an important characteristic 
and because this futility analysis occurs at an early stage of the trial it will not be 
able to provide the required data if the study is stopped prematurely; 
− Accumulation of longer term safety data than will be available at the interim 
analysis. 
If the futility analysis occurs and leads to a recommendation by the IDMC to file prior to 
study end for ethical reasons, it is mandated that, prior to final analysis, the significance 
level for all primary objectives, and also key secondary objectives, is set to 0.0001 for 
both HZ and overall PHN, considering the alternative hypotheses of true vaccine 
efficacies above 40%. As a consequence, the significance level of the final analysis will 
be adjusted to 4.9998% 2-sided.  
8.3.2. Interim analysis for Futility 
Two different approaches are proposed, based on all observed cases in both ZOSTER-
006 and ZOSTER-022 at interim. The first approach will calculate the predictive power 
using a Frequentist approach. The second one will evaluate the predictive power using a 
Bayesian approach.   
8.3.2.1. Frequentist approach 
This approach has three steps: 
1. VE and RR for HZ will be tabulated in each age stratum (50-59, 60-69 and 70+ 
YOA); 
2. An N-weighted VE, using as weight the expected number of HZ cases in each age 
stratum at final analysis in ZOSTER-006, will be calculated; 
3. Calculate the predictive power based on the calculated N-weighted VE and other 
parameters used when setting up the futility criteria (O’Brian-Fleming boundaries, 
assumed VE and Criteria of success at final analysis). 
Evaluate Vaccine efficacy in each strata 
Using all cases retrieved in both ZOSTER-006 and ZOSTER-022, we will evaluate VE in 
each of the three following age strata (50-59, 60-69 and 70+ YOA). 
The method used will be similar to the method described in section 7.1.2. VE and 95% CI 
will be tabulated. 
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Evaluate N-Weighted Vaccine efficacy 
Using details given in Appendix 1: 
1. Calculate RR (as 1-VE) and Loge (RR) of each of the three age strata; 
2. Calculate the Weight of each age stratum as expected number of  cases at final 
analysis (using incidence rates of the interim analysis) (noted wi; i = 1 to 3); 
3. Calculate the sum of weighted Loge(RR) of the three age strata and divide by the 
sum of weights; 
4. Use the back transformation (1-exp(.)) to retrieve the correspondent weighted VE. 
The 95% CI is approximated from the Asymptotic normality of the Loge(RR) and the 
associated variance of the Loge(RR) from Agresti (1990): 
1. Calculate the Standard Error (SE) of RR in each of the three age strata by  
 SE = sqrt((1/(nv+0.5))-(1/(Nv+0.5))+(1/(np+0.5))-(1/(Np+0.5))); 
2. Calculate the global SE using the Variance properties by    
 SE = sqrt(( Sum  wi^2  SE^2) / (sum wi)^2); 
3. Calculate 95% CI as Loge(RR)± 1.96 SE and deduce by back transformation the 
95% CI of weighted VE.  
The weighted VE calculated is noted as N-weighted VE, more details are provided in 
Appendix 1. 
Calculate predictive power 
The two following SAS procedures will be used to calculate the predictive power. The 
SEQDESIGN procedure used to evaluate designs interim analyses and the SEQTEST 
procedure performs the interim analyses based on the sample sizes and boundary values 
produced by the SEQDESIGN procedure. 
1. Based on the O’Brian-Fleming Method, evaluation of the boundary values using 
the PROC SEQDESIGN: 
The SEQDESIGN procedure designs interim analyses for clinical trials. PROC 
SEQDESIGN computes the boundary values for the trial. The boundary values 
are derived in such a way that the overall Type I and Type II error probability 
levels are maintained at the levels specified in the design. Method chosen is the 
O’Brian-Fleming method. The SEQDESIGN procedure computes the boundary 
values.  The following parameters have been fixed (during the determination of 
the futility rules) :  Assumed VE = 69% , Criteria of success LL > 25%, Gamma = 
-5 (Gamma family sepnding function linked to O’Brian-Fleming boundaries), 
Beta = 0.0031 (Type II error), Alpha = 0.025 (Type one error) 
2. Calculate the Predictive power using the PROC SEQTEST: 
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Based on the weighted VE calculated at interim, the SEQTEST procedure 
compare the test statistic on interim data with the corresponding boundary values 
computed by the SEQDESIGN procedure and provide the  predictive power. 
The predictive power calculated is the posterior probability that the test statistic at 
the final stage would exceed the rejection critical value given the observed 
statistic and a prior distribution of the hypothetical reference. A non-informative 
prior is used in the procedure. 
Illustration of the predictive power for different VE observed at interim is given in the 
figure 2. 
Figure 1 Predictive power to demonstrate the primary objective with lower 
limit of 95% CI ≥ 25% for different observed VEs with 49 cases  
 
 
8.3.2.2. Bayesian approach 
All HZ cases accrued from ZOSTER-006 and ZOSTER-022 will be used.  
A Bayesian framework is used to simulate accrual of HZ cases in each age stratum under 
vaccine and placebo over the period of time between interim and final analysis.   
The duration of accrual is determined in order for the median number of HZ cases to 
reach between 196 and 200 over the 3 age strata.  The joint posterior distribution of 
placebo incidence and vaccine efficacy is calculated separately for each age stratum using 
unblinded interim data and non-informative priors.  
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The joint distribution of the number of HZ cases under placebo and vaccine is simulated 
based on the joint posterior distribution of placebo incidence and vaccine efficacy and 
assuming (conditionally) independent Poisson distribution for the number of HZ cases.  
Provided that the sum of simulated HZ cases across the 3 age strata is between 196 and 
200, the simulations are analysed using the frequentist methodology planned for the final 
analysis.  
A success is considered when the LL of the  95% confidence interval for VE is above 
25%.  
The probability of success of the final analysis given the interim data is estimated as the 
ratio of successes over the total number of simulations presented a total of 196 to 200 HZ 
cases.   
Details on the Bayesian framework is described in Laurent & Legrand (2011). 
8.3.2.3. Testing the futility rule 
Both predictive powers calculated by the frequentist approach will be compared to the 
futility rule. 
• If the Predictive power calculated is less than the futility boundary, the study will be 
declared futile, and the IDMC will provide this statement to the team. 
• If the Predictive power calculated is greater than the futility boundary, the study will 
be declared not futile, and the IDMC will provide this statement to the team. 
The IDMC will have access to the full analysis results and will provide GSK the 
applicable statement.  
8.4. Final analysis 
When the conditions for triggering the final analysis of efficacy have been reached, the 
final analysis cut-off date will be defined. Any HZ episode occurring prior to the final 
analysis cut-off date will be followed, as described in the protocol, until the case of 
suspected HZ is disproved, OR until a 4-week pain-free period is documented, OR until 
the cut-off date for final analysis. For all subjects with ongoing HZ-associated pain at the 
time of cut-off date for final analysis, ZBPI data will be collected until suspected HZ is 
disproved, OR until a 4-week pain-free period is documented OR until at least Day HZ-
90 in order to document potential PHN episodes. 
Following achievement of criteria triggering analyses, final data collection and data 
cleaning, the write access to the clinical database will be removed and all eCRF data will 
become available for final analysis. A first report will document efficacy and safety 
results and provide immunogenicity results using descriptive methodology.  
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Analysis of correlate of protection may require extensive exploratory analyses and may 
be available as an annex report after completion of the primary report. Persistency data 
may be also provided in annex reports.  
9. CHANGES FROM PLANNED ANALYSES 
No changes from protocol planned analyses. 
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11. ABBREVIATIONS 
ATP According-To-Protocol 
AUC Area Under Curve 
BOI Burden-Of-Illness 
CI Confidence Interval 
Eli_type Internal GSK database code for type of elimination code 
eCRF Electronic Case Report Form 
HZ Herpes ZOSTER 
GSK GlaxoSmithKline 
IDMC Independent Data Monitoring Committee 
IR Incidence Rates 
LL Lower limit 
MAR Missing At Random 
MCAR Missing Completely At Random 
mTVc Modified Total Vaccinated Cohort 
N.A. Not Applicable 
OTH Other 
PHN Postherpetic Neuralgia 
QoL Quality of Life 
R R free software from free fondation software 
RDE Remote Data Entry 
RR Relative Risk 
SAP Statistical Analysis Plan 
SAS Statistical Analysis System 
SBIR GSK Biological’s Internet Randomization System 
SE Standard Error 
sqrt Square root 
SR Study Report 
SYN Synopsis 
TFL Tables Figures and Listing template annexed to SAP 
TVc Total Vaccinated Cohort 
UL Upper Limit 
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VE Vaccine Efficacy 
YOA Years Of Age 
ZBPI Zoster Brief Pain Inventory 
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APPENDIX 1 N-Weighted Vaccine efficacy 
The N-weighted estimate of vaccine efficacy is used to yield a single estimate of efficacy 
across the different age strata. At time of futility analysis, all cases accrued  in ZOSTER-
022 will be also used in the evaluation of the futility rule in order to account for all 
information available at this time.  
The Stratified Poisson analysis planned for the final analysis use implicitely the number 
of cases accrued in each strata as weight. In order to correct the bias made by including 
the cases from ZOSTER-022 (only in the [70+ years] strata,  we propose to use the 
weighted VE (using number of cases by strata expected at final analysis as weight)  as 
estimation of the vaccine efficacy  at futility analysis. 
Expected value of VE : The mean (or expected value of) VE across the three strata can be 
computed and be used as a measure of central tendency, to characterize the average VE 
that can be expected in the ZOSTER-006. 
Definition of Expected value: For a random variable X with two possible values (x1, x2) 
with corresponding probabilities (p, q), the mean (or expected value) of the random 
variable X is defined as: 
Expected value = mean =E(X) =x1.p = x2.p                                             (13.1) 
The expected value of VE across the three strata that can be computed and used to 
characterize the average VE that can be expected from the FAS may be obtained 
analogously using the computations shown in Equation 13.1 as follows. 
Calculation of Expected values of VE: Let the expected value of VE be denoted by 
E(VE). Then E(VE) cane be computed as 
E(VE) = 100% x (1-exp(Expected value of loge [relative risk]))             (13.2) 
The rationale for such a computation is that the estimate of loge[relative risk] that is 
asymptotically normally distributed.. The asymptotic normal distribution property of the 
estimate of loge[relative risk] can be used to obtain a 95% confidence interval 
corresponding to the estimate of E (VE). The N-weighted average estimate of vaccine 
efficacy in the FAS were computed based on the calculations given in Equation 13.2. The 
use of the term "N-weighted" arises from the calculation of the expected value of 
loge[relative risk]. 
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The SAP is divided into 2 parts: the first part details the analyses to be performed (current 
document) and the second part, annex (-es) (called TFL) describes the flow and format of 
tables, figures and listings to be annexed to the SR. 
1. DOCUMENT HISTORY 
Date  Version Description 
23-Mar-2012 First Version  Futility analysis and Efficacy objectives 
05-May-2014 Second Version Futility analysis and Efficacy 
objectives (adaptation to 
amendment 4 and small 
corrections) 
 
2. STUDY DESIGN 
The following group names will be used for the statistical analyses: 
Group order 
in tables 
Group label in 
tables 
Group definition for 
footnote 
Pooled Groups label in 
tables 
1 HZ/su Herpes Zoster  subunit 
vaccine
NA 
2 Placebo Placebo NA 
 
3. OBJECTIVES 
As per protocol 
4. ENDPOINTS 
As per protocol 
5. STUDY POPULATION 
5.1. Total Vaccinated cohort 
The Total Vaccinated cohort (TVc) will include all vaccinated subjects (at least one dose) 
with respect to the vaccine actually administered. 
5.2. Modified Total Vaccinated cohort 
The mTVc will be the primary population for efficacy analysis, which excludes subjects 
in the TVc from efficacy analysis who did not receive two doses of the planned vaccine 
or who develop a confirmed case of herpes zoster (HZ) prior to 1 month (30 days) after 
the second vaccination. 
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5.3. According To Protocol cohort for analysis of efficacy 
The According To Protocol cohort (ATPc) for analysis of efficacy will include all 
evaluable subjects (i.e., those meeting all eligibility criteria, complying with the 
procedures defined in the protocol, with no elimination criteria during the study) for 
whom efficacy data concerning endpoint measures are available, but excluding all 
subjects who developed a confirmed case of HZ prior to 1 month (30 days) after the 
second vaccination. The list of criteria used to exclude subjects from ATPc will be 
defined prospectively prior to database freeze. 
The ATPc will be the analysis set for supportive efficacy analysis, only including 
subjects who developed a confirmed case of HZ during the follow-up period starting from 
1 month after the second vaccination (Month 3). 
Cohort Elimination codes Eli Type 
ATP cohort for analysis of efficacy 900, 1030-1070, 1500-2010, 2500,3500 MA/ES 
mTVC 900,1030,1050,1070, 1500, 2500, 3500 FU/MA/ES 
TVC cohort  900, 1030 (subjects not vaccinated) MA/ES 
 
6. STATISTICAL METHODS 
6.1. Interim analysis for futility 
One futility analysis is planned. The following conditions are planned prior to futility 
analyses of vaccine efficacy against HZ in study ZOSTER-006. The number of HZ cases 
mentioned refers to the cases in the primary cohort for efficacy (mTVC). 
1. At least 49 HZ cases across all age group in ZOSTER-006; 
2. At least : 
a. 11 HZ cases in subjects in the 50-59 years of age (YOA) stratum in ZOSTER-
006; 
b. 12 HZ cases in subjects in the 60-69 YOA stratum in ZOSTER-006; 
c. 15 HZ cases in subjects in the 70+ YOA strata in both ZOSTER-006 and 
ZOSTER-022. 
6.1.1. Futility rules agreed by GSK Management 
The following futility rule has been agreed by GSK management (ref Futility rules 
document): 
A predictive power of 10% was selected as the threshold below which the ZOSTER-006 
study would be declared futile.  
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6.1.2. Statistical methodology for analysis of futility 
Two different approaches are proposed to evaluate futility, based on all observed HZ 
cases from ZOSTER-006 and ZOSTER-022 at futility analysis. The first approach will 
use a Frequentist approach. The second one will use a Bayesian approach.  The primary 
method will be the Frequentist approach.  
6.1.2.1. Frequentist approach 
This approach has three steps: 
1. Vaccine efficacy (VE) and relative risk (RR) for HZ will be tabulated for each 
age stratum (50-59, 60-69 and 70+ YOA); 
2. An N-weighted VE, using expected numbers of cases in each age stratum at 
final analysis in ZOSTER-006 as weight, will be calculated; 
3. Calculate the predictive power based on the calculated N-weighted VE and other 
parameters used when setting up the futility criteria (O’Brian-Fleming 
boundaries, assumed VE and criteria of success at final analysis). 
6.1.2.2. Bayesian approach 
Using all HZ cases accrued from ZOSTER-006 and ZOSTER-022, we will predict the 
accrual of further HZ cases using interim VE and incidence estimates (or distribution) 
and analyse both interim and predicted data with the planned method for Final analysis 
(stratified Poisson).  A non-informative Bayesian Poisson ratio model will be built for 
each of the 3 age-strata, and interim data will be used to estimate the posterior 
distribution of VE and incidence. The accrual of further HZ cases up to the final analysis 
will be simulated, using posterior predictive distribution, and the analysis of interim and 
simulated cases analysed. 
The proportion of simulated trials leading to success would be used as a proxy of the 
predictive power (probability of success) at final analysis. 
6.1.2.3. Testing the futility rule 
The predictive powers calculated by both the Frequentist and the Bayesian approaches 
will be compared to the futility rule. 
• If the calculated Predictive power is less than the futility boundary, the study will be 
declared futile, and the IDMC will provide this statement to the team. 
• If the calculated Predictive power is greater than the futility boundary, the study will 
be declared not futile, and the IDMC will provide this statement to the team. 
In case of disagreement between the Frequentist the Bayesian approaches, the Frequentist 
approach will be  considered as primary.  
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6.2. Final analysis for Efficacy 
The primary analysis will be based on the mTVC cohort for analysis of efficacy. A 
secondary analysis based on the Total Vaccinated Cohort (TVC) and the ATPc for 
efficacy will be performed to complement the mTVC analysis. 
When overall VE is presented, the age stratification factor will include the 3 main age 
strata. When VE by age is presented, the same model will be run using only the data 
pertaining to the strata under consideration. 
Additional tables will present the overall VE by region and overall VE by time (e.g., 
using 1-year intervals).  
All p-values reported are related to the null hypothesis test VE = 0, or absence of effect of 
the vaccine, and will account for p-value adjustment for multiple testing scheme when 
applicable.  
6.2.1. Reduction of HZ  
The following conditions are planned prior to final HZ analyses of study ZOSTER-006. 
The number of HZ and PHN cases mentioned refers to the cases in the primary cohort for 
efficacy. 
1. At least 196 HZ cases across all age groups for the overall HZ efficacy analysis; 
2. ~75% of the initial sample size (not accounting for any sample-size reassessment) in 
each strata with at least 36 months follow-up and the remaining subjects having 
completed at least 30 months follow-up after Dose 2 in order to ensure enough safety 
data; 
3. Approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ cases 
in subjects 60-69 YOA for the HZ analysis by age in the 50-59 and 60-69 YOA age 
strata, respectively; 
4. A total of at least 88 PHN cases when pooled with ZOSTER-022 PHN cases accrued. 
Primary Inferential Analyses 
The primary analysis method of the vaccine VE will consider the exact inference on the 
relative risk stratified for age strata and regions conditionally to the total number of HZ 
cases observed and time at risk. The method is implemented in the Poisson procedure of 
the StatXact package provided by Cytel. Relative risks will be calculated overall and by 
age-strata. Stratification will include age and regions for the overall analysis and region 
alone when analysis by age strata.  
Incidence rates and VE with 95% CI will be tabulated for primary efficacy endpoint. P-
value (to test H0 = [VE≤25%]) will be tabulated for the primary endpoint. 
The efficacy of ZOSTER vaccine against HZ will be demonstrated if the LL of the two-
sided 95% CI of VE is above 25%. 
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Secondary Inferential Analyses 
The elapsed time following the HZ-case exclusion period after the second vaccination to 
the first HZ episode may be analyzed using Cox’s proportional hazard regression 
stratified for age strata and region with vaccine groups as covariates. Wald test and CIs 
will be produced. 
Ties will be handled using the Efron method. Cox adjusted survival curves will be 
produced for each combination of vaccine group and age category. 
Descriptive statistics 
For each treatment group, the number of subjects at risk, person-time, number of 
confirmed events (HZ) and incidence rate, and incidence of confirmed HZ cases will be 
tabulated overall and by age strata. The results will be presented over the whole study and 
by visit interval. Similar tables will describe the median time-to-event and hazard rate. 
Survival curves for each vaccine group will be calculated non-parametrically, tabulated 
and presented graphically overall and by age strata using the Kaplan-Meier (i.e., Product-
Limit) method.  
Sensitivity analysis of the overall VE after each multiple of 12 months following last 
vaccination will be provided in order to assess consistency of VE over time. 
6.2.2. Secondary objectives 
6.2.2.1. Reduction in overall PHN risk 
The overall reduction in PHN risk will be evaluated similarly to the HZ risk using the 
exact inference on the relative risk stratified for age strata and regions conditionally to the 
total number of HZ cases observed and time at risk. Similarly to the HZ VE, a Poisson 
distribution for the number of PHN cases under placebo and vaccine groups is assumed. 
The efficacy of ZOSTER vaccine against PHN will be demonstrated if the LL of the two-
sided 95% CI of VE is above 0%. 
6.2.2.2. Reduction of duration of severe ‘worst’ pain in subjects with an HZ 
episode 
The time-to-cessation of severe ‘worst’ pain will be analyzed using a survival 
methodology. The primary analysis will consist in a Cox-proportional model to assess the 
hazard rate reduction in ZBPI worst pain duration due to the vaccine in those subjects that 
presented HZ. 
The efficacy of ZOSTER vaccine against duration of several worst pain will be 
demonstrated if  the LL of the two-sided 95% CI of VE derived from the Hasard ratio is 
above 0%. 
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A change-point piecewise exponential model [Arani, 2001; Desmond, 2002] may be used 
as sensitivity analysis to compare hazard rates related to acute (0-30 days), sub-acute (30-
120 days) and chronic (120+ days) pain between vaccine group and placebo. The cut-off 
points 30 days and 120 days were suggested according to Desmond [Desmond, 2002]. 
Those cut-off points may additionally be estimated using the data. The comparisons 
across both sub-acute pain and chronic pain will be combined using a likelihood-ratio 
test. 
For each treatment group, the number of subjects at risk (with confirmed HZ), number of 
subjects with severe “worst” pain and incidence rate will be tabulated overall and by age 
strata. Similar tables will describe the median, median, minimum and maximum duration 
of severe “worst” pain.  
Survival curves for each vaccine group will be calculated non-parametrically and 
presented graphically overall and by age strata using the Kaplan-Meier (i.e., Product-
Limit) method. 
6.2.2.3. Reduction of HZ-related mortality and hospitalizations 
The reduction of HZ-related mortality and hospitalizations will be evaluated through; 
• The vaccine VE will consider the exact inference on the relative risk stratified for 
age strata and regions conditionally to the total number of HZ cases observed and 
time at risk. The method is implemented in the Poisson procedure of the StatXact 
package provided by Cytel. Relative risks will be calculated overall and by age-
strata. Stratification will include age and regions for the overall analysis and region 
alone when analysis by age strata.  
The efficacy of ZOSTER vaccine against HZ-related mortality and hospitalizations will 
be demonstrated if the LL of the two-sided 95% CI of VE is above 0%. 
6.2.2.4. Reduction in incidence of HZ associated complications 
The overall incidence of HZ associated complications, in subjects with an HZ episode, 
overall and by age group will be presented and compared with placebo using asymptotic 
standardized unconditional binomial test [Miettinen, 1985]. The analysis will be stratified 
by age group and weights associated to each stratum will be pre-specified. 
The efficacy of ZOSTER vaccine against HZ associated complications will be 
demonstrated if the LL of the VE is above 0%. 
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6.2.2.5. Reduction in use of pain medications 
The reduction in use of pain medication will be evaluated through; 
• The vaccine VE will consider the exact inference on the relative risk stratified for 
age strata and regions conditionally to the total number of HZ cases observed and 
time at risk. The method is implemented in the Poisson procedure of the StatXact 
package provided by Cytel. Relative risks will be calculated overall and by age-
strata. Stratification will include age and regions for the overall analysis and region 
alone when analysis by age strata.  
The efficacy of ZOSTER vaccine in reduction in use of pain medications  will be 
demonstrated if the LL of the two-sided 95% CI of VE is above 0%. 
All analyses will be presented overall and by age strata. The main age strata for reporting 
purposes are 50-59, 60-69 and ≥70 YOA. In addition, the results for the ≥ 70 YOA 
stratum will also be presented separately for 70-79 and ≥ 80 YOA subjects. The study is 
not powered prospectively to demonstrate efficacy in these 2 sub-strata taken separately. 
Another set of analyses in subjects ≥ 60 YOA will also be presented. 
Any exploratory or sensitivity analysis may be performed in addition to the analyses 
described below on an ad-hoc basis. The significance level of those analyses may not 
however be fully controlled. 
6.2.3. Exploratory objectives 
6.2.3.1. Reduction in Burden-of-Illness 
The overall reduction in Burden-of-Illness will be evaluated through:  
• The “Chop-lump” test [Follmann, 2009] for the overall reduction in Burden-of-
Illness scores in all subjects between vaccine and placebo will be implemented 
and compared to the original analysis of the Burden-of-Illness proposed by 
Chang, 1994; 
• VE with respect to the BOI due to HZ (VE BOI ) is defined as the relative 
reduction in the BOI score in the vaccine group as compared with that in the 
placebo group and calculated as 1 - relative risk (i.e., 1- the HZ BOI score in the 
vaccine group divided by the HZ BOI score in the placebo group). 
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6.2.3.2. Reduction in HZ severity score 
The reduction in HZ severity score will be evaluated through:  
• The “Chop-lump” test [Chang, 1994] for the reduction in HZ severity scores in 
subjects with HZ between vaccine and placebo will be implemented. 
The HZ severity analysis applies to subjects with HZ and includes the first 4 weeks 
following the HZ episode.  
Additional analyses may be performed using partial AUC, calculated from 0 to specific 
elapsed time after HZ onset. That approach accounts partially for any difference in pain 
score profiles or pattern (e.g., long duration with low scores versus short score with high 
scores) even though subjects may have the same overall AUC. 
6.2.3.3. Reduction in PHN incidence in subjects with an HZ episode 
The reduction in PHN incidence in subjects with an HZ episode will be evaluated 
through: 
• The incidence of PHN in subjects with an HZ episode, overall and by age group 
will be presented and compared with placebo using asymptotic standardized 
unconditional binomial test [Miettinen, 1985]. The analysis will be stratified by 
age group and weights associated to each stratum will be pre-specified.  
6.2.3.4. Improvement of subject’s quality of life by ZBPI 
Descriptive statistics and inferential analysis of QoL subscale of ZBPI (item 9: questions 
A to G) total scores and scores per item over time will be provided overall and by age 
group.  
7. STATISTICAL CALCULATIONS 
7.1. Derived and transformed data 
7.1.1. Handling of missing data 
For a given subject and a given efficacy measurement, missing or non-evaluable 
measurements will not be imputed for the primary analysis. The missing endpoint and 
censoring are supposed to occur independently, and the pattern of the missingness being 
either Completely At Random (MCAR) or Missing At Random (MAR) only. 
Sensitivity analyses will be pre-specified prior to unblinding for each main efficacy 
endpoint in order to assess the sensitivity of the conclusions to missing-data pattern. 
When repeated measurements are planned, primary methodology will include mixed 
effect model for repeated measurement analysis [Mallinckrodt, 2008]. 
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7.1.2. Efficacy data 
The HZ incidence rate is determined with reference to the first confirmed HZ case 
observed in the patient, should several HZ cases occur in the same subject. 
The HZ-free period for a subject is calculated from HZ onset to time zero relative to the 
cohort considered: first vaccination for TVc and beyond the HZ-case exclusion period 
following the second injection for mTVc and ATP. 
The number of Person-Years at risk over an interval of time is the sum of the confirmed 
HZ-free episodes over all subjects at risk during that interval, either up to the cut-off date 
for the analysis, the censoring date or the occurrence of the first HZ case for a subject. 
RR is defined as the ratio of the incidence rates of the vaccine group over the placebo 
group. 
VE is defined as the 1 – RR. 
The following outputs will be derived from the efficacy data recorded using the ZBPI: 
Duration of severe worst pain 
For each confirmed HZ cases the follow up time is considered as starting from the date of 
HZ episode and ending the last day of ZBPI questionnaire period. The confirmed HZ 
cases without severe “worst” pain are considered as non-event cases. The cases with 
severe “worst” pain are considered as an event cases, their time to event is calculated as 
being the inverse of duration of pain (1/t). Those transformations allow computing 
vaccine efficacy in term of severe “worst” pain-free period. 
HZ burden-of-illness score 
For each confirmed case of HZ, responses to the “worst pain” question in the ZBPI are 
used to calculate a “HZ severity-of-illness” score, defined as the area under the curve 
(AUC) of HZ-associated pain plotted against time during the 182-day period after the 
onset of the case. Subjects developing HZ will present “severity-of-illness” scores 
ranging from 0 up to, theoretically, 1820. A score of 0 is recorded for subjects in whom 
HZ did not develop during the study period. 
HZ severity score  
The methodology described for the HZ burden-of-illness score will be applied to the 4 
weeks during which a daily measure is taken and provide the HZ severity score. The HZ 
severity score will apply only to subjects with HZ. Subjects not infected with HZ will not 
take part in this analysis. 
12 
CONFIDENTIAL 
7.2. Number of decimals 
The following decimal description will be used for the efficacy analyses. 
Display Table Parameters Number of decimal digits 
All summaries % of count, including LL & UL of CI 1 
All summaries % of difference, including LL & UL of CI 2 
All summaries p-value 3 
Efficacy VE, including LL & UL of CI 2 
IR 2 
T, T/N 1 
p-value 3 
 
7.3. Primary method for Vaccine Efficacy: 
VE will consider the exact inference on the relative risk stratified for age strata and 
regions conditionally to the total number of HZ cases observed and time at risk. 
Stratification will include age and regions for the overall analysis and region alone when 
analysis by age strata.  
This method computes an exact confidence interval (CI) around the rate ratio (ratio of the 
event rates in the vaccinated versus control group) and takes into account the follow-up 
time of the subjects within each group. VE is then defined as 1 minus the rate ratio. 
The follow-up time for each subject will start 
• at the day after first vaccination (Month 0) if analyses are done on the Total 
vaccinated cohort for efficacy, or 
• at 30 days after second vaccination (Month 3) if analyses are done on the mTVC or 
ATP cohort for efficacy.  
The follow-up time for each subject will end 
• at the time of the event; or,  
• at date of last visit for subjects who completed the study and did not have an event; 
or,  
• at the latest visit for which data is available for subjects who did not yet complete the 
study at the time of the interim analysis or final analysis (if criteria to reach final 
analyses are met before all subjects complete their last visit) and did not have an 
event: 
• For HZ endpoints, we take the minimum date of the start of the rash or start of 
the pain to assess the HZ, whichever comes first. 
The follow-up time will be calculated in days as Date of end of follow-up period – Date 
of vaccination, and expressed in person-years at risk (number of days/365.25).  
13 
CONFIDENTIAL 
7.4. Vaccine Efficacy using Cox regression model 
In addition to the primary analysis, VE and its CI will also be calculated using a Cox 
regression model. This methodology can take into account specific risk factors which 
might have been imbalanced, by chance, at the beginning of the trial between the 
vaccinated and control group. Risk factors that will be investigated are age strata and 
country. VE is then calculated as 1 minus the hazard ratio. 
Cox regression assumes proportional hazards throughout the follow-up period. This 
assumption will be checked by a test based on the Schoenfeld residuals. 
If there is strong evidence that the hazard rate is not constant over the surveillance period, 
then a non-parametric analysis will be performed. 
7.5. Time-to-first event methodology: follow-up time and status 
The study participants will be actively followed for the occurrence of HZ, PHN and use 
of pain medications during entire study follow up. The events linked to primary and 
secondary efficacy outcomes (with onset time) will be identified and in case multiple 
events are observed for the same subject, only the first event will be considered.  
For primary and secondary endpoints, the follow-up time and the status will be 
recorded as follows: 
• If the subject gets his/her first event of corresponding primary or secondary 
endpoints during the study follow up period, the status will be 1 and the 
associated time will be the number of days between start date of the considered 
period (30 days after last study vaccination) and the date of the appearance of the 
event. If he/she gets the same event afterwards, it will not be considered in the 
analysis. 
• If a subject does not get the event of corresponding endpoint during the study 
follow up, the status will be 0 and the associated time will be the number of days 
the subject is followed (if a subject is dropped-out from the study, his/her date of 
last contact will be taken into account). 
• Subjects meeting censoring criteria will be included in the analysis. 
7.6. Methods for Confidence Intervals (CIs) 
7.6.1. CIs for Vaccine Efficacy 
7.6.1.1. Poisson distribution 
The CI for vaccine efficacy can then be derived from the exact CI from RR (Miettinen, 
1985). This method is implemented in the Poisson procedure of the StatXact package 
provided by Cytel. 
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7.6.1.2. Binomial distribution 
The Vaccine Efficacy (VE) can be estimated by:  
2*
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1/11
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NnVE −=−=
 
where  n1 = number of cases in the vaccinated group 
N1 = follow-up time the vaccinated group 
n2 = number of cases in the control group 
N2 = follow-up time in the control group 
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where p = n1/n is binomially distributed. 
Therefore, there is a monotonic link between VE, the true vaccine efficacy, and p, the 
true proportion of subjects in the vaccine group among the total cases in the two groups. 
The CI for vaccine efficacy can then be derived from the exact CI from p (Dragalin, 
Fedorov and Cheuvart, 2002). This method is implemented in the Binomial procedure of 
the StatXact package provided by Cytel. 
7.6.1.3. Cox regression 
The CI for vaccine efficacy can then be derived from the Wald CI from Hazard Ratio. 
This method is implemented in the PHREG procedure of the SAS/STAT package (SAS 
V9.2). 
8. CONDUCT OF ANALYSES 
8.1. Sequence of analyses 
Description Analysis ID (SDD sub-
folder) 
TFL short title Blinded team 
status 
Futility analysis at 25% 
of HZ accrual 
2 Interim Blinded 
Final HZ Analysis  1 Final Blinded 
End of study analysis EOS EOS Unblinded 
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8.2. Prior to End of Study Analysis 
Blinded review of efficacy data will be performed in order to anticipate rate of accrual of 
HZ events within each age strata. 
Unblinded evaluation of futility efficacy will be performed by the IDMC.  
Access to results of Final HZ efficacy but all team remain blinded at level of subjects 
treatment 
8.3. Statistical considerations for interim analysis 
When 49 confirmed HZ cases have accrued in ZOSTER-006 and at least 20% of HZ 
cases are observed in each age strata [50-59 years], [60-69 years] and [70+ years] (see 
section 6.1), an interim analysis for futility will be performed. 
8.3.1. Interim analysis for Benefit 
GSK has no plan to proceed with early registration for efficacy (i.e., following the interim 
analysis) due to the following reasons: 
− The expected low accrual rate of PHN cases and the need to collect a sufficient 
number of events to achieve a robust estimate of PHN VE; 
− The duration of protection conferred by the vaccine is an important characteristic 
and because this futility analysis occurs at an early stage of the trial it will not be 
able to provide the required data if the study is stopped prematurely; 
− Accumulation of longer term safety data than will be available at the interim 
analysis. 
If the futility analysis occurs and leads to a recommendation by the IDMC to file prior to 
study end for ethical reasons, it is mandated that, prior to final analysis, the significance 
level for all primary objectives, and also key secondary objectives, is set to 0.0001 for 
both HZ and overall PHN, considering the alternative hypotheses of true vaccine 
efficacies above 40%. As a consequence, the significance level of the final analysis will 
be adjusted to 4.9998% 2-sided.  
8.3.2. Interim analysis for Futility 
Two different approaches are proposed, based on all observed cases in both ZOSTER-
006 and ZOSTER-022 at interim. The first approach will calculate the predictive power 
using a Frequentist approach. The second one will evaluate the predictive power using a 
Bayesian approach.   
16 
CONFIDENTIAL 
8.3.2.1. Frequentist approach 
This approach has three steps: 
1. VE and RR for HZ will be tabulated in each age stratum (50-59, 60-69 and 70+ 
YOA); 
2. An N-weighted VE, using as weight the expected number of HZ cases in each age 
stratum at final analysis in ZOSTER-006, will be calculated; 
3. Calculate the predictive power based on the calculated N-weighted VE and other 
parameters used when setting up the futility criteria (O’Brian-Fleming boundaries, 
assumed VE and Criteria of success at final analysis). 
Evaluate Vaccine efficacy in each strata 
Using all cases retrieved in both ZOSTER-006 and ZOSTER-022, we will evaluate VE in 
each of the three following age strata (50-59, 60-69 and 70+ YOA). 
The method used will be similar to the method described in section 7.1.2. VE and 95% CI 
will be tabulated. 
Evaluate N-Weighted Vaccine efficacy 
Using details given in Appendix 1: 
1. Calculate RR (as 1-VE) and Loge (RR) of each of the three age strata; 
2. Calculate the Weight of each age stratum as expected number of  cases at final 
analysis (using incidence rates of the interim analysis) (noted wi; i = 1 to 3); 
3. Calculate the sum of weighted Loge(RR) of the three age strata and divide by the 
sum of weights; 
4. Use the back transformation (1-exp(.)) to retrieve the correspondent weighted VE. 
The 95% CI is approximated from the Asymptotic normality of the Loge(RR) and the 
associated variance of the Loge(RR) from Agresti (1990): 
1. Calculate the Standard Error (SE) of RR in each of the three age strata by  
SE = sqrt((1/(nv+0.5))-(1/(Nv+0.5))+(1/(np+0.5))-(1/(Np+0.5))); 
2. Calculate the global SE using the Variance properties by  
SE = sqrt(( Sum  wi^2  SE^2) / (sum wi)^2); 
3. Calculate 95% CI as Loge(RR)± 1.96 SE and deduce by back transformation the 
95% CI of weighted VE.  
The weighted VE calculated is noted as N-weighted VE, more details are provided in 
Appendix 1. 
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Calculate predictive power 
The two following SAS procedures will be used to calculate the predictive power. The 
SEQDESIGN procedure used to evaluate designs interim analyses and the SEQTEST 
procedure performs the interim analyses based on the sample sizes and boundary values 
produced by the SEQDESIGN procedure. 
1. Based on the O’Brian-Fleming Method, evaluation of the boundary values using 
the PROC SEQDESIGN: 
The SEQDESIGN procedure designs interim analyses for clinical trials. PROC 
SEQDESIGN computes the boundary values for the trial. The boundary values 
are derived in such a way that the overall Type I and Type II error probability 
levels are maintained at the levels specified in the design. Method chosen is the 
O’Brian-Fleming method. The SEQDESIGN procedure computes the boundary 
values.  The following parameters have been fixed (during the determination of 
the futility rules) :  Assumed VE = 69% , Criteria of success LL > 25%, Gamma = 
-5 (Gamma family spending function linked to O’Brian-Fleming boundaries), 
Beta = 0.0031 (Type II error), Alpha = 0.025 (Type one error) 
2. Calculate the Predictive power using the PROC SEQTEST: 
Based on the weighted VE calculated at interim, the SEQTEST procedure 
compare the test statistic on interim data with the corresponding boundary values 
computed by the SEQDESIGN procedure and provide the  predictive power. 
The predictive power calculated is the posterior probability that the test statistic at 
the final stage would exceed the rejection critical value given the observed 
statistic and a prior distribution of the hypothetical reference. A non-informative 
prior is used in the procedure. 
Illustration of the predictive power for different VE observed at interim is given in the 
Figure 1. 
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Figure 1 Predictive power to demonstrate the primary objective with lower 
limit of 95% CI ≥ 25% for different observed VEs with 49 cases  
 
8.3.2.2. Bayesian approach 
All HZ cases accrued from ZOSTER-006 and ZOSTER-022 will be used.  
A Bayesian framework is used to simulate accrual of HZ cases in each age stratum under 
vaccine and placebo over the period of time between interim and final analysis.   
The duration of accrual is determined in order for the median number of HZ cases to 
reach between 196 and 200 over the 3 age strata.  The joint posterior distribution of 
placebo incidence and vaccine efficacy is calculated separately for each age stratum using 
unblinded interim data and non-informative priors.  
The joint distribution of the number of HZ cases under placebo and vaccine is simulated 
based on the joint posterior distribution of placebo incidence and vaccine efficacy and 
assuming (conditionally) independent Poisson distribution for the number of HZ cases.  
Provided that the sum of simulated HZ cases across the 3 age strata is between 196 and 
200, the simulations are analysed using the frequentist methodology planned for the final 
analysis.  
A success is considered when the LL of the  95% confidence interval for VE is above 
25%.  
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The probability of success of the final analysis given the interim data is estimated as the 
ratio of successes over the total number of simulations presented a total of 196 to 200 HZ 
cases.   
Details on the Bayesian framework is described in Laurent & Legrand (2011). 
8.3.2.3. Testing the futility rule 
Both predictive powers calculated by the frequentist approach will be compared to the 
futility rule. 
• If the Predictive power calculated is less than the futility boundary, the study will be 
declared futile, and the IDMC will provide this statement to the team. 
• If the Predictive power calculated is greater than the futility boundary, the study will 
be declared not futile, and the IDMC will provide this statement to the team. 
The IDMC will have access to the full analysis results and will provide GSK the 
applicable statement.  
8.4. Final analysis 
Two analyses are planned: Final HZ efficacy analysis and End of study analysis. 
8.4.1. Conditions for triggering analyses 
The conditions described below are minimum requirements prior to the specified 
analyses.  
The following conditions are planned prior to final HZ efficacy and end of study 
analyses of study ZOSTER-006. The number of HZ and PHN cases mentioned refers 
to the cases in the primary cohort for efficacy. 
1. At least 196 HZ cases across all age group for the overall HZ analysis; 
2. ~75% of the initial sample size (not accounting for any sample-size reassessment) 
in each strata with at least 36 months follow-up and the remaining subjects have 
completed at least 30 months follow-up after Dose 2 in order to ensure enough 
safety data; 
3. Approximately 60 HZ cases in subjects 50-59 YOA and approximately 60 HZ cases 
in subjects 60-69 YOA for the HZ analysis by-age in 50-59 and 60-69 YOA age 
strata respectively; 
The ZOSTER-006 study will continue until an adequate number of PHN cases will be 
accrued in both ZOSTER-006 and ZOSTER-022. 
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The end of study analysis of ZOSTER-006 will occur when the following conditions 
are met: 
1. All previous conditions are met for final HZ efficacy analysis in study ZOSTER-
022; 
2. A total of at least 35 PHN cases in subjects ≥ 70 YOA when pooled with ZOSTER-
022 PHN cases. 
The end of study analysis cannot be performed before the final HZ efficacy analysis. 
8.4.2. Control of type I error for the two steps analyses  
Although, the analyses of ZOSTER-006 will be performed in two steps. Each objective 
will be assessed only once. Therefore no adjustment of type I error is needed. 
8.4.3. Maintaining the blind 
It is planned to maintain the whole team (Central, Local, Investigators) and subjects 
blinded up to end of study.  
A firewall team will be set up in order to allow the planned analyses to be performed 
and results reported to the relevant authorities. All details of this approach can be 
found in the firewall charter. 
Dependent on the outcome of the studies ZOSTER-006 and ZOSTER-022, an single-
blind long-term follow-up study is planned. Therefore, after study end of ZOSTER-006 
and ZOSTER-022 the study blind will continue to be kept for those subjects who 
participated in the primary studies and are willing to participate in the single-blind 
long-term follow-up study; the central study team will be unblinded.   
8.4.4. List of objectives assessed at each analysis step  
The following table will provide an overview of the analyses which will be performed at 
final HZ efficacy analysis (step 1) and end of study analysis (step 2), respectively. 
For ZOSTER-006, step 1 will include analyses of the following objectives: 
• all  HZ VE objectives; 
• all reactogenicity/safety and immunogenicity objectives.  
At step 2, all objectives of study ZOSTER-006 will be analyzed. Objectives already 
analyzed at step 1 will be re-analyzed (as confirmatory descriptive in case of inferential 
analysis at step 1 or descriptive analysis otherwise).  
At step 2, overall PHN VE in subjects ≥ 70 YOA, and other pre-specified endpoints will 
be analyzed in the pooled analyses of studies ZOSTER-006 and ZOSTER-022. 
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8.4.5. Database freeze 
For the first step analysis, the time for database freeze for immunogenicity may not 
coincide with efficacy/safety database freeze. 
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Table 1 Overview of analyses performed at each analysis step (ZOSTER-006, pooled analysis of ZOSTER-006 and 
ZOSTER-022)  
 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable (NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis 
of 
objective 
Yes (Y)  
No (N) 
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive 
ZOSTER-006 
Primary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to 
placebo in adults ≥ 50 YOA, as measured by the reduction 
in HZ risk. 
Y I Y CD 
Secondary       
 Efficacy      
  To evaluate VE in the prevention of HZ compared to 
placebo in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, as measured 
by the reduction in HZ risk;  
Y I Y CD 
  To evaluate VE in the prevention of overall PHN compared 
to placebo in subjects ≥ 50 YOA and in subjects within 
each of the following age ranges: 50-59 YOA, 60-69 YOA 
and ≥ 70 YOA; 
N - Y D 
  To evaluate VE in reducing the total duration of severe 
‘worst’ HZ-associated pain over the entire pain reporting 
period compared to placebo in subjects ≥ 50 YOA and in 
subjects within each of the following age ranges: 50-59 
YOA, 60-69 YOA and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in the reduction of overall and HZ-related 
mortality and hospitalizations compared to placebo in 
subjects ≥ 50 YOA and in subjects within each of the 
following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 
YOA; 
N - Y I 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable (NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis 
of 
objective 
Yes (Y)  
No (N) 
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive 
  To evaluate VE in the reduction in incidence of HZ-
associated complications compared to placebo in subjects 
≥ 50 YOA and in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, with 
confirmed HZ; 
N - Y I 
  To evaluate VE in the reduction in use of pain medications 
compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 
YOA and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
 Safety       
  To evaluate vaccine safety and reactogenicity. Y D Y D 
Exploratory       
 Efficacy       
  To evaluate VE in reducing the severity of acute HZ-
associated pain compared to placebo in subjects ≥ 50 
YOA and in subjects within each of the following age 
ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, with 
confirmed HZ; 
N - Y I 
  To evaluate VE in improving Quality of Life (QoL) 
compared to placebo in subjects ≥ 50 YOA and in subjects 
within each of the following age ranges: 50-59 YOA, 60-69 
YOA and ≥ 70 YOA, with confirmed HZ; 
N - Y I 
  To evaluate VE in the mitigation of Burden-Of-Illness (BOI) 
caused by HZ compared to placebo in subjects ≥ 50 YOA 
and in subjects within each of the following age ranges: 
50-59 YOA, 60-69 YOA and ≥ 70 YOA. 
N - Y I 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable (NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis 
of 
objective 
Yes (Y)  
No (N) 
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive 
 Immunogenicity      
  To evaluate vaccine induced cell mediated and humoral 
immune responses and the persistence of each type of 
response after two injections of study vaccine in subjects 
≥ 50 YOA, and by age strata; 
Y I, D Y CD, D 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects ≥ 
50 YOA, and by age strata. 
Y I, D Y CD, D 
       
Pooled analysis of ZOSTER-006 and ZOSTER-022 
Co-primary       
 Efficacy      
  To evaluate VE in the prevention of overall PHN compared 
to placebo in subjects ≥ 70 YOA; 
NA  Y I 
  To consolidate VE estimation in the prevention of HZ 
compared to placebo in subjects ≥ 70 YOA across both 
phase III studies; 
NA Y CD 
Secondary      
 Efficacy     
  To evaluate VE in the prevention of PHN compared to 
placebo in subjects ≥ 50 YOA across both phase III 
studies; 
 Y I 
  To evaluate VE in the prevention of PHN compared to 
placebo in subjects ≥ 50 YOA with confirmed HZ; 
 Y I 
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 First  step* 
Final HZ efficacy analysis 
Second step** 
End of study analysis  
Analysis of 
objective 
Yes (Y)  
No (N) 
Not applicable (NA)  
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive  
Analysis 
of 
objective 
Yes (Y)  
No (N) 
Type of analysis  
I: inferential  
D: descriptive  
CD; confirmatory 
descriptive 
  To evaluate VE in reducing the total duration of severe 
‘worst’ HZ-associated pain over the entire pain reporting 
period compared to placebo in subjects ≥ 70 YOA, with 
confirmed HZ; 
 Y CD 
 Safety     
  To evaluate vaccine safety and reactogenicity in subjects 
≥ 70 YOA. 
NA Y D 
Exploratory      
 Efficacy     
  To evaluate VE in reducing the severity of acute HZ-
associated pain compared to placebo in subjects ≥ 70 
YOA, with confirmed HZ; 
NA Y CD 
  To evaluate VE in improving QoL compared to placebo in 
subjects ≥ 70 YOA, with confirmed HZ; 
NA Y CD 
 Immunogenicity     
  To evaluate vaccine induced humoral immune responses 
and the persistence of each type of response after two 
injections of study vaccine in subjects ≥ 50 YOA and by 
age cohort; 
NA Y CD 
  To evaluate anti-varicella-zoster virus (VZV) neutralizing 
antibody (Ab) titres in a subset of subjects at Month 0 (pre-
vaccination), and at Months 3, 14, 26 and 38, in subjects ≥ 
50 YOA and by age strata; 
NA Y CD 
  To assess correlation of the humoral immune responses at 
Month 3 with protection against HZ. 
NA Y D 
       
* The first step for Zoster-006 will occur more than approximately 6 months before the first step for Zoster-022. 
** The second analysis step for both studies will occur at the same time. 
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8.4.6. Study reports  
Depending on the further evolution of the case accrual rate, the generated data may be 
presented in one or more study reports per study (ZOSTER-006).  
• The first study report for each study will contain assessment of the HZ 
VE objectives (ZOSTER-006) and of safety, reactogenicity and immunogenicity 
objectives. 
• A final study report for each study will contain the assessment of remaining 
objectives not assessed at the first step, including, but not limited to, the 
confirmatory descriptive re-analysis of the previously assessed objectives. The final 
study report for each study will also contain the results presented in the first report 
(to provide a comprehensive all in one report).  Assessment of the objectives of the 
pooled analyses of both studies will be included in the final ZOSTER-022 study 
report. Analysis of correlate of protection may require extensive exploratory 
analyses and therefore may be available as an annex report after completion of 
this final ZOSTER-022 study report. 
9. CHANGES FROM PLANNED ANALYSES 
No changes from protocol planned analyses. 
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11. ABBREVIATIONS 
ATP According-To-Protocol 
AUC Area Under Curve 
BOI Burden-Of-Illness 
CI Confidence Interval 
Eli_type Internal GSK database code for type of elimination code 
eCRF Electronic Case Report Form 
HZ Herpes ZOSTER 
GSK GlaxoSmithKline 
IDMC Independent Data Monitoring Committee 
IR Incidence Rates 
LL Lower limit 
MAR Missing At Random 
MCAR Missing Completely At Random 
mTVc Modified Total Vaccinated Cohort 
N.A. Not Applicable 
OTH Other 
PHN Postherpetic Neuralgia 
QoL Quality of Life 
R R free software from free fondation software 
RDE Remote Data Entry 
RR Relative Risk 
SAP Statistical Analysis Plan 
SAS Statistical Analysis System 
SBIR GSK Biological’s Internet Randomization System 
SE Standard Error 
sqrt Square root 
SR Study Report 
SYN Synopsis 
TFL Tables Figures and Listing template annexed to SAP 
TVc Total Vaccinated Cohort 
UL Upper Limit 
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VE Vaccine Efficacy 
YOA Years Of Age 
ZBPI Zoster Brief Pain Inventory 
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Appendix 1 N-Weighted Vaccine efficacy 
The N-weighted estimate of vaccine efficacy is used to yield a single estimate of efficacy 
across the different age strata. At time of futility analysis, all cases accrued  in ZOSTER-
022 will be also used in the evaluation of the futility rule in order to account for all 
information available at this time.  
The Stratified Poisson analysis planned for the final analysis use implicitely the number 
of cases accrued in each strata as weight. In order to correct the bias made by including 
the cases from ZOSTER-022 (only in the [70+ years] strata,  we propose to use the 
weighted VE (using number of cases by strata expected at final analysis as weight)  as 
estimation of the vaccine efficacy  at futility analysis. 
Expected value of VE : The mean (or expected value of) VE across the three strata can be 
computed and be used as a measure of central tendency, to characterize the average VE 
that can be expected in the ZOSTER-006. 
Definition of Expected value: For a random variable X with two possible values (x1, x2) 
with corresponding probabilities (p, q), the mean (or expected value) of the random 
variable X is defined as: 
Expected value = mean =E(X) =x1.p = x2.p                                             (13.1) 
The expected value of VE across the three strata that can be computed and used to 
characterize the average VE that can be expected from the FAS may be obtained 
analogously using the computations shown in Equation 13.1 as follows. 
Calculation of Expected values of VE: Let the expected value of VE be denoted by 
E(VE). Then E(VE) cane be computed as 
E(VE) = 100% x (1-exp(Expected value of loge [relative risk]))             (13.2) 
The rationale for such a computation is that the estimate of loge[relative risk] that is 
asymptotically normally distributed.. The asymptotic normal distribution property of the 
estimate of loge[relative risk] can be used to obtain a 95% confidence interval 
corresponding to the estimate of E (VE). The N-weighted average estimate of vaccine 
efficacy in the FAS were computed based on the calculations given in Equation 13.2. The 
use of the term "N-weighted" arises from the calculation of the expected value of 
loge[relative risk]. 
